-DOCSTART - (8701013)

Lactobacillus	NOUN	O	O
plantarum	NOUN	O	O
CECT7315	NOUN	O	O
and	CCONJ	O	O
CECT7316	NOUN	O	O
stimulate	PUNCT	O	O
immunoglobulin	NOUN	O	B-PHYSICAL
production	NOUN	O	I-PHYSICAL
after	ADP	O	O
influenza	NOUN	O	O
vaccination	NOUN	O	O
in	ADP	O	O
elderly	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
influenza	NOUN	O	O
vaccination	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
illness	NOUN	O	O
is	VERB	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
elderly	ADJ	O	O
;	PUNCT	O	O
this	PUNCT	O	O
is	NUM	O	O
why	ADP	O	O
the	DET	O	O
ability	NOUN	O	O
of	ADP	O	O
Lactobacillus	NOUN	O	O
plantarum	NOUN	O	O
CECT	NOUN	O	O
7315/7316	NOUN	O	O
to	PART	O	O
stimulate	ADJ	O	O
the	DET	O	O
response	NOUN	O	O
to	ADP	O	B-PHYSICAL
influenza	NOUN	O	I-PHYSICAL
vaccination	NOUN	O	I-PHYSICAL
in	ADP	O	O
elderly	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

RESEARCH	NOUN	O	O
METHODS	NOUN	O	O
AND	CCONJ	O	O
PROCEDURES	NOUN	O	O
A	NUM	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
human	NOUN	O	O
trial	NOUN	O	O
including	VERB	O	O
60	NUM	O	O
institutionalized	ADV	O	O
volunteers	NOUN	O	O
aged	PROPN	O	O
65-85	NUM	O	O
years	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

All	DET	O	O
the	DET	O	O
volunteers	NOUN	O	O
were	VERB	O	O
vaccinated	VERB	O	O
with	ADP	O	O
a	DET	O	O
trivalent	ADJ	O	O
influenza	NOUN	O	O
vaccine	NOUN	O	O
(	PUNCT	O	O
A/Wisconsin/67/2005	NOUN	O	O
NYMC	NOUN	O	O
X-161B	NOUN	O	O
(	PUNCT	O	O
H3N2	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
A/Solomon	NOUN	O	O
Islands/3/2006	PUNCT	O	O
(	PUNCT	O	O
H1N1	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
B/Malaysia/2506/2004	PUNCT	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
Spanish	NOUN	O	O
vaccine	NOUN	O	O
campaign	VERB	O	O
2006/2007	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
consumption	NOUN	O	O
of	ADP	O	O
the	DET	O	O
probiotic	ADJ	O	O
began	VERB	O	O
between	ADP	O	O
three	NUM	O	O
and	CCONJ	O	O
four	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
the	DET	O	O
vaccination	NOUN	O	O
.	PUNCT	O	O

Volunteers	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
three	NUM	O	O
following	ADP	O	O
groups	NOUN	O	O
:	PUNCT	O	O
group	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
receiving	PUNCT	O	O
5*10	NOUN	O	O
(	PUNCT	O	O
9	NUM	O	O
)	PUNCT	O	O
cfu/day	NUM	O	O
of	ADP	O	O
L.	NOUN	O	O
plantarum	NOUN	O	O
CECT	NOUN	O	O
7315/7316	NOUN	O	O
in	ADP	O	O
20	NUM	O	O
g	NOUN	O	O
powdered	CCONJ	O	O
skim	ADJ	O	O
milk	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
group	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
receiving	PUNCT	O	O
5*10	NOUN	O	O
(	PUNCT	O	O
8	NUM	O	O
)	PUNCT	O	O
cfu/day	NUM	O	O
of	ADP	O	O
L.	NOUN	O	O
plantarum	NOUN	O	O
CECT	NOUN	O	O
7315/7316	NOUN	O	O
in	ADP	O	O
20	NUM	O	O
g	NOUN	O	O
powdered	CCONJ	O	O
skim	ADJ	O	O
milk	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
group	NOUN	O	O
C	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
g	NOUN	O	O
powered	CCONJ	O	O
skim	ADJ	O	O
milk	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
participants	NOUN	O	O
consumed	PUNCT	O	O
the	DET	O	O
probiotic	ADP	O	O
during	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
consumption	NOUN	O	O
of	ADP	O	O
L.	NOUN	O	O
plantarum	NOUN	O	O
CECT	NOUN	O	O
7315/7316	NOUN	O	O
during	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
influenza	NOUN	O	O
vaccination	NOUN	O	O
increased	VERB	O	O
the	DET	O	O
levels	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
influenza-specific	ADJ	O	I-PHYSICAL
IgA	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
IgG	NOUN	O	I-PHYSICAL
antibodies	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
a	DET	O	O
trend	NOUN	O	O
towards	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
influenza-specific	ADJ	O	B-PHYSICAL
IgM	NOUN	O	I-PHYSICAL
antibodies	NOUN	O	I-PHYSICAL
was	VERB	O	O
also	ADV	O	O
observed	VERB	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
L.	NOUN	O	O
plantarum	NOUN	O	O
CECT7315/7316	ADJ	O	O
has	PUNCT	O	O
an	DET	O	O
immunostimulating	ADP	O	O
effect	NOUN	O	O
and	CCONJ	O	O
could	ADJ	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
improve	ADJ	O	O
the	DET	O	O
response	NOUN	O	O
to	ADP	O	O
influenza	NOUN	O	O
vaccination	NOUN	O	O
in	ADP	O	O
elderly	NOUN	O	O
.	PUNCT	O	O

Computer-navigated	VERB	O	O
versus	CCONJ	O	O
conventional	ADJ	O	O
total	ADJ	O	O
knee	NOUN	O	O
arthroplasty	NOUN	O	O
a	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
literature	NOUN	O	O
lacks	NOUN	O	O
studies	NOUN	O	O
that	ADP	O	O
confirm	VERB	O	O
whether	ADP	O	O
the	DET	O	O
improved	VERB	O	O
radiographic	ADJ	O	O
alignment	NOUN	O	O
that	ADP	O	O
can	VERB	O	O
be	VERB	O	O
achieved	VERB	O	O
with	ADP	O	O
computer-navigated	VERB	O	O
total	ADJ	O	O
knee	NOUN	O	O
arthroplasty	NOUN	O	O
improves	PUNCT	O	O
patients?	NOUN	O	O
activities	NOUN	O	O
of	ADP	O	O
daily	PUNCT	O	O
living	ADP	O	O
or	CCONJ	O	O
the	DET	O	O
durability	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
knee	NOUN	O	O
prostheses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
computer-navigated	VERB	O	O
total	ADJ	O	O
knee	NOUN	O	O
arthroplasty	NOUN	O	O
improves	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	O
function	NOUN	O	O
,	PUNCT	O	O
alignment	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
survivorship	NOUN	O	O
of	ADP	O	O
the	DET	O	O
components	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
prospectively	ADV	O	O
compared	ADP	O	O
the	DET	O	O
results	NOUN	O	O
of	ADP	O	O
520	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
osteoarthritis	NOUN	O	O
who	ADP	O	O
underwent	VERB	O	O
computer-navigated	DET	O	O
total	ADJ	O	O
knee	NOUN	O	O
arthroplasty	NOUN	O	O
for	ADP	O	O
one	NUM	O	O
knee	NOUN	O	O
and	CCONJ	O	O
conventional	ADJ	O	O
total	ADJ	O	O
knee	NOUN	O	O
arthroplasty	NOUN	O	O
for	ADP	O	O
the	DET	O	O
other	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
assignment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
knee	NOUN	O	O
to	ADP	O	O
navigation	NOUN	O	O
or	CCONJ	O	O
not	ADV	O	O
was	PUNCT	O	O
done	PUNCT	O	O
randomly	ADV	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
452	NUM	O	O
women	NOUN	O	O
(	PUNCT	O	O
904	NUM	O	O
knees	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
sixty-eight	PUNCT	O	O
men	NOUN	O	O
(	PUNCT	O	O
136	NUM	O	O
knees	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
age	NOUN	O	O
of	ADP	O	O
sixty-eight	PUNCT	O	O
years	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
forty-nine	NOUN	O	O
to	ADP	O	O
eighty-eight	PUNCT	O	O
years	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
the	DET	O	O
index	NOUN	O	O
arthroplasty	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
follow-up	NOUN	O	O
period	NOUN	O	O
was	VERB	O	O
10.8	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
ten	NUM	O	O
to	ADP	O	O
twelve	PUNCT	O	O
years	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
clinically	ADV	O	O
and	CCONJ	O	O
radiographically	ADV	O	O
with	ADP	O	O
the	DET	O	O
rating	VERB	O	O
system	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Knee	NOUN	O	B-PHYSICAL
Society	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
with	ADP	O	O
the	DET	O	O
Western	NOUN	O	O
Ontario	NOUN	O	O
and	CCONJ	O	O
McMaster	ADJ	O	O
Universities	PROPN	O	O
Osteoarthritis	NOUN	O	O
Index	NOUN	O	O
(	PUNCT	O	O
WOMAC	NOUN	O	O
)	PUNCT	O	O
score	NOUN	O	O
at	ADP	O	O
three	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
year	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
annually	ADV	O	O
thereafter	ADV	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Total	VERB	O	O
knee	NOUN	O	B-PHYSICAL
scores	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
knee	NOUN	O	B-PHYSICAL
function	ADV	O	I-PHYSICAL
scores	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
pain	NOUN	O	B-PAIN
scores	NOUN	O	I-PAIN
,	PUNCT	O	O
WOMAC	ADP	O	B-PHYSICAL
scores	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
knee	NOUN	O	B-PHYSICAL
motion	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
activity	NOUN	O	B-PHYSICAL
scores	NOUN	O	I-PHYSICAL
did	PUNCT	O	O
not	ADV	O	O
show	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
preoperatively	ADV	O	O
or	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
the	DET	O	O
final	ADJ	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Alignment	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
survivorship	NOUN	O	O
of	ADP	O	O
the	DET	O	O
components	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
Kaplan-Meier	ADJ	O	O
survivorship	NOUN	O	O
with	ADP	O	O
revision	NOUN	O	O
as	ADP	O	O
the	DET	O	O
end	NOUN	O	O
point	NOUN	O	O
at	ADP	O	O
10.8	NUM	O	O
years	NOUN	O	O
was	VERB	O	O
98.8	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
[	PUNCT	O	O
CI	NOUN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
0.96	NUM	O	O
to	ADP	O	O
1.00	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
computernavigated	VERB	O	O
total	ADJ	O	O
knee	NOUN	O	O
arthroplasty	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
99.2	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
,	PUNCT	O	O
0.96	NUM	O	O
to	ADP	O	O
1.00	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
conventional	ADJ	O	O
total	ADJ	O	O
knee	NOUN	O	O
arthroplasty	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	ADP	O	O
Our	PUNCT	O	O
data	NOUN	O	O
demonstrated	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
clinical	ADJ	O	O
function	NOUN	O	O
or	CCONJ	O	O
alignment	NOUN	O	O
and	CCONJ	O	O
survivorship	NOUN	O	O
of	ADP	O	O
the	DET	O	O
components	NOUN	O	O
between	ADP	O	O
the	DET	O	O
knees	NOUN	O	O
that	PUNCT	O	O
underwent	PROPN	O	O
computer-navigated	DET	O	O
total	ADJ	O	O
knee	NOUN	O	O
arthroplasty	ADJ	O	O
and	CCONJ	O	O
those	ADP	O	O
that	PUNCT	O	O
underwent	PROPN	O	O
conventional	ADJ	O	O
total	ADJ	O	O
knee	NOUN	O	O
arthroplasty	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Methodologic	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
polyfrequency	NOUN	O	O
oscillation	NOUN	O	O
method	NOUN	O	O
,	PUNCT	O	O
transcutaneous	ADJ	O	O
oxygen	NOUN	O	O
pressure	NOUN	O	O
measurement	NOUN	O	O
and	CCONJ	O	O
body	NOUN	O	O
plethysmography	NOUN	O	O
in	ADP	O	O
bronchial	ADJ	O	O
provocation	NOUN	O	O
with	ADP	O	O
methacholine	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
bronchial	ADJ	O	O
provocation	NOUN	O	O
challenge	NOUN	O	O
test	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
with	ADP	O	O
30	NUM	O	O
subjects	NOUN	O	O
using	VERB	O	O
metacholin	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
randomised	VERB	O	O
sequence	NOUN	O	O
lung	NOUN	O	O
function	NOUN	O	O
analysis	NOUN	O	O
tests	NOUN	O	O
were	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
with	ADP	O	O
the	DET	O	O
bodyplethysmograph	ADJ	O	O
(	PUNCT	O	O
Raw	NOUN	O	O
,	PUNCT	O	O
FEV1	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
polyfrequent	NOUN	O	O
oscillation	NOUN	O	O
method	NOUN	O	O
(	PUNCT	O	O
resistance	NOUN	O	O
,	PUNCT	O	O
reactance	NOUN	O	O
between	ADP	O	O
2	NUM	O	O
and	CCONJ	O	O
52	NUM	O	O
Hz	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
transcutaneous	ADJ	O	O
oxygen	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
tc-PO2	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
measured	VERB	O	O
continuously	ADV	O	O
.	PUNCT	O	O

Correlations	NOUN	O	O
between	ADP	O	O
the	DET	O	O
various	ADJ	O	O
parameters	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
change	NOUN	O	O
of	ADP	O	O
the	DET	O	O
values	NOUN	O	O
at	ADP	O	O
PD60	NOUN	O	O
sGaw	PUNCT	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
values	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
interindividual	ADJ	O	O
variability	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
reactivity	NOUN	O	O
were	VERB	O	O
determined	VERB	O	O
.	PUNCT	O	O

Medium	ADJ	O	O
correlations	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
for	ADP	O	O
the	DET	O	O
oscillatory	ADJ	O	B-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
Raw	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
whereas	CCONJ	O	O
for	ADP	O	O
tc-PO2	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
Raw	NOUN	O	B-PHYSICAL
the	DET	O	O
correlation	NOUN	O	O
was	VERB	O	O
markedly	ADV	O	O
lower	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
percentage	NOUN	O	O
the	DET	O	O
greatest	PUNCT	O	O
change	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
reactance	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
value	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
Raw	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
FEV1	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
interindividual	ADJ	O	O
variability	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
the	DET	O	O
highest	PUNCT	O	O
values	NOUN	O	O
for	ADP	O	O
the	DET	O	O
reactance	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
Raw	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
FEV1	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Interindividual	ADJ	O	O
variability	NOUN	O	O
showed	VERB	O	O
the	DET	O	O
highest	PUNCT	O	O
values	NOUN	O	O
for	ADP	O	O
the	DET	O	O
reactance	NOUN	O	O
before	ADP	O	O
oscillatory	ADJ	O	B-PHYSICAL
resistance	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
Raw	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
respect	NOUN	O	O
of	ADP	O	O
reactivity	NOUN	O	O
,	PUNCT	O	O
reactance	NOUN	O	O
also	ADV	O	O
had	CCONJ	O	O
the	DET	O	O
highest	PUNCT	O	O
values	NOUN	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
evaluation	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
bodyplethysmography	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
polyfrequent	NOUN	O	O
oscillation	NOUN	O	O
method	NOUN	O	O
(	PUNCT	O	O
reactance	NOUN	O	O
or	CCONJ	O	O
resonance	NOUN	O	O
frequency	NOUN	O	O
)	PUNCT	O	O
are	VERB	O	O
comparably	ADV	O	O
sensitive	ADJ	O	O
.	PUNCT	O	O

Acute	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
decaffeinated	VERB	O	O
coffee	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
major	ADJ	O	O
coffee	NOUN	O	O
components	NOUN	O	O
chlorogenic	ADJ	O	O
acid	NOUN	O	O
and	CCONJ	O	O
trigonelline	VERB	O	O
on	ADP	O	O
glucose	NOUN	O	B-PHYSICAL
tolerance	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Coffee	NOUN	O	O
consumption	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
lower	PUNCT	O	O
risk	NOUN	O	O
of	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
acute	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
decaffeinated	VERB	O	O
coffee	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
major	ADJ	O	O
coffee	NOUN	O	O
components	NOUN	O	O
chlorogenic	ADJ	O	O
acid	NOUN	O	O
and	CCONJ	O	O
trigonelline	VERB	O	O
on	ADP	O	O
glucose	NOUN	O	O
tolerance	NOUN	O	O
.	PUNCT	O	O

RESEARCH	NOUN	O	O
DESIGN	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
crossover	NOUN	O	O
trial	NOUN	O	O
of	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
g	NOUN	O	O
decaffeinated	NOUN	O	O
coffee	ADJ	O	O
,	PUNCT	O	O
1	NUM	O	O
g	NOUN	O	O
chlorogenic	ADJ	O	O
acid	NOUN	O	O
,	PUNCT	O	O
500	NUM	O	O
mg	NOUN	O	O
trigonelline	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
1	NUM	O	O
g	NOUN	O	O
mannitol	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
glucose	NOUN	O	O
and	CCONJ	O	O
insulin	NOUN	O	O
concentrations	NOUN	O	O
during	ADP	O	O
a	DET	O	O
2-h	NOUN	O	O
oral	ADJ	O	O
glucose	NOUN	O	O
tolerance	NOUN	O	O
test	NOUN	O	O
(	PUNCT	O	O
OGTT	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
15	NUM	O	O
overweight	ADP	O	O
men	NOUN	O	O
.	PUNCT	O	O

RESULTS	ADJ	O	O
Chlorogenic	ADJ	O	O
acid	NOUN	O	O
and	CCONJ	O	O
trigonelline	ADJ	O	O
ingestion	NOUN	O	O
significantly	ADV	O	O
reduced	CCONJ	O	O
glucose	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
-0.7	NUM	O	O
mmol/l	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.007	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
-0.5	PUNCT	O	O
mmol/l	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.024	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
and	CCONJ	O	O
insulin	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
-73	NUM	O	O
pmol/l	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.038	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
-117	NUM	O	O
pmol/l	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.007	NUM	O	O
)	PUNCT	O	O
concentrations	NOUN	O	O
15	NUM	O	O
min	NOUN	O	O
following	VERB	O	O
an	DET	O	O
OGTT	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

None	NUM	O	O
of	ADP	O	O
the	DET	O	O
treatments	NOUN	O	O
affected	PUNCT	O	O
insulin	NOUN	O	B-PHYSICAL
or	CCONJ	O	I-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
curve	NOUN	O	O
values	NOUN	O	O
during	ADP	O	O
the	DET	O	O
OGTT	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Chlorogenic	ADJ	O	O
acid	NOUN	O	O
and	CCONJ	O	O
trigonelline	VERB	O	O
reduced	ADP	O	O
early	ADJ	O	O
glucose	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
insulin	NOUN	O	B-PHYSICAL
responses	NOUN	O	I-PHYSICAL
during	ADP	O	O
an	DET	O	O
OGTT	NOUN	O	O
.	PUNCT	O	O

PROCLAIM	NOUN	O	O
:	PUNCT	O	O
pilot	NOUN	O	O
study	PUNCT	O	O
to	DET	O	O
examine	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
clopidogrel	NOUN	O	O
on	ADP	O	O
inflammatory	ADJ	O	O
markers	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
metabolic	ADJ	O	O
syndrome	NOUN	O	O
receiving	VERB	O	O
low-dose	NOUN	O	O
aspirin	NOUN	O	O
.	PUNCT	O	O

Metabolic	ADJ	O	O
syndrome	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
intravascular	PUNCT	O	O
inflammation	NOUN	O	O
,	PUNCT	O	O
as	CCONJ	O	O
determined	VERB	O	O
by	ADP	O	O
increased	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
biomarkers	CCONJ	O	O
and	CCONJ	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
ischemic	ADJ	O	O
atherothrombotic	ADJ	O	O
events	NOUN	O	O
.	PUNCT	O	O

Evidence	NOUN	O	O
suggests	NOUN	O	O
that	ADP	O	O
atherothrombosis	NOUN	O	O
and	CCONJ	O	O
intravascular	PUNCT	O	O
inflammation	NOUN	O	O
share	VERB	O	O
predictive	ADJ	O	O
biomarkers	CCONJ	O	O
,	PUNCT	O	O
including	VERB	O	O
high-sensitivity	NOUN	O	O
C-reactive	ADJ	O	O
protein	NOUN	O	O
,	PUNCT	O	O
CD40	NOUN	O	O
ligand	NOUN	O	O
,	PUNCT	O	O
P-selectin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
N-terminal	ADJ	O	O
pro-brain	NOUN	O	O
natriuretic	ADJ	O	O
peptide	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	ADP	O	O
had	ADJ	O	O
metabolic	ADJ	O	O
syndrome	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
clopidogrel	NOUN	O	O
75	NUM	O	O
mg/day	NOUN	O	O
plus	CCONJ	O	O
aspirin	NOUN	O	O
81	NUM	O	O
mg/day	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
89	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
plus	CCONJ	O	O
aspirin	NOUN	O	O
81	NUM	O	O
mg/day	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
92	NUM	O	O
)	PUNCT	O	O
for	ADP	O	O
9	NUM	O	O
weeks	NOUN	O	O
to	PUNCT	O	O
assess	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
each	DET	O	O
treatment	NOUN	O	O
in	ADP	O	O
suppression	NOUN	O	O
of	ADP	O	O
inflammatory	ADJ	O	O
markers	NOUN	O	O
.	PUNCT	O	O

Change	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
the	DET	O	O
levels	NOUN	O	O
of	ADP	O	O
high-sensitivity	NOUN	O	B-PHYSICAL
C-reactive	ADJ	O	I-PHYSICAL
protein	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
CD40	NOUN	O	B-PHYSICAL
ligand	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
P-selectin	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
N-terminal	ADJ	O	B-PHYSICAL
pro-brain	NOUN	O	I-PHYSICAL
natriuretic	ADJ	O	I-PHYSICAL
peptide	NOUN	O	I-PHYSICAL
at	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
each	DET	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
at	ADP	O	O
Week	NOUN	O	O
6	NUM	O	O
in	ADP	O	O
model-adjusted	ADJ	O	B-PHYSICAL
CD40-ligand	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
in	ADP	O	O
favor	NOUN	O	O
of	ADP	O	O
clopidogrel	NOUN	O	O
plus	CCONJ	O	O
aspirin	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
plus	CCONJ	O	O
aspirin	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
the	DET	O	O
intent-to-treat	NOUN	O	O
population	NOUN	O	O
(	PUNCT	O	O
difference	NOUN	O	O
between	ADP	O	O
least-squares	ADJ	O	O
means	NOUN	O	O
=	ADJ	O	O
-186.5	ADJ	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
-342.3	NUM	O	O
to	ADP	O	O
-30.8	ADJ	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
per-protocol	NOUN	O	O
population	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
between	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
arms	NOUN	O	O
for	ADP	O	O
high-sensitivity	NOUN	O	B-PHYSICAL
C-reactive	ADJ	O	I-PHYSICAL
protein	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
P-selectin	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
N-terminal	ADJ	O	B-PHYSICAL
pro-brain	NOUN	O	I-PHYSICAL
natriuretic	ADJ	O	I-PHYSICAL
peptide	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
deaths	ADV	O	B-MORTALITY
or	CCONJ	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
in	ADP	O	O
either	CCONJ	O	O
treatment	NOUN	O	O
arm	ADP	O	O
.	PUNCT	O	O

Data	NOUN	O	O
from	ADP	O	O
this	DET	O	O
study	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
clopidogrel	NOUN	O	O
can	PART	O	O
decrease	VERB	O	O
the	DET	O	O
expression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
CD40-ligand	PUNCT	O	B-PHYSICAL
biomarker	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Timing	VERB	O	O
for	ADP	O	O
delivering	VERB	O	O
individualized	PUNCT	O	O
patient	NOUN	O	O
education	NOUN	O	O
intervention	NOUN	O	O
to	ADP	O	O
Coronary	ADJ	O	O
Artery	NOUN	O	O
Bypass	NOUN	O	O
Graft	NOUN	O	O
patients	NOUN	O	O
:	PUNCT	O	O
An	DET	O	O
RCT	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
primary	ADJ	O	O
focus	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
is	VERB	O	O
on	ADP	O	O
the	DET	O	O
timing	VERB	O	O
of	ADP	O	O
the	DET	O	O
delivery	NOUN	O	O
of	ADP	O	O
education	NOUN	O	O
to	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
CABG	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
an	DET	O	O
individualized	VERB	O	O
telephone	NOUN	O	O
patient	NOUN	O	O
education	NOUN	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
delivered	VERB	O	O
at	ADP	O	O
two	NUM	O	O
different	ADJ	O	O
points	DET	O	O
in	ADP	O	O
time	NOUN	O	O
(	PUNCT	O	O
1-2	NUM	O	O
days	NOUN	O	O
pre-discharge	NOUN	O	O
versus	CCONJ	O	O
1-2	NUM	O	O
days	NOUN	O	O
post-discharge	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
enhancing	VERB	O	O
the	DET	O	O
CABG	NOUN	O	O
patient	NOUN	O	O
's	PUNCT	O	O
knowledge	NOUN	O	O
of	ADP	O	O
self-care	PUNCT	O	O
behaviours	NOUN	O	O
,	PUNCT	O	O
performance	NOUN	O	O
of	ADP	O	O
self-care	PUNCT	O	O
behaviours	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
symptom	NOUN	O	O
frequency	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
A	NOUN	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
that	ADP	O	O
included	VERB	O	O
a	DET	O	O
convenience	NOUN	O	O
sample	NOUN	O	O
of	ADP	O	O
first	VERB	O	O
time	NOUN	O	O
CABG	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Individuals	NOUN	O	O
who	PROPN	O	O
received	VERB	O	O
education	NOUN	O	O
pre-discharge	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
to	ADP	O	O
individuals	NOUN	O	O
who	PROPN	O	O
received	VERB	O	O
education	NOUN	O	O
post-discharge	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Results	ADJ	O	O
indicated	VERB	O	O
no	ADP	O	O
statistically	ADV	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
outcomes	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
time	NOUN	O	O
points	NOUN	O	O
.	PUNCT	O	O

As	CCONJ	O	O
well	PUNCT	O	O
,	PUNCT	O	O
anxiety	NOUN	O	B-MENTAL
levels	NOUN	O	I-MENTAL
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
pre-discharge	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
post-discharge	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
individualized	VERB	O	O
nature	NOUN	O	O
of	ADP	O	O
the	DET	O	O
educational	ADJ	O	O
intervention	NOUN	O	O
may	VERB	O	O
have	PUNCT	O	O
accounted	VERB	O	O
for	ADP	O	O
non-significant	ADJ	O	O
findings	NOUN	O	O
reported	VERB	O	O
in	ADP	O	O
outcomes	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
time	NOUN	O	O
points	NOUN	O	O
.	PUNCT	O	O

PRACTICE	NOUN	O	O
IMPLICATIONS	DET	O	O
Nurses	PUNCT	O	O
may	PROPN	O	O
consider	VERB	O	O
assessing	CCONJ	O	O
anxiety	NOUN	O	B-MENTAL
levels	NOUN	O	I-MENTAL
prior	PUNCT	O	O
to	ADP	O	O
delivery	NOUN	O	O
of	ADP	O	O
educational	ADJ	O	O
interventions	NOUN	O	O
,	PUNCT	O	O
implement	ADP	O	O
interventions	NOUN	O	O
aimed	VERB	O	O
at	ADP	O	O
reducing	ADJ	O	O
anxiety	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
provide	VERB	O	O
individualized	VERB	O	O
teaching	ADV	O	O
.	PUNCT	O	O

Randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
fenretinide	NOUN	O	O
in	ADP	O	O
superficial	ADJ	O	O
bladder	NOUN	O	O
cancer	NOUN	O	O
using	VERB	O	O
DNA	NOUN	O	O
flow	NOUN	O	O
cytometry	NOUN	O	O
as	ADP	O	O
an	DET	O	O
intermediate	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
.	PUNCT	O	O

Retinoids	NOUN	O	O
have	CCONJ	O	O
shown	VERB	O	O
a	DET	O	O
potential	ADJ	O	O
activity	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
tumor	NOUN	O	O
recurrence	NOUN	O	O
in	ADP	O	O
superficial	ADJ	O	O
bladder	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
assessed	VERB	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
synthetic	ADJ	O	O
retinoid	NOUN	O	O
fenretinide	ADP	O	O
in	ADP	O	O
superficial	ADJ	O	O
bladder	NOUN	O	O
cancer	NOUN	O	O
using	VERB	O	O
DNA	NOUN	O	O
flow	NOUN	O	O
cytometry	NOUN	O	O
and	CCONJ	O	O
conventional	ADJ	O	O
cytology	NOUN	O	O
as	ADP	O	O
surrogate	ADJ	O	O
biomarkers	CCONJ	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
99	NUM	O	O
subjects	NOUN	O	O
with	ADP	O	O
resected	ADP	O	O
superficial	ADJ	O	O
bladder	NOUN	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
pTa	NOUN	O	O
,	PUNCT	O	O
pT1	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
fenretinide	NOUN	O	O
(	PUNCT	O	O
200	NUM	O	O
mg	NOUN	O	O
day	NOUN	O	O
p.o	ADV	O	O
.	PUNCT	O	O

for	ADP	O	O
24	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
no	DET	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

Cystoscopy	NOUN	O	O
and	CCONJ	O	O
bladder	NOUN	O	O
washing	CCONJ	O	O
for	ADP	O	O
DNA	NOUN	O	O
flow	NOUN	O	O
cytometry	NOUN	O	O
end	NOUN	O	O
points	NOUN	O	O
(	PUNCT	O	O
proportion	NOUN	O	O
of	ADP	O	O
DNA	NOUN	O	O
aneuploid	NOUN	O	O
histograms	NOUN	O	O
,	PUNCT	O	O
hyperdiploid	PUNCT	O	O
fraction	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
percentage	NOUN	O	O
of	ADP	O	O
apoptotic	ADJ	O	O
cells	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
proportion	NOUN	O	O
of	ADP	O	O
abnormal	ADJ	O	B-PHYSICAL
cytological	ADJ	O	I-PHYSICAL
examinations	NOUN	O	I-PHYSICAL
were	ADV	O	O
repeated	VERB	O	O
every	DET	O	O
4	NUM	O	O
months	NOUN	O	O
for	ADP	O	O
up	PUNCT	O	O
to	ADV	O	O
36	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
study	NOUN	O	O
end	NOUN	O	O
point	NOUN	O	O
was	VERB	O	O
the	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
DNA	NOUN	O	B-PHYSICAL
aneuploid	NOUN	O	I-PHYSICAL
histograms	NOUN	O	I-PHYSICAL
after	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
figure	NOUN	O	O
was	ADP	O	O
48.9	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
fenretinide	NOUN	O	O
arm	NOUN	O	O
and	CCONJ	O	O
41.9	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
arm	NOUN	O	O
(	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
1.16	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.44-3.07	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
any	DET	O	O
other	ADJ	O	O
response	NOUN	O	O
biomarker	NOUN	O	B-PHYSICAL
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
up	PUNCT	O	O
to	ADP	O	O
36	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
nor	CCONJ	O	O
was	VERB	O	O
any	DET	O	O
biomarker	NOUN	O	O
able	ADJ	O	O
to	PART	O	O
predict	NOUN	O	O
recurrence	NOUN	O	O
risk	NOUN	O	O
.	PUNCT	O	O

Recurrence-free	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
comparable	ADJ	O	O
between	ADP	O	O
the	DET	O	O
arms	NOUN	O	O
(	PUNCT	O	O
27	NUM	O	O
events	NOUN	O	O
in	ADP	O	O
the	DET	O	O
fenretinide	NOUN	O	O
arm	NOUN	O	O
versus	CCONJ	O	O
21	NUM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
arm	ADP	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.36	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Twelve	PUNCT	O	O
subjects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
fenretinide	NOUN	O	O
arm	NOUN	O	O
complained	PUNCT	O	O
of	ADP	O	O
diminished	VERB	O	O
dark	ADJ	O	B-ADVERSE-EFFECTS
adaptability	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
and	CCONJ	O	O
nine	NUM	O	O
subjects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
fenretinide	NOUN	O	O
arm	NOUN	O	O
versus	CCONJ	O	O
one	NUM	O	O
control	NUM	O	O
subject	NOUN	O	O
had	PUNCT	O	O
mild	ADJ	O	B-PHYSICAL
dermatological	ADJ	O	I-PHYSICAL
alterations	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
fenretinide	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
DNA	NOUN	O	O
content	NOUN	O	B-PHYSICAL
distribution	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
morphology	NOUN	O	O
of	ADP	O	O
urothelial	ADJ	O	B-PHYSICAL
cells	NOUN	O	I-PHYSICAL
obtained	VERB	O	O
in	ADP	O	O
serial	ADJ	O	O
bladder	NOUN	O	O
washings	NOUN	O	O
.	PUNCT	O	O

Recurrence-free	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
comparable	ADJ	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Because	PUNCT	O	O
our	ADP	O	O
data	NOUN	O	O
are	VERB	O	O
hampered	VERB	O	O
by	ADP	O	O
the	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
predictivity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
selected	VERB	O	O
biomarkers	CCONJ	O	O
,	PUNCT	O	O
additional	ADJ	O	O
studies	NOUN	O	O
are	VERB	O	O
necessary	ADJ	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
activity	NOUN	O	O
of	ADP	O	O
fenretinide	NOUN	O	O
in	ADP	O	O
preventing	VERB	O	O
bladder	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Lack	NOUN	O	O
of	ADP	O	O
effect	NOUN	O	O
of	ADP	O	O
food	NOUN	O	O
on	ADP	O	O
the	DET	O	O
steady	ADJ	O	B-OTHER
state	NOUN	O	I-OTHER
pharmacokinetics	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
BMS-181101	NOUN	O	I-OTHER
,	PUNCT	O	O
an	DET	O	O
antidepressant	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	B-OTHER
food	NOUN	O	I-OTHER
on	ADP	O	I-OTHER
the	DET	O	I-OTHER
pharmacokinetics	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
BMS-181101	NOUN	O	B-OTHER
,	PUNCT	O	O
a	DET	O	O
new	ADJ	O	O
anti-depressant	ADJ	O	O
under	ADP	O	O
development	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
12	NUM	O	O
healthy	ADJ	O	O
male	NOUN	O	O
volunteers	NOUN	O	O
at	ADP	O	O
steady	ADJ	O	O
state	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
subject	NOUN	O	O
received	VERB	O	O
a	DET	O	O
15	NUM	O	O
mg	NOUN	O	O
oral	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
BMS-181101	NOUN	O	O
twice	ADV	O	O
a	DET	O	O
day	NOUN	O	O
(	PUNCT	O	O
q	NOUN	O	O
12	NUM	O	O
h	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
11	NUM	O	O
days	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
morning	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
BMS-181101	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
12	NUM	O	O
.	PUNCT	O	O

Six	NUM	O	O
subjects	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
BMS-181101	NOUN	O	O
under	ADP	O	O
fasted	VERB	O	O
conditions	NOUN	O	O
from	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
to	ADP	O	O
6	NUM	O	O
and	CCONJ	O	O
then	ADV	O	O
crossed	VERB	O	O
over	PUNCT	O	O
to	PUNCT	O	O
fed	PUNCT	O	O
conditions	NOUN	O	O
from	ADP	O	O
days	NOUN	O	O
7	NUM	O	O
to	ADP	O	O
12	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
other	ADJ	O	O
six	NUM	O	O
subjects	NOUN	O	O
received	VERB	O	O
the	DET	O	O
reverse	ADJ	O	O
conditions	NOUN	O	O
,	PUNCT	O	O
fed	ADJ	O	O
for	ADP	O	O
days	NOUN	O	O
1-6	NUM	O	O
and	CCONJ	O	O
fasted	VERB	O	O
for	ADP	O	O
days	NOUN	O	O
7-12	NUM	O	O
.	PUNCT	O	O

Serial	ADJ	O	O
blood	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
up	CCONJ	O	O
to	ADP	O	O
12	NUM	O	O
h	NOUN	O	O
on	ADP	O	O
days	NOUN	O	O
6	NUM	O	O
and	CCONJ	O	O
12	NUM	O	O
following	VERB	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
morning	NOUN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
trough	PUNCT	O	O
blood	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
on	ADP	O	O
days	NOUN	O	O
4	NUM	O	O
,	PUNCT	O	O
5	NUM	O	O
,	PUNCT	O	O
10	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
11	NUM	O	O
prior	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
morning	NOUN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
analyzed	VERB	O	O
for	ADP	O	O
intact	ADJ	O	B-PHYSICAL
BMS-181101	NOUN	O	B-PHYSICAL
using	VERB	O	O
a	DET	O	O
validated	VERB	O	O
high-performance	NOUN	O	O
liquid	NOUN	O	O
chromatography	NOUN	O	O
method	NOUN	O	O
with	ADP	O	O
an	DET	O	O
electrochemical	ADJ	O	O
detector	NOUN	O	O
.	PUNCT	O	O

BMS-181101	NOUN	O	O
was	VERB	O	O
well	ADV	O	O
tolerated	PUNCT	O	B-OTHER
both	PUNCT	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
ingestion	NOUN	O	O
of	ADP	O	O
food	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
statistical	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Cmin	NOUN	O	B-OTHER
values	NOUN	O	I-OTHER
indicated	VERB	O	O
that	ADP	O	O
steady	ADJ	O	B-OTHER
state	NOUN	O	I-OTHER
of	ADP	O	O
BMS-181101	NOUN	O	O
was	VERB	O	O
achieved	VERB	O	O
by	ADP	O	O
the	DET	O	O
fourth	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
dosing	VERB	O	O
regardless	PUNCT	O	O
of	ADP	O	O
whether	ADP	O	O
the	DET	O	O
subject	NOUN	O	O
was	VERB	O	O
fasted	VERB	O	O
or	CCONJ	O	O
fed	DET	O	O
.	PUNCT	O	O

When	ADP	O	O
BMS-181101	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
with	ADP	O	O
food	NOUN	O	O
,	PUNCT	O	O
Cmax	NOUN	O	B-OTHER
was	VERB	O	B-OTHER
reduced	VERB	O	I-OTHER
by	ADP	O	O
about	VERB	O	O
25	NUM	O	O
%	PUNCT	O	O
and	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
controlled	DET	O	O
study	NOUN	O	O
of	ADP	O	O
parent-assisted	VERB	O	O
Children	NOUN	O	O
's	PUNCT	O	O
Friendship	NOUN	O	O
Training	PROPN	O	O
with	ADP	O	O
children	NOUN	O	O
having	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
evaluated	VERB	O	O
Children	ADP	O	O
's	PUNCT	O	O
Friendship	NOUN	O	O
Training	PROPN	O	O
(	PUNCT	O	O
CFT	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
manualized	VERB	O	O
parent-assisted	VERB	O	O
intervention	NOUN	O	O
to	PART	O	O
improve	VERB	O	O
social	ADJ	O	O
skills	NOUN	O	O
among	ADP	O	O
second	ADJ	O	O
to	PUNCT	O	O
fifth	ADJ	O	O
grade	NOUN	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
was	VERB	O	O
made	VERB	O	O
with	ADP	O	O
a	DET	O	O
delayed	VERB	O	O
treatment	NOUN	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
DTC	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Targeted	VERB	O	O
skills	NOUN	O	O
included	ADP	O	O
conversational	ADJ	O	B-MENTAL
skills	NOUN	O	I-MENTAL
,	PUNCT	O	O
peer	NOUN	O	B-MENTAL
entry	NOUN	O	I-MENTAL
skills	NOUN	O	I-MENTAL
,	PUNCT	O	O
developing	ADP	O	O
friendship	NOUN	O	B-MENTAL
networks	NOUN	O	O
,	PUNCT	O	O
good	ADJ	O	B-MENTAL
sportsmanship	NOUN	O	I-MENTAL
,	PUNCT	O	O
good	ADJ	O	B-MENTAL
host	NOUN	O	I-MENTAL
behavior	NOUN	O	I-MENTAL
during	ADP	O	I-MENTAL
play	VERB	O	I-MENTAL
dates	PUNCT	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
handling	ADP	O	B-MENTAL
teasing	PUNCT	O	I-MENTAL
.	PUNCT	O	O

At	ADP	O	O
post-testing	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
CFT	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
the	DET	O	O
DTC	NOUN	O	O
group	NOUN	O	O
on	ADP	O	O
parent	NOUN	O	O
measures	NOUN	O	O
of	ADP	O	O
social	ADJ	O	B-MENTAL
skill	NOUN	O	I-MENTAL
and	CCONJ	O	O
play	ADJ	O	B-MENTAL
date	NOUN	O	I-MENTAL
behavior	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
child	NOUN	O	O
measures	NOUN	O	O
of	ADP	O	O
popularity	NOUN	O	B-MENTAL
and	CCONJ	O	O
loneliness	NOUN	O	B-MENTAL
,	PUNCT	O	O
At	ADP	O	O
3-month	NOUN	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
parent	NOUN	O	O
measures	NOUN	O	O
showed	VERB	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

Post-hoc	PUNCT	O	O
analysis	NOUN	O	O
indicated	VERB	O	O
more	ADP	O	O
than	ADP	O	O
87	NUM	O	O
%	SYM	O	O
of	ADP	O	O
children	NOUN	O	O
receiving	VERB	O	O
CFT	NOUN	O	O
showed	VERB	O	O
reliable	ADJ	O	O
change	NOUN	O	O
on	ADP	O	O
at	ADP	O	O
least	ADV	O	O
one	NUM	O	O
measure	VERB	O	O
at	ADP	O	O
post-test	ADV	O	O
and	CCONJ	O	O
66.7	NUM	O	O
%	SYM	O	O
after	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

1999	NUM	O	O
WHO/ISH	NUM	O	O
Guidelines	PROPN	O	O
applied	VERB	O	O
to	ADP	O	O
a	PUNCT	O	O
1999	NUM	O	O
MONICA	ADJ	O	O
sample	NOUN	O	O
from	ADP	O	O
northern	ADJ	O	O
Sweden	NUM	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Treating	PUNCT	O	O
hypertension	NOUN	O	O
with	ADP	O	O
drugs	NOUN	O	O
is	VERB	O	O
so	ADP	O	O
far	ADP	O	O
the	DET	O	O
most	PUNCT	O	O
cost-effective	ADJ	O	O
way	NOUN	O	O
to	PROPN	O	O
reduce	VERB	O	O
this	DET	O	O
important	ADJ	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
cardiovascular	ADJ	O	O
disease	NOUN	O	O
(	PUNCT	O	O
CVD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
important	ADJ	O	O
to	PART	O	O
determine	ADJ	O	O
absolute	ADJ	O	O
risk	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
thereby	ADP	O	O
estimate	ADV	O	O
indication	NOUN	O	O
for	ADP	O	O
drug	NOUN	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
order	NOUN	O	O
to	PART	O	O
maintain	ADV	O	O
a	DET	O	O
cost-effective	ADJ	O	O
drug	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

WHO/ISH	NUM	O	O
Hypertension	NOUN	O	O
Guidelines	PROPN	O	O
from	ADP	O	O
1999	NUM	O	O
propose	ADJ	O	O
a	DET	O	O
risk	NOUN	O	O
stratification	NOUN	O	O
for	ADP	O	O
estimating	VERB	O	O
absolute	ADJ	O	O
risk	NOUN	O	O
for	ADP	O	O
CVD	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
additional	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
,	PUNCT	O	O
target	ADP	O	O
organ	NOUN	O	O
damage	VERB	O	O
(	PUNCT	O	O
TOD	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
CVD	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
We	PRON	O	O
studied	VERB	O	O
the	DET	O	O
consequences	NOUN	O	O
of	ADP	O	O
applying	VERB	O	O
the	DET	O	O
recent	ADJ	O	O
WHO/ISH	CCONJ	O	O
risk	NOUN	O	O
stratification	NOUN	O	O
scheme	ADJ	O	O
to	ADP	O	O
a	DET	O	O
MONICA	ADJ	O	O
sample	NOUN	O	O
of	ADP	O	O
6000	NUM	O	O
subjects	NOUN	O	O
from	ADP	O	O
a	DET	O	O
geographically	ADV	O	O
defined	VERB	O	O
population	NOUN	O	O
in	ADP	O	O
northern	ADJ	O	O
Sweden	PUNCT	O	O
,	PUNCT	O	O
regarding	VERB	O	O
indications	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
target	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
and	CCONJ	O	O
risk	NOUN	O	O
distribution	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
have	PUNCT	O	O
risk-classified	PROPN	O	O
each	DET	O	O
of	ADP	O	O
these	DET	O	O
patients	NOUN	O	O
using	VERB	O	O
a	DET	O	O
computer	NOUN	O	O
program	NOUN	O	O
,	PUNCT	O	O
according	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
WHO/ISH	PUNCT	O	O
scheme	NOUN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
on	ADP	O	O
TOD	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
available	ADJ	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
all	PUNCT	O	O
,	PUNCT	O	O
917	NUM	O	O
(	PUNCT	O	O
15	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
drug-treated	VERB	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

Three-quarters	ADJ	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
737	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
inadequately	ADV	O	O
treated	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
at	ADP	O	O
or	CCONJ	O	O
above	ADP	O	O
140	NUM	O	O
or	CCONJ	O	O
90	NUM	O	O
mmHg	NOUN	O	O
.	PUNCT	O	O

1773	NUM	O	O
(	PUNCT	O	O
30	NUM	O	O
%	SYM	O	O
of	ADP	O	O
5997	NUM	O	O
)	PUNCT	O	O
untreated	VERB	O	O
subjects	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
of	ADP	O	O
140/90	PUNCT	O	O
or	CCONJ	O	O
above	ADP	O	O
;	PUNCT	O	O
16	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
low-	ADJ	O	O
,	PUNCT	O	O
62	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
medium-	NOUN	O	O
,	PUNCT	O	O
8	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
high-	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
14	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
very-high-risk	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
corresponding	VERB	O	O
risk-group	NOUN	O	O
pattern	NOUN	O	O
for	ADP	O	O
the	DET	O	O
inadequately	ADV	O	O
treated	ADP	O	O
hypertensives	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
737	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
5.5	NUM	O	O
,	PUNCT	O	O
48.3	NUM	O	O
,	PUNCT	O	O
11.1	NUM	O	O
and	CCONJ	O	O
35.2	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

If	ADP	O	O
we	PRON	O	O
shifted	VERB	O	O
the	DET	O	O
target	NOUN	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
from	ADP	O	O
below	ADP	O	O
140/90	PUNCT	O	O
to	ADP	O	O
below	PUNCT	O	O
130/85	NOUN	O	O
for	ADP	O	O
drug-treated	ADJ	O	O
subjects	NOUN	O	O
under	ADP	O	O
60	NUM	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
278	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
inadequately	ADV	O	B-OTHER
treated	PUNCT	O	I-OTHER
subjects	NOUN	O	I-OTHER
increased	VERB	O	O
by	ADP	O	O
34	NUM	O	O
(	PUNCT	O	O
12.2	NUM	O	O
%	SYM	O	O
of	ADP	O	O
278	PUNCT	O	O
)	PUNCT	O	O
;	PUNCT	O	O
14	NUM	O	O
in	ADP	O	O
the	DET	O	O
low-risk	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
15	NUM	O	O
in	ADP	O	O
the	DET	O	O
medium-risk	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
only	ADV	O	O
five	NUM	O	O
in	ADP	O	O
the	DET	O	O
high-	NOUN	O	O
or	CCONJ	O	O
very-high-risk	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Only	ADJ	O	O
one-fifth	NOUN	O	O
of	ADP	O	O
the	DET	O	O
drug-treated	ADJ	O	O
hypertensives	NOUN	O	O
were	VERB	O	O
well	VERB	O	O
controlled	CCONJ	O	O
.	PUNCT	O	O

Moreover	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
newly	ADV	O	B-OTHER
detected	PUNCT	O	I-OTHER
blood	NOUN	O	I-OTHER
pressure	NOUN	O	I-OTHER
elevation	NOUN	O	I-OTHER
was	VERB	O	O
high	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
majority	NOUN	O	O
of	ADP	O	O
younger	PUNCT	O	O
subjects	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
had	PUNCT	O	O
low	ADJ	O	O
risk	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
in	ADP	O	O
those	PUNCT	O	O
aged	PROPN	O	O
45-54	NUM	O	O
this	PUNCT	O	O
had	PUNCT	O	O
already	ADV	O	O
risen	PROPN	O	O
to	ADP	O	O
a	DET	O	O
medium	ADJ	O	O
risk	NOUN	O	O
.	PUNCT	O	O

Changing	PROPN	O	O
the	DET	O	O
target	NOUN	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
to	ADP	O	O
below	PUNCT	O	O
130/85	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
subjects	NOUN	O	O
aged	VERB	O	O
below	ADP	O	O
60	NUM	O	O
,	PUNCT	O	O
as	PUNCT	O	O
recommended	VERB	O	O
by	ADP	O	O
WHO/ISH	ADV	O	O
,	PUNCT	O	O
affects	VERB	O	O
predominantly	ADV	O	O
low-	ADJ	O	O
and	CCONJ	O	O
medium-risk	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Effects	PROPN	O	O
of	ADP	O	O
small	ADJ	O	O
needle-knife	NOUN	O	O
comprehensive	ADJ	O	O
therapy	NOUN	O	O
on	ADP	O	O
pain	NOUN	O	O
and	CCONJ	O	O
lumbar	ADJ	O	O
flexion	NOUN	O	O
range	NOUN	O	O
in	ADP	O	O
the	DET	O	O
chronic	ADJ	O	O
nonspecific	ADJ	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
patient	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
observe	NOUN	O	O
therapeutic	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
small	ADJ	O	O
needle-knife	NOUN	O	O
comprehensive	ADJ	O	O
therapy	NOUN	O	O
on	ADP	O	O
pain	NOUN	O	B-PAIN
and	CCONJ	O	O
lumbar	ADJ	O	B-PHYSICAL
flexion	NOUN	O	I-PHYSICAL
range	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
chronic	ADJ	O	O
nonspecific	ADJ	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
patient	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Three	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
five	NUM	O	O
cases	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
a	DET	O	O
needle-knife	NOUN	O	O
group	NOUN	O	O
of	ADP	O	O
153	NUM	O	O
cases	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
physiotherapy	NOUN	O	O
group	NOUN	O	O
of	ADP	O	O
152	NUM	O	O
cases	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
needle-knife	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
small	ADJ	O	O
needle-knife	NOUN	O	O
releasing	DET	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
blocking	VERB	O	O
and	CCONJ	O	O
functional	ADJ	O	O
training	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
physiotherapy	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
ultra-short	ADJ	O	O
wave	NOUN	O	O
,	PUNCT	O	O
modulated	ADP	O	O
medium	ADJ	O	O
frequency	NOUN	O	O
current	NOUN	O	O
,	PUNCT	O	O
massage	NOUN	O	O
and	CCONJ	O	O
functional	ADJ	O	O
training	VERB	O	O
.	PUNCT	O	O

Pain	NOUN	O	B-PAIN
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
(	PUNCT	O	O
VAS	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
lumbar	ADJ	O	B-PHYSICAL
flexion	NOUN	O	I-PHYSICAL
range	NOUN	O	I-PHYSICAL
was	VERB	O	O
determined	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
pain	NOUN	O	B-PAIN
and	CCONJ	O	O
the	DET	O	O
lumbar	ADJ	O	B-PHYSICAL
flexion	NOUN	O	I-PHYSICAL
range	NOUN	O	I-PHYSICAL
were	VERB	O	O
significantly	ADV	O	O
improved	VERB	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
VAS	NOUN	O	O
score	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
lumbar	ADJ	O	B-PHYSICAL
flexion	NOUN	O	I-PHYSICAL
range	NOUN	O	I-PHYSICAL
were	VERB	O	O
(	PUNCT	O	O
1.60	NUM	O	O
+/-	SYM	O	O
0.38	NUM	O	O
)	PUNCT	O	O
points	DET	O	O
and	CCONJ	O	O
(	PUNCT	O	O
65.76	NUM	O	O
+/-	SYM	O	O
15.11	NUM	O	O
)	PUNCT	O	O
cm	NOUN	O	O
in	ADP	O	O
the	DET	O	O
needle-knife	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
(	PUNCT	O	O
4.59	NUM	O	O
+/-	SYM	O	O
1.09	NUM	O	O
)	PUNCT	O	O
points	DET	O	O
and	CCONJ	O	O
(	PUNCT	O	O
53.74	ADP	O	O
+/-	SYM	O	O
15.13	NUM	O	O
)	PUNCT	O	O
cm	NOUN	O	O
in	ADP	O	O
the	DET	O	O
physiotherapy	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
needle-knife	NOUN	O	O
group	NOUN	O	O
being	VERB	O	O
significantly	ADV	O	O
better	PUNCT	O	O
than	VERB	O	O
the	DET	O	O
physiotherapy	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Follow-up	NOUN	O	O
survey	NOUN	O	O
of	ADP	O	O
6-36	NUM	O	O
months	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
the	DET	O	O
VAS	NOUN	O	O
score	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
lumbar	ADJ	O	B-PHYSICAL
flexion	NOUN	O	I-PHYSICAL
range	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
needle-knife	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
superior	ADJ	O	O
to	ADP	O	O
those	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
physiotherapy	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Small	ADJ	O	O
needle-knife	NOUN	O	O
comprehensive	ADJ	O	O
therapy	NOUN	O	O
can	VERB	O	O
significantly	ADV	O	O
improve	VERB	O	O
pain	NOUN	O	B-PAIN
and	CCONJ	O	O
lumbar	ADJ	O	B-PHYSICAL
flexion	NOUN	O	I-PHYSICAL
range	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
chronic	ADJ	O	O
nonspecific	ADJ	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
patient	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
stable	ADJ	O	O
long-term	NOUN	O	O
therapeutic	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Observer	PUNCT	O	O
variation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
assessment	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
outcome	NOUN	O	I-OTHER
in	ADP	O	O
traumatic	ADJ	O	O
brain	NOUN	O	O
injury	NOUN	O	O
:	PUNCT	O	O
experience	CCONJ	O	O
from	ADP	O	O
a	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
international	ADJ	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Accurate	ADJ	O	O
and	CCONJ	O	O
consistent	ADJ	O	O
outcome	NOUN	O	O
assessment	NOUN	O	B-OTHER
is	VERB	O	O
essential	ADJ	O	O
to	ADP	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trials	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
explore	NOUN	O	O
observer	PUNCT	O	O
variation	NOUN	O	O
in	ADP	O	O
the	DET	O	O
assessment	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
outcome	NOUN	O	I-OTHER
in	ADP	O	O
a	DET	O	O
recently	ADV	O	O
completed	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
dexanabinol	NOUN	O	O
in	ADP	O	O
head	NOUN	O	O
injury	NOUN	O	O
and	CCONJ	O	O
to	PART	O	O
consider	ADJ	O	O
steps	NOUN	O	O
to	PART	O	O
reduce	NOUN	O	O
such	DET	O	O
variation	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Eight	NUM	O	O
hundred	NUM	O	O
sixty-one	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
traumatic	ADJ	O	O
brain	NOUN	O	O
injury	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
admitted	VERB	O	O
to	ADP	O	O
86	NUM	O	O
centers	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
a	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
Phase	NOUN	O	O
III	NUM	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Outcome	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
at	ADP	O	O
3	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
postinjury	NOUN	O	O
using	VERB	O	O
the	DET	O	O
extended	PUNCT	O	B-PHYSICAL
Glasgow	PUNCT	O	I-PHYSICAL
Outcome	NOUN	O	O
Scale	NOUN	O	B-PHYSICAL
;	PUNCT	O	O
standardized	VERB	O	O
assessment	NOUN	O	O
was	VERB	O	O
facilitated	VERB	O	O
by	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
structured	VERB	O	O
interview	NOUN	O	O
.	PUNCT	O	O

Before	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
trial	NOUN	O	O
centers	NOUN	O	O
,	PUNCT	O	O
outcome	NOUN	O	O
ratings	NOUN	O	B-OTHER
were	VERB	O	O
obtained	VERB	O	O
for	ADP	O	O
sample	NOUN	O	O
cases	NOUN	O	O
to	PART	O	O
establish	ADJ	O	O
initial	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
agreement	NOUN	O	O
.	PUNCT	O	O

Training	VERB	O	O
sessions	NOUN	O	O
in	ADP	O	O
outcome	NOUN	O	O
assessment	NOUN	O	O
were	VERB	O	O
held	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
problems	NOUN	O	O
in	ADP	O	O
assigning	PUNCT	O	O
outcome	NOUN	O	O
were	VERB	O	O
investigated	VERB	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
process	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
review	NOUN	O	O
was	VERB	O	O
established	VERB	O	O
to	ADJ	O	O
monitor	NOUN	O	O
performance	NOUN	O	O
.	PUNCT	O	O

Interobserver	PUNCT	O	O
variation	NOUN	O	O
was	VERB	O	O
analyzed	VERB	O	O
using	VERB	O	O
the	DET	O	O
kappa	NOUN	O	O
statistic	ADJ	O	O
.	PUNCT	O	O

RESULTS	ADJ	O	O
Substantial	ADJ	O	B-OTHER
observer	PUNCT	O	B-OTHER
variation	NOUN	O	I-OTHER
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
the	DET	O	O
rating	PUNCT	O	O
of	ADP	O	O
sample	NOUN	O	O
cases	NOUN	O	O
(	PUNCT	O	O
weighted	VERB	O	O
kappa	NOUN	O	O
,	PUNCT	O	O
0.72	NUM	O	O
;	PUNCT	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.68-0.75	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
assigning	PUNCT	O	O
outcome	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
completed	VERB	O	O
structured	VERB	O	O
interviews	NOUN	O	O
(	PUNCT	O	O
weighted	VERB	O	O
kappa	NOUN	O	O
,	PUNCT	O	O
0.61	NUM	O	O
;	PUNCT	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.57-0.64	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
early	ADJ	O	O
stages	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
relatively	ADV	O	O
large	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
discrepancies	NOUN	O	B-OTHER
(	PUNCT	O	O
29-37	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
identified	VERB	O	O
on	ADP	O	O
central	ADJ	O	O
review	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
number	NOUN	O	O
declined	PUNCT	O	O
as	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
progressed	ADJ	O	O
and	CCONJ	O	O
coincided	VERB	O	O
with	ADP	O	O
investigator	NOUN	O	O
training	VERB	O	O
and	CCONJ	O	O
feedback	NOUN	O	O
from	ADP	O	O
central	ADJ	O	O
review	NOUN	O	O
.	PUNCT	O	O

Centers	NOUN	O	O
with	ADP	O	O
higher	PUNCT	O	O
enrollment	NOUN	O	O
rates	NOUN	O	O
showed	VERB	O	O
better	PUNCT	O	O
performance	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	PUNCT	O	O

Chemotherapy	NOUN	O	O
of	ADP	O	O
large	ADJ	O	O
bowel	NOUN	O	O
carcinoma	NOUN	O	O
--	PUNCT	O	O
fluorouracil	NOUN	O	O
(	PUNCT	O	O
FU	NOUN	O	O
)	PUNCT	O	O
+	SYM	O	O
hydroxyurea	NOUN	O	O
(	PUNCT	O	O
HU	NOUN	O	O
)	PUNCT	O	O
vs.	CCONJ	O	O
methyl-CCNU	NOUN	O	O
,	PUNCT	O	O
oncovin	NOUN	O	O
,	PUNCT	O	O
fluorouracil	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
streptozotocin	NOUN	O	O
(	PUNCT	O	O
MOF-Strep	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

An	DET	O	O
Eastern	NUM	O	O
Cooperative	NOUN	O	O
Oncology	NOUN	O	O
Group	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
study	NOUN	O	O
of	ADP	O	O
initial	ADJ	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
advanced	VERB	O	O
measurable	ADJ	O	O
metastatic	ADJ	O	O
large	ADJ	O	O
bowel	NOUN	O	O
carcinoma	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
response	NOUN	O	O
rate	NOUN	O	B-PHYSICAL
was	VERB	O	O
6/32	NOUN	O	O
(	PUNCT	O	O
19	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
for	ADP	O	O
FU	NOUN	O	O
+	SYM	O	O
HU	NOUN	O	O
and	CCONJ	O	O
5/32	NOUN	O	O
(	PUNCT	O	O
16	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
for	ADP	O	O
MOF-Strep	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
estimated	ADJ	O	O
median	ADJ	O	O
survival	NOUN	O	B-MORTALITY
is	VERB	O	O
43	NUM	O	O
weeks	NOUN	O	O
for	ADP	O	O
both	PUNCT	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	PROPN	O	O
received	VERB	O	O
MOF-Strep	NOUN	O	O
experienced	ADP	O	O
substantially	ADV	O	O
greater	PUNCT	O	O
vomiting	PUNCT	O	B-ADVERSE-EFFECTS
and	CCONJ	O	O
hematologic	ADJ	O	B-ADVERSE-EFFECTS
toxicity	NOUN	O	I-ADVERSE-EFFECTS
than	PUNCT	O	O
patients	NOUN	O	O
who	PROPN	O	O
received	VERB	O	O
FU	NOUN	O	O
+	SYM	O	O
HU	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
H	NOUN	O	O
reflex	NOUN	O	O
and	CCONJ	O	O
V	NUM	O	O
wave	CCONJ	O	O
following	VERB	O	O
short-term	NOUN	O	O
endurance	NOUN	O	O
and	CCONJ	O	O
strength	NOUN	O	O
training	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
wk	NOUN	O	O
of	ADP	O	O
either	PUNCT	O	O
endurance	NOUN	O	O
or	CCONJ	O	O
strength	NOUN	O	O
training	VERB	O	O
on	ADP	O	O
plasticity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
neural	ADJ	O	O
mechanisms	NOUN	O	O
involved	VERB	O	O
in	ADP	O	O
the	DET	O	O
soleus	PUNCT	O	O
H	NOUN	O	O
reflex	NOUN	O	O
and	CCONJ	O	O
V	NUM	O	O
wave	NOUN	O	O
.	PUNCT	O	O

Twenty-five	PUNCT	O	O
sedentary	ADJ	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
an	DET	O	O
endurance	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
13	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
strength	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
12	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Evoked	VERB	O	O
V-wave	PUNCT	O	O
,	PUNCT	O	O
H-reflex	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
M-wave	NOUN	O	O
recruitment	NOUN	O	O
curves	NOUN	O	O
,	PUNCT	O	O
maximal	ADJ	O	O
voluntary	PUNCT	O	O
contraction	NOUN	O	O
(	PUNCT	O	O
MVC	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
time-to-task-failure	NOUN	O	O
(	PUNCT	O	O
isometric	ADJ	O	O
contraction	NOUN	O	O
at	ADP	O	O
40	NUM	O	O
%	SYM	O	O
MVC	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
plantar	NOUN	O	O
flexors	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
training	VERB	O	O
.	PUNCT	O	O

Following	ADP	O	O
strength	NOUN	O	O
training	VERB	O	O
,	PUNCT	O	O
MVC	NOUN	O	O
of	ADP	O	O
the	DET	O	O
plantar	NOUN	O	B-PHYSICAL
flexors	PUNCT	O	I-PHYSICAL
increased	VERB	O	O
by	ADP	O	O
14.4	NUM	O	O
?	PUNCT	O	O

5.2	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
strength	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
time-to-task-failure	NOUN	O	O
was	VERB	O	O
prolonged	VERB	O	O
in	ADP	O	O
the	DET	O	O
endurance	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
22.7	NUM	O	O
?	PUNCT	O	O

17.1	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
V	NOUN	O	B-PHYSICAL
wave-to-maximal	ADJ	O	I-PHYSICAL
M	NOUN	O	I-PHYSICAL
wave	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
V/M	NUM	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
max	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
ratio	NOUN	O	I-PHYSICAL
increased	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
55.1	NUM	O	O
?	PUNCT	O	O

28.3	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
following	VERB	O	O
strength	NOUN	O	O
training	VERB	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
maximal	ADJ	O	O
H	NOUN	O	B-PHYSICAL
wave-to-maximal	ADJ	O	I-PHYSICAL
M	NOUN	O	I-PHYSICAL
wave	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
H	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
max	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
/M	PUNCT	O	B-PHYSICAL
(	PUNCT	O	O
max	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
)	PUNCT	O	O
ratio	NOUN	O	B-PHYSICAL
remained	VERB	O	O
unchanged	VERB	O	O
.	PUNCT	O	O

Conversely	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
endurance	NOUN	O	O
group	NOUN	O	O
the	DET	O	O
V/M	NUM	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
max	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
ratio	NOUN	O	I-PHYSICAL
was	VERB	O	O
not	ADV	O	O
altered	VERB	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	PUNCT	O	O

Hydrogen	NOUN	O	O
peroxide	NOUN	O	O
mouth	NOUN	O	O
rinse	NOUN	O	O
:	PUNCT	O	O
an	DET	O	O
analgesic	ADP	O	O
post-tonsillectomy	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
analgesic	ADP	O	B-OTHER
efficacy	NOUN	O	I-OTHER
of	ADP	O	O
hydrogen	NOUN	O	O
peroxide	NOUN	O	O
(	PUNCT	O	O
H2O2	NOUN	O	O
)	PUNCT	O	O
mouth	NOUN	O	O
rinse	NOUN	O	O
with	ADP	O	O
control	NOUN	O	O
for	ADP	O	O
post-tonsillectomy	NOUN	O	B-PAIN
pain	NOUN	O	I-PAIN
management	NOUN	O	I-PAIN
.	PUNCT	O	O

DESIGN	NOUN	O	O
Double-blinded	PUNCT	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Thirty-seven	PUNCT	O	O
patients	NOUN	O	O
from	ADP	O	O
5	NUM	O	O
to	ADP	O	O
14	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
undergoing	CCONJ	O	O
electrocautery	NOUN	O	O
tonsillectomy	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
H2O2	NOUN	O	O
mouth	NOUN	O	O
rinse	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
water	NOUN	O	O
rinse	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
14	DET	O	O
days	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
recorded	CCONJ	O	O
pain	NOUN	O	O
levels	NOUN	O	O
twice	ADV	O	O
daily	ADJ	O	O
using	ADP	O	O
a	DET	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
.	PUNCT	O	O

Analgesic	ADJ	O	O
uses	ADJ	O	O
,	PUNCT	O	O
as	CCONJ	O	O
well	PUNCT	O	O
as	CCONJ	O	O
any	DET	O	O
complications	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
also	ADV	O	O
noted	VERB	O	O
by	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Thirty-seven	PUNCT	O	O
patients	NOUN	O	O
completed	NOUN	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
21	NUM	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
16	NUM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Mean	PUNCT	O	O
postoperative	ADJ	O	B-PAIN
days	NOUN	O	I-PAIN
of	ADP	O	I-PAIN
pain	NOUN	O	I-PAIN
were	VERB	O	O
10.3	NUM	O	O
and	CCONJ	O	O
8.3	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
differed	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.008	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mean	PUNCT	O	O
postoperative	ADJ	O	B-OTHER
days	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
analgesic	PUNCT	O	I-OTHER
use	NOUN	O	O
were	VERB	O	O
9.0	NUM	O	O
and	CCONJ	O	O
6.7	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
differed	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.005	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Only	ADV	O	O
one	NUM	O	O
incidence	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-ADVERSE-EFFECTS
hemorrhage	NOUN	O	I-ADVERSE-EFFECTS
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
In	ADP	O	O
our	PUNCT	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
H2O2	NOUN	O	O
mouth	NOUN	O	O
rinse	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
provide	VERB	O	O
a	DET	O	O
better	PUNCT	O	O
analgesic	ADP	O	B-OTHER
effect	ADJ	O	O
than	ADP	O	O
the	DET	O	O
water	NOUN	O	O
rinse	NOUN	O	O
for	ADP	O	O
post-tonsillectomy	NOUN	O	B-PAIN
pain	NOUN	O	I-PAIN
relief	NOUN	O	I-PAIN
.	PUNCT	O	O

Pilot	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
Panax	NOUN	O	O
quinquefolius	NOUN	O	O
(	PUNCT	O	O
American	ADJ	O	O
ginseng	PUNCT	O	O
)	PUNCT	O	O
to	PART	O	O
improve	NOUN	O	O
cancer-related	VERB	O	O
fatigue	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
dose-finding	ADJ	O	O
evaluation	NOUN	O	O
:	PUNCT	O	O
NCCTG	NUM	O	O
trial	NOUN	O	O
N03CA	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
This	PUNCT	O	O
pilot	NOUN	O	O
trial	NOUN	O	O
sought	NOUN	O	O
to	PART	O	O
investigate	NOUN	O	O
whether	ADP	O	O
any	PUNCT	O	O
of	ADP	O	O
three	NUM	O	O
doses	NOUN	O	O
of	ADP	O	O
American	ADJ	O	O
ginseng	PUNCT	O	O
(	PUNCT	O	O
Panax	NOUN	O	O
quinquefolius	NOUN	O	O
)	PUNCT	O	O
might	VERB	O	O
help	VERB	O	O
cancer-related	VERB	O	O
fatigue	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
secondary	ADJ	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
toxicity	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Eligible	ADJ	O	O
adults	NOUN	O	O
with	ADP	O	O
cancer	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
manner	NOUN	O	O
,	PUNCT	O	O
to	PUNCT	O	O
receive	NOUN	O	O
American	ADJ	O	O
ginseng	PUNCT	O	O
in	ADP	O	O
doses	NOUN	O	O
of	ADP	O	O
750	NUM	O	O
,	PUNCT	O	O
1,000	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
2,000	NUM	O	O
mg/day	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
given	VERB	O	O
in	ADP	O	O
twice	PUNCT	O	O
daily	ADJ	O	O
dosing	ADP	O	O
over	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Outcome	NOUN	O	O
measures	NOUN	O	O
included	VERB	O	O
the	DET	O	O
Brief	ADP	O	B-PHYSICAL
Fatigue	NOUN	O	I-PHYSICAL
Inventory	ADJ	O	I-PHYSICAL
,	PUNCT	O	O
vitality	NOUN	O	O
subscale	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Medical	ADJ	O	O
Outcome	NOUN	O	O
Scale	NOUN	O	O
Short	ADJ	O	O
Form-36	PUNCT	O	O
(	PUNCT	O	O
SF-36	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
Global	ADJ	O	B-PHYSICAL
Impression	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
Benefit	PUNCT	O	I-PHYSICAL
Scale	NOUN	O	O
at	ADP	O	O
4	NUM	O	O
and	CCONJ	O	O
8	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Two	NUM	O	O
hundred	NUM	O	O
ninety	NOUN	O	O
patients	NOUN	O	O
were	VERB	O	O
accrued	PUNCT	O	O
to	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Nonsignificant	ADJ	O	O
trends	NOUN	O	O
for	ADP	O	O
all	DET	O	O
outcomes	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
favor	NOUN	O	O
of	ADP	O	O
the	DET	O	O
1,000-	PUNCT	O	O
and	CCONJ	O	O
2,000-mg/day	NOUN	O	O
doses	NOUN	O	O
of	ADP	O	O
American	ADJ	O	O
ginseng	PUNCT	O	O
.	PUNCT	O	O

Area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
curve	NOUN	O	O
analysis	NOUN	O	O
of	ADP	O	O
activity	NOUN	O	O
interference	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Brief	ADP	O	B-PHYSICAL
Fatigue	NOUN	O	I-PHYSICAL
Inventory	ADJ	O	I-PHYSICAL
was	VERB	O	O
460-467	NUM	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
750	NUM	O	O
mg/day	NOUN	O	O
group	NOUN	O	O
versus	CCONJ	O	O
480-551	NUM	O	O
in	ADP	O	O
the	DET	O	O
1,000-	PUNCT	O	O
and	CCONJ	O	O
2,000-mg/day	NOUN	O	O
arms	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Change	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
the	DET	O	O
vitality	NOUN	O	B-PHYSICAL
subscale	NOUN	O	I-PHYSICAL
of	ADP	O	O
the	DET	O	O
SF-36	NOUN	O	O
was	VERB	O	O
7.3-7.8	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
750-mg/day	PUNCT	O	O
arm	NOUN	O	O
,	PUNCT	O	O
versus	CCONJ	O	O
10.5-14.6	NUM	O	O
in	ADP	O	O
the	DET	O	O
1,000-	PUNCT	O	O
and	CCONJ	O	O
2,000-mg/day	NOUN	O	O
arms	NOUN	O	O
.	PUNCT	O	O

Over	PUNCT	O	O
twice	VERB	O	O
as	CCONJ	O	O
many	DET	O	O
patients	NOUN	O	O
on	ADP	O	O
ginseng	PUNCT	O	O
perceived	VERB	O	O
a	DET	O	O
benefit	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
satisfied	VERB	O	B-OTHER
with	ADP	O	O
treatment	NOUN	O	O
over	ADP	O	O
those	PUNCT	O	O
on	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
any	DET	O	O
measured	PUNCT	O	O
toxicities	NOUN	O	B-ADVERSE-EFFECTS
between	ADP	O	O
any	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
arms	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
There	PUNCT	O	O
appears	NOUN	O	O
to	PART	O	O
be	CCONJ	O	O
some	DET	O	O
activity	NOUN	O	O
and	CCONJ	O	O
tolerable	ADJ	O	O
toxicity	NOUN	O	O
at	ADP	O	O
1,000-2,000	NUM	O	O
mg/day	NOUN	O	O
doses	NOUN	O	O
of	ADP	O	O
American	ADJ	O	O
ginseng	PUNCT	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
cancer-related	VERB	O	O
fatigue	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
further	DET	O	O
study	NOUN	O	O
of	ADP	O	O
American	ADJ	O	O
ginseng	PUNCT	O	O
is	PUNCT	O	O
warranted	VERB	O	O
.	PUNCT	O	O

Psychosocial	ADJ	O	O
nursing	DET	O	O
therapy	NOUN	O	O
following	PUNCT	O	O
sudden	ADJ	O	O
cardiac	ADJ	O	O
arrest	NOUN	O	O
:	PUNCT	O	O
impact	NOUN	O	O
on	ADP	O	O
two-year	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Although	ADP	O	O
psychosocial	ADJ	O	O
therapy	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
reduce	NOUN	O	O
mortality	NOUN	O	B-MORTALITY
after	ADP	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
,	PUNCT	O	O
it	PUNCT	O	O
is	VERB	O	O
unknown	VERB	O	O
whether	ADP	O	O
the	DET	O	O
benefits	NOUN	O	O
of	ADP	O	O
psychosocial	ADJ	O	O
therapy	NOUN	O	O
on	ADP	O	O
mortality	NOUN	O	O
reduction	NOUN	O	O
extend	ADJ	O	O
to	ADP	O	O
out-of-hospital	PUNCT	O	O
sudden	ADJ	O	O
cardiac	ADJ	O	O
arrest	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
main	ADJ	O	O
cause	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-MORTALITY
mortality	NOUN	O	I-MORTALITY
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Describe	ADV	O	O
efficacy	NOUN	O	O
of	ADP	O	O
psychosocial	ADJ	O	O
therapy	NOUN	O	O
on	ADP	O	O
two-year	ADJ	O	O
cardiovascular	ADJ	O	B-MORTALITY
mortality	NOUN	O	I-MORTALITY
in	ADP	O	O
sudden	ADJ	O	O
cardiac	ADJ	O	O
arrest	ADV	O	O
survivors	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Survivors	NOUN	O	O
of	ADP	O	O
out-of-hospital	ADJ	O	O
ventricular	ADJ	O	O
fibrillation	NOUN	O	O
or	CCONJ	O	O
asystole	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
129	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
documented	VERB	O	O
by	ADP	O	O
electrocardiograms	NOUN	O	O
from	ADP	O	O
registries	ADJ	O	O
of	ADP	O	O
a	DET	O	O
citywide	NOUN	O	O
Medic	NOUN	O	O
One	NUM	O	O
unit	NOUN	O	O
and	CCONJ	O	O
two	NUM	O	O
countywide	NOUN	O	O
emergency	NOUN	O	O
units	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
a	DET	O	O
two	NUM	O	O
group	NOUN	O	O
,	PUNCT	O	O
experimental	ADJ	O	O
,	PUNCT	O	O
longitudinal	ADJ	O	O
design	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
intervention	NOUN	O	O
consisted	ADJ	O	O
of	ADP	O	O
11	NUM	O	O
individual	ADJ	O	O
sessions	NOUN	O	O
,	PUNCT	O	O
implementing	PUNCT	O	O
three	NUM	O	O
components	NOUN	O	O
:	PUNCT	O	O
physiologic	ADJ	O	O
relaxation	NOUN	O	O
with	ADP	O	O
biofeedback	NOUN	O	O
training	PUNCT	O	O
focused	VERB	O	O
on	ADP	O	O
altering	VERB	O	O
autonomic	ADJ	O	O
tone	NOUN	O	O
;	PUNCT	O	O
cognitive	ADJ	O	O
behavioral	ADJ	O	O
therapy	NOUN	O	O
aimed	VERB	O	O
at	ADP	O	O
self-management	ADJ	O	O
and	CCONJ	O	O
coping	PUNCT	O	O
strategies	NOUN	O	O
for	ADP	O	O
depression	NOUN	O	O
,	PUNCT	O	O
anxiety	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
anger	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
cardiovascular	ADJ	O	O
health	NOUN	O	O
education	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
measure	ADV	O	O
was	VERB	O	O
cardiovascular	ADJ	O	B-MORTALITY
mortality	NOUN	O	I-MORTALITY
.	PUNCT	O	O

RESULTS	NOUN	O	O
Risk	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-MORTALITY
death	NOUN	O	I-MORTALITY
was	VERB	O	O
significantly	ADV	O	O
reduced	ADP	O	O
86	NUM	O	O
%	SYM	O	O
by	ADP	O	O
psychosocial	ADJ	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.03	PUNCT	O	O
.	PUNCT	O	O

Six	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
seven	NUM	O	O
cardiovascular	ADJ	O	B-MORTALITY
deaths	NOUN	O	I-MORTALITY
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
caused	VERB	O	O
by	ADP	O	O
ventricular	ADJ	O	O
arrhythmias	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
cardiovascular	ADJ	O	B-MORTALITY
death	NOUN	O	I-MORTALITY
in	ADP	O	O
the	DET	O	O
therapy	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
due	CCONJ	O	O
to	ADP	O	O
stroke	NOUN	O	O
.	PUNCT	O	O

Controlling	ADJ	O	O
for	ADP	O	O
depression	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
previous	ADJ	O	B-PHYSICAL
myocardial	ADJ	O	I-PHYSICAL
infarction	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
low	ADJ	O	B-PHYSICAL
ejection	NOUN	O	I-PHYSICAL
fraction	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
decreased	VERB	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
variability	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
ventricular	ADJ	O	B-PHYSICAL
ectopic	ADJ	O	I-PHYSICAL
beats	NOUN	O	I-PHYSICAL
had	PUNCT	O	O
little	DET	O	O
impact	NOUN	O	O
on	ADP	O	O
estimated	VERB	O	O
treatment	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
all-cause	NOUN	O	B-MORTALITY
mortality	NOUN	O	I-MORTALITY
was	VERB	O	O
reduced	VERB	O	O
by	ADP	O	O
62	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
therapy	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.13	NUM	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
deaths	NOUN	O	B-MORTALITY
in	ADP	O	O
the	DET	O	O
therapy	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
eight	NUM	O	O
deaths	NOUN	O	B-MORTALITY
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Psychosocial	PUNCT	O	O
therapy	NOUN	O	O
significantly	ADV	O	O
reduced	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	B-MORTALITY
death	NOUN	O	I-MORTALITY
in	ADP	O	O
sudden	ADJ	O	O
cardiac	ADJ	O	O
arrest	ADV	O	O
survivors	NOUN	O	O
.	PUNCT	O	O

Relation	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
homocysteine	PUNCT	O	O
and	CCONJ	O	O
lipid	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
to	ADP	O	O
premature	ADJ	O	O
cardiovascular	ADJ	O	O
death	NOUN	O	O
in	ADP	O	O
male	NOUN	O	O
relatives	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
assessed	VERB	O	O
the	DET	O	O
relative	ADJ	O	B-OTHER
importance	NOUN	O	I-OTHER
of	ADP	O	O
lipid	NOUN	O	B-PHYSICAL
,	PUNCT	O	I-PHYSICAL
apo	NOUN	O	I-PHYSICAL
B	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
lipoprotein	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
a	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
[	PUNCT	O	I-PHYSICAL
Lp	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
a	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
]	PUNCT	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
total	ADJ	O	O
homocysteine	ADJ	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
tHcy	PUNCT	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
levels	NOUN	O	B-PHYSICAL
in	ADP	O	O
children	NOUN	O	O
in	ADP	O	O
relation	NOUN	O	O
to	ADP	O	O
premature	ADJ	O	O
cardiovascular	ADJ	O	O
disease	NOUN	O	O
in	ADP	O	O
family	NOUN	O	O
members	NOUN	O	O
.	PUNCT	O	O

Parents	NOUN	O	O
of	ADP	O	O
381	NUM	O	O
girls	NOUN	O	O
and	CCONJ	O	O
375	NUM	O	O
boys	NOUN	O	O
age	NOUN	O	O
8-12	NUM	O	O
y	NUM	O	O
completed	VERB	O	O
family	NOUN	O	O
history	NOUN	O	O
questionnaires	NOUN	O	O
.	PUNCT	O	O

Nonfasting	ADJ	O	B-PHYSICAL
serum	NOUN	O	I-PHYSICAL
lipid	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
lipoproteins	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
plasma	NOUN	O	B-PHYSICAL
tHcy	PUNCT	O	I-PHYSICAL
and	PUNCT	O	I-PHYSICAL
cysteine	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
the	DET	O	O
children	NOUN	O	O
.	PUNCT	O	O

Serum	NOUN	O	B-PHYSICAL
folate	NOUN	O	I-PHYSICAL
and	CCONJ	O	B-PHYSICAL
vitamin	NOUN	O	B-PHYSICAL
B12	PUNCT	O	I-PHYSICAL

Motion	NOUN	O	O
style	NUM	O	O
acupuncture	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
MSAT	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
acute	ADJ	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
disability	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
protocol	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Acupuncture	ADP	O	O
is	VERB	O	O
widely-used	PUNCT	O	O
to	ADJ	O	O
treat	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
,	PUNCT	O	O
despite	ADP	O	O
insufficient	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
the	DET	O	O
technique	NOUN	O	O
's	PUNCT	O	O
efficacy	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
.	PUNCT	O	O

Motion	NOUN	O	O
style	NUM	O	O
acupuncture	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
MSAT	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
non-traditional	ADJ	O	O
acupuncture	ADP	O	O
treatment	NOUN	O	O
requiring	VERB	O	O
a	DET	O	O
patient	NOUN	O	O
to	ADP	O	O
exercise	NOUN	O	O
while	ADP	O	O
receiving	ADP	O	O
acupuncture	ADP	O	O
.	PUNCT	O	O

In	ADP	O	O
Korea	NOUN	O	O
,	PUNCT	O	O
MSAT	NOUN	O	O
is	VERB	O	O
used	VERB	O	O
to	PART	O	O
reduce	NOUN	O	O
musculoskeletal	ADJ	O	O
pain	NOUN	O	O
and	CCONJ	O	O
improve	VERB	O	O
functional	ADJ	O	O
status	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
aims	PART	O	O
to	PUNCT	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
MSAT	NOUN	O	O
on	ADP	O	O
acute	ADJ	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
with	ADP	O	O
severe	ADJ	O	O
disability	NOUN	O	O
.	PUNCT	O	O

METHODS/DESIGN	PUNCT	O	O
This	DET	O	O
study	NOUN	O	O
is	VERB	O	O
a	DET	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
active-controlled	VERB	O	O
trial	NOUN	O	O
with	ADP	O	O
two	NUM	O	O
parallel	ADJ	O	O
arms	NOUN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
and	CCONJ	O	O
severe	ADJ	O	O
functional	ADJ	O	O
disability	NOUN	O	O
,	PUNCT	O	O
defined	VERB	O	O
as	ADP	O	O
an	DET	O	O
Oswestry	NOUN	O	O
Disability	NOUN	O	O
Index	NOUN	O	O
(	PUNCT	O	O
ODI	NOUN	O	O
)	PUNCT	O	O
value	NOUN	O	O
>	SYM	O	O
60	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
will	VERB	O	O
be	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
the	DET	O	O
acupuncture	ADP	O	O
group	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
nonsteroidal	ADJ	O	O
anti-inflammatory	ADJ	O	O
drug	NOUN	O	O
(	PUNCT	O	O
NSAID	NOUN	O	O
)	PUNCT	O	O
injection	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
acupuncture	PUNCT	O	O
group	NOUN	O	O
will	VERB	O	O
receive	VERB	O	O
MSAT	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
NSAID	NOUN	O	O
injection	NOUN	O	O
group	NOUN	O	O
will	VERB	O	O
receive	VERB	O	O
an	DET	O	O
intramuscular	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
diclofenac	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
procedures	NOUN	O	O
will	CCONJ	O	O
be	VERB	O	O
limited	VERB	O	O
to	ADP	O	O
one	NUM	O	O
session	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
symptoms	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
assessors	NOUN	O	O
blinded	ADP	O	O
to	ADP	O	O
treatment	NOUN	O	O
allocation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
will	NOUN	O	O
be	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
using	VERB	O	O
the	DET	O	O
numerical	ADJ	O	O
rating	VERB	O	O
scale	NOUN	O	O
(	PUNCT	O	O
NRS	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
low	ADJ	O	O
back	ADP	O	O
pain	NOUN	O	O
while	ADP	O	O
the	DET	O	O
patient	NOUN	O	O
is	VERB	O	O
moving	PUNCT	O	O
.	PUNCT	O	O

Secondary	ADJ	O	O
outcomes	NOUN	O	O
will	VERB	O	O
be	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
30	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
treatment	NOUN	O	O
using	VERB	O	O
the	DET	O	O
NRS	NOUN	O	O
of	ADP	O	O
leg	NOUN	O	B-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
ODI	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
patient	NOUN	O	B-OTHER
global	ADJ	O	I-OTHER
impression	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
change	NOUN	O	I-OTHER
,	PUNCT	O	O
range	NOUN	O	O
of	ADP	O	B-PHYSICAL
motion	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
ROM	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
of	ADP	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
lumbar	ADJ	O	B-PHYSICAL
spine	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
degrees	PUNCT	O	O
of	ADP	O	O
straight	NOUN	O	B-PHYSICAL
leg	PUNCT	O	B-PHYSICAL

Short-term	NOUN	O	O
studies	NOUN	O	O
on	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
glycerol	NOUN	O	O
as	ADP	O	O
an	DET	O	O
osmotic	ADJ	O	O
agent	NOUN	O	O
in	ADP	O	O
continuous	ADJ	O	O
ambulatory	ADJ	O	O
peritoneal	ADJ	O	O
dialysis	NOUN	O	O
(	PUNCT	O	O
CAPD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
glycerol	NOUN	O	O
as	ADP	O	O
an	DET	O	O
osmotic	ADJ	O	O
agent	NOUN	O	O
in	ADP	O	O
two	NUM	O	O
different	ADJ	O	O
concentrations	NOUN	O	O
(	PUNCT	O	O
92	NUM	O	O
mmol/l	NOUN	O	O
and	CCONJ	O	O
272	NUM	O	O
mmol/l	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
peritoneal	ADJ	O	O
dialysis	NOUN	O	O
fluid	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
over	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
in	ADP	O	O
six	NUM	O	O
patients	NOUN	O	O
on	ADP	O	O
continuous	ADJ	O	O
ambulatory	ADJ	O	O
peritoneal	ADJ	O	O
dialysis	NOUN	O	O
and	CCONJ	O	O
compared	VERB	O	O
with	ADP	O	O
two	NUM	O	O
concentrations	NOUN	O	O
of	ADP	O	O
glucose	NOUN	O	O
(	PUNCT	O	O
76	NUM	O	O
mmol/l	NOUN	O	O
and	CCONJ	O	O
215	NUM	O	O
mmol/l	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
calorific	ADJ	O	B-PHYSICAL
value	NOUN	O	I-PHYSICAL
of	ADP	O	O
the	DET	O	O
absorbed	VERB	O	O
osmotic	ADJ	O	O
agent	NOUN	O	O
was	VERB	O	O
lower	PUNCT	O	O
,	PUNCT	O	O
by	ADP	O	O
19	NUM	O	O
%	SYM	O	O
with	ADP	O	O
isotonic	ADJ	O	O
and	CCONJ	O	O
22	NUM	O	O
%	SYM	O	O
with	ADP	O	O
hypertonic	ADJ	O	O
solutions	NOUN	O	O
,	PUNCT	O	O
when	ADP	O	O
glycerol	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
in	ADP	O	O
place	NOUN	O	O
of	ADP	O	O
glucose	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
glycerol	NOUN	O	O
provided	PROPN	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
total	ADJ	O	O
ultrafiltration	NOUN	O	B-PHYSICAL
than	PUNCT	O	O
glucose	NOUN	O	O
at	ADP	O	O
each	DET	O	O
concentration	NOUN	O	O
,	PUNCT	O	O
despite	ADP	O	O
a	DET	O	O
higher	PUNCT	O	O
initial	ADJ	O	O
osmotic	ADJ	O	O
pressure	NOUN	O	O
of	ADP	O	O
the	DET	O	O
glycerol-based	VERB	O	O
solutions	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
higher	PUNCT	O	O
concentration	NOUN	O	O
of	ADP	O	O
glycerol	NOUN	O	O
required	ADJ	O	O
to	PART	O	O
provide	NOUN	O	O
equal	ADJ	O	B-PHYSICAL
ultrafiltration	NOUN	O	I-PHYSICAL
may	VERB	O	O
offset	CCONJ	O	O
any	DET	O	O
calorific	ADJ	O	O
advantage	NOUN	O	O
.	PUNCT	O	O

Equilibration	NOUN	O	O
of	ADP	O	O
creatinine	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
urea	NOUN	O	B-PHYSICAL
was	VERB	O	O
slower	PUNCT	O	O
and	CCONJ	O	O
creatinine	NOUN	O	B-PHYSICAL
clearance	NOUN	O	I-PHYSICAL
lower	PUNCT	O	O
with	ADP	O	O
glycerol	NOUN	O	O
.	PUNCT	O	O

Solutions	NOUN	O	O
containing	CCONJ	O	O
glycerol	NOUN	O	O
were	VERB	O	O
initially	ADV	O	O
less	DET	O	O
acid	NOUN	O	O
(	PUNCT	O	O
pH	NOUN	O	O
6.5	NUM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
those	PUNCT	O	O
containing	ADJ	O	O
glucose	NOUN	O	O
(	PUNCT	O	O
pH	NOUN	O	O
5.1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Blood	NOUN	O	B-PHYSICAL
glycerol	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
which	ADP	O	O
were	VERB	O	O
in	ADP	O	O
the	DET	O	O
physiological	ADJ	O	O
range	NOUN	O	O
with	ADP	O	O
glucose	NOUN	O	O
as	ADP	O	O
the	DET	O	O
osmotic	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
reached	VERB	O	O
a	DET	O	O
peak	ADJ	O	O
80-fold	NOUN	O	O
greater	PUNCT	O	O
at	ADP	O	O
4.3	NUM	O	O
+/-	SYM	O	O
0.8	NUM	O	O
mmol/l	NOUN	O	O
during	ADP	O	O
dialysis	NOUN	O	O
with	ADP	O	O
fluid	NOUN	O	O
containing	DET	O	O
glycerol	NOUN	O	O
at	ADP	O	O
272	NUM	O	O
mmol/l	NOUN	O	O
and	CCONJ	O	O
eightfold	ADP	O	O
higher	PUNCT	O	O
at	ADP	O	O
0.42	NUM	O	O
+/-	SYM	O	O
0.09	NUM	O	O
mmol/l	NOUN	O	O
with	ADP	O	O
glycerol	NOUN	O	O
at	ADP	O	O
92	NUM	O	O
mmol/l	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
evidence	NOUN	O	O
of	ADP	O	O
haemolysis	NOUN	O	B-ADVERSE-EFFECTS
or	CCONJ	O	O
other	ADJ	O	O
toxic	ADJ	O	B-ADVERSE-EFFECTS
effect	NOUN	O	O
despite	ADP	O	O
these	DET	O	O
levels	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
rise	NOUN	O	O
in	ADP	O	O
blood	NOUN	O	O
glucose	NOUN	O	O
and	CCONJ	O	O
insulin	NOUN	O	O
noted	VERB	O	O
during	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
glucose-based	ADJ	O	O
solutions	NOUN	O	O
was	NUM	O	O
not	ADV	O	O
found	VERB	O	O
with	ADP	O	O
glycerol	NOUN	O	O
.	PUNCT	O	O

Circulating	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
lactate	NOUN	O	O
,	PUNCT	O	O
pyruvate	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
alanine	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
non-esterified	PUNCT	O	B-PHYSICAL
fatty	ADJ	O	I-PHYSICAL
acids	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
ketone	NOUN	O	O
bodies	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
with	ADP	O	O
the	DET	O	O
two	NUM	O	O
agents	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
these	DET	O	O
short-term	NOUN	O	O
studies	NOUN	O	O
have	CCONJ	O	O
shown	VERB	O	O
no	DET	O	O
conclusive	ADJ	O	O
advantage	NOUN	O	O
of	ADP	O	O
glycerol	NOUN	O	O
over	ADP	O	O
glucose	NOUN	O	O
,	PUNCT	O	O
long-term	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
glycerol	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
on	ADP	O	O
circulating	VERB	O	B-PHYSICAL
lipid	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
will	VERB	O	O
determine	VERB	O	O
its	ADP	O	O
future	ADJ	O	O
role	NOUN	O	O
as	ADP	O	O
an	DET	O	O
osmotic	ADJ	O	O
agent	NOUN	O	O
in	ADP	O	O
continuous	ADJ	O	O
ambulatory	ADJ	O	O
peritoneal	ADJ	O	O
dialysis	NOUN	O	O
.	PUNCT	O	O

Glibenclamide	ADV	O	O
vs	CCONJ	O	O
gliclazide	NOUN	O	O
in	ADP	O	O
reducing	VERB	O	O
oxidative	ADJ	O	B-PHYSICAL
stress	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
of	ADP	O	O
noninsulin	NOUN	O	O
dependent	ADJ	O	O
diabetes	NOUN	O	O
mellitus	NOUN	O	O
--	PUNCT	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADP	O	O
randomized	VERB	O	O
study	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	ADJ	O	O
Parameters	NOUN	O	O
of	ADP	O	O
oxidative	ADJ	O	B-PHYSICAL
stress	NOUN	O	I-PHYSICAL
were	VERB	O	O
quantitated	VERB	O	O
in	ADP	O	O
50	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
mellitus	NOUN	O	O
in	ADP	O	O
uncontrolled	VERB	O	O
state	NOUN	O	O
and	CCONJ	O	O
after	ADP	O	O
control	NOUN	O	O
using	SYM	O	O
oral	ADJ	O	O
glibenclamide	NUM	O	O
or	CCONJ	O	O
gliclazide	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
estimates	NOUN	O	O
were	VERB	O	O
further	ADV	O	O
compared	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
irrespective	ADJ	O	O
of	ADP	O	O
drug	NOUN	O	O
used	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
difference	NOUN	O	O
,	PUNCT	O	O
if	VERB	O	O
any	DET	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
was	ADV	O	O
a	DET	O	O
double	ADJ	O	O
blind	ADP	O	O
,	PUNCT	O	O
uncontrolled	PUNCT	O	O
,	PUNCT	O	O
noncrossover	ADP	O	O
and	CCONJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Fifty	ADJ	O	O
patients	NOUN	O	O
of	ADP	O	O
uncontrolled	VERB	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
in	ADP	O	O
to	PUNCT	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Group	NOUN	O	O
I	NUM	O	O
(	PUNCT	O	O
25	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
received	VERB	O	O
capsule	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
glibenclamide	NUM	O	O
)	PUNCT	O	O
while	ADP	O	O
Group	NOUN	O	O
II	NUM	O	O
(	PUNCT	O	O
25	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
received	ADV	O	O
capsule	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
gliclazide	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
parameters	NOUN	O	O
studied	VERB	O	O
were	VERB	O	O
Superoxide	NOUN	O	B-PHYSICAL
dismutase	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
SOD	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
malonyl-dialdehyde	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
MDA	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
reduced	VERB	O	B-PHYSICAL
glutathione	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
GSH	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
.	PUNCT	O	O

They	PRON	O	O
were	PUNCT	O	O
done	PUNCT	O	O
at	ADP	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
uncontrolled	DET	O	O
stage	NOUN	O	O
(	PUNCT	O	O
FBS	NOUN	O	O
--	PUNCT	O	O
165	NUM	O	O
+/-	SYM	O	O
16.7	NUM	O	O
mg/dl	NOUN	O	O
,	PUNCT	O	O
PP	NOUN	O	O
--	PUNCT	O	O
240	NUM	O	O
+/-	SYM	O	O
30.1	NUM	O	O
mg/dl	NOUN	O	O
and	CCONJ	O	O
HbA1	PUNCT	O	O
--	PUNCT	O	O
10.5	NUM	O	O
+/-	SYM	O	O
0.9	NUM	O	O
%	SYM	O	O
in	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
and	CCONJ	O	O
FBS	NOUN	O	O
--	PUNCT	O	O
150	NUM	O	O
+/-	SYM	O	O
15.8	NUM	O	O
mg/dl	NOUN	O	O
,	PUNCT	O	O
PP	NOUN	O	O
--	PUNCT	O	O
246	NUM	O	O
+/-	SYM	O	O
29.1	NUM	O	O
mg/dl	NOUN	O	O
HbA1	NOUN	O	O
10.6	NUM	O	O
+/-	SYM	O	O
0.8	NUM	O	O
%	SYM	O	O
in	ADP	O	O
group	NOUN	O	O
II	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
during	ADP	O	O
controlled	VERB	O	O
stage	NOUN	O	O
at	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
FBS	NOUN	O	O
--	PUNCT	O	O
120	NUM	O	O
+/-	SYM	O	O
18.5	NUM	O	O
mg/dl	NOUN	O	O
,	PUNCT	O	O
PP	NOUN	O	O
--	PUNCT	O	O
180	NUM	O	O
+/-	SYM	O	O
19.1	NUM	O	O
mg/dl	NOUN	O	O
and	CCONJ	O	O
HbA1	PUNCT	O	O
--	PUNCT	O	O
8.4	NUM	O	O
+/-	SYM	O	O
0.29	NUM	O	O
%	SYM	O	O
in	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
and	CCONJ	O	O
FBS	NOUN	O	O
--	PUNCT	O	O
118	NUM	O	O
+/-	SYM	O	O
17.6	NUM	O	O
mg/dl	NOUN	O	O
,	PUNCT	O	O
PP	NOUN	O	O
--	PUNCT	O	O
176	NUM	O	O
+/-	SYM	O	O
20.1	NUM	O	O
mg/dl	NOUN	O	O
and	CCONJ	O	O
HbA1	PUNCT	O	O
--	PUNCT	O	O
8.5	NUM	O	O
+/-	SYM	O	O
0.39	NUM	O	O
%	SYM	O	O
in	ADP	O	O
group	NOUN	O	O
II	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
significantly	ADV	O	O
raised	ADP	O	O
levels	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
MDA	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
SOD	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
decreased	ADV	O	O
levels	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
reduced	VERB	O	I-PHYSICAL
glutathione	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
GSH	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
during	ADP	O	O
uncontrolled	VERB	O	O
stage	NOUN	O	O
of	ADP	O	O
diabetes	NOUN	O	O
indicated	VERB	O	O
free	ADJ	O	O
radical	NOUN	O	O
stress	NOUN	O	O
induced	ADP	O	O
lipid	NOUN	O	O
peroxidation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
significant	ADJ	O	O
fall	NOUN	O	O
of	ADP	O	O
MDA	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
SOD	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
increased	ADV	O	O
levels	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
GSH	NOUN	O	I-PHYSICAL
in	ADP	O	O
blood	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
after	ADP	O	O
control	NOUN	O	O
revealed	VERB	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
glycemic	ADJ	O	O
control	NOUN	O	O
on	ADP	O	O
oxidative	ADJ	O	B-PHYSICAL
stress	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
levels	NOUN	O	O
were	ADJ	O	O
not	ADV	O	O
normalized	VERB	O	O
and	CCONJ	O	O
stayed	VERB	O	O
higher	PUNCT	O	O
than	CCONJ	O	O
those	PUNCT	O	O
in	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
intergroup	NOUN	O	O
comparison	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
control	NOUN	O	O
of	ADP	O	O
diabetes	NOUN	O	O
with	ADP	O	O
gliclazide	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
II	NUM	O	O
)	PUNCT	O	O
showed	VERB	O	O
improvement	NOUN	O	O
in	ADP	O	O
oxidative	ADJ	O	B-PHYSICAL
stress	NOUN	O	O
(	PUNCT	O	O
MDA	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
GSH	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
better	PUNCT	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
glibenclamide	NUM	O	O
(	PUNCT	O	O
group	NOUN	O	O
I	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	PUNCT	O	O

Prophylactic	ADJ	O	O
vs	CCONJ	O	O
therapeutic	ADJ	O	O
blood	NOUN	O	O
patch	NOUN	O	O
for	ADP	O	O
obstetric	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
accidental	ADJ	O	O
dural	ADJ	O	O
puncture	NOUN	O	O
--	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Epidural	ADJ	O	O
blood	NOUN	O	O
patch	NOUN	O	O
is	VERB	O	O
a	DET	O	O
standard	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
obstetric	ADJ	O	O
patients	NOUN	O	O
experiencing	PUNCT	O	O
a	DET	O	O
severe	ADJ	O	O
post-dural	ADJ	O	O
puncture	NOUN	O	O
headache	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	ADP	O	O
sustained	VERB	O	O
an	DET	O	O
accidental	ADJ	O	O
dural	ADJ	O	O
puncture	NOUN	O	O
during	ADP	O	O
establishment	NOUN	O	O
of	ADP	O	O
epidural	ADJ	O	O
analgesia	NOUN	O	O
during	ADP	O	O
labour	NOUN	O	O
or	CCONJ	O	O
at	ADP	O	O
caesarean	NOUN	O	O
delivery	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
a	DET	O	O
prophylactic	ADJ	O	O
epidural	ADJ	O	O
blood	NOUN	O	O
patch	NOUN	O	O
or	CCONJ	O	O
conservative	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
a	DET	O	O
therapeutic	ADJ	O	O
epidural	ADJ	O	O
blood	NOUN	O	O
patch	NOUN	O	O
if	ADP	O	O
required	VERB	O	O
.	PUNCT	O	O

Eleven	ADJ	O	O
of	ADP	O	O
60	NUM	O	O
(	PUNCT	O	O
18.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prophylactic	ADJ	O	O
epidural	ADJ	O	O
blood	NOUN	O	O
patch	NOUN	O	O
group	NOUN	O	O
developed	VERB	O	O
a	DET	O	O
post-dural	ADJ	O	B-ADVERSE-EFFECTS
puncture	NOUN	O	I-ADVERSE-EFFECTS
headache	NOUN	O	I-ADVERSE-EFFECTS
compared	VERB	O	O
with	ADP	O	O
39	PUNCT	O	O
of	ADP	O	O
49	NUM	O	O
(	PUNCT	O	O
79.6	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
therapeutic	ADJ	O	O
epidural	ADJ	O	O
blood	NOUN	O	O
patch	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
blood	NOUN	O	O
patch	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
36	NUM	O	O
(	PUNCT	O	O
73.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
therapeutic	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	B-OTHER
who	DET	O	I-OTHER
needed	VERB	O	I-OTHER
a	DET	O	I-OTHER
second	ADJ	O	I-OTHER
blood	NOUN	O	I-OTHER
patch	NOUN	O	I-OTHER
did	PUNCT	O	O
not	ADV	O	O
differ	VERB	O	O
significantly	ADV	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
6	NUM	O	O
(	PUNCT	O	O
10.0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
for	ADP	O	O
prophylactic	ADJ	O	O
epidural	ADJ	O	O
blood	NOUN	O	O
patch	NOUN	O	O
and	CCONJ	O	O
4	NUM	O	O
(	PUNCT	O	O
11.1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
for	ADP	O	O
therapeutic	ADJ	O	O
epidural	ADJ	O	O
blood	NOUN	O	O
patch	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
prophylactic	ADJ	O	O
epidural	ADJ	O	O
blood	NOUN	O	O
patch	NOUN	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
method	NOUN	O	O
to	PART	O	O
reduce	NOUN	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
post-dural	ADJ	O	O
puncture	NOUN	O	O
headache	NOUN	O	O
in	ADP	O	O
obstetric	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Combined	VERB	O	O
typhoid	NOUN	O	O
fever	NOUN	O	O
and	CCONJ	O	O
hepatitis	NOUN	O	O
A	NOUN	O	O
vaccine	NOUN	O	O
:	PUNCT	O	O
comparison	NOUN	O	O
of	ADP	O	O
immunogenicity	ADJ	O	B-OTHER
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
to	ADP	O	O
concomitant	ADJ	O	O
monovalent	ADJ	O	O
vaccine	NOUN	O	O
over	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
safety	NOUN	O	B-OTHER
and	CCONJ	O	O
immunogenicity	NOUN	O	B-OTHER
of	ADP	O	O
Viatim	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
combined	VERB	O	O
hepatitis	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
HA	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
typhoid	ADJ	O	O
fever	NOUN	O	O
(	PUNCT	O	O
Vi	NOUN	O	O
)	PUNCT	O	O
vaccine	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
monovalent	ADJ	O	O
component	NOUN	O	O
vaccines	NOUN	O	O
up	PUNCT	O	O
to	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
month	NOUN	O	O
after	ADP	O	O
a	DET	O	O
booster	NOUN	O	O
dose	NOUN	O	O
at	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Healthy	PUNCT	O	O
,	PUNCT	O	O
adult	NOUN	O	O
volunteers	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
Viatim	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
179	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
separate	ADJ	O	O
HA	NOUN	O	O
and	CCONJ	O	O
Vi	NOUN	O	O
vaccines	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
B	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
181	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
subgroups	ADP	O	O
were	VERB	O	O
boosted	VERB	O	O
after	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
Viatim	NOUN	O	O
(	PUNCT	O	O
groups	NOUN	O	O
C	NOUN	O	O
and	CCONJ	O	O
D	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
56	NUM	O	O
and	CCONJ	O	O
46	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Local	ADJ	O	O
and	CCONJ	O	O
systemic	ADJ	O	O
reactions	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
for	ADP	O	O
28	NUM	O	O
days	NOUN	O	O
postvaccination	NOUN	O	O
.	PUNCT	O	O

Seroconversion	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
seroprotection	NOUN	O	B-PHYSICAL
rates	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
geometric	ADJ	O	B-PHYSICAL
mean	NOUN	O	O
antibody	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	B-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
14	NUM	O	O
and	CCONJ	O	O
28	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3	NUM	O	O
years	NOUN	O	O
postvaccination	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
28	NUM	O	O
days	NOUN	O	O
after	ADP	O	O
the	DET	O	O
booster	NOUN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Local	ADJ	O	B-OTHER
and	CCONJ	O	I-OTHER
systemic	ADJ	O	I-OTHER
safety	NOUN	O	B-OTHER
profiles	NOUN	O	I-OTHER
were	VERB	O	O
equivalent	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Immediate	ADJ	O	B-PHYSICAL
local	ADJ	O	I-PHYSICAL
reactions	NOUN	O	I-PHYSICAL
were	VERB	O	O
infrequent	ADJ	O	O
(	PUNCT	O	O
1	NUM	O	O
in	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
and	CCONJ	O	O
2	NUM	O	O
in	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Local	ADJ	O	B-PHYSICAL
reactions	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
consisting	ADP	O	B-PAIN
mostly	NUM	O	I-PAIN
of	ADP	O	I-PAIN
mild	ADJ	O	B-PAIN
or	CCONJ	O	I-PAIN
moderate	ADJ	O	I-PAIN
pain	NOUN	O	B-PAIN
,	PUNCT	O	O
were	PUNCT	O	O
least	ADV	O	O
frequent	ADJ	O	O
with	ADP	O	O
monovalent	ADJ	O	O
HA	NOUN	O	O
.	PUNCT	O	O

Antibody	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	B-PHYSICAL
to	ADP	O	O
both	PUNCT	O	O
antigens	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
groups	NOUN	O	O
A	DET	O	O
and	CCONJ	O	O
B	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
which	ADP	O	O
HA	NOUN	O	B-PHYSICAL
seroprotection	NOUN	O	B-PHYSICAL
rates	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
20	NUM	O	O
mIU/mL	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
respectively	ADV	O	O
,	PUNCT	O	O
98.7	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
100	NUM	O	O
%	SYM	O	O
at	ADP	O	O
day	NOUN	O	O
28	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
99.1	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
99.0	NUM	O	O
%	SYM	O	O
after	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
achieving	ADP	O	O
100	NUM	O	O
%	SYM	O	O
after	ADP	O	O
the	DET	O	O
booster	NOUN	O	O
.	PUNCT	O	O

Vi	NOUN	O	B-PHYSICAL
seroprotection	NOUN	O	I-PHYSICAL
rates	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
1	NUM	O	O
microg/mL	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
85.2	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
84.9	NUM	O	O
%	SYM	O	O
after	ADP	O	O
28	NUM	O	O
days	NOUN	O	O
fell	ADP	O	O
to	ADP	O	O
32.1	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
35.6	NUM	O	O
%	SYM	O	O
after	ADP	O	O
3	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
increasing	ADP	O	O
to	ADP	O	O
67.3	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
69.8	NUM	O	O
%	SYM	O	O
after	ADP	O	O
the	DET	O	O
booster	NOUN	O	O
dose	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
combined	VERB	O	O
HA/Vi	NOUN	O	O
vaccine	NOUN	O	O
,	PUNCT	O	O
Viatim	ADP	O	O
,	PUNCT	O	O
had	PUNCT	O	O
equivalent	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
split	ADJ	O	O
course	NOUN	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
mitomycin	NUM	O	O
C	NOUN	O	O
and	CCONJ	O	O
5	NUM	O	O
fluorouracil	NOUN	O	O
as	PUNCT	O	O
initial	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
advanced	ADP	O	O
laryngeal	ADJ	O	O
and	CCONJ	O	O
hypopharyngeal	PUNCT	O	O
squamous	ADJ	O	O
carcinoma	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
twelve	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
previously	ADV	O	O
untreated	VERB	O	O
advanced	ADP	O	O
squamous	ADJ	O	O
carcinoma	NOUN	O	O
of	ADP	O	O
the	DET	O	O
larynx	NOUN	O	O
or	CCONJ	O	O
hypopharynx	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
initial	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
radiotherapy	NOUN	O	O
,	PUNCT	O	O
50	NUM	O	O
Gy	NOUN	O	O
in	ADP	O	O
20	NUM	O	O
fractions	NOUN	O	O
in	ADP	O	O
28	NUM	O	O
days	NOUN	O	O
or	CCONJ	O	O
split	PUNCT	O	O
course	NOUN	O	O
radiotherapy	NOUN	O	O
and	CCONJ	O	O
concurrent	ADJ	O	O
chemotherapy	NOUN	O	O
,	PUNCT	O	O
25	NUM	O	O
Gy	NOUN	O	O
in	ADP	O	O
10	NUM	O	O
fractions	NOUN	O	O
in	ADP	O	O
14	DET	O	O
days	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
4	NUM	O	O
week	NOUN	O	O
rest	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
further	ADJ	O	O
25	NUM	O	O
Gy	NOUN	O	O
in	ADP	O	O
10	NUM	O	O
fractions	NOUN	O	O
in	ADP	O	O
14	NUM	O	O
days	NOUN	O	O
starting	ADP	O	O
on	ADP	O	O
day	NOUN	O	O
43	NUM	O	O
;	PUNCT	O	O
Mitomycin	NOUN	O	O
C	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
day	NOUN	O	O
43	NUM	O	O
and	CCONJ	O	O
5FU	PUNCT	O	O
continuous	ADJ	O	O
infusions	NOUN	O	O
on	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
--	PUNCT	O	O
4	NUM	O	O
and	CCONJ	O	O
days	NOUN	O	O
43	NUM	O	O
--	PUNCT	O	O
46	NUM	O	O
.	PUNCT	O	O

Surgery	NOUN	O	O
was	VERB	O	O
reserved	VERB	O	O
for	ADP	O	O
persistent	ADJ	O	O
or	CCONJ	O	O
recurrent	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
nine	NUM	O	O
of	ADP	O	O
the	DET	O	O
212	NUM	O	O
patients	NOUN	O	O
randomized	VERB	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
analyses	NOUN	O	O
.	PUNCT	O	O

Outcome	NOUN	O	O
analyses	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
a	DET	O	O
median	ADJ	O	O
follow-up	NOUN	O	O
interval	NOUN	O	O
of	ADP	O	O
4.4	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
lost	VERB	O	O
to	ADP	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
arms	NOUN	O	O
for	ADP	O	O
the	DET	O	O
end	NOUN	O	O
points	NOUN	O	O
of	ADP	O	O
local	ADJ	O	B-PHYSICAL
relapse-free	PUNCT	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.91	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
regional	ADJ	O	B-PHYSICAL
relapse-free	PUNCT	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.17	NUM	O	O
,	PUNCT	O	O
adjusted	ADP	O	O
)	PUNCT	O	O
or	CCONJ	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.86	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Eight-eight	ADJ	O	O
patients	NOUN	O	O
had	PUNCT	O	O
attempted	VERB	O	O
surgical	ADJ	O	O
resection	NOUN	O	O
following	PUNCT	O	O
radiotherapy	NOUN	O	O
failure	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
contribution	NOUN	O	O
of	ADP	O	O
salvage	NOUN	O	O
surgery	NOUN	O	O
to	ADP	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
was	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
both	PUNCT	O	O
arms	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
as	PUNCT	O	O
was	VERB	O	O
the	DET	O	O
surgical	ADJ	O	B-ADVERSE-EFFECTS
complication	NOUN	O	I-ADVERSE-EFFECTS
rate	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Serious	ADJ	O	B-ADVERSE-EFFECTS
late	ADJ	O	I-ADVERSE-EFFECTS
radiation	NOUN	O	I-ADVERSE-EFFECTS
toxicity	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
minimal	ADJ	O	O
(	PUNCT	O	O
3	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
RT	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
0	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
radiation	NOUN	O	O
therapy	NOUN	O	O
plus	CCONJ	O	O
chemotherapy	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
result	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
shows	NOUN	O	O
no	DET	O	O
advantage	NOUN	O	O
in	ADP	O	O
terms	NOUN	O	O
of	ADP	O	O
local	ADJ	O	O
control	NOUN	O	O
or	CCONJ	O	O
survival	NOUN	O	O
for	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
treatment	NOUN	O	O
arm	ADP	O	O
of	ADP	O	O
split	PUNCT	O	O
course	NOUN	O	O
radiotherapy	NOUN	O	O
and	CCONJ	O	O
concurrent	ADJ	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
Mitomycin	NOUN	O	O
C	NOUN	O	O
and	CCONJ	O	O
5	NUM	O	O
Fluorouracil	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
radiotherapy	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

Gastric	ADJ	O	O
ulcer	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
intravenous	ADJ	O	O
human	NOUN	O	O
epidermal	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
double-blind	ADJ	O	O
controlled	VERB	O	O
clinical	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
introduced	VERB	O	O
a	DET	O	O
double-blind	ADJ	O	O
controlled	VERB	O	O
clinical	ADJ	O	O
study	NOUN	O	O
to	PART	O	O
compare	NOUN	O	O
intravenous	ADJ	O	O
human	NOUN	O	O
epidermal	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
(	PUNCT	O	O
hEGF	NOUN	O	O
)	PUNCT	O	O
to	PART	O	O
cetraxate	PUNCT	O	O
hydrochloride	NOUN	O	O
(	PUNCT	O	O
CH	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
antiulcer	NOUN	O	O
drug	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
their	PUNCT	O	O
healing	PROPN	O	O
effect	NOUN	O	O
on	ADP	O	O
gastric	ADJ	O	B-PHYSICAL
ulcers	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

We	PRON	O	O
also	ADV	O	O
prospected	ADJ	O	O
an	DET	O	O
oral	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
EGF	NOUN	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
our	PUNCT	O	O
experimental	ADJ	O	O
evidence	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
ulcer	NOUN	O	B-PHYSICAL
healing	VERB	O	I-PHYSICAL
within	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
was	VERB	O	O
77.9	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
67/86	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
6	NUM	O	O
micrograms	NOUN	O	O
EGF	NOUN	O	O
intravenously	ADV	O	O
twice	NOUN	O	O
a	DET	O	O
week	NOUN	O	O
,	PUNCT	O	O
being	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
than	PUNCT	O	O
51.7	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
45/87	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
those	PUNCT	O	O
given	VERB	O	O
CH	NOUN	O	O
.	PUNCT	O	O

Taking	PUNCT	O	O
together	ADV	O	O
all	DET	O	O
aspects	NOUN	O	O
assessed	VERB	O	O
including	VERB	O	O
the	DET	O	O
healing	VERB	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
pain	NOUN	O	B-PAIN
relief	NOUN	O	I-PAIN
,	PUNCT	O	O
blood	NOUN	O	B-PHYSICAL
examination	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
reactions	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
we	PRON	O	O
judged	VERB	O	O
the	DET	O	O
hEGF	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
a	DET	O	O
useful	ADJ	O	O
and	CCONJ	O	O
safe	ADJ	O	O
anticuler	PUNCT	O	O
drug	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
rats	NOUN	O	O
,	PUNCT	O	O
50	NUM	O	O
micrograms/kg	NOUN	O	O
mouse	NOUN	O	O
EGF	NOUN	O	O
(	PUNCT	O	O
mEGF	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
%	SYM	O	O
hydroxypropyl	NOUN	O	O
cellulose	NOUN	O	O
(	PUNCT	O	O
HPC	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
1.0	NUM	O	O
g/kg	NOUN	O	O
sucralfate	NOUN	O	O
given	VERB	O	O
by	ADP	O	O
gastric	ADJ	O	O
intubation	NOUN	O	O
significantly	ADV	O	O
raised	VERB	O	O
the	DET	O	O
residual	ADJ	O	O
mEGF	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
in	ADP	O	O
both	CCONJ	O	O
gastric	ADJ	O	O
luminal	ADJ	O	O
content	NOUN	O	O
(	PUNCT	O	O
HPC	NOUN	O	O
:	PUNCT	O	O
x	SYM	O	O
30	NUM	O	O
;	PUNCT	O	O
sucralfate	NOUN	O	O
:	PUNCT	O	O
x	SYM	O	O
300	NUM	O	O
as	VERB	O	O
high	ADJ	O	O
as	ADJ	O	O
those	PUNCT	O	O
in	ADP	O	O
EGF	NOUN	O	O
alone	ADJ	O	O
)	PUNCT	O	O
and	CCONJ	O	O
tissue	NOUN	O	O
(	PUNCT	O	O
HPC	NOUN	O	O
:	PUNCT	O	O
x	SYM	O	O
60	NUM	O	O
;	PUNCT	O	O
sucralfate	NOUN	O	O
:	PUNCT	O	O
x	SYM	O	O
100	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
combined	DET	O	O
treatments	NOUN	O	O
significantly	ADV	O	O
promoted	PUNCT	O	O
healing	VERB	O	O
of	ADP	O	O
rat	NOUN	O	B-PHYSICAL
gastric	ADJ	O	I-PHYSICAL
ulcers	NOUN	O	I-PHYSICAL
whereas	ADP	O	O
each	DET	O	O
agent	NOUN	O	O
alone	ADJ	O	O
had	CCONJ	O	O
no	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
(	PUNCT	O	O
saline	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
indicated	VERB	O	O
the	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
ulcers	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
EGF	NOUN	O	O
with	ADP	O	O
agents	NOUN	O	O
allowing	VERB	O	O
it	PRON	O	O
to	PUNCT	O	O
remain	ADP	O	O
at	ADP	O	O
high	ADJ	O	O
levels	NOUN	O	O
in	ADP	O	O
the	DET	O	O
stomach	NOUN	O	O
,	PUNCT	O	O
whereas	CCONJ	O	O
most	DET	O	O
reports	NOUN	O	O
suggested	VERB	O	O
less	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
EGF	NOUN	O	O
on	ADP	O	O
healing	VERB	O	O
of	ADP	O	O
gastroduodenal	ADJ	O	O
ulcers	NOUN	O	O
.	PUNCT	O	O

Subsequent	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
evaluation	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
EGF	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
expected	VERB	O	O
as	ADP	O	O
the	DET	O	O
next	ADJ	O	O
step	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
ulcers	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
experimental	ADJ	O	O
evidence	NOUN	O	O
above	PUNCT	O	O
would	PUNCT	O	O
possibly	ADV	O	O
be	ADP	O	O
a	DET	O	O
guide	NOUN	O	O
for	ADP	O	O
such	DET	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Long	ADJ	O	O
pediatric	ADJ	O	O
colonoscope	PUNCT	O	O
versus	CCONJ	O	O
intermediate	ADJ	O	O
length	NOUN	O	O
adult	NOUN	O	O
colonoscope	ADJ	O	O
for	ADP	O	O
colonoscopy	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Controversy	NOUN	O	O
exists	NOUN	O	O
on	ADP	O	O
how	ADP	O	O
the	DET	O	O
length	NOUN	O	O
and	CCONJ	O	O
diameter	NOUN	O	O
of	ADP	O	O
colonoscopes	NOUN	O	O
affect	VERB	O	O
the	DET	O	O
quality	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
colonoscopy	NOUN	O	I-OTHER
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
a	DET	O	O
long	ADJ	O	O
pediatric	ADJ	O	O
colonoscope	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
intermediate	ADJ	O	O
length	NOUN	O	O
adult	NOUN	O	O
colonoscope	ADJ	O	O
with	ADP	O	O
regards	ADP	O	O
to	ADP	O	O
completion	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
and	CCONJ	O	O
cecal	ADJ	O	B-OTHER
intubation	NOUN	O	I-OTHER
time	NOUN	O	I-OTHER
.	PUNCT	O	O

Whether	ADP	O	O
either	PUNCT	O	O
scope	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
more	ADV	O	O
efficient	ADJ	O	B-OTHER
in	ADP	O	O
any	DET	O	O
subgroups	NOUN	O	O
was	NUM	O	O
also	ADV	O	O
investigated	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Asymptomatic	ADJ	O	O
patients	NOUN	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
physical	ADJ	O	O
check-up	NOUN	O	O
department	NOUN	O	O
of	ADP	O	O
Buddhist	NOUN	O	O
Dalin	NOUN	O	O
Tzu	NOUN	O	O
Chi	NOUN	O	O
General	ADJ	O	O
Hospital	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
single	ADJ	O	O
endoscopist	NOUN	O	O
performed	VERB	O	O
all	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
colonoscopic	ADJ	O	O
examinations	NOUN	O	O
under	ADP	O	O
sedation	NOUN	O	O
.	PUNCT	O	O

Consecutive	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADJ	O	O
undergo	VERB	O	O
colonoscopy	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
intermediate	ADJ	O	O
length	NOUN	O	O
adult	NOUN	O	O
colonoscope	PUNCT	O	O
(	PUNCT	O	O
CF-240I	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
long	ADJ	O	O
pediatric	ADJ	O	O
colonoscope	ADJ	O	O
(	PUNCT	O	O
PCF-240L	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
success	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
and	CCONJ	O	O
time	NOUN	O	B-OTHER
required	ADJ	O	I-OTHER
to	ADP	O	I-OTHER
reach	PUNCT	O	I-OTHER
cecum	NOUN	O	I-OTHER
were	VERB	O	O
compared	VERB	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Between	ADP	O	O
April	NOUN	O	O
2005	NUM	O	O
and	CCONJ	O	O
February	PUNCT	O	O
2006	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
918	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
enrolled	VERB	O	O
.	PUNCT	O	O

Incomplete	PUNCT	O	B-OTHER
colonoscopy	NOUN	O	I-OTHER
occurred	VERB	O	O
in	ADP	O	O
21	NUM	O	O
(	PUNCT	O	O
2.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
cases	NOUN	O	O
(	PUNCT	O	O
14	NUM	O	O
in	ADP	O	O
the	DET	O	O
CF-240I	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
seven	NUM	O	O
in	ADP	O	O
the	DET	O	O
PCF-240L	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.1	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
overall	ADJ	O	B-OTHER
cecal	ADJ	O	I-OTHER
mean	NOUN	O	O
insertion	NOUN	O	B-OTHER
time	NOUN	O	B-OTHER
was	VERB	O	O
6.00	NUM	O	O
+/-	SYM	O	O
3.66	NUM	O	O
min	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
CF-240I	NOUN	O	O
and	CCONJ	O	O
PCF	NOUN	O	O
240L	NOUN	O	O
groups	NOUN	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
the	DET	O	O
cecal	ADJ	O	B-OTHER
intubation	NOUN	O	I-OTHER
rate	NOUN	O	B-OTHER
(	PUNCT	O	O
96.9	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
98.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.18	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
abdominal	ADJ	O	B-OTHER
pressure	NOUN	O	I-OTHER
(	PUNCT	O	O
71.7	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
73.4	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.55	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
change	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
position	NOUN	O	O
(	PUNCT	O	O
13.5	NUM	O	O
%	SYM	O	O
vs	CCONJ	O	O
11.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.37	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
cecal	ADJ	O	B-OTHER
intubation	NOUN	O	I-OTHER
time	NOUN	O	I-OTHER
was	VERB	O	O
shorter	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
CF-240I	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
5.75	NUM	O	O
+/-	SYM	O	O
3.18	NUM	O	O
vs	CCONJ	O	O
6.26	NUM	O	O
+/-	SYM	O	O
3.30	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Subgroup	NOUN	O	O
analysis	NOUN	O	O
by	ADP	O	O
sex	NOUN	O	O
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
showed	VERB	O	O
comparable	ADJ	O	O
outcomes	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
except	CCONJ	O	O
that	CCONJ	O	O
the	PUNCT	O	O

The	DET	O	O
acute	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
fluid	NOUN	O	O
intake	NOUN	O	O
on	ADP	O	O
urine	NOUN	O	O
specific	ADJ	O	O
gravity	NOUN	O	O
and	CCONJ	O	O
fluid	NOUN	O	O
retention	NOUN	O	O
in	ADP	O	O
a	DET	O	O
mildly	ADV	O	O
dehydrated	PUNCT	O	O
state	NOUN	O	O
.	PUNCT	O	O

Many	DET	O	O
athletes	NOUN	O	O
arrive	ADJ	O	O
at	ADP	O	O
training	ADP	O	O
sessions	NOUN	O	O
and	CCONJ	O	O
competitions	NOUN	O	O
in	ADP	O	O
a	DET	O	O
mildly	ADV	O	O
hypohydrated	PUNCT	O	O
(	PUNCT	O	O
HYPO	NOUN	O	O
)	PUNCT	O	O
state	NOUN	O	O
and	CCONJ	O	O
are	VERB	O	O
instructed	VERB	O	O
to	ADP	O	O
drink	NOUN	O	O
fluids	NOUN	O	O
before	ADP	O	O
exercise	NOUN	O	O
to	ADP	O	O
reach	NOUN	O	O
a	ADP	O	O
euhydrated	ADP	O	O
(	PUNCT	O	O
HYD	NOUN	O	O
)	PUNCT	O	O
state	NOUN	O	O
.	PUNCT	O	O

Ten	NUM	O	O
recreational	ADJ	O	O
athletes	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
women	NOUN	O	O
,	PUNCT	O	O
4	NUM	O	O
men	NOUN	O	O
;	PUNCT	O	O
71.9	NUM	O	O
?	PUNCT	O	O

4.6	NUM	O	O
kg	NOUN	O	O
,	PUNCT	O	O
25.2	NUM	O	O
?	PUNCT	O	O

0.9	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
participated	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
studies	NOUN	O	O
to	PART	O	O
examine	NOUN	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
the	DET	O	O
day-to-day	NOUN	O	O
variability	NOUN	O	O
of	ADP	O	O
morning	NOUN	O	O
urine	NOUN	O	O
specific	ADJ	O	O
gravity	NOUN	O	O
(	PUNCT	O	O
USG	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
consuming	SYM	O	O
600	NUM	O	O
ml	NOUN	O	O
of	ADP	O	O
water	NOUN	O	O
on	ADP	O	O
the	DET	O	O
hydration	NOUN	O	O
status	NOUN	O	O
of	ADP	O	O
HYD	NOUN	O	O
and	CCONJ	O	O
HYPO	NOUN	O	O
(	PUNCT	O	O
USG	NOUN	O	O
>	SYM	O	O
1.020	NUM	O	O
)	PUNCT	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
c	NOUN	O	O
)	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
consuming	ADJ	O	O
water	NOUN	O	O
(	PUNCT	O	O
W	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
salt-water	ADJ	O	O
(	PUNCT	O	O
SW	NOUN	O	O
,	PUNCT	O	O
40	NUM	O	O
mM	NOUN	O	O
Na	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
carbohydrate-electrolyte	NOUN	O	O
solution	NOUN	O	O
with	ADP	O	O
3	NUM	O	O
%	SYM	O	O
or	CCONJ	O	O
light	ADJ	O	O
carbohydrate	NOUN	O	O
(	PUNCT	O	O
CES-L	NOUN	O	O
,	PUNCT	O	O
20	NUM	O	O
mM	NOUN	O	O
Na	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
CES	NOUN	O	O
with	ADP	O	O
6	NUM	O	O
%	SYM	O	O
carbohydrate	NOUN	O	O
(	PUNCT	O	O
CES	NOUN	O	O
,	PUNCT	O	O
20	NUM	O	O
mM	NOUN	O	O
Na	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
hydration	NOUN	O	O
status	NOUN	O	O
of	ADP	O	O
HYPO	NOUN	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hydration	NOUN	O	O
status	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
with	ADP	O	O
USG	NOUN	O	O
and	CCONJ	O	O
body	NOUN	O	O
mass	NOUN	O	O
measures	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
volume	NOUN	O	O
collections	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
day-to-day	NOUN	O	O
variability	NOUN	O	O
in	ADP	O	O
morning	NOUN	O	O
USG	NOUN	O	O
(	PUNCT	O	O
coefficient	NOUN	O	O
of	ADP	O	O
variation	NOUN	O	O
=	SYM	O	O
0.2	NUM	O	O
?	PUNCT	O	O

0.1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
was	VERB	O	O
low	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
responses	NOUN	O	O
to	ADP	O	O
600	NUM	O	O
ml	NOUN	O	O
of	ADP	O	O
W	NOUN	O	O
ingestion	NOUN	O	O
were	VERB	O	O
repeatable	ADJ	O	O
.	PUNCT	O	O

Pretrial	ADJ	O	O
USG	NOUN	O	O
was	VERB	O	O
1.022	NUM	O	O
?	PUNCT	O	O

0.001	NUM	O	O
in	ADP	O	O
the	DET	O	O
HYPO	NOUN	O	O
trial	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
<	PROPN	O	O
1.020	NUM	O	O
by	ADP	O	O
45	NUM	O	O
minutes	NOUN	O	O
(	PUNCT	O	O
1.013	NUM	O	O
?	PUNCT	O	O

0.003	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
CES	NOUN	O	O
study	NOUN	O	O
,	PUNCT	O	O
HYPO	NOUN	O	O
subjects	NOUN	O	O
reached	PUNCT	O	O
HYD	NOUN	O	O
status	NOUN	O	O
at	ADP	O	O
45	NUM	O	O
minutes	NOUN	O	O
in	ADP	O	O
all	DET	O	O
conditions	NOUN	O	O
(	PUNCT	O	O
W	NOUN	O	O
1.013	NUM	O	O
?	PUNCT	O	O

0.003	NUM	O	O
,	PUNCT	O	O
SW	NOUN	O	O
1.013	NUM	O	O
?	PUNCT	O	O

0.003	NUM	O	O
,	PUNCT	O	O
CES-L	NOUN	O	O
1.011	NUM	O	O
?	PUNCT	O	O

0.003	NUM	O	O
,	PUNCT	O	O
CES	NOUN	O	O
1.017	NUM	O	O
?	PUNCT	O	O

0.004	NUM	O	O
)	PUNCT	O	O
because	PUNCT	O	O
salt	ADP	O	O
or	CCONJ	O	O
CES	NOUN	O	O
ingestion	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
affect	VERB	O	O
fluid	NOUN	O	B-PHYSICAL
retention	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
W	NOUN	O	O
68	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
SW	NOUN	O	O
72	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
CES-L	NOUN	O	O
68	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
CES	ADP	O	O
76	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
demonstrated	VERB	O	O
that	PUNCT	O	O
mildly	ADV	O	O
HYPO	NOUN	O	O
subjects	NOUN	O	O
could	ADP	O	O
reach	ADV	O	O
euhydration	NOUN	O	O
within	ADP	O	O
45	NUM	O	O
minutes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
ingestion	NOUN	O	O
of	ADP	O	O
600	NUM	O	O
ml	NOUN	O	O
of	ADP	O	O
W	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
salt	NOUN	O	O
and	CCONJ	O	O
CES	NOUN	O	O
solutions	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
this	DET	O	O
practice	NOUN	O	O
will	VERB	O	O
minimize	ADP	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
starting	PUNCT	O	O
a	DET	O	O
practice	NOUN	O	O
or	CCONJ	O	O
competition	NOUN	O	O
hypohydrated	ADP	O	O
.	PUNCT	O	O

Use	NOUN	O	B-OTHER
and	CCONJ	O	O
limitations	NOUN	O	B-OTHER
of	ADP	O	O
Holter	NOUN	O	O
electrocardiography	NOUN	O	O
in	ADP	O	O
assessing	VERB	O	O
drug	NOUN	O	O
therapy	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	O
ischemia	NOUN	O	O
during	ADP	O	O
the	DET	O	O
peri-PTCA	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Incidence	NOUN	O	O
and	CCONJ	O	O
pattern	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	O
ischemia	NOUN	O	O
during	ADP	O	O
the	DET	O	O
peri-PTCA	NOUN	O	O
(	PUNCT	O	O
percutaneous	ADJ	O	O
transluminal	ADJ	O	O
coronary	ADJ	O	O
angioplasty	NOUN	O	O
)	PUNCT	O	O
period	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
possible	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
continuous	ADJ	O	O
intravenous	ADJ	O	O
isosorbide	NOUN	O	O
dinitrate	PUNCT	O	O
in	ADP	O	O
its	PUNCT	O	O
prevention	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
prospectively	ADV	O	O
in	ADP	O	O
30	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Holter	NOUN	O	O
electrocardiographic	ADJ	O	O
monitoring	VERB	O	O
was	VERB	O	O
performed	VERB	O	O
for	ADP	O	O
21	NUM	O	O
+/-	SYM	O	O
3	NUM	O	O
h	NOUN	O	O
before	ADP	O	O
PTCA	NOUN	O	O
and	CCONJ	O	O
continued	PUNCT	O	O
during	ADP	O	O
and	CCONJ	O	O
for	ADP	O	O
41	NUM	O	O
+/-	SYM	O	O
8	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
the	DET	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

Before	ADP	O	O
PTCA	NOUN	O	O
,	PUNCT	O	O
19	NUM	O	O
ischemic	ADJ	O	O
episodes	NOUN	O	O
were	VERB	O	O
present	ADJ	O	O
in	ADP	O	O
10	NUM	O	O
(	PUNCT	O	O
33	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
30	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

PTCA	NOUN	O	O
produced	VERB	O	O
an	DET	O	O
abrupt	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
number	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.015	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
duration	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
spontaneous	ADJ	O	B-PHYSICAL
ischemic	ADJ	O	I-PHYSICAL
episodes	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
rarity	NOUN	O	O
of	ADP	O	O
recurrent	ADJ	O	B-PHYSICAL
myocardial	ADJ	O	I-PHYSICAL
ischemic	ADJ	O	I-PHYSICAL
events	NOUN	O	I-PHYSICAL
by	ADP	O	O
Holter	NOUN	O	O
monitoring	VERB	O	O
after	PUNCT	O	O
PTCA	NOUN	O	O
negated	VERB	O	O
any	DET	O	O
attempt	NOUN	O	O
at	ADP	O	O
assessing	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
intravenous	ADJ	O	O
isosorbide	NOUN	O	O
dinitrate	PUNCT	O	O
in	ADP	O	O
their	ADJ	O	O
prevention	NOUN	O	O
.	PUNCT	O	O

Holter	NOUN	O	O
monitoring	VERB	O	O
could	VERB	O	O
not	ADV	O	O
be	VERB	O	O
used	VERB	O	O
as	ADP	O	O
an	DET	O	O
early	ADJ	O	O
predictor	NOUN	O	O
of	ADP	O	O
late	ADJ	O	O
coronary	ADJ	O	O
restenosis	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
cigarette	NOUN	O	O
smoking	VERB	O	O
on	ADP	O	O
gastric	ADJ	O	O
emptying	PUNCT	O	O
of	ADP	O	O
solids	NOUN	O	O
in	ADP	O	O
Japanese	ADJ	O	O
smokers	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
crossover	NOUN	O	O
study	NOUN	O	O
using	VERB	O	O
the	DET	O	O
13C-octanoic	PUNCT	O	O
acid	NOUN	O	O
breath	NOUN	O	O
test	NUM	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Cigarette	NOUN	O	O
smoking	PUNCT	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
peptic	ADJ	O	O
ulcer	NOUN	O	O
and	CCONJ	O	O
gastroesophageal	ADJ	O	O
reflux	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Gastric	ADJ	O	O
emptying	PUNCT	O	O
disorders	NOUN	O	O
may	VERB	O	O
play	VERB	O	O
a	DET	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
these	DET	O	O
upper	ADJ	O	O
gastrointestinal	ADJ	O	O
diseases	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
studies	NOUN	O	O
examining	VERB	O	O
a	DET	O	O
link	NOUN	O	O
between	ADP	O	O
smoking	PUNCT	O	O
and	CCONJ	O	O
gastric	ADJ	O	O
emptying	PUNCT	O	O
disorders	NOUN	O	O
have	PUNCT	O	O
clinical	ADJ	O	O
relevance	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
smoking	VERB	O	B-PHYSICAL
on	ADP	O	O
gastric	ADJ	O	O
emptying	PUNCT	O	O
of	ADP	O	O
solids	NOUN	O	O
in	ADP	O	O
Japanese	ADJ	O	O
smokers	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
(	PUNCT	O	O
13	NUM	O	O
)	PUNCT	O	O
C-octanoic	ADJ	O	O
acid	NOUN	O	B-PHYSICAL
breath	NOUN	O	I-PHYSICAL
test	ADV	O	I-PHYSICAL
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
eight	NUM	O	O
male	NOUN	O	O
habitual	ADJ	O	O
smokers	NOUN	O	O
on	ADP	O	O
two	NUM	O	O
randomized	VERB	O	O
occasions	NOUN	O	O
(	PUNCT	O	O
either	CCONJ	O	O
sham	ADJ	O	O
smoking	ADP	O	O
or	CCONJ	O	O
actively	ADV	O	O
smoking	ADP	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
time	NOUN	O	O
vs	CCONJ	O	O
(	PUNCT	O	O
13	NUM	O	O
)	PUNCT	O	O
CO	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
excretion	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
curve	NOUN	O	O
was	VERB	O	O
mathematically	ADV	O	O
fitted	VERB	O	O
to	ADP	O	O
a	DET	O	O
conventional	ADJ	O	O
formula	NOUN	O	O
of	ADP	O	O
y	NOUN	O	O
(	PUNCT	O	O
t	NOUN	O	O
)	PUNCT	O	O
=	SYM	O	O
m*k*beta*e	NOUN	O	O
(	PUNCT	O	O
-k*t	NOUN	O	O
)	PUNCT	O	O
*	ADJ	O	O
(	PUNCT	O	O
1	NUM	O	O
-	PUNCT	O	O
e	NOUN	O	O
(	PUNCT	O	O
-k*t	NOUN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
(	PUNCT	O	O
beta-1	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
parameters	NOUN	O	O
of	ADP	O	O
k	NOUN	O	B-OTHER
and	CCONJ	O	O
beta	NOUN	O	B-OTHER
were	VERB	O	O
determined	VERB	O	O
:	PUNCT	O	O
under	ADP	O	O
the	DET	O	O
crossover	NOUN	O	O
protocol	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
larger	PUNCT	O	O
(	PUNCT	O	O
smaller	PUNCT	O	O
)	PUNCT	O	O
beta	NOUN	O	O
indicates	NOUN	O	O
slower	PUNCT	O	O
(	PUNCT	O	O
faster	PUNCT	O	O
)	PUNCT	O	O
emptying	ADJ	O	O
in	ADP	O	O
the	DET	O	O
early	ADJ	O	O
phase	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
larger	PUNCT	O	O
(	PUNCT	O	O
smaller	PUNCT	O	O
)	PUNCT	O	O
k	NOUN	O	O
indicates	ADP	O	O
faster	PUNCT	O	O
(	PUNCT	O	O
slower	PUNCT	O	O
)	PUNCT	O	O
emptying	ADJ	O	O
in	ADP	O	O
the	DET	O	O
later	PUNCT	O	O
phase	NOUN	O	O
.	PUNCT	O	O

The	PUNCT	O	O

Pedantic	ADJ	O	O
speaking	PUNCT	O	O
style	NUM	O	O
differentiates	NOUN	O	O
Asperger	ADJ	O	O
syndrome	NOUN	O	O
from	ADP	O	O
high-functioning	VERB	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Asperger	ADJ	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
AS	PUNCT	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
pervasive	ADJ	O	O
developmental	ADJ	O	O
disorder	NOUN	O	O
recently	ADV	O	O
introduced	ADP	O	O
as	ADP	O	O
a	DET	O	O
new	ADJ	O	O
diagnostic	ADJ	O	O
category	ADJ	O	O
in	ADP	O	O
the	DET	O	O
ICD-10	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
DSM-IV	NOUN	O	O
.	PUNCT	O	O

Along	PUNCT	O	O
with	ADP	O	O
motor	NOUN	O	O
clumsiness	NOUN	O	O
,	PUNCT	O	O
pedantic	ADJ	O	O
speech	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
proposed	VERB	O	O
as	ADP	O	O
a	DET	O	O
clinical	ADJ	O	O
feature	NOUN	O	O
of	ADP	O	O
AS	CCONJ	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
few	ADJ	O	O
attempts	PUNCT	O	O
have	PUNCT	O	O
been	PUNCT	O	O
made	VERB	O	O
to	PART	O	O
define	NOUN	O	O
and	CCONJ	O	O
measure	ADP	O	O
this	DET	O	O
symptom	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
studied	VERB	O	O
17	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
AS	ADP	O	O
(	PUNCT	O	O
ICD-10	NOUN	O	O
;	PUNCT	O	O
14	NUM	O	O
male	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
female	NOUN	O	O
;	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
16.4	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
mean	VERB	O	O
full-scale	NOUN	O	O
IQ	NOUN	O	O
97	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
compared	DET	O	O
them	CCONJ	O	O
with	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
of	ADP	O	O
13	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
normal-intelligence	NOUN	O	O
autism	NOUN	O	O
or	CCONJ	O	O
high-functioning	ADP	O	O
autism	NOUN	O	O
(	PUNCT	O	O
HFA	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
ICD-10/DSM-III-R	PUNCT	O	O
;	PUNCT	O	O
12	NUM	O	O
male	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
female	NOUN	O	O
;	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
15.5	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
mean	VERB	O	O
full-scale	NOUN	O	O
IQ	NOUN	O	O
81.2	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

An	DET	O	O
operational	ADJ	O	O
definition	NOUN	O	O
of	ADP	O	O
pedantic	ADJ	O	O
speech	NOUN	O	O
was	VERB	O	O
formulated	VERB	O	O
and	CCONJ	O	O
a	DET	O	O
rating	VERB	O	O
scale	NOUN	O	O
devised	VERB	O	O
.	PUNCT	O	O

13	NUM	O	O
(	PUNCT	O	O
76	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
AS	ADP	O	O
patients	NOUN	O	O
were	VERB	O	O
rated	VERB	O	O
as	ADP	O	O
pedantic	ADJ	O	B-OTHER
compared	VERB	O	O
to	ADP	O	O
4	NUM	O	O
(	PUNCT	O	O
31	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
HFA	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
chi	NOUN	O	O
2	NUM	O	O
=	SYM	O	O
6.3	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
pedantic	ADJ	O	O
speech	NOUN	O	O
is	ADJ	O	O
common	ADJ	O	O
in	ADP	O	O
AS	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
help	NOUN	O	O
differentiate	PUNCT	O	O
AS	PUNCT	O	O
from	ADP	O	O
high-functioning	VERB	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Comparative	ADJ	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
twice	PUNCT	O	O
daily	ADJ	O	O
fluticasone	NOUN	O	O
propionate	NOUN	O	O
powder	NOUN	O	O
versus	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
moderate	ADJ	O	O
asthma	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Fluticasone	NOUN	O	O
propionate	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
inhaled	VERB	O	O
corticosteroid	NOUN	O	O
with	ADP	O	O
negligible	ADJ	O	O
systemic	ADJ	O	O
bioavailability	NOUN	O	O
via	ADP	O	O
the	DET	O	O
oral	ADJ	O	O
route	NOUN	O	O
,	PUNCT	O	O
is	VERB	O	O
efficacious	ADJ	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
asthma	NOUN	O	O
when	ADP	O	O
administered	VERB	O	O
via	ADP	O	O
metered-dose	NOUN	O	O
inhaler	ADJ	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
inhaled	VERB	O	O
fluticasone	NOUN	O	O
propionate	NOUN	O	O
powder	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
moderate	ADJ	O	O
asthma	NOUN	O	O
previously	ADV	O	O
treated	VERB	O	O
with	ADP	O	O
an	DET	O	O
inhaled	VERB	O	O
corticosteroid	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
parallel-group	NOUN	O	O
,	PUNCT	O	O
multicenter	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
342	NUM	O	O
adolescent	NOUN	O	O
and	CCONJ	O	O
adult	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
moderate	ADJ	O	O
asthma	NOUN	O	O
[	PUNCT	O	O
forced	VERB	O	B-PHYSICAL
expiratory	ADJ	O	I-PHYSICAL
volume	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
1	NUM	O	I-PHYSICAL
second	ADJ	O	I-PHYSICAL
(	PUNCT	O	O
FEV1	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
between	ADP	O	O
50	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
80	NUM	O	O
%	SYM	O	O
of	ADP	O	O
predicted	PUNCT	O	O
]	PUNCT	O	O
treated	ADP	O	O
previously	ADV	O	O
by	ADP	O	O
beclomethasone	NOUN	O	O
dipropionate	PUNCT	O	O
or	CCONJ	O	O
triamcinolone	ADV	O	O
acetonide	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
received	VERB	O	O
fluticasone	NOUN	O	O
propionate	NOUN	O	O
powder	NOUN	O	O
50	NUM	O	O
micrograms	NOUN	O	O
,	PUNCT	O	O
100	NUM	O	O
micrograms	NOUN	O	O
,	PUNCT	O	O
250	NUM	O	O
micrograms	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
via	ADP	O	O
a	DET	O	O
breath-actuated	VERB	O	O
inhalation	NOUN	O	O
device	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
Diskhaler	ADJ	O	O
,	PUNCT	O	O
twice	ADV	O	O
daily	ADJ	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
fluticasone	NOUN	O	O
propionate	NOUN	O	O
groups	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
mean	NOUN	O	O
increase	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
to	PUNCT	O	B-PHYSICAL
endpoint	CCONJ	O	O
in	ADP	O	B-PHYSICAL
FEV1	NOUN	O	B-PHYSICAL
ranging	VERB	O	O
from	ADP	O	O
0.43	NUM	O	O
L	NOUN	O	O
to	ADP	O	O
0.47	NUM	O	O
L.	ADV	O	O
Patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
mean	NOUN	O	O
decrease	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
of	ADP	O	O
0.22	NUM	O	O
L	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
probability	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
remaining	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
over	ADP	O	O
time	NOUN	O	O
without	ADP	O	O
developing	VERB	O	O
signs	NOUN	O	O
of	ADP	O	O
exacerbating	ADV	O	B-PHYSICAL
asthma	NOUN	O	I-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
fluticasone	NOUN	O	O
propionate	NOUN	O	O
groups	NOUN	O	O
than	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Asthma	NOUN	O	B-PHYSICAL
symptom	NOUN	O	I-PHYSICAL
scores	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
supplemental	ADJ	O	B-OTHER
rescue	NOUN	O	I-OTHER
albuterol	NOUN	O	I-OTHER
use	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
number	NOUN	O	O
of	ADP	O	O
nighttime	VERB	O	B-PHYSICAL
awakenings	NOUN	O	I-PHYSICAL
due	VERB	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
asthma	NOUN	O	B-PHYSICAL
requiring	VERB	O	O
treatment	NOUN	O	O
also	ADV	O	O
improved	VERB	O	O
significantly	ADV	O	O
with	ADP	O	O
all	DET	O	O
fluticasone	NOUN	O	O
propionate	NOUN	O	O
treatment	NOUN	O	O
regimens	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
at	ADP	O	O
endpoint	NOUN	O	O
among	ADP	O	O
the	DET	O	O
three	NUM	O	O
fluticasone	NOUN	O	O
propionate	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
drug-related	VERB	O	I-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
occurred	VERB	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Fluticasone	NOUN	O	O
propionate	NOUN	O	O
powder	NOUN	O	O
(	PUNCT	O	O
50	NUM	O	O
,	PUNCT	O	O
100	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
250	NUM	O	O
micrograms	NOUN	O	O
)	PUNCT	O	O
was	PUNCT	O	O

Clonidine	NOUN	O	O
increases	PUNCT	O	O
the	DET	O	O
sweating	PUNCT	O	B-PHYSICAL
threshold	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
but	CCONJ	O	O
does	PUNCT	O	O
not	ADV	O	O
reduce	VERB	O	O
the	DET	O	O
gain	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
sweating	ADP	O	I-PHYSICAL
.	PUNCT	O	O

We	PRON	O	O
tested	VERB	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	VERB	O	O
clonidine	NOUN	O	O
produces	NOUN	O	O
a	DET	O	O
dose-dependent	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
the	DET	O	O
sweating	PUNCT	O	B-PHYSICAL
threshold	NOUN	O	I-PHYSICAL
but	CCONJ	O	O
does	PUNCT	O	O
not	ADV	O	O
reduce	VERB	O	O
the	DET	O	O
gain	NOUN	O	O
of	ADP	O	O
sweating	ADP	O	O
.	PUNCT	O	O

Six	NUM	O	O
healthy	ADJ	O	O
male	NOUN	O	O
volunteers	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
,	PUNCT	O	O
each	CCONJ	O	O
on	ADP	O	O
three	NUM	O	O
separate	ADJ	O	O
days	NOUN	O	O
in	ADP	O	O
random	ADJ	O	O
order	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
one	NUM	O	O
,	PUNCT	O	O
saline	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
;	PUNCT	O	O
in	ADP	O	O
another	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
2-micrograms/kg	NOUN	O	O
bolus	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
an	DET	O	O
infusion	NOUN	O	O
at	ADP	O	O
2	NUM	O	O
micrograms.kg-1.h-1	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
a	DET	O	O
third	ADJ	O	O
day	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
4-micrograms/kg	ADJ	O	O
bolus	NOUN	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
an	DET	O	O
infusion	NOUN	O	O
at	ADP	O	O
4	NUM	O	O
micrograms.kg-1.h-1	NOUN	O	O
.	PUNCT	O	O

Core	NOUN	O	B-PHYSICAL
temperature	NOUN	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
the	DET	O	O
tympanic	ADJ	O	O
membrane	NOUN	O	O
and	CCONJ	O	O
mean	NOUN	O	O
skin	NOUN	O	B-PHYSICAL
temperature	NOUN	O	I-PHYSICAL
was	VERB	O	O
determined	VERB	O	O
from	ADP	O	O
four	NUM	O	O
sites	NOUN	O	O
.	PUNCT	O	O

A	PUNCT	O	O
chest	NOUN	O	B-PHYSICAL
sweating	PUNCT	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	O
40	NUM	O	O
g.m-2.h-1	PUNCT	O	O
was	VERB	O	O
considered	VERB	O	O
significant	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
core	NOUN	O	O
temperature	NOUN	O	O
triggering	VERB	O	O
sweating	ADP	O	B-PHYSICAL
,	PUNCT	O	O
adjusted	ADP	O	O
to	ADP	O	O
a	DET	O	O
designated	PUNCT	O	O
mean	NOUN	O	O
skin	NOUN	O	O
temperature	NOUN	O	O
of	ADP	O	O
34	NUM	O	O
degrees	NOUN	O	O
C	NOUN	O	O
,	PUNCT	O	O
identified	ADP	O	O
the	DET	O	O
threshold	NOUN	O	O
for	ADP	O	O
this	DET	O	O
response	NOUN	O	O
.	PUNCT	O	O

Gain	NOUN	O	O
was	VERB	O	O
defined	VERB	O	O
by	ADP	O	O
the	DET	O	O
adjusted	ADJ	O	O
core	NOUN	O	B-PHYSICAL
temperature	NOUN	O	I-PHYSICAL
increase	NOUN	O	O
required	ADV	O	O
to	PART	O	O
augment	ADV	O	O
sweating	SYM	O	O
from	ADP	O	O
100	NUM	O	O
to	ADP	O	O
300	NUM	O	O
g.m-2.h-1	ADV	O	O
.	PUNCT	O	O

degree	NOUN	O	O
C-1	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-PHYSICAL
clonidine	NOUN	O	I-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
were	VERB	O	O
0.8	NUM	O	O
+/-	SYM	O	O
0.1	NUM	O	O
and	CCONJ	O	O
1.6	NUM	O	O
+/-	SYM	O	O
0.2	PUNCT	O	O
ng/mL	NOUN	O	O
on	ADP	O	O
the	DET	O	O
small-	NOUN	O	O
and	CCONJ	O	O
large-dose	NOUN	O	O
days	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Clonidine	NOUN	O	O
administration	NOUN	O	O
increased	VERB	O	O
the	DET	O	O
sweating	PUNCT	O	O
threshold	NOUN	O	O
approximately	ADV	O	O
0.4	NUM	O	O
degree	NOUN	O	O
C	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
increase	NOUN	O	O
was	VERB	O	O
comparable	ADJ	O	O
at	ADP	O	O
each	DET	O	O
dose	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
gain	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
sweating	SYM	O	I-PHYSICAL
was	ADV	O	O
approximately	ADV	O	O
0.2	NUM	O	O
degree	NOUN	O	O
C	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
not	ADV	O	O
influenced	VERB	O	O
by	ADP	O	O
clonidine	NOUN	O	O
administration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
thermoregulatory	ADJ	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
of	ADP	O	O
clonidine	NOUN	O	O
thus	ADP	O	O
resemble	VERB	O	O
those	PUNCT	O	O
of	ADP	O	O
volatile	ADJ	O	O
anesthetics	NOUN	O	O
,	PUNCT	O	O
opioids	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
propofol	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
antishivering	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	O
results	NOUN	O	O
from	ADP	O	O
central	ADJ	O	O
thermoregulatory	ADJ	O	O
inhibition	NOUN	O	O
rather	PUNCT	O	O
than	ADP	O	O
a	DET	O	O
specific	ADJ	O	O
peripheral	ADJ	O	O
action	NOUN	O	O
on	ADP	O	O
thermogenic	ADJ	O	O
muscular	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

Unlike	ADP	O	O
other	ADJ	O	O
sedatives	ADJ	O	O
and	CCONJ	O	O
anesthetics	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
concentration-dependence	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	O
demonstrates	NOUN	O	O
a	DET	O	O
ceiling	PUNCT	O	O
beyond	ADP	O	O
which	ADP	O	O
the	DET	O	O
administration	NOUN	O	O
of	ADP	O	O
an	DET	O	O
additional	ADJ	O	O
drug	NOUN	O	O
fails	NOUN	O	O
to	PART	O	O
enhance	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
that	ADP	O	O
the	DET	O	O
thermoregulatory	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
clonidine	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
limited	VERB	O	O
,	PUNCT	O	O
even	ADV	O	O
at	ADP	O	O
high	ADJ	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
gain	NOUN	O	O
of	ADP	O	O
sweating	ADP	O	O
was	VERB	O	O
well	VERB	O	O
preserved	CCONJ	O	O
indicating	VERB	O	O
that	ADP	O	O
this	DET	O	O
response	NOUN	O	O
remains	NOUN	O	O
effective	ADJ	O	O
in	ADP	O	O
the	DET	O	O
presence	NOUN	O	O
of	ADP	O	O
sedatives	ADV	O	O
and	CCONJ	O	O
anesthetics	NOUN	O	O
.	PUNCT	O	O

Coagulation	NOUN	O	O
factor	NOUN	O	O
concentrate	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
the	DET	O	O
haemorrhagic	ADJ	O	B-PHYSICAL
diathesis	NOUN	O	I-PHYSICAL
of	ADP	O	O
fulminant	ADJ	O	O
hepatic	ADJ	O	O
failure	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
assess	NOUN	O	O
the	DET	O	O
value	NOUN	O	O
of	ADP	O	O
clotting	VERB	O	O
factor	NOUN	O	O
concentrate	VERB	O	O
infusions	NOUN	O	O
in	ADP	O	O
fulminant	ADJ	O	O
hepatic	ADJ	O	B-PHYSICAL
failure	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
a	DET	O	O
controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
which	DET	O	O
nine	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
concentrate	ADJ	O	O
alone	ADJ	O	O
or	CCONJ	O	O
concentrate	NOUN	O	O
plus	CCONJ	O	O
heparin	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
five	NUM	O	O
patients	NOUN	O	O
receiving	CCONJ	O	O
concentrate	ADV	O	O
alone	PUNCT	O	O
all	PUNCT	O	O
died	ADP	O	B-MORTALITY
,	PUNCT	O	O
with	ADP	O	O
major	ADJ	O	B-ADVERSE-EFFECTS
bleeding	VERB	O	I-ADVERSE-EFFECTS
as	ADP	O	O
the	DET	O	O
direct	ADJ	O	O
cause	ADJ	O	O
of	ADP	O	O
death	NOUN	O	O
in	ADP	O	O
three	NUM	O	O
,	PUNCT	O	O
whereas	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
four	PUNCT	O	O
receiving	VERB	O	O
heparin	NOUN	O	O
as	PUNCT	O	O
well	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
only	ADV	O	O
one	NUM	O	O
instance	NOUN	O	O
of	ADP	O	O
bleeding	VERB	O	B-ADVERSE-EFFECTS
and	CCONJ	O	O
one	NUM	O	O
patient	NOUN	O	O
survived	PUNCT	O	B-MORTALITY
.	PUNCT	O	O

Clinical	ADJ	O	O
evidence	NOUN	O	O
of	ADP	O	O
intravascular	PUNCT	O	B-PHYSICAL
coagulation	NOUN	O	I-PHYSICAL
appeared	VERB	O	O
in	ADP	O	O
two	NUM	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
concentrate	NOUN	O	O
alone	ADJ	O	O
and	CCONJ	O	O
the	DET	O	O
laboratory	NOUN	O	O
evidence	NOUN	O	O
of	ADP	O	O
this	PUNCT	O	O
progressed	VERB	O	O
during	ADP	O	O
the	DET	O	O
period	NOUN	O	O
of	ADP	O	O
infusions	NOUN	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
to	ADP	O	O
a	DET	O	O
lesser	PUNCT	O	O
extent	NOUN	O	O
in	ADP	O	O
those	PUNCT	O	O
receiving	VERB	O	O
heparin	NOUN	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
evidence	NOUN	O	O
for	ADP	O	O
intravascular	PUNCT	O	O
coagulation	NOUN	O	O
came	VERB	O	O
from	ADP	O	O
the	DET	O	O
changes	NOUN	O	O
observed	VERB	O	O
in	ADP	O	O
factor	NOUN	O	O
VIII	NUM	O	O
levels	NOUN	O	O
which	ADP	O	O
,	PUNCT	O	O
although	ADP	O	O
initially	ADV	O	O
high	ADJ	O	O
in	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
fell	ADP	O	O
subsequently	ADV	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
those	DET	O	O
given	VERB	O	O
concentrate	ADV	O	O
alone	ADJ	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
some	DET	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prothrombin	NOUN	O	B-PHYSICAL
ratio	NOUN	O	I-PHYSICAL
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
complete	ADJ	O	O
correction	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
serial	ADJ	O	O
assays	NOUN	O	O
of	ADP	O	O
clotting	PROPN	O	O
factors	NOUN	O	O
showed	VERB	O	O
that	ADP	O	O
although	ADP	O	O
factor	NOUN	O	O
II	NUM	O	B-PHYSICAL
rose	CCONJ	O	O
to	ADP	O	O
high	ADJ	O	O
levels	NOUN	O	O
during	ADP	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
factors	NOUN	O	B-PHYSICAL
IX	ADJ	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
X	NUM	O	I-PHYSICAL
showed	VERB	O	O
little	DET	O	O
response	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
concentrate	NOUN	O	O
of	ADP	O	O
factor	NOUN	O	O
IX	NUM	O	O
in	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
,	PUNCT	O	O
as	CCONJ	O	O
well	PUNCT	O	O
as	CCONJ	O	O
potentiating	PUNCT	O	O
intravascular	ADJ	O	B-PHYSICAL
coagulation	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
was	VERB	O	O
inadequate	ADJ	O	O
as	VERB	O	O
replacement	NOUN	O	O
for	ADP	O	O
the	DET	O	O
clotting	VERB	O	O
factor	NOUN	O	O
deficiencies	NOUN	O	O
.	PUNCT	O	O

Maternal	ADJ	O	O
breast-milk	NOUN	O	O
and	CCONJ	O	O
intestinal	ADJ	O	O
bifidobacteria	NOUN	O	O
guide	VERB	O	O
the	DET	O	O
compositional	ADJ	O	O
development	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Bifidobacterium	NOUN	O	O
microbiota	NOUN	O	O
in	ADP	O	O
infants	NOUN	O	O
at	ADP	O	O
risk	NOUN	O	O
of	ADP	O	O
allergic	ADJ	O	O
disease	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
sources	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
maternal	ADJ	O	O
bacteria	NOUN	O	O
on	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
inoculum	NOUN	O	O
of	ADP	O	O
the	DET	O	O
intestinal	ADJ	O	O
microflora	NOUN	O	O
of	ADP	O	O
newborn	NOUN	O	O
infants	NOUN	O	O
remain	VERB	O	O
elusive	ADJ	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
assess	NOUN	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
maternal	ADJ	O	O
breast-milk	NOUN	O	O
and	CCONJ	O	O
fecal	ADJ	O	O
bifidobacteria	NOUN	O	O
and	CCONJ	O	O
infants	NOUN	O	O
'	PUNCT	O	O
fecal	ADJ	O	O
bifidobacteria	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Sixty-one	ADJ	O	O
mother-infant	NOUN	O	O
pairs	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
,	PUNCT	O	O
special	ADJ	O	O
emphasis	NOUN	O	O
being	VERB	O	O
placed	VERB	O	O
on	ADP	O	O
the	DET	O	O
maternal	ADJ	O	O
allergic	ADJ	O	O
status	NOUN	O	O
.	PUNCT	O	O

Bifidobacteria	ADV	O	B-PHYSICAL
were	VERB	O	O
analysed	VERB	O	O
by	ADP	O	O
a	DET	O	O
direct	ADJ	O	O
PCR	NOUN	O	O
method	NOUN	O	O
in	ADP	O	O
fecal	ADJ	O	O
samples	NOUN	O	O
from	ADP	O	O
mothers	NOUN	O	O
at	ADP	O	O
30-35	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
gestation	NOUN	O	O
and	CCONJ	O	O
from	ADP	O	O
infants	NOUN	O	O
at	ADP	O	O
1	NUM	O	O
month	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
and	CCONJ	O	O
from	ADP	O	O
breast-milk	ADJ	O	O
samples	NOUN	O	O
1	NUM	O	O
month	NOUN	O	O
post-partum	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Fecal	ADJ	O	O
Bifidobacterium	NOUN	O	O
adolescentis	NOUN	O	O
and	CCONJ	O	O
Bifidobacterium	NOUN	O	O
bifidum	PUNCT	O	O
colonization	NOUN	O	O
frequencies	NOUN	O	O
and	CCONJ	O	O
counts	NOUN	O	O
among	ADP	O	O
mother-infant	NOUN	O	O
pairs	NOUN	O	O
correlated	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
P=0.005	NOUN	O	O
and	CCONJ	O	O
0.02	NUM	O	O
for	ADP	O	O
frequencies	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
P=0.002	NOUN	O	O
and	CCONJ	O	O
0.01	NUM	O	O
for	ADP	O	O
counts	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Only	DET	O	O
infants	NOUN	O	O
of	ADP	O	O
allergic	ADJ	O	O
,	PUNCT	O	O
atopic	ADJ	O	O
mothers	NOUN	O	O
were	VERB	O	O
colonized	VERB	O	O
with	ADP	O	O
B.	NOUN	O	O
adolescentis	NOUN	O	O
.	PUNCT	O	O

Each	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
breast-milk	ADJ	O	O
samples	NOUN	O	O
contained	VERB	O	O
bifidobacteria	NOUN	O	O
[	PUNCT	O	O
median	ADJ	O	O
1.4	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
bacterial	ADJ	O	O
cells/mL	NOUN	O	O
;	PUNCT	O	O
interquartile	NOUN	O	O
range	NOUN	O	O
(	PUNCT	O	O
IQR	NOUN	O	O
)	PUNCT	O	O
48.7-3.8	PUNCT	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Bifidobacterium	NOUN	O	B-PHYSICAL
longum	NOUN	O	I-PHYSICAL
was	VERB	O	O
the	DET	O	O
most	PUNCT	O	O
frequently	ADV	O	O
detected	ADJ	O	O
species	DET	O	O
in	ADP	O	O
breast-milk	NOUN	O	O
.	PUNCT	O	O

Allergic	ADJ	O	O
mothers	NOUN	O	O
had	PUNCT	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
amounts	NOUN	O	O
of	ADP	O	O
bifidobacteria	NOUN	O	B-PHYSICAL
in	ADP	O	O
breast-milk	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
non-allergic	ADJ	O	O
mothers	NOUN	O	O
[	PUNCT	O	O
median	ADJ	O	O
1.3	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
bacterial	ADJ	O	O
cells/mL	NOUN	O	O
(	PUNCT	O	O
IQR	NOUN	O	O
22.4-3.0	PUNCT	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
vs.	CCONJ	O	O
5.6	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
bacterial	ADJ	O	O
cells/mL	NOUN	O	O
(	PUNCT	O	O
1.8	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
-1.8	NUM	O	O
x	ADJ	O	O
10	NUM	O	O
(	PUNCT	O	O
4	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
(	PUNCT	O	O
P=0.004	NOUN	O	O
)	PUNCT	O	O
]	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
their	DET	O	O
infants	NOUN	O	O
had	PUNCT	O	O
concurrently	ADV	O	O
lower	ADP	O	O
counts	NOUN	O	O
of	ADP	O	O
bifidobacteria	NOUN	O	B-PHYSICAL
in	ADP	O	O
feces	NOUN	O	O
[	PUNCT	O	O
3.9	ADP	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
8	NUM	O	O
)	PUNCT	O	O
bacterial	ADJ	O	O
cells/g	NOUN	O	O
(	PUNCT	O	O
IQR	NOUN	O	O
6.5	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
6	NUM	O	O
)	PUNCT	O	O
-1.5	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
infants	NOUN	O	O
of	ADP	O	O
allergic	ADJ	O	O
mothers	NOUN	O	O
,	PUNCT	O	O
vs.	CCONJ	O	O
2.5	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
)	PUNCT	O	O
bacterial	ADJ	O	O
cells/g	NOUN	O	O
(	PUNCT	O	O
6.5	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
8	NUM	O	O
)	PUNCT	O	O
-3.2	ADP	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
10	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
in	ADP	O	O
infants	NOUN	O	O
of	ADP	O	O
non-allergic	ADJ	O	O
mothers	NOUN	O	O
,	PUNCT	O	O
P=0.013	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Breast-milk	ADJ	O	O
contains	VERB	O	O
significant	ADJ	O	O
numbers	NOUN	O	O
of	ADP	O	O
bifidobacteria	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
maternal	ADJ	O	O
allergic	ADJ	O	O
status	NOUN	O	O
further	DET	O	O
deranges	VERB	O	O
the	DET	O	O
counts	NOUN	O	O
of	ADP	O	O
bifidobacteria	NOUN	O	O
in	ADP	O	O
breast-milk	NOUN	O	O
.	PUNCT	O	O

Maternal	ADJ	O	O
fecal	ADJ	O	O
and	CCONJ	O	O
breast-milk	NOUN	O	O
bifidobacterial	ADP	O	O
counts	NOUN	O	O
impacted	VERB	O	O
on	ADP	O	O
the	DET	O	O
infants	NOUN	O	O
'	PUNCT	O	O
fecal	ADJ	O	O
Bifidobacterium	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Breast-milk	ADV	O	O
bacteria	NOUN	O	O
should	SYM	O	O
thus	ADV	O	O
be	PUNCT	O	O
considered	VERB	O	O
an	DET	O	O
important	ADJ	O	O
source	NOUN	O	O
of	ADP	O	O
bacteria	NOUN	O	O
in	ADP	O	O
the	DET	O	O
establishment	NOUN	O	O
of	ADP	O	O
infantile	ADJ	O	O
intestinal	ADJ	O	O
microbiota	NOUN	O	O
.	PUNCT	O	O

Psychoeducational	ADJ	O	O
group	NOUN	O	O
intervention	NOUN	O	O
for	ADP	O	O
wives	PUNCT	O	O
of	ADP	O	O
men	NOUN	O	O
with	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
6-week	NOUN	O	O
psychoeducational	ADJ	O	O
group	NOUN	O	O
intervention	NOUN	O	O
on	ADP	O	O
the	DET	O	O
distress	NOUN	O	O
,	PUNCT	O	O
coping	ADP	O	O
,	PUNCT	O	O
personal	ADJ	O	O
growth	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
marital	ADJ	O	O
communication	NOUN	O	O
of	ADP	O	O
wives	PUNCT	O	O
of	ADP	O	O
men	NOUN	O	O
diagnosed	VERB	O	O
with	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
using	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Sixty	PUNCT	O	O
wives	PUNCT	O	O
completed	ADV	O	O
measures	NOUN	O	O
prior	PUNCT	O	O
to	ADP	O	O
random	ADJ	O	O
assignment	NOUN	O	O
to	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
psychoeducational	ADJ	O	O
group	NOUN	O	O
intervention	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
no-treatment	NOUN	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
month	NOUN	O	O
after	ADP	O	O
completion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
group	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
No	DET	O	O
differences	NOUN	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
wives	PUNCT	O	O
'	PUNCT	O	O
general	ADJ	O	B-MENTAL
distress	NOUN	O	I-MENTAL
or	CCONJ	O	O
cancer-specific	ADJ	O	B-MENTAL
distress	NOUN	O	I-MENTAL
were	VERB	O	O
noted	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
participants	NOUN	O	O
receiving	VERB	O	O
the	DET	O	O
intervention	NOUN	O	O
perceived	CCONJ	O	O
that	ADP	O	O
having	VERB	O	O
a	DET	O	O
spouse	NOUN	O	O
with	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
had	PUNCT	O	O
made	PUNCT	O	O
positive	ADJ	O	O
contributions	NOUN	O	O
to	ADP	O	O
their	PUNCT	O	O
lives	NOUN	O	O
,	PUNCT	O	O
reported	ADP	O	O
gains	NOUN	O	O
in	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
positive	ADJ	O	O
reappraisal	ADJ	O	B-MENTAL
coping	PUNCT	O	I-MENTAL
and	CCONJ	O	O
reductions	NOUN	O	O
in	ADP	O	O
denial	ADJ	O	B-MENTAL
coping	DET	O	I-MENTAL
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Although	ADP	O	O
the	DET	O	O
psychoeducational	ADJ	O	O
intervention	NOUN	O	O
did	DET	O	O
not	ADV	O	O
result	VERB	O	O
in	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
psychological	ADJ	O	B-MENTAL
distress	NOUN	O	I-MENTAL
,	PUNCT	O	O
improvements	ADJ	O	O
in	ADP	O	O
adaptive	ADJ	O	B-MENTAL
coping	PUNCT	O	I-MENTAL
and	CCONJ	O	O
indicators	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
psychological	ADJ	O	I-MENTAL
growth	NOUN	O	I-MENTAL
were	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
utility	NOUN	O	O
of	ADP	O	O
group	NOUN	O	O
interventions	NOUN	O	O
for	ADP	O	O
spouses	NOUN	O	O
of	ADP	O	O
men	NOUN	O	O
with	ADP	O	O
prostate	NOUN	O	O
cancer	NOUN	O	O
is	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O

Study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
therapeutic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
hippotherapy	CCONJ	O	O
simulator	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
cerebral	ADJ	O	O
palsy	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
stratified	ADJ	O	O
single-blind	NOUN	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
investigate	ADJ	O	O
whether	ADP	O	O
hippotherapy	CCONJ	O	O
(	PUNCT	O	O
when	ADP	O	O
applied	VERB	O	O
by	ADP	O	O
a	DET	O	O
simulator	NOUN	O	O
)	PUNCT	O	O
improves	NOUN	O	O
postural	ADJ	O	O
control	NOUN	O	O
and	CCONJ	O	O
balance	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
cerebral	ADJ	O	O
palsy	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Stratified	PUNCT	O	O
single-blind	NOUN	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
with	ADP	O	O
an	DET	O	O
independent	ADJ	O	O
assessor	NOUN	O	O
.	PUNCT	O	O

Stratification	NOUN	O	O
was	VERB	O	O
made	VERB	O	O
by	ADP	O	O
gross	ADJ	O	O
motor	NOUN	O	O
function	VERB	O	O
classification	NOUN	O	O
system	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
allocation	NOUN	O	O
was	VERB	O	O
concealed	PUNCT	O	O
.	PUNCT	O	O

SUBJECTS	NOUN	O	O
Children	PROPN	O	O
between	ADP	O	O
4	NUM	O	O
and	CCONJ	O	O
18	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
with	ADP	O	O
cerebral	ADJ	O	O
palsy	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
Participants	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
an	DET	O	O
intervention	NOUN	O	O
(	PUNCT	O	O
simulator	NOUN	O	O
ON	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
control	NOUN	O	O
(	PUNCT	O	O
simulator	NOUN	O	O
OFF	ADP	O	O
)	PUNCT	O	O
group	NOUN	O	O
after	ADP	O	O
getting	VERB	O	O
informed	VERB	O	O
consent	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
was	VERB	O	O
provided	PROPN	O	O
once	PUNCT	O	O
a	DET	O	O
week	NOUN	O	O
(	PUNCT	O	O
15	NUM	O	O
minutes	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
10	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
MEASURES	NOUN	O	O
Gross	ADJ	O	B-PHYSICAL
Motor	NOUN	O	I-PHYSICAL
Function	NOUN	O	I-PHYSICAL
Measure	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
dimension	NOUN	O	B-PHYSICAL
B	NOUN	O	I-PHYSICAL
for	ADP	O	I-PHYSICAL
balance	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
Total	ADJ	O	O
Score	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Sitting	PUNCT	O	B-PHYSICAL
Assessment	NOUN	O	I-PHYSICAL
Scale	NOUN	O	I-PHYSICAL
were	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
at	ADP	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
prior	PUNCT	O	O
to	ADP	O	O
randomization	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
end	NOUN	O	O
of	ADP	O	O
intervention	NOUN	O	O
and	CCONJ	O	O
12	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
completing	VERB	O	O
the	DET	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Thirty-eight	PUNCT	O	O
children	NOUN	O	O
participated	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
groups	NOUN	O	O
were	VERB	O	O
balanced	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

Sitting	ADP	O	B-PHYSICAL
balance	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
measured	PROPN	O	O
by	ADP	O	O
dimension	NOUN	O	O
B	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Gross	ADJ	O	O
Motor	NOUN	O	O
Function	NOUN	O	O
Measure	NOUN	O	O
)	PUNCT	O	O
improved	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
effect	NOUN	O	O
size	NOUN	O	O
=	SYM	O	O
0.36	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0.01-0.71	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
effect	NOUN	O	O
size	NOUN	O	O
was	VERB	O	O
greater	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
severely	PROPN	O	O
disabled	DET	O	O
group	NOUN	O	O
(	PUNCT	O	O
effect	NOUN	O	O
size	NOUN	O	O
=	SYM	O	O
0.80	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
0.13-1.47	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
improvements	NOUN	O	O
in	ADP	O	O
sitting	ADV	O	B-PHYSICAL
balance	NOUN	O	I-PHYSICAL
were	VERB	O	O
not	ADV	O	O
maintained	VERB	O	O
over	ADP	O	O
the	DET	O	O
follow-up	NOUN	O	O
period	NOUN	O	O
.	PUNCT	O	O

Changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
total	ADJ	O	O
score	NOUN	O	O
of	ADP	O	O
the	DET	O	B-PHYSICAL
Gross	ADJ	O	I-PHYSICAL
Motor	NOUN	O	I-PHYSICAL
Function	NUM	O	I-PHYSICAL
Measure	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
Sitting	PUNCT	O	B-PHYSICAL
Assessment	NOUN	O	I-PHYSICAL
Scale	NOUN	O	I-PHYSICAL
were	VERB	O	O
not	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Hippotherapy	CCONJ	O	O
with	ADP	O	O
a	DET	O	O
simulator	NOUN	O	O
can	VERB	O	O
improve	VERB	O	O
sitting	ADP	O	B-PHYSICAL
balance	NOUN	O	I-PHYSICAL
in	ADP	O	O
cerebral	ADJ	O	O
palsy	NOUN	O	O
children	NOUN	O	O
who	DET	O	O
have	PUNCT	O	O
higher	PUNCT	O	O
levels	NOUN	O	O
of	ADP	O	O
disability	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
this	PUNCT	O	O
did	PUNCT	O	O
not	ADV	O	O
lead	VERB	O	O
to	ADP	O	O
a	DET	O	O
change	NOUN	O	O
in	ADP	O	O
the	DET	O	O
overall	ADJ	O	O
function	NOUN	O	O
of	ADP	O	O
these	DET	O	O
children	NOUN	O	O
(	PUNCT	O	O
Gross	ADJ	O	O
Motor	NOUN	O	O
Function	NOUN	O	O
Classification	NOUN	O	O
System	NOUN	O	O
level	NOUN	O	O
V	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Clinical	ADJ	O	O
observation	NOUN	O	O
on	ADP	O	O
different	ADJ	O	O
acupuncture	ADP	O	O
and	CCONJ	O	O
moxibustion	NOUN	O	O
therapies	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
postsurgical	ADJ	O	O
gastroparesis	NOUN	O	O
syndrome	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
optimize	NOUN	O	O
therapy	NOUN	O	O
of	ADP	O	O
acupuncture	ADP	O	O
and	CCONJ	O	O
moxibustion	NOUN	O	O
for	ADP	O	O
postsurgical	ADJ	O	O
gastroparesis	NOUN	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
PGS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Forty-one	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
PGS	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
3	NUM	O	O
groups	NOUN	O	O
in	ADP	O	O
order	NOUN	O	O
of	ADP	O	O
visiting	NUM	O	O
.	PUNCT	O	O

Group	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
17	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
warming	VERB	O	O
needle	NOUN	O	O
moxibustion	NOUN	O	O
,	PUNCT	O	O
group	NOUN	O	O
B	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
12	NUM	O	O
)	PUNCT	O	O
by	ADP	O	O
acupuncture	ADP	O	O
plus	CCONJ	O	O
auricular	ADJ	O	O
point	NOUN	O	O
sticking	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
group	NOUN	O	O
C	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
12	NUM	O	O
)	PUNCT	O	O
by	ADP	O	O
routine	ADJ	O	O
acupuncture	ADP	O	O
.	PUNCT	O	O

Changes	NOUN	O	O
of	ADP	O	O
gastric	ADJ	O	B-PHYSICAL
drainage	NOUN	O	I-PHYSICAL
volume	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
therapeutic	ADJ	O	O
times	NOUN	O	O
and	CCONJ	O	O
cured	VERB	O	O
rate	NOUN	O	O
were	VERB	O	O
investigated	VERB	O	O
in	ADP	O	O
the	DET	O	O
3	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

RESULTS	ADP	O	O
All	PUNCT	O	O
the	DET	O	O
3	NUM	O	O
therapeutic	ADJ	O	O
methods	NOUN	O	O
could	ADP	O	O
significantly	NOUN	O	O
decrease	NOUN	O	O
gastric	ADJ	O	B-PHYSICAL
drainage	NOUN	O	I-PHYSICAL
volume	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
cured	PUNCT	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
was	VERB	O	O
100.0	CCONJ	O	O
%	SYM	O	O
and	CCONJ	O	O
the	DET	O	O
therapeutic	ADJ	O	B-PHYSICAL
times	NOUN	O	I-PHYSICAL
was	VERB	O	O
(	PUNCT	O	O
7.24	NUM	O	O
+/-	SYM	O	O
3.87	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
66.7	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
(	PUNCT	O	O
9.83	NUM	O	O
+/-	SYM	O	O
4.60	NUM	O	O
)	PUNCT	O	O
times	NOUN	O	O
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
B	NOUN	O	O
and	CCONJ	O	O
75.0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
(	PUNCT	O	O
15.25	NUM	O	O
+/-	SYM	O	O
3.81	NUM	O	O
)	PUNCT	O	O
times	NOUN	O	O
in	ADP	O	O
the	DET	O	O
group	NOUN	O	O
C	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cured	VERB	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
therapeutic	ADJ	O	B-PHYSICAL
times	NOUN	O	I-PHYSICAL
among	ADP	O	O
the	DET	O	O
3	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
warming	DET	O	O
needle	NOUN	O	O
moxibustion	NOUN	O	O
is	VERB	O	O
the	DET	O	O
best	PUNCT	O	O
method	NOUN	O	O
for	ADP	O	O
PGS	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
less	DET	O	O
therapeutic	ADJ	O	B-PHYSICAL
times	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
high	ADJ	O	O
cured	ADJ	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
rapid	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Transcutaneous	ADJ	O	O
electrical	ADJ	O	O
nerve	NOUN	O	O
stimulation	NOUN	O	O
following	VERB	O	O
appendicectomy	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
placebo	NOUN	O	O
effect	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
transcutaneous	ADJ	O	O
electrical	ADJ	O	O
nerve	NOUN	O	O
stimulation	NOUN	O	O
(	PUNCT	O	O
TENS	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
standard	ADJ	O	O
intramuscular	ADJ	O	O
opiate	ADJ	O	O
analgesia	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	O
pain	NOUN	O	O
following	VERB	O	O
appendicectomy	NOUN	O	O
.	PUNCT	O	O

Consecutive	ADJ	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
emergency	NOUN	O	O
appendicectomy	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
into	ADP	O	O
control	NOUN	O	O
,	PUNCT	O	O
sham	ADJ	O	O
TENS	NOUN	O	O
and	CCONJ	O	O
active	ADJ	O	O
TENS	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
pain	NOUN	O	B-PAIN
severity	NOUN	O	I-PAIN
and	CCONJ	O	O
analgesic	PUNCT	O	B-OTHER
intake	NOUN	O	I-OTHER
in	ADP	O	O
both	CCONJ	O	O
active	ADJ	O	O
and	CCONJ	O	O
sham	ADJ	O	O
TENS	NOUN	O	O
groups	NOUN	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
demonstrated	VERB	O	O
in	ADP	O	O
pain	NOUN	O	B-PAIN
severity	NOUN	O	I-PAIN
between	ADP	O	O
active	ADJ	O	O
and	CCONJ	O	O
sham	ADJ	O	O
TENS	NOUN	O	O
groups	NOUN	O	O
but	CCONJ	O	O
the	DET	O	O
active	ADJ	O	O
TENS	NOUN	O	O
group	NOUN	O	O
required	PUNCT	O	O
slightly	ADV	O	O
less	ADV	O	O
analgesia	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
results	CCONJ	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
major	ADJ	O	O
benefit	NOUN	O	O
of	ADP	O	O
TENS	NOUN	O	O
in	ADP	O	O
the	DET	O	O
postappendicectomy	NOUN	O	O
patient	NOUN	O	O
is	VERB	O	O
due	CCONJ	O	O
to	ADP	O	O
its	PUNCT	O	O
'placebo	PUNCT	O	O
effect	NOUN	O	O
'	PUNCT	O	O
and	CCONJ	O	O
its	PUNCT	O	O
use	NOUN	O	O
in	ADP	O	O
this	DET	O	O
situation	NOUN	O	O
can	VERB	O	O
not	ADV	O	O
be	VERB	O	O
recommended	VERB	O	O
.	PUNCT	O	O

Is	PUNCT	O	O
a	DET	O	O
calculated	VERB	O	O
total	ADJ	O	O
hip	NOUN	O	O
BMD	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	B-OTHER
use	NOUN	O	I-OTHER
?	PUNCT	O	O

The	DET	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
osteoporosis	NOUN	O	O
is	VERB	O	O
based	VERB	O	O
on	ADP	O	O
bone	NOUN	O	O
mass	NOUN	O	O
measurement	NOUN	O	O
.	PUNCT	O	O

To	DET	O	O
avoid	NOUN	O	O
the	DET	O	O
errors	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
measurement	NOUN	O	O
of	ADP	O	O
spinal	ADJ	O	O
bone	NOUN	O	O
density	NOUN	O	O
the	DET	O	O
total	ADJ	O	O
hip	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
accepted	VERB	O	O
as	ADP	O	O
the	DET	O	O
standard	ADJ	O	O
measurement	NOUN	O	O
site	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
information	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
available	ADJ	O	O
for	ADP	O	O
many	CCONJ	O	O
early	ADJ	O	O
measurements	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
have	ADP	O	O
assessed	VERB	O	O
whether	PUNCT	O	O
it	PRON	O	O
is	VERB	O	O
possible	ADJ	O	O
to	PART	O	O
derive	ADJ	O	O
clinically	ADV	O	O
useful	ADJ	O	O
information	NOUN	O	O
about	PUNCT	O	O
total	ADJ	O	O
hip	NOUN	O	O
bone	NOUN	O	O
mineral	NOUN	O	O
density	NOUN	O	O
(	PUNCT	O	O
BMD	NOUN	O	O
)	PUNCT	O	O
from	ADP	O	O
measurements	NOUN	O	O
at	ADP	O	O
other	ADJ	O	O
hip	NOUN	O	O
sites	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
bone	NOUN	O	O
mass	NOUN	O	O
measurements	NOUN	O	O
of	ADP	O	O
46	NUM	O	O
patients	NOUN	O	O
participating	VERB	O	O
in	ADP	O	O
a	DET	O	O
current	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
for	ADP	O	O
osteoporosis	NOUN	O	O
were	VERB	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
total	ADJ	O	O
hip	NOUN	O	B-PHYSICAL
BMD	NOUN	O	I-PHYSICAL
as	PUNCT	O	O
directly	VERB	O	O
measured	PUNCT	O	O
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
that	PUNCT	O	O
obtained	VERB	O	O
from	ADP	O	O
the	DET	O	O
formula	NOUN	O	O
:	PUNCT	O	O
Total	ADJ	O	O
hip	NOUN	O	B-PHYSICAL
BMD	NOUN	O	I-PHYSICAL
=	SYM	O	O
0.48	NUM	O	O
x	SYM	O	O
Neck	NOUN	O	B-PHYSICAL
BMD	NOUN	O	I-PHYSICAL
+	SYM	O	O
0.62	NUM	O	O
x	SYM	O	O
Trochanteric	NOUN	O	B-PHYSICAL
BMD	NOUN	O	I-PHYSICAL
+	SYM	O	O
0.03	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
30	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
follow-up	NOUN	O	O
data	NOUN	O	O
the	DET	O	O
rate	NOUN	O	O
of	ADP	O	O
change	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
hip	NOUN	O	I-PHYSICAL
BMD	NOUN	O	I-PHYSICAL
over	ADP	O	O
a	DET	O	O
year	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
determined	VERB	O	O
by	ADP	O	O
both	PUNCT	O	O
methods	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
pretreatment	NOUN	O	O
state	NOUN	O	O
there	PUNCT	O	O
was	VERB	O	O
good	ADJ	O	O
agreement	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
measures	NOUN	O	O
(	PUNCT	O	O
r2	NOUN	O	O
=	SYM	O	O
0.96	NUM	O	O
,	PUNCT	O	O
SEE	NOUN	O	O
0.012	NUM	O	O
g/cm2	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

If	PUNCT	O	O
the	DET	O	O
formula	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	ADJ	O	O
compute	NOUN	O	O
a	DET	O	O
change	NOUN	O	O
in	ADP	O	O
total	ADJ	O	O
hip	NOUN	O	B-PHYSICAL
BMD	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
the	DET	O	O
agreement	NOUN	O	O
between	ADP	O	O
both	PUNCT	O	O
methods	NOUN	O	O
remained	ADP	O	O
good	ADJ	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
standard	ADJ	O	O
error	NOUN	O	O
of	ADP	O	O
the	DET	O	O
estimate	NOUN	O	O
of	ADP	O	O
the	DET	O	O
change	NOUN	O	O
represented	ADP	O	O
59	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
observed	PUNCT	O	O
change	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
indicates	NOUN	O	O
that	ADP	O	O
the	DET	O	O
error	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
this	DET	O	O
estimate	NOUN	O	O
is	VERB	O	O
too	ADV	O	O
great	ADJ	O	O
to	PART	O	O
allow	ADJ	O	O
clinically	ADJ	O	O
meaningful	ADJ	O	O
conclusions	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
drawn	VERB	O	O
from	ADP	O	O
calculated	VERB	O	B-PHYSICAL
total	ADJ	O	O
hip	NOUN	O	B-PHYSICAL
BMD	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
whilst	CCONJ	O	O
it	PRON	O	O
may	VERB	O	O
be	VERB	O	O
possible	ADJ	O	O
to	PART	O	O
obtain	NOUN	O	O
reasonable	ADJ	O	O
point	NOUN	O	O
estimates	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
hip	NOUN	O	B-PHYSICAL
BMD	NOUN	O	I-PHYSICAL
from	ADP	O	O
other	ADJ	O	O
measures	NOUN	O	O
in	ADP	O	O
the	DET	O	O
hip	NOUN	O	O
,	PUNCT	O	O
these	DET	O	O
estimates	NOUN	O	O
are	PROPN	O	O
too	ADV	O	O
imprecise	PUNCT	O	O
to	PART	O	O
allow	NOUN	O	O
conclusions	NOUN	O	O
about	PUNCT	O	O

Autism-Spectrum	NOUN	O	O
Quotient-Japanese	ADV	O	O
version	NOUN	O	O
and	CCONJ	O	O
its	ADJ	O	O
short	ADJ	O	O
forms	NOUN	O	O
for	ADP	O	O
screening	PUNCT	O	O
normally	ADP	O	O
intelligent	VERB	O	O
persons	NOUN	O	O
with	ADP	O	O
pervasive	ADJ	O	O
developmental	ADJ	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
Japanese	ADJ	O	O
version	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Autism	NOUN	O	O
Spectrum	NOUN	O	O
Quotient	NOUN	O	O
(	PUNCT	O	O
AQ	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
AQ-J	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
25	NUM	O	O
normally	ADV	O	O
intelligent	PUNCT	O	O
high-functioning	ADP	O	O
pervasive	ADJ	O	O
developmental	ADJ	O	O
disorder	NOUN	O	O
(	PUNCT	O	O
HPDD	NOUN	O	O
)	PUNCT	O	O
patients	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
24.2	NUM	O	O
years	NOUN	O	O
;	PUNCT	O	O
24	NUM	O	O
male	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
female	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
215	NUM	O	O
controls	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
30.4	NUM	O	O
years	NOUN	O	O
;	PUNCT	O	O
86	NUM	O	O
male	NOUN	O	O
,	PUNCT	O	O
129	NUM	O	O
female	NOUN	O	O
)	PUNCT	O	O
randomly	ADV	O	O
selected	VERB	O	O
from	ADP	O	O
the	DET	O	O
general	ADJ	O	O
population	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
AQ-J	NOUN	O	O
had	PUNCT	O	O
satisfactory	ADJ	O	B-OTHER
internal	ADJ	O	I-OTHER
consistency	NOUN	O	O
reliability	NOUN	O	B-OTHER
(	PUNCT	O	O
Cronbach	NOUN	O	O
's	PUNCT	O	O
alpha	NOUN	O	O
>	SYM	O	O
0.70	NUM	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
test-retest	ADV	O	B-OTHER
reliability	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
discriminant	NOUN	O	B-OTHER
validity	NOUN	O	B-OTHER
[	PUNCT	O	O
i.e	ADV	O	O
.	PUNCT	O	O

the	DET	O	O
AQ-J	NOUN	O	O
score	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
HPDD	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
,	PUNCT	O	O
29.6	NUM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
controls	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
,	PUNCT	O	O
22.2	NUM	O	O
)	PUNCT	O	O
]	PUNCT	O	O
.	PUNCT	O	O

At	ADP	O	O
a	DET	O	O
cut-off	NOUN	O	O
of	ADP	O	O
26	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
AQ-J	NOUN	O	B-PHYSICAL
had	PUNCT	O	O
satisfactory	ADJ	O	B-OTHER
sensitivity	NOUN	O	I-OTHER
,	PUNCT	O	O
specificity	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
negative	ADJ	O	O
predictive	ADJ	O	B-OTHER
value	NOUN	O	I-OTHER
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
had	PUNCT	O	O
low	ADJ	O	B-OTHER
positive	ADJ	O	O
predictive	ADJ	O	B-OTHER
value	NOUN	O	I-OTHER
(	PUNCT	O	O
0.24	NUM	O	O
)	PUNCT	O	O
possibly	ADV	O	O
due	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
facts	NOUN	O	O
that	ADP	O	O
the	DET	O	O
25	NUM	O	O
mild	ADJ	O	O
HPDD	NOUN	O	O
patients	NOUN	O	O
scored	DET	O	O
lower	VERB	O	O
and	CCONJ	O	O
the	DET	O	O
controls	NOUN	O	O
scored	PUNCT	O	O
higher	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
AQ-J	NOUN	O	O
than	PUNCT	O	O
British	NOUN	O	O
counterparts	NOUN	O	O
on	ADP	O	O
the	DET	O	O
AQ	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
AQ-J-21	NOUN	O	B-PHYSICAL
(	PUNCT	O	B-PHYSICAL
consisting	PUNCT	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
21	NUM	O	B-PHYSICAL
items	PUNCT	O	I-PHYSICAL

Long-term	NOUN	O	O
evaluation	NOUN	O	O
of	ADP	O	O
tamsulosin	NOUN	O	O
in	ADP	O	O
benign	ADJ	O	O
prostatic	ADJ	O	O
hyperplasia	NOUN	O	O
:	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
extension	NOUN	O	O
of	ADP	O	O
phase	NOUN	O	O
III	NUM	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Tamsulosin	NOUN	O	O
Investigator	NOUN	O	O
Group	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	ADP	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
long-term	NOUN	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
once-daily	NOUN	O	O
tamsulosin	NOUN	O	O
(	PUNCT	O	O
0.4	NUM	O	O
and	CCONJ	O	O
0.8	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
unique	ADJ	O	O
selective	ADJ	O	O
alpha1A-adrenoceptor	NOUN	O	O
antagonist	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
benign	ADJ	O	O
prostatic	ADJ	O	O
hyperplasia	NOUN	O	O
(	PUNCT	O	O
BPH	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
trial	NOUN	O	O
extended	CCONJ	O	O
a	DET	O	O
13-week	NOUN	O	O
,	PUNCT	O	O
Phase	NOUN	O	O
III	NUM	O	O
multicenter	NOUN	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
outpatient	ADJ	O	O
trial	NOUN	O	O
for	ADP	O	O
an	DET	O	O
additional	ADJ	O	O
40	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
618	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
418	NUM	O	O
(	PUNCT	O	O
68	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
continued	VERB	O	O
into	ADP	O	O
the	DET	O	O
extension	NOUN	O	O
phase	NOUN	O	O
on	ADP	O	O
the	DET	O	O
same	ADJ	O	O
double-blind	ADJ	O	O
medication	NOUN	O	O
and	CCONJ	O	O
dose	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
efficacy	NOUN	O	O
parameters	NOUN	O	O
were	VERB	O	O
total	ADJ	O	O
American	ADJ	O	B-PHYSICAL
Urological	ADJ	O	I-PHYSICAL
Association	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
AUA	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
symptom	NOUN	O	B-PHYSICAL
score	NOUN	O	O
and	CCONJ	O	O
maximum	NOUN	O	B-PHYSICAL
urinary	ADJ	O	I-PHYSICAL
flow	NOUN	O	I-PHYSICAL
(	PUNCT	O	B-PHYSICAL
Qmax	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
mean	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
AUA	NOUN	O	B-PHYSICAL
symptom	NOUN	O	B-PHYSICAL
score	NOUN	O	B-PHYSICAL
from	ADP	O	O
baseline	NOUN	O	O
to	ADP	O	O
end	NOUN	O	O
point	NOUN	O	O
were	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
in	ADP	O	O
all	DET	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Significant	ADJ	O	O
improvements	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
Qmax	NOUN	O	B-PHYSICAL
for	ADP	O	O
both	CCONJ	O	O
tamsulosin	NOUN	O	O
groups	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
for	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
statistically	ADJ	O	O
significant	ADJ	O	B-PHYSICAL
improvements	NOUN	O	B-OTHER
from	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
efficacy	NOUN	O	O
parameters	NOUN	O	O
observed	VERB	O	O
for	ADP	O	O
each	DET	O	O
tamsulosin	NOUN	O	O
group	NOUN	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
13-week	ADJ	O	O
Phase	NOUN	O	O
III	NUM	O	O
trial	NOUN	O	O
were	VERB	O	O
maintained	VERB	O	O
during	ADP	O	O
the	DET	O	O
long-term	NOUN	O	O
extension	NOUN	O	O
phase	NOUN	O	O
.	PUNCT	O	O

Tamsulosin	NOUN	O	O
at	ADP	O	O
both	PUNCT	O	O
dosages	NOUN	O	O
was	VERB	O	O
well	VERB	O	O
tolerated	ADP	O	B-OTHER
as	ADP	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Clinically	ADV	O	O
significant	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
upper	ADJ	O	O
arm	NOUN	O	O
brachial	ADJ	O	O
basilic	NOUN	O	O
and	CCONJ	O	O
prosthetic	ADJ	O	O
forearm	NOUN	O	O
arteriovenous	ADJ	O	O
fistula	NOUN	O	O
on	ADP	O	O
left	ADJ	O	B-PHYSICAL
ventricular	ADJ	O	I-PHYSICAL
hypertrophy	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Creation	NOUN	O	O
of	ADP	O	O
an	DET	O	O
arteriovenous	PUNCT	O	O
fistula	NOUN	O	O
(	PUNCT	O	O
AVF	NOUN	O	O
)	PUNCT	O	O
may	ADJ	O	O
increase	NUM	O	O
left	ADJ	O	B-PHYSICAL
ventricular	ADJ	O	I-PHYSICAL
hypertrophy	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
hemodialysis	NOUN	O	O
population	NOUN	O	O
.	PUNCT	O	O

Aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
brachial-basilic	ADJ	O	O
(	PUNCT	O	O
BB	NOUN	O	O
)	PUNCT	O	O
AVF	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
prosthetic	ADJ	O	O
brachial-antecubital	ADJ	O	O
forearm	NOUN	O	O
loop	NOUN	O	O
access	NOUN	O	O
(	PUNCT	O	O
PTFE	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
cardiac	ADJ	O	B-PHYSICAL
performance	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

METHODS	NOUN	O	O
Patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
BB-AVF	NOUN	O	O
or	CCONJ	O	O
prosthetic	ADJ	O	O
brachial-antecubital	ADJ	O	O
forearm	NOUN	O	O
loop	NOUN	O	O
access	NOUN	O	O
.	PUNCT	O	O

Before	PUNCT	O	O
and	CCONJ	O	O
three	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
AVF	NOUN	O	O
creation	NOUN	O	O
patients	NOUN	O	O
underwent	VERB	O	O
an	DET	O	O
echocardiographic	ADJ	O	O
examination	NOUN	O	O
.	PUNCT	O	O

Mann-Whitney	NOUN	O	B-PHYSICAL
U-test	NOUN	O	I-PHYSICAL
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
relative	ADJ	O	O
increase	NOUN	O	O
between	ADP	O	O
the	DET	O	O
measured	PUNCT	O	B-PHYSICAL
cardiac	ADJ	O	I-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
for	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Twenty-seven	PUNCT	O	O
patients	NOUN	O	O
participated	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
relative	ADJ	O	O
increase	NOUN	O	O
in	ADP	O	O
left	ADJ	O	B-PHYSICAL
ventricular	ADJ	O	I-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Only	ADJ	O	O
left	ADJ	O	B-PHYSICAL
ventricular	ADJ	O	I-PHYSICAL
end-diastolic	ADJ	O	I-PHYSICAL
diameter	NOUN	O	I-PHYSICAL
tended	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
of	ADP	O	O
significance	NOUN	O	O
.	PUNCT	O	O

Mean	PUNCT	O	O
blood	NOUN	O	B-PHYSICAL
flow	NOUN	O	I-PHYSICAL
through	ADP	O	O
the	DET	O	O
brachial	ADJ	O	O
artery	NOUN	O	O
was	PRON	O	O
1680+/-156	PUNCT	O	O
and	CCONJ	O	O
1450+/-221	NOUN	O	O
mL/min	NOUN	O	O
three	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
surgery	NOUN	O	O
for	ADP	O	O
the	DET	O	O
PTFE	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
BB-AVF	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
After	ADP	O	O
three	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
cardiac	ADJ	O	B-PHYSICAL
structure	NOUN	O	I-PHYSICAL
were	VERB	O	O
comparable	ADJ	O	O
between	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
BB	NOUN	O	O
and	CCONJ	O	O
PTFE	NOUN	O	O
AVFs	NOUN	O	O
.	PUNCT	O	O

Also	ADV	O	O
access	NOUN	O	B-PHYSICAL
flow	NOUN	O	I-PHYSICAL
was	VERB	O	O
comparable	ADJ	O	O
at	ADP	O	O
this	DET	O	O
time	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
general	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
creation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
fistula	NOUN	O	O
on	ADP	O	O
LV	NOUN	O	O
structure	NOUN	O	O
were	VERB	O	O
limited	VERB	O	O
.	PUNCT	O	O

Longer	PUNCT	O	O
follow	CCONJ	O	O
up	PUNCT	O	O
time	NOUN	O	O
may	ADP	O	O
be	VERB	O	O
needed	VERB	O	O
to	PART	O	O
explore	VERB	O	O
the	DET	O	O
long	ADJ	O	O
term	NOUN	O	O
effects	NOUN	O	O
of	ADP	O	O
different	ADJ	O	O
vascular	ADJ	O	O
accesses	CCONJ	O	O
on	ADP	O	O
cardiac	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

B-domain	NOUN	O	O
deleted	VERB	O	O
recombinant	ADJ	O	O
factor	NOUN	O	O
VIII	PUNCT	O	O
preparations	NOUN	O	O
are	NOUN	O	O
bioequivalent	ADJ	O	O
to	ADP	O	O
a	DET	O	O
monoclonal	ADJ	O	O
antibody	NOUN	O	O
purified	DET	O	O
plasma-derived	VERB	O	O
factor	NOUN	O	O
VIII	PUNCT	O	O
concentrate	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
three-way	PUNCT	O	O
crossover	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Deletion	NOUN	O	O
of	ADP	O	O
the	DET	O	O
B-domain	NOUN	O	O
of	ADP	O	O
recombinant	ADJ	O	O
blood	NOUN	O	O
coagulation	NOUN	O	O
factor	NOUN	O	O
VIII	NUM	O	O
(	PUNCT	O	O
BDDrFVIII	PUNCT	O	O
)	PUNCT	O	O
increases	NOUN	O	O
the	DET	O	O
manufacturing	VERB	O	O
yield	NOUN	O	O
of	ADP	O	O
the	DET	O	O
product	NOUN	O	O
but	CCONJ	O	O
does	PUNCT	O	O
not	ADV	O	O
impair	CCONJ	O	O
in	ADP	O	O
vitro	ADJ	O	O
or	CCONJ	O	O
in	PUNCT	O	O
vivo	ADJ	O	O
functionality	NOUN	O	O
.	PUNCT	O	O

BDDrFVIII	PUNCT	O	O
(	PUNCT	O	O
ReFacto	NOUN	O	O
)	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
developed	VERB	O	O
with	ADP	O	O
the	DET	O	O
additional	ADJ	O	O
benefit	NOUN	O	O
of	ADP	O	O
being	VERB	O	O
formulated	VERB	O	O
without	ADP	O	O
human	NOUN	O	O
albumin	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
primary	ADJ	O	O
objective	NOUN	O	O
of	ADP	O	O
this	DET	O	O
three-way	PUNCT	O	O
crossover-design	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
pharmacokinetic	ADJ	O	O
(	PUNCT	O	O
PK	NOUN	O	O
)	PUNCT	O	O
parameters	NOUN	O	O
of	ADP	O	O
two	NUM	O	O
BDDrFVIII	PUNCT	O	O
formulations	NOUN	O	O
(	PUNCT	O	O
one	NUM	O	O
reconstituted	VERB	O	O
with	ADP	O	O
5	NUM	O	O
mL	NOUN	O	O
of	ADP	O	O
sterile	ADJ	O	O
water	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
other	ADP	O	O
reconstituted	PROPN	O	O
with	ADP	O	O
4	NUM	O	O
mL	NOUN	O	O
sodium	NOUN	O	O
chloride	ADP	O	O
0.9	NUM	O	O
%	SYM	O	O
USP	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
those	PUNCT	O	O
of	ADP	O	O
a	DET	O	O
plasma-derived	VERB	O	O
,	PUNCT	O	O
full-length	NOUN	O	O
FVIII	NUM	O	O
preparation	NOUN	O	O
(	PUNCT	O	O
Hemofil	NOUN	O	O
M	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
haemophilia	ADV	O	O
A	ADJ	O	O
to	PART	O	O
determine	NOUN	O	O
bioequivalence	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
series	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	B-PHYSICAL
samples	NOUN	O	I-PHYSICAL
were	VERB	O	O
collected	VERB	O	O
over	ADP	O	O
a	DET	O	O
period	NOUN	O	O
of	ADP	O	O
48	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
i.v	NUM	O	O
.	PUNCT	O	O

administration	NOUN	O	O
of	ADP	O	O
each	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
FVIII	NUM	O	O
preparations	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-PHYSICAL
FVIII	NUM	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
was	VERB	O	O
determined	VERB	O	O
using	VERB	O	O
a	DET	O	O
validated	VERB	O	O
chromogenic	ADJ	O	O
substrate	NOUN	O	O
assay	NOUN	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-PHYSICAL
FVIII	NUM	O	I-PHYSICAL
activity	NOUN	O	I-PHYSICAL
vs.	CCONJ	O	O
time	NOUN	O	B-OTHER
curves	NOUN	O	I-OTHER
was	VERB	O	O
characterized	VERB	O	O
for	ADP	O	O
a	DET	O	O
standard	ADJ	O	O
set	NOUN	O	O
of	ADP	O	O
PK	NOUN	O	O
parameter	NOUN	O	O
estimates	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
parameter	NOUN	O	O
estimates	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
maximum	NOUN	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
concentration	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
Cmax	NOUN	O	I-PHYSICAL
)	PUNCT	O	B-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
area	NOUN	O	O
under	ADP	O	O
plasma	NOUN	O	B-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
vs.	CCONJ	O	O
time	NOUN	O	B-PHYSICAL
curves	NOUN	O	I-PHYSICAL
(	PUNCT	O	B-PHYSICAL
AUCs	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
bioequivalence	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
two	NUM	O	O
preparations	NOUN	O	O
were	VERB	O	O
considered	NOUN	O	O
bioequivalent	ADJ	O	O
if	PUNCT	O	O
the	DET	O	O
90	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
intervals	NOUN	O	O
for	ADP	O	O
the	DET	O	O
ratio	NOUN	O	O
of	ADP	O	O
geometric	ADJ	O	B-PHYSICAL
means	PUNCT	O	B-PHYSICAL

Extracorporeal	ADJ	O	O
shock	NOUN	O	O
wave	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
ESWT	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
proximal	ADJ	O	O
plantar	NOUN	O	O
fasciitis	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
2-year	NOUN	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
extracorporeal	ADJ	O	O
shock	NOUN	O	O
wave	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
ESWT	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronically	ADV	O	O
painful	ADJ	O	O
proximal	ADJ	O	O
plantar	NOUN	O	O
fasciitis	NOUN	O	O
with	ADP	O	O
a	DET	O	O
further	ADJ	O	O
conventional	ADJ	O	O
conservative	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Forty-seven	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
49	NUM	O	O
feet	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
previously	ADV	O	O
unsuccessful	ADJ	O	O
nonsurgical	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
at	ADJ	O	O
least	ADV	O	O
6	NUM	O	O
months	NOUN	O	O
were	VERB	O	O
randomized	ADP	O	O
to	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Heel	NOUN	O	O
cups	NOUN	O	O
had	CCONJ	O	O
to	PART	O	O
be	PUNCT	O	O
worn	VERB	O	O
throughout	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Group	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
25	NUM	O	O
heels	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
treated	VERB	O	O
immediately	ADV	O	O
with	ADP	O	O
three	NUM	O	O
sessions	NOUN	O	O
of	ADP	O	O
ESWT	NOUN	O	O
(	PUNCT	O	O
3000	NUM	O	O
shock	NOUN	O	O
waves/session	NOUN	O	O
of	ADP	O	O
0.2	NUM	O	O
mJ/mm2	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
weekly	ADV	O	O
intervals	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
of	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
24	NUM	O	O
heels	NOUN	O	O
)	PUNCT	O	O
continued	ADP	O	O
nonsurgical	ADJ	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
iontophoresis	NOUN	O	O
with	ADP	O	O
diclofenac	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
oral	ADJ	O	O
nonsteroidal	ADJ	O	O
anti-inflammatory	ADJ	O	O
drug	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
this	DET	O	O
period	NOUN	O	O
they	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
using	VERB	O	O
the	DET	O	O
protocol	NOUN	O	O
of	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	B-PAIN
and	CCONJ	O	O
walking	DET	O	B-PHYSICAL
time	NOUN	O	I-PHYSICAL
after	ADP	O	O
further	PUNCT	O	O
nonsurgical	ADJ	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
3	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
.	PUNCT	O	O

At	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
ESWT	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
pain	NOUN	O	O
estimation	NOUN	O	O
on	ADP	O	O
the	DET	O	B-PAIN
visual	ADJ	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
(	PUNCT	O	B-PAIN
VAS	NOUN	O	O
)	PUNCT	O	B-PAIN
for	ADP	O	I-PAIN
activities	NOUN	O	B-PAIN
of	ADP	O	I-PAIN
daily	PUNCT	O	I-PAIN
living	ADP	O	B-PAIN
diminished	VERB	O	O
significantly	ADV	O	O
by	ADP	O	O
62.9	NUM	O	O
%	SYM	O	O
in	ADP	O	O
group	NOUN	O	O
1	NUM	O	O
and	CCONJ	O	O
by	ADP	O	O
63.0	NUM	O	O
%	SYM	O	O
in	ADP	O	O
group	NOUN	O	O
2	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
comfortable	PUNCT	O	B-PHYSICAL
walking	DET	O	I-PHYSICAL
time	NOUN	O	I-PHYSICAL
had	PUNCT	O	O
increased	PUNCT	O	O
significantly	ADV	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
ESWT	NOUN	O	O
,	PUNCT	O	O
pain	NOUN	O	O
during	PUNCT	O	O

Reactive	ADJ	O	O
balance	NOUN	O	O
adjustments	NOUN	O	O
to	ADP	O	O
unexpected	VERB	O	O
perturbations	NOUN	O	O
during	ADP	O	O
human	NOUN	O	O
walking	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	PUNCT	O	O
investigation	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
unexpected	ADP	O	O
forward	PUNCT	O	O
perturbations	NOUN	O	O
(	PUNCT	O	O
FP	NOUN	O	O
)	PUNCT	O	O
during	ADP	O	O
gait	NOUN	O	O
on	ADP	O	O
lower	PUNCT	O	O
extremity	NOUN	O	B-PHYSICAL
joint	NOUN	O	I-PHYSICAL
mechanics	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
muscle	NOUN	O	B-PHYSICAL
Electromyographic	ADJ	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
EMG	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
patterns	NOUN	O	I-PHYSICAL
in	ADP	O	O
healthy	ADJ	O	O
adults	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
muscles	NOUN	O	O
surrounding	VERB	O	O
the	DET	O	O
hip	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
most	PUNCT	O	O
important	ADJ	O	O
in	ADP	O	O
maintaining	VERB	O	O
control	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trunk	NOUN	O	O
and	CCONJ	O	O
preventing	ADP	O	B-PHYSICAL
collapse	NOUN	O	I-PHYSICAL
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
the	DET	O	O
FP	NOUN	O	O
.	PUNCT	O	O

Distinct	ADJ	O	B-PHYSICAL
lower	PUNCT	O	O
extremity	NOUN	O	B-PHYSICAL
joint	NOUN	O	I-PHYSICAL
moment	VERB	O	B-PHYSICAL
and	CCONJ	O	O
power	NOUN	O	O
patterns	NOUN	O	B-PHYSICAL
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
the	DET	O	O
FP	NOUN	O	O
but	CCONJ	O	O
an	DET	O	O
overall	ADJ	O	O
positive	ADJ	O	O
moment	NOUN	O	O
of	ADP	O	O
support	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
M	NOUN	O	O
(	PUNCT	O	O
s	NOUN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
maintained	VERB	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O

Niacin	NOUN	O	O
revisited	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
wax-matrix	NOUN	O	O
sustained-release	NOUN	O	O
niacin	NOUN	O	O
in	ADP	O	O
hypercholesterolemia	NOUN	O	O
.	PUNCT	O	O

Two	NUM	O	O
hundred	NUM	O	O
one	NUM	O	O
male	NOUN	O	O
and	CCONJ	O	O
female	NOUN	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
aged	ADP	O	O
20	NUM	O	O
to	ADP	O	O
70	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
elevated	VERB	O	O
low-density	NOUN	O	O
lipoprotein	NOUN	O	O
cholesterol	NOUN	O	O
values	NOUN	O	O
(	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
75th	PUNCT	O	O
to	ADP	O	O
95th	ADJ	O	O
percentiles	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
participated	DET	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	PUNCT	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
using	VERB	O	O
a	DET	O	O
new	ADJ	O	O
form	NOUN	O	O
of	ADP	O	O
niacin	NOUN	O	O
(	PUNCT	O	O
Enduracin	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
which	DET	O	O
employs	NOUN	O	O
a	DET	O	O
wax-matrix	NOUN	O	O
vehicle	NOUN	O	O
for	ADP	O	O
sustained	VERB	O	O
release	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
niacin	NOUN	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
daily	PUNCT	O	O
doses	NOUN	O	O
of	ADP	O	O
2000	NUM	O	O
,	PUNCT	O	O
1500	NUM	O	O
,	PUNCT	O	O
1250	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1000	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
placebo-	NOUN	O	O
and	CCONJ	O	O
diet-treated	VERB	O	O
controls	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
side-effect	NOUN	O	O
profile	ADJ	O	O
and	CCONJ	O	O
optimal	ADJ	O	O
range	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
groups	NOUN	O	O
given	VERB	O	O
2000	NUM	O	O
and	CCONJ	O	O
1500	NUM	O	O
mg	NOUN	O	O
demonstrated	VERB	O	O
significant	ADJ	O	O
reductions	NOUN	O	O
in	ADP	O	O
values	NOUN	O	O
of	ADP	O	O
low-density	NOUN	O	B-PHYSICAL
lipoprotein	NOUN	O	I-PHYSICAL
cholesterol	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
-26	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
-19.3	ADJ	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
total	ADJ	O	O
cholesterol	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
-18.4	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
-13.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
total	ADJ	O	O
cholesterol-high-density	NOUN	O	B-PHYSICAL
lipoprotein	NOUN	O	I-PHYSICAL
cholesterol	NOUN	O	I-PHYSICAL
ratio	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
-20.4	ADV	O	O
%	SYM	O	O
and	CCONJ	O	O
-19.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
diet-	NOUN	O	O
and	CCONJ	O	O
placebo-treated	ADP	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Smaller	PUNCT	O	O
improvements	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
high-density	NOUN	O	B-PHYSICAL
lipoprotein	NOUN	O	I-PHYSICAL
cholesterol	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
triglyceride	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Blood	NOUN	O	O
chemistry	NOUN	O	O
monitoring	PUNCT	O	O
indicated	PUNCT	O	O
that	ADP	O	O
reduction	NOUN	O	O
in	ADP	O	O
low-density	NOUN	O	B-PHYSICAL
lipoprotein	NOUN	O	I-PHYSICAL
cholesterol	NOUN	O	I-PHYSICAL
level	NOUN	O	I-PHYSICAL
strongly	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
baseline	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
some	DET	O	O
enzymes	NOUN	O	O
for	ADP	O	O
niacin-treated	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
improved	VERB	O	O
side-effect	NOUN	O	O
profile	NOUN	O	O
of	ADP	O	O
the	DET	O	O
wax-matrix	NOUN	O	O
form	ADP	O	O
of	ADP	O	O
niacin	NOUN	O	O
was	VERB	O	O
particularly	ADV	O	O
notable	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
dropout	ADP	O	O
rate	NOUN	O	B-OTHER
due	PUNCT	O	O
to	ADP	O	O
side	NOUN	O	O
effects	NOUN	O	O
was	VERB	O	O
only	ADV	O	O
3.4	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
was	VERB	O	O
coupled	VERB	O	O
with	ADP	O	O
good	ADJ	O	O
medication	NOUN	O	O
compliance	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
with	ADP	O	O
metformin	NOUN	O	O
of	ADP	O	O
non-diabetic	ADJ	O	O
men	NOUN	O	O
with	ADP	O	O
hypertension	NOUN	O	O
,	PUNCT	O	O
hypertriglyceridaemia	NOUN	O	O
and	CCONJ	O	O
central	ADJ	O	O
fat	NOUN	O	O
distribution	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
BIGPRO	NOUN	O	O
1.2	NUM	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
In	ADP	O	O
the	DET	O	O
BIGPRO	NOUN	O	O
1	NUM	O	O
trial	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
year	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
metformin	NOUN	O	O
in	ADP	O	O
non-diabetic	ADJ	O	O
obese	ADP	O	O
subjects	NOUN	O	O
with	ADP	O	O
a	DET	O	O
central	ADJ	O	O
fat	NOUN	O	O
distribution	NOUN	O	O
had	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
fasting	VERB	O	O
plasma	NOUN	O	O
triglyceride	NOUN	O	O
concentration	NOUN	O	O
or	CCONJ	O	O
on	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
despite	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
weight	NOUN	O	O
,	PUNCT	O	O
fasting	VERB	O	O
plasma	NOUN	O	O
insulin	NOUN	O	O
and	CCONJ	O	O
glucose	NOUN	O	O
concentrations	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
re-evaluate	PUNCT	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
metformin	NOUN	O	O
on	ADP	O	O
fasting	VERB	O	O
triglyceride	NOUN	O	O
concentration	NOUN	O	O
and	CCONJ	O	O
on	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
BIGPRO	NOUN	O	O
1.2	NUM	O	O
trial	NOUN	O	O
included	VERB	O	O
non-diabetic	ADJ	O	O
men	NOUN	O	O
(	PUNCT	O	O
n=168	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
fasting	VERB	O	O
plasma	NOUN	O	O
triglyceride	NOUN	O	O
concentration	NOUN	O	O
>	SYM	O	O
or	CCONJ	O	O
=1.7	ADJ	O	O
and	CCONJ	O	O
<	SYM	O	O
or	CCONJ	O	O
=6.5	DET	O	O
mmol/l	NOUN	O	O
,	PUNCT	O	O
high	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
systolic	ADJ	O	O
>	NOUN	O	O
or	CCONJ	O	O
=140	NOUN	O	O
and	CCONJ	O	O
<	SYM	O	O
or	CCONJ	O	O
=180	ADJ	O	O
and/or	CCONJ	O	O
diastolic	ADJ	O	O
>	SYM	O	O
or	CCONJ	O	O
=90	ADP	O	O
and	CCONJ	O	O
<	SYM	O	O
or	CCONJ	O	O
=105	PUNCT	O	O
mmHg	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
hypertension	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
waist-to-hip	PUNCT	O	O
ratio	NOUN	O	O
>	SYM	O	O
or	CCONJ	O	O
=0.95	NUM	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
randomised	VERB	O	O
double-blind	ADJ	O	O
trial	NOUN	O	O
comparing	VERB	O	O
metformin	NOUN	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
850	NUM	O	O
mg	NOUN	O	O
bid	CCONJ	O	O
)	PUNCT	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Metformin	NOUN	O	O
had	PUNCT	O	O
no	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
either	PUNCT	O	O
on	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
plasma	NOUN	O	B-PHYSICAL
triglyceride	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
comparison	NOUN	O	O
with	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
fasting	VERB	O	B-PHYSICAL
plasma	NOUN	O	I-PHYSICAL
insulin	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
total	ADJ	O	O
cholesterol	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
Apo	NOUN	O	B-PHYSICAL
B	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.008	NUM	O	O
)	PUNCT	O	O
concentrations	NOUN	O	O
decreased	VERB	O	O
more	ADV	O	O
in	ADP	O	O
the	DET	O	O
metformin	NOUN	O	O
group	NOUN	O	O
in	ADP	O	O
the	DET	O	O
BIGPRO	NOUN	O	O
1	NUM	O	O
.	PUNCT	O	O

2	NUM	O	O
trial	NOUN	O	O
,	PUNCT	O	O
confirming	CCONJ	O	O
most	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
previous	ADJ	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
BIGPRO	NOUN	O	O
1	NUM	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Tissue	NOUN	O	B-PHYSICAL
plasminogen	NOUN	O	I-PHYSICAL
activator	NOUN	O	I-PHYSICAL
antigen	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
decreased	VERB	O	O
significantly	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
metformin	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
this	DET	O	O
was	NUM	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.12	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
further	ADV	O	O
,	PUNCT	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
change	NOUN	O	O
in	ADP	O	O
plasminogen	NOUN	O	O
activator	NOUN	O	O
inhibitor	NOUN	O	O
1	NUM	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
consistency	NOUN	O	O
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
BIGPRO	NOUN	O	O
trials	NOUN	O	O
supports	NOUN	O	O
the	DET	O	O
conclusion	NOUN	O	O
that	ADP	O	O
metformin	NOUN	O	O
affects	VERB	O	O
several	ADJ	O	O
cardiovascular	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	O
favourably	ADV	O	O
in	ADP	O	O
non-diabetic	ADJ	O	O
subjects	NOUN	O	O
with	ADP	O	O
a	DET	O	O
central	ADJ	O	O
fat	NOUN	O	O
distribution	NOUN	O	O
.	PUNCT	O	O

Bitewing	PUNCT	O	O
film	NOUN	O	O
quality	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
clinical	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
loop	NOUN	O	O
vs.	CCONJ	O	O
holder	ADJ	O	O
techniques	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
in	DET	O	O
vivo	ADJ	O	O
bitewing	PUNCT	O	O
film	NOUN	O	O
quality	NOUN	O	O
using	VERB	O	O
the	DET	O	O
holder	ADJ	O	O
versus	CCONJ	O	O
the	DET	O	O
paper	NOUN	O	O
loop	NOUN	O	O
technique	NOUN	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
AND	CCONJ	O	O
MATERIALS	NOUN	O	O
Four	NUM	O	O
bitewing	VERB	O	O
films	ADV	O	O
were	VERB	O	O
taken	VERB	O	O
from	ADP	O	O
the	DET	O	O
right	ADJ	O	O
and	CCONJ	O	O
left	ADJ	O	O
premolar	ADJ	O	O
and	CCONJ	O	O
molar	ADJ	O	O
regions	NOUN	O	O
of	ADP	O	O
45	NUM	O	O
dental	ADJ	O	O
students	NOUN	O	O
using	VERB	O	O
both	CCONJ	O	O
the	DET	O	O
bitewing	ADJ	O	O
holder	ADJ	O	O
and	CCONJ	O	O
paper	NOUN	O	O
loop	NOUN	O	O
techniques	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
360	NUM	O	O
films	ADV	O	O
were	VERB	O	O
taken	VERB	O	O
and	CCONJ	O	O
assessed	VERB	O	O
by	ADP	O	O
an	DET	O	O
experienced	VERB	O	O
practitioner	NOUN	O	O
not	ADV	O	O
apprised	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
bitewing	ADP	O	O
technique	NOUN	O	O
used	VERB	O	O
.	PUNCT	O	O

Of	ADP	O	O
interest	NOUN	O	O
were	VERB	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
overlaps	DET	O	O
and	CCONJ	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
teeth	NOUN	O	O
showing	VERB	O	O
the	DET	O	O
alveolar	ADJ	O	O
crest	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
proper	ADJ	O	O
film	NOUN	O	O
positioning	ADV	O	O
;	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
percentage	NOUN	O	O
of	ADP	O	O
cone	NOUN	O	O
cutting	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
Poisson	PUNCT	O	O
regression	NOUN	O	O
using	VERB	O	O
generalized	VERB	O	O
estimating	ADV	O	O
equations	NOUN	O	O
(	PUNCT	O	O
GEEs	PUNCT	O	O
)	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
estimate	NOUN	O	O
the	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
overlap	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
techniques	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
proper	ADJ	O	O
positioning	PROPN	O	O
and	CCONJ	O	O
cone	NOUN	O	O
cutting	ADP	O	O
,	PUNCT	O	O
logistic	ADJ	O	O
regressions	NOUN	O	O
using	VERB	O	O
GEEs	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
average	ADJ	O	O
number	NOUN	O	O
of	ADP	O	O
horizontal	ADJ	O	B-OTHER
overlaps	PUNCT	O	I-OTHER
for	ADP	O	I-OTHER
the	DET	O	I-OTHER
loop	NOUN	O	I-OTHER
and	CCONJ	O	O
holder	ADJ	O	B-OTHER
techniques	NOUN	O	I-OTHER
at	ADP	O	O
the	DET	O	O
right	ADJ	O	O
premolar	ADJ	O	O
,	PUNCT	O	O
right	ADJ	O	O
molar	ADJ	O	O
,	PUNCT	O	O
left	ADJ	O	O
premolar	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
left	ADJ	O	O
molar	ADJ	O	O
were	VERB	O	O
1.64	NUM	O	O
,	PUNCT	O	O
2.11	NUM	O	O
,	PUNCT	O	O
2.16	NUM	O	O
,	PUNCT	O	O
2.78	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1.64	NUM	O	O
,	PUNCT	O	O
2.00	NUM	O	O
,	PUNCT	O	O
2.00	NUM	O	O
,	PUNCT	O	O
2.18	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
loop	NOUN	O	O
technique	NOUN	O	O
was	VERB	O	O
1.11	NUM	O	O
times	NOUN	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
cause	CCONJ	O	O
overlapping	PUNCT	O	B-OTHER
than	PUNCT	O	O
the	DET	O	O
holder	ADJ	O	O
technique	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
highest	ADP	O	B-OTHER
percentage	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
teeth	NOUN	O	I-OTHER
showing	VERB	O	I-OTHER
the	DET	O	I-OTHER
alveolar	ADJ	O	I-OTHER
crest	NOUN	O	I-OTHER
by	ADP	O	I-OTHER
the	DET	O	I-OTHER
loop	NOUN	O	I-OTHER
technique	NOUN	O	I-OTHER
was	VERB	O	O
97.8	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
mandibular	ADJ	O	O
second	ADJ	O	O
premolar	ADJ	O	O
and	CCONJ	O	O
first	ADJ	O	O
molar	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
film	NOUN	O	O
positioning	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
loop	NOUN	O	O
technique	NOUN	O	O
was	VERB	O	O
1.12	NUM	O	O
times	NOUN	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
cause	PROPN	O	O
improper	ADP	O	B-OTHER
positioning	PUNCT	O	O
than	PUNCT	O	O
the	DET	O	O
holder	ADJ	O	O
technique	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
techniques	NOUN	O	O
demonstrated	VERB	O	O
minimal	ADJ	O	B-OTHER
cone	NOUN	O	I-OTHER
cutting	CCONJ	O	I-OTHER
(	PUNCT	O	O
1	NUM	O	O
in	ADP	O	O
the	DET	O	O
loop	NOUN	O	O
versus	CCONJ	O	O
0	NUM	O	O
in	ADP	O	O
the	DET	O	O
holder	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
quality	NOUN	O	O
of	ADP	O	O
bitewing	ADJ	O	O
films	NOUN	O	O
taken	VERB	O	O
by	ADP	O	O
the	DET	O	O
loop	NOUN	O	O
and	CCONJ	O	O
holder	ADJ	O	O
techniques	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
significantly	ADV	O	O
different	ADJ	O	O
.	PUNCT	O	O

Optimization	NOUN	O	O
of	ADP	O	O
acid	NOUN	O	O
suppression	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
peptic	ADJ	O	O
ulcer	NOUN	O	O
bleeding	ADV	O	O
:	PUNCT	O	O
an	DET	O	O
intragastric	ADJ	O	O
pH-metry	NOUN	O	O
study	NOUN	O	O
with	ADP	O	O
omeprazole	NUM	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PART	O	O
study	NOUN	O	O
whether	PUNCT	O	O
an	DET	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
dose	ADJ	O	O
of	ADP	O	O
omeprazole	NUM	O	O
(	PUNCT	O	O
80	NUM	O	O
mg	NOUN	O	O
+	SYM	O	O
8	NUM	O	O
mg/h	NUM	O	O
)	PUNCT	O	O
during	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
subsequently	ADV	O	O
reduced	ADP	O	O
with	ADP	O	O
maintained	VERB	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Second	NOUN	O	O
,	PUNCT	O	O
to	VERB	O	O
study	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
omeprazole	NUM	O	O
20	NUM	O	O
mg	NOUN	O	O
given	NOUN	O	O
once	PUNCT	O	O
or	CCONJ	O	O
twice	PUNCT	O	O
daily	ADJ	O	O
up	PUNCT	O	O
to	ADP	O	O
day	NOUN	O	O
10	NUM	O	O
,	PUNCT	O	O
after	ADP	O	O
cessation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
3-day	NOUN	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
(	PUNCT	O	O
80	NUM	O	O
mg	NOUN	O	O
+	SYM	O	O
8	NUM	O	O
mg/h	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
partly	ADV	O	O
blinded	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Twelve	PUNCT	O	O
Helicobacter	NOUN	O	O
pylori	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
and	CCONJ	O	O
12	NUM	O	O
H.	NOUN	O	O
pylori	NOUN	O	O
(	PUNCT	O	O
-	SYM	O	O
)	PUNCT	O	O
subjects	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
part	NOUN	O	O
I	NUM	O	O
the	DET	O	O
patients	NOUN	O	O
received	ADJ	O	O
omeprazole	NUM	O	O
,	PUNCT	O	O
80	NUM	O	O
mg	NOUN	O	O
+	SYM	O	O
8	NUM	O	O
mg/h	NUM	O	O
,	PUNCT	O	O
during	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
8	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
or	CCONJ	O	O
2	NUM	O	O
mg/h	NUM	O	O
.	PUNCT	O	O

In	ADP	O	O
part	NOUN	O	O
II	NUM	O	O
the	DET	O	O
subjects	NOUN	O	O
received	ADJ	O	O
80	NUM	O	O
mg	NOUN	O	O
+	SYM	O	O
8	NUM	O	O
mg/h	ADV	O	O
during	ADP	O	O
3	NUM	O	O
days	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
20	NUM	O	O
mg	NOUN	O	O
omeprazole	NUM	O	O
orally	ADV	O	O
,	PUNCT	O	O
once	PUNCT	O	O
or	CCONJ	O	O
twice	ADV	O	O
daily	ADJ	O	O
until	ADP	O	O
day	NOUN	O	O
10	NUM	O	O
.	PUNCT	O	O

Intragastric	ADJ	O	B-PHYSICAL
pH	NOUN	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
All	PUNCT	O	O
H.	NOUN	O	O
pylori	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
rapid	ADJ	O	O
increase	NOUN	O	O
of	ADP	O	O
intragastric	ADJ	O	B-PHYSICAL
pH	NOUN	O	I-PHYSICAL
with	ADP	O	I-PHYSICAL
a	DET	O	I-PHYSICAL
mean	NOUN	O	O
intragastric	ADJ	O	B-PHYSICAL
pH	NOUN	O	B-PHYSICAL
of	ADP	O	O
6.7	NUM	O	O
during	ADP	O	O
the	DET	O	O
second	ADJ	O	O
half	NOUN	O	O
of	ADP	O	O
the	DET	O	O
first	ADJ	O	O
day	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
the	DET	O	O
subsequent	ADJ	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
mean	NOUN	O	O
pH	NOUN	O	B-PHYSICAL
decreased	VERB	O	O
to	ADP	O	O
6.1-6.2	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
continuing	PUNCT	O	O
on	ADP	O	O
8	NUM	O	O
mg/h	NUM	O	O
showed	VERB	O	O
the	DET	O	O
best	PUNCT	O	O
results	NOUN	O	O
.	PUNCT	O	O

Likewise	ADV	O	O
,	PUNCT	O	O
all	DET	O	O
H.	NOUN	O	O
pylori	NOUN	O	O
(	PUNCT	O	O
-	SYM	O	O
)	PUNCT	O	O
subjects	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
rapid	ADJ	O	O
and	CCONJ	O	O
sustained	VERB	O	O
reduction	NOUN	O	O
of	ADP	O	O
intragastric	ADJ	O	B-PHYSICAL
acidity	NOUN	O	I-PHYSICAL
during	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
.	PUNCT	O	O

Subsequent	ADJ	O	O
dose	NOUN	O	O
reduction	NOUN	O	O
to	ADP	O	O
20	NUM	O	O
mg	NOUN	O	O
once	PUNCT	O	O
daily	ADJ	O	O
led	ADP	O	O
to	ADP	O	O
a	DET	O	O
stable	ADJ	O	O
fraction	NOUN	O	O
of	ADP	O	O
time	NOUN	O	O
with	ADP	O	O
pH	NOUN	O	O
>	SYM	O	O
3	NUM	O	O
of	ADP	O	O
72	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Omeprazole	ADV	O	O
given	VERB	O	O
as	ADP	O	O
a	DET	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
80	NUM	O	O
mg	NOUN	O	O
+	SYM	O	O
8	NUM	O	O
mg/h	ADV	O	O
for	ADP	O	O
72	NUM	O	O
h	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
omeprazole	NUM	O	O
20	NUM	O	O
mg	NOUN	O	O
once	PUNCT	O	O
daily	PUNCT	O	O
raised	PUNCT	O	O
the	PUNCT	O	O

The	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
repetitive	ADJ	O	B-MENTAL
behaviors	NOUN	O	I-MENTAL
and	CCONJ	O	O
growth	NOUN	O	B-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
response	NOUN	O	I-PHYSICAL
to	PUNCT	O	O
sumatriptan	NOUN	O	O
challenge	NOUN	O	O
in	ADP	O	O
adult	NOUN	O	O
autistic	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

Autism	NOUN	O	O
is	VERB	O	O
heterogeneous	ADJ	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
clinical	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
etiology	NOUN	O	O
.	PUNCT	O	O

To	ADP	O	O
sort	PUNCT	O	O
out	DET	O	O
this	DET	O	O
heterogeneity	NOUN	O	O
in	ADP	O	O
autism	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
investigated	VERB	O	O
whether	ADP	O	O
specific	ADJ	O	B-PHYSICAL
neurobiological	ADJ	O	I-PHYSICAL
markers	NOUN	O	I-PHYSICAL
vary	VERB	O	O
in	ADP	O	O
parallel	PUNCT	O	O
to	ADP	O	O
core	NOUN	O	B-PHYSICAL
symptomatology	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Specifically	ADV	O	O
,	PUNCT	O	O
we	NOUN	O	O
assessed	VERB	O	O
growth	NOUN	O	B-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
response	NOUN	O	I-PHYSICAL
to	ADP	O	O
the	DET	O	O
5-HT	NOUN	O	O
1d	NOUN	O	O
agonist	NOUN	O	O
,	PUNCT	O	O
sumatriptan	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
linked	ADP	O	B-PHYSICAL
this	DET	O	I-PHYSICAL
measure	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
serotonergic	ADJ	O	I-PHYSICAL
function	NOUN	O	I-PHYSICAL
to	ADP	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
repetitive	ADJ	O	B-MENTAL
behaviors	NOUN	O	I-MENTAL
in	ADP	O	O
adult	NOUN	O	O
autistic	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Eleven	ADP	O	O
adult	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
or	CCONJ	O	O
Asperger	ADJ	O	O
's	PUNCT	O	O
disorder	NOUN	O	O
were	VERB	O	O
randomized	ADP	O	O
to	ADP	O	O
single	ADJ	O	O
dose	NOUN	O	O
sumatriptan	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
mg	NOUN	O	O
SQ	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
challenges	NOUN	O	O
,	PUNCT	O	O
separated	VERB	O	O
by	ADP	O	O
a	DET	O	O
one-week	NOUN	O	O
interval	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
adult	NOUN	O	O
autistic	ADJ	O	O
disorders	NOUN	O	O
,	PUNCT	O	O
severity	NOUN	O	O
of	ADP	O	O
repetitive	ADJ	O	B-MENTAL
behaviors	NOUN	O	I-MENTAL
at	ADP	O	I-MENTAL
baseline	NOUN	O	I-MENTAL
,	PUNCT	O	O
as	PUNCT	O	O
measured	VERB	O	O
by	ADP	O	O
YBOCS-compulsion	NOUN	O	B-MENTAL
score	NOUN	O	I-MENTAL
,	PUNCT	O	O
significantly	ADV	O	O
positively	ADV	O	O
correlated	VERB	O	O
with	ADP	O	O
both	CCONJ	O	O
peak	ADJ	O	O
delta	NOUN	O	B-PHYSICAL
growth	NOUN	O	I-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
response	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	B-PHYSICAL
curve	NOUN	O	O
growth	NOUN	O	B-PHYSICAL
hormone	NOUN	O	I-PHYSICAL
response	NOUN	O	B-PHYSICAL
to	ADP	O	O
sumatriptan	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
a	DET	O	O
specific	ADJ	O	B-MENTAL
behavioral	ADJ	O	I-MENTAL
dimension	NOUN	O	I-MENTAL
in	ADP	O	O
autism	NOUN	O	O
(	PUNCT	O	O
repetitive	ADJ	O	B-MENTAL
behaviors	NOUN	O	I-MENTAL
)	PUNCT	O	O
parallels	PUNCT	O	B-MENTAL

0.1	NUM	O	O
%	SYM	O	O
bupivacaine	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
reduce	VERB	O	O
the	DET	O	O
requirement	NOUN	O	O
for	ADP	O	O
epidural	ADJ	O	O
fentanyl	NOUN	O	O
infusion	NOUN	O	O
after	ADP	O	O
major	ADJ	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
AND	CCONJ	O	O
OBJECTIVES	NOUN	O	O
Although	PUNCT	O	O
local	ADJ	O	O
anesthesia	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
demonstrated	VERB	O	O
to	PART	O	O
potentiate	ADJ	O	O
spinal	ADJ	O	O
morphine	NOUN	O	O
analgesia	NOUN	O	O
in	ADP	O	O
animal	NOUN	O	O
studies	NOUN	O	O
,	PUNCT	O	O
results	ADP	O	O
comparing	VERB	O	O
epidural	ADJ	O	O
local	ADJ	O	O
anesthesia/opioid	NOUN	O	O
mixtures	NOUN	O	O
with	ADP	O	O
opioid	NOUN	O	O
alone	ADJ	O	O
are	VERB	O	O
contradictory	ADJ	O	O
in	ADP	O	O
clinical	ADJ	O	O
studies	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
hypothesis	NOUN	O	O
was	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
although	ADP	O	O
the	DET	O	O
concentration	NOUN	O	O
of	ADP	O	O
bupivacaine	NOUN	O	O
(	PUNCT	O	O
0.1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
was	VERB	O	O
low	ADJ	O	O
to	ADJ	O	O
minimize	NOUN	O	O
its	ADP	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
,	PUNCT	O	O
if	PUNCT	O	O
the	DET	O	O
infusion	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
a	DET	O	O
fentanyl/bupivacaine	NOUN	O	O
solution	NOUN	O	O
was	VERB	O	O
closely	ADV	O	O
adjusted	VERB	O	O
according	CCONJ	O	O
to	PUNCT	O	O
need	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
presence	NOUN	O	O
bupivacaine	NOUN	O	O
would	VERB	O	O
reduce	VERB	O	O
the	DET	O	O
requirement	NOUN	O	O
for	ADP	O	O
epidural	ADJ	O	O
fentanyl	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Forty	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
fentanyl	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
micrograms/mL	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
fentanyl/bupivacaine	NOUN	O	O
(	PUNCT	O	O
0.1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
mixture	NOUN	O	O
epidurally	ADV	O	O
corresponding	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
dermatome	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
surgical	ADJ	O	O
incision	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
fashion	NOUN	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
18	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
major	ADJ	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
infusion	NOUN	O	O
was	VERB	O	O
titrated	VERB	O	O
for	ADP	O	O
each	DET	O	O
patient	NOUN	O	O
to	ADP	O	O
the	DET	O	O
rate	NOUN	O	O
required	VERB	O	O
for	ADP	O	O
pain	NOUN	O	O
relief	NOUN	O	O
during	ADP	O	O
forced	ADJ	O	O
inspiration	NOUN	O	O
(	PUNCT	O	O
pain	NOUN	O	O
score	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
2	NUM	O	O
,	PUNCT	O	O
maximum	NOUN	O	O
10	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Pain	NOUN	O	O
scores	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
fentanyl	NOUN	O	O
doses	NOUN	O	O
required	ADP	O	O
,	PUNCT	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	O
at	ADP	O	O
18	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Patients	NOUN	O	O
reported	ADP	O	O
similar	ADJ	O	O
median	ADJ	O	O
pain	NOUN	O	B-PAIN
scores	NOUN	O	I-PAIN
and	CCONJ	O	O
were	VERB	O	O
equally	ADV	O	O
satisfied	VERB	O	O
with	ADP	O	O
pain	NOUN	O	B-PAIN
relief	NOUN	O	I-PAIN
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
required	VERB	O	O
post-operative	ADJ	O	B-OTHER
fentanyl	NOUN	O	I-OTHER
infusion	NOUN	O	I-OTHER
rate	NOUN	O	I-OTHER
(	PUNCT	O	O
57.7	NUM	O	O
+/-	SYM	O	O
19.5	NUM	O	O
micrograms/h	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
plasma	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
0.84	NUM	O	O
+/-	SYM	O	O
0.36	NUM	O	O
ng/mL	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
fentanyl	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
comparable	ADJ	O	O
to	ADP	O	O
the	DET	O	O
infusion	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
(	PUNCT	O	O
54.4	NUM	O	O
+/-	SYM	O	O
19.2	NUM	O	O
micrograms/h	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
plasma	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
0.86	NUM	O	O
+/-	SYM	O	O
0.36	NUM	O	O
ng/mL	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
fentanyl/bupivacaine	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Respiratory	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
cardiovascular	ADJ	O	I-PHYSICAL
functions	NOUN	O	I-PHYSICAL
were	VERB	O	O
preserved	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
nausea	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
pruritus	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
and	CCONJ	O	O
periods	NOUN	O	O
of	ADP	O	O
drowsiness	NOUN	O	B-ADVERSE-EFFECTS
or	CCONJ	O	O
sleep	NOUN	O	B-ADVERSE-EFFECTS
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
low	ADJ	O	O
concentrations	NOUN	O	O
(	PUNCT	O	O
0.1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
bupivacaine	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
reduce	VERB	O	O
the	DET	O	O
titrated	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
epidural	ADJ	O	O
fentanyl	NOUN	O	O
required	VERB	O	O
for	ADP	O	O
adequate	ADJ	O	O
pain	NOUN	O	O
relief	NOUN	O	O
during	ADP	O	O
forced	ADJ	O	O
inspiration	NOUN	O	O
after	ADP	O	O
major	ADJ	O	O
abdominal	ADJ	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
severity	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
comparable	ADJ	O	O
whether	PUNCT	O	O
or	CCONJ	O	O
not	ADV	O	O
low-dose	NOUN	O	O
bupivacaine	NOUN	O	O
infusion	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

Factors	NOUN	O	O
predictive	ADJ	O	O
of	ADP	O	O
severe	ADJ	O	B-PHYSICAL
hypoglycemia	NOUN	O	I-PHYSICAL
in	ADP	O	O
type	NOUN	O	O
1	NUM	O	O
diabetes	NOUN	O	O
:	PUNCT	O	O
analysis	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Juvenile	ADJ	O	O
Diabetes	NOUN	O	O
Research	NOUN	O	O
Foundation	NOUN	O	O
continuous	ADJ	O	O
glucose	NOUN	O	O
monitoring	VERB	O	O
randomized	VERB	O	O
control	NOUN	O	O
trial	NOUN	O	O
dataset	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Identify	ADV	O	O
factors	NOUN	O	O
predictive	ADJ	O	O
of	ADP	O	O
severe	ADJ	O	B-PHYSICAL
hypoglycemia	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
SH	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
assess	ADJ	O	O
the	DET	O	O
clinical	ADJ	O	B-OTHER
utility	NOUN	O	I-OTHER
of	ADP	O	O
continuous	ADJ	O	B-OTHER
glucose	NOUN	O	I-OTHER
monitoring	VERB	O	I-OTHER
(	PUNCT	O	I-OTHER
CGM	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
to	ADP	O	O
warn	ADJ	O	O
of	ADP	O	O
impending	NUM	O	O
SH	NOUN	O	O
.	PUNCT	O	O

RESEARCH	NOUN	O	O
DESIGN	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
In	ADP	O	O
a	DET	O	O
multicenter	NOUN	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
436	NUM	O	O
children	NOUN	O	O
and	CCONJ	O	O
adults	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
1	NUM	O	O
diabetes	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
a	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
that	PUNCT	O	O
used	PUNCT	O	O
CGM	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
224	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
that	PUNCT	O	O
used	VERB	O	O
standard	ADJ	O	O
home	NOUN	O	O
blood	NOUN	O	O
glucose	NOUN	O	O
monitoring	VERB	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
212	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
completed	VERB	O	O
12	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
original	ADJ	O	O
control	NOUN	O	O
group	NOUN	O	O
initiated	ADP	O	O
CGM	NOUN	O	O
while	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
continued	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
CGM	CCONJ	O	O
for	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Baseline	NOUN	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
SH	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
over	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
using	SYM	O	O
proportional	ADJ	O	O
hazards	NOUN	O	O
regression	NOUN	O	O
.	PUNCT	O	O

CGM-derived	ADJ	O	B-PHYSICAL
indices	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
hypoglycemia	NOUN	O	I-PHYSICAL
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
predict	NOUN	O	O
episodes	NOUN	O	O
of	ADP	O	O
SH	NOUN	O	O
over	ADP	O	O
a	DET	O	O
24-h	NOUN	O	O
time	NOUN	O	O
horizon	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
SH	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
was	VERB	O	O
17.9	ADV	O	O
per	ADP	O	O
100	NUM	O	O
person-years	PROPN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
higher	PUNCT	O	O
rate	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
SH	NOUN	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
prior	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
and	CCONJ	O	O
female	NOUN	O	O
sex	NOUN	O	O
.	PUNCT	O	O

SH	NOUN	O	B-PHYSICAL
frequency	NOUN	O	I-PHYSICAL
increased	VERB	O	O
eightfold	ADJ	O	O
when	ADP	O	O
30	NUM	O	O
%	SYM	O	O
of	ADP	O	O
CGM	NOUN	O	B-PHYSICAL
values	NOUN	O	I-PHYSICAL
were	VERB	O	O
?	PUNCT	O	O

70	NUM	O	O
mg/dL	NOUN	O	O
on	ADP	O	O
the	DET	O	O
prior	PUNCT	O	O
day	NOUN	O	O
(	PUNCT	O	O
4.5	NUM	O	O
vs.	CCONJ	O	O
0.5	ADP	O	O
%	SYM	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
positive	ADJ	O	O
predictive	ADJ	O	O
value	NOUN	O	O
(	PUNCT	O	O
PPV	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
low	ADJ	O	O
(	PUNCT	O	O
<	PROPN	O	O
5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Results	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
for	ADP	O	O
hypoglycemic	ADJ	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
curve	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
low	ADJ	O	O
blood	NOUN	O	O
glucose	NOUN	O	O
index	NOUN	O	O
calculated	VERB	O	O
by	ADP	O	O
CGM	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
SH	NOUN	O	O
in	ADP	O	O
the	DET	O	O
6	NUM	O	O
months	NOUN	O	O
prior	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
the	DET	O	O
strongest	PUNCT	O	O
predictor	NOUN	O	O
of	ADP	O	O
SH	NOUN	O	O
during	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

CGM-measured	ADJ	O	O
hypoglycemia	NOUN	O	O
over	ADP	O	O
a	DET	O	O
24-h	NOUN	O	O
span	NOUN	O	O
is	VERB	O	O
highly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
SH	NOUN	O	O
the	DET	O	O
following	PUNCT	O	O
day	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
PPV	NOUN	O	O
is	VERB	O	O
low	ADJ	O	O
.	PUNCT	O	O

A	DET	O	O
prospective	ADJ	O	O
randomised	VERB	O	O
comparison	NOUN	O	O
of	ADP	O	O
sublingual	ADJ	O	O
and	CCONJ	O	O
vaginal	ADJ	O	O
misoprostol	NOUN	O	O
in	ADP	O	O
second	ADJ	O	O
trimester	NOUN	O	O
termination	NOUN	O	O
of	ADP	O	O
pregnancy	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
,	PUNCT	O	O
side	NOUN	O	O
effects	NOUN	O	O
and	CCONJ	O	O
acceptability	NOUN	O	B-OTHER
of	ADP	O	O
sublingual	ADJ	O	O
and	CCONJ	O	O
vaginal	ADJ	O	O
misoprostol	NOUN	O	O
for	ADP	O	O
second	ADJ	O	O
trimester	NOUN	O	O
medical	ADJ	O	O
abortion	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Prospective	ADJ	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Tertiary	ADJ	O	O
referral	NOUN	O	O
unit	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
teaching	VERB	O	O
hospital	NOUN	O	O
.	PUNCT	O	O

POPULATION	NOUN	O	O
Two	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
twenty-four	PUNCT	O	O
women	NOUN	O	O
at	ADP	O	O
12	NUM	O	O
to	ADP	O	O
20	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
gestation	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
women	NOUN	O	O
were	VERB	O	O
randomised	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
sublingual	ADP	O	O
or	CCONJ	O	O
vaginal	ADJ	O	O
misoprostol	NOUN	O	O
400	NUM	O	O
microg	NOUN	O	O
every	DET	O	O
3	NUM	O	O
hours	NOUN	O	O
for	ADP	O	O
a	DET	O	O
maximum	NOUN	O	O
of	ADP	O	O
five	NUM	O	O
doses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
course	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	O
was	VERB	O	O
repeated	VERB	O	O
if	ADP	O	O
the	DET	O	O
woman	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
abort	PUNCT	O	O
within	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
The	DET	O	O
success	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
at	ADP	O	I-OTHER
48	NUM	O	I-OTHER
hours	NOUN	O	I-OTHER
,	PUNCT	O	O
induction-to-abortion	NOUN	O	B-OTHER
interval	NOUN	O	I-OTHER
and	CCONJ	O	O
the	DET	O	O
side	NOUN	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
success	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
at	ADP	O	I-OTHER
48	NUM	O	I-OTHER
hours	NOUN	O	I-OTHER
(	PUNCT	O	O
sublingual	ADP	O	O
:	PUNCT	O	O
91	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
vaginal	ADJ	O	O
:	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
success	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
at	ADP	O	I-OTHER
24	NUM	O	I-OTHER
hours	NOUN	O	I-OTHER
was	NUM	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
vaginal	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
85	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
sublingual	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
64	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
median	ADJ	O	O
induction-to-abortion	NOUN	O	B-OTHER
interval	NOUN	O	I-OTHER
(	PUNCT	O	O
sublingual	ADP	O	O
:	PUNCT	O	O
13.8	NUM	O	O
hours	NOUN	O	O
;	PUNCT	O	O
vaginal	ADJ	O	O
:	PUNCT	O	O
12.0	NUM	O	O
hours	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Significantly	ADV	O	O
more	DET	O	O
women	NOUN	O	O
in	ADP	O	O
the	DET	O	O
sublingual	ADJ	O	O
group	NOUN	O	O
preferred	VERB	O	O
the	DET	O	O
route	NOUN	O	O
to	ADP	O	O
which	CCONJ	O	O
they	PRON	O	O
were	VERB	O	O
assigned	VERB	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
vaginal	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
fever	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
also	ADV	O	O
less	ADV	O	O
in	ADP	O	O
the	DET	O	O
sublingual	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
vaginal	ADJ	O	O
misoprostol	NOUN	O	O
for	ADP	O	O
second	ADJ	O	O
trimester	NOUN	O	O
medical	ADJ	O	O
abortion	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
higher	PUNCT	O	O
success	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
than	PUNCT	O	O
sublingual	ADJ	O	O
misoprostol	NOUN	O	O
at	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
but	CCONJ	O	O
the	DET	O	O
abortion	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
was	VERB	O	O
similar	ADJ	O	O
at	ADP	O	O
48	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

Vaginal	ADJ	O	O
misoprostol	NOUN	O	O
should	VERB	O	O
be	VERB	O	O
the	DET	O	O
regimen	NOUN	O	O
of	ADP	O	O
choice	NOUN	O	O
but	CCONJ	O	O
sublingual	ADJ	O	O
misoprostol	NOUN	O	O
is	VERB	O	O
also	ADV	O	O
an	DET	O	O
effective	ADJ	O	O
alternative	NOUN	O	O
.	PUNCT	O	O

18F-FDG	NOUN	O	O
PET/CT	NOUN	O	O
for	ADP	O	O
early	ADJ	O	O
prediction	NOUN	O	O
of	ADP	O	O
response	NOUN	O	O
to	PUNCT	O	O
neoadjuvant	PUNCT	O	O
lapatinib	NOUN	O	O
,	PUNCT	O	O
trastuzumab	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
combination	NOUN	O	O
in	ADP	O	O
HER2-positive	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
results	CCONJ	O	O
from	ADP	O	O
Neo-ALTTO	NOUN	O	O
.	PUNCT	O	O

UNLABELLED	NOUN	O	O
Molecular	ADJ	O	O
imaging	ADV	O	O
receives	VERB	O	O
increased	VERB	O	O
attention	NOUN	O	O
for	ADP	O	O
selecting	VERB	O	O
patients	NOUN	O	O
who	DET	O	O
will	VERB	O	O
benefit	VERB	O	O
from	ADP	O	O
targeted	VERB	O	O
anticancer	NOUN	O	O
therapies	NOUN	O	O
.	PUNCT	O	O

Neo-ALTTO	ADP	O	O
(	PUNCT	O	O
Neoadjuvant	ADV	O	O
Lapatinib	ADJ	O	O
and/or	CCONJ	O	O
Trastuzumab	NOUN	O	O
Treatment	NOUN	O	O
Optimisation	NOUN	O	O
)	PUNCT	O	O
enrolled	VERB	O	O
455	NUM	O	O
women	NOUN	O	O
with	ADP	O	O
invasive	ADJ	O	O
human	NOUN	O	O
epidermal	ADJ	O	O
growth	NOUN	O	O
factor	NOUN	O	O
receptor	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
HER2	NOUN	O	O
)	PUNCT	O	O
-positive	PUNCT	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
and	CCONJ	O	O
compared	VERB	O	O
rates	NOUN	O	O
of	ADP	O	O
pathologic	ADJ	O	O
complete	ADJ	O	O
response	NOUN	O	O
(	PUNCT	O	O
pCR	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
neoadjuvant	PUNCT	O	O
lapatinib	NOUN	O	O
,	PUNCT	O	O
trastuzumab	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
their	ADJ	O	O
combination	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
anti-HER2	NOUN	O	O
therapy	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
alone	ADJ	O	O
for	ADP	O	O
6	NUM	O	O
wk	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
12	NUM	O	O
wk	NOUN	O	O
of	ADP	O	O
the	DET	O	O
same	ADJ	O	O
therapy	NOUN	O	O
plus	CCONJ	O	O
weekly	ADV	O	O
paclitaxel	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
early	ADJ	O	O
metabolic	ADJ	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
of	ADP	O	O
the	DET	O	O
anti-HER2	NOUN	O	O
therapies	NOUN	O	O
on	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
tumors	NOUN	O	O
and	CCONJ	O	O
their	PUNCT	O	O
predictive	ADJ	O	O
values	NOUN	O	O
for	ADP	O	O
pCR	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
a	DET	O	O
subset	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Eighty-six	NUM	O	O
patients	NOUN	O	O
underwent	VERB	O	O
(	PUNCT	O	O
18	NUM	O	O
)	PUNCT	O	O
F-FDG	NOUN	O	O
PET/CT	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
weeks	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
of	ADP	O	O
anti-HER2	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
imaging	ADJ	O	O
core	NOUN	O	O
laboratory	NOUN	O	O
provided	VERB	O	O
central	ADJ	O	O
validation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
independent	ADJ	O	O
reviewers	NOUN	O	O
,	PUNCT	O	O
masked	ADV	O	O
to	ADP	O	O
assigned	PUNCT	O	O
treatment	NOUN	O	O
arm	NOUN	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
outcomes	NOUN	O	O
,	PUNCT	O	O
performed	ADP	O	O
consensus	NOUN	O	O
(	PUNCT	O	O
18	NUM	O	O
)	PUNCT	O	O
F-FDG	NOUN	O	O
PET/CT	NOUN	O	O
readings	NOUN	O	O
.	PUNCT	O	O

Maximum	NOUN	O	O
standardized	VERB	O	O
uptake	NOUN	O	O
value	NOUN	O	O
(	PUNCT	O	O
SUVmax	NOUN	O	O
)	PUNCT	O	O
reductions	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
measure	VERB	O	O
metabolic	ADJ	O	O
response	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Seventy-seven	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
86	NUM	O	O
enrolled	VERB	O	O
patients	NOUN	O	O
presented	VERB	O	O
an	DET	O	O
evaluable	ADJ	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
18	NUM	O	O
)	PUNCT	O	O
F-FDG	NOUN	O	O
PET/CT	NOUN	O	O
scan	NOUN	O	O
;	PUNCT	O	O
of	ADP	O	O
these	PUNCT	O	O
,	PUNCT	O	O
68	NUM	O	O
and	CCONJ	O	O
66	NUM	O	O
were	VERB	O	O
evaluable	ADJ	O	O
at	ADP	O	O
weeks	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Metabolic	ADJ	O	B-PHYSICAL
responses	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
primary	ADJ	O	O
tumors	NOUN	O	O
were	VERB	O	O
evident	ADJ	O	O
after	ADP	O	O
2	NUM	O	O
wk	NOUN	O	O
of	ADP	O	O
targeted	VERB	O	O
therapy	NOUN	O	O
and	CCONJ	O	O
correlated	VERB	O	O
highly	ADV	O	O
with	ADP	O	O
metabolic	ADJ	O	O
responses	NOUN	O	O
at	ADP	O	O
week	NOUN	O	O
6	NUM	O	O
(	PUNCT	O	O
R	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
=	SYM	O	O
0.81	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

pCRs	ADV	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
greater	PUNCT	O	O
SUVmax	NOUN	O	O
reductions	NOUN	O	O
at	ADP	O	O
both	CCONJ	O	O
time	NOUN	O	O
points	NOUN	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
SUVmax	NOUN	O	O
reductions	NOUN	O	O
for	ADP	O	O
pCR	NOUN	O	O
and	CCONJ	O	O
non-pCR	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
were	VERB	O	O
54.3	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
32.8	NUM	O	O
%	SYM	O	O
at	ADP	O	O
week	NOUN	O	O
2	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
61.5	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
34.1	NUM	O	O
%	SYM	O	O
at	ADP	O	O
week	NOUN	O	O
6	NUM	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O
(	PUNCT	O	O

18	NUM	O	B-PHYSICAL
)	PUNCT	O	O
F-FDG	NOUN	O	B-PHYSICAL
PET/CT	NOUN	O	I-PHYSICAL
metabolic	ADJ	O	I-PHYSICAL
response	PUNCT	O	O

Comparing	ADP	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
peer	NOUN	O	O
mentoring	PUNCT	O	O
and	CCONJ	O	O
student	ADJ	O	O
mentoring	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
35-week	NOUN	O	O
fitness	PUNCT	O	O
program	NOUN	O	O
for	ADP	O	O
older	PUNCT	O	O
adults	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
applicability	NOUN	O	B-OTHER
and	CCONJ	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
a	DET	O	O
peer-mentored	VERB	O	O
exercise	NOUN	O	O
program	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
study	NOUN	O	O
compared	VERB	O	O
the	DET	O	O
retention	NOUN	O	B-OTHER
and	CCONJ	O	O
participation	NOUN	O	B-OTHER
rates	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
physical	ADJ	O	B-PHYSICAL
improvements	NOUN	O	I-PHYSICAL
of	ADP	O	O
older	PUNCT	O	O
adults	NOUN	O	O
trained	NOUN	O	O
by	ADP	O	O
peer	NOUN	O	O
mentors	NOUN	O	O
(	PUNCT	O	O
PM	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
group	NOUN	O	O
trained	PUNCT	O	O
by	ADP	O	O
young	ADJ	O	O
qualified	VERB	O	O
student	NOUN	O	O
mentors	NOUN	O	O
(	PUNCT	O	O
SM	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
group	NOUN	O	O
of	ADP	O	O
older	PUNCT	O	O
adults	NOUN	O	O
were	VERB	O	O
prepared	VERB	O	O
as	ADP	O	O
peer	NOUN	O	O
mentors	CCONJ	O	O
through	ADP	O	O
a	DET	O	O
30-week	NOUN	O	O
preparation	NOUN	O	O
program	NOUN	O	O
.	PUNCT	O	O

Later	ADJ	O	O
,	PUNCT	O	O
60	NUM	O	O
older	PUNCT	O	O
adults	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
?	PUNCT	O	O

SD	NOUN	O	O
age	NOUN	O	O
:	PUNCT	O	O
68.7	NUM	O	O
?	PUNCT	O	O

6.1	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
recruited	VERB	O	O
and	CCONJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
PM	NOUN	O	O
or	CCONJ	O	O
SM	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
groups	NOUN	O	O
completed	ADV	O	O
an	DET	O	O
identical	ADJ	O	O
35-week	NOUN	O	O
fitness	PUNCT	O	O
program	NOUN	O	O
.	PUNCT	O	O

Pre-	ADJ	O	O
,	PUNCT	O	O
midterm-	ADJ	O	O
and	CCONJ	O	O
post-training	VERB	O	O
assessments	NOUN	O	O
of	ADP	O	O
fitness	PUNCT	O	O
were	VERB	O	O
completed	VERB	O	O
and	CCONJ	O	O
rates	NOUN	O	O
of	ADP	O	O
participation	NOUN	O	O
and	CCONJ	O	O
retention	NOUN	O	O
were	VERB	O	O
documented	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
same	ADJ	O	O
retention	NOUN	O	O
rates	NOUN	O	O
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
SM	NOUN	O	O
group	NOUN	O	O
had	VERB	O	O
higher	PUNCT	O	O
participation	NOUN	O	O
.	PUNCT	O	O

Both	DET	O	O
groups	NOUN	O	O
improved	VERB	O	O
significantly	ADV	O	O
in	ADP	O	O
all	DET	O	O
measures	NOUN	O	O
of	ADP	O	O
fitness	PUNCT	O	O
and	CCONJ	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
post-test	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
groups	NOUN	O	O
in	ADP	O	O
the	DET	O	O
fitness	PUNCT	O	O
measures	NOUN	O	O
.	PUNCT	O	O

Findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
the	DET	O	O
peer	NOUN	O	O
mentor	NOUN	O	O
model	NOUN	O	O
is	VERB	O	O
applicable	ADJ	O	O
in	ADP	O	O
an	DET	O	O
older	PUNCT	O	O
adult	NOUN	O	O
exercise	NOUN	O	O
program	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
be	PUNCT	O	O
as	CCONJ	O	O
effective	ADJ	O	O
as	ADP	O	O
a	DET	O	O
program	NOUN	O	O
mentored	PUNCT	O	O
by	ADP	O	O
young	ADJ	O	O
professionals	NOUN	O	O
.	PUNCT	O	O

Mechanical	ADJ	O	B-PHYSICAL
efficiency	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
propulsion	NOUN	O	B-PHYSICAL
technique	NOUN	O	I-PHYSICAL
after	ADP	O	O
7	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
low-intensity	NOUN	O	O
wheelchair	ADJ	O	O
training	VERB	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
To	ADV	O	O
evaluate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
7-week	NOUN	O	O
low-intensity	NOUN	O	O
hand	NOUN	O	O
rim	NOUN	O	O
wheelchair	ADJ	O	O
training	VERB	O	O
on	ADP	O	O
the	DET	O	O
submaximal	ADJ	O	O
metabolic	ADJ	O	O
cost	NOUN	O	O
,	PUNCT	O	O
mechanical	ADJ	O	B-PHYSICAL
efficiency	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
propulsion	NOUN	O	O
technique	NOUN	O	O
in	ADP	O	O
able-bodied	VERB	O	O
participants	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Participants	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
over	ADP	O	O
an	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=14	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=7	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
received	VERB	O	O
7	NUM	O	O
weeks	NOUN	O	O
wheelchair	ADJ	O	O
training	VERB	O	O
(	PUNCT	O	O
3	NUM	O	O
week	NOUN	O	O
(	PUNCT	O	O
-1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
70	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
low	ADJ	O	O
intensity	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
heart	NOUN	O	O
rate	NOUN	O	O
reserve	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
receive	VERB	O	O
training	ADV	O	O
.	PUNCT	O	O

During	ADP	O	O
pre-	ADJ	O	O
and	CCONJ	O	O
post-tests	NOUN	O	O
,	PUNCT	O	O
submaximal	ADJ	O	O
exercise	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
on	ADP	O	O
a	DET	O	O
stationary	ADJ	O	O
wheelchair	ADJ	O	O
ergometer	NOUN	O	O
at	ADP	O	O
fixed	VERB	O	O
levels	NOUN	O	O
of	ADP	O	O
power	NOUN	O	O
output	NOUN	O	O
.	PUNCT	O	O

Mechanical	ADJ	O	B-PHYSICAL
efficiency	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
oxygen	NOUN	O	B-PHYSICAL
uptake	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
timing	PUNCT	O	B-OTHER
parameters	NOUN	O	I-OTHER
and	CCONJ	O	O
stroke	NOUN	O	B-PHYSICAL
angles	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
.	PUNCT	O	O

Video	PUNCT	O	O
recordings	NOUN	O	O
were	VERB	O	O
made	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
stroke	NOUN	O	B-PHYSICAL
pattern	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

FINDINGS	NOUN	O	O
Mechanical	ADJ	O	B-PHYSICAL
efficiency	NOUN	O	I-PHYSICAL
increased	VERB	O	O
and	CCONJ	O	O
metabolic	ADJ	O	B-PHYSICAL
cost	NOUN	O	I-PHYSICAL
decreased	ADP	O	O
significantly	ADV	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Push	NOUN	O	B-OTHER
time	NOUN	O	I-OTHER
increased	VERB	O	O
and	CCONJ	O	O
cycle	NOUN	O	O
frequency	NOUN	O	B-OTHER
decreased	PART	O	O
as	ADP	O	O
a	DET	O	O
result	NOUN	O	O
of	ADP	O	O
training	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
stroke	NOUN	O	B-PHYSICAL
angle	NOUN	O	I-PHYSICAL
increased	VERB	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
during	ADP	O	O
the	DET	O	O
training	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
preferred	VERB	O	O
double-looping	ADJ	O	O
over	ADP	O	O
propulsion	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
mainly	ADV	O	O
used	PUNCT	O	O
single-looping	PUNCT	O	B-OTHER
over	ADP	O	I-OTHER
propulsion	NOUN	O	I-OTHER
patterns	NOUN	O	O
during	ADP	O	O
the	DET	O	O
post-test	ADV	O	O
.	PUNCT	O	O

INTERPRETATION	NOUN	O	O
A	DET	O	O
low-intensity	NOUN	O	O
,	PUNCT	O	O
7-week	NOUN	O	O
training	VERB	O	O
protocol	NOUN	O	O
has	ADJ	O	O
a	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
mechanical	ADJ	O	B-PHYSICAL
efficiency	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
metabolic	ADJ	O	B-PHYSICAL
cost	NOUN	O	I-PHYSICAL
of	ADP	O	O
wheelchair	ADJ	O	O
propulsion	NOUN	O	O
in	ADP	O	O
able-bodied	VERB	O	O
participants	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
improved	VERB	O	O
mechanical	ADJ	O	O
efficiency	NOUN	O	O
seems	NOUN	O	O
to	DET	O	O
be	PUNCT	O	O
the	DET	O	O
result	NOUN	O	O
of	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
propulsion	NOUN	O	O
technique	NOUN	O	O
that	PUNCT	O	O
were	VERB	O	O
found	VERB	O	O
.	PUNCT	O	O

Double-blind	ADJ	O	O
randomized	VERB	O	O
evaluation	NOUN	O	O
of	ADP	O	O
intercostal	ADJ	O	O
nerve	NOUN	O	O
blocks	PUNCT	O	O
as	ADP	O	O
an	DET	O	O
adjuvant	NOUN	O	O
to	ADP	O	O
subarachnoid	NOUN	O	O
administered	VERB	O	O
morphine	NOUN	O	O
for	ADP	O	O
post-thoracotomy	NOUN	O	O
analgesia	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
AND	CCONJ	O	O
OBJECTIVES	NOUN	O	O
Thoracotomy	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
pain	NOUN	O	O
and	CCONJ	O	O
compromised	VERB	O	O
pulmonary	ADJ	O	O
function	NOUN	O	O
.	PUNCT	O	O

Intercostal	ADJ	O	O
nerve	NOUN	O	O
blocks	PUNCT	O	O
(	PUNCT	O	O
INB	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
subarachnoid	NOUN	O	O
morphine	NOUN	O	O
(	PUNCT	O	O
SM	NOUN	O	O
)	PUNCT	O	O
act	VERB	O	O
on	ADP	O	O
different	ADJ	O	O
portions	NOUN	O	O
of	ADP	O	O
the	DET	O	O
pain	NOUN	O	O
pathway	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
is	ADJ	O	O
effective	ADJ	O	O
for	ADP	O	O
post-thoracotomy	NOUN	O	O
pain	NOUN	O	B-PAIN
relief	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
these	DET	O	O
two	NUM	O	O
modalities	NOUN	O	O
in	ADP	O	O
relieving	NUM	O	O
post-thoracotomy	NOUN	O	B-PAIN
pain	NOUN	O	I-PAIN
and	CCONJ	O	O
improving	VERB	O	O
postoperative	ADJ	O	B-PHYSICAL
pulmonary	ADJ	O	I-PHYSICAL
function	NOUN	O	I-PHYSICAL
has	VERB	O	O
not	ADV	O	O
been	PUNCT	O	O
investigated	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
In	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
20	NUM	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
lateral	ADJ	O	O
thoracotomy	NOUN	O	O
for	ADP	O	O
lung	NOUN	O	O
resection	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
0.5	NUM	O	O
mg	NOUN	O	O
SM	NOUN	O	O
preoperatively	ADV	O	O
and	CCONJ	O	O
INB	NOUN	O	O
with	ADP	O	O
bupivacaine	NOUN	O	O
(	PUNCT	O	O
INB+	NOUN	O	O
)	PUNCT	O	O
prior	PUNCT	O	O
to	ADP	O	O
wound	NOUN	O	O
closure	NOUN	O	O
or	CCONJ	O	O
0.5	NUM	O	O
mg	NOUN	O	O
SM	NOUN	O	O
with	ADP	O	O
INB	NOUN	O	O
using	VERB	O	O
saline	NOUN	O	O
(	PUNCT	O	O
INB-	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Visual	ADJ	O	O
analog	NOUN	O	O
scale	NOUN	O	O
pain	NOUN	O	B-PAIN
scores	NOUN	O	I-PAIN
at	ADP	O	O
rest	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
cough	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
with	ADP	O	O
movement	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
ipsilateral	ADJ	O	I-PHYSICAL
arm	NOUN	O	O
,	PUNCT	O	O
forced	VERB	O	B-PHYSICAL
expiratory	ADJ	O	I-PHYSICAL
volume	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
1	NUM	O	I-PHYSICAL
second	ADJ	O	I-PHYSICAL
(	PUNCT	O	O
FEV1	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
forced	VERB	O	B-PHYSICAL
vital	ADJ	O	I-PHYSICAL
capacity	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
FVC	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
4	NUM	O	O
,	PUNCT	O	O
24	NUM	O	O
,	PUNCT	O	O
48	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
72	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
operation	NOUN	O	O
.	PUNCT	O	O

Opioid	NOUN	O	B-OTHER
use	NOUN	O	I-OTHER
was	VERB	O	O
measured	VERB	O	O
during	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
the	DET	O	O
operation	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
4	NUM	O	O
hours	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
INB+	NOUN	O	O
group	NOUN	O	O
demonstrated	ADP	O	O
better	CCONJ	O	O
FEV1	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
56.6	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
40.4	NUM	O	O
%	SYM	O	O
of	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
FVC	NOUN	O	B-PHYSICAL
values	NOUN	O	O
(	PUNCT	O	O
54.6	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
39.6	NUM	O	O
%	SYM	O	O
of	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
less	ADV	O	O
resting	VERB	O	O
and	CCONJ	O	O
cough	NOUN	O	O
pain	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
FEV1	NOUN	O	B-PHYSICAL
continued	VERB	O	O
to	PART	O	O
decline	VERB	O	O
in	ADP	O	O
the	DET	O	O
INB+	NOUN	O	O
group	NOUN	O	O
at	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
to	VERB	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
the	DET	O	O
INB-	NOUN	O	O
group	NOUN	O	O
although	ADP	O	O
pain	NOUN	O	B-PAIN
scores	NOUN	O	I-PAIN
were	VERB	O	O
similar	ADJ	O	O
beyond	ADP	O	O
4	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

Opioid	NOUN	O	B-OTHER
usage	NOUN	O	I-OTHER
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
24	NUM	O	O
hours	NOUN	O	O
was	VERB	O	O
similar	ADJ	O	O
(	PUNCT	O	O
INB-	NOUN	O	O
,	PUNCT	O	O
16.7	NUM	O	O
mg	NOUN	O	O
vs.	CCONJ	O	O
INB+	NOUN	O	O
,	PUNCT	O	O
13.2	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.7	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Although	ADP	O	O
postoperative	ADJ	O	O
INB	NOUN	O	O
provided	VERB	O	O
modest	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
pain	NOUN	O	O
and	CCONJ	O	O
pulmonary	ADJ	O	O
function	NOUN	O	O
when	ADP	O	O
used	VERB	O	O
as	ADP	O	O
an	DET	O	O
adjuvant	NOUN	O	O
to	ADP	O	O
0.5	NUM	O	O
mg	NOUN	O	O
SM	NOUN	O	O
for	ADP	O	O
post-thoracotomy	NOUN	O	O
analgesia	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
benefits	NOUN	O	O
were	VERB	O	O
transient	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
do	PUNCT	O	O
not	ADV	O	O
recommend	VERB	O	O
adding	ADP	O	O
INB	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
lateral	ADJ	O	O
thoracotomy	NOUN	O	O
who	ADP	O	O
receive	VERB	O	O
0.5	NUM	O	O
mg	NOUN	O	O
SM	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
enamel	NOUN	O	O
matrix	NOUN	O	O
derivative	ADJ	O	O
proteins	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
proximal	ADJ	O	O
class-II	NOUN	O	O
furcation	NOUN	O	O
involvements	ADJ	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
of	ADP	O	O
proximal	ADJ	O	O
furcations	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
enamel	NOUN	O	O
matrix	NOUN	O	O
derivative	ADJ	O	O
proteins	NOUN	O	O
(	PUNCT	O	O
EMD	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MATERIAL	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Fifteen	PUNCT	O	O
patients	NOUN	O	O
,	PUNCT	O	O
each	CCONJ	O	O
with	ADP	O	O
a	DET	O	O
pair	NOUN	O	O
of	ADP	O	O
contralateral	ADJ	O	O
class-II	NOUN	O	O
proximal	ADJ	O	O
furcation	NOUN	O	O
involvements	ADJ	O	O
,	PUNCT	O	O
presenting	PUNCT	O	O
probing	DET	O	O
depths	NOUN	O	O
(	PUNCT	O	O
PDs	NOUN	O	O
)	PUNCT	O	O
>	SYM	O	O
/=5	PUNCT	O	O
mm	NOUN	O	O
and	CCONJ	O	O
bleeding	VERB	O	O
on	ADP	O	O
probing	ADP	O	O
(	PUNCT	O	O
BOP	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
selected	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
:	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=15	NOUN	O	O
)	PUNCT	O	O
-	PUNCT	O	O
open	PUNCT	O	O
flap	PUNCT	O	O
debridement	NOUN	O	O
(	PUNCT	O	O
OFD	NOUN	O	O
)	PUNCT	O	O
+24	ADP	O	O
%	SYM	O	O
ethylenediaminetetraacetic	ADJ	O	O
acid	NOUN	O	O
(	PUNCT	O	O
EDTA	NOUN	O	O
)	PUNCT	O	O
conditioning	ADV	O	O
;	PUNCT	O	O
test	ADP	O	O
group	NOUN	O	O
(	PUNCT	O	O
n=15	NOUN	O	O
)	PUNCT	O	O
-	PUNCT	O	O
OFD+24	PUNCT	O	O
%	SYM	O	O
EDTA	NOUN	O	O
conditioning+EMD	PUNCT	O	O
application	NOUN	O	O
.	PUNCT	O	O

Plaque	NOUN	O	B-PHYSICAL
index	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
PI	NOUN	O	I-PHYSICAL
)	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
BOP	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
PD	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
gingival	ADJ	O	B-PHYSICAL
margin	NOUN	O	I-PHYSICAL
position	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
GMP	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
relative	ADJ	O	B-PHYSICAL
vertical	ADJ	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
horizontal	ADJ	O	I-PHYSICAL
clinical	ADJ	O	I-PHYSICAL
attachment	NOUN	O	I-PHYSICAL
level	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
RVCAL	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
RHCAL	ADJ	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
vertical	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
horizontal	ADJ	O	I-PHYSICAL
bone	NOUN	O	I-PHYSICAL
level	NOUN	O	I-PHYSICAL
(	PUNCT	O	B-PHYSICAL
VBL	NOUN	O	I-PHYSICAL
and	CCONJ	O	B-PHYSICAL
HBL	NOUN	O	B-PHYSICAL
)	PUNCT	O	B-PHYSICAL
and	CCONJ	O	O
furcation	NOUN	O	O
closure	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
immediately	ADV	O	O
before	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
the	DET	O	O
surgeries	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
RVCAL	ADJ	O	B-PHYSICAL
gains	NOUN	O	B-PHYSICAL
of	ADP	O	O
the	DET	O	O
control	NOUN	O	O
and	CCONJ	O	O
test	ADV	O	O
group	NOUN	O	O
were	VERB	O	O
0.39	NUM	O	O
+/-	SYM	O	O
1.00	NUM	O	O
and	CCONJ	O	O
0.54	NUM	O	O
+/-	SYM	O	O
0.95	NUM	O	O
mm	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
the	DET	O	O
RHCAL	PUNCT	O	B-PHYSICAL
gains	NOUN	O	O
were	VERB	O	O
1.21	NUM	O	O
+/-	SYM	O	O
2.28	NUM	O	O
and	CCONJ	O	O
1.36	NUM	O	O
+/-	SYM	O	O
1.26	NUM	O	O
mm	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	PUNCT	O	O

Social	ADJ	O	O
support	NOUN	O	O
and	CCONJ	O	O
abstinence	NOUN	O	B-MENTAL
from	ADP	O	O
opiates	NOUN	O	O
and	CCONJ	O	O
cocaine	NOUN	O	O
during	ADP	O	O
opioid	NOUN	O	O
maintenance	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Social	ADJ	O	O
support	NOUN	O	O
may	VERB	O	O
play	VERB	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
helping	ADP	O	O
drug	NOUN	O	O
users	NOUN	O	O
achieve	VERB	O	O
abstinence	ADJ	O	B-MENTAL
;	PUNCT	O	O
however	ADV	O	O
these	DET	O	O
benefits	NOUN	O	O
may	VERB	O	O
depend	VERB	O	O
on	ADP	O	O
the	DET	O	O
type	NOUN	O	O
of	ADP	O	O
support	NOUN	O	O
experienced	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
prospective	ADJ	O	O
observational	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
examined	VERB	O	O
the	DET	O	O
extent	NOUN	O	O
to	ADP	O	O
which	PUNCT	O	O
general	VERB	O	O
and	CCONJ	O	O
abstinence-specific	ADJ	O	O
support	NOUN	O	O
,	PUNCT	O	O
both	CCONJ	O	O
structural	ADJ	O	O
and	CCONJ	O	O
functional	ADJ	O	O
,	PUNCT	O	O
predicted	ADP	O	O
opiate	ADJ	O	O
and	CCONJ	O	O
cocaine	NOUN	O	O
abstinence	NOUN	O	O
in	ADP	O	O
128	NUM	O	O
opioid	NOUN	O	O
maintenance	NOUN	O	O
patients	NOUN	O	O
receiving	VERB	O	O
either	PUNCT	O	O
methadone	NOUN	O	O
or	CCONJ	O	O
LAAM	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
new	ADJ	O	O
multidimensional	ADJ	O	O
self-report	ADJ	O	O
instrument	ADJ	O	O
assessing	ADJ	O	O
abstinence-specific	ADJ	O	O
functional	ADJ	O	O
support	NOUN	O	O
was	VERB	O	O
developed	VERB	O	O
for	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Previously	ADV	O	O
validated	VERB	O	O
measures	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
remaining	ADJ	O	O
types	NOUN	O	O
of	ADP	O	O
support	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
baseline	NOUN	O	O
abstinence	ADJ	O	O
and	CCONJ	O	O
other	ADJ	O	O
statistically	ADV	O	O
important	ADJ	O	O
covariates	NOUN	O	O
adjusted	VERB	O	O
,	PUNCT	O	O
hierarchical	ADJ	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
analyses	NOUN	O	O
demonstrated	VERB	O	O
that	ADP	O	O
the	DET	O	O
associations	NOUN	O	O
between	ADP	O	O
social	ADJ	O	O
support	NOUN	O	O
at	ADP	O	O
study	NOUN	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
biochemically	ADV	O	O
confirmed	PUNCT	O	O
abstinence	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
later	ADJ	O	O
varied	VERB	O	O
by	ADP	O	O
type	NOUN	O	O
of	ADP	O	O
support	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Greater	PUNCT	O	O
abstinence-specific	ADJ	O	B-MENTAL
structural	ADJ	O	I-MENTAL
support	NOUN	O	I-MENTAL
(	PUNCT	O	O
operationalized	PUNCT	O	O
as	ADP	O	O
fewer	PUNCT	O	O
drug	NOUN	O	O
users	NOUN	O	O
in	ADP	O	O
the	DET	O	O
social	ADJ	O	O
network	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
decreases	NOUN	O	O
in	ADP	O	O
three	DET	O	O
types	NOUN	O	O
of	ADP	O	O
negative	ADJ	O	O
abstinence-specific	ADJ	O	B-MENTAL
functional	ADJ	O	I-MENTAL
support	NOUN	O	O
(	PUNCT	O	O
Complaints	PROPN	O	B-MENTAL
about	PUNCT	O	I-MENTAL
Drug	NOUN	O	I-MENTAL
Use	NOUN	O	B-MENTAL
,	PUNCT	O	O
Drug	NOUN	O	B-MENTAL
Exposure	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
Demoralization	NOUN	O	B-MENTAL
)	PUNCT	O	O
predicted	PUNCT	O	B-MENTAL
cocaine	ADV	O	B-MENTAL
,	PUNCT	O	O
but	CCONJ	O	O
not	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
bifidobacterium	NOUN	O	O
breve	NOUN	O	O
supplementation	NOUN	O	O
on	ADP	O	O
intestinal	ADJ	O	O
flora	NOUN	O	O
of	ADP	O	O
low	ADJ	O	O
birth	NOUN	O	O
weight	NOUN	O	O
infants	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
It	PRON	O	O
is	VERB	O	O
known	VERB	O	O
that	ADP	O	O
the	DET	O	O
bifidobacteria	NOUN	O	O
flora	PUNCT	O	O
play	NOUN	O	O
important	ADJ	O	O
roles	NOUN	O	O
in	ADP	O	O
mucosal	ADJ	O	O
host	NOUN	O	O
defense	NOUN	O	O
and	CCONJ	O	O
can	VERB	O	O
prevent	ADV	O	O
infectious	ADJ	O	O
diseases	NOUN	O	O
.	PUNCT	O	O

Because	PUNCT	O	O
bacterial	ADJ	O	O
populations	NOUN	O	O
develop	VERB	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
examined	VERB	O	O
whether	ADP	O	O
the	DET	O	O
early	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
bifidobacteria	NOUN	O	O
has	DET	O	O
a	DET	O	O
positive	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
health	NOUN	O	B-PHYSICAL
of	ADP	O	O
low	ADJ	O	O
birth	NOUN	O	O
weight	NOUN	O	O
infants	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
Bifidobacterium	NOUN	O	O
breve	NOUN	O	O
(	PUNCT	O	O
B.	NOUN	O	O
breve	PUNCT	O	O
)	PUNCT	O	O
supplements	NOUN	O	O
were	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
a	DET	O	O
controlled	VERB	O	O
trial	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
birth	NOUN	O	O
weight	NOUN	O	O
infants	NOUN	O	O
(	PUNCT	O	O
average	PUNCT	O	O
birth	NOUN	O	O
weight	NOUN	O	O
1489	NUM	O	O
g	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
infants	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
Group	NOUN	O	O
A	NOUN	O	O
and	CCONJ	O	O
B	NOUN	O	O
received	VERB	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
1.6	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
8	NUM	O	O
)	PUNCT	O	O
cells	NOUN	O	O
of	ADP	O	O
B.	NOUN	O	O
breve	NUM	O	O
supplement	NOUN	O	O
twice	CCONJ	O	O
a	DET	O	O
day	NOUN	O	O
,	PUNCT	O	O
commencing	ADP	O	O
either	PUNCT	O	O
from	ADP	O	O
several	ADJ	O	O
hours	NOUN	O	O
after	ADP	O	O
birth	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
A	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
24	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
birth	NOUN	O	O
(	PUNCT	O	O
group	NOUN	O	O
B	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Group	NOUN	O	O
C	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
received	VERB	O	O
no	DET	O	O
supplement	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
birth	NOUN	O	B-PHYSICAL
weight	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
treatment	NOUN	O	O
with	ADP	O	O
antibiotics	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
starting	DET	O	O
time	NOUN	O	O
of	ADP	O	O
breast-feeding	VERB	O	O
among	ADP	O	O
the	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

A	CCONJ	O	O
Bifidobacterium-predominant	ADJ	O	O
flora	NOUN	O	O
was	VERB	O	O
formed	VERB	O	O
at	ADP	O	O
an	DET	O	O
average	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
birth	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
an	DET	O	O
average	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
birth	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
B	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
no	DET	O	O
Bifidobacterium	NOUN	O	O
was	VERB	O	O
isolated	VERB	O	O
in	ADP	O	O
eight	NUM	O	O
out	PUNCT	O	O
of	ADP	O	O
10	NUM	O	O
infants	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
C	NOUN	O	O
during	ADP	O	O
the	DET	O	O
observation	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
7	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
comparison	NOUN	O	O
between	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
and	CCONJ	O	O
B	NOUN	O	O
,	PUNCT	O	O
Bifidobacterium	NOUN	O	O
was	VERB	O	O
detected	ADJ	O	O
significantly	ADV	O	O
earlier	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
Enterobacteriaceae	NOUN	O	O
present	ADJ	O	O
in	ADP	O	O
the	DET	O	O
infants	NOUN	O	O
at	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
after	ADP	O	O
birth	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
A	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
The	DET	O	O
results	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
very	ADV	O	O
early	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
B.	NOUN	O	O
breve	PUNCT	O	O
to	ADP	O	O
low	ADJ	O	O
birth	NOUN	O	O
weight	NOUN	O	O
infants	NOUN	O	O
is	VERB	O	O
useful	ADJ	O	O
in	ADP	O	O
promoting	VERB	O	O
the	DET	O	O
colonization	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Bifidobacterium	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
formation	NOUN	O	O
of	ADP	O	O
a	DET	O	O
normal	ADJ	O	O
intestinal	ADJ	O	O
flora	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
ScanBrit	NOUN	O	O
randomised	VERB	O	O
,	PUNCT	O	O
controlled	PUNCT	O	O
,	PUNCT	O	O
single-blind	ADP	O	O
study	NOUN	O	O
of	ADP	O	O
a	DET	O	O
gluten-	ADP	O	O
and	CCONJ	O	O
casein-free	ADJ	O	O
dietary	ADJ	O	O
intervention	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
is	VERB	O	O
increasing	ADJ	O	O
interest	NOUN	O	O
in	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
gluten-	PUNCT	O	O
and	CCONJ	O	O
casein-free	ADJ	O	O
diets	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
(	PUNCT	O	O
ASDs	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
report	NOUN	O	O
results	PUNCT	O	O
from	ADP	O	O
a	DET	O	O
two-stage	NOUN	O	O
,	PUNCT	O	O
24-month	NOUN	O	O
,	PUNCT	O	O
randomised	DET	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
incorporating	ADJ	O	O
an	DET	O	O
adaptive	ADJ	O	O
'catch-up	PUNCT	O	O
'	PUNCT	O	O
design	NOUN	O	O
and	CCONJ	O	O
interim	ADJ	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Stage	NOUN	O	O
1	NUM	O	O
of	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
saw	VERB	O	O
72	NUM	O	O
Danish	NOUN	O	O
children	NOUN	O	O
(	PUNCT	O	O
aged	DET	O	O
4	NUM	O	O
years	NOUN	O	O
to	ADP	O	O
10	NUM	O	O
years	NOUN	O	O
11	NUM	O	O
months	NOUN	O	O
)	PUNCT	O	O
assigned	PUNCT	O	O
to	ADP	O	O
diet	NOUN	O	O
(	PUNCT	O	O
A	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
non-diet	NOUN	O	O
(	PUNCT	O	O
B	NOUN	O	O
)	PUNCT	O	O
groups	NOUN	O	O
by	ADP	O	O
stratified	DET	O	O
randomisation	NOUN	O	O
.	PUNCT	O	O

Autism	NOUN	O	B-MENTAL
Diagnostic	ADJ	O	I-MENTAL
Observation	NOUN	O	I-MENTAL
Schedule	NOUN	O	O
(	PUNCT	O	B-MENTAL
ADOS	NOUN	O	I-MENTAL
)	PUNCT	O	B-MENTAL
and	CCONJ	O	O
the	DET	O	O
Gilliam	NOUN	O	O
Autism	NOUN	O	O
Rating	PUNCT	O	O
Scale	NOUN	O	O
(	PUNCT	O	O
GARS	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
core	NOUN	O	B-MENTAL
autism	NOUN	O	B-MENTAL
behaviours	NOUN	O	B-MENTAL
,	PUNCT	O	O
Vineland	PUNCT	O	O
Adaptive	ADJ	O	O
Behaviour	NOUN	O	O
Scales	NOUN	O	O
(	PUNCT	O	O
VABS	NOUN	O	O
)	PUNCT	O	O
to	PART	O	O
ascertain	NOUN	O	O
developmental	ADJ	O	O
level	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Attention-Deficit	PUNCT	O	O
Hyperactivity	NOUN	O	O
Disorder	NOUN	O	O
-	PUNCT	O	O
IV	NUM	O	O
scale	NOUN	O	O
(	PUNCT	O	O
ADHD-IV	NOUN	O	O
)	PUNCT	O	O
to	PART	O	O
determine	NOUN	O	O
inattention	NOUN	O	O
and	CCONJ	O	O
hyperactivity	NOUN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
were	VERB	O	O
tested	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
8	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Based	VERB	O	O
on	ADP	O	O
per	PUNCT	O	O
protocol	NOUN	O	O
repeated	VERB	O	O
measures	DET	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
data	NOUN	O	O
for	ADP	O	O
26	NUM	O	O
diet	NOUN	O	O
children	NOUN	O	O
and	CCONJ	O	O
29	NUM	O	O
controls	NOUN	O	O
were	VERB	O	O
available	ADJ	O	O
at	ADP	O	O
12	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
this	DET	O	O
point	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
to	ADP	O	O
mean	NOUN	O	O
diet	NOUN	O	O
group	NOUN	O	O
scores	NOUN	O	O
(	PUNCT	O	O
time*treatment	DET	O	O
interaction	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
sub-domains	NOUN	O	O
of	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
neodymium-doped	VERB	O	O
yttrium	NOUN	O	O
aluminum	NOUN	O	O
garnet	NOUN	O	O
laser	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
cold	ADJ	O	O
knife	NOUN	O	O
endoscopic	ADJ	O	O
incision	NOUN	O	O
of	ADP	O	O
urethral	ADJ	O	O
strictures	CCONJ	O	O
in	ADP	O	O
male	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
assess	NOUN	O	O
the	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
visual	ADJ	O	O
laser	NOUN	O	O
ablation	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
neodymium-doped	VERB	O	O
yttrium	NOUN	O	O
aluminum	NOUN	O	O
garnet	NOUN	O	O
(	PUNCT	O	O
Nd	NOUN	O	O
:	PUNCT	O	O
YAG	NOUN	O	O
)	PUNCT	O	O
laser	NOUN	O	O
in	ADP	O	O
male	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
urethral	ADJ	O	O
strictures	ADP	O	O
and	CCONJ	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
with	ADP	O	O
those	DET	O	O
obtained	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
Sachse	NOUN	O	O
's	PUNCT	O	O
optical	ADJ	O	O
urethrotomy	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Fifty	PUNCT	O	O
patients	NOUN	O	O
aged	PROPN	O	O
22	NUM	O	O
to	ADP	O	O
83	NUM	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
61.8	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
primary	ADJ	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
26	NUM	O	O
,	PUNCT	O	O
52	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
recurrent	ADJ	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
24	NUM	O	O
,	PUNCT	O	O
48	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
urethral	ADJ	O	O
strictures	ADP	O	O
0.3	NUM	O	O
to	ADP	O	O
2.4	NUM	O	O
cm	NOUN	O	O
long	ADP	O	O
qualified	NOUN	O	O
for	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
30	DET	O	O
men	NOUN	O	O
treated	VERB	O	O
using	VERB	O	O
visual	ADJ	O	O
laser	NOUN	O	O
ablation	NOUN	O	O
of	ADP	O	O
urethral	ADJ	O	O
strictures	ADP	O	O
(	PUNCT	O	O
VLASU	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
Nd	NOUN	O	O
:	PUNCT	O	O
YAGlaser	PUNCT	O	O
and	CCONJ	O	O
20	NUM	O	O
men	NOUN	O	O
treated	VERB	O	O
by	ADP	O	O
correction	NOUN	O	O
of	ADP	O	O
urethral	ADJ	O	O
strictures	ADP	O	O
using	SYM	O	O
Sachse	NOUN	O	O
's	PUNCT	O	O
optical	ADJ	O	O
urethrotomy	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
12-month	NOUN	O	O
follow-up	NOUN	O	O
,	PUNCT	O	O
seven	NUM	O	O
(	PUNCT	O	O
35	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
patients	NOUN	O	O
who	ADP	O	O
underwent	VERB	O	O
optical	ADJ	O	O
urethrotomy	NOUN	O	O
and	CCONJ	O	O
21	NUM	O	O
(	PUNCT	O	O
70	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
VLASU	NOUN	O	O
group	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
require	VERB	O	O
repetition	NOUN	O	O
of	ADP	O	O
the	DET	O	O
procedure	NOUN	O	B-OTHER
.	PUNCT	O	O

The	DET	O	O
choice	NOUN	O	O
of	ADP	O	O
VLASU	NOUN	O	O
as	ADP	O	O
a	DET	O	O
method	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
significantly	ADV	O	O
decreased	VERB	O	O
the	DET	O	O
probability	NOUN	O	O
of	ADP	O	O
therapeutic	ADJ	O	B-OTHER
failure	NOUN	O	I-OTHER
and	CCONJ	O	O
recurrence	NOUN	O	O
of	ADP	O	O
urethral	ADJ	O	B-PHYSICAL
strictures	ADP	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
VLASU	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
method	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
this	PUNCT	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
,	PUNCT	O	O
modern	NOUN	O	O
,	PUNCT	O	O
low-invasive	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
repeatable	ADJ	O	O
technique	NOUN	O	O
and	CCONJ	O	O
is	VERB	O	O
technically	ADV	O	O
simple	ADJ	O	O
and	CCONJ	O	O
easy	PUNCT	O	O
to	ADP	O	O
master	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
can	VERB	O	O
be	VERB	O	O
used	VERB	O	O
in	ADP	O	O
cases	NOUN	O	O
in	ADP	O	O
which	DET	O	O
introduction	NOUN	O	O
of	ADP	O	O
a	DET	O	O
22	NUM	O	O
Char	NOUN	O	O
optical	ADJ	O	O
urethrotome	NOUN	O	O
into	ADP	O	O
the	DET	O	O
stricture	NOUN	O	O
site	NOUN	O	O
is	VERB	O	O
impossible	ADJ	O	O
,	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
multiple	ADJ	O	O
strictures	CCONJ	O	O
during	ADP	O	O
one	NUM	O	O
procedure	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
dietary	ADJ	O	O
fibre	NOUN	O	O
source	NOUN	O	O
and	CCONJ	O	O
gender	NOUN	O	O
on	ADP	O	O
the	DET	O	O
postprandial	ADJ	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
lipid	NOUN	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
in	ADP	O	O
healthy	ADJ	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Consumption	NOUN	O	O
of	ADP	O	O
soluble	ADJ	O	O
dietary	ADJ	O	O
fibre	NOUN	O	O
is	VERB	O	O
correlated	VERB	O	O
with	ADP	O	O
decreased	VERB	O	O
postprandial	ADJ	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
insulin	NOUN	O	B-PHYSICAL
responses	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
hence	NUM	O	O
has	PUNCT	O	O
beneficial	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
the	DET	O	O
metabolic	ADJ	O	O
syndrome	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
OF	ADP	O	O
THE	DET	O	O
STUDY	NOUN	O	O
To	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
on	ADP	O	O
postprandial	ADJ	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
insulin	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
triglyceride	NOUN	O	B-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
of	ADP	O	O
meals	NOUN	O	O
enriched	VERB	O	O
with	ADP	O	O
soluble	ADJ	O	O
dietary	ADJ	O	O
fibres	NOUN	O	O
from	ADP	O	O
oats	NOUN	O	O
,	PUNCT	O	O
rye	ADJ	O	O
bran	NOUN	O	O
,	PUNCT	O	O
sugar	NOUN	O	O
beet	NOUN	O	O
fibre	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
mixture	NOUN	O	O
of	ADP	O	O
these	DET	O	O
three	NUM	O	O
fibres	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Thirteen	PUNCT	O	O
healthy	ADJ	O	O
human	NOUN	O	O
volunteers	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
men	NOUN	O	O
and	CCONJ	O	O
7	NUM	O	O
women	NOUN	O	O
,	PUNCT	O	O
aged	ADP	O	O
20-28	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
subjects	NOUN	O	O
came	VERB	O	O
to	ADP	O	O
the	DET	O	O
study	ADJ	O	O
centre	NOUN	O	O
once	PUNCT	O	O
a	DET	O	O
week	NOUN	O	O
after	ADP	O	O
an	DET	O	O
overnight	CCONJ	O	O
fast	ADJ	O	O
to	ADP	O	O
ingest	ADV	O	O
test	VERB	O	O
meals	VERB	O	O
and	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
meal	NOUN	O	O
in	ADP	O	O
random	ADJ	O	O
order	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
meals	NOUN	O	O
contained	VERB	O	O
either	PUNCT	O	O
oat	NOUN	O	O
powder	NOUN	O	O
(	PUNCT	O	O
62	NUM	O	O
g	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
which	ADP	O	O
2.7	NUM	O	O
soluble	ADJ	O	O
fibre	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
rye	ADJ	O	O
bran	NOUN	O	O
(	PUNCT	O	O
31	NUM	O	O
g	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
which	ADP	O	O
1.7	NUM	O	O
g	NOUN	O	O
soluble	ADJ	O	O
fibre	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
sugar	NOUN	O	O
beet	NOUN	O	O
fibre	NOUN	O	O
(	PUNCT	O	O
19	NUM	O	O
g	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
which	ADP	O	O
5	NUM	O	O
g	NOUN	O	O
soluble	ADJ	O	O
fibre	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
mixture	NOUN	O	O
of	ADP	O	O
these	DET	O	O
three	NUM	O	O
fibres	NOUN	O	O
(	PUNCT	O	O
74	NUM	O	O
g	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
which	ADP	O	O
1.7	NUM	O	O
g	NOUN	O	O
soluble	ADJ	O	O
fibre	NOUN	O	O
from	ADP	O	O
each	DET	O	O
source	NOUN	O	O
,	PUNCT	O	O
giving	VERB	O	O
5	NUM	O	O
g	NOUN	O	O
soluble	ADJ	O	O
fibre	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
no	DET	O	O
added	PUNCT	O	O
fibre	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
all	DET	O	O
adjusted	ADV	O	O
to	PART	O	O
contain	ADJ	O	O
the	DET	O	O
same	ADJ	O	O
total	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
available	ADJ	O	O
carbohydrates	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
drawn	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
every	DET	O	O
30	NUM	O	O
min	NOUN	O	O
up	PUNCT	O	O
to	ADP	O	O
180	NUM	O	O
min	NOUN	O	O
after	ADP	O	O
the	DET	O	O
meals	NOUN	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Meals	PROPN	O	O
with	ADP	O	O
rye	ADJ	O	O
bran	NOUN	O	O
gave	VERB	O	O
a	DET	O	O
lower	PUNCT	O	O
postprandial	ADJ	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
peak	ADJ	O	I-PHYSICAL
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
meal	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
this	DET	O	O
effect	NOUN	O	O
was	VERB	O	O
more	ADV	O	O
pronounced	VERB	O	O
in	ADP	O	O
women	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
men	NOUN	O	O
.	PUNCT	O	O

Oat	ADP	O	O
powder	NOUN	O	O
,	PUNCT	O	O
containing	VERB	O	O
a	DET	O	O
low	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
total	ADJ	O	O
fibre	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
high	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
carbohydrates	CCONJ	O	O
in	ADP	O	O
liquid	ADJ	O	O
matrix	NOUN	O	O
,	PUNCT	O	O
gave	VERB	O	O
a	DET	O	O
higher	PUNCT	O	O
incremental	ADJ	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
peak	ADJ	O	O
concentration	NOUN	O	B-PHYSICAL
compared	VERB	O	O
to	ADP	O	O
rye	CCONJ	O	O
bran	ADJ	O	O
and	CCONJ	O	O
sugar	NOUN	O	O
beet	NOUN	O	O
fibre	NOUN	O	O
and	CCONJ	O	O
higher	PUNCT	O	O
insulin	NOUN	O	B-PHYSICAL
incremental	ADJ	O	I-PHYSICAL
area	NOUN	O	O
under	ADP	O	O
curve	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
control	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
oat	NOUN	O	O
powder	NOUN	O	O
also	ADV	O	O
influenced	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
mixed	VERB	O	O
meal	NOUN	O	O
,	PUNCT	O	O
diminishing	CCONJ	O	O
the	DET	O	O
glucose-lowering	VERB	O	B-PHYSICAL
effects	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Postprandial	ADJ	O	B-PHYSICAL
triglyceride	NOUN	O	I-PHYSICAL
levels	NOUN	O	B-PHYSICAL
tended	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
higher	PUNCT	O	O
after	ADP	O	O
all	ADP	O	O
fibre-rich	VERB	O	O
meals	ADJ	O	O
,	PUNCT	O	O
but	CCONJ	O	O
only	ADV	O	O
significant	ADJ	O	O
for	ADP	O	O
oat	NOUN	O	O
powder	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
mixed	VERB	O	O
meal	NOUN	O	O
when	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
meal	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Postprandial	PUNCT	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
,	PUNCT	O	O

VLDL	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
apolipoproteins	NOUN	O	B-PHYSICAL
B	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
CIII	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
E	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
risk	NOUN	O	O
of	ADP	O	O
recurrent	ADJ	O	B-PHYSICAL
coronary	ADJ	O	I-PHYSICAL
events	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
Cholesterol	NOUN	O	O
and	CCONJ	O	O
Recurrent	ADJ	O	O
Events	NOUN	O	O
(	PUNCT	O	O
CARE	NOUN	O	O
)	PUNCT	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Plasma	NOUN	O	O
triglyceride	NOUN	O	O
concentration	NOUN	O	O
has	PUNCT	O	O
been	ADP	O	O
an	DET	O	O
inconsistent	ADP	O	O
independent	ADJ	O	O
risk	NOUN	O	O
factor	NOUN	O	O
for	ADP	O	O
coronary	ADJ	O	O
heart	NOUN	O	O
disease	NOUN	O	O
,	PUNCT	O	O
perhaps	ADV	O	O
because	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
metabolic	ADJ	O	O
heterogeneity	NOUN	O	O
among	ADP	O	O
VLDL	NOUN	O	O
particles	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
main	ADJ	O	O
carriers	NOUN	O	O
of	ADP	O	O
triglycerides	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	NOUN	O	O
We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
nested	VERB	O	O
case-control	NOUN	O	O
study	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Cholesterol	NOUN	O	O
and	CCONJ	O	O
Recurrent	ADJ	O	O
Events	NOUN	O	O
(	PUNCT	O	O
CARE	NOUN	O	O
)	PUNCT	O	O
trial	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
pravastatin	NOUN	O	O
in	ADP	O	O
4159	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
and	CCONJ	O	O
average	ADJ	O	O
LDL	NOUN	O	O
concentrations	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
(	PUNCT	O	O
115	NUM	O	O
to	ADP	O	O
174	NUM	O	O
mg/dL	NOUN	O	O
,	PUNCT	O	O
mean	PUNCT	O	O
139	NUM	O	O
mg/dL	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Baseline	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
VLDL-apolipoprotein	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
apo	NOUN	O	O
)	PUNCT	O	O
B	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
the	DET	O	B-PHYSICAL
VLDL	NOUN	O	I-PHYSICAL
particle	NOUN	O	I-PHYSICAL
concentration	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
VLDL	NOUN	O	B-PHYSICAL
lipids	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
apoCIII	NUM	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
apoE	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
VLDL+LDL	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
HDL	NOUN	O	I-PHYSICAL
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
had	ADP	O	O
either	PUNCT	O	O
a	DET	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
or	CCONJ	O	O
coronary	ADJ	O	O
death	NOUN	O	O
(	PUNCT	O	O
cases	NOUN	O	O
,	PUNCT	O	O
n=418	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
those	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
who	DET	O	O
did	CCONJ	O	O
not	ADV	O	O
have	PUNCT	O	O
a	DET	O	O
cardiovascular	ADJ	O	O
event	NOUN	O	O
(	PUNCT	O	O
control	NOUN	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
n=370	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
5	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

VLDL-cholesterol	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
VLDL-triglyceride	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
VLDL-apoB	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
apoCIII	NUM	O	B-PHYSICAL
and	CCONJ	O	O
apoE	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
VLDL+LDL	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
apoE	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
HDL	NOUN	O	I-PHYSICAL
were	VERB	O	O
all	CCONJ	O	O
interrelated	ADV	O	O
,	PUNCT	O	O
and	CCONJ	O	O
each	DET	O	O
was	VERB	O	O
a	DET	O	O
univariate	ADJ	O	O
predictor	NOUN	O	O
of	ADP	O	O
subsequent	ADJ	O	O
coronary	ADJ	O	O
events	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
significant	ADJ	O	O
independent	ADJ	O	O
predictors	NOUN	O	O
were	VERB	O	O
VLDL-apoB	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
relative	ADJ	O	O
risk	NOUN	O	O
[	PUNCT	O	O
RR	NOUN	O	O
]	PUNCT	O	O
3.2	NUM	O	O
for	ADP	O	O
highest	PUNCT	O	O
to	PUNCT	O	O
lowest	PUNCT	O	O
quintiles	VERB	O	O
,	PUNCT	O	O
P	NOUN	O	O
:	PUNCT	O	O
=0.04	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
apoCIII	NUM	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
VLDL+LDL	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
RR	NOUN	O	O
2.3	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
:	PUNCT	O	O
=0.04	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
apoE	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
HDL	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
RR	NOUN	O	O
1.8	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
:	PUNCT	O	O
=0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Plasma	NOUN	O	B-PHYSICAL
triglycerides	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
a	DET	O	O
univariate	ADJ	O	O
predictor	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	B-PHYSICAL
events	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
RR	NOUN	O	O
1.6	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
:	PUNCT	O	O
=0.03	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
related	PUNCT	O	O
to	ADP	O	O
coronary	ADJ	O	B-PHYSICAL
events	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
RR	NOUN	O	O
1.3	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
:	PUNCT	O	O
=0.6	DET	O	O
)	PUNCT	O	O
when	ADP	O	O
apoCIII	NUM	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
VLDL+LDL	NOUN	O	I-PHYSICAL
was	ADV	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
model	NOUN	O	O
,	PUNCT	O	O
whereas	ADP	O	O
apoCIII	NOUN	O	B-PHYSICAL
remained	VERB	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Adjustment	NOUN	O	O
for	ADP	O	O
LDL-	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
HDL-cholesterol	NOUN	O	B-PHYSICAL
did	PUNCT	O	O
not	ADV	O	O
affect	VERB	O	O
these	DET	O	O
results	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
of	ADP	O	O
VLDL	NOUN	O	B-PHYSICAL
particles	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
apoCIII	NUM	O	O
in	ADP	O	O
VLDL	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
LDL	NOUN	O	B-PHYSICAL
are	VERB	O	O
more	ADV	O	O
specific	ADJ	O	O
measures	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	O
heart	NOUN	O	O
disease	NOUN	O	O
risk	NOUN	O	O
than	ADP	O	O
plasma	NOUN	O	O
triglycerides	NOUN	O	O
perhaps	ADV	O	O
because	ADP	O	O
their	ADP	O	O
known	VERB	O	O
metabolic	ADJ	O	O
properties	NOUN	O	O
link	NOUN	O	O
them	PROPN	O	O
more	ADV	O	O
closely	ADV	O	O
to	ADP	O	O
atherosclerosis	NOUN	O	O
.	PUNCT	O	O

Laser	NOUN	O	O
conization	NOUN	O	O
versus	CCONJ	O	O
cold	ADJ	O	O
knife	NOUN	O	O
conization	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
compares	NOUN	O	O
,	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
,	PUNCT	O	O
measured	DET	O	O
blood	NOUN	O	O
loss	NOUN	O	O
at	ADP	O	O
conization	NOUN	O	O
and	CCONJ	O	O
within	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
after	PUNCT	O	O
using	ADP	O	O
either	CCONJ	O	O
the	DET	O	O
cold	ADJ	O	O
knife	NOUN	O	O
technique	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
carbon	NOUN	O	O
dioxide	PUNCT	O	O
laser	NOUN	O	O
scalpel	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
ten	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
blood	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
laser	NOUN	O	O
group	NOUN	O	O
of	ADP	O	O
55	NUM	O	O
patients	NOUN	O	O
was	VERB	O	O
4.6	NUM	O	O
milliliters	NOUN	O	O
at	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
within	ADP	O	O
,	PUNCT	O	O
24	NUM	O	O
hours	NOUN	O	O
after	ADP	O	O
operation	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
30.1	NUM	O	O
milliliters	NOUN	O	O
in	ADP	O	O
the	DET	O	O
cold	ADJ	O	O
knife	NOUN	O	O
group	NOUN	O	O
of	ADP	O	O
55	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

More	DET	O	O
important	ADJ	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
is	CCONJ	O	O
that	ADP	O	O
the	DET	O	O
corresponding	VERB	O	O
figures	NOUN	O	O
for	ADP	O	O
the	DET	O	O
range	NOUN	O	O
of	ADP	O	O
bleeding	VERB	O	B-PHYSICAL
were	VERB	O	O
0.4	NUM	O	O
to	ADP	O	O
155.4	ADP	O	O
milliliters	ADJ	O	O
and	CCONJ	O	O
5.6	NUM	O	O
to	ADP	O	O
1,570.9	NOUN	O	O
milliliters	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
rate	NOUN	O	O
for	ADP	O	O
bleeding	ADP	O	O
complications	NOUN	O	B-PHYSICAL
requiring	DET	O	I-PHYSICAL
surgical	ADJ	O	I-PHYSICAL
intervention	NOUN	O	I-PHYSICAL
was	VERB	O	O
1.8	NUM	O	O
per	CCONJ	O	O
cet	ADV	O	O
for	ADP	O	O
the	DET	O	O
laser	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
14.6	NUM	O	O
per	ADP	O	O
cent	NUM	O	O
for	ADP	O	O
the	DET	O	O
cold	ADJ	O	O
knife	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
,	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.015	NUM	O	O
--	PUNCT	O	O
Fischer	NOUN	O	O
's	PUNCT	O	O
exact	ADJ	O	O
test	NOUN	O	O
.	PUNCT	O	O

Conization	NOUN	O	O
for	ADP	O	O
treatment	NOUN	O	O
of	ADP	O	O
premalignant	ADJ	O	O
changes	NOUN	O	O
of	ADP	O	O
the	DET	O	O
cervix	NOUN	O	O
uteri	NOUN	O	O
will	PRON	O	O
probably	ADV	O	O
remain	VERB	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
choice	NOUN	O	O
for	ADP	O	O
some	DET	O	O
time	NOUN	O	O
to	PUNCT	O	O
come	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
our	PUNCT	O	O
opinion	NOUN	O	O
that	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
future	NOUN	O	O
,	PUNCT	O	O
laser	NOUN	O	O
conization	NOUN	O	O
will	VERB	O	O
replace	VERB	O	O
cold	ADJ	O	O
knife	NOUN	O	O
conization	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
long-term	NOUN	O	O
vitamin	NOUN	O	O
E	NOUN	O	O
supplementation	NOUN	O	O
on	ADP	O	O
cardiovascular	ADJ	O	B-PHYSICAL
events	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
cancer	NOUN	O	B-PHYSICAL
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

CONTEXT	NOUN	O	O
Experimental	ADJ	O	O
and	CCONJ	O	O
epidemiological	ADJ	O	O
data	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
vitamin	NOUN	O	O
E	NOUN	O	O
supplementation	NOUN	O	O
may	VERB	O	O
prevent	DET	O	O
cancer	NOUN	O	O
and	CCONJ	O	O
cardiovascular	ADJ	O	O
events	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
trials	NOUN	O	O
have	ADP	O	O
generally	ADV	O	O
failed	PUNCT	O	O
to	ADP	O	O
confirm	DET	O	O
benefits	NOUN	O	O
,	PUNCT	O	O
possibly	ADV	O	O
due	CCONJ	O	O
to	ADP	O	O
their	PUNCT	O	O
relatively	ADV	O	O
short	ADJ	O	O
duration	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
whether	ADP	O	O
long-term	NOUN	O	O
supplementation	NOUN	O	O
with	ADP	O	O
vitamin	NOUN	O	O
E	NOUN	O	O
decreases	NOUN	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
cancer	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
cancer	NOUN	O	B-ADVERSE-EFFECTS
death	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
and	CCONJ	O	O
major	ADJ	O	B-PHYSICAL
cardiovascular	ADJ	O	I-PHYSICAL
events	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

DESIGN	NOUN	O	O
,	PUNCT	O	O
SETTING	VERB	O	O
,	PUNCT	O	O
AND	CCONJ	O	O
PATIENTS	NOUN	O	O
A	CCONJ	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	DET	O	O
international	ADJ	O	O
trial	NOUN	O	O
(	PUNCT	O	O
the	DET	O	O
initial	ADJ	O	O
Heart	NOUN	O	O
Outcomes	NOUN	O	O
Prevention	NOUN	O	O
Evaluation	NOUN	O	O
[	PUNCT	O	O
HOPE	NOUN	O	O
]	PUNCT	O	O
trial	NOUN	O	O
conducted	VERB	O	O
between	ADP	O	O
December	NOUN	O	O
21	NUM	O	O
,	PUNCT	O	O
1993	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
April	NOUN	O	O
15	NUM	O	O
,	PUNCT	O	O
1999	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
at	ADP	O	O
least	ADV	O	O
55	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
with	ADP	O	O
vascular	ADJ	O	O
disease	NOUN	O	O
or	CCONJ	O	O
diabetes	NOUN	O	O
mellitus	NOUN	O	O
was	VERB	O	O
extended	VERB	O	O
(	PUNCT	O	O
HOPE-The	ADP	O	O
Ongoing	PUNCT	O	O
Outcomes	NOUN	O	O
[	PUNCT	O	O
HOPE-TOO	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
between	ADP	O	O
April	NOUN	O	O
16	NUM	O	O
,	PUNCT	O	O
1999	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
May	NOUN	O	O
26	NUM	O	O
,	PUNCT	O	O
2003	NUM	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
267	NUM	O	O
HOPE	NOUN	O	O
centers	NOUN	O	O
that	ADP	O	O
had	PUNCT	O	O
enrolled	VERB	O	O
9541	NUM	O	O
patients	NOUN	O	O
,	PUNCT	O	O
174	NUM	O	O
centers	NOUN	O	O
participated	VERB	O	O
in	ADP	O	O
the	DET	O	O
HOPE-TOO	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
7030	NUM	O	O
patients	NOUN	O	O
enrolled	VERB	O	O
at	ADP	O	O
these	DET	O	O
centers	NOUN	O	O
,	PUNCT	O	O
916	NUM	O	O
were	VERB	O	O
deceased	VERB	O	O
at	ADP	O	O
the	DET	O	O
beginning	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
extension	NOUN	O	O
,	PUNCT	O	O
1382	NUM	O	O
refused	VERB	O	O
participation	NOUN	O	O
,	PUNCT	O	O
3994	NUM	O	O
continued	VERB	O	O
to	PART	O	O
take	NOUN	O	O
the	DET	O	O
study	ADJ	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
738	NUM	O	O
agreed	PROPN	O	O
to	ADP	O	O
passive	ADJ	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Median	ADJ	O	O
duration	NOUN	O	O
of	ADP	O	O
follow-up	NOUN	O	O
was	VERB	O	O
7.0	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
Daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
natural	ADJ	O	O
source	NOUN	O	O
vitamin	NOUN	O	O
E	NOUN	O	O
(	PUNCT	O	O
400	NUM	O	O
IU	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
matching	VERB	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
Primary	ADJ	O	O
outcomes	NOUN	O	O
included	DET	O	O
cancer	NOUN	O	B-PHYSICAL
incidence	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
cancer	NOUN	O	B-ADVERSE-EFFECTS
deaths	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
and	CCONJ	O	O
major	ADJ	O	B-PHYSICAL
cardiovascular	ADJ	O	I-PHYSICAL
events	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
myocardial	ADJ	O	B-PHYSICAL
infarction	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
stroke	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
hydrochlorothiazide	NOUN	O	O
therapy	NOUN	O	O
on	ADP	O	O
cardiac	ADJ	O	B-PHYSICAL
arrhythmias	NOUN	O	I-PHYSICAL
in	ADP	O	O
African-American	ADJ	O	O
men	NOUN	O	O
with	ADP	O	O
systemic	ADJ	O	O
hypertension	NOUN	O	O
and	CCONJ	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
hypertrophy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
hydrochlorothiazide	NOUN	O	O
therapy	NOUN	O	O
on	ADP	O	O
ventricular	ADJ	O	B-PHYSICAL
arrhythmias	NOUN	O	I-PHYSICAL
was	VERB	O	O
studied	VERB	O	O
in	ADP	O	O
45	NUM	O	O
hypertensive	ADJ	O	O
African-American	ADJ	O	O
men	NOUN	O	O
with	ADP	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
(	PUNCT	O	O
LV	NOUN	O	O
)	PUNCT	O	O
hypertrophy	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
medication	NOUN	O	O
washout	PUNCT	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
hydrochlorothiazide	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	B-PHYSICAL
,	PUNCT	O	O
biochemical	ADJ	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
48-hour	NOUN	O	B-PHYSICAL
ambulatory	ADJ	O	I-PHYSICAL
electrocardiographic	ADJ	O	I-PHYSICAL
data	NOUN	O	I-PHYSICAL
was	VERB	O	O
collected	VERB	O	O
after	ADP	O	O
each	DET	O	O
treatment	NOUN	O	O
phase	NOUN	O	O
.	PUNCT	O	O

Signal-averaged	ADJ	O	B-PHYSICAL
electrocardiograms	NOUN	O	I-PHYSICAL
were	VERB	O	O
recorded	VERB	O	O
in	ADP	O	O
a	DET	O	O
subgroup	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Average	ADJ	O	O
LV	NOUN	O	B-PHYSICAL
posterior	ADJ	O	I-PHYSICAL
wall	NOUN	O	I-PHYSICAL
thickness	NOUN	O	I-PHYSICAL
was	VERB	O	O
15	NUM	O	O
+/-	SYM	O	O
1.1	NUM	O	O
mm	NOUN	O	O
,	PUNCT	O	O
septum	NOUN	O	O
16	NUM	O	O
+/-	SYM	O	O
2	NUM	O	O
mm	NOUN	O	O
,	PUNCT	O	O
LV	NOUN	O	O
mass	NOUN	O	O
420	NUM	O	O
+/-	SYM	O	O
90	NUM	O	O
g	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
LV	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
212	NUM	O	O
=	SYM	O	O
51	NUM	O	O
g/m2	NOUN	O	O
.	PUNCT	O	O

Systolic	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
BP	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
was	VERB	O	O
168	NUM	O	O
+/-	SYM	O	O
18	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
after	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
phase	NOUN	O	O
and	CCONJ	O	O
146	NUM	O	O
+/-	SYM	O	O
15	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
after	ADP	O	O
hydrochlorothiazide	NOUN	O	O
;	PUNCT	O	O
diastolic	ADJ	O	O
BP	NOUN	O	O
was	VERB	O	O
103	NUM	O	O
+/-	SYM	O	O
6	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
and	CCONJ	O	O
89	NUM	O	O
+/-	SYM	O	O
9	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Serum	NOUN	O	B-PHYSICAL
potassium	NOUN	O	I-PHYSICAL
decreased	VERB	O	O
significantly	ADV	O	O
from	ADP	O	O
4.2	NUM	O	O
+/-	SYM	O	O
0.4	NUM	O	O
mmol/L	NOUN	O	O
to	ADP	O	O
3.7	NUM	O	O
+/-	SYM	O	O
0.6	NUM	O	O
mmol/L	NOUN	O	O
after	ADP	O	O
hydrochlorothiazide	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
hourly	PUNCT	O	O
incidence	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-PHYSICAL
premature	ADJ	O	I-PHYSICAL
contractions	NOUN	O	I-PHYSICAL
was	VERB	O	O
22	PUNCT	O	O
with	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
25	NUM	O	O
with	ADP	O	O
hydrochlorothiazide	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
3	NUM	O	O
and	CCONJ	O	O
1	NUM	O	O
couplets	NOUN	O	O
and	CCONJ	O	O
0.2	NUM	O	O
and	CCONJ	O	O
0.2	NUM	O	O
runs	NOUN	O	O
of	ADP	O	O
ventricular	ADJ	O	B-PHYSICAL
tachycardia	NOUN	O	I-PHYSICAL
per	ADP	O	O
patient	NOUN	O	O
per	ADP	O	O
hour	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Variables	NOUN	O	O
of	ADP	O	O
signal-averaged	VERB	O	B-PHYSICAL
electrocardiography	NOUN	O	I-PHYSICAL
did	PUNCT	O	O
not	ADV	O	O
differ	VERB	O	O
between	ADP	O	O
the	DET	O	O
2	NUM	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
hypertensive	ADJ	O	O
African-American	ADJ	O	O
men	NOUN	O	O
with	ADP	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
LV	NOUN	O	O
hypertrophy	NOUN	O	O
,	PUNCT	O	O
hydrochlorothiazide	NOUN	O	O
does	PUNCT	O	O
not	ADP	O	O
worsen	PUNCT	O	O
ventricular	ADJ	O	B-PHYSICAL
arrhythmias	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
signal-averaged	NOUN	O	B-PHYSICAL
electrocardiographic	ADJ	O	I-PHYSICAL
variables	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Learning	PUNCT	O	O
about	ADP	O	O
the	DET	O	O
equal	ADJ	O	O
sign	NOUN	O	O
:	PUNCT	O	O
does	PUNCT	O	O
comparing	ADJ	O	O
with	ADP	O	O
inequality	NOUN	O	O
symbols	NOUN	O	O
help	NOUN	O	O
?	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
investigated	VERB	O	O
whether	ADP	O	O
instruction	NOUN	O	O
that	ADJ	O	O
involves	PART	O	O
comparing	ADP	O	O
the	DET	O	O
equal	ADJ	O	O
sign	NOUN	O	O
with	ADP	O	O
other	ADJ	O	O
relational	ADJ	O	O
symbols	NOUN	O	O
is	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
at	ADP	O	O
imparting	PUNCT	O	O
a	DET	O	O
relational	ADJ	O	B-MENTAL
interpretation	NOUN	O	I-MENTAL
of	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
equal	ADJ	O	I-MENTAL
sign	NOUN	O	I-MENTAL
than	PUNCT	O	O
instruction	NOUN	O	O
about	PUNCT	O	O
the	DET	O	O
equal	ADJ	O	O
sign	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

Third-	ADV	O	O
and	CCONJ	O	O
fourth-grade	PUNCT	O	O
students	NOUN	O	O
in	ADP	O	O
a	DET	O	O
comparing	PUNCT	O	O
symbols	VERB	O	O
group	NOUN	O	O
learned	ADP	O	O
about	PUNCT	O	O
the	DET	O	O
greater	PUNCT	O	O
than	PUNCT	O	O
,	PUNCT	O	O
less	ADV	O	O
than	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
equal	ADJ	O	O
signs	NOUN	O	O
and	CCONJ	O	O
had	PUNCT	O	O
the	DET	O	O
opportunity	NOUN	O	O
to	PART	O	O
compare	NOUN	O	O
the	DET	O	O
inequality	NOUN	O	O
symbols	ADJ	O	O
with	ADP	O	O
the	DET	O	O
equal	ADJ	O	O
sign	NOUN	O	O
.	PUNCT	O	O

Students	NOUN	O	O
in	ADP	O	O
an	DET	O	O
equal	ADJ	O	O
sign	ADJ	O	O
group	NOUN	O	O
learned	ADP	O	O
about	PUNCT	O	O
the	DET	O	O
equal	ADJ	O	O
sign	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

A	DET	O	O
third	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
students	NOUN	O	O
served	VERB	O	O
as	ADP	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
aspects	NOUN	O	O
of	ADP	O	O
students	NOUN	O	O
'	PUNCT	O	O
knowledge	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
lesson	ADJ	O	O
:	PUNCT	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
conceptual	ADJ	O	B-MENTAL
understanding	VERB	O	I-MENTAL
of	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
equal	ADJ	O	I-MENTAL
sign	NOUN	O	I-MENTAL
,	PUNCT	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
equation	NOUN	O	B-MENTAL
encoding	ADJ	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
c	NOUN	O	O
)	PUNCT	O	O
problem	NOUN	O	B-MENTAL
solving	PROPN	O	I-MENTAL
.	PUNCT	O	O

Students	NOUN	O	O
in	ADP	O	O
the	DET	O	O
comparing	PUNCT	O	O
symbols	DET	O	O
group	NOUN	O	O
showed	VERB	O	O
greater	PUNCT	O	O
gains	NOUN	O	O
in	ADP	O	O
conceptual	ADJ	O	B-MENTAL
understanding	VERB	O	I-MENTAL
from	ADP	O	O
pretest	NOUN	O	O
to	ADP	O	O
posttest	NOUN	O	O
than	VERB	O	O
students	NOUN	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
two	NUM	O	O
groups	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
students	NOUN	O	O
in	ADP	O	O
the	DET	O	O
comparing	PUNCT	O	O
symbols	DET	O	O
group	NOUN	O	O
also	ADV	O	O
scored	PUNCT	O	O
higher	PUNCT	O	O
on	ADP	O	O
a	DET	O	O
posttest	ADV	O	O
that	PUNCT	O	O
assessed	PUNCT	O	O
knowledge	NOUN	O	O
about	PUNCT	O	O
inequality	NOUN	O	B-MENTAL
symbols	ADJ	O	I-MENTAL
and	CCONJ	O	O
inequality	NOUN	O	B-MENTAL
problem	NOUN	O	I-MENTAL
solving	PROPN	O	I-MENTAL
.	PUNCT	O	O

Thus	ADV	O	O
,	PUNCT	O	O
they	PRON	O	O
learned	ADP	O	O
about	ADP	O	O
three	NUM	O	O
symbols	ADJ	O	O
in	ADP	O	O
the	DET	O	O
same	ADJ	O	O
amount	NOUN	O	O
of	ADP	O	O
time	NOUN	O	O
as	ADP	O	O
other	ADJ	O	O
students	NOUN	O	O
learned	VERB	O	O
about	PUNCT	O	O
the	DET	O	O
equal	ADJ	O	O
sign	NOUN	O	O
alone	ADJ	O	O
or	CCONJ	O	O
not	ADV	O	O
at	ADP	O	O
all	PUNCT	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
an	DET	O	O
instructional	ADJ	O	O
approach	NOUN	O	O
involving	VERB	O	O
comparison	NOUN	O	O
can	VERB	O	O
be	ADJ	O	O
an	DET	O	O
effective	ADJ	O	O
tool	NOUN	O	O
for	ADP	O	O
learning	ADP	O	O
about	PUNCT	O	O
concepts	NOUN	O	O
in	ADP	O	O
mathematics	NOUN	O	O
.	PUNCT	O	O

Sodium	NOUN	O	O
bicarbonate	NOUN	O	O
,	PUNCT	O	O
N-acetylcysteine	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
saline	NOUN	O	O
for	ADP	O	O
prevention	NOUN	O	O
of	ADP	O	O
radiocontrast-induced	VERB	O	B-ADVERSE-EFFECTS
nephropathy	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
regimens	NOUN	O	O
for	ADP	O	O
protecting	VERB	O	O
contrast-induced	VERB	O	O
nephropathy	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
coronary	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
single-center	NOUN	O	O
prospective	ADJ	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Several	ADJ	O	O
protective	ADJ	O	O
therapies	NOUN	O	O
have	ADJ	O	O
been	PUNCT	O	O
developed	VERB	O	O
to	PART	O	O
prevent	ADJ	O	O
contrast-induced	VERB	O	B-ADVERSE-EFFECTS
nephropathy	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	I-ADVERSE-EFFECTS
CIN	NOUN	O	I-ADVERSE-EFFECTS
)	PUNCT	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

We	PRON	O	O
aimed	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	O
bicarbonate	NOUN	O	O
by	ADP	O	O
comparing	VERB	O	O
2	NUM	O	O
other	ADJ	O	O
regimens	NOUN	O	O
,	PUNCT	O	O
including	ADP	O	O
combination	NOUN	O	O
of	ADP	O	O
N-acetylcysteine	NOUN	O	O
(	PUNCT	O	O
NAC	NOUN	O	O
)	PUNCT	O	O
plus	CCONJ	O	O
sodium	NOUN	O	O
chloride	ADP	O	O
and	CCONJ	O	O
sodium	NOUN	O	O
chloride	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
to	PART	O	O
prevent	NOUN	O	O
CIN	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
cardiovascular	ADJ	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	ADP	O	O
prospectively	ADV	O	O
enrolled	VERB	O	O
264	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
scheduled	VERB	O	O
for	ADP	O	O
cardiovascular	ADJ	O	O
procedures	NOUN	O	O
and	CCONJ	O	O
had	PUNCT	O	O
a	DET	O	O
baseline	NOUN	O	O
creatinine	NOUN	O	O
level	NOUN	O	O
>	SYM	O	O
1.2	NUM	O	O
mg/dL	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
1	NUM	O	O
of	ADP	O	O
3	NUM	O	O
prophylactic	ADJ	O	O
regimens	NOUN	O	O
:	PUNCT	O	O
infusion	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	O
bicarbonate	NOUN	O	O
,	PUNCT	O	O
sodium	NOUN	O	O
chloride	ADP	O	O
,	PUNCT	O	O
sodium	NOUN	O	O
chloride	ADP	O	O
plus	CCONJ	O	O
oral	ADJ	O	O
NAC	NOUN	O	O
(	PUNCT	O	O
600	NUM	O	O
mg	NOUN	O	O
bid	CCONJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Contrast-induced	VERB	O	B-ADVERSE-EFFECTS
nephropathy	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
defined	VERB	O	O
as	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
serum	NOUN	O	O
creatinine	NOUN	O	O
level	NOUN	O	O
>	SYM	O	O
25	NUM	O	O
%	SYM	O	O
or	CCONJ	O	O
0.5	NUM	O	O
mg/dL	NOUN	O	O
after	ADP	O	O
48	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
There	CCONJ	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
among	ADP	O	O
groups	NOUN	O	O
regarding	DET	O	O
baseline	NOUN	O	O
demographic	ADJ	O	O
properties	NOUN	O	O
and	CCONJ	O	O
nephropathy	NOUN	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
change	NOUN	O	O
in	ADP	O	O
creatinine	NOUN	O	B-ADVERSE-EFFECTS
clearance	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
significantly	ADV	O	O
better	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
sodium	NOUN	O	O
bicarbonate	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
other	ADJ	O	O
2	NUM	O	O
groups	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.007	ADP	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
CIN	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
sodium	NOUN	O	O
bicarbonate	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
4.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
sodium	NOUN	O	O
chloride	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
13.6	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.036	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
tended	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
lower	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
12.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.059	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
adjusting	VERB	O	O
the	DET	O	O
Mehran	NOUN	O	B-ADVERSE-EFFECTS
nephropathy	NOUN	O	I-ADVERSE-EFFECTS
risk	NOUN	O	O
score	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
CIN	NOUN	O	B-ADVERSE-EFFECTS
significantly	ADV	O	O
reduced	VERB	O	O
with	ADP	O	O
sodium	NOUN	O	O
bicarbonate	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
sodium	NOUN	O	O
chloride	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
adjusted	PUNCT	O	O
risk	NOUN	O	O
ratio	NOUN	O	O
0.29	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.043	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Hydration	NOUN	O	O
with	ADP	O	O
sodium	NOUN	O	O
bicarbonate	NOUN	O	O
provides	PART	O	O
better	PUNCT	O	O
protection	NOUN	O	O
against	PUNCT	O	O

The	DET	O	O
additional	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
a	DET	O	O
night	NOUN	O	O
splint	VERB	O	O
to	ADP	O	O
eccentric	ADJ	O	O
exercises	NOUN	O	O
in	ADP	O	O
chronic	ADJ	O	O
midportion	NOUN	O	O
Achilles	NOUN	O	O
tendinopathy	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	ADV	O	O
assess	NOUN	O	O
whether	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
night	NOUN	O	O
splint	PUNCT	O	O
is	ADJ	O	O
of	ADP	O	O
added	PUNCT	O	O
benefit	NOUN	O	O
on	ADP	O	O
functional	ADJ	O	O
outcome	NOUN	O	O
in	ADP	O	O
treating	VERB	O	O
chronic	ADJ	O	O
midportion	NOUN	O	O
Achilles	NOUN	O	O
tendinopathy	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
single-blind	NOUN	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
single	ADJ	O	O
centre	NOUN	O	O
,	PUNCT	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
set	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Sports	NOUN	O	O
Medical	ADJ	O	O
Department	NOUN	O	O
,	PUNCT	O	O
The	DET	O	O
Hague	NOUN	O	O
Medical	ADJ	O	O
Centre	NOUN	O	O
,	PUNCT	O	O
The	DET	O	O
Netherlands	ADV	O	O
.	PUNCT	O	O

Inclusion	NOUN	O	O
criteria	NOUN	O	O
were	VERB	O	O
:	PUNCT	O	O
age	NOUN	O	O
18-70	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
active	ADJ	O	O
participation	NOUN	O	O
in	ADP	O	O
sports	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
tendon	NOUN	O	O
pain	NOUN	O	O
localised	VERB	O	O
at	ADP	O	O
2-7	NUM	O	O
cm	NOUN	O	O
from	ADP	O	O
distal	ADJ	O	O
insertion	NOUN	O	O
.	PUNCT	O	O

Exclusion	NOUN	O	O
criteria	NOUN	O	O
were	ADV	O	O
:	PUNCT	O	O
insertional	ADJ	O	O
disorders	NOUN	O	O
,	PUNCT	O	O
partial	ADJ	O	O
or	CCONJ	O	O
complete	ADJ	O	O
ruptures	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
systemic	ADJ	O	O
illness	NOUN	O	O
.	PUNCT	O	O

70	NUM	O	O
tendons	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
and	CCONJ	O	O
randomised	NOUN	O	O
into	ADP	O	O
one	NUM	O	O
of	ADP	O	O
two	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
:	PUNCT	O	O
eccentric	ADJ	O	O
exercises	NOUN	O	O
with	ADP	O	O
a	DET	O	O
night	NOUN	O	O
splint	PUNCT	O	O
(	PUNCT	O	O
night	NOUN	O	O
splint	PUNCT	O	O
group	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
36	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
eccentric	ADJ	O	O
exercises	NOUN	O	O
only	ADV	O	O
(	PUNCT	O	O
eccentric	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
34	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
Both	PUNCT	O	O
groups	NOUN	O	O
completed	NOUN	O	O
a	DET	O	O
12-week	NOUN	O	O
heavy-load	NOUN	O	O
eccentric	ADJ	O	O
training	DET	O	O
programme	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
group	NOUN	O	O
received	VERB	O	O
a	DET	O	O
night	NOUN	O	O
splint	PUNCT	O	O
in	ADP	O	O
addition	NOUN	O	O
to	ADP	O	O
eccentric	ADJ	O	O
exercises	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
follow-up	NOUN	O	O
at	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
patient	NOUN	O	B-OTHER
satisfaction	NOUN	O	I-OTHER
,	PUNCT	O	O
Victorian	ADJ	O	B-PHYSICAL
Institute	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
Sport	NOUN	O	I-PHYSICAL
Assessment-Achilles	NOUN	O	I-PHYSICAL
questionnaire	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
VISA-A	NOUN	O	I-PHYSICAL
)	PUNCT	O	B-PHYSICAL
score	NOUN	O	O
and	CCONJ	O	O
reported	VERB	O	B-OTHER
compliance	NOUN	O	I-OTHER
were	VERB	O	O
recorded	VERB	O	O
by	ADP	O	O
a	DET	O	O
single-blind	NOUN	O	O
trained	ADP	O	O
researcher	ADP	O	O
who	CCONJ	O	O
was	ADV	O	O
blinded	ADP	O	O
to	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
After	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
patient	NOUN	O	B-OTHER
satisfaction	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
eccentric	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
63	NUM	O	O
%	SYM	O	O
compared	VERB	O	O
with	ADP	O	O
48	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
night	NOUN	O	O
splint	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
VISA-A	NOUN	O	B-PHYSICAL
score	VERB	O	I-PHYSICAL
significantly	ADV	O	O
improved	VERB	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
;	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
eccentric	ADJ	O	O
group	NOUN	O	O
from	ADP	O	O
50.1	NUM	O	O
to	ADP	O	O
68.8	NUM	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
night	NOUN	O	O
splint	PUNCT	O	O
group	NOUN	O	O
from	ADP	O	O
49.4	NUM	O	O
to	ADP	O	O
67.0	NUM	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
groups	NOUN	O	O
in	ADP	O	O
VISA-A	NOUN	O	B-PHYSICAL
score	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.815	PUNCT	O	O
)	PUNCT	O	O
and	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
vitamin/mineral	ADJ	O	O
supplement	NOUN	O	O
on	ADP	O	O
children	NOUN	O	O
and	CCONJ	O	O
adults	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Vitamin/mineral	ADJ	O	O
supplements	NOUN	O	O
are	VERB	O	O
among	ADP	O	O
the	DET	O	O
most	PUNCT	O	O
commonly	ADV	O	O
used	DET	O	O
treatments	NOUN	O	O
for	ADP	O	O
autism	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
the	DET	O	O
research	NOUN	O	O
on	ADP	O	O
their	PUNCT	O	O
use	NOUN	O	O
for	ADP	O	O
treating	VERB	O	O
autism	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
limited	VERB	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
is	VERB	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
three	NUM	O	O
month	NOUN	O	O
vitamin/mineral	ADJ	O	O
treatment	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
involved	VERB	O	O
141	NUM	O	O
children	NOUN	O	O
and	CCONJ	O	O
adults	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
pre	ADP	O	O
and	CCONJ	O	O
post	PUNCT	O	O
symptoms	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

None	NUM	O	O
of	ADP	O	O
the	DET	O	O
participants	NOUN	O	O
had	PUNCT	O	O
taken	VERB	O	O
a	DET	O	O
vitamin/mineral	ADJ	O	O
supplement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
months	NOUN	O	O
prior	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
start	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
a	DET	O	O
subset	NOUN	O	O
of	ADP	O	O
the	DET	O	O
participants	NOUN	O	O
(	PUNCT	O	O
53	NUM	O	O
children	ADJ	O	O
ages	NOUN	O	O
5-16	ADJ	O	O
)	PUNCT	O	O
pre	ADP	O	O
and	CCONJ	O	O
post	PUNCT	O	O
measurements	NOUN	O	O
of	ADP	O	O
nutritional	ADJ	O	O
and	CCONJ	O	O
metabolic	ADJ	O	O
status	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
conducted	VERB	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
vitamin/mineral	ADJ	O	O
supplement	NOUN	O	O
was	VERB	O	O
generally	ADV	O	O
well-tolerated	VERB	O	B-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
individually	ADV	O	O
titrated	PROPN	O	O
to	ADP	O	O
optimum	PUNCT	O	O
benefit	PUNCT	O	O
.	PUNCT	O	O

Levels	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
many	DET	O	I-PHYSICAL
vitamins	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
minerals	ADP	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
biomarkers	PUNCT	O	B-PHYSICAL
improved/increased	PUNCT	O	O
showing	CCONJ	O	O
good	ADJ	O	O
compliance	NOUN	O	B-MENTAL
and	CCONJ	O	O
absorption	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Statistically	ADV	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
in	ADP	O	O
metabolic	ADJ	O	O
status	NOUN	O	O
were	VERB	O	O
many	PUNCT	O	O
including	CCONJ	O	O
:	PUNCT	O	O
total	ADJ	O	O
sulfate	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
+17	CCONJ	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
S-adenosylmethionine	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
SAM	NOUN	O	O
;	PUNCT	O	O
+6	VERB	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
reduced	VERB	O	O
glutathione	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
+17	CCONJ	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0008	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ratio	NOUN	O	O
of	ADP	O	O
oxidized	VERB	O	B-PHYSICAL
glutathione	NOUN	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
reduced	NOUN	O	I-PHYSICAL
glutathione	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
GSSG	NOUN	O	O
:	PUNCT	O	O
GSH	NOUN	O	O
;	PUNCT	O	O
-27	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.002	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
nitrotyrosine	ADJ	O	B-PHYSICAL
(	PUNCT	O	O
-29	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.004	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
ATP	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
+25	ADP	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.000001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
NADH	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
+28	ADP	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0002	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
NADPH	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
+30	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Most	PUNCT	O	O
of	ADP	O	O
these	DET	O	O
metabolic	ADJ	O	O
biomarkers	CCONJ	O	O
improved	ADJ	O	O
to	ADP	O	O
normal	ADJ	O	O
or	CCONJ	O	O
near-normal	NOUN	O	O
levels.The	PUNCT	O	O
supplement	NOUN	O	O
group	NOUN	O	O
had	PUNCT	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
improvements	NOUN	O	O
than	PUNCT	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
on	ADP	O	O
the	DET	O	O
Parental	ADJ	O	B-PHYSICAL
Global	NOUN	O	I-PHYSICAL
Impressions-Revised	PUNCT	O	I-PHYSICAL
(	PUNCT	O	O
PGI-R	NOUN	O	O
,	PUNCT	O	O
Average	ADJ	O	O
Change	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.008	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
subscores	NOUN	O	O
for	ADP	O	O
Hyperactivity	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Tantrumming	PUNCT	O	B-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.009	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Overall	ADP	O	B-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Receptive	ADJ	O	B-PHYSICAL
Language	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

For	ADP	O	O
the	DET	O	O
other	ADJ	O	O
three	NUM	O	O
assessment	NOUN	O	O
tools	DET	O	O
the	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
treatment	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant.Regression	NUM	O	O
analysis	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
improvement	NOUN	O	O
on	ADP	O	O
the	DET	O	O
Average	ADJ	O	O
Change	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
the	DET	O	I-PHYSICAL
PGI-R	NOUN	O	I-PHYSICAL
was	VERB	O	O
strongly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
several	ADJ	O	O
biomarkers	CCONJ	O	O
(	PUNCT	O	O
adj	CCONJ	O	O
.	PUNCT	O	O

R2	NOUN	O	O
=	SYM	O	O
0.61	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0005	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
initial	ADJ	O	O
levels	NOUN	O	O
of	ADP	O	O
biotin	NOUN	O	O
and	CCONJ	O	O
vitamin	NOUN	O	O
K	NOUN	O	O
being	VERB	O	O
the	DET	O	O
most	VERB	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
both	PUNCT	O	O
biotin	NOUN	O	O
and	CCONJ	O	O
vitamin	NOUN	O	O
K	NOUN	O	O
are	VERB	O	O
made	VERB	O	O
by	ADP	O	O
beneficial	ADJ	O	O
intestinal	ADJ	O	O
flora	ADJ	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Oral	ADJ	O	O
vitamin/mineral	ADJ	O	O
supplementation	NOUN	O	O
is	VERB	O	O
beneficial	ADJ	O	O
in	ADP	O	O
improving	VERB	O	O
the	DET	O	O
nutritional	ADJ	O	O
and	CCONJ	O	O
metabolic	ADJ	O	O
status	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
improvements	NOUN	O	O
in	ADP	O	O
methylation	NOUN	O	O
,	PUNCT	O	O
glutathione	NOUN	O	O
,	PUNCT	O	O
oxidative	ADJ	O	O
stress	NOUN	O	O
,	PUNCT	O	O
sulfation	NOUN	O	O
,	PUNCT	O	O
ATP	NOUN	O	O
,	PUNCT	O	O
NADH	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
NADPH	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
supplement	ADJ	O	O
group	NOUN	O	O
had	PUNCT	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
improvements	NOUN	O	O
than	CCONJ	O	O
did	PUNCT	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
on	ADP	O	O
the	DET	O	O
PGI-R	NOUN	O	O
Average	VERB	O	O
Change	NOUN	O	O
.	PUNCT	O	O

This	ADJ	O	O
suggests	NOUN	O	O
that	ADP	O	O
a	DET	O	O
vitamin/mineral	ADJ	O	O
supplement	NOUN	O	O
is	VERB	O	O
a	DET	O	O
reasonable	ADJ	O	O
adjunct	ADJ	O	O
therapy	NOUN	O	O
to	PART	O	O
consider	NOUN	O	O
for	ADP	O	O
most	PUNCT	O	O
children	NOUN	O	O
and	CCONJ	O	O
adults	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

TRIAL	NOUN	O	O
REGISTRATION	NOUN	O	O
CLINICAL	ADJ	O	O
TRIAL	NOUN	O	O
REGISTRATION	NOUN	O	O
NUMBER	NOUN	O	O
NCT01225198	NOUN	O	O
.	PUNCT	O	O

Clinically	ADV	O	O
relevant	ADJ	O	O
improvement	NOUN	O	O
of	ADP	O	O
recurrence-free	ADJ	O	B-OTHER
survival	NOUN	O	I-OTHER
with	ADP	O	O
5-aminolevulinic	ADJ	O	O
acid	NOUN	O	O
induced	VERB	O	O
fluorescence	NOUN	O	O
diagnosis	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
superficial	ADJ	O	O
bladder	NOUN	O	O
tumors	NOUN	O	O
.	PUNCT	O	O

PURPOSES	NOUN	O	O
Fluorescence	NOUN	O	O
diagnosis	NOUN	O	O
induced	VERB	O	O
by	ADP	O	O
5-aminolevulinic	ADJ	O	O
acid	NOUN	O	O
enables	VERB	O	O
more	DET	O	O
thorough	ADP	O	O
transurethral	ADJ	O	O
resection	NOUN	O	O
of	ADP	O	O
superficial	ADJ	O	O
bladder	NOUN	O	O
carcinoma	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
conventional	ADJ	O	O
white	ADJ	O	O
light	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
single	ADJ	O	O
institution	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
trial	NOUN	O	O
to	PART	O	O
investigate	NOUN	O	O
whether	ADP	O	O
the	DET	O	O
residual	ADJ	O	O
tumor	NOUN	O	O
rate	NOUN	O	O
and	CCONJ	O	O
long-term	NOUN	O	O
tumor	NOUN	O	O
recurrence	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
decreased	VERB	O	O
by	ADP	O	O
fluorescence	NOUN	O	O
diagnosis	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
301	NUM	O	O
patients	NOUN	O	O
underwent	VERB	O	O
transurethral	ADJ	O	O
resection	NOUN	O	O
of	ADP	O	O
bladder	NOUN	O	O
tumors	NOUN	O	O
with	ADP	O	O
white	ADJ	O	O
light	ADJ	O	O
or	CCONJ	O	O
fluorescence	NOUN	O	O
diagnosis	NOUN	O	O
.	PUNCT	O	O

Transurethral	ADJ	O	O
resection	NOUN	O	O
was	VERB	O	O
repeated	VERB	O	O
5	NUM	O	O
to	ADP	O	O
6	NUM	O	O
weeks	NOUN	O	O
later	ADJ	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
residual	ADJ	O	O
tumor	NOUN	O	O
rate	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
determine	ADP	O	O
recurrence-free	ADJ	O	B-OTHER
survival	NOUN	O	I-OTHER
patient	NOUN	O	O
followup	NOUN	O	O
was	VERB	O	O
performed	ADP	O	O
every	DET	O	O
3	NUM	O	O
months	NOUN	O	O
by	ADP	O	O
white	ADJ	O	O
light	ADJ	O	O
cystoscopy	NOUN	O	O
and	CCONJ	O	O
urine	NOUN	O	O
cytology	NOUN	O	O
.	PUNCT	O	O

Recurrence-free	ADJ	O	B-OTHER
survival	NOUN	O	I-OTHER
was	VERB	O	O
analyzed	VERB	O	O
via	ADP	O	O
Kaplan-Meier	ADJ	O	O
methods	NOUN	O	O
and	CCONJ	O	O
multivariable	ADJ	O	O
Cox	NOUN	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
191	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
superficial	ADJ	O	O
bladder	NOUN	O	O
carcinoma	NOUN	O	O
were	VERB	O	O
available	ADJ	O	O
for	ADP	O	O
efficacy	NOUN	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
residual	ADJ	O	O
tumor	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
was	VERB	O	O
25.2	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
white	ADJ	O	O
light	ADP	O	O
arm	NOUN	O	O
versus	CCONJ	O	O
4.5	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
fluorescence	NOUN	O	O
diagnosis	NOUN	O	O
arm	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Median	ADJ	O	O
followup	NOUN	O	O
in	ADP	O	O
the	DET	O	O
white	ADJ	O	O
light	ADP	O	O
arm	NOUN	O	O
in	ADP	O	O
103	NUM	O	O
cases	NOUN	O	O
was	VERB	O	O
21.2	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
4	NUM	O	O
to	ADP	O	O
40	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
20.5	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
3	NUM	O	O
to	ADP	O	O
40	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
88	NUM	O	O
in	ADP	O	O
the	DET	O	O
fluorescence	NOUN	O	O
diagnosis	NOUN	O	O
arm	NOUN	O	O
.	PUNCT	O	O

Recurrence-free	ADJ	O	B-OTHER
survival	NOUN	O	I-OTHER
in	ADP	O	O
the	DET	O	O
fluorescence	NOUN	O	O
diagnosis	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
89.6	NUM	O	O
%	SYM	O	O
after	ADP	O	O
12	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
months	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
73.8	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
65.9	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
white	ADJ	O	O
light	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.004	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
superiority	NOUN	O	O
proved	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
independent	ADJ	O	O
of	ADP	O	O
risk	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
adjusted	ADV	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
of	ADP	O	O
fluorescence	NOUN	O	O
diagnosis	NOUN	O	O
versus	CCONJ	O	O
white	ADJ	O	O
light	ADJ	O	O
transurethral	ADJ	O	O
resection	NOUN	O	O
was	VERB	O	O
0.33	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
0.16	NUM	O	O
to	ADP	O	O
0.67	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Fluorescence	NOUN	O	O
diagnosis	NOUN	O	O
is	VERB	O	O
significantly	ADV	O	O
superior	ADJ	O	O
to	ADP	O	O
conventional	ADJ	O	O
white	ADJ	O	O
light	ADJ	O	O
transurethral	ADJ	O	O
resection	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
the	DET	O	O
residual	ADJ	O	O
tumor	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
recurrence-free	ADJ	O	B-OTHER
survival	NOUN	O	I-OTHER
.	PUNCT	O	O

The	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
recurrence-free	ADJ	O	B-OTHER
survival	NOUN	O	I-OTHER
imply	PUNCT	O	O
that	ADP	O	O
fluorescence	NOUN	O	O
diagnosis	NOUN	O	O
is	VERB	O	O
a	DET	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
procedure	NOUN	O	O
for	ADP	O	O
decreasing	VERB	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
tumor	NOUN	O	B-PHYSICAL
recurrences	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Echocardiographic	ADJ	O	O
evaluation	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
systemic	ADJ	O	O
ventricular	ADJ	O	O
dysfunction	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
carvedilol	NOUN	O	O
.	PUNCT	O	O

Echocardiography	NOUN	O	O
is	VERB	O	O
used	VERB	O	O
to	PART	O	O
measure	VERB	O	O
the	DET	O	O
therapeutic	ADJ	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	O
failure	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
adults	NOUN	O	O
and	CCONJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purposes	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
were	VERB	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
to	PART	O	O
assess	ADJ	O	O
baseline	NOUN	O	O
echocardiographic	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
to	PART	O	O
investigate	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
echocardiographic	ADJ	O	O
parameters	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
to	PART	O	O
compare	NOUN	O	O
these	DET	O	O
echocardiographic	ADJ	O	O
changes	NOUN	O	O
with	ADP	O	O
changes	NOUN	O	O
in	ADP	O	O
plasma	NOUN	O	O
levels	NOUN	O	O
of	ADP	O	O
b-type	NOUN	O	O
natriuretic	ADJ	O	O
peptide	NOUN	O	O
(	PUNCT	O	O
BNP	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
population	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
systemic	ADJ	O	O
ventricular	ADJ	O	O
dysfunction	NOUN	O	O
and	CCONJ	O	O
symptomatic	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
carvedilol	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
available	ADJ	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
6-month	NOUN	O	O
echocardiograms	NOUN	O	O
from	ADP	O	O
Pediatric	ADJ	O	O
Carvedilol	NOUN	O	O
Trial	NOUN	O	O
(	PUNCT	O	O
PCT	NOUN	O	O
)	PUNCT	O	O
participants	NOUN	O	O
(	PUNCT	O	O
carvedilol	NOUN	O	O
n	NOUN	O	O
=	SYM	O	O
161	NUM	O	O
;	PUNCT	O	O
placebo	NOUN	O	O
n	NOUN	O	O
=	SYM	O	O
55	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
reviewed	VERB	O	O
.	PUNCT	O	O

Systolic	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
diastolic	ADJ	O	B-PHYSICAL
sphericity	NOUN	O	I-PHYSICAL
index	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
SI	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
110	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
TEI	NOUN	O	O
index	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
145	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
systemic	ADJ	O	O
ventricular	ADJ	O	O
dP/dt	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
70	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
measured	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
PCT	NOUN	O	O
composite	NOUN	O	O
definition	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
outcome	NOUN	O	O
(	PUNCT	O	O
i.e.	CCONJ	O	O
,	PUNCT	O	O
worsened	VERB	O	O
,	PUNCT	O	O
improved	DET	O	O
,	PUNCT	O	O
or	CCONJ	O	O
unchanged	ADJ	O	O
)	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
.	PUNCT	O	O

For	ADP	O	O
all	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
baseline	NOUN	O	O
TEI	NOUN	O	O
index	NOUN	O	O
was	VERB	O	O
a	DET	O	O
predictor	NOUN	O	O
of	ADP	O	O
worsened	VERB	O	B-PHYSICAL
outcome	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Only	ADV	O	O
children	ADJ	O	O
treated	VERB	O	O
with	ADP	O	O
carvedilol	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
systolic	ADJ	O	B-PHYSICAL
SI	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
B	NOUN	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
diastolic	ADJ	O	B-PHYSICAL
SI	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
B	NOUN	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
TEI	NOUN	O	B-PHYSICAL
index	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

An	DET	O	O
inverse	ADJ	O	O
correlation	NOUN	O	O
between	ADP	O	O
changes	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
BNP	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
changes	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
dP/dt	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
-0.45	PUNCT	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
found	VERB	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
carvedilol	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
conclusion	NOUN	O	O
,	PUNCT	O	O
TEI	NOUN	O	O
index	NOUN	O	O
predicted	VERB	O	O
outcome	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
systemic	ADJ	O	O
ventricular	ADJ	O	O
dysfunction	NOUN	O	O
and	CCONJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
.	PUNCT	O	O

Carvedilol	NOUN	O	O
may	VERB	O	O
have	PUNCT	O	O
a	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
reversal	NOUN	O	O
of	ADP	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
remodeling	VERB	O	O
and	CCONJ	O	O
global	ADJ	O	O
ventricular	ADJ	O	O
function	NOUN	O	O
in	ADP	O	O
pediatric	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
dipeptidyl	PUNCT	O	O
peptidase-4	NOUN	O	O
inhibitor	NOUN	O	O
PHX1149	NOUN	O	O
improves	NOUN	O	O
blood	NOUN	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
control	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
mellitus	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
of	ADP	O	O
PHX1149	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
novel	ADJ	O	O
dipeptidyl	PUNCT	O	O
peptidase-4	NOUN	O	O
(	PUNCT	O	O
DPP4	NOUN	O	O
)	PUNCT	O	O
inhibitor	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	ADV	O	O
is	VERB	O	O
a	DET	O	O
multicentre	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
4-week	NOUN	O	O
study	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
type	NOUN	O	O
2	NUM	O	O
diabetes	PUNCT	O	O
with	ADP	O	O
suboptimal	ADJ	O	O
metabolic	ADJ	O	O
control	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
baseline	NOUN	O	O
haemoglobin	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
1c	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
HbA	NOUN	O	O
(	PUNCT	O	O
1c	NOUN	O	O
)	PUNCT	O	O
)	PUNCT	O	O
of	ADP	O	O
7.3	NUM	O	O
to	ADP	O	O
11.0	NUM	O	O
%	SYM	O	O
were	VERB	O	O
randomized	VERB	O	O
1	NUM	O	O
:	PUNCT	O	O
1	NUM	O	O
:	PUNCT	O	O
1	NUM	O	O
:	PUNCT	O	O
1	NUM	O	O
to	PART	O	O
receive	VERB	O	O
once-daily	ADV	O	O
oral	ADJ	O	O
therapy	NOUN	O	O
with	ADP	O	O
either	CCONJ	O	O
PHX1149	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
,	PUNCT	O	O
200	NUM	O	O
or	CCONJ	O	O
400	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
;	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
on	ADP	O	O
a	DET	O	O
constant	ADJ	O	O
background	NOUN	O	O
therapy	NOUN	O	O
of	ADP	O	O
either	CCONJ	O	O
metformin	NOUN	O	O
alone	ADJ	O	O
or	CCONJ	O	O
metformin	NOUN	O	O
plus	CCONJ	O	O
a	DET	O	O
glitazone	ADJ	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Treatment	NOUN	O	O
with	ADP	O	O
100	NUM	O	O
,	PUNCT	O	O
200	NUM	O	O
or	CCONJ	O	O
400	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
PHX1149	NOUN	O	O
significantly	ADV	O	O
decreased	ADV	O	O
postprandial	ADJ	O	B-PHYSICAL
glucose	NOUN	O	I-PHYSICAL
area	NOUN	O	O
under	ADP	O	B-PHYSICAL
the	DET	O	I-PHYSICAL
curve	NOUN	O	O
AUC	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
0-2	NUM	O	B-PHYSICAL
h	NOUN	O	O
)	PUNCT	O	O
by	ADP	O	O
approximately	ADV	O	O
20	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
+0.11	PUNCT	O	O
+/-	ADP	O	O
0.50	NUM	O	O
,	PUNCT	O	O
-2.08	NUM	O	O
+/-	SYM	O	O
0.51	NUM	O	O
,	PUNCT	O	O
-1.73	NUM	O	O
+/-	SYM	O	O
0.49	NUM	O	O
and	CCONJ	O	O
-1.88	NUM	O	O
+/-	SYM	O	O
0.48	NUM	O	O
mmol/l	NOUN	O	O
x	SYM	O	O
h	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
for	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
100	NUM	O	O
,	PUNCT	O	O
200	NUM	O	O
and	CCONJ	O	O
400	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.002	NUM	O	O
,	PUNCT	O	O
0.008	NUM	O	O
and	CCONJ	O	O
0.004	NUM	O	O
vs.	CCONJ	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Postprandial	ADJ	O	B-PHYSICAL
AUC	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
0-2	NUM	O	B-PHYSICAL
h	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
of	ADP	O	B-PHYSICAL
intact	ADJ	O	I-PHYSICAL
glucagon-like	ADJ	O	B-PHYSICAL
peptide-1	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
the	DET	O	O
principal	ADJ	O	O
mediator	NOUN	O	O
of	ADP	O	O
the	DET	O	O
biological	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
DPP4	NOUN	O	O
inhibitors	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
increased	VERB	O	O
by	ADP	O	O
3.90	NUM	O	O
+/-	SYM	O	O
2.83	NUM	O	O
,	PUNCT	O	O
11.63	NUM	O	O
+/-	SYM	O	O
2.86	NUM	O	O
,	PUNCT	O	O
16.42	NUM	O	O
+/-	SYM	O	O
2.72	NUM	O	O
and	CCONJ	O	O
15.75	NUM	O	O
+/-	SYM	O	O
2.71	NUM	O	O
pmol/l	NOUN	O	O
x	SYM	O	O
h	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
for	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
100	NUM	O	O
,	PUNCT	O	O
200	NUM	O	O
and	CCONJ	O	O
400	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.053	NUM	O	O
,	PUNCT	O	O
0.001	NUM	O	O
and	CCONJ	O	O
0.002	NUM	O	O
vs.	CCONJ	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
HbA	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
1c	PUNCT	O	I-PHYSICAL

Dose	NOUN	O	O
response	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
cyclical	ADJ	O	O
medroxyprogesterone	NOUN	O	O
on	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
in	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
with	ADP	O	O
placebo	NOUN	O	O
the	DET	O	O
dose-response	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
cyclical	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
the	DET	O	O
C21	NOUN	O	O
progestogen	NOUN	O	O
,	PUNCT	O	O
medroxyprogesterone	NOUN	O	O
acetate	NOUN	O	O
(	PUNCT	O	O
MPA	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
(	PUNCT	O	O
BP	NOUN	O	O
)	PUNCT	O	O
when	ADP	O	O
administered	VERB	O	O
to	PUNCT	O	O
normotensive	ADJ	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
receiving	VERB	O	O
a	DET	O	O
fixed	VERB	O	O
mid-range	NOUN	O	O
daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
conjugated	PUNCT	O	O
equine	ADJ	O	O
oestrogen	NOUN	O	O
(	PUNCT	O	O
CEE	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Twenty	NUM	O	O
normotensive	ADJ	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
age	NOUN	O	O
53	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
participated	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
which	DET	O	O
used	VERB	O	O
a	DET	O	O
double-blind	ADJ	O	O
crossover	NOUN	O	O
design	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
four	NUM	O	O
randomised	VERB	O	O
treatment	NOUN	O	O
phases	NOUN	O	O
,	PUNCT	O	O
each	ADP	O	O
of	ADP	O	O
4	NUM	O	O
weeks	ADJ	O	O
duration	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
four	NUM	O	O
blinded	DET	O	O
treatments	NOUN	O	O
were	VERB	O	O
MPA	NOUN	O	O
2.5	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
MPA	NOUN	O	O
5	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
MPA	NOUN	O	O
10	NUM	O	O
mg	NOUN	O	O
and	CCONJ	O	O
matching	PRON	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
taken	VERB	O	O
for	ADP	O	O
the	DET	O	O
last	ADJ	O	O
14	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
each	DET	O	O
28	NUM	O	O
day	NOUN	O	O
treatment	NOUN	O	O
cycle	NOUN	O	O
.	PUNCT	O	O

CEE	NOUN	O	O
0.625	NUM	O	O
mg	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
administered	VERB	O	O
once	PUNCT	O	O
daily	VERB	O	O
as	PUNCT	O	O
open	PUNCT	O	O
labelled	VERB	O	O
tablets	NOUN	O	O
to	ADP	O	O
all	DET	O	O
subjects	NOUN	O	O
throughout	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Clinic	ADJ	O	B-PHYSICAL
BP	NOUN	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
weekly	ADV	O	O
with	ADP	O	O
the	DET	O	O
mean	NOUN	O	O
values	NOUN	O	O
of	ADP	O	O
weeks	NOUN	O	O
3	NUM	O	O
and	CCONJ	O	O
4	NUM	O	O
of	ADP	O	O
each	DET	O	O
phase	NOUN	O	O
used	VERB	O	O
for	ADP	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

Ambulatory	ADJ	O	B-PHYSICAL
BP	NOUN	O	I-PHYSICAL
was	VERB	O	O
performed	VERB	O	O
in	ADP	O	O
the	DET	O	O
final	ADJ	O	O
week	NOUN	O	O
of	ADP	O	O
each	DET	O	O
phase	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
phase	NOUN	O	O
,	PUNCT	O	O
end	NOUN	O	O
of	ADP	O	O
phase	NOUN	O	O
clinic	VERB	O	B-PHYSICAL
BP	NOUN	O	I-PHYSICAL
was	VERB	O	O
unchanged	VERB	O	O
by	ADP	O	O
any	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
progestogen	NOUN	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
dose-dependent	ADJ	O	O
decrease	NOUN	O	O
in	ADP	O	O
ambulatory	ADJ	O	B-PHYSICAL
daytime	NOUN	O	I-PHYSICAL
diastolic	ADJ	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
mean	NOUN	O	O
arterial	ADJ	O	B-PHYSICAL
BP	NOUN	O	B-PHYSICAL
with	ADP	O	O
the	DET	O	O
progestogen	NOUN	O	O
treatments	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
In	ADP	O	O
a	DET	O	O
regimen	NOUN	O	O
of	ADP	O	O
postmenopausal	ADJ	O	O
hormone	NOUN	O	O
replacement	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
a	DET	O	O
fixed	VERB	O	O
mid-range	NOUN	O	O
daily	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
CEE	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
a	DET	O	O
cyclical	ADJ	O	O
regimen	NOUN	O	O
of	ADP	O	O
a	DET	O	O
C21	NOUN	O	O
progestogen	NOUN	O	O
spanning	PROPN	O	O
the	DET	O	O
current	ADJ	O	O
clinical	ADJ	O	O
dose	NOUN	O	O
range	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
progestogen	NOUN	O	O
has	PUNCT	O	O
either	PUNCT	O	O
no	DET	O	O
effect	NOUN	O	O
or	CCONJ	O	O
a	DET	O	O
small	ADJ	O	O
dose-dependent	ADJ	O	O
reduction	NOUN	O	O
in	PUNCT	O	O

LNH-84	NOUN	O	O
regimen	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
multicenter	NOUN	O	O
study	NOUN	O	O
of	ADP	O	O
intensive	ADJ	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
737	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
aggressive	ADJ	O	O
malignant	ADJ	O	O
lymphoma	NOUN	O	O
.	PUNCT	O	O

From	ADP	O	O
July	NOUN	O	O
1984	NUM	O	O
to	ADP	O	O
September	NOUN	O	O
1987	NUM	O	O
,	PUNCT	O	O
737	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
aggressive	ADJ	O	O
malignant	ADJ	O	O
lymphoma	NOUN	O	O
(	PUNCT	O	O
ML	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
treated	VERB	O	O
by	ADP	O	O
an	DET	O	O
intensive	ADJ	O	O
regimen	NOUN	O	O
(	PUNCT	O	O
LNH-84	NOUN	O	O
)	PUNCT	O	O
comprising	CCONJ	O	O
three	NUM	O	O
or	CCONJ	O	O
four	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
doxorubicin	NOUN	O	O
,	PUNCT	O	O
75	NUM	O	O
mg/m2	ADV	O	O
;	PUNCT	O	O
cyclophosphamide	NOUN	O	O
,	PUNCT	O	O
1,200	NUM	O	O
mg/m2	ADV	O	O
;	PUNCT	O	O
vindesine	NOUN	O	O
,	PUNCT	O	O
2	NUM	O	O
mg/m2	NOUN	O	O
x	ADJ	O	O
2	NUM	O	O
;	PUNCT	O	O
bleomycin	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
x	SYM	O	O
2	NUM	O	O
;	PUNCT	O	O
and	CCONJ	O	O
prednisolone	NOUN	O	O
,	PUNCT	O	O
60	NUM	O	O
mg/m2	NOUN	O	O
x	SYM	O	O
5	NUM	O	O
(	PUNCT	O	O
ACVB	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
consolidation	NOUN	O	O
with	ADP	O	O
high-dose	NOUN	O	O
methotrexate	NOUN	O	O
,	PUNCT	O	O
ifosfamide	PUNCT	O	O
,	PUNCT	O	O
etoposide	NOUN	O	O
,	PUNCT	O	O
asparaginase	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cytarabine	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
randomized	VERB	O	O
late	ADJ	O	O
intensification	NOUN	O	O
with	ADP	O	O
two	NUM	O	O
courses	NOUN	O	O
of	ADP	O	O
cytarabine	NOUN	O	O
,	PUNCT	O	O
cyclophosphamide	NOUN	O	O
,	PUNCT	O	O
teniposide	NOUN	O	O
,	PUNCT	O	O
bleomycin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
prednisone	NOUN	O	O
(	PUNCT	O	O
AraCVmB	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Four	NUM	O	O
hundred	NUM	O	O
forty-two	PUNCT	O	O
patients	NOUN	O	O
had	PUNCT	O	O
intermediate-grade	NOUN	O	O
ML	NOUN	O	O
,	PUNCT	O	O
221	NUM	O	O
highgrade	PUNCT	O	O
ML	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
74	NUM	O	O
unclassified	VERB	O	O
ML	NOUN	O	O
.	PUNCT	O	O

Most	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
had	PUNCT	O	O
advanced	VERB	O	O
disease	NOUN	O	O
:	PUNCT	O	O
stage	NOUN	O	O
IIE	NOUN	O	O
(	PUNCT	O	O
23	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
III	NUM	O	O
(	PUNCT	O	O
13	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
IV	NUM	O	O
(	PUNCT	O	O
47	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
38	NUM	O	O
%	SYM	O	O
disseminated	VERB	O	O
nodes	NOUN	O	O
;	PUNCT	O	O
38	NUM	O	O
%	SYM	O	O
two	NUM	O	O
or	CCONJ	O	O
more	DET	O	O
extranodal	ADJ	O	O
sites	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
41	NUM	O	O
%	SYM	O	O
a	DET	O	O
tumoral	ADJ	O	O
mass	NOUN	O	O
greater	PUNCT	O	O
than	CCONJ	O	O
10	NUM	O	O
cm	NOUN	O	O
.	PUNCT	O	O

Five	NUM	O	O
hundred	NUM	O	O
fifty-three	ADP	O	O
patients	NOUN	O	O
(	PUNCT	O	O
75	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
went	VERB	O	O
into	ADP	O	O
complete	ADJ	O	B-PHYSICAL
remission	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
CR	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
63	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
into	ADP	O	O
partial	ADJ	O	B-PHYSICAL
remission	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
62	NUM	O	O
(	PUNCT	O	O
8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
failed	VERB	O	B-PHYSICAL
to	PART	O	I-PHYSICAL
respond	ADP	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
59	NUM	O	O
(	PUNCT	O	O
8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
died	VERB	O	B-MORTALITY
during	ADP	O	O
ACVB	NOUN	O	O
courses	NOUN	O	O
,	PUNCT	O	O
17	NUM	O	O
of	ADP	O	O
them	PRON	O	O
from	ADP	O	O
progression	NOUN	O	O
of	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
a	DET	O	O
median	ADJ	O	O
follow-up	NOUN	O	O
of	ADP	O	O
23	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
estimated	VERB	O	O
2-year	NOUN	O	O
overall	ADJ	O	O
survival	NOUN	O	O
time	NOUN	O	O
to	ADP	O	O
failure	NOUN	O	O
(	PUNCT	O	O
TTF	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
time	NOUN	O	B-PHYSICAL
to	ADP	O	I-PHYSICAL
relapse	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
TTR	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
survival	NOUN	O	I-PHYSICAL
are	ADP	O	O
67	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
56	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
67	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
receiving	VERB	O	O
a	DET	O	O
late	ADJ	O	O
intensification	NOUN	O	O
had	PUNCT	O	O
the	DET	O	O
same	ADJ	O	O
relapse	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
as	PUNCT	O	O
the	DET	O	O
other	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
persistent	ADJ	O	B-PHYSICAL
fibronecrotic	ADJ	O	I-PHYSICAL
mass	NOUN	O	I-PHYSICAL
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
150	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
did	DET	O	O
not	ADV	O	O
influence	VERB	O	O
the	DET	O	O
relapse	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Toxicity	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
mainly	ADV	O	O
neutropenia	NOUN	O	B-ADVERSE-EFFECTS
and	CCONJ	O	O
infection	NOUN	O	B-PHYSICAL
during	ADP	O	O
the	DET	O	O
ACVB	NOUN	O	O
courses	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
40	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
dying	CCONJ	O	O
from	ADP	O	O
septic	ADJ	O	B-MORTALITY
complications	NOUN	O	I-MORTALITY
while	ADP	O	O
responding	PUNCT	O	O
to	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Fifty-three	PUNCT	O	O
percent	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
had	DET	O	O
a	DET	O	O
neutropenia	NOUN	O	B-ADVERSE-EFFECTS
less	ADV	O	O
than	PUNCT	O	O
0.500	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
9	NUM	O	O
)	PUNCT	O	O
/L	PUNCT	O	O
,	PUNCT	O	O
58	NUM	O	O
%	SYM	O	O
fever	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
%	SYM	O	O
grade	NOUN	O	O
4	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
49	NUM	O	O
%	SYM	O	O
a	DET	O	O
documented	VERB	O	B-ADVERSE-EFFECTS
infection	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
8	NUM	O	O
%	SYM	O	O
grade	NOUN	O	O
4	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
obtained	VERB	O	O
with	ADP	O	O
the	DET	O	O
LNH-84	NOUN	O	O
regimen	NOUN	O	O
demonstrate	VERB	O	O
that	ADP	O	O
this	DET	O	O
therapeutic	ADJ	O	O
scheme	NOUN	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
treatment	NOUN	O	O
for	ADP	O	O
aggressive	ADJ	O	O
ML	NOUN	O	O
.	PUNCT	O	O

Smoking	VERB	O	B-MENTAL
cessation	NOUN	O	I-MENTAL
with	ADP	O	O
smokeless	PUNCT	O	O
tobacco	NOUN	O	O
and	CCONJ	O	O
group	NOUN	O	O
therapy	NOUN	O	O
:	PUNCT	O	O
an	DET	O	O
open	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Smokeless	NOUN	O	O
tobacco	NOUN	O	O
might	VERB	O	O
be	NOUN	O	O
effective	ADJ	O	O
as	ADP	O	O
an	DET	O	O
adjunct	NOUN	O	O
for	ADP	O	O
smoking	VERB	O	B-MENTAL
cessation	NOUN	O	I-MENTAL
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
smokeless	PUNCT	O	O
tobacco	NOUN	O	O
and	CCONJ	O	O
group	NOUN	O	O
support	NOUN	O	O
for	ADP	O	O
smoking	VERB	O	B-MENTAL
cessation	NOUN	O	I-MENTAL
in	ADP	O	O
an	DET	O	O
open	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
study	NOUN	O	O
that	PUNCT	O	O
compared	PUNCT	O	O
smokeless	ADP	O	O
tobacco	NOUN	O	O
plus	CCONJ	O	O
group	NOUN	O	O
support	NOUN	O	O
versus	CCONJ	O	O
group	NOUN	O	O
support	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
study	NOUN	O	O
enrolled	VERB	O	O
263	NUM	O	O
healthy	ADJ	O	O
smokers	NOUN	O	O
(	PUNCT	O	O
M	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
)	PUNCT	O	O
=	ADP	O	O
49	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
who	ADP	O	O
smoked	PROPN	O	O
a	DET	O	O
mean	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
cigarettes/day	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
mean	NOUN	O	O
of	ADP	O	O
31	NUM	O	O
pack-years	ADP	O	O
.	PUNCT	O	O

Smokeless	NOUN	O	O
tobacco	NOUN	O	O
was	VERB	O	O
provided	VERB	O	O
for	ADP	O	O
7	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
or	CCONJ	O	O
up	PUNCT	O	O
to	ADP	O	O
12	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
combined	VERB	O	O
with	ADP	O	O
eight	NUM	O	O
group	NOUN	O	O
support	NOUN	O	O
visits	NOUN	O	O
provided	VERB	O	O
by	ADP	O	O
nurses	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
received	ADV	O	O
group	NOUN	O	O
support	NOUN	O	O
only	ADV	O	O
.	PUNCT	O	O

Smoking	VERB	O	B-OTHER
cessation	NOUN	O	I-OTHER
rates	NOUN	O	I-OTHER
were	VERB	O	O
statistically	ADV	O	O
significantly	ADV	O	O
better	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
smokeless	PUNCT	O	O
tobacco	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
7	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

Point-prevalence	NOUN	O	B-OTHER
abstinence	ADJ	O	I-OTHER
rates	NOUN	O	I-OTHER
at	ADP	O	O
7	NUM	O	O
weeks	NOUN	O	O
were	VERB	O	O
36.4	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
20.8	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
OR	NOUN	O	O
=	ADP	O	O
2.52	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
and	CCONJ	O	O
continuous	ADJ	O	B-OTHER
abstinence	ADJ	O	I-OTHER
rates	NOUN	O	I-OTHER
from	ADP	O	O
weeks	NOUN	O	O
4	NUM	O	O
to	ADP	O	O
7	PUNCT	O	O
were	VERB	O	O
31.5	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
19.2	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
OR	NOUN	O	O
=	SYM	O	O
1.94	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
.023	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcomes	NOUN	O	O
(	PUNCT	O	O
i.e.	CCONJ	O	O
,	PUNCT	O	O
6-month	NOUN	O	B-OTHER
point	NOUN	O	I-OTHER
prevalence	NOUN	O	I-OTHER
)	PUNCT	O	O
were	VERB	O	O
23.1	NUM	O	O
%	SYM	O	O
versus	CCONJ	O	O
20.8	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
OR	NOUN	O	O
=	ADP	O	O
1.31	PUNCT	O	O
,	PUNCT	O	O
ns	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Smokeless	NOUN	O	O
tobacco	NOUN	O	O
was	ADJ	O	O
relatively	VERB	O	O
well	VERB	O	O
tolerated	ADP	O	B-OTHER
,	PUNCT	O	O
although	ADP	O	O
15	NUM	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
11.2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
stopped	CCONJ	O	O
use	NOUN	O	O
due	VERB	O	O
to	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
25	NUM	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
17.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
still	ADV	O	O
using	ADJ	O	O
smokeless	NOUN	O	O
tobacco	NOUN	O	O
after	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
trial	NOUN	O	O
demonstrated	VERB	O	O
short-term	NOUN	O	B-OTHER
efficacy	NOUN	O	O
of	ADP	O	B-OTHER
smokeless	PUNCT	O	I-OTHER
tobacco	NOUN	O	B-OTHER
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
group	NOUN	O	O
support	NOUN	O	O
for	ADP	O	O
smoking	VERB	O	O
cessation	NOUN	O	O
but	CCONJ	O	O
no	PUNCT	O	O

Brief	ADP	O	O
report	NOUN	O	O
:	PUNCT	O	O
imitation	NOUN	O	O
effects	NOUN	O	O
on	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
,	PUNCT	O	O
5	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
recruited	VERB	O	O
for	ADP	O	O
the	DET	O	O
study	NOUN	O	O
from	ADP	O	O
a	DET	O	O
school	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
children	NOUN	O	O
were	ADJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
an	DET	O	O
imitation	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
contingently	ADV	O	O
responsive	ADJ	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
10	NUM	O	O
)	PUNCT	O	O
interaction	NOUN	O	O
group	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
a	DET	O	O
stratification	NOUN	O	O
table	NOUN	O	O
for	ADP	O	O
gender	NOUN	O	O
and	CCONJ	O	O
developmental	ADJ	O	O
and	CCONJ	O	O
chronological	ADJ	O	O
age	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
sessions	NOUN	O	O
consisted	DET	O	O
of	ADP	O	O
four	NUM	O	O
phases	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
each	DET	O	O
phase	NOUN	O	O
lasting	ADP	O	O
3	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
first	ADJ	O	O
phase	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
child	NOUN	O	O
walked	ADP	O	O
into	ADP	O	O
a	DET	O	O
room	NOUN	O	O
that	PUNCT	O	O
was	VERB	O	O
furnished	VERB	O	O
with	ADP	O	O
a	DET	O	O
sofa	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
table	NOUN	O	O
,	PUNCT	O	O
chairs	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
two	NUM	O	O
sets	NOUN	O	O
of	ADP	O	O
identical	ADJ	O	O
toys	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
adult	NOUN	O	O
was	VERB	O	O
in	ADP	O	O
the	DET	O	O
room	NOUN	O	O
sitting	PUNCT	O	O
very	ADV	O	O
still	ADV	O	O
like	ADP	O	O
a	DET	O	O
statue	NOUN	O	O
(	PUNCT	O	O
first	ADJ	O	O
still-face	NOUN	O	O
condition	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
second	ADJ	O	O
phase	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
adult	ADJ	O	O
either	CCONJ	O	O
imitated	VERB	O	O
the	DET	O	O
child	NOUN	O	O
or	CCONJ	O	O
was	VERB	O	O
contingently	ADV	O	O
responsive	ADJ	O	O
to	ADP	O	O
the	DET	O	O
child	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
third	ADJ	O	O
phase	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
adult	NOUN	O	O
sat	VERB	O	O
still	ADP	O	O
again	ADV	O	O
(	PUNCT	O	O
second	ADJ	O	O
still-face	NOUN	O	O
condition	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
fourth	ADJ	O	O
phase	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
adult	NOUN	O	O
engaged	VERB	O	O
in	ADP	O	O
a	DET	O	O
spontaneous	ADJ	O	O
interaction	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
the	DET	O	O
third	ADJ	O	O
phase	NOUN	O	O
(	PUNCT	O	O
the	DET	O	O
second	ADJ	O	O
still-face	NOUN	O	O
condition	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
children	NOUN	O	O
in	ADP	O	O
the	DET	O	O
imitation	NOUN	O	O
group	NOUN	O	O
spent	ADJ	O	O
less	DET	O	O
time	NOUN	O	O
in	ADP	O	O
gross	ADJ	O	O
motor	NOUN	O	O
activity	NOUN	O	O
and	CCONJ	O	O
more	DET	O	O
time	NOUN	O	B-OTHER
touching	PUNCT	O	I-OTHER
the	DET	O	I-OTHER
adult	NOUN	O	I-OTHER
,	PUNCT	O	O
as	PUNCT	O	O
if	PUNCT	O	O
attempting	VERB	O	O
to	ADJ	O	O
initiate	NOUN	O	O
an	DET	O	O
interaction	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
contingency	NOUN	O	O
condition	NOUN	O	O
appeared	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
a	DET	O	O
more	ADV	O	O
effective	ADJ	O	O
way	NOUN	O	O
to	PART	O	O
facilitate	NOUN	O	O
a	DET	O	O
distal	ADJ	O	B-MENTAL
social	ADJ	O	I-MENTAL
behavior	NOUN	O	I-MENTAL
(	PUNCT	O	I-MENTAL
attention	NOUN	O	I-MENTAL
)	PUNCT	O	I-MENTAL
,	PUNCT	O	O
whereas	ADP	O	O
the	DET	O	O
imitative	ADJ	O	O
condition	NOUN	O	O
was	VERB	O	O
a	DET	O	O
more	ADV	O	O
effective	ADJ	O	O
way	NOUN	O	O
to	PART	O	O
facilitate	NOUN	O	O
a	DET	O	O
proximal	ADJ	O	B-MENTAL
social	ADJ	O	I-MENTAL
behavior	NOUN	O	I-MENTAL
(	PUNCT	O	O
touching	VERB	O	B-MENTAL
)	PUNCT	O	O
.	PUNCT	O	O

Study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
vaginal	ADJ	O	O
tolerance	NOUN	O	O
to	ADP	O	O
Acidform	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
acid-buffering	ADJ	O	O
,	PUNCT	O	O
bioadhesive	ADJ	O	O
gel	NOUN	O	O
.	PUNCT	O	O

Vaginal	ADJ	O	O
tolerance	NOUN	O	O
tests	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
with	ADP	O	O
a	DET	O	O
new	ADJ	O	O
potential	ADJ	O	O
microbicidal	ADJ	O	O
and	CCONJ	O	O
spermicidal	ADJ	O	O
product	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
acid-buffering	ADJ	O	O
vaginal	ADJ	O	O
gel	NOUN	O	O
(	PUNCT	O	O
Acidform	NOUN	O	O
)	PUNCT	O	O
without	ADP	O	O
or	CCONJ	O	O
with	ADP	O	O
nonoxynol-9	NOUN	O	O
(	PUNCT	O	O
N-9	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
potential	ADJ	O	O
advantages	NOUN	O	O
over	ADP	O	O
other	ADJ	O	O
vaginal	ADJ	O	O
products	NOUN	O	O
include	VERB	O	O
keeping	ADP	O	O
a	DET	O	O
low	ADJ	O	O
pH	NOUN	O	O
,	PUNCT	O	O
decrease	NOUN	O	O
of	ADP	O	O
the	DET	O	O
irritating	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
N-9	NOUN	O	O
on	ADP	O	O
the	DET	O	O
cervix	NOUN	O	O
or	CCONJ	O	O
vaginal	ADJ	O	O
mucosa	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
greater	PUNCT	O	O
retention	NOUN	O	O
of	ADP	O	O
the	DET	O	O
product	NOUN	O	O
after	PUNCT	O	O
application	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
decreasing	VERB	O	O
messiness	NOUN	O	O
as	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
other	CCONJ	O	O
vaginal	ADJ	O	O
products	NOUN	O	O
.	PUNCT	O	O

Three	DET	O	O
groups	NOUN	O	O
of	ADP	O	O
six	NUM	O	O
women	NOUN	O	O
were	VERB	O	O
admitted	VERB	O	O
and	CCONJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PUNCT	O	O
use	NOUN	O	O
Acidform	NOUN	O	O
with	ADP	O	O
0	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
2.5	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
5	NUM	O	O
%	SYM	O	O
N-9	NOUN	O	O
.	PUNCT	O	O

Colposcopic	ADJ	O	O
evaluation	NOUN	O	O
for	ADP	O	O
vulvar	CCONJ	O	O
,	PUNCT	O	O
vaginal	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cervical	ADJ	O	O
signs	NOUN	O	O
of	ADP	O	O
irritation	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
and	CCONJ	O	O
photographs	PUNCT	O	O
were	ADP	O	O
taken	VERB	O	O
,	PUNCT	O	O
following	VERB	O	O
a	DET	O	O
specific	ADJ	O	O
World	NOUN	O	O
Health	NOUN	O	O
Organization	NOUN	O	O
protocol	NOUN	O	O
,	PUNCT	O	O
at	ADP	O	O
time	NOUN	O	O
0	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
and	CCONJ	O	O
6	NUM	O	O
days	NOUN	O	O
of	ADP	O	O
application	NOUN	O	O
of	ADP	O	O
the	DET	O	O
gel	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
irritation	NOUN	O	B-ADVERSE-EFFECTS
or	CCONJ	O	O
symptom	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
reported	VERB	O	O
by	ADP	O	O
users	NOUN	O	O
of	ADP	O	O
Acidform	NOUN	O	O
without	ADP	O	O
N-9	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
generalized	VERB	O	B-ADVERSE-EFFECTS
and	CCONJ	O	I-ADVERSE-EFFECTS
intense	ADJ	O	I-ADVERSE-EFFECTS
erythema	NOUN	O	I-ADVERSE-EFFECTS
in	ADP	O	I-ADVERSE-EFFECTS
cervix	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
10	NUM	O	O
of	ADP	O	O
12	NUM	O	O
Acidform/N-9	PUNCT	O	O
users	NOUN	O	O
and	CCONJ	O	O
abrasion	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
nine	NUM	O	O
of	ADP	O	O
them	PRON	O	O
.	PUNCT	O	O

Vulvar	NOUN	O	B-ADVERSE-EFFECTS
irritation	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
seen	VERB	O	O
in	ADP	O	O
seven	NUM	O	O
of	ADP	O	O
these	DET	O	O
10	NUM	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

N-9	NOUN	O	O
concentration	NOUN	O	O
in	ADP	O	O
the	DET	O	O
gel	NOUN	O	O
(	PUNCT	O	O
2.5	NUM	O	O
%	SYM	O	O
or	CCONJ	O	O
5.0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
was	VERB	O	O
not	ADV	O	O
related	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
findings	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
ulcer	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
exulceration	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
or	CCONJ	O	O
de-epithelialization	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Acidform	NOUN	O	O
without	ADP	O	O
N-9	NOUN	O	O
was	VERB	O	O
well	VERB	O	O
tolerated	VERB	O	O
by	ADP	O	O
volunteers	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
was	VERB	O	O
unable	ADJ	O	O
to	ADJ	O	O
protect	ADV	O	O
the	DET	O	O
cervix	NOUN	O	O
,	PUNCT	O	O
vagina	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
vulva	NOUN	O	O
from	ADP	O	O
the	DET	O	O
N-9	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Tetracaine	NOUN	O	O
(	PUNCT	O	O
ametop	NOUN	O	O
)	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
for	ADP	O	O
reducing	VERB	O	O
pain	NOUN	O	O
associated	VERB	O	O
with	ADP	O	O
intramuscular	ADJ	O	O
injection	NOUN	O	O
of	ADP	O	O
palivizumab	NOUN	O	O
(	PUNCT	O	O
synagis	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Infants	NOUN	O	O
receive	VERB	O	O
many	DET	O	O
painful	ADJ	O	O
immunizations	NOUN	O	O
before	PUNCT	O	O
they	PRON	O	O
are	VERB	O	O
2	NUM	O	O
years	NOUN	O	O
old	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	ADP	O	O
if	PUNCT	O	O
topical	ADJ	O	O
tetracaine	NOUN	O	O
reduces	NOUN	O	O
the	DET	O	O
pain	NOUN	O	O
of	ADP	O	O
intramuscular	ADJ	O	O
palivizumab	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
two	NUM	O	O
study	ADV	O	O
injections	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
with	ADP	O	O
tetracaine	NOUN	O	O
and	CCONJ	O	O
one	NUM	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Pain	NOUN	O	B-PAIN
was	VERB	O	O
scored	VERB	O	O
by	ADP	O	O
their	PUNCT	O	O
parents	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
pediatric	ADJ	O	O
nurse	PUNCT	O	O
.	PUNCT	O	O

Topical	ADJ	O	O
tetracaine	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
pain	NOUN	O	B-PAIN
score	NOUN	O	I-PAIN
,	PUNCT	O	O
although	ADP	O	O
it	PRON	O	O
did	PUNCT	O	O
lead	PUNCT	O	O
to	ADP	O	O
faster	PUNCT	O	O
recovery	NOUN	O	B-OTHER
times	NOUN	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
pain-reduction	NOUN	O	O
strategies	NOUN	O	O
are	VERB	O	O
required	VERB	O	O
.	PUNCT	O	O

Long-term	NOUN	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	ADP	O	O
study	NOUN	O	O
using	VERB	O	O
repetitive	ADJ	O	O
education	NOUN	O	O
at	ADP	O	O
six-month	NOUN	O	O
intervals	NOUN	O	O
and	CCONJ	O	O
monitoring	VERB	O	O
for	ADP	O	O
adherence	NOUN	O	O
in	ADP	O	O
heart	NOUN	O	O
failure	NOUN	O	O
outpatients	ADJ	O	O
:	PUNCT	O	O
the	DET	O	O
REMADHE	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
effectiveness	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	O
failure	NOUN	O	O
disease	NOUN	O	O
management	NOUN	O	O
programs	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
under	ADP	O	O
cardiologists	NOUN	O	O
'	PUNCT	O	O
care	NOUN	O	O
over	ADP	O	O
long-term	NOUN	O	O
follow-up	NOUN	O	O
is	VERB	O	O
not	ADV	O	O
established	VERB	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	NOUN	O	O
We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
a	DET	O	O
disease	NOUN	O	O
management	NOUN	O	O
program	NOUN	O	O
with	ADP	O	O
repetitive	ADJ	O	O
education	NOUN	O	O
and	CCONJ	O	O
telephone	NOUN	O	O
monitoring	VERB	O	O
on	ADP	O	O
primary	ADJ	O	O
(	PUNCT	O	O
combined	PUNCT	O	B-PHYSICAL
death	NOUN	O	B-OTHER
or	CCONJ	O	O
unplanned	VERB	O	B-OTHER
first	ADJ	O	I-OTHER
hospitalization	NOUN	O	I-OTHER
and	CCONJ	O	O
quality-of-life	NOUN	O	B-OTHER
changes	NOUN	O	I-OTHER
)	PUNCT	O	O
and	CCONJ	O	O
secondary	ADJ	O	O
end	NOUN	O	O
points	NOUN	O	O
(	PUNCT	O	O
hospitalization	NOUN	O	B-OTHER
,	PUNCT	O	O
death	NOUN	O	B-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
adherence	NOUN	O	B-MENTAL
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
REMADHE	NOUN	O	O
[	PUNCT	O	O
Repetitive	ADJ	O	O
Education	NOUN	O	O
and	CCONJ	O	O
Monitoring	PROPN	O	O
for	ADP	O	O
ADherence	NOUN	O	O
for	ADP	O	O
Heart	NOUN	O	O
Failure	NOUN	O	O
]	PUNCT	O	O
trial	NOUN	O	O
is	VERB	O	O
a	DET	O	O
long-term	NOUN	O	O
randomized	VERB	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
parallel	ADJ	O	O
trial	NOUN	O	O
designed	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
intervention	NOUN	O	O
with	ADP	O	O
control	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
seventeen	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
usual	ADJ	O	O
care	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
233	NUM	O	O
to	ADP	O	O
additional	ADJ	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
follow-up	NOUN	O	O
was	VERB	O	O
2.47+/-1.75	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
54	NUM	O	O
%	SYM	O	O
adherence	NOUN	O	O
to	ADP	O	O
the	DET	O	O
program	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
composite	NOUN	O	B-MORTALITY
of	ADP	O	I-MORTALITY
death	NOUN	O	I-MORTALITY
or	CCONJ	O	O
unplanned	VERB	O	B-MORTALITY
hospitalization	NOUN	O	I-MORTALITY
was	VERB	O	O
reduced	VERB	O	O
(	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
0.64	NUM	O	O
;	PUNCT	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.43	NUM	O	O
to	ADP	O	O
0.88	NUM	O	O
;	PUNCT	O	O
P=0.008	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
driven	VERB	O	O
by	ADP	O	O
reduction	NOUN	O	O
in	ADP	O	O
hospitalization	NOUN	O	B-OTHER
.	PUNCT	O	O

The	DET	O	O
quality-of-life	NOUN	O	B-OTHER
questionnaire	NOUN	O	O
score	NOUN	O	B-OTHER
improved	VERB	O	O
only	ADV	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.003	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Mortality	NOUN	O	B-MORTALITY
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Number	NOUN	O	B-ADVERSE-EFFECTS
of	ADP	O	I-ADVERSE-EFFECTS
hospitalizations	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
1.3+/-1.7	NOUN	O	O
versus	PUNCT	O	O
0.8+/-1.3	ADP	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
total	ADJ	O	O
hospital	NOUN	O	B-OTHER
days	NOUN	O	I-OTHER
during	ADP	O	B-OTHER
the	DET	O	I-OTHER
follow-up	NOUN	O	B-OTHER
(	PUNCT	O	O
19.9+/-51	NUM	O	O
versus	CCONJ	O	O
11.1+/-24	PUNCT	O	O
days	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
emergency	NOUN	O	B-OTHER
visits	NOUN	O	I-OTHER
(	PUNCT	O	O
4.5+/-10.6	VERB	O	O
versus	CCONJ	O	O
1.6+/-2.4	ADP	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.0001	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Beneficial	ADJ	O	B-OTHER
effects	NOUN	O	I-OTHER
were	VERB	O	O
homogeneous	ADJ	O	O
for	ADP	O	O
sex	NOUN	O	O
,	PUNCT	O	O
race	ADP	O	O
,	PUNCT	O	O
diabetes	NOUN	O	O
and	CCONJ	O	O
no	DET	O	O
diabetes	NOUN	O	O
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
functional	ADJ	O	O
class	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
etiology	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
For	ADP	O	O
a	DET	O	O
longer	PUNCT	O	O
follow-up	NOUN	O	O
period	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
previous	ADJ	O	O
studies	NOUN	O	O
,	PUNCT	O	O
this	DET	O	O
heart	NOUN	O	O
failure	NOUN	O	O
disease	NOUN	O	O
management	NOUN	O	O
program	NOUN	O	O
model	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
under	ADP	O	O
the	DET	O	O
supervision	NOUN	O	O
of	ADP	O	O
a	DET	O	O
cardiologist	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
unplanned	VERB	O	B-OTHER
hospitalization	NOUN	O	B-OTHER
,	PUNCT	O	O
a	DET	O	O
reduction	NOUN	O	O
of	PUNCT	O	O
total	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
weight-bearing	ADP	O	O
versus	CCONJ	O	O
nonweight-bearing	VERB	O	O
exercise	NOUN	O	O
on	ADP	O	O
function	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
walking	ADJ	O	B-PHYSICAL
speed	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
position	NOUN	O	O
sense	NOUN	O	B-PHYSICAL
in	ADP	O	O
participants	NOUN	O	O
with	ADP	O	O
knee	NOUN	O	O
osteoarthritis	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
investigate	ADJ	O	O
whether	ADP	O	O
weight-bearing	VERB	O	O
(	PUNCT	O	O
WB	NOUN	O	O
)	PUNCT	O	O
exercise	NOUN	O	O
enhances	NOUN	O	O
functional	ADJ	O	B-PHYSICAL
capacity	NOUN	O	I-PHYSICAL
to	ADP	O	O
a	DET	O	O
greater	PUNCT	O	O
extent	NOUN	O	O
than	PUNCT	O	O
nonweight-bearing	PUNCT	O	O
(	PUNCT	O	O
NWB	NOUN	O	O
)	PUNCT	O	O
exercise	NOUN	O	O
in	ADP	O	O
participants	NOUN	O	O
with	ADP	O	O
knee	NOUN	O	O
osteoarthritis	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Randomized	PROPN	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

SETTING	NUM	O	O
Kinesiology	NOUN	O	O
laboratory	NOUN	O	O
.	PUNCT	O	O

PARTICIPANTS	ADP	O	O
Participants	NOUN	O	O
(	PUNCT	O	O
N=106	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
WB	NOUN	O	O
exercise	NOUN	O	O
,	PUNCT	O	O
NWB	NOUN	O	O
exercise	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
no	DET	O	O
exercise	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
WB	NOUN	O	O
exercise	NOUN	O	O
and	CCONJ	O	O
NWB	NOUN	O	O
exercise	NOUN	O	O
groups	NOUN	O	O
underwent	VERB	O	O
an	DET	O	O
8-week	NOUN	O	O
knee	NOUN	O	O
extension-flexion	NOUN	O	O
exercise	NOUN	O	O
program	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
Western	NOUN	O	O
Ontario	NOUN	O	O
and	CCONJ	O	O
McMaster	ADJ	O	O
Universities	PROPN	O	O
Osteoarthritis	NOUN	O	O
Index	NOUN	O	O
(	PUNCT	O	O
WOMAC	ADJ	O	O
)	PUNCT	O	O
function	ADV	O	O
scale	NOUN	O	O
,	PUNCT	O	O
walking	ADJ	O	B-PHYSICAL
speed	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
muscle	NOUN	O	B-PHYSICAL
torque	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
knee	NOUN	O	B-PHYSICAL
reposition	NOUN	O	I-PHYSICAL
error	NOUN	O	I-PHYSICAL
were	VERB	O	O
assessed	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Equally	PUNCT	O	O
significant	ADJ	O	O
improvements	NOUN	O	O
were	VERB	O	O
apparent	ADJ	O	O
for	ADP	O	O
all	DET	O	O
outcomes	NOUN	O	O
after	ADP	O	O
WB	NOUN	O	O
exercise	NOUN	O	O
and	CCONJ	O	O
NWB	NOUN	O	O
exercise	NOUN	O	O
,	PUNCT	O	O
except	PUNCT	O	O
for	ADP	O	O
reposition	NOUN	O	B-PHYSICAL
error	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
for	ADP	O	O
which	ADP	O	O
improvement	NOUN	O	O
was	VERB	O	O
greater	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
WB	NOUN	O	O
exercise	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
contrast	NOUN	O	O
,	PUNCT	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
improvements	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Simple	ADJ	O	O
knee	NOUN	O	O
flexion	NOUN	O	O
and	CCONJ	O	O
extension	NOUN	O	O
exercises	NOUN	O	O
(	PUNCT	O	O
WB	NOUN	O	O
and	CCONJ	O	O
NWB	NOUN	O	O
)	PUNCT	O	O
performed	VERB	O	O
over	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
WOMAC	PUNCT	O	B-PHYSICAL
function	ADV	O	I-PHYSICAL
scale	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
knee	NOUN	O	O
strength	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

NWB	NOUN	O	O
exercise	NOUN	O	O
alone	ADJ	O	O
may	ADP	O	O
be	VERB	O	O
sufficient	ADJ	O	O
enough	DET	O	O
to	ADP	O	O
improve	CCONJ	O	O
function	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
muscle	NOUN	O	B-PHYSICAL
strength	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
additional	ADJ	O	O
benefit	NOUN	O	O
of	ADP	O	O
WB	NOUN	O	O
exercise	NOUN	O	O
was	VERB	O	O
improved	VERB	O	O
position	NOUN	O	O
sense	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
which	DET	O	O
may	VERB	O	O
enhance	VERB	O	O
complex	ADJ	O	B-PHYSICAL
walking	ADJ	O	I-PHYSICAL
tasks	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
walking	ADP	O	O
on	ADP	O	O
figure	NOUN	O	O
of	ADP	O	O
8	NUM	O	O
route	NOUN	O	O
and	CCONJ	O	O
spongy	NOUN	O	O
surface	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
body	NOUN	O	O
positioning	ADV	O	O
upon	ADP	O	O
maximal	ADJ	O	O
oxygenation	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
unilateral	ADJ	O	O
lung	NOUN	O	O
pathology	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
quasi-experimental	ADJ	O	O
,	PUNCT	O	O
repeated-measures	ADP	O	O
cross-over	NOUN	O	O
design	NOUN	O	O
study	NUM	O	O
on	ADP	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
body	NOUN	O	O
position	NOUN	O	O
on	ADP	O	O
oxygenation	NOUN	O	O
(	PUNCT	O	O
SaO2	NOUN	O	O
)	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
respiration	NOUN	O	O
and	CCONJ	O	O
pulse	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
unilateral	ADJ	O	O
lung	NOUN	O	O
pathology	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
.	PUNCT	O	O

Previous	ADJ	O	O
research	NOUN	O	O
strongly	ADV	O	O
suggests	NOUN	O	O
that	ADP	O	O
positioning	VERB	O	O
with	ADP	O	O
the	DET	O	O
healthy	ADJ	O	O
(	PUNCT	O	O
unaffected	PUNCT	O	O
)	PUNCT	O	O
lung	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dependent	ADJ	O	O
lateral	ADJ	O	O
(	PUNCT	O	O
down	ADJ	O	O
)	PUNCT	O	O
position	NOUN	O	O
is	VERB	O	O
related	VERB	O	O
to	ADP	O	O
improved	PUNCT	O	O
oxygenation	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
knowledge	NOUN	O	O
about	PUNCT	O	O
whether	VERB	O	O
this	DET	O	O
effect	NOUN	O	O
is	VERB	O	O
maintained	VERB	O	O
over	PUNCT	O	O
time	NOUN	O	O
is	VERB	O	O
lacking	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	PUNCT	O	O
investigation	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	ADP	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
Is	PUNCT	O	O
positioning	VERB	O	O
with	ADP	O	O
the	DET	O	O
unaffected	VERB	O	O
lung	NOUN	O	O
in	ADP	O	O
the	DET	O	O
dependent	ADJ	O	O
lateral	ADJ	O	O
position	NOUN	O	O
related	VERB	O	O
to	ADP	O	O
increased	VERB	O	O
arterial	ADJ	O	O
blood	NOUN	O	O
saturation	NOUN	O	O
levels	NOUN	O	O
and	CCONJ	O	O
decreased	VERB	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
pulse	NOUN	O	O
and	CCONJ	O	O
respiration	NOUN	O	O
?	PUNCT	O	O
(	PUNCT	O	O

2	NUM	O	O
)	PUNCT	O	O
What	PUNCT	O	O
is	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
the	DET	O	O
dependent	ADJ	O	O
variables	NOUN	O	O
--	PUNCT	O	O
oxygenation	NOUN	O	O
saturation	NOUN	O	O
levels	NOUN	O	O
,	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
pulse	NOUN	O	O
and	CCONJ	O	O
respiration	NOUN	O	O
--	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
independent	ADJ	O	O
variables	NOUN	O	O
--	PUNCT	O	O
body	NOUN	O	O
position	NOUN	O	O
and	CCONJ	O	O
time	NOUN	O	O
in	ADP	O	O
the	DET	O	O
position	NOUN	O	O
?	PUNCT	O	O

Thirty-nine	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
unilateral	ADJ	O	O
lung	NOUN	O	O
pathology	NOUN	O	O
were	VERB	O	O
positioned	VERB	O	O
on	ADP	O	O
their	ADP	O	O
sides	NOUN	O	O
with	ADP	O	O
the	DET	O	O
unaffected	VERB	O	O
lung	NOUN	O	O
down	ADJ	O	O
,	PUNCT	O	O
on	ADP	O	O
their	ADP	O	O
sides	NOUN	O	O
with	ADP	O	O
the	DET	O	O
affected	VERB	O	O
lung	NOUN	O	O
down	ADJ	O	O
,	PUNCT	O	O
and	CCONJ	O	O
also	ADV	O	O
in	ADP	O	O
semi-Fowler	ADJ	O	O
's	PUNCT	O	O
position	NOUN	O	O
.	PUNCT	O	O

Arterial	ADJ	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
SaO2	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
saturation	NOUN	O	O
and	CCONJ	O	O
vital	ADJ	O	B-PHYSICAL
signs	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
0	NUM	O	O
,	PUNCT	O	O
15	NUM	O	O
and	CCONJ	O	O
30	NUM	O	O
minutes	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
relationship	NOUN	O	O
between	ADP	O	O
oxygenation	NOUN	O	O
level	NOUN	O	O
or	CCONJ	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

Diastolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
respiration	NOUN	O	O
and	CCONJ	O	O
pulse	NOUN	O	O
did	PUNCT	O	O
vary	VERB	O	O
significantly	ADV	O	O
with	ADP	O	O
position	NOUN	O	O
.	PUNCT	O	O

Whole-body	NOUN	O	O
CT	NOUN	O	O
screening	ADV	O	O
:	PUNCT	O	O
scan	NOUN	O	O
delay	NOUN	O	O
and	CCONJ	O	O
contrast	NOUN	O	O
injection	NOUN	O	O
duration	NOUN	O	O
for	ADP	O	O
optimal	ADJ	O	B-OTHER
enhancement	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
abdominal	ADJ	O	I-OTHER
organs	NOUN	O	I-OTHER
and	CCONJ	O	O
deep	ADJ	O	B-OTHER
vessels	NOUN	O	I-OTHER
.	PUNCT	O	O

PURPOSE	NOUN	O	O
To	ADJ	O	O
assess	NOUN	O	O
the	DET	O	O
optimal	ADJ	O	O
scan	NOUN	O	O
delays	ADP	O	O
and	CCONJ	O	O
contrast	NOUN	O	O
injection	NOUN	O	O
durations	NOUN	O	O
for	ADP	O	O
contrast-enhanced	VERB	O	O
whole-body	NOUN	O	O
computed	PUNCT	O	O
tomography	NOUN	O	O
(	PUNCT	O	O
CT	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
One	NUM	O	O
hundred	NUM	O	O
forty-two	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
:	PUNCT	O	O
protocol	NOUN	O	O
A-scan	ADJ	O	O
delay	NOUN	O	O
of	ADP	O	O
65	NUM	O	O
s	NOUN	O	O
after	ADP	O	O
starting	ADP	O	O
contrast	NOUN	O	O
injection	NOUN	O	O
over	ADP	O	O
30	NUM	O	O
s	NOUN	O	O
;	PUNCT	O	O
protocol	NOUN	O	O
B-105	NOUN	O	O
and	CCONJ	O	O
70	NUM	O	O
s	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
protocol	NOUN	O	O
C-145	NOUN	O	O
and	CCONJ	O	O
110	NUM	O	O
s	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

Contrast	NOUN	O	O
enhancement	NOUN	O	B-OTHER
and	CCONJ	O	O
diagnostic	ADJ	O	B-OTHER
acceptability	NOUN	O	I-OTHER
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

RESULTS	ADJ	O	O
Qualitative	ADJ	O	B-OTHER
assessment	NOUN	O	I-OTHER
was	VERB	O	O
subtle	ADJ	O	O
among	ADP	O	O
the	DET	O	O
three	NUM	O	O
protocols	NOUN	O	O
.	PUNCT	O	O

Homogenous	ADJ	O	B-OTHER
enhancement	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
deep	ADJ	O	I-OTHER
veins	NOUN	O	I-OTHER
was	VERB	O	O
more	ADV	O	O
assuredly	ADV	O	O
achieved	VERB	O	O
with	ADP	O	O
protocol	ADJ	O	O
C.	NOUN	O	O
CONCLUSION	NOUN	O	O
With	ADP	O	O
protocol	NOUN	O	O
C	NOUN	O	O
,	PUNCT	O	O
qualitatively	CCONJ	O	O
acceptable	ADJ	O	O
enhancement	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
obtained	VERB	O	O
in	ADP	O	O
whole-body	NOUN	O	O
CT	NOUN	O	O
.	PUNCT	O	O

Clofarabine	VERB	O	O
?	PUNCT	O	O

fludarabine	NOUN	O	O
with	ADP	O	O
once	PUNCT	O	O
daily	PUNCT	O	O
i.v	NUM	O	O
.	PUNCT	O	O

busulfan	VERB	O	O
as	PUNCT	O	O
pretransplant	PUNCT	O	O
conditioning	DET	O	O
therapy	NOUN	O	O
for	ADP	O	O
advanced	VERB	O	O
myeloid	NOUN	O	O
leukemia	NOUN	O	O
and	CCONJ	O	O
MDS	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
a	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
i.v	NUM	O	O
.	PUNCT	O	O

busulfan	ADJ	O	O
(	PUNCT	O	O
Bu	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
fludarabine	NOUN	O	O
(	PUNCT	O	O
Flu	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
safe	ADJ	O	O
,	PUNCT	O	O
reduced-toxicity	NOUN	O	O
conditioning	PUNCT	O	O
program	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
myelogenous	ADJ	O	O
leukemia/myelodysplastic	ADJ	O	O
syndromes	NOUN	O	O
(	PUNCT	O	O
AML/MDS	ADP	O	O
)	PUNCT	O	O
,	PUNCT	O	O
recurrent	ADJ	O	O
leukemia	NOUN	O	O
posttransplantation	NOUN	O	O
remains	NOUN	O	O
a	DET	O	O
problem	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
enhance	NOUN	O	O
the	DET	O	O
conditioning	VERB	O	O
regimen	NOUN	O	O
's	PUNCT	O	O
antileukemic	ADJ	O	O
effect	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
decided	VERB	O	O
to	ADP	O	O
supplant	PUNCT	O	O
Flu	NOUN	O	O
with	ADP	O	O
clofarabine	VERB	O	O
(	PUNCT	O	O
Clo	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
assayed	VERB	O	O
the	DET	O	O
interactions	NOUN	O	O
of	ADP	O	O
these	DET	O	O
nucleoside	NOUN	O	O
analogs	NOUN	O	O
alone	ADJ	O	O
and	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
with	ADP	O	O
Bu	PUNCT	O	O
in	ADP	O	O
Bu-resistant	ADJ	O	O
human	NOUN	O	O
cell	NOUN	O	O
lines	NOUN	O	O
in	DET	O	O
vitro	ADV	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
pronounced	VERB	O	O
synergy	NOUN	O	O
between	ADP	O	O
each	DET	O	O
nucleoside	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
alkylator	NOUN	O	O
but	CCONJ	O	O
even	ADV	O	O
more	ADV	O	O
enhanced	ADP	O	O
cytotoxic	ADJ	O	O
synergy	NOUN	O	O
when	ADP	O	O
the	DET	O	O
nucleoside	NOUN	O	O
analogs	NOUN	O	O
were	VERB	O	O
combined	VERB	O	O
prior	PUNCT	O	O
to	ADP	O	O
exposing	PUNCT	O	O
the	DET	O	O
cells	NOUN	O	O
to	ADP	O	O
Bu	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
then	ADV	O	O
designed	PUNCT	O	O
a	DET	O	O
4-arm	NOUN	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
myeloid	NOUN	O	O
leukemia	NOUN	O	O
undergoing	SYM	O	O
allogeneic	ADJ	O	O
stem	NOUN	O	O
cell	NOUN	O	O
transplantation	NOUN	O	O
(	PUNCT	O	O
allo-SCT	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
adaptively	CCONJ	O	O
randomized	ADP	O	O
as	ADP	O	O
follows	DET	O	O
:	PUNCT	O	O
Arm	NOUN	O	O
I-Clo	NOUN	O	O
:	PUNCT	O	O
Flu	NOUN	O	O
10:30	NOUN	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Arm	NOUN	O	O
II-20:20	PUNCT	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Arm	NOUN	O	O
III-30:10	PUNCT	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Arm	NOUN	O	O
IV-single-agent	NOUN	O	O
Clo	ADV	O	O
at	ADP	O	O
40	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
nucleoside	NOUN	O	O
analog	NOUN	O	O
(	PUNCT	O	O
s	NOUN	O	O
)	PUNCT	O	O
were/was	PUNCT	O	O
infused	VERB	O	O
over	ADP	O	O
1	NUM	O	O
hour	NOUN	O	O
once	PUNCT	O	O
daily	ADJ	O	O
for	ADP	O	O
4	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
followed	VERB	O	O
on	ADP	O	O
each	DET	O	O
day	NOUN	O	O
by	ADP	O	O
Bu	NOUN	O	O
,	PUNCT	O	O
infused	VERB	O	O
over	ADP	O	O
3	NUM	O	O
hours	NOUN	O	O
to	ADP	O	O
a	DET	O	O
pharmacokinetically	ADV	O	O
targeted	VERB	O	O
daily	ADJ	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
curve	NOUN	O	O
(	PUNCT	O	O
AUC	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
6000	NUM	O	O
?Mol-min	PUNCT	O	O
?	PUNCT	O	O

10	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

Fifty-one	NUM	O	O
patients	NOUN	O	O
have	VERB	O	O
been	PUNCT	O	O
enrolled	VERB	O	O
with	ADP	O	O
a	DET	O	O
minimum	NOUN	O	O
follow-up	NOUN	O	O
exceeding	VERB	O	O
100	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
32	NUM	O	O
males	NOUN	O	O
and	CCONJ	O	O
19	NUM	O	O
females	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
a	DET	O	O
median	ADJ	O	O
age	NOUN	O	O
of	ADP	O	O
45	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
range	NOUN	O	O
:	PUNCT	O	O
6-59	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Nine	NUM	O	O
patients	NOUN	O	O
had	VERB	O	O
chronic	ADJ	O	O
myeloid	NOUN	O	O
leukemia	NOUN	O	O
(	PUNCT	O	O
CML	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
BC	NOUN	O	O
:	PUNCT	O	O
2	NUM	O	O
,	PUNCT	O	O
second	ADJ	O	O
AP	NOUN	O	O
:	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
tyrosine-kinase	NOUN	O	O
inhibitor	NOUN	O	O
refractory	ADJ	O	O
first	ADJ	O	O
chronic	ADJ	O	O
phase	NOUN	O	O
[	PUNCT	O	O
CP	NOUN	O	O
]	PUNCT	O	O
:	PUNCT	O	O
4	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Forty-two	NUM	O	O
patients	NOUN	O	O
had	PUNCT	O	O
AML	NOUN	O	O
:	PUNCT	O	O
14	NUM	O	O
were	VERB	O	O
induction	NOUN	O	O
failures	NOUN	O	O
,	PUNCT	O	O
8	NUM	O	O
in	ADP	O	O
first	ADJ	O	O
chemotherapy-refractory	ADJ	O	O
relapse	NOUN	O	O
,	PUNCT	O	O
7	NUM	O	O
in	ADP	O	O
untreated	VERB	O	O
relapse	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
in	ADP	O	O
second	ADJ	O	O
or	CCONJ	O	O
subsequent	ADJ	O	O
relapse	NOUN	O	O
,	PUNCT	O	O
4	NUM	O	O
were	VERB	O	O
in	ADP	O	O
second	ADJ	O	O
complete	ADJ	O	O
remission	NOUN	O	O
(	PUNCT	O	O
CR	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3	NUM	O	O
in	ADP	O	O
second	ADJ	O	O
CR	NOUN	O	O
without	ADP	O	O
platelet	NOUN	O	O
recovery	NOUN	O	O
(	PUNCT	O	O
CRp	ADP	O	O
)	PUNCT	O	O
,	PUNCT	O	O
2	NUM	O	O
were	VERB	O	O
in	ADP	O	O
high-risk	NOUN	O	O
CR1	NOUN	O	O
.	PUNCT	O	O

Finally	ADV	O	O
,	PUNCT	O	O
1	NUM	O	O
patient	NOUN	O	O
was	VERB	O	O
in	ADP	O	O
first	ADJ	O	O
CRp	NOUN	O	O
.	PUNCT	O	O

Graft-versus-host	ADJ	O	O
disease	NOUN	O	O
(	PUNCT	O	O
GVHD	NOUN	O	O
)	PUNCT	O	O
prophylaxis	NOUN	O	O
was	VERB	O	O
tacrolimus	NOUN	O	O
and	CCONJ	O	O
mini-methorexate	NOUN	O	O
(	PUNCT	O	O
MTX	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
those	ADP	O	O
who	ADP	O	O
had	ADJ	O	O
an	DET	O	O
unrelated	ADV	O	O
or	CCONJ	O	O
1	NUM	O	O
antigen-mismatched	ADJ	O	O
donor	NOUN	O	O
received	PUNCT	O	O
low-dose	NOUN	O	O
rabbit-ATG	NOUN	O	O
(	PUNCT	O	O
Thymoglobulin?	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
engrafted	VERB	O	O
.	PUNCT	O	O

Forty-one	NUM	O	O
patients	NOUN	O	O
had	ADP	O	O
active	ADJ	O	O
leukemia	NOUN	O	O
at	ADP	O	O
the	DET	O	O
time	NOUN	O	O
of	ADP	O	O
transplant	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
35	NUM	O	O
achieved	PUNCT	O	O
CR	NOUN	O	O
(	PUNCT	O	O
85	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Twenty	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
42	NUM	O	O
AML	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
5	NUM	O	O
of	ADP	O	O
9	NUM	O	O
CML	NOUN	O	O
patients	NOUN	O	O
are	VERB	O	O
alive	ADJ	O	O
with	ADP	O	O
a	DET	O	O
projected	VERB	O	O
median	ADJ	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	I-MORTALITY
OS	NOUN	O	I-MORTALITY
)	PUNCT	O	I-MORTALITY
of	ADP	O	O
23	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Marrow	NOUN	O	O
and	CCONJ	O	O
blood	NOUN	O	O
(	PUNCT	O	O
T	NOUN	O	O
cell	NOUN	O	O
)	PUNCT	O	O
chimerism	NOUN	O	O
studies	NOUN	O	O
at	ADP	O	O
day	NOUN	O	O
+100	PUNCT	O	O
revealed	VERB	O	O
that	ADP	O	O
both	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
lower-dose	NOUN	O	O
Clo	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
groups	NOUN	O	O
1+2	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
higher-dose	PUNCT	O	O
Clo	NOUN	O	O
groups	NOUN	O	O
(	PUNCT	O	O
groups	NOUN	O	O
3+4	PUNCT	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
had	VERB	O	O
a	DET	O	O
median	ADJ	O	O
of	ADP	O	O
100	NUM	O	O
%	SYM	O	O
donor	NOUN	O	O
(	PUNCT	O	O
T	NOUN	O	O
cell	NOUN	O	O
)	PUNCT	O	O
-derived	VERB	O	O
DNA	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
has	PUNCT	O	O
been	ADP	O	O
no	CCONJ	O	O
secondary	ADJ	O	B-ADVERSE-EFFECTS
graft	NOUN	O	I-ADVERSE-EFFECTS
failure	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
first	ADJ	O	O
100	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
1	NUM	O	O
patient	NOUN	O	O
died	VERB	O	O
of	ADP	O	O
pneumonia	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
1	NUM	O	O
of	ADP	O	O
liver	NOUN	O	O
GVHD	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
Clo	ADV	O	O
?	PUNCT	O	O

Flu	ADP	O	O
with	ADP	O	O
i.v	NUM	O	O
.	PUNCT	O	O

Bu	PUNCT	O	O
as	PUNCT	O	O
pretransplant	PUNCT	O	O
conditioning	VERB	O	O
is	VERB	O	O
safe	ADJ	O	O
in	ADP	O	O
high-risk	NOUN	O	O
myeloid	NOUN	O	O
leukemia	NOUN	O	O
patients	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
clofarabine	VERB	O	O
is	VERB	O	O
sufficiently	ADV	O	O
immunosuppressive	ADJ	O	O
to	ADP	O	O
support	ADJ	O	O
allo-SCT	NOUN	O	O
in	ADP	O	O
myeloid	NOUN	O	O
leukemia	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
median	ADJ	O	O
OS	NOUN	O	O
of	ADP	O	O
23	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
this	DET	O	O
high-risk	NOUN	O	O
patient	NOUN	O	O
population	NOUN	O	O
is	VERB	O	O
encouraging	PUNCT	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
studies	NOUN	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
antileukemic	ADJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
Clo	ADV	O	O
?	PUNCT	O	O

Flu	ADP	O	O
with	ADP	O	O
i.v	NUM	O	O
.	PUNCT	O	O

Bu	PUNCT	O	O
as	PUNCT	O	O
pretransplant	PUNCT	O	O
conditioning	VERB	O	O
therapy	NOUN	O	O
are	VERB	O	O
warranted	VERB	O	O
.	PUNCT	O	O

Mechanisms	NOUN	O	O
underlying	VERB	O	O
the	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
effect	NOUN	O	O
of	ADP	O	O
implantable	ADJ	O	O
cardioverter-defibrillator	NOUN	O	O
therapy	NOUN	O	O
on	ADP	O	O
mortality	NOUN	O	B-MORTALITY
in	ADP	O	O
high-risk	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
recent	ADJ	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
:	PUNCT	O	O
insights	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Defibrillation	NOUN	O	O
in	ADP	O	O
Acute	ADJ	O	O
Myocardial	ADJ	O	O
Infarction	NOUN	O	O
Trial	NOUN	O	O
(	PUNCT	O	O
DINAMIT	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
although	ADP	O	O
implantable	ADJ	O	O
cardioverter-defibrillators	NOUN	O	O
(	PUNCT	O	O
ICDs	NOUN	O	O
)	PUNCT	O	O
lower	PUNCT	O	O
mortality	NOUN	O	O
in	ADP	O	O
stable	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
low	ADJ	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
late	ADJ	O	O
after	ADP	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
trials	NOUN	O	O
of	ADP	O	O
ICD	NOUN	O	O
versus	CCONJ	O	O
control	NOUN	O	O
subjects	NOUN	O	O
implanted	VERB	O	O
early	DET	O	O
after	ADP	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
do	PUNCT	O	O
not	ADV	O	O
show	VERB	O	O
mortality	NOUN	O	O
benefit	NOUN	O	O
.	PUNCT	O	O

Our	PUNCT	O	O
objective	ADJ	O	O
was	VERB	O	O
to	PART	O	O
investigate	ADV	O	O
possible	ADJ	O	O
mechanisms	NOUN	O	O
underlying	VERB	O	O
the	DET	O	O
lack	NOUN	O	O
of	ADP	O	O
mortality	NOUN	O	B-MORTALITY
benefit	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Defibrillation	NOUN	O	O
in	ADP	O	O
Acute	ADJ	O	O
Myocardial	ADJ	O	O
Infarction	NOUN	O	O
Trial	NOUN	O	O
(	PUNCT	O	O
DINAMIT	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	PUNCT	O	O
this	ADP	O	O
is	VERB	O	O
a	DET	O	O
secondary	ADJ	O	O
analysis	NOUN	O	O
of	ADP	O	O
the	DET	O	O
prospective	ADJ	O	O
randomized	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Outpatients	ADJ	O	O
with	ADP	O	O
recent	ADJ	O	O
(	PUNCT	O	O
6	NUM	O	O
to	ADP	O	O
40	NUM	O	O
days	NOUN	O	O
)	PUNCT	O	O
acute	ADJ	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
,	PUNCT	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
dysfunction	NOUN	O	O
(	PUNCT	O	O
ejection	NOUN	O	O
fraction	NOUN	O	O
<	SYM	O	O
35	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
low	ADJ	O	O
heart	NOUN	O	O
rate	NOUN	O	O
variability	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
ICD	NOUN	O	O
(	PUNCT	O	O
n=311	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
to	ADP	O	O
standard	ADJ	O	O
medical	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
n=342	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
competing-risks	VERB	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
those	PUNCT	O	O
factors	NOUN	O	O
that	ADP	O	O
increased	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
arrhythmic	ADJ	O	B-MORTALITY
death	NOUN	O	I-MORTALITY
also	ADV	O	O
increased	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
nonarrhythmic	ADJ	O	B-MORTALITY
deaths	NOUN	O	I-MORTALITY
.	PUNCT	O	O

After	ADP	O	O
adjustment	NOUN	O	O
for	ADP	O	O
these	DET	O	O
factors	NOUN	O	O
,	PUNCT	O	O
receiving	VERB	O	O
an	DET	O	O
ICD	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
decreased	VERB	O	O
risk	NOUN	O	O
of	ADP	O	O
arrhythmic	ADJ	O	B-MORTALITY
death	NOUN	O	I-MORTALITY
(	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
0.33	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.15	NUM	O	O
to	ADP	O	O
0.71	NUM	O	O
)	PUNCT	O	O
but	CCONJ	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
nonarrhythmic	ADJ	O	B-MORTALITY
death	NOUN	O	I-MORTALITY
(	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
1.70	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
1.00	NUM	O	O
to	ADP	O	O
2.80	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
an	DET	O	O
adjusted	VERB	O	O
time-dependent	ADJ	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
receiving	VERB	O	O
an	DET	O	O
ICD	NOUN	O	O
and	CCONJ	O	O
having	VERB	O	O
appropriate	ADJ	O	O
ICD	NOUN	O	O
therapy	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
15.1	NUM	O	O
%	ADP	O	O
yearly	ADJ	O	B-MORTALITY
hazard	NOUN	O	O
of	ADP	O	B-MORTALITY
mortality	NOUN	O	B-MORTALITY
compared	VERB	O	O
with	ADP	O	O
5.2	NUM	O	O
%	SYM	O	O
in	ADP	O	O
ICD	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
no	DET	O	O
appropriate	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
sudden	ADJ	O	B-MORTALITY
death	NOUN	O	I-MORTALITY
in	ADP	O	O
ICD	NOUN	O	O
patients	NOUN	O	O
was	VERB	O	O
completely	ADV	O	O
offset	PUNCT	O	O
by	ADP	O	O
increased	CCONJ	O	O
nonarrhythmic	ADJ	O	B-MORTALITY
deaths	NOUN	O	I-MORTALITY
,	PUNCT	O	O
which	ADP	O	O
were	VERB	O	O
greatest	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
ICD	NOUN	O	O
shock	NOUN	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
,	PUNCT	O	O
6.0	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
2.8	NUM	O	O
to	ADP	O	O
12.7	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
receiving	VERB	O	O
ICDs	NOUN	O	O
early	ADJ	O	O
after	ADP	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
,	PUNCT	O	O
those	PUNCT	O	O
factors	NOUN	O	O
that	ADP	O	O
are	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
arrhythmia	NOUN	O	O
requiring	PUNCT	O	O
ICD	NOUN	O	O
therapy	NOUN	O	O
are	VERB	O	O
also	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
high	ADJ	O	O
risk	NOUN	O	O
of	PUNCT	O	O

Menopausal	PUNCT	O	B-OTHER
quality	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
life	NOUN	O	I-OTHER
:	PUNCT	O	O
RCT	NOUN	O	O
of	ADP	O	O
yoga	NOUN	O	O
,	PUNCT	O	O
exercise	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
omega-3	NOUN	O	O
supplements	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
3	NUM	O	O
nonhormonal	ADJ	O	O
therapies	NOUN	O	O
for	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
menopause-related	VERB	O	B-OTHER
quality	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
life	NOUN	O	I-OTHER
in	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
vasomotor	NOUN	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
We	PRON	O	O
conducted	VERB	O	O
a	DET	O	O
12-week	NOUN	O	O
3	NUM	O	O
?	PUNCT	O	O

2	NUM	O	O
randomized	VERB	O	O
,	PUNCT	O	O
controlled	PUNCT	O	O
,	PUNCT	O	O
factorial	ADJ	O	O
design	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Peri-	PUNCT	O	O
and	CCONJ	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
,	PUNCT	O	O
40-62	DET	O	O
years	NOUN	O	O
old	ADJ	O	O
,	PUNCT	O	O
were	VERB	O	O
assigned	VERB	O	O
randomly	ADV	O	O
to	PUNCT	O	O
yoga	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
107	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
exercise	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
106	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
usual	ADJ	O	O
activity	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
142	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
also	ADV	O	O
assigned	PUNCT	O	O
randomly	ADV	O	O
to	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
omega-3	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
177	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
178	NUM	O	O
)	PUNCT	O	O
capsules	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
performed	VERB	O	O
the	DET	O	O
following	PUNCT	O	O
interventions	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
weekly	ADP	O	O
90-minute	CCONJ	O	O
yoga	NOUN	O	O
classes	NOUN	O	O
with	ADP	O	O
daily	CCONJ	O	O
at-home	DET	O	O
practice	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
individualized	ADP	O	O
facility-based	NOUN	O	O
aerobic	ADJ	O	O
exercise	NOUN	O	O
training	VERB	O	O
3	NUM	O	O
times/week	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
3	NUM	O	O
)	PUNCT	O	O
0.615	NUM	O	O
g	NOUN	O	O
omega-3	NOUN	O	O
supplement	NOUN	O	O
,	PUNCT	O	O
3	NUM	O	O
times/day	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
outcomes	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
with	ADP	O	O
the	DET	O	O
following	PUNCT	O	O
scores	NOUN	O	O
:	PUNCT	O	O
Menopausal	PUNCT	O	O
Quality	NOUN	O	O
of	ADP	O	O
Life	NOUN	O	O
Questionnaire	NOUN	O	O
(	PUNCT	O	O
MENQOL	NOUN	O	O
)	PUNCT	O	O
total	ADP	O	O
and	CCONJ	O	O
domain	NOUN	O	O
(	PUNCT	O	O
vasomotor	NOUN	O	O
symptoms	NOUN	O	O
,	PUNCT	O	O
psychosocial	ADJ	O	O
,	PUNCT	O	O
physical	ADJ	O	O
and	CCONJ	O	O
sexual	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Among	ADP	O	O
355	NUM	O	O
randomly	ADV	O	O
assigned	PUNCT	O	O
women	NOUN	O	O
who	ADP	O	O
average	PUNCT	O	O
age	NOUN	O	O
was	VERB	O	O
54.7	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
338	NUM	O	O
women	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
completed	DET	O	O
12-week	NOUN	O	O
assessments	NOUN	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
baseline	NOUN	O	O
vasomotor	NOUN	O	O
symptoms	NOUN	O	O
frequency	NOUN	O	O
was	VERB	O	O
7.6/day	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
mean	NOUN	O	O
baseline	NOUN	O	O
total	ADJ	O	O
MENQOL	NOUN	O	O
score	NOUN	O	O
was	ADV	O	O
3.8	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
,	PUNCT	O	O
1-8	NUM	O	O
from	ADP	O	O
better	PUNCT	O	O
to	ADP	O	O
worse	ADJ	O	O
)	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
between-group	NOUN	O	O
differences	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
yoga	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
usual	ADJ	O	O
activity	NOUN	O	O
,	PUNCT	O	O
baseline	NOUN	O	O
to	PUNCT	O	O
12-week	NOUN	O	O
improvements	NOUN	O	O
were	VERB	O	O
seen	VERB	O	O
for	ADP	O	O
MENQOL	NOUN	O	O
total	VERB	O	O
-0.3	ADP	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
-0.6	ADJ	O	O
to	ADP	O	O
0	NUM	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
vasomotor	NOUN	O	O
symptom	NOUN	O	O
domain	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sexuality	NOUN	O	O
domain	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.03	NUM	O	O
)	PUNCT	O	O
scores	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
women	NOUN	O	O
who	ADP	O	O
underwent	PROPN	O	O
exercise	NOUN	O	O
and	CCONJ	O	O
omega-3	NOUN	O	O
therapy	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
control	NOUN	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
improvements	ADJ	O	O
in	ADP	O	O
baseline	NOUN	O	O
to	PUNCT	O	O
12-week	NOUN	O	O
total	ADJ	O	O
MENQOL	NOUN	O	O
scores	NOUN	O	O
were	VERB	O	O
not	ADV	O	O
observed	VERB	O	O
.	PUNCT	O	O

Exercise	NOUN	O	O
showed	CCONJ	O	O
benefit	NOUN	O	O
in	ADP	O	O
the	DET	O	O
MENQOL	NOUN	O	O
physical	ADJ	O	O
domain	NOUN	O	O
score	NOUN	O	O
at	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
All	DET	O	O
women	NOUN	O	O
become	VERB	O	O
menopausal	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
many	DET	O	O
of	ADP	O	O
them	PRON	O	O
seek	PUNCT	O	O
medical	ADJ	O	O
advice	NOUN	O	O
on	ADP	O	O
ways	NOUN	O	O
to	DET	O	O
improve	ADP	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
;	PUNCT	O	O
little	DET	O	O
evidence-based	ADJ	O	O
information	NOUN	O	O
exists	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
found	VERB	O	O
that	ADP	O	O
,	PUNCT	O	O
among	ADP	O	O
healthy	ADJ	O	O
sedentary	ADJ	O	O
menopausal	ADJ	O	O
women	NOUN	O	O
,	PUNCT	O	O
yoga	NOUN	O	O
appears	NOUN	O	O
to	PART	O	O
improve	PUNCT	O	O
menopausal	ADJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
clinical	ADJ	O	O
significance	NOUN	O	O
of	ADP	O	O
our	PUNCT	O	O
finding	ADP	O	O
is	ADP	O	O
uncertain	PUNCT	O	O
because	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
modest	ADJ	O	O
effect	NOUN	O	O
.	PUNCT	O	O

Short-	PUNCT	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
long-term	NOUN	O	I-PHYSICAL
effects	NOUN	O	I-PHYSICAL
of	ADP	O	O
tactile	NOUN	O	O
massage	NOUN	O	O
on	ADP	O	O
salivary	ADJ	O	B-PHYSICAL
cortisol	NOUN	O	I-PHYSICAL
concentrations	NOUN	O	I-PHYSICAL
in	ADP	O	O
Parkinson	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
randomised	VERB	O	O
controlled	DET	O	O
pilot	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Parkinson	NOUN	O	O
's	PUNCT	O	O
disease	NOUN	O	O
(	PUNCT	O	O
PD	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
chronic	ADJ	O	O
neurodegenerative	ADJ	O	O
disorder	NOUN	O	O
with	ADP	O	O
limited	VERB	O	O
knowledge	NOUN	O	O
about	PUNCT	O	O
the	DET	O	O
normal	ADJ	O	O
function	NOUN	O	O
and	CCONJ	O	O
effects	NOUN	O	O
of	ADP	O	O
non-pharmacological	ADJ	O	O
therapies	NOUN	O	O
on	ADP	O	O
the	DET	O	O
hypothalamic-pituitary-adrenal	ADJ	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
HPA	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
axis	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADJ	O	O
analyse	ADJ	O	O
the	DET	O	O
basal	ADJ	O	B-PHYSICAL
diurnal	ADJ	O	I-PHYSICAL
and	CCONJ	O	O
total	ADJ	O	O
secretion	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
salivary	ADJ	O	I-PHYSICAL
cortisol	NOUN	O	I-PHYSICAL
in	ADP	O	O
short-	ADJ	O	O
and	CCONJ	O	O
long-term	NOUN	O	O
aspects	NOUN	O	O
of	ADP	O	O
tactile	NOUN	O	O
massage	NOUN	O	O
(	PUNCT	O	O
TM	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
DESIGN	NOUN	O	O
Prospective	ADJ	O	O
,	PUNCT	O	O
Controlled	PROPN	O	O
and	CCONJ	O	O
Randomised	PROPN	O	O
Multicentre	NOUN	O	O
Trial	NOUN	O	O
.	PUNCT	O	O

SETTING	VERB	O	O
AND	CCONJ	O	O
INTERVENTIONS	NOUN	O	O
Forty-five	PUNCT	O	O
women	NOUN	O	O
and	CCONJ	O	O
men	NOUN	O	O
,	PUNCT	O	O
aged	PUNCT	O	O
50-79	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
recruited	VERB	O	O
.	PUNCT	O	O

Twenty-nine	PUNCT	O	O
of	ADP	O	O
them	PRON	O	O
were	VERB	O	O
blindly	ADV	O	O
randomised	PROPN	O	O
to	PUNCT	O	O
tactile	NOUN	O	O
massage	NOUN	O	O
(	PUNCT	O	O
TM	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
16	NUM	O	O
of	ADP	O	O
them	PRON	O	O
to	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
rest	PUNCT	O	O
to	ADP	O	O
music	ADJ	O	O
(	PUNCT	O	O
RTM	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Ten	NUM	O	O
interventions	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
during	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
26	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
follow	PUNCT	O	O
up	PUNCT	O	O
.	PUNCT	O	O

Salivary	ADJ	O	B-PHYSICAL
cortisol	NOUN	O	I-PHYSICAL
was	VERB	O	O
collected	VERB	O	O
at	ADP	O	O
8	NUM	O	O
am	ADP	O	O
,	PUNCT	O	O
1	NUM	O	O
pm	NOUN	O	O
,	PUNCT	O	O
8	NUM	O	O
pm	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
8	NUM	O	O
am	PUNCT	O	O
the	DET	O	O
next	ADJ	O	O
day	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
five	NUM	O	O
occasions	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
the	DET	O	O
first	ADJ	O	O
and	CCONJ	O	O
eighth	PUNCT	O	O
interventions	NOUN	O	O
,	PUNCT	O	O
it	PUNCT	O	O
was	VERB	O	O
collected	VERB	O	O
immediately	ADV	O	O
before	PUNCT	O	O
and	CCONJ	O	O
after	ADP	O	O
intervention	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
The	DET	O	O
primary	ADJ	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
assess	NOUN	O	O
and	PUNCT	O	O
compare	PUNCT	O	O

Sunbathing	ADP	O	O
and	CCONJ	O	O
sunbed	PUNCT	O	O
use	NOUN	O	O
related	PRON	O	O
to	ADP	O	O
self-image	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
sample	NOUN	O	O
of	ADP	O	O
Swedish	PUNCT	O	O
adolescents	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
1996	NUM	O	O
a	DET	O	O
randomized	VERB	O	O
sample	NOUN	O	O
of	ADP	O	O
4,020	NUM	O	O
Swedish	PUNCT	O	O
adolescents	NOUN	O	O
from	ADP	O	O
three	NUM	O	O
birth	NOUN	O	O
cohorts	NOUN	O	O
were	VERB	O	O
sent	NOUN	O	O
a	DET	O	O
questionnaire	NOUN	O	O
consisting	PUNCT	O	O
of	ADP	O	O
50	NUM	O	O
items	ADJ	O	O
concerning	PRON	O	O
habitual	ADJ	O	O
sun-related	VERB	O	O
behaviours	NOUN	O	O
and	CCONJ	O	O
attitudes	ADP	O	O
,	PUNCT	O	O
knowledge	NOUN	O	O
about	PUNCT	O	O
melanoma	NOUN	O	O
,	PUNCT	O	O
risk	NOUN	O	O
perception	NOUN	O	O
and	CCONJ	O	O
self-image	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
2,615	NUM	O	O
questionnaires	NOUN	O	O
were	VERB	O	O
returned	PUNCT	O	O
.	PUNCT	O	O

Girls	PROPN	O	O
sunbathed	PUNCT	O	O
and	CCONJ	O	O
used	VERB	O	O
sunbeds	ADJ	O	O
more	ADV	O	O
than	ADP	O	O
boys	NOUN	O	O
at	ADP	O	O
all	DET	O	O
ages	NOUN	O	O
.	PUNCT	O	O

Sunbathing	ADP	O	B-MENTAL
and	CCONJ	O	O
sunbed	PUNCT	O	B-MENTAL
use	NOUN	O	I-MENTAL
increased	VERB	O	O
with	ADP	O	O
age	NOUN	O	O
.	PUNCT	O	O

Boys	ADP	O	O
who	ADP	O	O
were	VERB	O	O
most	PUNCT	O	O
satisfied	ADP	O	O
and	CCONJ	O	O
girls	PUNCT	O	O
least	DET	O	O
satisfied	VERB	O	O
with	ADP	O	O
themselves	PUNCT	O	O
sunbathed	ADP	O	B-MENTAL
most	PUNCT	O	O
.	PUNCT	O	O

Those	ADV	O	O
who	PROPN	O	O
were	VERB	O	O
least	ADV	O	O
satisfied	VERB	O	O
with	ADP	O	O
themselves	ADV	O	O
used	VERB	O	B-MENTAL
sunbeds	ADP	O	I-MENTAL
most	PUNCT	O	O
frequently	ADV	O	O
.	PUNCT	O	O

Girls	PROPN	O	O
reported	VERB	O	O
a	DET	O	O
higher	PUNCT	O	O
perceived	DET	O	O
susceptibility	NOUN	O	B-MENTAL
to	ADP	O	I-MENTAL
melanoma	NOUN	O	I-MENTAL
than	PUNCT	O	O
did	PUNCT	O	O
boys	ADP	O	O
.	PUNCT	O	O

The	DET	O	O
perception	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
susceptibility	NOUN	O	I-MENTAL
increased	VERB	O	O
with	ADP	O	O
age	NOUN	O	O
.	PUNCT	O	O

Those	ADV	O	O
who	PROPN	O	O
were	VERB	O	O
least	ADV	O	O
satisfied	VERB	O	O
with	ADP	O	O
themselves	ADP	O	O
reported	VERB	O	O
feeling	CCONJ	O	O
most	PUNCT	O	O
susceptible	ADJ	O	B-MENTAL
.	PUNCT	O	O

The	DET	O	O
overall	ADJ	O	O
main	ADJ	O	O
reason	NOUN	O	B-MENTAL
for	ADP	O	I-MENTAL
sunbathing	VERB	O	I-MENTAL
was	DET	O	O
appearance	NOUN	O	O
,	PUNCT	O	O
both	PUNCT	O	O
for	ADP	O	O
own	ADJ	O	O
sunbathing	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
to	ADP	O	O
an	DET	O	O
even	ADV	O	O
higher	PUNCT	O	O
degree	NOUN	O	O
,	PUNCT	O	O
as	ADP	O	O
a	DET	O	O
supposed	VERB	O	O
reason	NOUN	O	O
for	ADP	O	O
other	ADJ	O	O
adolescents	NOUN	O	O
'	PUNCT	O	O
behaviour	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
was	VERB	O	O
reported	VERB	O	O
most	PUNCT	O	O
frequently	ADV	O	O
by	ADP	O	O
girls	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
older	PUNCT	O	O
age	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
second	ADJ	O	O
most	ADP	O	O
'important	PUNCT	O	O
'	PUNCT	O	O
reason	NOUN	O	O
for	ADP	O	O
sunbathing	VERB	O	O
was	ADJ	O	O
'feeling	PUNCT	O	O
warm	NUM	O	O
and	CCONJ	O	O
comfortable	ADJ	O	O
'	PUNCT	O	O
.	PUNCT	O	O

Preventive	ADJ	O	O
programmes	NOUN	O	O
aimed	VERB	O	O
at	ADP	O	O
a	DET	O	O
change	NOUN	O	O
of	ADP	O	O
sun	PUNCT	O	O
related	VERB	O	O
behaviours	NOUN	O	O
among	ADP	O	O
Swedish	PUNCT	O	O
adolescents	NOUN	O	O
have	PUNCT	O	O
to	ADJ	O	O
be	PUNCT	O	O
tailored	VERB	O	O
to	ADP	O	O
the	DET	O	O
climate	NOUN	O	O
and	CCONJ	O	O
cultural	ADJ	O	O
conditions	NOUN	O	O
and	CCONJ	O	O
must	VERB	O	O
take	PUNCT	O	O
into	ADP	O	O
account	PUNCT	O	O
that	VERB	O	O
having	VERB	O	O
a	DET	O	O
tan	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
warmth	ADP	O	O
of	ADP	O	O
the	DET	O	O
sun	ADJ	O	O
,	PUNCT	O	O
are	VERB	O	O
highly	ADV	O	O
valued	PUNCT	O	O
by	ADP	O	O
most	DET	O	O
adolescents	NOUN	O	O
.	PUNCT	O	O

Predictors	NOUN	O	O
of	ADP	O	O
postdischarge	NOUN	O	O
outcomes	NOUN	O	O
from	ADP	O	O
information	NOUN	O	O
acquired	VERB	O	O
shortly	ADV	O	O
after	ADP	O	O
admission	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
report	NOUN	O	O
from	ADP	O	O
the	DET	O	O
Placebo-Controlled	ADV	O	O
Randomized	NOUN	O	O
Study	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Selective	ADJ	O	O
A1	NOUN	O	O
Adenosine	NOUN	O	O
Receptor	NOUN	O	O
Antagonist	NOUN	O	O
Rolofylline	NOUN	O	O
for	ADP	O	O
Patients	NOUN	O	O
Hospitalized	PROPN	O	O
With	ADP	O	O
Acute	ADJ	O	O
Decompensated	ADJ	O	O
Heart	NOUN	O	O
Failure	NOUN	O	O
and	CCONJ	O	O
Volume	NOUN	O	O
Overload	PUNCT	O	O
to	DET	O	O
Assess	NOUN	O	O
Treatment	NOUN	O	O
Effect	NOUN	O	O
on	ADP	O	O
Congestion	NOUN	O	O
and	CCONJ	O	O
Renal	ADJ	O	O
Function	NOUN	O	O
(	PUNCT	O	O
PROTECT	NOUN	O	O
)	PUNCT	O	O
Study	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Acute	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
is	VERB	O	O
a	DET	O	O
common	ADJ	O	O
reason	NOUN	O	O
for	ADP	O	O
admission	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
outcome	NOUN	O	O
is	VERB	O	O
often	ADV	O	O
poor	ADJ	O	O
.	PUNCT	O	O

Improved	VERB	O	O
prognostic	ADJ	O	O
risk	NOUN	O	O
stratification	NOUN	O	O
may	VERB	O	O
assist	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
design	NOUN	O	O
of	ADP	O	O
future	ADJ	O	O
trials	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
patient	NOUN	O	O
management	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
data	NOUN	O	O
from	ADP	O	O
a	DET	O	O
large	ADJ	O	O
randomized	VERB	O	O
trial	NOUN	O	O
,	PUNCT	O	O
we	PRON	O	O
explored	PUNCT	O	O
the	DET	O	O
prognostic	ADJ	O	O
value	NOUN	O	O
of	ADP	O	O
clinical	ADJ	O	O
variables	NOUN	O	O
,	PUNCT	O	O
measured	VERB	O	O
at	ADP	O	O
hospital	NOUN	O	O
admission	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
,	PUNCT	O	O
to	PART	O	O
determine	NOUN	O	O
whether	ADP	O	O
a	DET	O	O
few	ADJ	O	O
selected	VERB	O	O
variables	NOUN	O	O
were	VERB	O	O
inferior	ADJ	O	O
to	ADP	O	O
an	DET	O	O
extended	ADJ	O	O
data	NOUN	O	O
set	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	PUNCT	O	O
The	DET	O	O
prognostic	ADJ	O	O
model	NOUN	O	O
included	VERB	O	O
37	NUM	O	O
clinical	ADJ	O	O
characteristics	NOUN	O	O
collected	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
in	ADP	O	O
PROTECT	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
study	NOUN	O	O
comparing	ADP	O	O
rolofylline	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
2033	NUM	O	O
patients	NOUN	O	O
admitted	VERB	O	O
with	ADP	O	O
acute	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
.	PUNCT	O	O

Prespecified	ADJ	O	O
outcomes	NOUN	O	O
at	ADP	O	O
30	NUM	O	O
days	NOUN	O	O
were	VERB	O	O
death	NOUN	O	B-MORTALITY
or	CCONJ	O	O
rehospitalization	NOUN	O	B-MORTALITY
for	ADP	O	I-MORTALITY
any	DET	O	I-MORTALITY
reason	NOUN	O	I-MORTALITY
;	PUNCT	O	O
death	NOUN	O	B-MORTALITY
or	CCONJ	O	O
rehospitalization	NOUN	O	O
for	ADP	O	O
cardiovascular	ADJ	O	B-MORTALITY
or	CCONJ	O	O
renal	ADJ	O	B-MORTALITY
reasons	NOUN	O	I-MORTALITY
;	PUNCT	O	O
and	CCONJ	O	O
,	PUNCT	O	O
at	ADP	O	O
both	CCONJ	O	O
30	NUM	O	O
and	CCONJ	O	O
180	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
all-cause	NOUN	O	O
mortality	NOUN	O	O
.	PUNCT	O	O

No	DET	O	O
variable	ADJ	O	O
had	PUNCT	O	O
a	DET	O	O
c-index	NOUN	O	O
>	SYM	O	O
0.70	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
few	ADJ	O	O
had	PUNCT	O	O
values	NOUN	O	O
>	SYM	O	O
0.60	NUM	O	O
;	PUNCT	O	O
c-indices	ADV	O	O
were	VERB	O	O
lower	PUNCT	O	O
for	ADP	O	O
composite	ADJ	O	O
outcomes	NOUN	O	O
than	PUNCT	O	O
for	ADP	O	O
mortality	NOUN	O	O
.	PUNCT	O	O

Blood	NOUN	O	B-PHYSICAL
urea	NOUN	O	I-PHYSICAL
was	VERB	O	O
generally	PUNCT	O	O
the	DET	O	O
strongest	PUNCT	O	O
single	ADJ	O	O
predictor	NOUN	O	O
.	PUNCT	O	O

Eighteen	PUNCT	O	O
variables	NOUN	O	O
contributed	DET	O	O
independent	ADJ	O	O
prognostic	ADJ	O	O
information	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
a	DET	O	O
reduced	VERB	O	O
model	NOUN	O	O
using	VERB	O	O
only	ADV	O	O
8	NUM	O	O
items	ADJ	O	O
(	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
previous	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
hospitalization	NOUN	O	O
,	PUNCT	O	O
peripheral	ADJ	O	O
edema	NOUN	O	O
,	PUNCT	O	O
systolic	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
serum	NOUN	O	O
sodium	NOUN	O	O
,	PUNCT	O	O
urea	NOUN	O	O
,	PUNCT	O	O
creatinine	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
albumin	NOUN	O	O
)	PUNCT	O	O
performed	PART	O	O
similarly	ADV	O	O
.	PUNCT	O	O

For	ADP	O	O
prediction	NOUN	O	O
of	ADP	O	O
all-cause	NOUN	O	B-MORTALITY
mortality	NOUN	O	I-MORTALITY
at	ADP	O	O
180	NUM	O	O
days	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
model	NOUN	O	O
c-index	NOUN	O	O
using	VERB	O	O
all	DET	O	O
variables	NOUN	O	O
was	VERB	O	O
0.72	NUM	O	O
and	CCONJ	O	O
for	ADP	O	O
the	DET	O	O
simplified	ADJ	O	O
model	NOUN	O	O
,	PUNCT	O	O
also	ADV	O	O
0.72	NUM	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
A	PUNCT	O	O
few	ADJ	O	O
simple	ADJ	O	O
clinical	ADJ	O	O
variables	NOUN	O	O
measured	VERB	O	O
on	ADP	O	O
admission	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
acute	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
predict	VERB	O	O
a	DET	O	O
variety	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
outcomes	NOUN	O	I-ADVERSE-EFFECTS
with	ADP	O	O
accuracy	NOUN	O	O
similar	ADJ	O	O
to	ADP	O	O
more	DET	O	O
complex	PUNCT	O	O
models	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
predictive	ADJ	O	O
models	NOUN	O	O
were	ADJ	O	O
of	ADP	O	O
only	ADV	O	O
moderate	ADJ	O	B-OTHER
accuracy	NOUN	O	I-OTHER
,	PUNCT	O	O
especially	ADV	O	O
for	ADP	O	O
outcomes	NOUN	O	O
that	ADP	O	O
included	ADJ	O	B-ADVERSE-EFFECTS
nonfatal	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Better	PUNCT	O	O
methods	NOUN	O	O
of	ADP	O	O
risk	NOUN	O	O
stratification	NOUN	O	O
are	VERB	O	O
required	VERB	O	O
.	PUNCT	O	O

CLINICAL	ADJ	O	O
TRIAL	NOUN	O	O
REGISTRATION	NOUN	O	O
URL	NOUN	O	O
:	PUNCT	O	O
http	PUNCT	O	O
:	PUNCT	O	O
//www.clinicaltrials.gov	PUNCT	O	O
.	PUNCT	O	O

Unique	ADJ	O	O
identifiers	NOUN	O	O
:	PUNCT	O	O
NCT00328692	PUNCT	O	O
and	CCONJ	O	O
NCT00354458	NOUN	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
testosterone	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
nutritional	ADJ	O	O
supplement	NOUN	O	O
,	PUNCT	O	O
alone	ADJ	O	O
and	CCONJ	O	O
in	ADP	O	O
combination	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
hospital	NOUN	O	B-OTHER
admissions	NOUN	O	I-OTHER
in	ADP	O	O
undernourished	NOUN	O	O
older	PUNCT	O	O
men	NOUN	O	O
and	CCONJ	O	O
women	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
In	ADP	O	O
older	PUNCT	O	O
people	NOUN	O	O
,	PUNCT	O	O
undernutrition	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
hospitalization	NOUN	O	B-PHYSICAL
rates	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
mortality	NOUN	O	B-ADVERSE-EFFECTS
.	PUNCT	O	O

Because	PUNCT	O	O
weight	NOUN	O	O
loss	NOUN	O	O
in	ADP	O	O
older	PUNCT	O	O
people	NOUN	O	O
often	ADV	O	O
reflects	NOUN	O	O
a	DET	O	O
disproportionate	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
skeletal	ADJ	O	O
muscle	NOUN	O	O
,	PUNCT	O	O
anabolic	ADJ	O	O
treatments	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
beneficial	ADJ	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Our	PUNCT	O	O
aim	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
hypothesis	NOUN	O	O
that	ADP	O	O
testosterone	NOUN	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
nutritional	ADJ	O	O
supplement	NOUN	O	O
have	PUNCT	O	O
additive	ADJ	O	O
benefits	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Oral	ADJ	O	O
testosterone	NOUN	O	O
undecanoate	NOUN	O	O
(	PUNCT	O	O
40	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
for	ADP	O	O
women	NOUN	O	O
,	PUNCT	O	O
80	NUM	O	O
mg	NOUN	O	O
twice	ADV	O	O
daily	ADJ	O	O
for	ADP	O	O
men	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
an	DET	O	O
oral	ADJ	O	O
nutritional	ADJ	O	O
supplement	NOUN	O	O
(	PUNCT	O	O
475	NUM	O	O
kcal/d	ADJ	O	O
)	PUNCT	O	O
were	VERB	O	O
administered	VERB	O	O
,	PUNCT	O	O
alone	ADJ	O	O
or	CCONJ	O	O
combined	ADV	O	O
,	PUNCT	O	O
for	ADP	O	O
1	NUM	O	O
y	NUM	O	O
to	ADP	O	O
49	NUM	O	O
community-dwelling	PUNCT	O	O
,	PUNCT	O	O
undernourished	DET	O	O
people	NOUN	O	O
[	PUNCT	O	O
Mini	NOUN	O	O
Nutritional	ADJ	O	O
Assessment	NOUN	O	O
score	NOUN	O	O
<	SYM	O	O
24	NUM	O	O
and	CCONJ	O	O
low	ADJ	O	O
body	NOUN	O	O
weight	NOUN	O	O
(	PUNCT	O	O
body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
kg/m	NUM	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
:	PUNCT	O	O
<	SYM	O	O
22	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
recent	ADJ	O	O
weight	NOUN	O	O
loss	NOUN	O	O
(	PUNCT	O	O
>	PROPN	O	O
7.5	NUM	O	O
%	SYM	O	O
over	ADP	O	O
3	NUM	O	O
mo	NOUN	O	O
)	PUNCT	O	O
]	PUNCT	O	O
aged	DET	O	O
>	ADP	O	O
65	NUM	O	O
y	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
age	NOUN	O	O
:	PUNCT	O	O
77	NUM	O	O
y	NOUN	O	O
;	PUNCT	O	O
26	DET	O	O
women	NOUN	O	O
and	CCONJ	O	O
23	NUM	O	O
men	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Hospital	NOUN	O	B-OTHER
admissions	NOUN	O	I-OTHER
and	CCONJ	O	O
other	ADJ	O	O
variables	NOUN	O	B-OTHER
were	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
In	ADP	O	O
subjects	NOUN	O	O
receiving	DET	O	O
combined	VERB	O	O
testosterone	NOUN	O	O
and	CCONJ	O	O
nutritional	ADJ	O	O
supplements	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
11	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
hospital	NOUN	O	B-OTHER
admissions	NOUN	O	I-OTHER
,	PUNCT	O	O
whereas	ADP	O	O
there	PUNCT	O	O
were	VERB	O	O
9	NUM	O	O
admissions	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
elective	ADJ	O	O
)	PUNCT	O	O
in	ADP	O	O
13	NUM	O	O
subjects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
no-treatment	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
4	NUM	O	O
in	ADP	O	O
the	DET	O	O
testosterone-treated	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
12	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
5	NUM	O	O
in	ADP	O	O
the	DET	O	O
supplement-treated	VERB	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
13	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.06	NUM	O	O
with	ADP	O	O
no-treatment	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
combined	VERB	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

When	ADP	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
no-treatment	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
combined-treatment	PUNCT	O	O
group	NOUN	O	O
had	PUNCT	O	O
significantly	ADV	O	O
fewer	PUNCT	O	O
subjects	NOUN	O	B-OTHER
admitted	VERB	O	I-OTHER
to	ADP	O	I-OTHER
hospital	NOUN	O	I-OTHER
(	PUNCT	O	O
0	NUM	O	O
compared	VERB	O	O
with	ADP	O	O
5	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
fewer	PUNCT	O	O
days	NOUN	O	B-OTHER
in	ADP	O	I-OTHER
hospital	NOUN	O	I-OTHER
(	PUNCT	O	O
0	NUM	O	O
compared	VERB	O	O
with	ADP	O	O
74	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.041	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
longer	PUNCT	O	O
time	NOUN	O	O
to	ADP	O	O
hospital	NOUN	O	O
admission	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.017	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
undernourished	NOUN	O	O
older	PUNCT	O	O
people	NOUN	O	O
,	PUNCT	O	O
combined	ADP	O	O
treatment	NOUN	O	O
with	ADP	O	O
testosterone	NOUN	O	O
and	CCONJ	O	O
nutritional	ADJ	O	O
supplementation	NOUN	O	O
reduced	VERB	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
people	NOUN	O	O
hospitalized	ADP	O	O
and	CCONJ	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
hospital	NOUN	O	O
admissions	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
are	VERB	O	O
important	ADJ	O	O
endpoints	NOUN	O	O
in	ADP	O	O
this	DET	O	O
group	NOUN	O	O
.	PUNCT	O	O

Larger	PUNCT	O	O
,	PUNCT	O	O
confirmatory	ADJ	O	O
studies	NOUN	O	O
are	VERB	O	O
now	ADV	O	O
needed	VERB	O	O
.	PUNCT	O	O

This	DET	O	O
trial	NOUN	O	O
was	VERB	O	O
registered	PUNCT	O	O
before	ADP	O	O
commencement	ADJ	O	O
at	ADP	O	O
clinical	ADJ	O	O
trials.gov	NOUN	O	O
as	VERB	O	O
NCT00117000	NOUN	O	O
.	PUNCT	O	O

Double-blind	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
trandolapril	NOUN	O	O
2	NUM	O	O
mg	NOUN	O	O
and	CCONJ	O	O
hydrochlorothiazide	NOUN	O	O
25	NUM	O	O
mg	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
mild-to-moderate	ADJ	O	O
essential	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

Investigator	NOUN	O	O
Study	NOUN	O	O
Group	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
multicenter	NOUN	O	O
international	ADJ	O	O
trial	NOUN	O	O
recruited	VERB	O	O
205	NUM	O	O
patients	NOUN	O	O
from	ADP	O	O
16	NUM	O	O
investigators	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
a	DET	O	O
4-week	NOUN	O	O
,	PUNCT	O	O
single-blind	NUM	O	O
placebo	NOUN	O	O
run-in	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
16	DET	O	O
weeks	NOUN	O	O
of	ADP	O	O
trandolapril	NOUN	O	O
2	NUM	O	O
mg/day	NOUN	O	O
(	PUNCT	O	O
68	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
hydrochlorothiazide	NOUN	O	O
(	PUNCT	O	O
HCTZ	NOUN	O	O
)	PUNCT	O	O
25	NUM	O	O
mg/day	NOUN	O	O
(	PUNCT	O	O
68	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
combination	NOUN	O	O
(	PUNCT	O	O
69	NUM	O	O
patients	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Morning	NOUN	O	B-PHYSICAL
predosing	ADV	O	I-PHYSICAL
supine	NOUN	O	I-PHYSICAL
diastolic	ADJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
DBP	NOUN	O	B-PHYSICAL
)	PUNCT	O	O
was	VERB	O	O
the	DET	O	O
primary	ADJ	O	O
efficacy	NOUN	O	O
measurement	NOUN	O	O
.	PUNCT	O	O

Intention-to-treat	NOUN	O	O
analysis	NOUN	O	O
showed	VERB	O	O
significant	ADJ	O	O
decreases	NOUN	O	O
in	ADP	O	O
all	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
in	ADP	O	O
mean	NOUN	O	O
(	PUNCT	O	O
+/-	PROPN	O	O
SEM	NOUN	O	O
)	PUNCT	O	O
supine	NOUN	O	B-PHYSICAL
DBP	NOUN	O	I-PHYSICAL
throughout	ADP	O	O
the	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
at	ADP	O	O
week	NOUN	O	O
16	NUM	O	O
between	ADP	O	O
trandolapril	NOUN	O	O
(	PUNCT	O	O
-10.6	NUM	O	O
+/-	SYM	O	O
1.3	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
HCTZ	ADJ	O	O
(	PUNCT	O	O
-10.9	ADV	O	O
+/-	SYM	O	O
1.3	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
gave	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
reduction	NOUN	O	O
than	ADP	O	O
either	PUNCT	O	O
drug	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
-15.1	NUM	O	O
+/-	SYM	O	O
1.13	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
was	VERB	O	O
normalized	VERB	O	O
in	ADP	O	O
the	DET	O	O
combination	NOUN	O	O
group	NOUN	O	O
in	ADP	O	O
67	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
proportion	NOUN	O	O
than	PUNCT	O	O
either	PUNCT	O	O
trandolapril	NOUN	O	O
(	PUNCT	O	O
63	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
HCTZ	ADJ	O	O
(	PUNCT	O	O
60	NUM	O	O
%	SYM	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Each	DET	O	O
treatment	NOUN	O	O
was	VERB	O	O
well	VERB	O	O
tolerated	ADP	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
all	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Trandolapril	NOUN	O	O
2	NUM	O	O
mg	NOUN	O	O
once	PUNCT	O	O
daily	ADP	O	O
is	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
antihypertensive	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
comparable	ADJ	O	O
to	ADP	O	O
HCTZ	PUNCT	O	O
.	PUNCT	O	O

Furthermore	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
drugs	NOUN	O	O
was	VERB	O	O
shown	VERB	O	O
to	PART	O	O
enhance	NOUN	O	O
the	DET	O	O
antihypertensive	ADJ	O	B-PHYSICAL
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
two	NUM	O	O
compounds	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

Direct	ADJ	O	O
trocar	ADJ	O	O
insertion	NOUN	O	O
vs.	CCONJ	O	O
Verres	ADJ	O	O
needle	NOUN	O	O
use	NOUN	O	O
for	ADP	O	O
laparoscopic	ADJ	O	O
sterilization	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
trial	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
compare	NOUN	O	O
direct	ADJ	O	O
trocar	ADJ	O	O
insertion	NOUN	O	O
with	ADP	O	O
prior	CCONJ	O	O
peritoneal	ADJ	O	O
insufflation	NOUN	O	O
with	ADP	O	O
a	DET	O	O
Verres	ADJ	O	O
needle	NOUN	O	O
for	ADP	O	O
laparoscopic	ADJ	O	O
tubal	ADJ	O	O
sterilization	NOUN	O	O
.	PUNCT	O	O

Direct	ADJ	O	O
trocar	ADJ	O	O
insertion	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
fewer	PUNCT	O	O
instrument	ADP	O	B-OTHER
insertions	NOUN	O	I-OTHER
(	PUNCT	O	O
21.8	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
7.8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
use	NOUN	O	O
of	ADP	O	O
smaller	PUNCT	O	O
volumes	NOUN	O	O
of	ADP	O	O
CO2	NOUN	O	B-OTHER
(	PUNCT	O	O
2.67	NUM	O	O
vs.	CCONJ	O	O
2.32	NUM	O	O
L	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Direct	ADJ	O	O
trocar	ADJ	O	O
use	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
operating	DET	O	B-OTHER
time	NOUN	O	I-OTHER
from	ADP	O	O
9	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
40	NUM	O	O
seconds	NOUN	O	O
in	ADP	O	O
the	DET	O	O
needle	NOUN	O	O
group	NOUN	O	O
to	ADP	O	O
7	NUM	O	O
minutes	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
seconds	NOUN	O	O
in	ADP	O	O
the	DET	O	O
trocar	ADJ	O	O
group	NOUN	O	O
.	PUNCT	O	O

Minor	ADJ	O	B-ADVERSE-EFFECTS
omental	ADJ	O	I-ADVERSE-EFFECTS
injuries	NOUN	O	I-ADVERSE-EFFECTS
occurred	VERB	O	O
in	ADP	O	O
a	DET	O	O
small	ADJ	O	O
percentage	NOUN	O	O
of	ADP	O	O
each	DET	O	O
group	NOUN	O	O
,	PUNCT	O	O
while	ADP	O	O
serious	ADJ	O	O
complications	NOUN	O	O
occurred	VERB	O	O
once	PUNCT	O	O
in	ADP	O	O
each	DET	O	O
group	NOUN	O	O
.	PUNCT	O	O

How	ADP	O	O
does	PUNCT	O	O
Cash	NOUN	O	O
and	CCONJ	O	O
Counseling	PROPN	O	O
affect	PUNCT	O	O
costs	NOUN	O	O
?	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
test	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
consumer-directed	VERB	O	O
model	NOUN	O	O
(	PUNCT	O	O
Cash	NOUN	O	O
and	CCONJ	O	O
Counseling	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
Medicaid	NOUN	O	O
personal	ADJ	O	O
care	NOUN	O	O
services	NOUN	O	O
(	PUNCT	O	O
PCS	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
home-	NOUN	O	O
and	CCONJ	O	O
community-based	PUNCT	O	O
waiver	PUNCT	O	O
services	NOUN	O	O
(	PUNCT	O	O
HCBS	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
cost	NOUN	O	O
of	ADP	O	O
Medicaid	NOUN	O	O
services	NOUN	O	O
.	PUNCT	O	O

DATA	NOUN	O	O
SOURCES/STUDY	CCONJ	O	O
SETTING	NUM	O	O
Medicaid	NOUN	O	O
claims	NOUN	O	O
data	NOUN	O	O
were	VERB	O	O
collected	VERB	O	O
for	ADP	O	O
all	DET	O	O
enrollees	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Cash	NOUN	O	O
and	CCONJ	O	O
Counseling	PUNCT	O	O
demonstration	NOUN	O	O
.	PUNCT	O	O

Demonstration	NOUN	O	O
enrollees	NOUN	O	O
included	PUNCT	O	O
those	ADP	O	O
eligible	ADJ	O	O
for	ADP	O	O
PCS	NOUN	O	O
(	PUNCT	O	O
in	ADP	O	O
Arkansas	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
those	PUNCT	O	O
assessed	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
such	DET	O	O
services	NOUN	O	O
(	PUNCT	O	O
in	ADP	O	O
New	ADJ	O	O
Jersey	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
recipients	NOUN	O	O
of	ADP	O	O
Medicaid	NOUN	O	O
HCBS	NOUN	O	O
(	PUNCT	O	O
in	ADP	O	O
Florida	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Enrollment	NOUN	O	O
occurred	VERB	O	O
from	ADP	O	O
December	NOUN	O	O
1998	NUM	O	O
through	ADP	O	O
April	NOUN	O	O
2001	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
follow-up	NOUN	O	O
period	NOUN	O	O
covered	VERB	O	O
up	PUNCT	O	O
to	ADP	O	O
24	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
enrollment	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
Demonstration	NOUN	O	O
volunteers	NOUN	O	O
were	ADJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PUNCT	O	O
have	PUNCT	O	O
the	DET	O	O
option	NOUN	O	O
to	PART	O	O
participate	NOUN	O	O
in	ADP	O	O
Cash	NOUN	O	O
and	CCONJ	O	O
Counseling	PUNCT	O	O
(	PUNCT	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
to	PART	O	O
receive	NOUN	O	O
Medicaid	NOUN	O	O
services	NOUN	O	O
as	VERB	O	O
usual	ADJ	O	O
from	ADP	O	O
an	DET	O	O
agency	NOUN	O	O
(	PUNCT	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Ordinary	PUNCT	O	O
least	ADJ	O	O
squares	NOUN	O	O
regressions	NOUN	O	O
were	VERB	O	O
used	VERB	O	O
to	PART	O	O
estimate	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
program	NOUN	O	O
on	ADP	O	O
costs	NOUN	O	O
for	ADP	O	O
Medicaid	NOUN	O	B-OTHER
PCS/waiver	NOUN	O	I-OTHER
services	NOUN	O	I-OTHER
and	CCONJ	O	O
other	ADJ	O	O
Medicaid	NOUN	O	B-OTHER
services	NOUN	O	I-OTHER
,	PUNCT	O	O
while	ADP	O	O
controlling	ADJ	O	O
for	ADP	O	O
consumers	NOUN	O	O
'	PUNCT	O	O
preenrollment	ADJ	O	O
characteristics	NOUN	O	O
and	CCONJ	O	O
preenrollment	ADJ	O	O
Medicaid	NOUN	O	O
spending	PROPN	O	O
.	PUNCT	O	O

Models	NOUN	O	O
were	VERB	O	O
estimated	VERB	O	O
separately	ADV	O	O
for	ADP	O	O
nonelderly	PUNCT	O	O
and	CCONJ	O	O
elderly	ADJ	O	O
adults	NOUN	O	O
in	ADP	O	O
each	DET	O	O
state	NOUN	O	O
and	CCONJ	O	O
for	ADP	O	O
children	NOUN	O	O
in	ADP	O	O
Florida	NOUN	O	O
.	PUNCT	O	O

DATA	NOUN	O	O
EXTRACTION	NOUN	O	O
METHODS	NOUN	O	O
Each	PUNCT	O	O
state	NOUN	O	O
supplied	PUNCT	O	O
claims	NOUN	O	O
data	NOUN	O	O
for	ADP	O	O
demonstration	NOUN	O	O
enrollees	NOUN	O	O
.	PUNCT	O	O

PRINCIPAL	NOUN	O	O
FINDINGS	NOUN	O	O
Largely	PROPN	O	O
because	PUNCT	O	O
the	DET	O	O
program	NOUN	O	O
increased	ADJ	O	O
consumers	NOUN	O	O
'	PUNCT	O	O
ability	NOUN	O	O
to	DET	O	O
get	CCONJ	O	O
the	DET	O	O
authorized	DET	O	O
amount	NOUN	O	O
of	ADP	O	O
paid	NOUN	O	O
care	NOUN	O	O
,	PUNCT	O	O
expenditures	PUNCT	O	O
for	ADP	O	O
personal	ADJ	O	B-OTHER
care/waiver	NOUN	O	I-OTHER
services	NOUN	O	I-OTHER
were	VERB	O	O
higher	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
in	ADP	O	O
each	DET	O	O
state	NOUN	O	O
and	CCONJ	O	O
age	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
except	PUNCT	O	O
among	ADP	O	O
the	DET	O	O
elderly	ADJ	O	O
in	ADP	O	O
Florida	NOUN	O	O
.	PUNCT	O	O

Higher	PUNCT	O	O
costs	NOUN	O	O
for	ADP	O	O
personal	ADJ	O	B-OTHER
care/waiver	NOUN	O	I-OTHER
services	NOUN	O	I-OTHER
were	VERB	O	O
partially	ADV	O	O
offset	CCONJ	O	O
by	ADP	O	O
savings	NOUN	O	O
in	ADP	O	O
other	ADJ	O	O
Medicaid	NOUN	O	O
services	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
those	ADJ	O	O
related	VERB	O	O
to	ADP	O	O
long-term	NOUN	O	O
care	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
year	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
total	ADJ	O	O
Medicaid	NOUN	O	B-OTHER
costs	NOUN	O	I-OTHER
were	VERB	O	O
generally	ADV	O	O
higher	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
control	ADV	O	O
group	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
treatment-control	NOUN	O	O
cost	NOUN	O	O
differences	NOUN	O	O
ranging	VERB	O	O
from	ADP	O	O
1	NUM	O	O
percent	NOUN	O	O
(	PUNCT	O	O
and	CCONJ	O	O
statistically	ADV	O	O
insignificant	ADJ	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
elderly	ADJ	O	O
in	ADP	O	O
Florida	NOUN	O	O
to	ADP	O	O
17	NUM	O	O
percent	NOUN	O	O
for	ADP	O	O
the	DET	O	O
elderly	ADJ	O	O
in	ADP	O	O
Arkansas	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
year	NOUN	O	O
2	NUM	O	O
,	PUNCT	O	O
these	DET	O	O
cost	NOUN	O	B-OTHER
differences	NOUN	O	I-OTHER
were	VERB	O	O
generally	ADV	O	O
greater	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
year	NOUN	O	O
1	NUM	O	O
.	PUNCT	O	O

Only	ADV	O	O
in	ADP	O	O
Arkansas	NOUN	O	O
did	PUNCT	O	O
the	DET	O	O
treatment-control	NOUN	O	O
difference	NOUN	O	O
in	ADP	O	O
total	ADJ	O	O
cost	NOUN	O	B-OTHER
shrink	NOUN	O	I-OTHER
over	ADP	O	I-OTHER
time-to	ADJ	O	I-OTHER
less	ADP	O	O
than	CCONJ	O	O
5	NUM	O	O
percent	NOUN	O	O
(	PUNCT	O	O
and	CCONJ	O	O
statistically	ADV	O	O
insignificant	ADJ	O	O
)	PUNCT	O	O
in	ADP	O	O
year	NOUN	O	O
2	NUM	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Medicaid	NOUN	O	B-OTHER
costs	NOUN	O	I-OTHER
were	VERB	O	O
generally	ADV	O	O
higher	PUNCT	O	O
under	ADP	O	O
Cash	NOUN	O	O
and	CCONJ	O	O
Counseling	PROPN	O	O
because	PUNCT	O	O
those	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
traditional	ADJ	O	O
system	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
get	PUNCT	O	O
the	ADP	O	O
services	NOUN	O	O
they	ADJ	O	O
were	VERB	O	O
entitled	VERB	O	O
to	DET	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
control	NOUN	O	O
group	NOUN	O	O
members	NOUN	O	O
were	VERB	O	O
less	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
receive	NOUN	O	B-OTHER
any	DET	O	I-OTHER
services	NOUN	O	I-OTHER
at	ADP	O	O
all	PUNCT	O	O
(	PUNCT	O	O
despite	ADP	O	O
being	VERB	O	O
authorized	ADJ	O	O
for	ADP	O	O
them	PRON	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
service	NOUN	O	O
recipients	NOUN	O	O
received	VERB	O	O
a	DET	O	O
lower	PUNCT	O	O
proportion	NOUN	O	O
of	ADP	O	B-OTHER
the	DET	O	I-OTHER
amount	NOUN	O	I-OTHER
of	PUNCT	O	I-OTHER

Effects	NOUN	O	O
of	ADP	O	O
interaction	NOUN	O	O
of	ADP	O	O
RRR-alpha-tocopheryl	NOUN	O	O
acetate	NOUN	O	O
and	CCONJ	O	O
fish	NOUN	O	O
oil	NOUN	O	O
on	ADP	O	O
low-density-lipoprotein	NOUN	O	O
oxidation	NOUN	O	O
in	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
hormone-replacement	ADJ	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
RRR-alpha-tocpheryl	NOUN	O	O
acetate	NOUN	O	O
(	PUNCT	O	O
alpha-tocopheryl	NOUN	O	O
acetate	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
hormone-replacement	ADJ	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
HRT	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
oxidative	ADJ	O	O
susceptibility	NOUN	O	O
of	ADP	O	O
low-density	NOUN	O	O
lipoprotein	NOUN	O	O
(	PUNCT	O	O
LDL	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
consuming	PUNCT	O	O
a	DET	O	O
fish	NOUN	O	O
oil	NOUN	O	O
supplement	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
independent	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
fish	NOUN	O	O
oil	NOUN	O	O
was	VERB	O	O
also	ADV	O	O
assessed	VERB	O	O
.	PUNCT	O	O

Forty-eight	ADJ	O	O
women	NOUN	O	O
,	PUNCT	O	O
equally	ADV	O	O
divided	VERB	O	O
between	ADP	O	O
women	NOUN	O	O
using	VERB	O	O
and	CCONJ	O	O
not	ADV	O	O
using	PUNCT	O	O
HRT	NOUN	O	O
,	PUNCT	O	O
participated	DET	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
crossover	ADP	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Each	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
four	PUNCT	O	O
periods	NOUN	O	O
lasted	ADP	O	O
5	NUM	O	O
wk	NOUN	O	O
and	CCONJ	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
4-wk	PUNCT	O	O
washout	PUNCT	O	O
interval	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
each	DET	O	O
period	NOUN	O	O
all	DET	O	O
subjects	NOUN	O	O
were	VERB	O	O
given	VERB	O	O
a	DET	O	O
15-g	NOUN	O	O
supplement	NOUN	O	O
of	ADP	O	O
fish	NOUN	O	O
oil	NOUN	O	O
and	CCONJ	O	O
either	CCONJ	O	O
0	NUM	O	O
(	PUNCT	O	O
placebo	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
100	NUM	O	O
,	PUNCT	O	O
200	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
400	NUM	O	O
mg	NOUN	O	O
alpha-tocopheryl	NOUN	O	O
acetate	NOUN	O	O
daily	ADJ	O	O
.	PUNCT	O	O

LDL	NOUN	O	B-PHYSICAL
resistance	NOUN	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
oxidative	ADJ	O	I-PHYSICAL
modification	NOUN	O	I-PHYSICAL
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
calculating	ADP	O	B-PHYSICAL
lag	NOUN	O	O
time	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
propagation	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
maximum	NOUN	O	B-PHYSICAL
production	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
conjugated	VERB	O	I-PHYSICAL
dienes	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Supplementation	NOUN	O	O
with	ADP	O	O
fish	NOUN	O	O
oil	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
shortened	VERB	O	O
lag	NOUN	O	O
time	NOUN	O	O
and	CCONJ	O	O
slowed	PUNCT	O	B-PHYSICAL
propagation	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
in	ADP	O	O
women	NOUN	O	O
both	CCONJ	O	O
using	VERB	O	O
and	CCONJ	O	O
not	ADV	O	O
using	PUNCT	O	O
HRT	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
subjects	NOUN	O	O
consumed	PUNCT	O	O
fish	NOUN	O	O
oil	NOUN	O	O
,	PUNCT	O	O
supplementation	NOUN	O	O
with	ADP	O	O
alpha-tocopheryl	NOUN	O	O
acetate	NOUN	O	O
increased	ADV	O	O
plasma	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
LDL	NOUN	O	B-PHYSICAL
alpha-tocopherol	ADJ	O	I-PHYSICAL
contents	ADJ	O	B-PHYSICAL
significantly	ADV	O	O
and	CCONJ	O	O
lengthened	ADJ	O	B-PHYSICAL
lag	NOUN	O	O
time	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
at	ADP	O	O
even	ADV	O	O
the	DET	O	O
lowest	PUNCT	O	O
concentration	NOUN	O	O
)	PUNCT	O	O
but	CCONJ	O	O
had	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
propagation	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
or	CCONJ	O	O
maximum	NOUN	O	B-PHYSICAL
production	NOUN	O	I-PHYSICAL
compared	VERB	O	O
with	ADP	O	O
values	NOUN	O	O
measured	VERB	O	O
after	ADP	O	O
consumption	NOUN	O	O
of	ADP	O	O
fish	NOUN	O	O
oil	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

Women	NOUN	O	O
not	ADV	O	O
using	PUNCT	O	O
HRT	NOUN	O	O
had	PUNCT	O	O
faster	PUNCT	O	O

Perioperative	PUNCT	O	B-PHYSICAL
fever	NOUN	O	O
and	CCONJ	O	O
outcome	NOUN	O	O
in	ADP	O	O
surgical	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
aneurysmal	ADJ	O	O
subarachnoid	NOUN	O	O
hemorrhage	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
We	PRON	O	O
examined	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
perioperative	ADJ	O	O
fever	NOUN	O	O
and	CCONJ	O	O
its	PUNCT	O	O
relationship	NOUN	O	O
to	ADP	O	O
outcome	NOUN	O	O
among	ADP	O	O
patients	NOUN	O	O
enrolled	VERB	O	O
in	ADP	O	O
the	DET	O	O
Intraoperative	ADJ	O	O
Hypothermia	NOUN	O	O
for	ADP	O	O
Aneurysm	NOUN	O	O
Surgery	NOUN	O	O
Trial	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
One	NUM	O	O
thousand	CCONJ	O	O
patients	NOUN	O	O
with	ADP	O	O
initial	ADJ	O	O
World	NOUN	O	O
Federation	NOUN	O	O
of	ADP	O	O
Neurological	ADJ	O	O
Surgeons	NOUN	O	O
grades	PUNCT	O	O
of	ADP	O	O
I	NUM	O	O
to	ADP	O	O
III	PUNCT	O	O
undergoing	ADP	O	O
clipping	VERB	O	O
of	ADP	O	O
intracranial	ADJ	O	O
aneurysms	NOUN	O	O
after	ADP	O	O
subarachnoid	NOUN	O	O
hemorrhage	NOUN	O	O
were	VERB	O	O
randomized	ADP	O	O
to	ADP	O	O
intraoperative	ADJ	O	O
normothermia	NOUN	O	O
(	PUNCT	O	O
36	NUM	O	O
degrees	ADJ	O	O
C-37	NOUN	O	O
degrees	PUNCT	O	O
C	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
hypothermia	NOUN	O	O
(	PUNCT	O	O
32.5	NUM	O	O
degrees	NOUN	O	O
C-33.5	PUNCT	O	O
degrees	NOUN	O	O
C	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Fever	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
>	ADJ	O	O
or	CCONJ	O	O
=38.5	PUNCT	O	O
degrees	NOUN	O	O
C	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
other	ADJ	O	O
complications	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
including	PUNCT	O	B-ADVERSE-EFFECTS
infections	NOUN	O	I-ADVERSE-EFFECTS
)	PUNCT	O	O
occurring	CCONJ	O	B-PHYSICAL
between	ADP	O	I-PHYSICAL
admission	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
discharge	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
or	CCONJ	O	O
death	NOUN	O	B-ADVERSE-EFFECTS
)	PUNCT	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

Functional	ADJ	O	B-PHYSICAL
and	CCONJ	O	O
neuropsychologic	ADJ	O	B-MENTAL
outcomes	NOUN	O	I-MENTAL
were	VERB	O	O
assessed	VERB	O	O
3	NUM	O	O
months	NOUN	O	O
postoperatively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
variable	ADJ	O	O
for	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
was	VERB	O	O
dichotomized	NUM	O	O
Glasgow	PUNCT	O	O
Outcome	NOUN	O	O
Scale	NOUN	O	O
(	PUNCT	O	O
good	ADJ	O	O
outcome	NOUN	O	O
versus	CCONJ	O	O
all	DET	O	O
others	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	DET	O	O
Fever	NOUN	O	B-PHYSICAL
was	VERB	O	O
reported	VERB	O	O
in	ADP	O	O
41	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
97	NUM	O	O
%	SYM	O	O
of	ADP	O	O
these	PUNCT	O	O
,	PUNCT	O	O
fever	NOUN	O	B-PHYSICAL
occurred	VERB	O	O
in	ADP	O	O
the	DET	O	O
postoperative	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
time	NOUN	O	B-PHYSICAL
from	ADP	O	I-PHYSICAL
surgery	NOUN	O	I-PHYSICAL
to	ADP	O	I-PHYSICAL
first	ADJ	O	I-PHYSICAL
fever	NOUN	O	I-PHYSICAL
was	VERB	O	O
3	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
measures	NOUN	O	O
of	ADP	O	O
outcome	NOUN	O	O
were	VERB	O	O
worse	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
who	PROPN	O	O
developed	VERB	O	O
fever	NOUN	O	O
,	PUNCT	O	O
even	ADV	O	O
in	ADP	O	O
those	PUNCT	O	O
without	ADP	O	O
infections	NOUN	O	B-ADVERSE-EFFECTS
or	CCONJ	O	O
who	ADP	O	O
were	VERB	O	O
World	NOUN	O	O
Federation	NOUN	O	O
of	ADP	O	O
Neurological	ADJ	O	O
Surgeons	NOUN	O	O
grade	NOUN	O	O
I.	ADV	O	O
Logistic	ADJ	O	O
regression	NOUN	O	O
analyses	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
to	ADP	O	O
adjust	PUNCT	O	O
for	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
preoperative	ADJ	O	O
factors	NOUN	O	O
(	PUNCT	O	O
e.g.	ADP	O	O
,	PUNCT	O	O
age	NOUN	O	O
,	PUNCT	O	O
Fisher	NOUN	O	O
grade	NOUN	O	O
,	PUNCT	O	O
initial	ADJ	O	O
neurological	ADJ	O	O
status	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

This	DET	O	O
demonstrated	VERB	O	O
that	ADP	O	O
fever	ADP	O	B-PHYSICAL
continued	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
significantly	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
most	DET	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
,	PUNCT	O	O
even	ADV	O	O
when	ADP	O	O
infection	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
added	VERB	O	O
to	ADP	O	O
the	DET	O	O
model	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
alternative	ADJ	O	O
stepwise	ADJ	O	O
model	NOUN	O	O
selection	NOUN	O	O
process	NOUN	O	O
including	DET	O	O
all	DET	O	O
fever-related	VERB	O	B-PHYSICAL
measures	NOUN	O	O
from	ADP	O	O
the	DET	O	O
preoperative	ADJ	O	O
and	CCONJ	O	O
intraoperative	ADJ	O	O
period	NOUN	O	O
(	PUNCT	O	O
e.g.	ADP	O	O
,	PUNCT	O	O
hydrocephalus	NOUN	O	O
,	PUNCT	O	O
duration	NOUN	O	O
of	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
intraoperative	ADJ	O	O
blood	NOUN	O	O
loss	NOUN	O	O
)	PUNCT	O	O
resulted	VERB	O	O
in	ADP	O	O
the	DET	O	O
loss	NOUN	O	O
of	ADP	O	O
significance	NOUN	O	O
for	ADP	O	O
dichotomized	PUNCT	O	O
Glasgow	PUNCT	O	O
Outcome	NOUN	O	O
Scale	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
significant	ADJ	O	O
associations	NOUN	O	O
between	ADP	O	O
fever	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
several	ADJ	O	O
other	ADJ	O	O
outcome	NOUN	O	O
measures	NOUN	O	O
remained	VERB	O	O
.	PUNCT	O	O

After	ADP	O	O
adding	VERB	O	O
postoperative	ADJ	O	O
delayed	VERB	O	O
ischemic	ADJ	O	B-PHYSICAL
neurological	ADJ	O	I-PHYSICAL
deficits	CCONJ	O	I-PHYSICAL
to	ADP	O	O
the	DET	O	O
model	NOUN	O	O
,	PUNCT	O	O
only	ADV	O	O
worsened	VERB	O	O
National	ADJ	O	B-PHYSICAL
Institutes	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
Health	NOUN	O	I-PHYSICAL
Stroke	NOUN	O	I-PHYSICAL
Scale	NOUN	O	I-PHYSICAL
score	NOUN	O	O
,	PUNCT	O	O
Barthel	PUNCT	O	B-PHYSICAL
Activities	PROPN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
Daily	PUNCT	O	I-PHYSICAL
Living	PROPN	O	I-PHYSICAL
index	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
discharge	NOUN	O	B-OTHER
destination	NOUN	O	I-OTHER
(	PUNCT	O	O
home	NOUN	O	O
versus	CCONJ	O	O
other	PUNCT	O	O
)	PUNCT	O	O
remained	VERB	O	O
independently	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
fever	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
fever	NOUN	O	B-PHYSICAL
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
worsened	VERB	O	O
outcome	NOUN	O	O
in	ADP	O	O
surgical	ADJ	O	O
subarachnoid	NOUN	O	O
hemorrhage	NOUN	O	O
patients	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
,	PUNCT	O	O
because	PUNCT	O	O
the	DET	O	O
association	NOUN	O	O
between	ADP	O	O
fever	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
primary	ADJ	O	O
outcome	NOUN	O	O
measure	NOUN	O	O
for	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
is	VERB	O	O
dependent	ADJ	O	O
on	ADP	O	O
the	DET	O	O
covariates	ADJ	O	O
used	VERB	O	O
in	ADP	O	O
the	DET	O	O
analysis	NOUN	O	O
(	PUNCT	O	O
particularly	ADV	O	O
operative	ADJ	O	O
events	NOUN	O	O
and	CCONJ	O	O
delayed	ADV	O	B-PHYSICAL
ischemic	ADJ	O	I-PHYSICAL
neurological	ADJ	O	I-PHYSICAL
deficits	NOUN	O	I-PHYSICAL
)	PUNCT	O	O
,	PUNCT	O	O
we	PRON	O	O
can	ADP	O	O
not	NOUN	O	O
rule	NOUN	O	O
out	PUNCT	O	O
the	DET	O	O
possibility	NOUN	O	O
that	ADP	O	O
fever	NOUN	O	B-PHYSICAL
is	VERB	O	O
a	DET	O	O
marker	NOUN	O	O
for	ADP	O	O
other	ADJ	O	O
events	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
a	DET	O	O
formal	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
fever	NOUN	O	B-PHYSICAL
treatment	NOUN	O	O
or	CCONJ	O	O
prevention	NOUN	O	O
can	VERB	O	O
address	VERB	O	O
this	DET	O	O
issue	NOUN	O	O
.	PUNCT	O	O

Cytokine	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
systemic	ADJ	O	B-ADVERSE-EFFECTS
toxicity	NOUN	O	I-ADVERSE-EFFECTS
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
isolated	VERB	O	O
limb	NOUN	O	O
perfusion	NOUN	O	O
with	ADP	O	O
high-dose	NOUN	O	O
tumor	NOUN	O	O
necrosis	NOUN	O	O
factor	NOUN	O	O
,	PUNCT	O	O
interferon	NOUN	O	O
gamma	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
melphalan	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
Isolated	VERB	O	O
limb	NOUN	O	O
perfusion	NOUN	O	O
(	PUNCT	O	O
ILP	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
tumor	NOUN	O	O
necrosis	NOUN	O	O
factor	NOUN	O	O
(	PUNCT	O	O
TNF	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
interferon	NOUN	O	O
gamma	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
melphalan	NOUN	O	O
(	PUNCT	O	O
M	NOUN	O	O
)	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
reported	VERB	O	O
to	PART	O	O
result	NOUN	O	O
in	ADP	O	O
high	ADJ	O	O
response	NOUN	O	O
rates	NOUN	O	B-PHYSICAL
for	ADP	O	O
extremity	NOUN	O	O
melanoma	NOUN	O	O
and	CCONJ	O	O
sarcoma	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
have	VERB	O	O
evaluated	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
TNF	NOUN	O	O
exposure	NOUN	O	O
to	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
several	ADJ	O	O
secondary	ADJ	O	B-PHYSICAL
mediators	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	B-ADVERSE-EFFECTS
toxicity	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Nineteen	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
extremity	NOUN	O	O
melanoma	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
16	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
sarcoma	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
3	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
underwent	VERB	O	O
90-minute	ADJ	O	O
ILP	NOUN	O	O
with	ADP	O	O
TNF-alpha	NOUN	O	O
,	PUNCT	O	O
interferon	NOUN	O	O
gamma	NOUN	O	O
(	PUNCT	O	O
0.2	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
M	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
to	ADP	O	O
13	NUM	O	O
mg/L	NOUN	O	O
of	ADP	O	O
limb	NOUN	O	O
volume	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
TNF/IFN/M	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
12	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
M	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
7	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Continuous	ADJ	O	O
intraoperative	ADJ	O	O
monitoring	VERB	O	O
(	PUNCT	O	O
CIM	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
systemic	ADJ	O	O
leak	ADJ	O	O
from	ADP	O	O
the	DET	O	O
perfusion	NOUN	O	O
circuit	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
using	VERB	O	O
radioactive	ADJ	O	O
iodine-131	NOUN	O	O
albumin	NOUN	O	O
.	PUNCT	O	O

Cytokine	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
the	DET	O	O
perfusate	NOUN	O	O
and	CCONJ	O	O
systemic	ADJ	O	O
circulation	NOUN	O	O
during	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
ILP	NOUN	O	O
were	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
enzyme-linked	VERB	O	O
immunosorbent	ADJ	O	O
assay	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Systemic	ADJ	O	O
leaks	PUNCT	O	O
>	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
1	NUM	O	O
%	SYM	O	O
from	ADP	O	O
the	DET	O	O
perfusion	NOUN	O	O
circuit	NOUN	O	O
occurred	VERB	O	O
in	ADP	O	O
six	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
TNF/IFN/M	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
four	NUM	O	O
who	ADP	O	O
received	VERB	O	O
M	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

Hypotension	NOUN	O	O
that	ADP	O	O
required	DET	O	B-ADVERSE-EFFECTS
vasopressor	NOUN	O	I-ADVERSE-EFFECTS
support	NOUN	O	I-ADVERSE-EFFECTS
occurred	VERB	O	O
in	ADP	O	O
six	NUM	O	O
of	ADP	O	O
six	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
evidence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
leak	ADP	O	O
(	PUNCT	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
zero	NUM	O	O
of	ADP	O	O
six	NUM	O	O
patients	NOUN	O	O
without	ADP	O	O
a	DET	O	O
leak	ADP	O	O
(	PUNCT	O	O
<	PROPN	O	O
1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

These	DET	O	O
six	NUM	O	O
patients	NOUN	O	O
had	PUNCT	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
peak	ADJ	O	O
systemic	ADJ	O	B-PHYSICAL
TNF	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
during	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
perfusion	NOUN	O	O
than	ADP	O	O
patients	NOUN	O	O
without	ADP	O	O
a	DET	O	O
leak	ADP	O	O
(	PUNCT	O	O
2.8	NUM	O	O
and	CCONJ	O	O
8.2	NUM	O	O
ng/mL	NOUN	O	O
v	CCONJ	O	O
0.7	NUM	O	O
and	CCONJ	O	O
2.0	NUM	O	O
ng/mL	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

All	DET	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
TNF/IFN/M	NOUN	O	O
had	PUNCT	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
increases	CCONJ	O	O
in	ADP	O	O
systemic	ADJ	O	B-PHYSICAL
interleukin-6	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
IL-6	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
than	CCONJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
M	NOUN	O	O
alone	ADJ	O	O
(	PUNCT	O	O
12,395	NUM	O	O
+/-	SYM	O	O
10,374	ADJ	O	O
pg/mL	ADJ	O	O
v	NUM	O	O
79.4	NUM	O	O
+/-	SYM	O	O
7.2	NUM	O	O
pg/mL	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
;	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Intracellular	ADJ	O	B-PHYSICAL
adhesion	NOUN	O	I-PHYSICAL
molecule	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
ICAM	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
IL-8	NOUN	O	I-PHYSICAL
,	PUNCT	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
TNF-R	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
also	ADV	O	O
increased	VERB	O	O
after	ADP	O	O
ILP	NOUN	O	O
with	ADP	O	O
TNF/IFN/M	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
ILP	NOUN	O	O
with	ADP	O	O
TNF/IFN/M	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
safely	ADV	O	O
performed	VERB	O	O
,	PUNCT	O	O
as	PUNCT	O	O
I131	NOUN	O	O
albumin	NOUN	O	O
provides	NOUN	O	O
a	DET	O	O
sensitive	ADJ	O	O
measure	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
leakage	NOUN	O	O
from	ADP	O	O
the	DET	O	O
perfusion	NOUN	O	O
circuit	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
a	DET	O	O
measured	PUNCT	O	O
leak	ADJ	O	O
of	ADP	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
1	NUM	O	O
%	ADJ	O	O
develop	VERB	O	O
mild	ADJ	O	O
and	CCONJ	O	O
transient	ADJ	O	O
postoperative	ADJ	O	O
hypotension	NOUN	O	O
with	ADP	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
systemic	ADJ	O	O
TNF	NOUN	O	O
levels	NOUN	O	O
and	CCONJ	O	O
lower	PUNCT	O	O
perfusate	NOUN	O	O
TNF	NOUN	O	O
levels	NOUN	O	O
than	CCONJ	O	O
in	ADP	O	O
patients	NOUN	O	O
without	PUNCT	O	O
leaks	PUNCT	O	O
.	PUNCT	O	O

Epirubicin	NOUN	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	O
versus	CCONJ	O	O
epirubicin	NOUN	O	O
and	CCONJ	O	O
docetaxel	PUNCT	O	O
as	ADP	O	O
first-line	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
women	NOUN	O	O
with	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
final	ADJ	O	O
results	NOUN	O	O
of	ADP	O	O
a	DET	O	O
randomised	VERB	O	O
phase	NOUN	O	O
III	NUM	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
This	PUNCT	O	O
randomised	VERB	O	O
phase	NOUN	O	O
III	NUM	O	O
trial	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
to	ADP	O	O
compare	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
epirubicin	NOUN	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	O
(	PUNCT	O	O
EC	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
epirubicin	NOUN	O	O
and	CCONJ	O	O
docetaxel	VERB	O	O
(	PUNCT	O	O
Taxotere	ADV	O	O
)	PUNCT	O	O
(	PUNCT	O	O
ED	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
first-line	NOUN	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
metastatic	ADJ	O	O
breast	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
Patients	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
240	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
ED	NOUN	O	O
(	PUNCT	O	O
epirubicin	NOUN	O	O
75	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
docetaxel	PUNCT	O	O
75	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
EC	NOUN	O	O
(	PUNCT	O	O
epirubicin	NOUN	O	O
90	PUNCT	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
cyclophosphamide	NOUN	O	O
600	NUM	O	O
mg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
was	VERB	O	O
objective	ADJ	O	B-PHYSICAL
response	NOUN	O	O
rate	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
ORR	NOUN	O	I-PHYSICAL
)	PUNCT	O	B-PHYSICAL
.	PUNCT	O	O

Secondary	ADJ	O	O
end	NOUN	O	O
points	NOUN	O	O
were	VERB	O	O
progression-free	ADJ	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
(	PUNCT	O	I-MORTALITY
PFS	NOUN	O	I-MORTALITY
)	PUNCT	O	I-MORTALITY
,	PUNCT	O	O
overall	ADJ	O	B-MORTALITY
survival	NOUN	O	B-MORTALITY
(	PUNCT	O	B-MORTALITY
OS	NOUN	O	B-MORTALITY
)	PUNCT	O	B-MORTALITY
,	PUNCT	O	O
and	CCONJ	O	O
safety	NOUN	O	B-MORTALITY
.	PUNCT	O	O

RESULTS	NOUN	O	O
ORR	NOUN	O	B-PHYSICAL
for	ADP	O	O
patients	NOUN	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
EC	NOUN	O	O
and	CCONJ	O	O
ED	NOUN	O	O
were	VERB	O	O
42	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
47	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.63	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Median	ADJ	O	O
PFS	NOUN	O	B-MORTALITY
[	PUNCT	O	O
10.1	ADP	O	O
versus	CCONJ	O	O
10.3	NUM	O	O
months	NOUN	O	O
;	PUNCT	O	O
hazard	NOUN	O	O
ratio	NOUN	O	O
(	PUNCT	O	O
HR	NOUN	O	O
)	PUNCT	O	O
0.98	NUM	O	O
;	PUNCT	O	O
log-rank	NOUN	O	O
P	NOUN	O	O
=	SYM	O	O
0.38	NUM	O	O
]	PUNCT	O	O
and	CCONJ	O	O
OS	PUNCT	O	B-MORTALITY
(	PUNCT	O	O
19.9	ADJ	O	O
versus	CCONJ	O	O
30.0	NUM	O	O
months	NOUN	O	O
;	PUNCT	O	O
HR	NOUN	O	O
0.663	NUM	O	O
;	PUNCT	O	O
log-rank	NOUN	O	O
P	NOUN	O	O
=	SYM	O	O
0.21	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
comparable	ADJ	O	O
in	ADP	O	O
both	PUNCT	O	O
arms	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
grade	NOUN	O	O
3/4	PUNCT	O	O

Anxiety	NOUN	O	O
sensitivity	NOUN	O	O
as	ADP	O	O
an	DET	O	O
incremental	ADJ	O	O
predictor	NOUN	O	O
of	ADP	O	O
later	ADJ	O	O
anxiety	NOUN	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
syndromes	NOUN	O	O
.	PUNCT	O	O

Although	ADP	O	O
anxiety	NOUN	O	O
sensitivity	NOUN	O	O
(	PUNCT	O	O
AS	ADP	O	O
)	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
predict	PUNCT	O	O
anxiety	NOUN	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
panic	ADJ	O	O
,	PUNCT	O	O
this	DET	O	O
literature	NOUN	O	O
is	VERB	O	O
limited	VERB	O	O
in	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
evaluating	VERB	O	O
AS	PUNCT	O	O
as	PUNCT	O	O
an	DET	O	O
incremental	ADJ	O	O
predictor	NOUN	O	O
of	ADP	O	O
anxiety	NOUN	O	O
psychopathology	NOUN	O	O
relative	ADJ	O	O
to	ADP	O	O
other	PUNCT	O	O
established	PUNCT	O	O
risk	NOUN	O	O
factors	NOUN	O	O
including	VERB	O	O
sex	NOUN	O	O
and	CCONJ	O	O
negative	ADJ	O	O
affect	ADP	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
report	NOUN	O	O
prospectively	ADV	O	O
evaluated	ADJ	O	O
whether	PUNCT	O	O
AS	CCONJ	O	O
was	VERB	O	O
predictive	ADJ	O	O
of	ADP	O	O
later	PUNCT	O	O
changes	NOUN	O	O
in	ADP	O	O
anxiety	NOUN	O	B-MENTAL
symptoms	NOUN	O	I-MENTAL
after	PUNCT	O	O
controlling	ADJ	O	O
for	ADP	O	O
potential	ADJ	O	O
confounding	VERB	O	O
factors	NOUN	O	O
.	PUNCT	O	O

Consistent	ADJ	O	O
with	ADP	O	O
hypothesis	NOUN	O	O
,	PUNCT	O	O
AS	PUNCT	O	O
was	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
,	PUNCT	O	O
incremental	ADJ	O	O
predictor	NOUN	O	O
of	ADP	O	O
anxiety	NOUN	O	B-MENTAL
symptoms	NOUN	O	I-MENTAL
over	ADP	O	O
time	NOUN	O	O
,	PUNCT	O	O
even	ADV	O	O
after	PUNCT	O	O
controlling	ADJ	O	O
for	ADP	O	O
sex	NOUN	O	O
and	CCONJ	O	O
negative	ADJ	O	O
affectivity	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
data	NOUN	O	O
provide	VERB	O	O
novel	ADJ	O	O
evidence	NOUN	O	O
for	ADP	O	O
the	DET	O	O
unique	ADJ	O	O
association	NOUN	O	O
between	ADP	O	O
AS	CCONJ	O	O
of	ADP	O	O
the	DET	O	O
development	NOUN	O	O
of	ADP	O	O
anxiety	NOUN	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Endeavor	PUNCT	O	O
zotarolimus-eluting	ADP	O	O
stent	NOUN	O	O
versus	CCONJ	O	O
the	DET	O	O
TAXUS	NOUN	O	O
paclitaxel-eluting	VERB	O	O
stent	NOUN	O	O
in	ADP	O	O
de	PUNCT	O	O
novo	ADJ	O	O
native	ADJ	O	O
coronary	ADJ	O	O
lesions	NOUN	O	O
12-month	NOUN	O	O
outcomes	NOUN	O	O
from	ADP	O	O
the	DET	O	O
ENDEAVOR	NOUN	O	O
IV	NUM	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
The	DET	O	O
ENDEAVOR	NOUN	O	O
IV	NUM	O	O
(	PUNCT	O	O
Randomized	NOUN	O	O
Comparison	NOUN	O	O
of	ADP	O	O
Zotarolimus-Eluting	PUNCT	O	O
and	CCONJ	O	O
Paclitaxel-Eluting	PUNCT	O	O
Stents	NOUN	O	O
in	ADP	O	O
Patients	NOUN	O	O
with	ADP	O	O
Coronary	ADJ	O	O
Artery	NOUN	O	O
Disease	NOUN	O	O
)	PUNCT	O	O
trial	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
safety	NOUN	O	B-OTHER
and	CCONJ	O	O
efficacy	NOUN	O	O
of	ADP	O	O
the	DET	O	O
zotarolimus-eluting	ADP	O	O
stent	NOUN	O	O
(	PUNCT	O	O
ZES	NOUN	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
paclitaxel-eluting	VERB	O	O
stent	NOUN	O	O
(	PUNCT	O	O
PES	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
First-generation	NOUN	O	O
drug-eluting	ADP	O	O
stents	NOUN	O	O
have	ADP	O	O
reduced	VERB	O	O
angiographic	ADJ	O	O
and	CCONJ	O	O
clinical	ADJ	O	O
restenosis	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
long-term	NOUN	O	O
safety	NOUN	O	O
remains	NOUN	O	O
controversial	ADJ	O	O
.	PUNCT	O	O

A	DET	O	O
second-generation	NOUN	O	O
drug-eluting	PART	O	O
stent	NOUN	O	O
,	PUNCT	O	O
which	DET	O	O
delivers	PUNCT	O	O
zotarolimus	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
potent	ADJ	O	O
antiproliferative	ADJ	O	O
agent	NOUN	O	O
,	PUNCT	O	O
via	ADP	O	O
a	DET	O	O
biocompatible	PUNCT	O	O
phosphorylcholine	NOUN	O	O
polymer	NOUN	O	O
on	ADP	O	O
a	DET	O	O
cobalt	NOUN	O	O
alloy	NOUN	O	O
thin-strut	NOUN	O	O
stent	NOUN	O	O
has	PUNCT	O	O
shown	VERB	O	O
promising	VERB	O	O
experimental	ADJ	O	O
and	CCONJ	O	O
early	ADJ	O	O
clinical	ADJ	O	O
results	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
This	ADV	O	O
is	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	ADP	O	O
(	PUNCT	O	O
1:1	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
single-blind	ADP	O	O
,	PUNCT	O	O
controlled	VERB	O	O
trial	NOUN	O	O
comparing	VERB	O	O
outcomes	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
single	ADJ	O	O
de	PUNCT	O	O
novo	ADJ	O	O
coronary	ADJ	O	O
lesions	NOUN	O	O
treated	VERB	O	O
with	ADP	O	O
ZES	NOUN	O	O
or	CCONJ	O	O
PES	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
was	ADP	O	O
noninferiority	NOUN	O	O
of	ADP	O	O
9-month	NOUN	O	B-PHYSICAL
target	NOUN	O	I-PHYSICAL
vessel	NOUN	O	I-PHYSICAL
failure	NOUN	O	I-PHYSICAL
defined	VERB	O	I-PHYSICAL
as	DET	O	O
cardiac	ADJ	O	B-ADVERSE-EFFECTS
death	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
myocardial	ADJ	O	B-PHYSICAL
infarction	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
or	PUNCT	O	O

Hyperbaric	ADJ	O	O
oxygen	NOUN	O	O
attenuation	NOUN	O	O
of	ADP	O	O
lipopolysaccharide-induced	VERB	O	O
acute	ADJ	O	O
lung	NOUN	O	O
injury	NOUN	O	O
involves	NOUN	O	O
heme	NOUN	O	O
oxygenase-1	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Hyperbaric	ADJ	O	O
oxygen	NOUN	O	O
(	PUNCT	O	O
HBO	NOUN	O	O
)	PUNCT	O	O
attenuates	PUNCT	O	O
lipopolysaccharide	NOUN	O	O
(	PUNCT	O	O
LPS	NOUN	O	O
)	PUNCT	O	O
-induced	VERB	O	O
acute	ADJ	O	O
lung	NOUN	O	O
injury	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
HBO	NOUN	O	O
involves	NOUN	O	O
inhibition	NOUN	O	O
of	ADP	O	O
inducible	ADJ	O	O
nitric	ADJ	O	O
oxide	NOUN	O	O
synthase	NOUN	O	O
(	PUNCT	O	O
iNOS	NOUN	O	O
)	PUNCT	O	O
expression	NOUN	O	O
and	CCONJ	O	O
subsequent	ADJ	O	O
nitric	ADJ	O	O
oxide	NOUN	O	O
(	PUNCT	O	O
NO	NOUN	O	O
)	PUNCT	O	O
biosynthesis	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
sought	PROPN	O	O
to	PART	O	O
investigate	NOUN	O	O
the	DET	O	O
role	NOUN	O	O
of	ADP	O	O
heme	NOUN	O	O
oxygenase-1	NOUN	O	O
(	PUNCT	O	O
HO-1	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
this	DET	O	O
HBO	NOUN	O	O
inhibition	NOUN	O	O
of	ADP	O	O
iNOS	NOUN	O	O
induction	NOUN	O	O
and	CCONJ	O	O
acute	ADJ	O	O
lung	NOUN	O	O
injury	NOUN	O	O
in	ADP	O	O
septic	ADJ	O	O
rat	NOUN	O	O
lungs	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Before	ADP	O	O
the	DET	O	O
experiment	NOUN	O	O
,	PUNCT	O	O
72	NUM	O	O
rats	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
allocated	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
HBO	NOUN	O	O
or	CCONJ	O	O
air	NOUN	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

With	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
HBO	NOUN	O	O
pre-treatment	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
rats	NOUN	O	O
were	VERB	O	O
further	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
the	DET	O	O
following	PUNCT	O	O
subgroups	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
:	PUNCT	O	O
(	PUNCT	O	O
i	NUM	O	O
)	PUNCT	O	O
LPS	NOUN	O	O
injection	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
ii	NUM	O	O
)	PUNCT	O	O
normal	ADJ	O	O
saline	NOUN	O	O
(	PUNCT	O	O
N/S	PUNCT	O	O
)	PUNCT	O	O
injection	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
iii	NUM	O	O
)	PUNCT	O	O
hemin	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
HO-1	NOUN	O	O
inducer	NOUN	O	O
)	PUNCT	O	O
plus	CCONJ	O	O
LPS	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
iv	PUNCT	O	O
)	PUNCT	O	O
hemin	NOUN	O	O
alone	ADJ	O	O
,	PUNCT	O	O
(	PUNCT	O	O
v	NUM	O	O
)	PUNCT	O	O
tin	NOUN	O	O
protoporphyrin	NOUN	O	O
(	PUNCT	O	O
SnPP	NOUN	O	O
;	PUNCT	O	O
a	DET	O	O
HO-1	NOUN	O	O
inhibitor	NOUN	O	O
)	PUNCT	O	O
plus	CCONJ	O	O
LPS	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
vi	PUNCT	O	O
)	PUNCT	O	O
SnPP	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

All	DET	O	O
rats	NOUN	O	O
were	VERB	O	O
maintained	VERB	O	O
for	ADP	O	O
6	NUM	O	O
h	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
sacrificed	VERB	O	O
with	ADP	O	O
a	DET	O	O
high-dose	NOUN	O	O
pentobarbital	ADJ	O	O
injection	NOUN	O	O
.	PUNCT	O	O

Lung	NOUN	O	O
injuries	NOUN	O	O
and	CCONJ	O	O
relevant	ADJ	O	O
enzymes	NOUN	O	O
expression	NOUN	O	O
were	VERB	O	O
thus	ADV	O	O
assayed	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Histological	ADJ	O	B-PHYSICAL
analysis	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
PMNs/alveoli	NOUN	O	B-PHYSICAL
ratio	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
wet/dry	PUNCT	O	B-PHYSICAL
weight	NOUN	O	O
ratio	NOUN	O	B-PHYSICAL
measurements	NOUN	O	B-OTHER
demonstrated	VERB	O	O
that	ADP	O	O
LPS	NOUN	O	O
caused	VERB	O	O
significant	ADJ	O	O
lung	NOUN	O	O
injury	NOUN	O	O
and	CCONJ	O	O
HBO	NOUN	O	O
and/or	CCONJ	O	O
hemin	NOUN	O	O
significantly	ADV	O	O
attenuated	ADP	O	O
this	ADP	O	O
LPS-induced	VERB	O	O
lung	NOUN	O	O
injury	NOUN	O	O
.	PUNCT	O	O

Increased	VERB	O	O
pulmonary	ADJ	O	O
iNOS	NOUN	O	B-PHYSICAL
expression	NOUN	O	I-PHYSICAL
and	PUNCT	O	O

Small	ADJ	O	O
but	CCONJ	O	O
important	ADJ	O	O
errors	NOUN	O	O
in	ADP	O	O
cardiovascular	ADJ	O	O
risk	NOUN	O	O
calculation	NOUN	O	O
by	ADP	O	O
practice	NOUN	O	O
nurses	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
cross-sectional	ADJ	O	O
study	NOUN	O	O
in	ADP	O	O
randomised	VERB	O	O
trial	NOUN	O	O
setting	VERB	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Practice	NOUN	O	O
nurses	NOUN	O	O
play	VERB	O	O
an	DET	O	O
increasingly	ADV	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
cardiovascular	ADJ	O	O
diseases	NOUN	O	O
but	CCONJ	O	O
we	NOUN	O	O
do	PUNCT	O	O
not	ADV	O	O
have	VERB	O	O
evidence	NOUN	O	O
about	ADP	O	O
the	DET	O	O
accuracy	NOUN	O	O
of	ADP	O	O
their	ADP	O	O
cardiovascular	ADJ	O	O
risk	NOUN	O	O
assessments	NOUN	O	O
during	ADP	O	O
real	ADJ	O	O
practice	NOUN	O	O
consultations	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	ADP	O	O
To	PROPN	O	O
examine	NOUN	O	O
how	ADP	O	O
nurses	NOUN	O	O
perform	PUNCT	O	O
with	ADP	O	O
regard	NOUN	O	O
to	ADP	O	O
absolute	PUNCT	O	O
10-year	ADP	O	O
cardiovascular	ADJ	O	B-OTHER
risk	NOUN	O	O
assessment	NOUN	O	B-OTHER
in	ADP	O	O
actual	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Cross-sectional	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

SETTING	ADP	O	O
This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
nested	VERB	O	O
in	ADP	O	O
the	DET	O	O
IMPALA	NOUN	O	O
study	ADP	O	O
,	PUNCT	O	O
a	DET	O	O
clustered	ADJ	O	O
randomised	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
involving	VERB	O	O
24	NUM	O	O
general	ADJ	O	O
practices	NOUN	O	O
in	ADP	O	O
The	DET	O	O
Netherlands	ADV	O	O
.	PUNCT	O	O

PARTICIPANTS	VERB	O	O
24	NUM	O	O
practice	NOUN	O	O
nurses	NOUN	O	O
,	PUNCT	O	O
trained	PUNCT	O	O
in	ADP	O	O
10-year	ADJ	O	O
cardiovascular	ADJ	O	O
risk	NOUN	O	O
assessment	NOUN	O	O
,	PUNCT	O	O
calculated	VERB	O	O
the	DET	O	O
risk	NOUN	O	O
of	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
421	NUM	O	O
patients	NOUN	O	O
without	ADP	O	O
established	ADP	O	O
cardiovascular	ADJ	O	O
diseases	NOUN	O	O
but	CCONJ	O	O
eligible	ADJ	O	O
for	ADP	O	O
cardiovascular	ADJ	O	B-OTHER
risk	NOUN	O	O
assessment	NOUN	O	B-OTHER
.	PUNCT	O	O

METHODS	NOUN	O	O
The	DET	O	O
main	ADJ	O	O
outcome	NOUN	O	O
measure	ADV	O	O
was	VERB	O	O
the	DET	O	O
accuracy	NOUN	O	O
of	ADP	O	O
risk	NOUN	O	O
assessments	NOUN	O	B-OTHER
,	PUNCT	O	O
defined	SYM	O	O
as	PUNCT	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
difference	NOUN	O	O
between	ADP	O	O
the	DET	O	O
10-year	ADP	O	B-OTHER
cardiovascular	ADJ	O	I-OTHER
risk	NOUN	O	O
percentage	NOUN	O	B-OTHER
calculated	PRON	O	I-OTHER
by	ADP	O	B-OTHER
nurses	NOUN	O	B-OTHER
and	CCONJ	O	O
an	DET	O	B-OTHER
independent	ADJ	O	B-OTHER
assessor	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
the	DET	O	O
agreement	NOUN	O	O
between	ADP	O	O
the	DET	O	B-OTHER
treatment	PUNCT	O	O

Perioperative	ADJ	O	O
myocardial	ADJ	O	O
infarctions	NOUN	O	O
are	PROPN	O	O
common	ADJ	O	O
and	CCONJ	O	O
often	ADV	O	O
unrecognized	ADP	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
hip	NOUN	O	O
fracture	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
this	DET	O	O
prospective	ADJ	O	O
cohort	NOUN	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
assess	NOUN	O	O
the	DET	O	O
incidence	NOUN	O	O
and	CCONJ	O	O
characteristics	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
surgery	NOUN	O	O
for	ADP	O	O
acute	ADJ	O	O
hip	NOUN	O	O
fracture	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	CCONJ	O	O
consecutive	ADJ	O	O
cohort	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	ADP	O	O
200	NUM	O	O
,	PUNCT	O	O
68	NUM	O	O
men	NOUN	O	O
)	PUNCT	O	O
referred	VERB	O	O
to	ADP	O	O
acute	ADJ	O	O
surgical	ADJ	O	O
correction	NOUN	O	O
of	ADP	O	O
hip	NOUN	O	O
fracture	NOUN	O	O
was	VERB	O	O
studied	VERB	O	O
.	PUNCT	O	O

Troponin	NOUN	O	O
T	NOUN	O	O
(	PUNCT	O	O
TnT	NOUN	O	O
)	PUNCT	O	O
measurements	NOUN	O	O
and	CCONJ	O	O
electrocardiographic	ADJ	O	O
(	PUNCT	O	O
ECG	NOUN	O	O
)	PUNCT	O	O
recordings	NOUN	O	O
were	VERB	O	O
performed	VERB	O	O
at	ADP	O	O
admission	NOUN	O	O
,	PUNCT	O	O
before	ADP	O	O
operation	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
first	ADJ	O	O
and	CCONJ	O	O
2nd	ADJ	O	O
postoperative	ADJ	O	O
days	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
were	VERB	O	O
used	VERB	O	O
for	ADP	O	O
diagnosis	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
age	NOUN	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
ranged	VERB	O	O
from	ADP	O	O
32	NUM	O	O
to	ADP	O	O
98	NUM	O	O
years	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
,	PUNCT	O	O
80.8	NUM	O	O
years	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
65	NUM	O	O
patients	NOUN	O	O
had	ADP	O	O
a	DET	O	O
history	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
significant	ADJ	O	O
rise	NOUN	O	B-PHYSICAL
in	ADP	O	I-PHYSICAL
TnT	NOUN	O	I-PHYSICAL
as	ADP	O	O
a	DET	O	O
sign	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
71	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
35.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
25	NUM	O	O
of	ADP	O	O
them	PRON	O	O
had	PUNCT	O	O
a	DET	O	O
TnT	NOUN	O	B-PHYSICAL
elevation	NOUN	O	I-PHYSICAL
exceeding	VERB	O	O
five	PUNCT	O	O
times	NOUN	O	O
the	DET	O	O
upper	ADJ	O	O
normal	ADJ	O	O
limit	NOUN	O	O
.	PUNCT	O	O

TnT	NOUN	O	B-PHYSICAL
elevation	NOUN	O	I-PHYSICAL
was	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
36	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
51	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
already	ADV	O	O
before	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Seven	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
ST	NOUN	O	O
elevation	NOUN	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
,	PUNCT	O	O
23	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
32	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
new	ADJ	O	B-PHYSICAL
ST	NOUN	O	I-PHYSICAL
depressions	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
21	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
30	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	DET	O	O
no	DET	O	O
new	ADJ	O	O
ST	NOUN	O	O
segment	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
the	DET	O	O
serial	ADJ	O	O
electrocardiographic	ADJ	O	O
recordings	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
40	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
56	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
perioperative	ADJ	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
was	VERB	O	O
the	DET	O	O
first	ADJ	O	O
manifestation	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	O
artery	NOUN	O	O
disease	NOUN	O	O
.	PUNCT	O	O

Multivariate	ADJ	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
revealed	VERB	O	O
that	ADP	O	O
old	ADJ	O	O
age	NOUN	O	O
(	PUNCT	O	O
odds	NOUN	O	O
ratio	NOUN	O	O
[	PUNCT	O	O
OR	CCONJ	O	O
]	PUNCT	O	O
,	PUNCT	O	O
1.06	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
[	PUNCT	O	O
CI	NOUN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
1.02-1.10	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.002	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
earlier	PUNCT	O	O
revascularization	NOUN	O	O
(	PUNCT	O	O
OR	NOUN	O	O
,	PUNCT	O	O
3.29	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
1.12-9.73	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
(	PUNCT	O	O
OR	NOUN	O	O
,	PUNCT	O	O
2.42	NUM	O	O
;	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
1.04-5.61	NUM	O	O
;	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.04	NUM	O	O
)	PUNCT	O	O
were	VERB	O	O
independent	ADJ	O	O
predictors	NOUN	O	O
of	ADP	O	O
TnT	NOUN	O	O
elevation	NOUN	O	O
.	PUNCT	O	O

Majority	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	B-PHYSICAL
infarctions	NOUN	O	I-PHYSICAL
were	VERB	O	O
asymptomatic	ADJ	O	O
or	CCONJ	O	O
unrecognized	DET	O	O
.	PUNCT	O	O

Evidence-based	ADJ	O	O
medications	NOUN	O	O
of	ADP	O	O
myocardial	ADJ	O	O
infarction	NOUN	O	O
were	PUNCT	O	O
seldom	ADV	O	O
started	PUNCT	O	O
and	CCONJ	O	O
cardiologist	NOUN	O	O
was	VERB	O	O
consulted	VERB	O	O
in	ADP	O	O
12	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
16.9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
hip	NOUN	O	O
fracture	NOUN	O	O
often	ADV	O	O
develop	VERB	O	O
asymptomatic	ADJ	O	O
and	CCONJ	O	O
clinically	ADV	O	O
unrecognized	VERB	O	O
perioperative	ADJ	O	O
myocardial	ADJ	O	O
infarctions	NOUN	O	O
.	PUNCT	O	O

Earlier	PUNCT	O	O
diagnosis	NOUN	O	O
and	CCONJ	O	O
appropriate	ADJ	O	O
treatment	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
infarction	NOUN	O	O
may	VERB	O	O
improve	VERB	O	O
survival	NOUN	O	O
of	ADP	O	O
hip	NOUN	O	O
fracture	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

LEVEL	NOUN	O	O
OF	ADP	O	O
EVIDENCE	NOUN	O	O
Epidemiologic	ADJ	O	O
study	NOUN	O	O
,	PUNCT	O	O
level	NOUN	O	O
III	NUM	O	O
.	PUNCT	O	O

Failure	NOUN	O	O
of	ADP	O	O
naltrexone	NUM	O	O
hydrochloride	NOUN	O	O
to	PART	O	O
reduce	NOUN	O	O
self-injurious	PUNCT	O	O
and	CCONJ	O	O
autistic	ADJ	O	O
behavior	NOUN	O	O
in	ADP	O	O
mentally	ADV	O	O
retarded	PRON	O	O
adults	ADP	O	O
.	PUNCT	O	O

Double-blind	ADJ	O	O
placebo-controlled	DET	O	O
studies	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
It	PRON	O	O
is	VERB	O	O
hypothesized	VERB	O	O
that	ADP	O	O
self-injurious	ADJ	O	O
behavior	NOUN	O	O
(	PUNCT	O	O
SIB	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
autism	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
due	PUNCT	O	O
to	ADP	O	O
overactivity	NOUN	O	O
in	ADP	O	O
some	DET	O	O
opioid	NOUN	O	O
systems	NOUN	O	O
in	ADP	O	O
the	DET	O	O
brain	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
examined	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
of	ADP	O	O
naltrexone	NUM	O	O
hydrochloride	NOUN	O	O
,	PUNCT	O	O
an	DET	O	O
opioid	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
SIB	NOUN	O	O
and	CCONJ	O	O
autism	NOUN	O	O
in	ADP	O	O
mentally	ADV	O	O
retarded	PRON	O	O
adults	ADP	O	O
.	PUNCT	O	O

METHOD	NOUN	O	O
Thirty-three	PUNCT	O	O
mentally	ADV	O	O
retarded	PRON	O	O
adults	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
and/or	CCONJ	O	O
SIB	NOUN	O	O
participated	DET	O	O
in	ADP	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
crossover	NOUN	O	O
studies	NOUN	O	O
.	PUNCT	O	O

Active	ADJ	O	O
treatment	NOUN	O	O
was	VERB	O	O
first	CCONJ	O	O
a	DET	O	O
single	ADJ	O	O
100-mg	NOUN	O	O
dose	NOUN	O	O
of	ADP	O	O
naltrexone	NUM	O	O
hydrochloride	NOUN	O	O
.	PUNCT	O	O

Subsequently	ADV	O	O
,	PUNCT	O	O
19	NUM	O	O
subjects	NOUN	O	O
were	VERB	O	O
treated	VERB	O	O
with	ADP	O	O
50	NUM	O	O
mg/d	NOUN	O	O
and	CCONJ	O	O
14	NUM	O	O
with	ADP	O	O
150	NUM	O	O
mg/d	NOUN	O	O
of	ADP	O	O
naltrexone	NUM	O	O
hydrochloride	NOUN	O	O
for	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
outcome	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
direct	ADJ	O	O
observations	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
11	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
scores	NOUN	O	O
on	ADP	O	O
a	DET	O	O
list	NOUN	O	O
of	CCONJ	O	O
target	NOUN	O	B-MENTAL
behaviors	NOUN	O	I-MENTAL
,	PUNCT	O	O
the	DET	O	O
Aberrant	ADJ	O	B-MENTAL
Behavior	NOUN	O	I-MENTAL
Checklist	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
Clinical	ADJ	O	B-MENTAL
Global	ADJ	O	I-MENTAL
Impression	NOUN	O	I-MENTAL
Scale	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Thirty-two	ADJ	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
seven	NUM	O	O
with	ADP	O	O
autism	NOUN	O	O
,	PUNCT	O	O
16	NUM	O	O
with	ADP	O	O
autism	NOUN	O	O
and	CCONJ	O	O
SIB	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
nine	NUM	O	O
with	ADP	O	O
SIB	NOUN	O	O
)	PUNCT	O	O
completed	VERB	O	O
the	DET	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Naltrexone	PUNCT	O	O
treatment	NOUN	O	O
failed	VERB	O	O
to	ADP	O	O
have	PUNCT	O	O
therapeutic	ADJ	O	O
effects	NOUN	O	O
on	ADP	O	O
SIB	NOUN	O	O
and	CCONJ	O	O
autism	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
contrary	PUNCT	O	O
,	PUNCT	O	O
naltrexone	NUM	O	O
increased	VERB	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
stereotypic	ADJ	O	B-MENTAL
behavior	NOUN	O	I-MENTAL
on	ADP	O	O
the	DET	O	O
Aberrant	ADJ	O	B-MENTAL
Behavior	NOUN	O	I-MENTAL
Checklist	NOUN	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
care	NOUN	O	O
staff	NOUN	O	O
evaluated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
the	DET	O	O
50-mg/d	NUM	O	O
treatment	NOUN	O	O
as	VERB	O	O
being	VERB	O	O
significantly	ADV	O	O
worse	ADJ	O	O
than	CCONJ	O	O
that	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
treatment	NOUN	O	O
as	PUNCT	O	O
measured	VERB	O	O
by	ADP	O	O
the	DET	O	O
Clinical	ADJ	O	B-MENTAL
Global	ADJ	O	I-MENTAL
Impression	NOUN	O	I-MENTAL
Scale	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Our	PUNCT	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
naltrexone	NUM	O	O
has	VERB	O	O
no	DET	O	O
clinical	ADJ	O	O
value	NOUN	O	O
for	ADP	O	O
a	DET	O	O
broad	ADJ	O	O
group	NOUN	O	O
of	ADP	O	O
mentally	ADV	O	O
retarded	VERB	O	O
subjects	NOUN	O	O
with	ADP	O	O
SIB	NOUN	O	O
and/or	CCONJ	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Oral	ADJ	O	O
health	NOUN	O	O
impacts	NOUN	O	O
on	ADP	O	O
daily	PUNCT	O	O
living	ADP	O	O
related	VERB	O	O
to	ADP	O	O
four	NUM	O	O
different	ADJ	O	O
treatment	NOUN	O	O
protocols	NOUN	O	O
for	ADP	O	O
chronic	ADJ	O	O
periodontitis	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
aims	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
were	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
oral	ADJ	O	O
health	NOUN	O	O
impacts	NOUN	O	O
perceived	VERB	O	O
by	ADP	O	O
patients	NOUN	O	O
submitted	VERB	O	O
to	ADP	O	O
different	ADJ	O	O
treatments	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
periodontitis	NOUN	O	O
and	CCONJ	O	O
their	ADP	O	O
association	NOUN	O	O
with	ADP	O	O
clinical	ADJ	O	O
parameters	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Sixty	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
to	ADP	O	O
one	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
following	PUNCT	O	O
therapeutic	ADJ	O	O
groups	NOUN	O	O
:	PUNCT	O	O
control	NOUN	O	O
,	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
full-mouth	NOUN	O	O
scaling	PUNCT	O	O
and	CCONJ	O	O
root	NOUN	O	O
planing	PUNCT	O	O
(	PUNCT	O	O
SRP	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
test	PUNCT	O	O
1	NUM	O	O
,	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
SRP	NOUN	O	O
and	CCONJ	O	O
400	NUM	O	O
mg	NOUN	O	O
systemically	ADV	O	O
administered	VERB	O	O
metronidazole	NOUN	O	O
(	PUNCT	O	O
MET	NOUN	O	O
)	PUNCT	O	O
three	NUM	O	O
times	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
for	ADP	O	O
10	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
test	CCONJ	O	O
2	NUM	O	O
,	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
SRP	NOUN	O	O
and	CCONJ	O	O
professional	ADJ	O	O
supragingival	ADP	O	O
plaque	NOUN	O	O
removal	NOUN	O	O
(	PUNCT	O	O
PP	NOUN	O	O
)	PUNCT	O	O
every	DET	O	O
week	NOUN	O	O
for	ADP	O	O
3	NUM	O	O
months	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
test	ADP	O	O
3	NUM	O	O
,	PUNCT	O	O
treated	VERB	O	O
with	ADP	O	O
SRP	NOUN	O	O
and	CCONJ	O	O
MET	NOUN	O	O
plus	CCONJ	O	O
PP	NOUN	O	O
.	PUNCT	O	O

Clinical	ADJ	O	O
periodontal	ADJ	O	O
measurements	NOUN	O	O
and	CCONJ	O	O
data	NOUN	O	O
regarding	VERB	O	O
patients	NOUN	O	O
'	PUNCT	O	O
oral	ADJ	O	B-PHYSICAL
health	NOUN	O	I-PHYSICAL
impacts	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
perceived	PUNCT	O	B-PHYSICAL
impacts	NOUN	O	I-PHYSICAL
on	ADP	O	I-PHYSICAL
bleeding	ADP	O	I-PHYSICAL
gums	ADJ	O	I-PHYSICAL
,	PUNCT	O	O
gingival	ADJ	O	B-PHYSICAL
recession	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
sensitivity	NOUN	O	B-PHYSICAL
to	ADP	O	I-PHYSICAL
cold	ADP	O	I-PHYSICAL
,	PUNCT	O	O
packing	VERB	O	B-PHYSICAL
foods	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
aesthetics	ADJ	O	B-PHYSICAL
,	PUNCT	O	O
bad	CCONJ	O	B-PHYSICAL
breath	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
tooth	NOUN	O	B-PHYSICAL
mobility	NOUN	O	I-PHYSICAL
)	PUNCT	O	O
were	VERB	O	O
collected	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
3	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
All	DET	O	O
groups	NOUN	O	O
presented	VERB	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
oral	ADJ	O	B-PHYSICAL
health	NOUN	O	I-PHYSICAL
perceived	VERB	O	I-PHYSICAL
impacts	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
improvement	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	B-PHYSICAL
health	NOUN	O	I-PHYSICAL
impacts	NOUN	O	I-PHYSICAL
among	DET	O	O
groups	NOUN	O	O
subjected	VERB	O	O
to	ADP	O	O
different	ADJ	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
data	NOUN	O	O
of	ADP	O	O
percentage	NOUN	O	O
of	ADP	O	O
deep	ADJ	O	O
probing	VERB	O	O
depth	NOUN	O	O
,	PUNCT	O	O
deep	ADJ	O	O
clinical	ADJ	O	O
attachment	NOUN	O	O
level	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
bleeding	VERB	O	O
on	ADP	O	O
probing	VERB	O	O
were	VERB	O	O
found	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
correlated	VERB	O	O
significantly	ADV	O	O
with	ADP	O	O
oral	ADJ	O	O
health	NOUN	O	O
impacts	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Periodontal	PUNCT	O	O
treatment	NOUN	O	O
leads	NOUN	O	O
to	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
self-perceived	VERB	O	B-PHYSICAL
impacts	NOUN	O	I-PHYSICAL
regardless	CCONJ	O	O
of	ADP	O	O
the	DET	O	O
non-surgical	ADJ	O	O
treatment	NOUN	O	O
protocol	NOUN	O	O
employed	VERB	O	O
.	PUNCT	O	O

Most	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
data	NOUN	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
oral	ADJ	O	O
health	NOUN	O	O
impacts	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
description	NOUN	O	O
of	ADP	O	O
the	DET	O	O
clinical	ADJ	O	O
characteristics	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
recruited	VERB	O	O
into	ADP	O	O
the	DET	O	O
Carvedilol	NOUN	O	O
or	CCONJ	O	O
Metoprolol	NOUN	O	O
European	NOUN	O	O
Trial	NOUN	O	O
(	PUNCT	O	O
COMET	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
&	CCONJ	O	O
AIMS	PUNCT	O	O
The	DET	O	O
COMET	NOUN	O	O
trial	NOUN	O	O
was	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
randomised	VERB	O	O
trial	NOUN	O	O
comparing	VERB	O	O
carvedilol	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
comprehensive	ADJ	O	O
adrenergic	ADJ	O	O
receptor	NOUN	O	O
antagonist	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
metoprolol	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
beta-1-selective	ADJ	O	O
agent	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
heart	NOUN	O	O
failure	NOUN	O	O
and	CCONJ	O	O
left	ADJ	O	O
ventricular	ADJ	O	O
systolic	ADJ	O	O
dysfunction	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
trial	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
mortality	NOUN	O	B-MORTALITY
with	ADP	O	O
carvedilol	NOUN	O	O
that	ADP	O	O
was	VERB	O	O
consistent	ADJ	O	O
across	ADP	O	O
subgroups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
purpose	NOUN	O	O
of	ADP	O	O
this	DET	O	O
report	NOUN	O	O
is	PUNCT	O	O
to	PART	O	O
describe	ADP	O	O
in	ADP	O	O
greater	PUNCT	O	O
detail	NOUN	O	O
the	DET	O	O
heterogeneity	NOUN	O	O
of	ADP	O	O
this	DET	O	O
population	NOUN	O	O
at	ADP	O	O
baseline	NOUN	O	O
with	ADP	O	O
particular	ADJ	O	O
reference	NOUN	O	O
to	ADP	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
symptomatic	ADJ	O	O
severity	NOUN	O	O
,	PUNCT	O	O
age	NOUN	O	O
and	CCONJ	O	O
gender	NOUN	O	O
on	ADP	O	O
patient	NOUN	O	O
characteristics	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	DET	O	O
descriptive	ADJ	O	O
report	NOUN	O	O
using	PUNCT	O	O
data	NOUN	O	O
entered	VERB	O	O
in	ADP	O	O
the	DET	O	O
COMET	NOUN	O	O
study	PUNCT	O	O
data-base	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
characteristics	NOUN	O	O
of	ADP	O	O
the	DET	O	O
population	NOUN	O	O
studied	VERB	O	O
were	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	DET	O	O
reported	VERB	O	O
in	ADP	O	O
previous	ADJ	O	O
trials	NOUN	O	O
of	ADP	O	O
beta-blockers	NOUN	O	O
.	PUNCT	O	O

Almost	ADV	O	O
all	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
receiving	PROPN	O	O
diuretics	NOUN	O	O
and	CCONJ	O	O
ACE	NOUN	O	O
inhibitors	NOUN	O	O
with	ADP	O	O
few	ADJ	O	O
patients	NOUN	O	O
taking	ADJ	O	O
angiotensin	NOUN	O	O
receptor	NOUN	O	O
blockers	NOUN	O	O
.	PUNCT	O	O

As	PUNCT	O	O
expected	PUNCT	O	O
,	PUNCT	O	O
older	PUNCT	O	O
patients	NOUN	O	O
had	PUNCT	O	O
more	DET	O	O
co-morbidity	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Older	PUNCT	O	O
patients	NOUN	O	O
and	CCONJ	O	O
women	NOUN	O	O
reported	ADP	O	O
worse	ADJ	O	O
symptoms	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
poorer	PUNCT	O	O
well-being	CCONJ	O	B-PHYSICAL
despite	ADP	O	O
similar	ADJ	O	O
ventricular	ADJ	O	B-PHYSICAL
dimensions	NOUN	O	I-PHYSICAL
and	CCONJ	O	I-PHYSICAL
systolic	ADJ	O	I-PHYSICAL
dysfunction	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

NT-proBNP	NOUN	O	B-PHYSICAL
was	VERB	O	O
higher	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
more	ADV	O	O
severe	ADJ	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
older	PUNCT	O	O
patients	NOUN	O	O
but	CCONJ	O	O
not	ADV	O	O
in	ADP	O	O
women	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
NT-proBNP	NOUN	O	O
may	VERB	O	O
have	PUNCT	O	O
been	PUNCT	O	O
confounded	VERB	O	O
by	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	B-PHYSICAL
function	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Age	NOUN	O	O
and	CCONJ	O	O
gender	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
cardiac	ADJ	O	O
dysfunction	NOUN	O	O
,	PUNCT	O	O
appear	VERB	O	O
to	DET	O	O
have	PUNCT	O	O
an	DET	O	O
important	ADJ	O	O
effect	NOUN	O	O
on	ADP	O	O
the	DET	O	O
severity	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	B-PHYSICAL
failure	PUNCT	O	I-PHYSICAL

Long-term	NOUN	O	O
exposure	NOUN	O	O
to	ADP	O	O
belatacept	PUNCT	O	O
in	ADP	O	O
recipients	NOUN	O	O
of	ADP	O	O
extended	VERB	O	O
criteria	NOUN	O	O
donor	NOUN	O	O
kidneys	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
BENEFIT-EXT	PUNCT	O	O
study	NOUN	O	O
received	VERB	O	O
extended	VERB	O	O
criteria	NOUN	O	O
donor	NOUN	O	O
kidneys	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
more	ADV	O	O
intensive	ADJ	O	O
(	PUNCT	O	O
MI	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
less	DET	O	O
intensive	ADJ	O	O
(	PUNCT	O	O
LI	NOUN	O	O
)	PUNCT	O	O
belatacept	PUNCT	O	O
immunosuppression	NOUN	O	O
regimen	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
cyclosporine	NOUN	O	O
A	NOUN	O	O
(	PUNCT	O	O
CsA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
who	ADP	O	O
remained	VERB	O	O
on	ADP	O	O
assigned	PUNCT	O	O
therapy	NOUN	O	O
through	ADP	O	O
year	NOUN	O	O
3	NUM	O	O
were	VERB	O	O
eligible	ADJ	O	O
to	PART	O	O
enter	NOUN	O	O
a	DET	O	O
long-term	NOUN	O	O
extension	NOUN	O	O
(	PUNCT	O	O
LTE	NOUN	O	O
)	PUNCT	O	O
study	NOUN	O	O
.	PUNCT	O	O

Three	NUM	O	O
hundred	NUM	O	O
four	NUM	O	O
patients	NOUN	O	O
entered	VERB	O	O
the	DET	O	O
LTE	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
104	NUM	O	O
MI	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
113	NUM	O	O
LI	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
87	NUM	O	O
CsA	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
260	NUM	O	O
continued	VERB	O	O
treatment	NOUN	O	O
through	ADP	O	O
year	NOUN	O	O
5	NUM	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
91	NUM	O	O
MI	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
100	NUM	O	O
LI	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
69	NUM	O	O
CsA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Twenty	NUM	O	O
patients	NOUN	O	O
died	VERB	O	B-MORTALITY
during	ADP	O	O
the	DET	O	O
LTE	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
5	NUM	O	O
MI	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
9	NUM	O	O
LI	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
6	NUM	O	O
CsA	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
eight	NUM	O	O
experienced	ADJ	O	O
graft	NOUN	O	B-ADVERSE-EFFECTS
loss	NOUN	O	I-ADVERSE-EFFECTS
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
2	NUM	O	O
MI	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
1	NUM	O	O
LI	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
5	NUM	O	O
CsA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Three	NUM	O	O
patients	NOUN	O	O
experienced	VERB	O	O
an	DET	O	O
acute	ADJ	O	B-ADVERSE-EFFECTS
rejection	NOUN	O	I-ADVERSE-EFFECTS
episode	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
2	NUM	O	O
MI	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
1	NUM	O	O
LI	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
incidence	NOUN	O	O
rate	NOUN	O	O
of	ADP	O	O
serious	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
,	PUNCT	O	O
viral	ADJ	O	B-ADVERSE-EFFECTS
infections	NOUN	O	O
and	CCONJ	O	O
fungal	ADJ	O	B-ADVERSE-EFFECTS
infections	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
similar	ADJ	O	O
across	ADP	O	O
groups	NOUN	O	O
during	ADP	O	O
the	DET	O	O
LTE	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
four	NUM	O	O
cases	NOUN	O	O
of	ADP	O	O
posttransplant	NOUN	O	B-ADVERSE-EFFECTS
lymphoproliferative	ADJ	O	O
disorder	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
PTLD	NOUN	O	O
)	PUNCT	O	O
from	ADP	O	O
the	DET	O	O
beginning	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
LTE	NOUN	O	O
to	ADP	O	O
year	NOUN	O	O
5	NUM	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
3	NUM	O	O
LI	NOUN	O	O
;	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
1	NUM	O	O
CsA	NOUN	O	O
)	PUNCT	O	O
;	PUNCT	O	O
two	NUM	O	O
of	ADP	O	O
three	NUM	O	O
PTLD	NOUN	O	O
cases	NOUN	O	O
in	ADP	O	O
the	DET	O	O
LI	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
seronegative	PUNCT	O	O
for	ADP	O	O
Epstein-Barr	NOUN	O	O
virus	NOUN	O	O
(	PUNCT	O	O
EBV	NOUN	O	O
(	PUNCT	O	O
-	SYM	O	O
)	PUNCT	O	O
)	PUNCT	O	O
at	ADP	O	O
transplantation	NOUN	O	O
.	PUNCT	O	O

Mean	NOUN	O	O
?	PUNCT	O	O

SD	NOUN	O	O
calculated	VERB	O	O
GFR	NOUN	O	O
at	ADP	O	O
year	NOUN	O	O
5	NUM	O	O
was	VERB	O	O
55.9	NUM	O	O
?	PUNCT	O	O

17.5	NUM	O	O
(	PUNCT	O	O
MI	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
59.0	NUM	O	O
?	PUNCT	O	O

29.1	NUM	O	O
(	PUNCT	O	O
LI	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
44.6	NUM	O	O
?	PUNCT	O	O

16.4	NUM	O	O
(	PUNCT	O	O
CsA	NOUN	O	O
)	PUNCT	O	O
mL/min/1.73	NOUN	O	O
m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Continued	DET	O	O
treatment	NOUN	O	O
with	ADP	O	O
belatacept	CCONJ	O	O
was	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
a	DET	O	O
consistent	ADJ	O	O
safety	NOUN	O	O
profile	ADJ	O	O
and	CCONJ	O	O
sustained	VERB	O	O
improvement	NOUN	O	O
in	ADP	O	O
renal	ADJ	O	O
function	NOUN	O	O
versus	CCONJ	O	O
CsA	NOUN	O	O
over	PUNCT	O	O
time	NOUN	O	O
.	PUNCT	O	O

Induction	NOUN	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
head	NOUN	O	O
and	CCONJ	O	O
neck	ADJ	O	O
cancer	NOUN	O	O
:	PUNCT	O	O
results	NOUN	O	O
of	ADP	O	O
a	DET	O	O
phase	NOUN	O	O
III	NUM	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Between	ADP	O	O
December	NOUN	O	O
1982	NUM	O	O
and	CCONJ	O	O
October	NOUN	O	O
1986	NUM	O	O
,	PUNCT	O	O
131	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
stage	NOUN	O	O
II-III-IV	NOUN	O	O
squamous	ADJ	O	O
cell	NOUN	O	O
carcinoma	NOUN	O	O
of	ADP	O	O
the	DET	O	O
oropharynx	ADJ	O	O
or	CCONJ	O	O
oral	ADJ	O	O
cavity	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
induction	NOUN	O	O
chemotherapy	NOUN	O	O
,	PUNCT	O	O
consisting	SYM	O	O
of	ADP	O	O
bleomycin	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
mg/m2/day	NOUN	O	O
in	ADP	O	O
continuous	ADJ	O	O
infusion	NOUN	O	O
from	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
to	ADP	O	O
day	NOUN	O	O
5	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
methotrexate	NOUN	O	O
(	PUNCT	O	O
120	ADP	O	O
mg/m2	ADV	O	O
on	ADP	O	O
day	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
folinic	ADJ	O	O
acid	NOUN	O	O
,	PUNCT	O	O
5-fluorouracil	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
FU	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
600	NUM	O	O
mg/m2	NUM	O	O
on	ADP	O	O
day	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
cisplatin	NOUN	O	O
(	PUNCT	O	O
120	ADP	O	O
mg/m2	ADV	O	O
on	ADP	O	O
day	NOUN	O	O
4	NUM	O	O
)	PUNCT	O	O
every	DET	O	O
4	NUM	O	O
weeks	NOUN	O	O
for	ADP	O	O
a	DET	O	O
total	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
cycles	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
definitive	ADJ	O	O
locoregional	ADJ	O	O
treatment	NOUN	O	O
versus	CCONJ	O	O
locoregional	ADJ	O	O
treatment	NOUN	O	O
alone	ADJ	O	O
.	PUNCT	O	O

The	DET	O	O
modalities	NOUN	O	O
of	ADP	O	O
definitive	ADJ	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
radiotherapy	NOUN	O	O
+/-	SYM	O	O
surgery	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
chosen	VERB	O	O
prior	PUNCT	O	O
to	ADP	O	O
randomization	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
116	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
evaluable	ADJ	O	O
.	PUNCT	O	O

Of	ADP	O	O
55	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
arm	ADP	O	O
,	PUNCT	O	O
four	NUM	O	O
(	PUNCT	O	O
7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	PUNCT	O	O
a	DET	O	O
complete	ADJ	O	O
response	NOUN	O	O
(	PUNCT	O	O
CR	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
23	NUM	O	O
(	PUNCT	O	O
42	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
a	DET	O	O
partial	ADJ	O	O
response	NOUN	O	O
(	PUNCT	O	O
PR	NOUN	O	O
)	PUNCT	O	O
following	VERB	O	O
the	DET	O	O
induction	NOUN	O	O
regimen	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
the	DET	O	O
completion	NOUN	O	O
of	ADP	O	O
locoregional	ADJ	O	O
treatment	NOUN	O	O
,	PUNCT	O	O
76	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
42	NUM	O	O
of	ADP	O	O
55	NUM	O	O
)	PUNCT	O	O
of	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
group	NOUN	O	O
were	VERB	O	O
in	ADP	O	O
CR	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
89	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
54	NUM	O	O
of	ADP	O	O
61	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
survival	NOUN	O	B-OTHER
,	PUNCT	O	O
cause-specific	ADJ	O	B-OTHER
survival	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
pattern	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
relapse	NOUN	O	I-PHYSICAL
between	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
survival	NOUN	O	B-OTHER
was	ADV	O	O
22	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
chemotherapy	NOUN	O	O
group	NOUN	O	O
and	CCONJ	O	O
29	NUM	O	O
months	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Responders	NOUN	O	O
to	ADP	O	O
chemotherapy	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
fare	DET	O	O
better	PUNCT	O	O
than	VERB	O	O
nonresponders	NOUN	O	O
.	PUNCT	O	O

Chemotherapy-related	VERB	O	B-ADVERSE-EFFECTS
toxicities	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
few	ADJ	O	O
and	CCONJ	O	O
most	PUNCT	O	O
of	ADP	O	O
them	PRON	O	O
related	PUNCT	O	O
to	ADP	O	O
cisplatin	NOUN	O	O
which	PUNCT	O	O
was	VERB	O	O
reduced	VERB	O	O
to	ADP	O	O
100	NUM	O	O
mg/m2	NOUN	O	O
for	ADP	O	O
35	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
treatment-related	ADV	O	O
deaths	NOUN	O	B-MORTALITY
and	CCONJ	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
arm	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
,	PUNCT	O	O
no	DET	O	O
increased	ADV	O	O
morbidity	NOUN	O	B-ADVERSE-EFFECTS
from	ADP	O	O
locoregional	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
induction	NOUN	O	O
regimen	NOUN	O	O
does	PUNCT	O	O
not	ADV	O	O
offer	VERB	O	O
any	DET	O	O
advantages	NOUN	O	O
over	ADP	O	O
standard	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Comparative	ADJ	O	O
drug	NOUN	O	O
effects	NOUN	O	O
and	CCONJ	O	O
abuse	NOUN	O	O
liability	NOUN	O	O
of	ADP	O	O
lorazepam	NOUN	O	O
,	PUNCT	O	O
buspirone	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
secobarbital	ADJ	O	O
in	ADP	O	O
nondependent	VERB	O	O
subjects	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
pharmacologic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
lorazepam	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
buspirone	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
mg	NOUN	O	O
,	PUNCT	O	O
10	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
secobarbital	ADJ	O	O
(	PUNCT	O	O
100	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
in	ADP	O	O
15	NUM	O	O
male	NOUN	O	O
,	PUNCT	O	O
experienced	ADP	O	O
,	PUNCT	O	O
intermittent	ADJ	O	O
nontherapeutic	ADJ	O	O
drug	NOUN	O	O
users	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
drugs	NOUN	O	O
produced	VERB	O	O
a	DET	O	O
drug	NOUN	O	O
effect	NOUN	O	O
,	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
buspirone	NOUN	O	O
20	NUM	O	O
mg	NOUN	O	O
was	VERB	O	O
significantly	ADV	O	O
less	ADV	O	O
liked	VERB	O	O
than	PUNCT	O	O
were	ADP	O	O
lorazepam	NOUN	O	O
,	PUNCT	O	O
secobarbital	ADJ	O	O
,	PUNCT	O	O
or	CCONJ	O	O
buspirone	NOUN	O	O
10	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
.05	NUM	O	O
)	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Lorazepam	NOUN	O	O
was	VERB	O	O
liked	ADP	O	O
better	PUNCT	O	O
than	VERB	O	O
were	VERB	O	O
other	ADJ	O	O
drugs	NOUN	O	O
only	ADV	O	O
at	ADP	O	O
1	NUM	O	O
hour	NOUN	O	O
and	CCONJ	O	O
only	ADV	O	O
compared	VERB	O	O
with	ADP	O	O
buspirone	NOUN	O	O
20	NUM	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
other	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
lorazepam	NOUN	O	O
drug	NOUN	O	B-OTHER
effects	NOUN	O	I-OTHER
were	VERB	O	O
greater	PUNCT	O	O
and	CCONJ	O	O
resulted	VERB	O	O
in	ADP	O	O
more	DET	O	O
prolonged	ADJ	O	B-PHYSICAL
impairment	NOUN	O	I-PHYSICAL
of	ADP	O	O
a	DET	O	O
motor	NOUN	O	B-PHYSICAL
tracking	PUNCT	O	I-PHYSICAL
task	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
standing	ADP	O	B-PHYSICAL
steadiness	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
memory	NOUN	O	B-MENTAL
.	PUNCT	O	O

Buspirone	NOUN	O	O
20	NUM	O	O
mg	NOUN	O	O
significantly	ADV	O	B-MENTAL
impaired	PUNCT	O	I-MENTAL
memory	NOUN	O	I-MENTAL
at	ADP	O	O
1	NUM	O	O
hour	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
identify	NOUN	O	O
buspirone	NOUN	O	O
as	ADP	O	O
unfamiliar	ADJ	O	O
.	PUNCT	O	O

Because	PUNCT	O	O
buspirone	NOUN	O	O
20	NUM	O	O
mg	NOUN	O	O
was	VERB	O	O
less	ADV	O	O
liked	VERB	O	O
than	PUNCT	O	O
were	VERB	O	O
other	ADJ	O	O
drugs	NOUN	O	O
,	PUNCT	O	O
dose	NOUN	O	O
escalation	NOUN	O	O
as	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
drug	NOUN	O	B-MENTAL
abuse	NOUN	O	I-MENTAL
is	VERB	O	O
not	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
occur	ADV	O	O
.	PUNCT	O	O

Lorazepam	NOUN	O	O
also	ADV	O	O
was	VERB	O	O
not	ADV	O	O
particularly	ADV	O	O
liked	ADP	O	O
and	CCONJ	O	O
was	ADJ	O	O
not	ADV	O	O
different	ADJ	O	O
from	ADP	O	O
placebo	NOUN	O	O
on	ADP	O	O
most	PUNCT	O	O
subjective	ADJ	O	B-OTHER
abuse-relevant	ADJ	O	I-OTHER
measures	NOUN	O	I-OTHER
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
patient-controlled	VERB	O	O
and	CCONJ	O	O
nurse-administered	DET	O	O
analgesia	NOUN	O	O
using	SYM	O	O
intravenous	ADJ	O	O
fentanyl	NOUN	O	O
during	ADP	O	O
labor	NOUN	O	O
.	PUNCT	O	O

Preliminary	ADJ	O	O
observations	NOUN	O	O
have	PUNCT	O	O
shown	VERB	O	O
that	ADP	O	O
fentanyl	NOUN	O	O
citrate	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
potent	ADJ	O	O
narcotic	ADJ	O	O
,	PUNCT	O	O
is	VERB	O	O
helpful	ADJ	O	O
during	ADP	O	O
labor	NOUN	O	O
without	ADP	O	O
undue	NOUN	O	O
side	NOUN	O	O
effects	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
randomized	VERB	O	O
prospective	ADJ	O	O
investigation	NOUN	O	O
compared	VERB	O	O
the	DET	O	O
patient-controlled	VERB	O	O
administration	NOUN	O	O
of	ADP	O	O
fentanyl	NOUN	O	O
with	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
administration	NOUN	O	O
by	ADP	O	O
nurses	NOUN	O	O
on	ADP	O	O
request	ADV	O	O
.	PUNCT	O	O

Eighty	PUNCT	O	O
healthy	ADJ	O	O
women	NOUN	O	O
beginning	VERB	O	O
active	ADJ	O	O
labor	NOUN	O	O
(	PUNCT	O	O
cervical	ADJ	O	O
dilation	NOUN	O	O
4	NUM	O	O
cm	NOUN	O	O
)	PUNCT	O	O
at	ADP	O	O
term	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
fentanyl	NOUN	O	O
intravenously	ADV	O	O
by	ADP	O	O
either	CCONJ	O	O
patient-controlled	VERB	O	O
administration	NOUN	O	O
(	PUNCT	O	O
n=37	PUNCT	O	O
)	PUNCT	O	O
or	CCONJ	O	O
nurse	ADJ	O	O
administration	NOUN	O	O
on	ADP	O	O
demand	NOUN	O	O
(	PUNCT	O	O
n=43	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Pain	NOUN	O	B-PAIN
intensity	NOUN	O	O
measurements	NOUN	O	B-PAIN
during	ADP	O	O
early	ADJ	O	O
and	CCONJ	O	O
late	ADJ	O	O
labor	NOUN	O	O
revealed	VERB	O	O
the	DET	O	O
degree	NOUN	O	B-PAIN
of	ADP	O	I-PAIN
analgesia	NOUN	O	I-PAIN
to	PART	O	O
be	PUNCT	O	O
the	DET	O	O
same	ADP	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
delay	NOUN	O	O
in	ADP	O	O
setting	VERB	O	B-OTHER
up	PUNCT	O	I-OTHER
the	DET	O	I-OTHER
infusion	NOUN	O	I-OTHER
system	NOUN	O	I-OTHER
and	CCONJ	O	O
the	DET	O	O
short	ADJ	O	O
time	NOUN	O	B-OTHER
between	ADP	O	I-OTHER
requesting	PUNCT	O	B-OTHER
analgesia	NOUN	O	B-OTHER
and	CCONJ	O	I-OTHER
vaginal	ADJ	O	I-OTHER
delivery	NOUN	O	B-OTHER
were	DET	O	O
limitations	NOUN	O	O
with	ADP	O	O
self-administration	NOUN	O	O
.	PUNCT	O	O

Maternal	ADJ	O	B-ADVERSE-EFFECTS
oversedation	NOUN	O	I-ADVERSE-EFFECTS
and	CCONJ	O	O
vomiting	ADP	O	B-ADVERSE-EFFECTS
did	PUNCT	O	O
not	ADV	O	O
occur	VERB	O	O
.	PUNCT	O	O

Neonatal	ADJ	O	B-OTHER
naloxone	PUNCT	O	B-OTHER

Salbutamol	NOUN	O	O
or	CCONJ	O	O
mist	NOUN	O	O
in	ADP	O	O
acute	ADJ	O	O
bronchiolitis	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
The	DET	O	O
role	NOUN	O	O
of	ADP	O	O
bronchodilators	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
bronchiolitis	NOUN	O	O
remains	NOUN	O	O
controversial	ADJ	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
nebulized	ADJ	O	O
salbutamol	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
and	CCONJ	O	O
fifty-six	PUNCT	O	O
infants	NOUN	O	O
aged	VERB	O	O
between	ADP	O	O
7	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
24	NUM	O	O
months	NOUN	O	O
who	ADP	O	O
had	ADP	O	O
had	PUNCT	O	O
an	DET	O	O
episode	NOUN	O	O
of	ADP	O	O
wheezing	PROPN	O	O
and	CCONJ	O	O
other	ADJ	O	O
signs	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
bronchiolitis	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
three	NUM	O	O
groups	NOUN	O	O
as	ADP	O	O
follows	VERB	O	O
:	PUNCT	O	O
(	PUNCT	O	O
i	NUM	O	O
)	PUNCT	O	O
nebulized	VERB	O	O
salbutamol	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
52	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
0.15	NUM	O	O
mg/kg	NOUN	O	O
in	ADP	O	O
2	NUM	O	O
mL	NOUN	O	O
saline	NOUN	O	O
;	PUNCT	O	O
(	PUNCT	O	O
ii	NUM	O	O
)	PUNCT	O	O
saline	NOUN	O	O
was	VERB	O	O
nebulized	VERB	O	O
to	ADP	O	O
52	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
II	NUM	O	O
and	CCONJ	O	O
(	PUNCT	O	O
iii	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
III	NUM	O	O
52	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
mist	NOUN	O	O
in	ADP	O	O
a	DET	O	O
tent	ADJ	O	O
.	PUNCT	O	O

All	DET	O	O
three	NUM	O	O
groups	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
oxygen	NOUN	O	O
during	ADP	O	O
the	DET	O	O
procedures	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
was	VERB	O	O
repeated	VERB	O	O
with	ADP	O	O
the	DET	O	O
same	ADJ	O	O
agent	NOUN	O	O
after	ADP	O	O
30	NUM	O	O
min	NOUN	O	O
if	ADP	O	O
the	DET	O	O
respiratory	ADJ	O	O
score	NOUN	O	O
was	VERB	O	O
5	NUM	O	O
or	CCONJ	O	O
more	DET	O	O
.	PUNCT	O	O

Respiratory	ADJ	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
oxygen	NOUN	O	B-PHYSICAL
saturation	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
presence	NOUN	O	O
of	ADP	O	O
cyanosis	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
wheezing	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
retractions	ADP	O	B-PHYSICAL
were	VERB	O	O
recorded	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
each	DET	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
the	DET	O	O
respiratory	ADJ	O	B-PHYSICAL
score	NOUN	O	I-PHYSICAL
was	VERB	O	O
5.2	NUM	O	O
+/-	SYM	O	O
1.8	NUM	O	O
,	PUNCT	O	O
0.82	NUM	O	O
+/-	SYM	O	O
2.4	NUM	O	O
and	CCONJ	O	O
1.7	NUM	O	O
+/-	SYM	O	O
1.3	NUM	O	O
in	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
,	PUNCT	O	O
II	NUM	O	O
and	CCONJ	O	O
III	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
.	PUNCT	O	O

The	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
was	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
other	ADJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
was	VERB	O	O
similar	ADJ	O	O
between	ADP	O	O
groups	NOUN	O	O
.	PUNCT	O	O

Oxygen	NOUN	O	B-PHYSICAL
saturation	NOUN	O	I-PHYSICAL
decreased	VERB	O	O
in	ADP	O	O
group	NOUN	O	O
I	NUM	O	O
without	ADP	O	O
reaching	VERB	O	O
statistical	ADJ	O	O
significance	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Salbutamol	NOUN	O	O
was	VERB	O	O
shown	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
effective	ADJ	O	O
and	CCONJ	O	O
safe	ADJ	O	B-OTHER
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
bronchiolitis	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
time	NOUN	O	B-OTHER
required	ADV	O	I-OTHER
to	PART	O	O
administer	NOUN	O	O
three	NUM	O	O
different	ADJ	O	O
fluke	PUNCT	O	O
and	CCONJ	O	O
worm	NOUN	O	O
combination	NOUN	O	O
products	NOUN	O	O
to	ADP	O	O
commercial	ADJ	O	O
beef	NOUN	O	O
cattle	NOUN	O	O
at	ADP	O	O
housing	VERB	O	O
.	PUNCT	O	O

Larger	PUNCT	O	O
livestock	NOUN	O	O
units	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
decline	NOUN	O	O
in	ADP	O	O
the	DET	O	O
farm	NOUN	O	O
labor	NOUN	O	O
force	NOUN	O	O
,	PUNCT	O	O
animal	NOUN	O	O
welfare	ADP	O	O
concerns	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
more	DET	O	O
selective	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
drugs	NOUN	O	O
have	PUNCT	O	O
increased	DET	O	O
the	DET	O	O
focus	NOUN	O	O
on	ADP	O	O
animal	NOUN	O	O
handling	PROPN	O	O
,	PUNCT	O	O
time	NOUN	O	O
management	NOUN	O	O
,	PUNCT	O	O
convenience	ADP	O	O
,	PUNCT	O	O
and	CCONJ	O	O
compliance	NOUN	O	O
in	ADP	O	O
administering	NOUN	O	O
veterinary	ADJ	O	O
therapeutics	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
undertaken	VERB	O	O
to	PART	O	O
quantify	NOUN	O	B-OTHER
and	CCONJ	O	O
compare	ADJ	O	O
the	DET	O	O
time	NOUN	O	O
needed	ADP	O	O
to	PART	O	O
treat	NOUN	O	O
commercial	PUNCT	O	O
beef	NOUN	O	O
cattle	NOUN	O	O
with	ADP	O	O
three	PUNCT	O	O
fluke	PUNCT	O	O
and	CCONJ	O	O
worm	NOUN	O	O
combination	NOUN	O	O
products	NOUN	O	O
with	ADP	O	O
different	ADJ	O	O
administration	NOUN	O	O
profiles	NOUN	O	O
.	PUNCT	O	O

Young	ADJ	O	O
beef	NOUN	O	O
cattle	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
270	NUM	O	O
)	PUNCT	O	O
weighing	PUNCT	O	O
approximately	ADV	O	O
400	NUM	O	O
kg	NOUN	O	O
were	VERB	O	O
allocated	VERB	O	O
to	PUNCT	O	O
batches	NOUN	O	O
of	ADP	O	O
five	NUM	O	O
,	PUNCT	O	O
which	ADP	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
ivermectin	NOUN	O	O
+	SYM	O	O
clorsulon	NOUN	O	O
injection	NOUN	O	O
,	PUNCT	O	O
ivermectin	NOUN	O	O
+	ADJ	O	O
closantel	PUNCT	O	O
injection	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
levamisole	NOUN	O	O
+	SYM	O	O
triclabendazole	NOUN	O	O
oral	ADJ	O	O
drench	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	ADV	O	O
time	NOUN	O	B-OTHER
needed	ADP	O	I-OTHER
to	PART	O	O
administer	ADJ	O	O
ivermectin	NOUN	O	O
+	SYM	O	O
clorsulon	NOUN	O	O
(	PUNCT	O	O
single	ADJ	O	O
injection	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
five	NUM	O	O
cattle	NOUN	O	O
was	VERB	O	O
31	NUM	O	O
seconds	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
was	VERB	O	O
significantly	ADV	O	O
less	ADV	O	O
than	PUNCT	O	O
the	DET	O	O
100	NUM	O	O
seconds	NOUN	O	O
needed	VERB	O	O
for	ADP	O	O
ivermectin	NOUN	O	O
+	ADJ	O	O
closantel	CCONJ	O	O
(	PUNCT	O	O
two	NUM	O	O
injections	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
126	ADJ	O	O
seconds	NOUN	O	O
needed	VERB	O	O
for	ADP	O	O
levamisole	NOUN	O	O
+	SYM	O	O
triclabendazole	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Such	DET	O	O
quantitative	ADJ	O	O
data	NOUN	O	O
can	VERB	O	O
allow	VERB	O	O
for	ADP	O	O
better	PUNCT	O	O
planning	VERB	O	O
and	CCONJ	O	O
selection	NOUN	O	O
of	ADP	O	O
parasiticide	NOUN	O	O
treatment	NOUN	O	O
approaches	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
farm	NOUN	O	O
level	NOUN	O	O
.	PUNCT	O	O

B-type	NOUN	O	O
natriuretic	ADJ	O	O
peptide	NOUN	O	O
in	ADP	O	O
the	DET	O	O
evaluation	NOUN	O	O
and	CCONJ	O	O
management	NOUN	O	O
of	ADP	O	O
dyspnoea	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	NOUN	O	O
The	DET	O	O
rapid	ADJ	O	O
and	CCONJ	O	O
accurate	ADJ	O	O
diagnosis	NOUN	O	O
of	ADP	O	O
heart	NOUN	O	O
failure	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
is	VERB	O	O
a	DET	O	O
major	ADJ	O	O
unmet	VERB	O	O
clinical	ADJ	O	O
need	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
evaluated	VERB	O	O
the	DET	O	O
additional	ADJ	O	O
use	NOUN	O	O
of	ADP	O	O
B-type	NOUN	O	B-PHYSICAL
natriuretic	ADJ	O	I-PHYSICAL
peptide	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
BNP	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

DESIGN	NOUN	O	O
A	NOUN	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

SETTING	VERB	O	O
Twenty-nine	NUM	O	O
primary	ADJ	O	O
care	NOUN	O	O
physicians	NOUN	O	O
in	ADP	O	O
Switzerland	ADV	O	O
and	CCONJ	O	O
Germany	PUNCT	O	O
coordinated	PROPN	O	O
by	ADP	O	O
the	DET	O	O
University	NOUN	O	O
Hospital	NOUN	O	O
Basel	NOUN	O	O
,	PUNCT	O	O
Switzerland	PUNCT	O	O
.	PUNCT	O	O

SUBJECTS	NOUN	O	O
A	PUNCT	O	O
total	NOUN	O	O
of	ADP	O	O
323	NUM	O	O
consecutive	ADJ	O	O
patients	NOUN	O	O
presenting	VERB	O	O
with	ADP	O	O
dyspnoea	NOUN	O	O
.	PUNCT	O	O

INTERVENTIONS	NOUN	O	O
Assignment	NOUN	O	O
in	ADP	O	O
a	DET	O	O
1	NUM	O	O
:	PUNCT	O	O
1	NUM	O	O
ratio	NOUN	O	O
to	ADP	O	O
a	DET	O	O
diagnostic	ADJ	O	O
strategy	NOUN	O	O
including	VERB	O	O
point-of-care	PUNCT	O	O
measurement	NOUN	O	O
of	ADP	O	O
BNP	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
163	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
standard	PUNCT	O	O
assessment	NOUN	O	O
without	ADP	O	O
BNP	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
160	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
total	ADJ	O	O
medical	ADJ	O	B-OTHER
cost	NOUN	O	I-OTHER
at	ADP	O	I-OTHER
3	NUM	O	I-OTHER
months	NOUN	O	I-OTHER
was	VERB	O	O
the	DET	O	O
primary	ADJ	O	O
end-point	NOUN	O	O
.	PUNCT	O	O

Secondary	ADJ	O	O
end-points	NOUN	O	O
were	VERB	O	O
diagnostic	ADJ	O	B-OTHER
certainty	NOUN	O	I-OTHER
,	PUNCT	O	O
time	NOUN	O	B-OTHER
to	ADP	O	I-OTHER
appropriate	ADJ	O	I-OTHER
therapy	NOUN	O	I-OTHER
,	PUNCT	O	O
functional	ADJ	O	B-OTHER
capacity	NOUN	O	I-OTHER
,	PUNCT	O	O
hospitalization	NOUN	O	B-ADVERSE-EFFECTS
and	CCONJ	O	O
mortality	NOUN	O	B-MORTALITY
.	PUNCT	O	O

The	DET	O	O
final	ADJ	O	O
diagnosis	NOUN	O	O
was	VERB	O	O
adjudicated	VERB	O	O
by	ADP	O	O
a	DET	O	O
physician	NOUN	O	O
blinded	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
BNP	NOUN	O	O
levels	NOUN	O	O
.	PUNCT	O	O

RESULTS	VERB	O	O
Heart	NOUN	O	B-PHYSICAL
failure	NOUN	O	I-PHYSICAL
was	VERB	O	O
the	DET	O	O
final	ADJ	O	O
diagnosis	NOUN	O	O
in	ADP	O	O
34	NUM	O	O
%	SYM	O	O
of	ADP	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
hospitalizations	NOUN	O	I-OTHER
,	PUNCT	O	O
functional	ADJ	O	B-OTHER
status	NOUN	O	I-OTHER
and	CCONJ	O	O
total	ADJ	O	O
medical	ADJ	O	B-OTHER
cost	NOUN	O	I-OTHER
at	ADP	O	I-OTHER
3	NUM	O	I-OTHER
months	NOUN	O	I-OTHER
[	PUNCT	O	O
median	ADJ	O	O
$	SYM	O	O
1655	NUM	O	O
,	PUNCT	O	O
interquartile	NOUN	O	O
range	NOUN	O	O
(	PUNCT	O	O
IQR	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
850-3331	NOUN	O	O
vs.	CCONJ	O	O
$	SYM	O	O
1541	NUM	O	O
,	PUNCT	O	O
IQR	NOUN	O	O
859-2827	ADJ	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.68	NUM	O	O
]	PUNCT	O	O
were	VERB	O	O
similar	ADJ	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
.	PUNCT	O	O

BNP	NOUN	O	B-PHYSICAL
increased	DET	O	O
diagnostic	ADJ	O	B-OTHER
certainty	NOUN	O	I-OTHER
as	PUNCT	O	O
defined	VERB	O	O
by	ADP	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
further	PUNCT	O	O
diagnostic	ADJ	O	O
work-up	ADJ	O	O
(	PUNCT	O	O
33	NUM	O	O
%	SYM	O	O
vs.	CCONJ	O	O
45	NUM	O	O
%	ADJ	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
accelerated	VERB	O	O
the	DET	O	O
initiation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
appropriate	ADJ	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
13	NUM	O	O
days	NOUN	O	O
vs.	CCONJ	O	O
25	NUM	O	O
days	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
area	NOUN	O	O
under	ADP	O	O
the	DET	O	O
receiver-operating	ADJ	O	O
characteristics	NOUN	O	O
curve	NOUN	O	O
for	ADP	O	O
BNP	NOUN	O	O
to	PART	O	O
identify	NOUN	O	O
heart	NOUN	O	O
failure	NOUN	O	O
was	VERB	O	O
0.87	NUM	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
0.81-0.93	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
BNP	NOUN	O	O
levels	NOUN	O	O
in	ADP	O	O
primary	ADJ	O	O
care	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
reduce	VERB	O	O
total	ADJ	O	O
medical	ADJ	O	O
cost	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
improved	PROPN	O	O
some	ADP	O	O
of	ADP	O	O
the	DET	O	O
secondary	ADJ	O	O
end-points	NOUN	O	O
including	VERB	O	O
diagnostic	ADJ	O	O
certainty	NOUN	O	O
and	CCONJ	O	O
time	NOUN	O	O
to	ADP	O	O
initiation	NOUN	O	O
of	ADP	O	O
appropriate	ADJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Warfarin	NOUN	O	O
for	ADP	O	O
atrial	ADJ	O	O
fibrillation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patient	NOUN	O	O
's	PUNCT	O	O
perspective	ADJ	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
determine	NOUN	O	O
the	DET	O	O
minimal	ADJ	O	B-OTHER
clinically	ADV	O	I-OTHER
important	ADJ	O	I-OTHER
difference	NOUN	O	I-OTHER
(	PUNCT	O	I-OTHER
MCID	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
of	ADP	O	O
warfarin	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
nonvalvular	ADJ	O	O
atrial	ADJ	O	O
fibrillation	NOUN	O	O
from	ADP	O	O
the	DET	O	O
perspective	ADJ	O	O
of	ADP	O	O
patients	NOUN	O	O
using	VERB	O	O
2	NUM	O	O
different	ADJ	O	O
elicitation	NOUN	O	O
methods	NOUN	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
All	DET	O	O
patients	NOUN	O	O
completed	DET	O	O
2	NUM	O	O
face-to-face	PUNCT	O	O
interviews	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
were	VERB	O	O
2	NUM	O	O
weeks	NOUN	O	O
apart	PUNCT	O	O
.	PUNCT	O	O

For	ADP	O	O
each	DET	O	O
interview	NOUN	O	O
,	PUNCT	O	O
they	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
1	NUM	O	O
of	ADP	O	O
2	NUM	O	O
elicitation	NOUN	O	O
methods	NOUN	O	O
:	PUNCT	O	O
ping-ponging	ADP	O	O
or	CCONJ	O	O
starting	VERB	O	O
at	ADP	O	O
the	DET	O	O
known	VERB	O	O
efficacy	NOUN	O	O
.	PUNCT	O	O

SETTING	VERB	O	O
The	DET	O	O
practices	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
university-affiliated	VERB	O	O
family	NOUN	O	O
medicine	NOUN	O	O
centers	NOUN	O	O
(	PUNCT	O	O
8	NUM	O	O
physicians	NOUN	O	O
each	ADP	O	O
)	PUNCT	O	O
,	PUNCT	O	O
14	NUM	O	O
community-based	VERB	O	O
family	NOUN	O	O
physicians	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2	NUM	O	O
cardiologists	NOUN	O	O
.	PUNCT	O	O

PATIENTS	ADP	O	O
Sixty-four	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
nonvalvular	ADJ	O	O
atrial	ADJ	O	O
fibrillation	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
initiated	VERB	O	O
with	ADP	O	O
warfarin	NOUN	O	O
therapy	NOUN	O	O
at	ADP	O	O
least	ADV	O	O
3	NUM	O	O
months	NOUN	O	O
before	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
During	ADP	O	O
each	DET	O	O
interview	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
patients	NOUN	O	O
'	PUNCT	O	O
MCIDs	ADV	O	O
were	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
using	SYM	O	O
(	PUNCT	O	O
1	NUM	O	O
)	PUNCT	O	O
a	DET	O	O
pictorial	ADJ	O	B-OTHER
flip	NOUN	O	I-OTHER
chart	PUNCT	O	I-OTHER
to	ADJ	O	I-OTHER
describe	NOUN	O	I-OTHER
atrial	ADJ	O	O
fibrillation	NOUN	O	B-PHYSICAL
;	PUNCT	O	O
the	DET	O	O
consequences	NOUN	O	O
of	ADP	O	O
a	DET	O	B-PHYSICAL
minor	ADJ	O	I-PHYSICAL
stroke	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
a	DET	O	B-PHYSICAL
major	ADJ	O	B-PHYSICAL
stroke	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	B-PHYSICAL
major	ADJ	O	I-PHYSICAL
bleeding	ADJ	O	I-PHYSICAL
episode	NOUN	O	I-PHYSICAL
;	PUNCT	O	O
the	DET	O	O
chance	NOUN	O	O
of	ADP	O	O
stroke	NOUN	O	B-PHYSICAL
if	ADP	O	I-PHYSICAL
not	PUNCT	O	I-PHYSICAL
taking	CCONJ	O	I-PHYSICAL
warfarin	NOUN	O	I-PHYSICAL
;	PUNCT	O	O
the	DET	O	O
chance	NOUN	O	O
of	ADP	O	O
a	DET	O	O
major	ADJ	O	B-PHYSICAL
bleeding	ADJ	O	B-PHYSICAL
episode	NOUN	O	I-PHYSICAL
if	PUNCT	O	I-PHYSICAL
taking	PUNCT	O	B-PHYSICAL
warfarin	NOUN	O	I-PHYSICAL
;	PUNCT	O	O
examples	NOUN	O	O
of	ADP	O	O
the	DET	O	O
inconvenience	NOUN	O	B-OTHER
,	PUNCT	O	O
minor	ADJ	O	B-PHYSICAL
side	NOUN	O	I-PHYSICAL
effects	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
costs	NOUN	O	O
of	ADP	O	B-OTHER
warfarin	NOUN	O	I-OTHER
therapy	NOUN	O	I-OTHER
;	PUNCT	O	O
and	CCONJ	O	O
then	ADV	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
1	NUM	O	O
of	ADP	O	O
the	DET	O	O
2	NUM	O	O
elicitation	NOUN	O	O
methods	NOUN	O	O
to	PART	O	O
determine	NOUN	O	O
their	ADP	O	O
MCIDs	NOUN	O	B-OTHER
(	PUNCT	O	O
the	DET	O	B-OTHER
smallest	ADV	O	I-OTHER
reduction	NOUN	O	I-OTHER
in	ADP	O	I-OTHER
stroke	NOUN	O	B-OTHER
risk	NOUN	O	O
at	ADP	O	B-OTHER
which	ADP	O	I-OTHER
the	DET	O	I-OTHER
patients	NOUN	O	B-OTHER
were	VERB	O	I-OTHER
willing	ADP	O	I-OTHER
to	ADV	O	I-OTHER
take	ADJ	O	B-OTHER
warfarin	NOUN	O	B-OTHER
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	B-MENTAL
'	PUNCT	O	O
knowledge	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
their	ADJ	O	I-MENTAL
stroke	NOUN	O	B-MENTAL
risk	NOUN	O	B-MENTAL
,	PUNCT	O	O
acceptability	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
the	DET	O	I-OTHER
interview	NOUN	O	I-OTHER
process	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
factors	NOUN	O	B-OTHER
determining	VERB	O	I-OTHER
their	PUNCT	O	I-OTHER
preferences	NOUN	O	B-OTHER
were	NUM	O	O
also	ADV	O	O
assessed	VERB	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
RESULTS	NOUN	O	O
Given	PROPN	O	O
a	DET	O	O
baseline	NOUN	O	O
risk	NOUN	O	O
of	ADP	O	O
having	VERB	O	O
a	DET	O	O
stroke	NOUN	O	O
in	ADP	O	O
the	DET	O	O
next	ADJ	O	O
2	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
if	CCONJ	O	O
not	PUNCT	O	O
taking	CCONJ	O	O
warfarin	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
10	NUM	O	O
of	ADP	O	O
100	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
mean	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
hypoxemia	NOUN	O	O
on	ADP	O	O
cardiac	ADJ	O	O
output	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
dose-response	NOUN	O	O
curve	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
establish	ADJ	O	O
a	DET	O	O
dose-response	NOUN	O	O
curve	NOUN	O	O
for	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
isocapnic	ADJ	O	O
hypoxemia	NOUN	O	O
on	ADP	O	O
cardiac	ADJ	O	B-PHYSICAL
output	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
CO	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
we	PRON	O	O
studied	VERB	O	O
20	NUM	O	O
healthy	ADJ	O	O
men	NOUN	O	O
,	PUNCT	O	O
aged	ADP	O	O
20	NUM	O	O
to	ADP	O	O
34	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
using	VERB	O	O
a	DET	O	O
tight-fitting	VERB	O	O
face	NOUN	O	O
mask	NOUN	O	O
and	CCONJ	O	O
an	DET	O	O
isocapnic	ADJ	O	O
partial	ADJ	O	O
rebreathing	VERB	O	O
system	NOUN	O	O
(	PUNCT	O	O
a	DET	O	O
modified	VERB	O	O
anesthesia	NOUN	O	O
machine	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

We	PRON	O	O
blended	VERB	O	O
oxygen	NOUN	O	O
and	CCONJ	O	O
hypoxic	ADJ	O	O
gas	NOUN	O	O
to	PART	O	O
achieve	NOUN	O	O
arterial	ADJ	O	O
oxygen	NOUN	O	O
saturations	NOUN	O	O
(	PUNCT	O	O
SaO2	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
80	NUM	O	O
,	PUNCT	O	O
85	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
90	NUM	O	O
percent	NOUN	O	O
;	PUNCT	O	O
subjects	NOUN	O	O
also	ADV	O	O
breathed	PUNCT	O	O
100	NUM	O	O
percent	NOUN	O	O
oxygen	NOUN	O	O
and	CCONJ	O	O
room	NOUN	O	O
air	NOUN	O	O
(	PUNCT	O	O
RA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Target	NOUN	O	O
SaO2	NOUN	O	O
and	CCONJ	O	O
end-tidal	PUNCT	O	O
carbon	NOUN	O	O
dioxide	NOUN	O	O
were	VERB	O	O
continuously	ADV	O	O
monitored	VERB	O	O
using	VERB	O	O
an	DET	O	O
ear	NOUN	O	O
oximeter	NOUN	O	O
and	CCONJ	O	O
CO2	NOUN	O	O
gas	NOUN	O	O
analyzer	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
experienced	VERB	O	O
the	DET	O	O
five	NUM	O	O
SaO2	NOUN	O	O
measurements	NOUN	O	O
in	ADP	O	O
random	ADJ	O	O
order	NOUN	O	O
.	PUNCT	O	O

CO	NOUN	O	B-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
noninvasively	ADV	O	O
at	ADP	O	O
approximately	ADV	O	O
two-minute	ADJ	O	O
intervals	NOUN	O	O
,	PUNCT	O	O
using	SYM	O	O
continuous-wave	PUNCT	O	O
Doppler	NOUN	O	O
echocardiography	NOUN	O	O
.	PUNCT	O	O

Mean	DET	O	O
cardiac	ADJ	O	B-PHYSICAL
output	NOUN	O	I-PHYSICAL
increased	VERB	O	O
with	ADP	O	O
increasing	ADJ	O	O
hypoxemia	NOUN	O	B-PHYSICAL
from	ADP	O	O
6.84	NUM	O	O
L/min	NOUN	O	O
at	ADP	O	O
FIo2	NOUN	O	O
1.0	NUM	O	O
to	ADP	O	O
8.44	NUM	O	O
L/min	NOUN	O	O
at	ADP	O	O
SaO2	NOUN	O	O
80	NUM	O	O
percent	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.0005	NUM	O	O
)	PUNCT	O	O
;	PUNCT	O	O
the	DET	O	O
increase	NOUN	O	O
was	VERB	O	O
entirely	ADV	O	O
due	CCONJ	O	O
to	ADP	O	O
increased	NOUN	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

We	PRON	O	O
concluded	VERB	O	O
that	ADP	O	O
cardiac	ADJ	O	B-PHYSICAL
output	NOUN	O	I-PHYSICAL
increases	PART	O	O
significantly	ADV	O	O
in	ADP	O	O
a	DET	O	O
dose-response	NOUN	O	O
manner	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
acute	ADJ	O	O
isocapnic	ADJ	O	O
hypoxemia	NOUN	O	O
in	ADP	O	O
normal	ADJ	O	O
persons	NOUN	O	O
.	PUNCT	O	O

Cyclosporin	NOUN	O	O
versus	CCONJ	O	O
cyclophosphamide	NOUN	O	O
for	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
steroid-dependent	ADJ	O	O
and	CCONJ	O	O
frequently	ADV	O	O
relapsing	VERB	O	O
idiopathic	ADJ	O	O
nephrotic	ADJ	O	O
syndrome	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
multicentre	NOUN	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
(	PUNCT	O	O
maintenance	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
remission	NOUN	O	I-OTHER
)	PUNCT	O	O
,	PUNCT	O	O
safety	NOUN	O	B-OTHER
and	CCONJ	O	O
tolerability	NOUN	O	B-OTHER
of	ADP	O	O
cyclosporin	NOUN	O	O
(	PUNCT	O	O
CsA	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
those	PUNCT	O	O
of	ADP	O	O
cyclophosphamide	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
steroid-dependent	ADJ	O	O
or	CCONJ	O	O
frequently	ADV	O	O
relapsing	VERB	O	O
nephrotic	ADJ	O	O
syndrome	NOUN	O	O
(	PUNCT	O	O
NS	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
Open	VERB	O	O
,	PUNCT	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
multicentre	NOUN	O	O
,	PUNCT	O	O
controlled	ADP	O	O
study	NOUN	O	O
for	ADP	O	O
parallel	PUNCT	O	O
groups	NOUN	O	O
,	PUNCT	O	O
stratified	VERB	O	O
for	ADP	O	O
adults	NOUN	O	O
and	CCONJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
setting	VERB	O	O
was	VERB	O	O
in	ADP	O	O
nephrological	ADJ	O	O
departments	NOUN	O	O
in	ADP	O	O
Italy	PUNCT	O	O
.	PUNCT	O	O

SUBJECTS	NOUN	O	O
AND	CCONJ	O	O
INTERVENTIONS	NOUN	O	O
Seventy-three	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
steroid-sensitive	ADJ	O	O
idiopathic	ADJ	O	O
NS	NOUN	O	O
admitted	VERB	O	O
to	ADP	O	O
the	DET	O	O
study	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
cyclophosphamide	NOUN	O	O
(	PUNCT	O	O
2.5	ADP	O	O
mg/kg/day	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
8	NUM	O	O
weeks	NOUN	O	O
or	CCONJ	O	O
CsA	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
mg/kg/day	PUNCT	O	O
in	ADP	O	O
adults	NOUN	O	O
,	PUNCT	O	O
6	NUM	O	O
mg/kg/day	PUNCT	O	O
in	ADP	O	O
children	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
9	NUM	O	O
months	NOUN	O	O
,	PUNCT	O	O
tapered	CCONJ	O	O
off	PUNCT	O	O
by	ADP	O	O
25	NUM	O	O
%	SYM	O	O
every	DET	O	O
month	NOUN	O	O
until	ADP	O	O
complete	ADJ	O	O
discontinuation	NOUN	O	O
at	ADP	O	O
month	NOUN	O	O
12	NUM	O	O
.	PUNCT	O	O

Seven	NUM	O	O
patients	NOUN	O	O
lost	ADJ	O	O
to	ADP	O	O
follow	ADV	O	O
up	PUNCT	O	O
were	ADV	O	O
not	ADV	O	O
considered	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
remaining	VERB	O	O
66	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
up	ADJ	O	O
for	ADP	O	O
3-24	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
randomization	NOUN	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
Relapse-free	PUNCT	O	B-MORTALITY
survival	NOUN	O	I-MORTALITY
;	PUNCT	O	O
number	NOUN	O	O
of	ADP	O	O
N.S	NOUN	O	O
.	PUNCT	O	O

relapses/patient/year	ADJ	O	B-PHYSICAL
;	PUNCT	O	O
cumulative	ADJ	O	B-OTHER
dose	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
prednisone/patient	ADJ	O	I-OTHER
;	PUNCT	O	O
laboratory	NOUN	O	B-PHYSICAL
investigations	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
kidney	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
liver	NOUN	O	B-PHYSICAL
functions	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
haematological	ADJ	O	B-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
)	PUNCT	O	O
;	PUNCT	O	O
incidence	NOUN	O	O
of	PUNCT	O	O

Enhancing	ADP	O	O
the	DET	O	O
self-esteem	CCONJ	O	B-MENTAL
of	ADP	O	O
inpatient	NOUN	O	O
alcoholics	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
pairing	VERB	O	O
inpatient	NOUN	O	O
alcoholics	NOUN	O	O
with	ADP	O	O
nursing	VERB	O	O
home	NOUN	O	O
residents	NOUN	O	O
(	PUNCT	O	O
NHRs	ADJ	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
alcoholics	ADJ	O	B-MENTAL
'	PUNCT	O	O
self-esteem	CCONJ	O	B-MENTAL
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
PALS	PUNCT	O	O
program	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
alcoholic	ADJ	O	O
inpatients	NOUN	O	O
assumed	VERB	O	O
a	DET	O	O
helping-companion	NOUN	O	O
relationship	NOUN	O	O
with	ADP	O	O
the	DET	O	O
NHRs	PUNCT	O	O
for	ADP	O	O
2	NUM	O	O
hr	NOUN	O	O
per	ADP	O	O
day	NOUN	O	O
during	ADP	O	O
their	ADP	O	O
last	ADJ	O	O
2	NUM	O	O
weeks	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Fifty	NUM	O	O
alcoholic	ADJ	O	O
inpatients	NOUN	O	O
were	ADJ	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
the	DET	O	O
PALS	PUNCT	O	O
program	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
25	NUM	O	O
)	PUNCT	O	O
or	CCONJ	O	O
to	ADP	O	O
the	DET	O	O
library	NOUN	O	O
for	ADP	O	O
free	ADJ	O	O
reading	PART	O	O
time	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
25	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
Tennessee	PUNCT	O	O
Self-Concept	PUNCT	O	O
Scale	NOUN	O	O
(	PUNCT	O	O
TSCS	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
all	DET	O	O
subjects	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
interventions	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
nine	NUM	O	O
TSCS	NOUN	O	B-MENTAL
scales	NOUN	O	I-MENTAL
,	PUNCT	O	O
the	DET	O	O
improvement	NOUN	O	O
on	ADP	O	O
the	DET	O	O
Moral-Ethical	PUNCT	O	B-MENTAL
scale	NOUN	O	I-MENTAL
was	VERB	O	O
significantly	ADV	O	O
greater	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
PALS	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

Because	PUNCT	O	O
the	DET	O	O
alcoholic	ADJ	O	O
inpatients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
PALS	PUNCT	O	O
group	NOUN	O	O
engaged	PUNCT	O	O
in	PUNCT	O	O

Information	NOUN	O	O
source	NOUN	O	O
affects	NOUN	O	O
peers	NOUN	O	O
'	PUNCT	O	O
initial	ADJ	O	O
attitudes	NOUN	O	O
toward	ADP	O	O
autism	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Authors	NOUN	O	O
examined	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
information	NOUN	O	O
source	NOUN	O	O
on	ADP	O	O
peers	NOUN	O	O
'	PUNCT	O	O
cognitive	ADJ	O	B-MENTAL
and	CCONJ	O	I-MENTAL
behavioral	ADJ	O	I-MENTAL
attitudes	NOUN	O	I-MENTAL
toward	ADP	O	O
an	DET	O	O
unfamiliar	ADJ	O	O
child	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

Children	NOUN	O	O
(	PUNCT	O	O
N=296	NOUN	O	O
;	PUNCT	O	O
M	NOUN	O	O
age=10.21	PUNCT	O	O
years	NOUN	O	O
)	PUNCT	O	O
received	ADP	O	O
information	NOUN	O	O
about	PUNCT	O	O
an	DET	O	O
unfamiliar	ADJ	O	O
child	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
from	ADP	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
following	PUNCT	O	O
sources	NOUN	O	O
:	PUNCT	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
videotape	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
teacher	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
c	NOUN	O	O
)	PUNCT	O	O
hypothetical	ADJ	O	O
mother	NOUN	O	O
,	PUNCT	O	O
(	PUNCT	O	O
d	NOUN	O	O
)	PUNCT	O	O
hypothetical	ADJ	O	O
father	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
(	PUNCT	O	O
e	NOUN	O	O
)	PUNCT	O	O
hypothetical	ADJ	O	O
doctor	NOUN	O	O
.	PUNCT	O	O

Interactive	ADJ	O	O
effects	NOUN	O	O
between	ADP	O	O
source	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
sex	NOUN	O	O
and	CCONJ	O	O
grade	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
for	ADP	O	O
cognitive	ADJ	O	O
and	CCONJ	O	O
behavioral	ADJ	O	O
attitudes	NOUN	O	O
.	PUNCT	O	O

Fifth-graders	NOUN	O	O
reported	PUNCT	O	O
more	ADV	O	O
favorable	ADJ	O	O
cognitive	ADJ	O	B-MENTAL
and	CCONJ	O	I-MENTAL
behavioral	ADJ	O	I-MENTAL
attitudes	NOUN	O	I-MENTAL
when	ADP	O	O
information	NOUN	O	O
was	VERB	O	O
provided	VERB	O	O
by	ADP	O	O
extra-familial	PUNCT	O	O
sources	NOUN	O	O
(	PUNCT	O	O
i.e.	CCONJ	O	O
,	PUNCT	O	O
doctor	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
parent	NOUN	O	O
sources	NOUN	O	O
.	PUNCT	O	O

Mother	NOUN	O	O
yielded	VERB	O	O
more	ADV	O	O
persuasive	ADJ	O	B-MENTAL
effects	NOUN	O	I-MENTAL
on	ADP	O	I-MENTAL
behavioral	ADJ	O	I-MENTAL
attitudes	NOUN	O	I-MENTAL
for	ADP	O	O
third-graders	NOUN	O	O
versus	CCONJ	O	O
fifth-graders	NOUN	O	O
.	PUNCT	O	O

Attitudes	NOUN	O	O
toward	ADP	O	O
autism	NOUN	O	O
differ	VERB	O	O
depending	PUNCT	O	O
on	ADP	O	O
who	ADP	O	O
provides	NOUN	O	O
information	NOUN	O	O
about	PUNCT	O	O
the	DET	O	O
disability	NOUN	O	O
.	PUNCT	O	O

Persuasion	NOUN	O	O
theory	NOUN	O	O
appears	NOUN	O	O
useful	ADJ	O	O
to	PART	O	O
guide	NOUN	O	O
evaluation	NOUN	O	O
of	ADP	O	O
educational	ADJ	O	O
interventions	NOUN	O	O
to	PROPN	O	O
improve	ADP	O	O
attitudes	NOUN	O	O
towards	ADP	O	O
autism	NOUN	O	B-MENTAL
.	PUNCT	O	O

Implications	NOUN	O	O
of	ADP	O	O
the	DET	O	O
findings	NOUN	O	O
,	PUNCT	O	O
study	PUNCT	O	O
limitations	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
recommendations	NOUN	O	O
for	ADP	O	O
future	ADJ	O	O
research	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O

Effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
multi-faceted	VERB	O	O
intervention	NOUN	O	O
on	ADP	O	O
gingival	ADJ	O	B-PHYSICAL
health	NOUN	O	I-PHYSICAL
among	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
systemic	ADJ	O	O
sclerosis	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	ADP	O	O
To	PROPN	O	O
evaluate	NOUN	O	B-OTHER
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
adaptive	ADJ	O	O
oral	ADJ	O	O
hygiene	NOUN	O	O
devices	NOUN	O	O
and	CCONJ	O	O
orofacial	ADP	O	O
exercise	NOUN	O	O
to	PART	O	O
improve	PUNCT	O	O
gingival	ADJ	O	B-PHYSICAL
health	NOUN	O	I-PHYSICAL
among	ADP	O	O
adults	NOUN	O	O
with	ADP	O	O
systemic	ADJ	O	O
sclerosis	NOUN	O	O
(	PUNCT	O	O
SSc	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Forty-eight	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
SSc	NOUN	O	O
were	VERB	O	O
assigned	VERB	O	O
randomly	ADV	O	O
to	ADP	O	O
the	DET	O	O
multifaceted	ADP	O	O
oral	ADJ	O	O
health	NOUN	O	O
intervention	NOUN	O	O
or	CCONJ	O	O
usual	ADJ	O	O
dental	ADJ	O	O
care	NOUN	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
received	VERB	O	O
a	DET	O	O
rechargeable	PUNCT	O	O
,	PUNCT	O	O
powered	ADJ	O	O
Oral-B?	NOUN	O	O
oscillating-rotating-pulsating	NOUN	O	O
toothbrush	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
Reach?	NOUN	O	O
Access?	NOUN	O	O
Flosser	NOUN	O	O
that	PUNCT	O	O
has	ADJ	O	O
a	DET	O	O
toothbrush-like	ADJ	O	O
handle	NOUN	O	O
.	PUNCT	O	O

For	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
an	DET	O	O
oral	ADJ	O	O
aperture	ADJ	O	O
of	ADP	O	O
less	ADV	O	O
than	ADP	O	O
40	NUM	O	O
mm	NOUN	O	O
,	PUNCT	O	O
orofacial	ADP	O	O
exercises	NOUN	O	O
were	VERB	O	O
taught	NOUN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
were	VERB	O	O
each	DET	O	O
given	VERB	O	O
a	DET	O	O
manual	ADJ	O	O
toothbrush	NOUN	O	O
and	CCONJ	O	O
dental	ADJ	O	O
floss	ADP	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
groups	NOUN	O	O
received	VERB	O	O
instructions	NOUN	O	O
and	CCONJ	O	O
demonstration	NOUN	O	O
on	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
devices	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
were	VERB	O	O
requested	VERB	O	O
to	PART	O	O
perform	NOUN	O	O
the	DET	O	O
respective	ADJ	O	O
intervention	NOUN	O	O
twice	ADV	O	O
a	DET	O	O
day	NOUN	O	O
for	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Evaluations	NOUN	O	O
were	VERB	O	O
at	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
3-	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
6-months	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
main	ADJ	O	O
outcome	NOUN	O	O
was	VERB	O	O
gingival	ADJ	O	B-PHYSICAL
index	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
GI	NOUN	O	I-PHYSICAL
)	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
an	DET	O	O
indicator	NOUN	O	O
of	ADP	O	O
gingival	ADJ	O	O
inflammation	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Both	PUNCT	O	O
groups	NOUN	O	O
showed	VERB	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
GI	NOUN	O	O
scores	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
ps	NOUN	O	O
<	SYM	O	O
0.005	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Reduction	NOUN	O	O
in	ADP	O	O
GI	NOUN	O	O
scores	NOUN	O	O
of	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
was	VERB	O	O
20.8	NUM	O	O
%	SYM	O	O
which	ADP	O	O
is	VERB	O	O
considered	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
clinically	ADV	O	O
significant	ADJ	O	O
.	PUNCT	O	O

Compared	VERB	O	O
to	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
intervention	NOUN	O	O
group	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
significant	ADJ	O	O
and	CCONJ	O	O
larger	PUNCT	O	O
reduction	NOUN	O	O
in	ADP	O	O
GI	NOUN	O	O
score	NOUN	O	O
by	ADP	O	O
8	NUM	O	O
%	SYM	O	O
at	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
(	PUNCT	O	O
p=0.0007	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	DET	O	O
Results	ADJ	O	O
support	VERB	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
adaptive	ADJ	O	O
devices	NOUN	O	O
and	CCONJ	O	O
orofacial	ADP	O	O
exercise	NOUN	O	O
to	PUNCT	O	O
improve	PUNCT	O	O

Monitoring	ADV	O	O
tumour	NOUN	O	O
cells	NOUN	O	O
in	ADP	O	O
the	DET	O	O
peripheral	ADJ	O	O
blood	NOUN	O	O
of	ADP	O	O
small	ADJ	O	O
cell	NOUN	O	O
lung	NOUN	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Flow	NOUN	O	O
cytometry	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
to	PUNCT	O	O
enumerate	ADJ	O	O
tumour	NOUN	O	O
cells	NOUN	O	O
in	ADP	O	O
longitudinal	ADJ	O	O
studies	NOUN	O	O
of	ADP	O	O
peripheral	ADJ	O	O
blood	NOUN	O	O
from	ADP	O	O
small	ADJ	O	O
cell	NOUN	O	O
lung	NOUN	O	O
cancer	NOUN	O	O
(	PUNCT	O	O
SCLC	NOUN	O	O
)	PUNCT	O	O
patients	NOUN	O	O
,	PUNCT	O	O
together	ADV	O	O
with	ADP	O	O
magnetic	ADJ	O	O
bead	NOUN	O	O
selection	NOUN	O	O
to	ADJ	O	O
isolate	NOUN	O	O
and	CCONJ	O	O
identify	ADJ	O	O
these	DET	O	O
cells	NOUN	O	O
.	PUNCT	O	O

As	ADP	O	O
part	NOUN	O	O
of	ADP	O	O
a	DET	O	O
trial	NOUN	O	O
,	PUNCT	O	O
11	NUM	O	O
patients	NOUN	O	O
received	VERB	O	O
either	CCONJ	O	O
standard	ADJ	O	O
(	PUNCT	O	O
four	NUM	O	O
weekly	ADV	O	O
)	PUNCT	O	O
chemotherapy	NOUN	O	O
with	ADP	O	O
ifosfamide	PUNCT	O	O
,	PUNCT	O	O
carboplatin	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
etoposide	NOUN	O	O
(	PUNCT	O	O
ICE	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
accelerated	VERB	O	O
(	PUNCT	O	O
two	NUM	O	O
weekly	ADV	O	O
)	PUNCT	O	O
ICE	NOUN	O	O
with	ADP	O	O
filgrastim	NOUN	O	O
(	PUNCT	O	O
granulocyte	NOUN	O	O
colony-stimulating	VERB	O	O
factor	NOUN	O	O
[	PUNCT	O	O
G-CSF	NOUN	O	O
]	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
autologous	ADJ	O	O
stem	NOUN	O	O
cell	NOUN	O	O
support	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Fresh	ADJ	O	O
venous	ADJ	O	O
blood	NOUN	O	O
was	VERB	O	O
taken	VERB	O	O
throughout	ADP	O	O
treatment	NOUN	O	O
and	CCONJ	O	O
follow-up	NOUN	O	O
.	PUNCT	O	O

Aliquots	NOUN	O	O
were	VERB	O	O
stained	VERB	O	O
with	ADP	O	O
a	DET	O	O
tumour-specific	ADJ	O	O
antibody	NOUN	O	O
against	ADP	O	O
epithelial	ADJ	O	O
tissue	NOUN	O	O
(	PUNCT	O	O
Ber	NOUN	O	O
EP4	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
verified	VERB	O	O
as	ADP	O	O
a	DET	O	O
good	ADJ	O	O
marker	NOUN	O	O
of	ADP	O	O
SCLC	NOUN	O	O
cells	NOUN	O	O
by	ADP	O	O
immunohistochemistry	NOUN	O	O
.	PUNCT	O	O

Matched	VERB	O	O
samples	NOUN	O	O
labelled	VERB	O	O
with	ADP	O	O
Ber	NOUN	O	O
EP4	NOUN	O	O
were	VERB	O	O
separated	VERB	O	O
magnetically	ADV	O	O
by	ADP	O	O
adding	VERB	O	O
a	DET	O	O
secondary	ADJ	O	O
bead-antibody	NOUN	O	O
conjugate	ADP	O	O
for	ADP	O	O
confirmation	NOUN	O	O
of	ADP	O	O
tumour	NOUN	O	O
cell	NOUN	O	O
identity	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Circulating	ADP	O	B-PHYSICAL
tumour	NOUN	O	I-PHYSICAL
cells	NOUN	O	I-PHYSICAL
were	VERB	O	O
detected	VERB	O	O
and	CCONJ	O	O
monitored	VERB	O	O
throughout	ADP	O	O
treatment	NOUN	O	O
periods	NOUN	O	O
.	PUNCT	O	O

An	DET	O	O
initial	ADJ	O	O
rise	NOUN	O	O
in	ADP	O	O
circulating	VERB	O	B-PHYSICAL
cells	NOUN	O	I-PHYSICAL
after	ADP	O	O
the	DET	O	O
first	ADJ	O	O
cycle	NOUN	O	O
was	VERB	O	O
followed	VERB	O	O
by	ADP	O	O
a	DET	O	O
fall	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
treatment	NOUN	O	O
arms	NOUN	O	O
to	ADP	O	O
baseline	NOUN	O	O
levels	NOUN	O	O
set	PUNCT	O	O
by	ADP	O	O
normal	ADJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
was	VERB	O	O
achieved	VERB	O	O
by	ADP	O	O
week	NOUN	O	O
12	NUM	O	O
in	ADP	O	O
the	DET	O	O
accelerated	VERB	O	O
treatment	NOUN	O	O
arm	NOUN	O	O
and	CCONJ	O	O
by	ADP	O	O
week	NOUN	O	O
24	NUM	O	O
in	ADP	O	O
the	DET	O	O
standard	ADJ	O	O
arm	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Flow	NOUN	O	O
cytometry	NOUN	O	O
and	CCONJ	O	O
magnetic	ADJ	O	O
bead	NOUN	O	O
isolation	NOUN	O	O
can	PROPN	O	O
be	VERB	O	O
used	VERB	O	O
to	PART	O	O
identify	NOUN	O	O
changes	NOUN	O	O
in	ADP	O	O
numbers	NOUN	O	O
of	ADP	O	O
circulating	VERB	O	O
tumour	NOUN	O	O
cells	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
SCLC	NOUN	O	O
and	CCONJ	O	O
thereafter	ADV	O	O
during	ADP	O	O
follow-up	NOUN	O	O
periods	NOUN	O	O
.	PUNCT	O	O

Absence	NOUN	O	O
of	ADP	O	O
tumour	NOUN	O	O
cells	NOUN	O	O
may	VERB	O	O
indicate	VERB	O	O
a	DET	O	O
more	ADV	O	O
favourable	ADJ	O	O
patient	NOUN	O	O
group	NOUN	O	O
who	DET	O	O
would	VERB	O	O
benefit	VERB	O	O
from	ADP	O	O
a	DET	O	O
more	DET	O	O
intense	ADJ	O	O
course	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Behavioral	ADJ	O	B-MENTAL
effects	NOUN	O	I-MENTAL
of	ADP	O	O
Org	PUNCT	O	O
2766	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
synthetic	ADJ	O	O
analog	NOUN	O	O
of	ADP	O	O
the	DET	O	O
adrenocorticotrophic	ADJ	O	O
hormone	NOUN	O	O
(	PUNCT	O	O
4-9	ADP	O	O
)	PUNCT	O	O
,	PUNCT	O	O
in	ADP	O	O
14	NUM	O	O
outpatient	ADJ	O	O
autistic	ADJ	O	O
children	NOUN	O	O
.	PUNCT	O	O

Fourteen	NUM	O	O
children	NOUN	O	O
(	PUNCT	O	O
12	NUM	O	O
infantile	ADJ	O	O
autism	NOUN	O	O
full	ADJ	O	O
syndrome	NOUN	O	O
present	VERB	O	O
,	PUNCT	O	O
2	NUM	O	O
atypical	ADJ	O	O
pervasive	ADJ	O	O
developmental	ADJ	O	O
disorder	NOUN	O	O
)	PUNCT	O	O
between	ADP	O	O
5	NUM	O	O
and	CCONJ	O	O
13	NUM	O	O
years	NOUN	O	O
of	ADP	O	O
age	NOUN	O	O
participated	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
placebo-controlled	VERB	O	O
cross-over	NOUN	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Each	DET	O	O
child	NOUN	O	O
received	VERB	O	O
20	NUM	O	O
mg	NOUN	O	O
Org	PUNCT	O	O
2766	NUM	O	O
(	PUNCT	O	O
synthetic	ADJ	O	O
analog	NOUN	O	O
of	ADP	O	O
ACTH	NOUN	O	O
4-9	PUNCT	O	O
)	PUNCT	O	O
/day	NOUN	O	O
during	ADP	O	O
4	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
in	ADP	O	O
a	DET	O	O
randomly	ADV	O	O
assigned	PUNCT	O	O
sequence	NOUN	O	O
.	PUNCT	O	O

Drug	NOUN	O	B-MENTAL
effects	NOUN	O	I-MENTAL
were	VERB	O	O
monitored	VERB	O	O
by	ADP	O	O
ethological	CCONJ	O	B-MENTAL
playroom	NOUN	O	I-MENTAL
observation	NOUN	O	I-MENTAL
and	CCONJ	O	O
by	ADP	O	O
Aberrant	ADJ	O	B-MENTAL
Behavior	NOUN	O	I-MENTAL
Checklist	NOUN	O	I-MENTAL
ratings	NOUN	O	I-MENTAL
by	ADP	O	O
parents	NOUN	O	O
and	CCONJ	O	O
teachers	NOUN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
of	ADP	O	O
the	DET	O	O
playroom	CCONJ	O	O
observation	NOUN	O	O
pointed	PRON	O	O
to	ADP	O	O
an	DET	O	O
activating	VERB	O	B-MENTAL
influence	NOUN	O	I-MENTAL
of	ADP	O	O
Org	PUNCT	O	O
2766	NUM	O	O
,	PUNCT	O	O
as	PUNCT	O	O
revealed	VERB	O	O
by	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
decrease	NOUN	O	O
of	ADP	O	O
stereotypic	ADJ	O	B-MENTAL
behavior	NOUN	O	I-MENTAL
and	CCONJ	O	O
significant	ADJ	O	O
increases	NOUN	O	O
in	ADP	O	O
change	NUM	O	B-MENTAL
toys	NOUN	O	I-MENTAL
,	PUNCT	O	O
locomote	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
talk	NOUN	O	B-MENTAL
.	PUNCT	O	O

Checklist	NOUN	O	O
ratings	NOUN	O	O
did	CCONJ	O	O
not	ADV	O	O
show	VERB	O	O
significant	ADJ	O	O
changes	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
clinical	ADJ	O	O
implications	NOUN	O	O
of	ADP	O	O
these	DET	O	O
findings	NOUN	O	O
are	VERB	O	O
discussed	VERB	O	O
.	PUNCT	O	O

Controlled	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
of	ADP	O	O
IV	NUM	O	O
cyclophosphamide	NOUN	O	O
versus	CCONJ	O	O
IV	NUM	O	O
methylprednisolone	NUM	O	O
in	ADP	O	O
severe	ADJ	O	O
neurological	ADJ	O	O
manifestations	NOUN	O	O
in	ADP	O	O
systemic	ADJ	O	O
lupus	NOUN	O	O
erythematosus	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Severe	ADJ	O	O
neurological	ADJ	O	O
involvement	NOUN	O	O
in	ADP	O	O
systemic	ADJ	O	O
lupus	NOUN	O	O
erythematosus	NOUN	O	O
(	PUNCT	O	O
NPSLE	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
most	PUNCT	O	O
dreadful	ADJ	O	O
complications	NOUN	O	O
of	ADP	O	O
the	DET	O	O
disease	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
identify	NOUN	O	O
the	DET	O	O
best	PUNCT	O	O
drug	NOUN	O	O
,	PUNCT	O	O
dose	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
The	DET	O	O
study	NOUN	O	O
was	ADV	O	O
a	DET	O	O
controlled	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
at	ADP	O	O
two	NUM	O	O
tertiary	ADJ	O	O
care	NOUN	O	O
centres	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
SLE	NOUN	O	O
according	PUNCT	O	O
to	ADP	O	O
the	DET	O	O
ACR	NOUN	O	O
criteria	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
incident	ADJ	O	O
(	PUNCT	O	O
no	ADP	O	O
more	ADV	O	O
than	ADP	O	O
15	DET	O	O
days	NOUN	O	O
)	PUNCT	O	O
onset	NOUN	O	O
of	ADP	O	O
severe	ADJ	O	O
NP	NOUN	O	O
manifestations	NOUN	O	O
such	CCONJ	O	O
as	ADP	O	O
seizures	NOUN	O	O
,	PUNCT	O	O
optic	ADJ	O	O
neuritis	NOUN	O	O
,	PUNCT	O	O
peripheral	ADJ	O	O
or	CCONJ	O	O
cranial	ADJ	O	O
neuropathy	NOUN	O	O
,	PUNCT	O	O
coma	NOUN	O	O
,	PUNCT	O	O
brainstem	NOUN	O	O
disease	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
transverse	ADJ	O	O
myelitis	NOUN	O	O
.	PUNCT	O	O

Induction	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
3	NUM	O	O
g	NOUN	O	O
of	ADP	O	O
IV	NUM	O	O
methylprednisolone	NOUN	O	O
(	PUNCT	O	O
MP	NOUN	O	O
)	PUNCT	O	O
followed	VERB	O	O
by	ADP	O	O
either	CCONJ	O	O
IV	NUM	O	O
monthly	ADV	O	O
cyclophosphamide	NOUN	O	O
(	PUNCT	O	O
Cy	NOUN	O	O
)	PUNCT	O	O
versus	CCONJ	O	O
IV	NUM	O	O
MP	NOUN	O	O
bimonthly	PUNCT	O	O
every	DET	O	O
4	NUM	O	O
months	NOUN	O	O
for	ADP	O	O
1	NUM	O	O
year	NOUN	O	O
and	CCONJ	O	O
then	ADV	O	O
IV	NUM	O	O
Cy	NOUN	O	O
or	CCONJ	O	O
IV	NUM	O	O
MP	NOUN	O	O
every	DET	O	O
3	NUM	O	O
months	NOUN	O	O
for	ADP	O	O
another	DET	O	O
year	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
was	ADP	O	O
response	NOUN	O	O
to	ADP	O	O
treatment	NOUN	O	B-PHYSICAL
:	PUNCT	O	O
at	VERB	O	O
least	ADV	O	O
20	NUM	O	O
%	SYM	O	B-PHYSICAL
improvement	NOUN	O	I-PHYSICAL
from	ADP	O	I-PHYSICAL
basal	ADJ	O	I-PHYSICAL
conditions	NOUN	O	I-PHYSICAL
on	ADP	O	O
clinical	ADJ	O	O
,	PUNCT	O	O
laboratory	NOUN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
specific	ADJ	O	O
neurological	ADJ	O	O
testing	ADJ	O	O
variables	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Overall	ADJ	O	O
,	PUNCT	O	O
a	DET	O	O
response	NOUN	O	O
rate	NOUN	O	B-PHYSICAL
of	ADP	O	O
75	NUM	O	O
%	SYM	O	O
was	VERB	O	O
observed	VERB	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
32	NUM	O	O
patients	NOUN	O	O
studied	VERB	O	O
,	PUNCT	O	O
18/19	PUNCT	O	O
receiving	DET	O	O
Cy	NOUN	O	O
and	CCONJ	O	O
7/13	NOUN	O	O
receiving	ADP	O	O
MP	NOUN	O	O
responded	VERB	O	O
to	ADP	O	O
treatment	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.03	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Cy	NOUN	O	O
seems	NOUN	O	O
to	DET	O	O
be	PUNCT	O	O
more	ADV	O	O
effective	ADJ	O	O
than	PUNCT	O	O
MP	NOUN	O	O
in	ADP	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
,	PUNCT	O	O
severe	ADJ	O	O
NPSLE	NOUN	O	O
.	PUNCT	O	O

Acute	ADJ	O	O
exposure	NOUN	O	O
to	ADP	O	O
acid	NOUN	O	O
fog	NOUN	O	O
:	PUNCT	O	O
influence	NOUN	O	O
of	ADP	O	O
breathing	PUNCT	O	O
pattern	NOUN	O	O
on	ADP	O	O
effective	ADJ	O	B-PHYSICAL
dose	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Concern	ADJ	O	O
about	ADP	O	O
the	DET	O	O
possible	ADJ	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
health	NOUN	O	I-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
of	ADP	O	O
acid	NOUN	O	O
fog	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
fed	ADJ	O	O
by	ADP	O	O
two	NUM	O	O
observations	NOUN	O	O
:	PUNCT	O	O
air	NOUN	O	O
pollution	NOUN	O	O
disasters	PUNCT	O	O
earlier	PUNCT	O	O
in	ADP	O	O
this	DET	O	O
century	NOUN	O	O
were	VERB	O	O
typically	ADV	O	O
associated	VERB	O	O
with	ADP	O	O
fog	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
current	ADJ	O	O
samples	NOUN	O	O
of	ADP	O	O
fog	NOUN	O	O
water	NOUN	O	O
can	VERB	O	O
be	ADP	O	O
strongly	ADV	O	O
acid	NOUN	O	O
.	PUNCT	O	O

To	ADJ	O	O
study	NOUN	O	O
the	DET	O	O
acute	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
acid	NOUN	O	O
fog	NOUN	O	O
on	ADP	O	O
the	DET	O	O
lung	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
authors	NOUN	O	O
generated	VERB	O	O
a	DET	O	O
monodisperse	ADJ	O	O
10	NUM	O	O
microM	NOUN	O	O
MMAD	NOUN	O	O
aerosol	NOUN	O	O
of	ADP	O	O
H2SO4	NOUN	O	O
with	ADP	O	O
a	DET	O	O
pH	NOUN	O	O
of	ADP	O	O
2.0	NUM	O	O
and	CCONJ	O	O
a	DET	O	O
nominal	ADJ	O	O
concentration	NOUN	O	O
of	ADP	O	O
500	NUM	O	O
micrograms/m3	NUM	O	O
.	PUNCT	O	O

They	PRON	O	O
exposed	ADP	O	O
seven	NUM	O	O
healthy	ADJ	O	O
young	ADJ	O	O
men	NOUN	O	O
on	ADP	O	O
alternate	NOUN	O	O
days	NOUN	O	O
to	ADP	O	O
acid	NOUN	O	O
or	CCONJ	O	O
control	NOUN	O	O
equiosmolar	ADJ	O	O
NaCl	NOUN	O	O
aerosol	NOUN	O	O
during	ADP	O	O
40	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
resting	ADP	O	O
ventilation	NOUN	O	O
and	CCONJ	O	O
20	NUM	O	O
min	NOUN	O	O
of	ADP	O	O
exercise	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
latter	NOUN	O	O
was	VERB	O	O
sufficiently	ADV	O	O
intense	ADJ	O	O
to	PART	O	O
induce	NOUN	O	O
oronasal	ADJ	O	B-PHYSICAL
breathing	VERB	O	I-PHYSICAL
.	PUNCT	O	O

Exposure	NOUN	O	O
was	VERB	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
a	DET	O	O
head	NOUN	O	O
dome	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
head-only	PUNCT	O	O
exposure	NOUN	O	O
device	NOUN	O	O
that	PUNCT	O	O
permitted	ADJ	O	O
continuous	ADJ	O	O
measurement	NOUN	O	O
(	PUNCT	O	O
unfettered	PUNCT	O	O
breathing	VERB	O	O
)	PUNCT	O	O
of	ADP	O	O
Vr	NOUN	O	O
,	PUNCT	O	O
f	NOUN	O	O
,	PUNCT	O	O
VE	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
onset	NOUN	O	O
and	CCONJ	O	O
persistence	NOUN	O	O
of	ADP	O	O
oronasal	ADJ	O	B-PHYSICAL
breathing	VERB	O	I-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
article	NOUN	O	O
the	DET	O	O
authors	NOUN	O	O
compare	VERB	O	O
the	DET	O	O
relative	ADJ	O	O
importance	NOUN	O	O
of	ADP	O	O
parameters	NOUN	O	O
contributing	VERB	O	O
to	ADP	O	O
the	DET	O	O
between-subject	NOUN	O	O
variability	NOUN	O	O
in	ADP	O	O
estimated	VERB	O	O
hydrogen	NOUN	O	O
ion	NOUN	O	O
dose	ADJ	O	O
to	ADP	O	O
the	DET	O	O
lower	PUNCT	O	O
airways	NOUN	O	O
(	PUNCT	O	O
H+LAW	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
analysis	NOUN	O	O
of	ADP	O	O
variance	NOUN	O	O
.	PUNCT	O	O

Physiologic	ADJ	O	O
parameters	NOUN	O	O
accounted	VERB	O	O
for	ADP	O	O
70	NUM	O	O
%	SYM	O	O
of	ADP	O	O
the	DET	O	O
variability	NOUN	O	O
,	PUNCT	O	O
of	ADP	O	O
which	ADP	O	O
34	NUM	O	O
%	SYM	O	O
was	VERB	O	O
due	CCONJ	O	O
to	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
duration	NOUN	O	O
of	ADP	O	O
oronasal	ADJ	O	B-PHYSICAL
breathing	DET	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
tON	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
and	CCONJ	O	O
36	NUM	O	O
%	SYM	O	O
to	ADP	O	O
differences	NOUN	O	O
in	ADP	O	O
ventilation	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
during	ADP	O	I-PHYSICAL
oronasal	ADJ	O	I-PHYSICAL
breathing	DET	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
VE	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
ON	PUNCT	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
;	PUNCT	O	O
inhaled	VERB	O	B-PHYSICAL
hydrogen	NOUN	O	I-PHYSICAL
ion	NOUN	O	I-PHYSICAL
concentration	NOUN	O	O
[	PUNCT	O	B-PHYSICAL
H+	PUNCT	O	I-PHYSICAL

The	DET	O	O
prophylactic	ADJ	O	B-OTHER
effect	NOUN	O	O
of	ADP	O	O
valproate	NOUN	O	O
on	ADP	O	O
glyceryltrinitrate	NOUN	O	B-PHYSICAL
induced	PUNCT	O	I-PHYSICAL
migraine	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
the	DET	O	O
human	NOUN	O	O
glyceryltrinitrate	NOUN	O	O
(	PUNCT	O	O
GTN	NOUN	O	O
)	PUNCT	O	O
model	NOUN	O	O
of	ADP	O	O
migraine	NOUN	O	O
was	VERB	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
time	NOUN	O	O
used	ADV	O	O
to	PART	O	O
test	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
a	DET	O	O
prophylactic	ADJ	O	O
drug	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
chose	PUNCT	O	O
to	PART	O	O
test	NOUN	O	O
valproate	NOUN	O	O
due	CCONJ	O	O
to	ADP	O	O
its	PUNCT	O	O
well	VERB	O	O
documented	CCONJ	O	O
effect	NOUN	O	O
as	ADP	O	O
a	DET	O	O
migraine	NOUN	O	O
prophylactic	ADJ	O	O
drug	NOUN	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
of	ADP	O	O
this	DET	O	O
compound	NOUN	O	O
would	PUNCT	O	O
support	VERB	O	O
the	DET	O	O
usefulness	NOUN	O	O
of	ADP	O	O
the	DET	O	O
model	NOUN	O	O
in	ADP	O	O
prophylactic	ADJ	O	O
antimigraine	ADJ	O	O
drug	NOUN	O	O
development	NOUN	O	O
.	PUNCT	O	O

Twelve	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
migraine	NOUN	O	O
without	ADP	O	O
aura	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
double	PUNCT	O	O
blind	ADJ	O	O
crossover	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

Valproate	NOUN	O	O
1000	NUM	O	O
mg	NOUN	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
daily	ADJ	O	O
,	PUNCT	O	O
each	CCONJ	O	O
for	ADP	O	O
a	DET	O	O
minimum	NOUN	O	O
of	ADP	O	O
13	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
the	DET	O	O
last	ADJ	O	O
treatment	NOUN	O	O
day	NOUN	O	O
of	ADP	O	O
each	DET	O	O
arm	NOUN	O	O
a	DET	O	O
20	NUM	O	O
min	NOUN	O	O
intravenous	ADJ	O	O
infusion	NOUN	O	O
of	ADP	O	O
GTN	NOUN	O	O
(	PUNCT	O	O
0.25	NUM	O	O
microg/kg/min	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
given	VERB	O	O
.	PUNCT	O	O

Headache	NOUN	O	B-ADVERSE-EFFECTS
was	VERB	O	O
registered	PUNCT	O	O
for	ADP	O	O
12	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
the	DET	O	O
infusion	NOUN	O	O
and	CCONJ	O	O
headache	ADJ	O	B-ADVERSE-EFFECTS
intensity	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
scored	VERB	O	O
on	ADP	O	O
a	DET	O	O
scale	NOUN	O	O
from	ADP	O	O
0	NUM	O	O
to	ADP	O	O
10	NUM	O	O
.	PUNCT	O	O

Fulfillment	NOUN	O	O
of	ADP	O	O
IHS	NOUN	O	O
criteria	NOUN	O	O
was	VERB	O	O
recorded	VERB	O	O
for	ADP	O	O
24	NUM	O	O
h.	NOUN	O	O
The	DET	O	O
middle	ADJ	O	B-PHYSICAL
cerebral	ADJ	O	I-PHYSICAL
arteries	NOUN	O	I-PHYSICAL
were	VERB	O	O
evaluated	VERB	O	O
by	ADP	O	O
transcranial	ADJ	O	B-PHYSICAL
Doppler	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
diameter	NOUN	O	O
of	ADP	O	O
the	DET	O	O
superficial	ADJ	O	B-PHYSICAL
temporal	ADJ	O	I-PHYSICAL
and	CCONJ	O	O
radial	ADJ	O	B-PHYSICAL
arteries	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
with	ADP	O	O
high	ADJ	O	B-PHYSICAL
frequency	NOUN	O	O
ultrasound	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

GTN	NOUN	O	B-PHYSICAL
evoked	DET	O	I-PHYSICAL
migraine	NOUN	O	B-PAIN
fulfilling	PROPN	O	I-PAIN
IHS	NOUN	O	B-PAIN
criteria	NOUN	O	I-PAIN
1.1	NUM	O	O
in	ADP	O	O
6	NUM	O	O
patients	NOUN	O	O
after	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
2	NUM	O	O
patients	NOUN	O	O
after	ADP	O	O
valproate	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.125	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Including	VERB	O	O
additionally	ADV	O	O
3	NUM	O	O
patients	NOUN	O	O
on	ADP	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
1	NUM	O	O
patient	NOUN	O	O
on	ADP	O	O
valproate	NOUN	O	O
who	PROPN	O	O
felt	PUNCT	O	O
they	ADJ	O	O
had	PUNCT	O	O
suffered	PUNCT	O	O
a	DET	O	O
migraine	NOUN	O	B-ADVERSE-EFFECTS
attack	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
but	CCONJ	O	O
who	ADP	O	O
had	PUNCT	O	O
as	PUNCT	O	O
associated	PUNCT	O	O
symptoms	NOUN	O	O
only	ADV	O	O
photophobia	PUNCT	O	B-PHYSICAL
or	CCONJ	O	O
phonophobia	PUNCT	O	B-PHYSICAL
,	PUNCT	O	O
a	DET	O	O
significant	ADJ	O	O
reduction	NOUN	O	O
in	ADP	O	O
the	DET	O	O
number	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	B-OTHER
with	ADP	O	I-OTHER
induced	VERB	O	B-OTHER
migraine	NOUN	O	B-OTHER
after	ADP	O	O
valproate	NOUN	O	O
was	VERB	O	O
seen	VERB	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.031	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Median	ADJ	O	O
peak	ADJ	O	O
headache	NOUN	O	B-PHYSICAL
intensity	NOUN	O	I-PHYSICAL
was	VERB	O	O
1	NUM	O	O
(	PUNCT	O	O
range	NOUN	O	O
0-9	NUM	O	O
)	PUNCT	O	O
after	ADP	O	O
valproate	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
4.5	DET	O	O
(	PUNCT	O	O
range	NOUN	O	O
0-8	NUM	O	O
)	PUNCT	O	O
after	ADP	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
0.120	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Pretreatment	NOUN	O	O
with	ADP	O	O
valproate	NOUN	O	O
as	PUNCT	O	O
compared	VERB	O	O
to	ADP	O	O
placebo	NOUN	O	O
reduced	VERB	O	O
the	DET	O	O
velocity	NOUN	O	B-PHYSICAL
in	ADP	O	O
both	CCONJ	O	O
middle	ADJ	O	B-OTHER
cerebral	PUNCT	O	I-OTHER

White	ADJ	O	O
coat	NOUN	O	O
effect	NOUN	O	O
detected	ADJ	O	O
using	SYM	O	O
self-monitoring	PUNCT	O	O
of	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
at	ADP	O	O
home	NOUN	O	O
:	PUNCT	O	O
comparison	NOUN	O	O
with	ADP	O	O
ambulatory	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
objective	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
investigate	NOUN	O	O
whether	PUNCT	O	O
home	NOUN	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
HBP	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
a	DET	O	O
reliable	ADJ	O	O
alternative	ADJ	O	O
to	ADP	O	O
ambulatory	PUNCT	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
ABP	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
the	DET	O	O
white	ADJ	O	O
coat	NOUN	O	O
effect	NOUN	O	O
(	PUNCT	O	O
WCE	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Hypertensive	ADJ	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
measure	VERB	O	O
HBP	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
or	CCONJ	O	O
ABP	NOUN	O	O
for	ADP	O	O
24	NUM	O	O
h.	NOUN	O	O
The	DET	O	O
alternative	ADJ	O	O
measurement	NOUN	O	O
was	ADJ	O	O
then	ADV	O	O
performed	VERB	O	O
.	PUNCT	O	O

Clinic	PUNCT	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
CBP	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
in	ADP	O	O
the	DET	O	O
beginning	PUNCT	O	O
and	CCONJ	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
with	ADP	O	O
a	DET	O	O
difference	NOUN	O	O
of	ADP	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
20	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
systolic	ADJ	O	O
or	CCONJ	O	O
>	ADJ	O	O
or	CCONJ	O	O
=	SYM	O	O
10	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
diastolic	ADJ	O	O
BP	NOUN	O	O
between	ADP	O	O
CBP	NOUN	O	O
and	CCONJ	O	O
awake	NOUN	O	O
ABP	NOUN	O	O
or	CCONJ	O	O
CBP	NOUN	O	O
and	CCONJ	O	O
HBP	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
classified	VERB	O	O
as	ADP	O	O
clinic	ADJ	O	O
reactors	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
189	NUM	O	O
patients	NOUN	O	O
completed	NOUN	O	O
the	DET	O	O
study	NOUN	O	O
(	PUNCT	O	O
79	NUM	O	O
on	ADP	O	O
stable	ADJ	O	O
antihypertensive	ADJ	O	O
treatment	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
difference	NOUN	O	O
in	ADP	O	O
the	DET	O	O
magnitude	NOUN	O	O
of	ADP	O	O
WCE	NOUN	O	B-PHYSICAL
assessed	VERB	O	O
using	SYM	O	O
the	DET	O	O
ABP	NOUN	O	B-OTHER
or	CCONJ	O	O
the	DET	O	O
HBP	NOUN	O	B-OTHER
method	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
discrepancy	NOUN	O	O
,	PUNCT	O	O
systolic	ADJ	O	B-PHYSICAL
BP	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
-1.5	NUM	O	O
+/-	SYM	O	O
11.7	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
-3.2	NUM	O	O
,	PUNCT	O	O
0.2	NUM	O	O
;	PUNCT	O	O
diastolic	ADJ	O	B-PHYSICAL
BP	NOUN	O	I-PHYSICAL
:	PUNCT	O	O
0.9	NUM	O	O
+/-	SYM	O	O
7.0	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
CI	NOUN	O	O
-0.1	NUM	O	O
,	PUNCT	O	O
1.9	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
strong	ADJ	O	O
association	NOUN	O	O
existed	VERB	O	O
between	ADP	O	O
WCE	NOUN	O	B-PHYSICAL
calculated	ADV	O	O
using	VERB	O	O
the	DET	O	O
HBP	NOUN	O	B-OTHER
or	CCONJ	O	O
the	DET	O	O
ABP	NOUN	O	B-OTHER
method	NOUN	O	O
(	PUNCT	O	O
r	NOUN	O	O
=	SYM	O	O
0.64/0.59	ADV	O	O
systolic/diastolic	ADJ	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
classified	PUNCT	O	O
as	ADP	O	O
clinic	ADJ	O	B-PHYSICAL
reactors	NOUN	O	I-PHYSICAL
was	VERB	O	O
identical	VERB	O	O
using	VERB	O	O
the	DET	O	O
HBP	NOUN	O	O
or	CCONJ	O	O
the	DET	O	O
ABP	NOUN	O	O
method	NOUN	O	O
(	PUNCT	O	O
25.9	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Agreement	NOUN	O	O
between	ADP	O	O
methods	NOUN	O	O
in	ADP	O	O
the	DET	O	O
classification	NOUN	O	O
of	ADP	O	O
clinic	NOUN	O	O
reactors	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
in	ADP	O	O
147	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
78	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
sensitivity	NOUN	O	O
and	CCONJ	O	O
specificity	NOUN	O	O
of	ADP	O	O
the	DET	O	O
HBP	NOUN	O	O
method	NOUN	O	O
to	PART	O	O
classify	ADJ	O	O
correctly	DET	O	O
clinic	PUNCT	O	O
reactors	NOUN	O	O
(	PUNCT	O	O
ABP	NOUN	O	O
method	NOUN	O	O
used	ADV	O	O
as	ADP	O	O
the	DET	O	O
standard	ADJ	O	O
)	PUNCT	O	O
were	VERB	O	O
57	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
85	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
whereas	ADP	O	O
its	PUNCT	O	O
positive	ADJ	O	O
and	CCONJ	O	O
negative	ADJ	O	O
predictive	ADJ	O	O
value	NOUN	O	O
were	VERB	O	O
57	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
85	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

These	DET	O	O
results	NOUN	O	O
indicate	VERB	O	O
that	ADP	O	O
HBP	NOUN	O	B-OTHER
is	VERB	O	O
not	ADV	O	O
appropriate	ADJ	O	O
as	ADP	O	O
an	DET	O	O
alternative	ADJ	O	O
to	ADP	O	O
ABP	NOUN	O	O
diagnostic	ADJ	O	O
testing	VERB	O	O
in	ADP	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
WCE	NOUN	O	O
.	PUNCT	O	O

Nevertheless	ADV	O	O
,	PUNCT	O	O
HBP	NOUN	O	B-OTHER
appears	NOUN	O	O
useful	ADJ	O	O
as	ADP	O	O
a	DET	O	O
screening	VERB	O	O
test	NOUN	O	O
for	ADP	O	O
the	DET	O	O
detection	NOUN	O	O
of	ADP	O	O
this	DET	O	O
phenomenon	NOUN	O	O
.	PUNCT	O	O

Physostigmine	ADP	O	O
reverses	ADV	O	O
propofol-induced	VERB	O	O
unconsciousness	NOUN	O	O
and	CCONJ	O	O
attenuation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
auditory	ADJ	O	O
steady	ADJ	O	O
state	NOUN	O	O
response	NOUN	O	O
and	CCONJ	O	O
bispectral	ADJ	O	O
index	NOUN	O	O
in	ADP	O	O
human	NOUN	O	O
volunteers	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
It	PRON	O	O
is	VERB	O	O
postulated	ADV	O	O
that	ADP	O	O
alteration	NOUN	O	O
of	ADP	O	O
central	ADJ	O	O
cholinergic	ADJ	O	O
transmission	NOUN	O	O
plays	NOUN	O	O
an	DET	O	O
important	ADJ	O	O
role	NOUN	O	O
in	ADP	O	O
the	DET	O	O
mechanism	NOUN	O	O
by	ADP	O	O
which	DET	O	O
anesthetics	NOUN	O	O
produce	VERB	O	O
unconsciousness	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
authors	NOUN	O	O
investigated	VERB	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
altering	VERB	O	O
central	ADJ	O	O
cholinergic	ADJ	O	O
transmission	NOUN	O	O
,	PUNCT	O	O
by	ADP	O	O
physostigmine	NOUN	O	O
and	CCONJ	O	O
scopolamine	NOUN	O	O
,	PUNCT	O	O
on	ADP	O	O
unconsciousness	NOUN	O	O
produced	VERB	O	O
by	ADP	O	O
propofol	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Propofol	NOUN	O	O
was	VERB	O	O
administered	VERB	O	O
to	ADP	O	O
American	ADJ	O	O
Society	NOUN	O	O
of	ADP	O	O
Anesthesiologists	PROPN	O	O
physical	ADJ	O	O
status	NOUN	O	O
1	NUM	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
17	NUM	O	O
)	PUNCT	O	O
volunteers	NOUN	O	O
with	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
a	DET	O	O
computer-controlled	VERB	O	O
infusion	NOUN	O	O
pump	NOUN	O	O
at	ADP	O	O
increasing	ADJ	O	O
concentrations	NOUN	O	O
until	ADP	O	O
unconsciousness	NOUN	O	O
resulted	VERB	O	O
(	PUNCT	O	O
inability	NOUN	O	O
to	PART	O	O
respond	ADP	O	O
to	ADP	O	O
verbal	ADJ	O	O
commands	NOUN	O	O
,	PUNCT	O	O
abolition	NOUN	O	O
of	ADP	O	O
spontaneous	ADJ	O	O
movement	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Central	ADJ	O	B-PHYSICAL
nervous	ADJ	O	I-PHYSICAL
system	NOUN	O	I-PHYSICAL
function	NOUN	O	I-PHYSICAL
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
use	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Auditory	ADJ	O	B-PHYSICAL
Steady	CCONJ	O	I-PHYSICAL
State	NOUN	O	I-PHYSICAL
Response	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
ASSR	NOUN	O	I-PHYSICAL
)	PUNCT	O	B-PHYSICAL
and	CCONJ	O	O
Bispectral	PUNCT	O	B-PHYSICAL
Index	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
BIS	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
analysis	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
electrooculogram	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

During	ADP	O	O
continuous	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
propofol	NOUN	O	O
,	PUNCT	O	O
reversal	NOUN	O	B-PHYSICAL
of	ADP	O	B-PHYSICAL
unconsciousness	NOUN	O	B-PHYSICAL
produced	VERB	O	O
by	ADP	O	O
physostigmine	NOUN	O	O
(	PUNCT	O	O
28	NUM	O	O
microgram/kg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
block	NOUN	O	O
of	ADP	O	O
this	DET	O	O
reversal	NOUN	O	B-PHYSICAL
by	ADP	O	O
scopolamine	NOUN	O	O
(	PUNCT	O	O
8.6	NUM	O	O
microgram/kg	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Propofol	NOUN	O	O
produced	PUNCT	O	O
unconsciousness	NOUN	O	B-PHYSICAL
at	ADP	O	O
a	DET	O	O
plasma	NOUN	O	O
concentration	NOUN	O	O
of	ADP	O	O
3.2	NUM	O	O
+/-	SYM	O	O
0.8	NUM	O	O
(	PUNCT	O	O
+/-	SYM	O	O
SD	NOUN	O	O
)	PUNCT	O	O
microgram/ml	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
17	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Unconsciousness	NOUN	O	B-PHYSICAL
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
reductions	NOUN	O	O
in	ADP	O	O
ASSR	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
0.10	NUM	O	O
+/-	SYM	O	O
0.08	NUM	O	O
microV	NOUN	O	O
[	PUNCT	O	O
awake	NOUN	O	O
baseline	NOUN	O	O
0.32	NUM	O	O
+/-	SYM	O	O
0.18	NUM	O	O
microV	NOUN	O	O
]	PUNCT	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
BIS	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
55.7	NUM	O	O
+/-	SYM	O	O
8.8	NUM	O	O
[	PUNCT	O	O
awake	NOUN	O	O
baseline	NOUN	O	O
92.4	NUM	O	O
+/-	SYM	O	O
3.9	NUM	O	O
]	PUNCT	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Physostigmine	ADP	O	O
restored	PUNCT	O	B-PHYSICAL
consciousness	NOUN	O	I-PHYSICAL
in	ADP	O	O
9	NUM	O	O
of	ADP	O	O
11	NUM	O	O
subjects	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
concomitant	ADJ	O	O
increases	CCONJ	O	O
in	ADP	O	O
ASSR	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
0.38	NUM	O	O
+/-	SYM	O	O
0.17	NUM	O	O
microV	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
BIS	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
75.3	NUM	O	O
+/-	SYM	O	O
8.3	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
all	DET	O	O
subjects	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
6	NUM	O	O
)	PUNCT	O	O
scopolamine	NOUN	O	O
blocked	VERB	O	O
the	DET	O	O
physostigmine-induced	VERB	O	B-PHYSICAL
reversal	NOUN	O	B-PHYSICAL
of	ADP	O	B-PHYSICAL
unconsciousness	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
increase	NOUN	O	O
of	ADP	O	O
the	PUNCT	O	O

A	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
evaluator-blind	PUNCT	O	O
,	PUNCT	O	O
multicenter	NOUN	O	O
comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
tolerability	NOUN	O	O
of	ADP	O	O
Perlane	NOUN	O	O
versus	CCONJ	O	O
Zyplast	NOUN	O	O
in	ADP	O	O
the	DET	O	O
correction	NOUN	O	O
of	ADP	O	O
nasolabial	ADJ	O	O
folds	PUNCT	O	O
.	PUNCT	O	O

Bovine	ADJ	O	O
collagen	NOUN	O	O
is	VERB	O	O
widely	ADV	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
dermal	ADJ	O	O
filler	ADP	O	O
for	ADP	O	O
facial	ADJ	O	O
soft-tissue	NOUN	O	O
augmentation	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
provides	NOUN	O	O
only	ADV	O	O
temporary	PUNCT	O	O
cosmetic	ADJ	O	O
improvement	NOUN	O	O
.	PUNCT	O	O

Nonanimal	ADJ	O	O
stabilized	ADP	O	O
hyaluronic	ADJ	O	O
acid	NOUN	O	O
has	PUNCT	O	O
reduced	PUNCT	O	O
potential	NOUN	O	O
for	ADP	O	O
immunogenicity	ADJ	O	O
and	CCONJ	O	O
hypersensitivity	NOUN	O	O
and	CCONJ	O	O
may	VERB	O	O
provide	VERB	O	O
a	DET	O	O
more	PUNCT	O	O
durable	ADJ	O	O
aesthetic	ADJ	O	O
result	NOUN	O	O
.	PUNCT	O	O

Sixty-eight	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
prominent	ADJ	O	O
nasolabial	ADJ	O	O
folds	VERB	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
intradermal	ADJ	O	O
treatment	NOUN	O	O
with	ADP	O	O
nonanimal	ADJ	O	O
stabilized	ADP	O	O
hyaluronic	ADJ	O	O
acid	NOUN	O	O
gel	NOUN	O	O
(	PUNCT	O	O
Perlane	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
bovine	ADJ	O	O
collagen	NOUN	O	O
(	PUNCT	O	O
Zyplast	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
contralateral	ADJ	O	O
sides	NOUN	O	O
of	ADP	O	O
the	DET	O	O
face	NOUN	O	O
.	PUNCT	O	O

On	ADP	O	O
achievement	NOUN	O	O
of	ADP	O	O
optimal	ADJ	O	B-PHYSICAL
cosmetic	ADJ	O	I-PHYSICAL
result	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
baseline	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
patients	NOUN	O	O
were	VERB	O	O
followed	VERB	O	O
up	ADJ	O	O
for	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
;	PUNCT	O	O
bilateral	ADJ	O	O
retreatment	ADJ	O	O
with	ADP	O	O
Perlane	NOUN	O	O
was	VERB	O	O
offered	VERB	O	O
at	ADP	O	O
6	NUM	O	O
or	CCONJ	O	O
9	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

Responses	NOUN	O	O
were	VERB	O	O
evaluated	VERB	O	O
at	ADP	O	O
2	NUM	O	O
,	PUNCT	O	O
4	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
9	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
baseline	NOUN	O	O
.	PUNCT	O	O

Investigator-based	VERB	O	B-OTHER
and	CCONJ	O	I-OTHER
patient-based	VERB	O	I-OTHER
ratings	NOUN	O	I-OTHER
indicated	VERB	O	O
that	ADP	O	O
Perlane	NOUN	O	O
was	VERB	O	O
more	ADV	O	O
effective	ADJ	O	O
than	PUNCT	O	O
Zyplast	NOUN	O	O
in	ADP	O	O
maintaining	VERB	O	O
cosmetic	ADJ	O	O
correction	NOUN	O	O
.	PUNCT	O	O

According	CCONJ	O	O
to	ADP	O	O
investigator-based	VERB	O	O
Wrinkle	NOUN	O	O
Severity	NOUN	O	O
Rating	PUNCT	O	O
Scale	NOUN	O	O
assessments	NOUN	O	O
at	ADP	O	O
6	NUM	O	O
and	CCONJ	O	O
9	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
baseline	NOUN	O	O
,	PUNCT	O	O
Perlane	NOUN	O	O
was	VERB	O	O
superior	ADJ	O	B-OTHER
in	ADP	O	O
50.0	NUM	O	O
percent	NOUN	O	O
and	CCONJ	O	O
48.8	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
,	PUNCT	O	O
whereas	CCONJ	O	O
Zyplast	NOUN	O	O
was	VERB	O	O
superior	ADJ	O	B-OTHER
in	ADP	O	O
10.3	NUM	O	O
percent	NOUN	O	O
and	CCONJ	O	O
14.0	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.0004	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Investigator-based	VERB	O	O
Global	PUNCT	O	O
Aesthetic	ADJ	O	O
Improvement	NOUN	O	O
Scale	NOUN	O	O
assessment	NOUN	O	O
at	ADP	O	O
9	NUM	O	O
months	NOUN	O	O
after	ADP	O	O
baseline	NOUN	O	O
indicated	VERB	O	O
that	ADP	O	O
Perlane	NOUN	O	O
was	VERB	O	O
superior	ADJ	O	B-OTHER
in	ADP	O	O
48.8	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
,	PUNCT	O	O
whereas	CCONJ	O	O
Zyplast	NOUN	O	O
was	VERB	O	O
superior	ADJ	O	B-OTHER
in	ADP	O	O
14.0	NUM	O	O
percent	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0025	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Optimal	ADJ	O	B-PHYSICAL
cosmetic	ADJ	O	I-PHYSICAL
result	NOUN	O	I-PHYSICAL
was	VERB	O	O
achieved	VERB	O	O
with	ADP	O	O
a	DET	O	O
smaller	PUNCT	O	O
volume	NOUN	O	O
of	ADP	O	O
Perlane	NOUN	O	O
than	VERB	O	O
Zyplast	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
,	PUNCT	O	O
1.2	NUM	O	O
ml	NOUN	O	O
versus	CCONJ	O	O
2.1	NUM	O	O
ml	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Local	ADJ	O	O
injection-site	NOUN	O	O
reactions	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
redness	PUNCT	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
swelling	VERB	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
pruritus	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
and	CCONJ	O	O
induration	NOUN	O	B-ADVERSE-EFFECTS
)	PUNCT	O	O
were	VERB	O	O
less	ADV	O	O
frequent	ADP	O	O
with	ADP	O	O
Perlane	NOUN	O	O
than	PUNCT	O	O
with	ADP	O	O
Zyplast	NOUN	O	O
.	PUNCT	O	O

Delayed-onset	NOUN	O	O
reactions	NOUN	O	O
were	VERB	O	O
rare	ADJ	O	O
and	CCONJ	O	O
did	PUNCT	O	O
not	ADV	O	O
reoccur	PUNCT	O	O
after	ADP	O	O
Perlane	NOUN	O	O
retreatment	ADJ	O	O
.	PUNCT	O	O

Perlane	NOUN	O	O
has	PUNCT	O	O
acceptable	ADJ	O	O
long-term	NOUN	O	B-OTHER
safety	NOUN	O	I-OTHER
and	CCONJ	O	O
offers	NUM	O	O
a	DET	O	O
longer-lasting	ADV	O	O
aesthetic	ADJ	O	O
improvement	NOUN	O	O
than	PUNCT	O	O
Zyplast	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
aging	ADJ	O	O
motor	NOUN	O	O
system	NOUN	O	O
as	ADP	O	O
a	DET	O	O
model	NOUN	O	O
for	ADP	O	O
plastic	NOUN	O	O
changes	NOUN	O	O
of	ADP	O	O
GABA-mediated	VERB	O	O
intracortical	ADJ	O	O
inhibition	NOUN	O	O
and	CCONJ	O	O
their	ADP	O	O
behavioral	ADJ	O	O
relevance	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
GABAA-mediated	VERB	O	O
intracortical	ADJ	O	O
inhibition	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
to	PART	O	O
underlie	ADP	O	O
plastic	NOUN	O	O
changes	NOUN	O	O
throughout	ADP	O	O
the	DET	O	O
lifespan	CCONJ	O	O
from	ADP	O	O
development	NOUN	O	O
to	ADP	O	O
aging	DET	O	O
,	PUNCT	O	O
here	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
aging	ADJ	O	O
motor	NOUN	O	O
system	NOUN	O	O
was	VERB	O	O
used	VERB	O	O
as	ADP	O	O
a	DET	O	O
model	NOUN	O	O
to	PART	O	O
analyze	NOUN	O	O
the	DET	O	O
interdependence	NOUN	O	O
of	ADP	O	O
plastic	NOUN	O	O
alterations	NOUN	O	O
within	ADP	O	O
the	DET	O	O
inhibitory	ADJ	O	O
motorcortical	ADJ	O	O
network	NOUN	O	O
and	CCONJ	O	O
level	NOUN	O	O
of	ADP	O	O
behavioral	ADJ	O	O
performance	NOUN	O	O
.	PUNCT	O	O

Double-pulse	PUNCT	O	O
transcranial	ADJ	O	O
magnetic	ADJ	O	O
stimulation	NOUN	O	O
(	PUNCT	O	O
dpTMS	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
examine	NOUN	O	O
inhibition	NOUN	O	O
by	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
short-interval	PUNCT	O	O
intracortical	ADJ	O	O
inhibition	NOUN	O	O
(	PUNCT	O	O
SICI	CCONJ	O	O
)	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
contralateral	ADJ	O	O
primary	ADJ	O	O
motor	NOUN	O	O
cortex	NOUN	O	O
in	ADP	O	O
a	DET	O	O
sample	NOUN	O	O
of	ADP	O	O
64	NUM	O	O
healthy	ADJ	O	O
right-handed	VERB	O	O
human	NOUN	O	O
subjects	NOUN	O	O
covering	ADP	O	O
a	DET	O	O
wide	ADJ	O	O
range	NOUN	O	O
of	ADP	O	O
the	DET	O	O
adult	NOUN	O	O
lifespan	NOUN	O	O
(	PUNCT	O	O
age	NOUN	O	O
range	NOUN	O	O
20-88	ADV	O	O
years	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
47.6	NUM	O	O
?	PUNCT	O	O

20.7	NUM	O	O
,	PUNCT	O	O
34	NUM	O	O
female	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

SICI	ADJ	O	O
was	VERB	O	O
evaluated	VERB	O	O
during	ADP	O	O
resting	VERB	O	O
state	NOUN	O	O
and	CCONJ	O	O
in	ADP	O	O
an	DET	O	O
event-related	VERB	O	O
condition	NOUN	O	O
during	ADP	O	O
movement	NOUN	O	O
preparation	NOUN	O	O
in	ADP	O	O
a	DET	O	O
visually	ADV	O	O
triggered	PUNCT	O	O
simple	ADJ	O	O
reaction	NOUN	O	O
time	NOUN	O	O
task	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
a	DET	O	O
subgroup	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
23	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
manual	ADJ	O	O
motor	NOUN	O	B-PHYSICAL
performance	NOUN	O	I-PHYSICAL
was	VERB	O	O
tested	VERB	O	O
with	ADP	O	O
tasks	NOUN	O	O
of	ADP	O	O
graded	VERB	O	O
dexterous	ADJ	O	O
demand	NOUN	O	O
.	PUNCT	O	O

Weak	ADJ	O	O
resting-state	NOUN	O	O
inhibition	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
an	DET	O	O
overall	ADJ	O	O
lower	PUNCT	O	O
manual	ADJ	O	O
motor	NOUN	O	O
performance	NOUN	O	O
.	PUNCT	O	O

Better	PUNCT	O	O
event-related	VERB	O	O
modulation	NOUN	O	O
of	ADP	O	O
inhibition	NOUN	O	O
correlated	VERB	O	O
with	ADP	O	O
better	PUNCT	O	O
performance	NOUN	O	O
in	ADP	O	O
more	PUNCT	O	O
demanding	PUNCT	O	O
tasks	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
which	ADP	O	O
fast	ADJ	O	O
alternating	ADP	O	O
activation	NOUN	O	O
of	ADP	O	O
cortical	ADJ	O	O
representations	NOUN	O	O
are	VERB	O	O
necessary	ADJ	O	O
.	PUNCT	O	O

Declining	PROPN	O	O
resting-state	NOUN	O	O
inhibition	NOUN	O	O
was	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
weakened	VERB	O	O
event-related	VERB	O	O
modulation	NOUN	O	O
of	ADP	O	O
inhibition	NOUN	O	O
.	PUNCT	O	O

Therefore	ADV	O	O
,	PUNCT	O	O
reduced	VERB	O	O
resting-state	NOUN	O	O
inhibition	NOUN	O	O
might	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
a	DET	O	O
subsequent	ADJ	O	O
loss	NOUN	O	O
of	ADP	O	O
modulatory	ADJ	O	O
capacity	NOUN	O	O
,	PUNCT	O	O
possibly	ADV	O	O
reflecting	ADJ	O	O
malfunctioning	DET	O	O
precision	NOUN	O	O
in	ADP	O	O
GABAAergic	ADJ	O	O
neurotransmission	NOUN	O	O
;	PUNCT	O	O
the	DET	O	O
consequence	NOUN	O	O
is	VERB	O	O
an	DET	O	O
inevitable	ADJ	O	O
decline	NOUN	O	O
in	ADP	O	O
motor	NOUN	O	O
function	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
thiopentone/guaifenesin	NOUN	O	O
,	PUNCT	O	O
ketamine/guaifenesin	NOUN	O	O
and	CCONJ	O	O
ketamine/midazolam	NOUN	O	O
for	ADP	O	O
the	DET	O	O
induction	NOUN	O	O
of	ADP	O	O
horses	NOUN	O	O
to	PART	O	O
be	PUNCT	O	O
anaesthetised	VERB	O	O
with	ADP	O	O
isoflurane	NOUN	O	O
.	PUNCT	O	O

Forty-eight	ADJ	O	O
horses	NOUN	O	O
subjected	VERB	O	O
to	ADP	O	O
elective	ADJ	O	O
surgery	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
three	DET	O	O
groups	NOUN	O	O
of	ADP	O	O
16	NUM	O	O
horses	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
premedication	NOUN	O	O
with	ADP	O	O
0.1	NUM	O	O
mg/kg	NOUN	O	O
acepromazine	NOUN	O	O
intramuscularly	ADV	O	O
and	CCONJ	O	O
0.6	NUM	O	O
mg/kg	NOUN	O	O
xylazine	NOUN	O	O
intravenously	ADV	O	O
,	PUNCT	O	O
anaesthesia	NOUN	O	O
was	VERB	O	O
induced	ADP	O	O
either	PUNCT	O	O
with	ADP	O	O
2	NUM	O	O
g	NOUN	O	O
thiopentone	NOUN	O	O
in	ADP	O	O
500	NUM	O	O
ml	NOUN	O	O
of	ADP	O	O
a	DET	O	O
10	NUM	O	O
per	ADP	O	O
cent	ADP	O	O
guaifenesin	NOUN	O	O
solution	NOUN	O	O
,	PUNCT	O	O
given	VERB	O	O
intravenously	ADV	O	O
at	ADP	O	O
a	DET	O	O
dose	NOUN	O	O
of	ADP	O	O
1	NUM	O	O
ml/kg	NUM	O	O
(	PUNCT	O	O
group	NOUN	O	O
TG	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
with	ADP	O	O
100	NUM	O	O
mg/kg	NOUN	O	O
guaifenesin	NOUN	O	O
and	CCONJ	O	O
2.2	NUM	O	O
mg/kg	NOUN	O	O
ketamine	NOUN	O	O
given	ADJ	O	O
intravenously	DET	O	O
(	PUNCT	O	O
group	NOUN	O	O
KG	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
with	ADP	O	O
0.06	NUM	O	O
mg/kg	NOUN	O	O
midazolam	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2.2	NUM	O	O
mg/kg	NOUN	O	O
ketamine	NOUN	O	O
given	ADJ	O	O
intravenously	DET	O	O
(	PUNCT	O	O
group	NOUN	O	O
KM	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Anaesthesia	NOUN	O	B-OTHER
was	VERB	O	O
maintained	VERB	O	O
with	ADP	O	O
isoflurane	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
(	PUNCT	O	B-OTHER
sd	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
end	NOUN	O	I-OTHER
tidal	ADJ	O	I-OTHER
isoflurane	ADJ	O	I-OTHER
concentration	NOUN	O	O
(	PUNCT	O	B-OTHER
per	ADP	O	I-OTHER
cent	NUM	O	I-OTHER
)	PUNCT	O	B-OTHER
needed	ADV	O	O
to	PART	O	O
maintain	ADV	O	O
a	DET	O	O
light	PUNCT	O	B-OTHER
surgical	ADJ	O	I-OTHER
anaesthesia	NOUN	O	I-OTHER
(	PUNCT	O	O
stage	NOUN	O	O
III	NUM	O	O
,	PUNCT	O	O
plane	NOUN	O	O
2	NUM	O	O
)	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
KM	NOUN	O	O
(	PUNCT	O	O
0.91	NUM	O	O
[	PUNCT	O	O
0.03	ADP	O	O
]	PUNCT	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
groups	NOUN	O	O
TG	NOUN	O	O
(	PUNCT	O	O
1.11	NUM	O	O
[	PUNCT	O	O
0.03	ADP	O	O
]	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
KG	NOUN	O	O
(	PUNCT	O	O
1.14	NUM	O	O
[	PUNCT	O	O
0.03	ADP	O	O
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
(	PUNCT	O	B-PHYSICAL
sd	NOUN	O	I-PHYSICAL
)	PUNCT	O	B-PHYSICAL
arterial	ADJ	O	I-PHYSICAL
pressure	NOUN	O	B-PHYSICAL
(	PUNCT	O	I-PHYSICAL
mmHg	NOUN	O	I-PHYSICAL
)	PUNCT	O	B-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
group	NOUN	O	O
KG	NOUN	O	O
(	PUNCT	O	O
67.4	NUM	O	O
[	PUNCT	O	O
2.07	ADP	O	O
]	PUNCT	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
groups	NOUN	O	O
TC	NOUN	O	O
(	PUNCT	O	O
75.6	NUM	O	O
[	PUNCT	O	O
2.23	NUM	O	O
]	PUNCT	O	O
)	PUNCT	O	O
and	CCONJ	O	O
KM	NOUN	O	O
(	PUNCT	O	O
81.0	NUM	O	O
[	PUNCT	O	O
2.16	ADP	O	O
]	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
the	DET	O	O
logarithm	NOUN	O	O
of	ADP	O	O
the	PUNCT	O	O

Junctional	ADJ	O	B-PHYSICAL
ectopic	ADJ	O	I-PHYSICAL
tachycardia	NOUN	O	I-PHYSICAL
after	ADP	O	O
congenital	ADJ	O	O
heart	NOUN	O	O
surgery	NOUN	O	O
in	ADP	O	O
the	DET	O	O
current	ADJ	O	O
surgical	ADJ	O	O
era	NOUN	O	O
.	PUNCT	O	O

To	PART	O	O
determine	NOUN	O	O
the	DET	O	O
incidence	NOUN	O	O
of	ADP	O	O
postoperative	ADJ	O	B-PHYSICAL
junctional	ADJ	O	I-PHYSICAL
ectopic	ADJ	O	I-PHYSICAL
tachycardia	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
JET	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
in	ADP	O	O
a	DET	O	O
modern	ADJ	O	O
cohort	NOUN	O	O
of	ADP	O	O
pediatric	ADJ	O	O
patients	NOUN	O	O
,	PUNCT	O	O
evaluate	ADP	O	O
possible	ADJ	O	O
risk	NOUN	O	O
factors	NOUN	O	B-PHYSICAL
for	ADP	O	I-PHYSICAL
JET	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
examine	VERB	O	O
the	DET	O	O
effects	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
JET	NOUN	O	I-PHYSICAL
on	ADP	O	O
postoperative	ADJ	O	B-PHYSICAL
morbidity	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
mortality	NOUN	O	B-MORTALITY
.	PUNCT	O	O

JET	NOUN	O	O
is	ADJ	O	O
common	ADJ	O	O
after	ADP	O	O
congenital	ADJ	O	O
heart	NOUN	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

JET-related	VERB	O	O
mortality	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
a	DET	O	O
rare	ADJ	O	O
event	NOUN	O	O
at	ADP	O	O
our	PUNCT	O	O
center	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
is	VERB	O	O
different	ADJ	O	O
from	ADP	O	O
previous	ADJ	O	O
reports	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
reviewed	VERB	O	O
records	NOUN	O	O
for	ADP	O	O
pediatric	ADJ	O	O
patients	NOUN	O	O
who	ADP	O	O
had	PUNCT	O	O
postoperative	ADJ	O	O
arrhythmias	NOUN	O	O
between	ADP	O	O
January	NOUN	O	O
2006	NUM	O	O
and	CCONJ	O	O
June	NOUN	O	O
2010	NUM	O	O
at	ADP	O	O
a	DET	O	O
large	ADJ	O	O
tertiary-care	PUNCT	O	O
children	NOUN	O	O
's	PUNCT	O	O
hospital	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
performed	VERB	O	O
a	DET	O	O
matched	VERB	O	O
case-control	NOUN	O	O
study	ADP	O	O
to	PART	O	O
identify	NOUN	O	O
risk	NOUN	O	O
factors	NOUN	O	O
for	ADP	O	O
JET	NOUN	O	O
and	CCONJ	O	O
a	DET	O	O
matched-cohort	ADJ	O	O
study	NOUN	O	O
to	PART	O	O
compare	NOUN	O	O
outcomes	NOUN	O	O
between	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
controls	NOUN	O	O
.	PUNCT	O	O

Whenever	NOUN	O	O
possible	ADJ	O	O
,	PUNCT	O	O
each	DET	O	O
JET	NOUN	O	O
case	NOUN	O	O
was	VERB	O	O
randomly	ADV	O	O
matched	VERB	O	O
to	ADP	O	O
two	ADJ	O	O
controls	NOUN	O	O
on	ADP	O	O
the	DET	O	O
basis	NOUN	O	O
of	ADP	O	O
lesion	NOUN	O	O
,	PUNCT	O	O
repair	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
surgical	ADJ	O	O
period	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
identified	VERB	O	O
54	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
JET	NOUN	O	O
(	PUNCT	O	O
incidence	NOUN	O	O
=	SYM	O	O
1.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

After	ADP	O	O
multivariate	PUNCT	O	O
logistic	ADJ	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
low	ADJ	O	B-PHYSICAL
operative	ADJ	O	I-PHYSICAL
weight	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
cardiopulmonary	ADJ	O	B-PHYSICAL
bypass	NOUN	O	I-PHYSICAL
(	PUNCT	O	I-PHYSICAL
CPB	NOUN	O	I-PHYSICAL
)	PUNCT	O	I-PHYSICAL
duration	NOUN	O	I-PHYSICAL
>	SYM	O	O
100	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
immediate	ADJ	O	B-PHYSICAL
postoperative	ADJ	O	I-PHYSICAL
serum	NOUN	O	I-PHYSICAL
lactic	ADJ	O	I-PHYSICAL
acid	NOUN	O	I-PHYSICAL
level	NOUN	O	I-PHYSICAL
>	SYM	O	O
20	NUM	O	O
mg/dl	NOUN	O	O
were	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
increased	VERB	O	O
odds	NOUN	O	O
of	ADP	O	O
developing	ADJ	O	O
JET	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
JET	NOUN	O	O
had	PUNCT	O	O
longer	PUNCT	O	O
mechanical	ADJ	O	B-PHYSICAL
ventilation	NOUN	O	I-PHYSICAL
time	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
cardiac	ADJ	O	B-OTHER
intensive	ADJ	O	I-OTHER
care	NOUN	O	I-OTHER
unit	NOUN	O	I-OTHER
(	PUNCT	O	I-OTHER
CICU	NOUN	O	I-OTHER
)	PUNCT	O	I-OTHER
stay	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
hospital	NOUN	O	B-OTHER
stay	NOUN	O	I-OTHER
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
only	ADV	O	O
one	NUM	O	O
death	NOUN	O	B-MORTALITY
in	ADP	O	O
JET	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
1.8	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
with	ADP	O	O
no	DET	O	O
significant	ADJ	O	O
difference	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

JET	NOUN	O	O
remains	NOUN	O	O
a	DET	O	O
relatively	ADV	O	O
common	ADJ	O	O
postoperative	ADJ	O	B-PHYSICAL
arrhythmia	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
but	CCONJ	O	O
it	PRON	O	O
is	VERB	O	O
less	ADV	O	O
frequent	ADP	O	O
than	PUNCT	O	O
previously	ADV	O	O
reported	VERB	O	O
.	PUNCT	O	O

JET	NOUN	O	O
occurs	NOUN	O	O
more	ADV	O	O
commonly	ADV	O	O
in	ADP	O	O
smaller	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
longer	PUNCT	O	O
CPB	NOUN	O	O
runs	NOUN	O	O
and	CCONJ	O	O
significant	ADJ	O	O
postoperative	ADJ	O	B-PHYSICAL
lactic	ADJ	O	I-PHYSICAL
acidosis	NOUN	O	I-PHYSICAL
levels	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Mortality	NOUN	O	B-MORTALITY
associated	VERB	O	O
with	ADP	O	O
JET	NOUN	O	O
is	VERB	O	O
lower	VERB	O	O
than	PUNCT	O	O
historically	ADV	O	O
reported	ADP	O	O
,	PUNCT	O	O
but	CCONJ	O	O
morbidity	NOUN	O	B-PHYSICAL
remains	NOUN	O	O
high	ADJ	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Long	ADJ	O	O
term	NOUN	O	O
observation	NOUN	O	O
in	ADP	O	O
effects	NOUN	O	O
of	ADP	O	O
potassium	NOUN	O	O
and	CCONJ	O	O
calcium	NOUN	O	O
supplementation	NOUN	O	O
on	ADP	O	O
arterial	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
sodium	NOUN	O	B-PHYSICAL
metabolism	NOUN	O	I-PHYSICAL
in	ADP	O	O
adolescents	NOUN	O	O
with	ADP	O	O
higher	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
investigate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
potassium	NOUN	O	O
and	CCONJ	O	O
calcium	NOUN	O	O
supplementation	NOUN	O	O
in	ADP	O	O
table	ADJ	O	O
salt	NOUN	O	O
on	ADP	O	O
reduction	NOUN	O	O
of	ADP	O	O
arterial	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
sodium	NOUN	O	B-PHYSICAL
metabolism	NOUN	O	I-PHYSICAL
in	ADP	O	O
adolescents	NOUN	O	O
with	ADP	O	O
higher	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
A	PUNCT	O	O
single	ADJ	O	O
blind	ADJ	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
was	VERB	O	O
carried	VERB	O	O
out	ADP	O	O
for	ADP	O	O
two	NUM	O	O
years	NOUN	O	O
in	ADP	O	O
220	NUM	O	O
adolescents	NOUN	O	O
with	ADP	O	O
higher	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
aged	PUNCT	O	O
18	NUM	O	O
-	PUNCT	O	O
22	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
who	ADP	O	O
were	VERB	O	O
randomly	ADV	O	O
divided	VERB	O	O
into	ADP	O	O
supplementary	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
110	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
110	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Each	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
subjects	NOUN	O	O
in	ADP	O	O
the	DET	O	O
supplementary	ADJ	O	O
group	NOUN	O	O
and	CCONJ	O	O
their	ADJ	O	O
family	NOUN	O	O
members	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
10	NUM	O	O
mmol	NOUN	O	O
of	ADP	O	O
potassium	NOUN	O	O
and	CCONJ	O	O
10	NUM	O	O
mmol	NOUN	O	O
of	ADP	O	O
calcium	NOUN	O	O
mixed	PROPN	O	O
in	ADP	O	O
their	PUNCT	O	O
table	PUNCT	O	O
salt	NOUN	O	O
daily	ADJ	O	O
for	ADP	O	O
24	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Night	NOUN	O	B-PHYSICAL
urinary	ADJ	O	I-PHYSICAL
sodium	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
potassium	NOUN	O	B-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
increased	VERB	O	O
(	PUNCT	O	O
urinary	ADJ	O	O
Na	NOUN	O	O
(	PUNCT	O	O
+	ADV	O	O
)	PUNCT	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
;	PUNCT	O	O
urinary	ADJ	O	O
K	NOUN	O	O
(	PUNCT	O	O
+	SYM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
lowered	VERB	O	O
by	ADP	O	O
5.3	NUM	O	O
mm	NOUN	O	O
Hg/1.8	PUNCT	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
in	ADP	O	O
average	CCONJ	O	O
from	ADP	O	O
the	DET	O	O
baseline	NOUN	O	O
in	ADP	O	O
the	DET	O	O
supplementary	ADJ	O	O
group	NOUN	O	O
two	NUM	O	O
years	NOUN	O	O
after	ADP	O	O
potassium	NOUN	O	O
and	CCONJ	O	O
calcium	NOUN	O	O
supplementation	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
that	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
increased	VERB	O	O
by	ADP	O	O
(	PUNCT	O	O
1.3/1.7	NUM	O	O
)	PUNCT	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
Adequate	ADJ	O	O
supplement	NOUN	O	O
of	ADP	O	O
potassium	NOUN	O	O
and	CCONJ	O	O
calcium	NOUN	O	O
in	ADP	O	O
daily	PUNCT	O	O
table	ADJ	O	O
salt	NOUN	O	O
intake	NOUN	O	O
was	VERB	O	O
an	DET	O	O
effective	ADJ	O	O
way	NOUN	O	O
to	PUNCT	O	O
prevent	CCONJ	O	O
form	VERB	O	O
hypertension	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
could	VERB	O	O
promote	VERB	O	O
their	ADP	O	O
urinary	ADJ	O	B-PHYSICAL
sodium	NOUN	O	I-PHYSICAL
excretion	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
reduction	NOUN	O	O
of	ADP	O	O
arterial	ADJ	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
in	ADP	O	O
adolescents	NOUN	O	O
with	ADP	O	O
higher	PUNCT	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
.	PUNCT	O	O

Immunologic	ADJ	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
after	ADP	O	O
laparoscopic	ADJ	O	O
colon	NOUN	O	O
cancer	NOUN	O	O
operation	NOUN	O	O
within	ADP	O	O
an	DET	O	O
enhanced	VERB	O	O
recovery	NOUN	O	O
program	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
It	PRON	O	O
has	PUNCT	O	O
been	PUNCT	O	O
demonstrated	VERB	O	O
that	ADP	O	O
colon	NOUN	O	O
operation	NOUN	O	O
combined	VERB	O	O
with	ADP	O	O
fast-track	NOUN	O	O
(	PUNCT	O	O
FT	NOUN	O	O
)	PUNCT	O	O
surgery	NOUN	O	O
and	CCONJ	O	O
laparoscopic	ADJ	O	O
technique	NOUN	O	O
can	PUNCT	O	O
shorten	VERB	O	O
the	DET	O	O
length	NOUN	O	O
of	ADP	O	B-PHYSICAL
hospital	NOUN	O	I-PHYSICAL
stay	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
accelerate	VERB	O	O
recovery	NOUN	O	B-PHYSICAL
of	ADP	O	B-PHYSICAL
intestinal	ADJ	O	I-PHYSICAL
function	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	O
reduce	VERB	O	O
the	DET	O	O
occurrence	NOUN	O	O
of	ADP	O	O
post-operative	ADJ	O	B-PHYSICAL
complications	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
there	PUNCT	O	O
are	VERB	O	O
no	DET	O	O
reports	NOUN	O	O
regarding	VERB	O	O
the	DET	O	O
combined	VERB	O	O
effects	NOUN	O	O
of	ADP	O	O
FT	NOUN	O	O
colon	NOUN	O	O
operation	NOUN	O	O
and	CCONJ	O	O
laparoscopic	ADJ	O	O
technique	NOUN	O	O
on	ADP	O	O
humoral	ADJ	O	B-PHYSICAL
inflammatory	ADJ	O	I-PHYSICAL
cellular	ADJ	O	I-PHYSICAL
immunity	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

METHODS	NOUN	O	O
This	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
prospective	ADJ	O	O
,	PUNCT	O	O
controlled	ADP	O	O
study	NOUN	O	O
.	PUNCT	O	O

One	NUM	O	O
hundred	NUM	O	O
sixty-three	PUNCT	O	O
colon	NOUN	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
underwent	VERB	O	O
the	DET	O	O
traditional	ADJ	O	O
protocol	NOUN	O	O
and	CCONJ	O	O
open	VERB	O	O
operation	NOUN	O	O
(	PUNCT	O	O
traditional	ADJ	O	O
open	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
n=42	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
traditional	ADJ	O	O
protocol	NOUN	O	O
and	CCONJ	O	O
laparoscopic	ADJ	O	O
operation	NOUN	O	O
(	PUNCT	O	O
traditional	ADJ	O	O
laparoscopic	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
n=40	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
the	DET	O	O
FT	NOUN	O	O
protocol	NOUN	O	O
and	CCONJ	O	O
open	VERB	O	O
operation	NOUN	O	O
(	PUNCT	O	O
FT	NUM	O	O
open	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
n=41	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
FT	NOUN	O	O
protocol	NOUN	O	O
and	CCONJ	O	O
laparoscopic	ADJ	O	O
operation	NOUN	O	O
(	PUNCT	O	O
FT	PUNCT	O	O
laparoscopic	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
n=40	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Blood	NOUN	O	O
samples	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
prior	PUNCT	O	O
to	ADP	O	O
operation	NOUN	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
on	ADP	O	O
days	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
3	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
5	NUM	O	O
after	ADP	O	O
operation	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
number	NOUN	O	O
of	ADP	O	O
lymphocyte	NOUN	O	B-PHYSICAL
subpopulations	NOUN	O	I-PHYSICAL
was	VERB	O	O
determined	VERB	O	O
by	ADP	O	O
flow	NOUN	O	O
cytometry	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
serum	NOUN	O	B-PHYSICAL
interleukin-6	NOUN	O	I-PHYSICAL
and	CCONJ	O	B-PHYSICAL
C-reactive	ADJ	O	I-PHYSICAL
protein	NOUN	O	B-PHYSICAL
levels	NOUN	O	I-PHYSICAL
were	VERB	O	O
measured	VERB	O	O
.	PUNCT	O	O

Post-operative	ADP	O	B-OTHER
hospital	NOUN	O	I-OTHER
stay	NOUN	O	I-OTHER
,	PUNCT	O	O
post-operative	ADP	O	B-PHYSICAL
morbidity	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
readmission	NOUN	O	B-OTHER
rate	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
in-hospital	NOUN	O	B-MORTALITY
mortality	NOUN	O	B-MORTALITY
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Compared	VERB	O	O
with	ADP	O	O
open	ADJ	O	O
operation	NOUN	O	O
,	PUNCT	O	O
laparoscopic	ADJ	O	O
colon	NOUN	O	O
operation	NOUN	O	O
effectively	ADV	O	O
inhibited	VERB	O	O
the	DET	O	O
release	NOUN	O	O
of	ADP	O	O
post-operative	ADJ	O	B-PHYSICAL
inflammatory	ADJ	O	I-PHYSICAL
factors	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
yielded	VERB	O	O
good	ADJ	O	O
protection	NOUN	O	O
via	ADP	O	O
post-operative	ADJ	O	O
cell	NOUN	O	O
immunity	NOUN	O	O
.	PUNCT	O	O

FT	NUM	O	O
surgery	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
better	PUNCT	O	O
protective	ADJ	O	O
role	NOUN	O	O
with	ADP	O	O
respect	NOUN	O	O
to	ADP	O	O
the	DET	O	O
post-operative	ADJ	O	O
immune	ADJ	O	O
system	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
traditional	ADJ	O	O
peri-operative	ADJ	O	O
care	NOUN	O	O
.	PUNCT	O	O

Inflammatory	ADJ	O	B-PHYSICAL
reactions	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
based	VERB	O	O
on	ADP	O	O
interleukin-6	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
C-reactive	ADJ	O	B-PHYSICAL
protein	NOUN	O	I-PHYSICAL
levels	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
were	VERB	O	O
less	ADV	O	O
intense	ADJ	O	O
following	ADP	O	O
FT	NOUN	O	O
laparoscopic	ADJ	O	O
operation	NOUN	O	O
compared	VERB	O	O
to	ADP	O	O
FT	CCONJ	O	O
open	PUNCT	O	O
operation	NOUN	O	O
;	PUNCT	O	O
however	ADV	O	O
,	PUNCT	O	O
there	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
differences	NOUN	O	O
in	ADP	O	O
specific	ADJ	O	B-PHYSICAL
immunity	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
CD3+	NOUN	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
CD4+	NOUN	O	I-PHYSICAL
counts	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
and	CCONJ	O	B-PHYSICAL
the	PUNCT	O	I-PHYSICAL

Randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
oral	ADJ	O	O
sirolimus	NOUN	O	O
for	ADP	O	O
restenosis	NOUN	O	B-PHYSICAL
prevention	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
in-stent	NOUN	O	O
restenosis	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
Oral	ADJ	O	O
Sirolimus	NOUN	O	O
to	ADJ	O	O
Inhibit	PROPN	O	O
Recurrent	ADJ	O	O
In-stent	NOUN	O	O
Stenosis	NOUN	O	O
(	PUNCT	O	O
OSIRIS	NOUN	O	O
)	PUNCT	O	O
trial	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Despite	ADP	O	O
recent	ADJ	O	O
advances	NOUN	O	O
in	ADP	O	O
interventional	ADJ	O	O
cardiology	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
the	DET	O	O
introduction	NOUN	O	O
of	ADP	O	O
drug-eluting	VERB	O	O
stents	NOUN	O	O
for	ADP	O	O
de	PUNCT	O	O
novo	ADJ	O	O
coronary	ADJ	O	O
lesions	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
treatment	NOUN	O	O
of	ADP	O	O
in-stent	NOUN	O	O
restenosis	NOUN	O	O
(	PUNCT	O	O
ISR	PUNCT	O	O
)	PUNCT	O	O
remains	NOUN	O	O
a	DET	O	O
challenging	VERB	O	O
clinical	ADJ	O	O
issue	NOUN	O	O
.	PUNCT	O	O

Given	VERB	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
systemic	ADJ	O	O
sirolimus	NOUN	O	O
administration	NOUN	O	O
to	PUNCT	O	O
prevent	ADJ	O	O
neointimal	ADJ	O	B-PHYSICAL
hyperplasia	NOUN	O	I-PHYSICAL
in	ADP	O	O
animal	NOUN	O	O
models	NOUN	O	O
and	CCONJ	O	O
to	ADP	O	O
halt	PROPN	O	O
and	CCONJ	O	O
even	ADV	O	O
reverse	CCONJ	O	O
the	DET	O	O
progression	NOUN	O	O
of	ADP	O	O
allograft	NOUN	O	O
vasculopathy	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
aim	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
was	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
a	DET	O	O
10-day	NOUN	O	O
oral	ADJ	O	O
sirolimus	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
2	NUM	O	O
different	ADJ	O	O
loading	ADV	O	O
regimens	NOUN	O	O
for	ADP	O	O
the	DET	O	O
prevention	NOUN	O	O
of	ADP	O	O
recurrent	ADJ	O	O
restenosis	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ISR	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
AND	CCONJ	O	O
RESULTS	PROPN	O	O
Three	NUM	O	O
hundred	NUM	O	O
symptomatic	ADJ	O	O
patients	NOUN	O	O
with	ADP	O	O
ISR	PUNCT	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
1	PUNCT	O	O
of	ADP	O	O
3	NUM	O	O
treatment	NOUN	O	O
arms	NOUN	O	O
:	PUNCT	O	O
placebo	NOUN	O	O
or	CCONJ	O	O
usual-dose	NOUN	O	O
or	CCONJ	O	O
high-dose	NOUN	O	O
sirolimus	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
received	VERB	O	O
a	DET	O	O
cumulative	ADJ	O	O
loading	PART	O	O
dose	NOUN	O	O
of	ADP	O	O
0	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
24	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
sirolimus	NOUN	O	O
2	NUM	O	O
days	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
the	DET	O	O
day	NOUN	O	O
of	ADP	O	O
repeat	NOUN	O	O
intervention	NOUN	O	O
followed	VERB	O	O
by	ADP	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
of	ADP	O	O
2	NUM	O	O
mg/d	NOUN	O	O
for	ADP	O	O
7	NUM	O	O
days	NOUN	O	O
.	PUNCT	O	O

Angiographic	ADJ	O	B-PHYSICAL
restenosis	NOUN	O	I-PHYSICAL
at	ADP	O	I-PHYSICAL
6-month	NOUN	O	I-PHYSICAL
angiography	NOUN	O	I-PHYSICAL
was	VERB	O	O
the	DET	O	O
primary	ADJ	O	O
end	NOUN	O	O
point	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Restenosis	NOUN	O	B-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
reduced	VERB	O	O
from	ADP	O	O
42.2	NUM	O	O
%	SYM	O	O
to	ADP	O	O
38.6	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
to	ADP	O	O
22.1	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
usual-dose	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
high-dose	NOUN	O	O
sirolimus	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P=0.005	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Similarly	ADV	O	O
,	PUNCT	O	O
the	DET	O	O
need	NOUN	O	O
for	ADP	O	O
target	NOUN	O	B-OTHER
vessel	NOUN	O	I-OTHER
revascularization	NOUN	O	I-OTHER
was	VERB	O	O
reduced	VERB	O	O
from	ADP	O	O
25.5	NUM	O	O
%	SYM	O	O
to	ADP	O	O
24.2	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
to	ADP	O	O
15.2	NUM	O	O
%	SYM	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
usual-dose	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
high-dose	NOUN	O	O
groups	NOUN	O	O
,	PUNCT	O	O
respectively	ADV	O	O
(	PUNCT	O	O
P=0.08	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
sirolimus	NOUN	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
concentration	NOUN	O	I-PHYSICAL
on	ADP	O	O
the	DET	O	O
day	NOUN	O	O
of	ADP	O	O
the	DET	O	O
procedure	NOUN	O	O
correlated	VERB	O	O
significantly	ADV	O	O
with	ADP	O	O
the	DET	O	O
late	ADJ	O	O
lumen	NOUN	O	O
loss	NOUN	O	O
at	ADP	O	O
follow-up	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
In	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
ISR	PUNCT	O	O
,	PUNCT	O	O
an	DET	O	O
oral	ADJ	O	O
adjunctive	ADJ	O	O
sirolimus	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
an	DET	O	O
intensified	ADP	O	O
loading	PROPN	O	O
regimen	NOUN	O	O
before	ADP	O	O
coronary	ADJ	O	O
intervention	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
a	DET	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
the	DET	O	O
angiographic	ADJ	O	B-PHYSICAL
parameters	NOUN	O	I-PHYSICAL
of	ADP	O	I-PHYSICAL
restenosis	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Step-down	NOUN	O	O
approach	NOUN	O	O
using	VERB	O	O
either	CCONJ	O	O
cyclosporin	NOUN	O	O
A	DET	O	O
or	CCONJ	O	O
methotrexate	ADJ	O	O
as	PUNCT	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
in	ADP	O	O
early	ADJ	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
evaluate	NOUN	O	O
the	DET	O	O
feasibility	NOUN	O	B-OTHER
and	CCONJ	O	O
outcome	NOUN	O	O
of	ADP	O	O
the	DET	O	O
step-down	NOUN	O	O
approach	NOUN	O	O
using	VERB	O	O
either	CCONJ	O	O
cyclosporin	NOUN	O	O
A	DET	O	O
(	PUNCT	O	O
CSA	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
methotrexate	NOUN	O	O
(	PUNCT	O	O
MTX	NOUN	O	O
)	PUNCT	O	O
as	ADP	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
following	VERB	O	O
6	NUM	O	O
months	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
these	DET	O	O
2	NUM	O	O
agents	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
in	ADP	O	O
early	ADJ	O	O
,	PUNCT	O	O
nonerosive	PUNCT	O	O
rheumatoid	ADJ	O	O
arthritis	NOUN	O	O
(	PUNCT	O	O
RA	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
Fifty-seven	PUNCT	O	O
patients	NOUN	O	O
younger	PUNCT	O	O
than	PUNCT	O	O
65	NUM	O	O
years	NOUN	O	O
with	ADP	O	O
early	ADJ	O	O
,	PUNCT	O	O
nonerosive	ADJ	O	O
RA	NOUN	O	O
were	VERB	O	O
first	ADJ	O	O
treated	VERB	O	O
with	ADP	O	O
CSA	NOUN	O	O
and	CCONJ	O	O
MTX	NOUN	O	O
in	ADP	O	O
combination	NOUN	O	O
for	ADP	O	O
6	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
then	ADV	O	O
randomly	ADV	O	O
stepped	PUNCT	O	O
down	ADJ	O	O
to	ADP	O	O
single-agent	PUNCT	O	O
maintenance	NOUN	O	O
treatment	NOUN	O	O
for	ADP	O	O
another	CCONJ	O	O
18	NUM	O	O
months	NOUN	O	O
.	PUNCT	O	O

Safety	NOUN	O	B-OTHER
,	PUNCT	O	O
clinical	ADJ	O	B-OTHER
efficacy	NOUN	O	I-OTHER
,	PUNCT	O	O
survival	NOUN	O	B-OTHER
on	ADP	O	I-OTHER
treatment	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
radiographic	ADJ	O	B-PHYSICAL
progression	NOUN	O	I-PHYSICAL
were	VERB	O	O
evaluated	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
When	ADP	O	O
being	DET	O	O
treated	VERB	O	O
with	ADP	O	O
combination	NOUN	O	O
therapy	NOUN	O	O
,	PUNCT	O	O
7	NUM	O	O
of	ADP	O	O
the	DET	O	O
57	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
12.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
withdrew	PUNCT	O	O
because	PUNCT	O	O
of	ADP	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
remaining	VERB	O	O
50	DET	O	O
patients	NOUN	O	O
,	PUNCT	O	O
42	NUM	O	O
(	PUNCT	O	O
84.0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	ADP	O	O
American	ADJ	O	O
College	NOUN	O	O
of	ADP	O	O
Rheumatology	NOUN	O	O
(	PUNCT	O	O
ACR	NOUN	O	O
)	PUNCT	O	O
20	NUM	O	O
%	SYM	O	O
responders	NOUN	O	O
,	PUNCT	O	O
30	NUM	O	O
(	PUNCT	O	O
60.0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
ACR	NOUN	O	O
50	NUM	O	O
%	SYM	O	O
responders	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
23	NUM	O	O
(	PUNCT	O	O
46.0	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	ADP	O	O
ACR	NOUN	O	O
70	NUM	O	O
%	SYM	O	O
responders	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
month	NOUN	O	O
6	NUM	O	O
,	PUNCT	O	O
22	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	ADP	O	O
CSA	NOUN	O	O
and	CCONJ	O	O
27	NUM	O	O
to	ADP	O	O
MTX	NOUN	O	O
.	PUNCT	O	O

During	ADP	O	O
this	DET	O	O
trial	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
treatment	NOUN	O	O
was	VERB	O	O
discontinued	VERB	O	O
by	ADP	O	O
16	NUM	O	O
patients	NOUN	O	O
taking	ADP	O	O
CSA	NOUN	O	O
(	PUNCT	O	O
mainly	ADV	O	O
because	PUNCT	O	O
of	ADP	O	O
loss	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
by	ADP	O	O
4	NUM	O	O
taking	ADJ	O	O
MTX	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
month	NOUN	O	O
24	NUM	O	O
,	PUNCT	O	O
the	DET	O	O
probability	NOUN	O	O
(	PUNCT	O	O
+/-	ADP	O	O
SEM	NOUN	O	O
)	PUNCT	O	O
of	ADP	O	O
survival	NOUN	O	B-MORTALITY
on	ADP	O	O
treatment	NOUN	O	O
was	VERB	O	O
0.273	NUM	O	O
+/-	SYM	O	O
0.09	NUM	O	O
for	ADP	O	O
CSA	NOUN	O	O
and	CCONJ	O	O
0.852	NUM	O	O
+/-	SYM	O	O
0.07	NUM	O	O
for	ADP	O	O
MTX	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
6	NUM	O	O
CSA	NOUN	O	O
patients	NOUN	O	O
who	PROPN	O	O
completed	PROPN	O	O
the	DET	O	O
trial	NOUN	O	O
,	PUNCT	O	O
4	NUM	O	O
(	PUNCT	O	O
66.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
ACR	NOUN	O	O
20	NUM	O	O
%	SYM	O	O
responders	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
3	NUM	O	O
(	PUNCT	O	O
50	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	ADP	O	O
both	CCONJ	O	O
ACR	NOUN	O	O
50	NUM	O	O
%	SYM	O	O
and	CCONJ	O	O
ACR	NOUN	O	O
70	NUM	O	O
%	SYM	O	O
responders	NOUN	O	O
.	PUNCT	O	O

Of	ADP	O	O
the	DET	O	O
23	NUM	O	O
completers	NOUN	O	O
in	ADP	O	O
the	DET	O	O
MTX	NOUN	O	O
arm	ADP	O	O
,	PUNCT	O	O
21	NUM	O	O
(	PUNCT	O	O
91.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
ACR	NOUN	O	O
20	NUM	O	O
%	SYM	O	O
responders	NOUN	O	O
,	PUNCT	O	O
18	NUM	O	O
(	PUNCT	O	O
78.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	VERB	O	O
ACR	NOUN	O	O
50	NUM	O	O
%	SYM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
10	NUM	O	O
(	PUNCT	O	O
43.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
were	ADP	O	O
ACR	NOUN	O	O
70	NUM	O	O
%	SYM	O	O
responders	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
treatment	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
responsible	ADJ	O	O
for	ADP	O	O
severe	ADJ	O	O
adverse	ADJ	O	B-ADVERSE-EFFECTS
events	NOUN	O	I-ADVERSE-EFFECTS
.	PUNCT	O	O

Radiography	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
slow	ADJ	O	O
progression	NOUN	O	O
in	ADP	O	O
the	DET	O	O
damage	ADV	O	B-PHYSICAL
score	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
number	NOUN	O	O
of	ADP	O	O
eroded	VERB	O	B-PHYSICAL
joints	NOUN	O	I-PHYSICAL
in	ADP	O	O
both	CCONJ	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Stepping	PUNCT	O	O
down	ADJ	O	O
to	ADP	O	O
single	ADJ	O	O
agent	NOUN	O	O
maintenance	NOUN	O	O
therapy	NOUN	O	O
following	VERB	O	O
6	NUM	O	O
months	NOUN	O	O
of	ADP	O	O
combination	NOUN	O	O
treatment	NOUN	O	O
with	ADP	O	O
CSA	NOUN	O	O
and	CCONJ	O	O
MTX	NOUN	O	O
in	ADP	O	O
early	ADJ	O	O
RA	NOUN	O	O
was	VERB	O	O
only	ADV	O	O
successful	ADJ	O	O
with	ADP	O	O
MTX	NOUN	O	O
.	PUNCT	O	O

Because	PUNCT	O	O
this	DET	O	O
treatment	NOUN	O	O
did	VERB	O	O
not	ADV	O	O
prevent	VERB	O	O
some	DET	O	O
radiographic	ADJ	O	B-PHYSICAL
progression	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
other	ADJ	O	O
approaches	NOUN	O	O
(	PUNCT	O	O
e.g.	ADP	O	O
,	PUNCT	O	O
step-up	ADV	O	O
approach	NOUN	O	O
)	PUNCT	O	O
may	VERB	O	O
be	VERB	O	O
more	ADV	O	O
appropriate	ADJ	O	O
in	ADP	O	O
early	ADJ	O	O
RA	NOUN	O	O
.	PUNCT	O	O

Pilot	NOUN	O	O
comparison	NOUN	O	O
between	ADP	O	O
potassium	NOUN	O	O
titanyl	NOUN	O	O
phosphate	NOUN	O	O
laser	NOUN	O	O
and	CCONJ	O	O
bipolar	ADJ	O	O
radiofrequency	NOUN	O	O
in	ADP	O	O
paediatric	ADJ	O	O
tonsillectomy	NOUN	O	O
.	PUNCT	O	O

OBJECTIVES	ADP	O	O
To	PROPN	O	O
compare	NOUN	O	O
the	DET	O	O
advantages	NOUN	O	O
and	CCONJ	O	O
disadvantages	NOUN	O	O
of	ADP	O	O
potassium	NOUN	O	O
titanyl	NOUN	O	O
phosphate	NOUN	O	O
laser	NOUN	O	O
with	ADP	O	O
those	PUNCT	O	O
of	ADP	O	O
bipolar	ADJ	O	O
radiofrequency	NOUN	O	O
techniques	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
paediatric	ADJ	O	O
tonsillectomy	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
Prospective	ADJ	O	O
,	PUNCT	O	O
randomised	DET	O	O
,	PUNCT	O	O
clinical	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

PATIENTS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
From	ADP	O	O
July	NOUN	O	O
2004	NUM	O	O
to	ADP	O	O
April	NOUN	O	O
2006	NUM	O	O
,	PUNCT	O	O
80	NUM	O	O
patients	NOUN	O	O
aged	VERB	O	O
between	ADP	O	O
10	NUM	O	O
and	CCONJ	O	O
15	NUM	O	O
years	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
tonsillectomy	NOUN	O	O
planned	PUNCT	O	O
for	ADP	O	O
chronic	ADJ	O	O
tonsillitis	NOUN	O	O
,	PUNCT	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Children	NOUN	O	O
were	VERB	O	O
prospectively	ADV	O	O
randomised	ADP	O	O
into	ADP	O	O
two	NUM	O	O
equal	ADJ	O	O
groups	NOUN	O	O
:	PUNCT	O	O
potassium	NOUN	O	O
titanyl	NOUN	O	O
phosphate	NOUN	O	O
laser	NOUN	O	O
tonsillectomy	NOUN	O	O
and	CCONJ	O	O
bipolar	ADJ	O	O
radiofrequency	NOUN	O	O
tonsillectomy	NOUN	O	O
.	PUNCT	O	O

Operative	ADJ	O	O
time	NOUN	O	O
and	CCONJ	O	O
intra-operative	ADJ	O	O
blood	NOUN	O	O
loss	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
were	VERB	O	O
scheduled	VERB	O	O
for	ADP	O	O
follow	PUNCT	O	O
up	CCONJ	O	O
during	ADP	O	O
the	DET	O	O
first	ADJ	O	O
,	PUNCT	O	O
second	ADJ	O	O
and	CCONJ	O	O
fourth	ADJ	O	O
post-operative	ADJ	O	O
weeks	NOUN	O	O
.	PUNCT	O	O

They	PRON	O	O
were	VERB	O	O
asked	ADV	O	O
to	PUNCT	O	O
record	PUNCT	O	O
their	PUNCT	O	O
pain	NOUN	O	O
and	CCONJ	O	O
discomfort	NOUN	O	O
on	ADP	O	O
a	DET	O	O
standardised	VERB	O	O
visual	ADJ	O	O
analogue	NOUN	O	O
scale	NOUN	O	O
,	PUNCT	O	O
from	ADP	O	O
zero	NUM	O	O
(	PUNCT	O	O
no	DET	O	O
pain	NOUN	O	O
)	PUNCT	O	O
to	ADP	O	O
10	NUM	O	O
(	PUNCT	O	O
severe	ADJ	O	O
pain	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Post-operative	ADP	O	O
complications	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
recorded	ADP	O	O
and	CCONJ	O	O
managed	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
potassium	NOUN	O	O
titanyl	NOUN	O	O
phosphate	NOUN	O	O
laser	NOUN	O	O
group	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
slightly	ADV	O	O
longer	PUNCT	O	B-OTHER
operative	ADJ	O	I-OTHER
time	NOUN	O	I-OTHER
(	PUNCT	O	O
mean	NOUN	O	O
12	NUM	O	O
minutes	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
the	DET	O	O
bipolar	ADJ	O	O
radiofrequency	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
10	NUM	O	O
minutes	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Intra-operative	PUNCT	O	B-PHYSICAL
blood	NOUN	O	I-PHYSICAL
loss	NOUN	O	I-PHYSICAL
was	VERB	O	O
significantly	ADV	O	O
less	ADV	O	O
in	ADP	O	O
the	DET	O	O
potassium	NOUN	O	O
titanyl	NOUN	O	O
phosphate	NOUN	O	O
laser	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
21	NUM	O	O
cm3	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
bipolar	ADJ	O	O
radiofrequency	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
mean	NOUN	O	O
30	NUM	O	O
cm3	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
first	ADJ	O	O
week	NOUN	O	O
,	PUNCT	O	O
post-operative	ADP	O	B-PAIN
pain	NOUN	O	I-PAIN
scores	NOUN	O	I-PAIN
were	VERB	O	O
less	ADV	O	O
in	ADP	O	O
the	DET	O	O
potassium	NOUN	O	O
titanyl	NOUN	O	O
phosphate	NOUN	O	O
laser	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
bipolar	ADJ	O	O
radiofrequency	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
means	NOUN	O	O
7.5	NUM	O	O
and	CCONJ	O	O
8.5	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
second	ADJ	O	O
week	NOUN	O	O
pain	NOUN	O	B-PAIN
scores	NOUN	O	I-PAIN
increased	VERB	O	O
more	ADV	O	O
in	ADP	O	O
the	DET	O	O
potassium	NOUN	O	O
titanyl	NOUN	O	O
phosphate	NOUN	O	O
laser	NOUN	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
bipolar	ADJ	O	O
radiofrequency	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
means	NOUN	O	O
8.5	NUM	O	O
and	CCONJ	O	O
6	NUM	O	O
,	PUNCT	O	O
respectively	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
fourth	ADJ	O	O
week	NOUN	O	O
,	PUNCT	O	O
both	CCONJ	O	O
groups	NOUN	O	O
showed	VERB	O	O
equal	ADJ	O	O
and	CCONJ	O	O
nearly	ADV	O	O
normal	ADJ	O	O
pain	NOUN	O	B-PAIN
scores	NOUN	O	I-PAIN
.	PUNCT	O	O

No	DET	O	O
case	NOUN	O	O
of	ADP	O	O
reactionary	ADJ	O	B-ADVERSE-EFFECTS
post-tonsillectomy	NOUN	O	I-ADVERSE-EFFECTS
haemorrhage	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
recorded	VERB	O	O
in	ADP	O	O
either	PUNCT	O	O
group	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
one	NUM	O	O
case	NOUN	O	O
of	ADP	O	O
secondary	ADJ	O	B-ADVERSE-EFFECTS
post-tonsillectomy	NOUN	O	I-ADVERSE-EFFECTS
haemorrhage	NOUN	O	I-ADVERSE-EFFECTS
was	VERB	O	O
recorded	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
potassium	NOUN	O	O
titanyl	NOUN	O	O
phosphate	NOUN	O	O
laser	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
2.5	NUM	O	O
per	ADP	O	O
cent	ADP	O	O
)	PUNCT	O	O
,	PUNCT	O	O
managed	ADV	O	O
conservatively	ADV	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
Both	CCONJ	O	O
the	DET	O	O
potassium	NOUN	O	O
titanyl	NOUN	O	O
phosphate	NOUN	O	O
and	CCONJ	O	O
the	DET	O	O
bipolar	ADJ	O	O
radiofrequency	NOUN	O	O
techniques	NOUN	O	O
were	VERB	O	O
safe	ADJ	O	B-OTHER
and	CCONJ	O	O
easy	PUNCT	O	B-OTHER
to	ADP	O	I-OTHER
use	PUNCT	O	I-OTHER
for	ADP	O	O
tonsillectomy	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
reduced	VERB	O	O
operative	ADJ	O	B-OTHER
time	NOUN	O	I-OTHER
,	PUNCT	O	O
blood	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
complication	NOUN	O	B-ADVERSE-EFFECTS
rates	NOUN	O	I-ADVERSE-EFFECTS
and	CCONJ	O	O
better	PUNCT	O	O
post-operative	ADJ	O	O
general	ADJ	O	O
patient	NOUN	O	O
condition	NOUN	O	O
.	PUNCT	O	O

Potassium	NOUN	O	O
titanyl	NOUN	O	O
phosphate	NOUN	O	O
laser	NOUN	O	O
resulted	VERB	O	O
in	ADP	O	O
reduced	VERB	O	O
operative	ADJ	O	B-PHYSICAL
bleeding	VERB	O	I-PHYSICAL
and	CCONJ	O	O
immediate	ADJ	O	B-PAIN
post-operative	ADJ	O	I-PAIN
pain	NOUN	O	I-PAIN
,	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
the	DET	O	O
bipolar	ADJ	O	O
radiofrequency	NOUN	O	O
technique	NOUN	O	O
.	PUNCT	O	O

However	ADV	O	O
,	PUNCT	O	O
potassium	NOUN	O	O
titanyl	NOUN	O	O
phosphate	NOUN	O	O
laser	NOUN	O	O
required	PUNCT	O	O
slightly	ADV	O	O
more	ADV	O	O
operative	ADJ	O	B-OTHER
time	NOUN	O	I-OTHER
and	CCONJ	O	O
caused	VERB	O	O
more	DET	O	O
late	ADJ	O	B-PAIN
post-operative	ADJ	O	I-PAIN
pain	NOUN	O	I-PAIN
than	VERB	O	O
the	DET	O	O
bipolar	ADJ	O	O
radiofrequency	NOUN	O	O
technique	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
low	ADJ	O	O
rate	NOUN	O	O
of	ADP	O	O
recorded	VERB	O	O
complications	NOUN	O	O
showed	VERB	O	O
that	PUNCT	O	O
both	PUNCT	O	O
techniques	NOUN	O	O
cause	DET	O	O
little	DET	O	O
damage	NOUN	O	O
to	ADP	O	O
the	DET	O	O
tonsillar	ADJ	O	O
bed	PUNCT	O	O
during	ADP	O	O
dissection	NOUN	O	O
,	PUNCT	O	O
thus	ADV	O	O
minimising	PUNCT	O	O
complications	NOUN	O	O
.	PUNCT	O	O

Teacher	NOUN	O	O
and	CCONJ	O	O
child	NOUN	O	O
predictors	NOUN	O	O
of	ADP	O	O
achieving	NUM	O	O
IEP	NOUN	O	O
goals	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
is	VERB	O	O
encouraging	VERB	O	O
that	PUNCT	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
show	VERB	O	O
a	DET	O	O
strong	ADJ	O	O
response	NOUN	O	O
to	ADP	O	O
early	ADJ	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
yet	ADV	O	O
more	DET	O	O
research	NOUN	O	O
is	VERB	O	O
needed	VERB	O	O
for	ADP	O	O
understanding	VERB	O	O
the	DET	O	O
variability	NOUN	O	O
in	ADP	O	O
responsiveness	NOUN	O	O
to	ADP	O	O
specialized	ADP	O	O
programs	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
predictor	NOUN	O	O
variables	NOUN	O	O
from	ADP	O	O
47	NUM	O	O
teachers	NOUN	O	O
and	CCONJ	O	O
children	NOUN	O	O
who	PROPN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
the	DET	O	O
COMPASS	NOUN	O	O
intervention	NOUN	O	O
(	PUNCT	O	O
Ruble	PUNCT	O	O
et	CCONJ	O	O
al	NOUN	O	O
.	PUNCT	O	O

in	ADP	O	O
The	DET	O	O
collaborative	ADJ	O	O
model	NOUN	O	O
for	ADP	O	O
promoting	VERB	O	O
competence	NOUN	O	O
and	CCONJ	O	O
success	NOUN	O	O
for	ADP	O	O
students	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
.	PUNCT	O	O

Springer	ADV	O	O
,	PUNCT	O	O
New	ADJ	O	O
York	NOUN	O	O
,	PUNCT	O	O
2012a	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
analyzed	VERB	O	O
.	PUNCT	O	O

Predictors	PROPN	O	O
evaluated	VERB	O	O
against	ADP	O	O
child	NOUN	O	B-OTHER
IEP	NOUN	O	I-OTHER
goal	NOUN	O	I-OTHER
attainment	NOUN	O	I-OTHER
included	ADP	O	O
child	NOUN	O	O
,	PUNCT	O	O
teacher	NOUN	O	O
,	PUNCT	O	O
intervention	NOUN	O	O
practice	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
implementation	NOUN	O	O
practice	NOUN	O	O
variables	NOUN	O	O
based	VERB	O	O
on	ADP	O	O
an	DET	O	O
implementation	NOUN	O	O
science	NOUN	O	O
framework	NOUN	O	O
(	PUNCT	O	O
Dunst	NOUN	O	O
and	CCONJ	O	O
Trivette	ADJ	O	O
in	ADP	O	O
J	NOUN	O	O
Soc	NOUN	O	O
Sci	NOUN	O	O
8:143-148	NOUN	O	O
,	PUNCT	O	O
2012	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Findings	NOUN	O	O
revealed	VERB	O	O
one	NUM	O	O
child	NOUN	O	O
(	PUNCT	O	O
engagement	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
one	NUM	O	O
teacher	NOUN	O	O
(	PUNCT	O	O
exhaustion	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
two	NUM	O	O
intervention	NOUN	O	O
quality	NOUN	O	O
(	PUNCT	O	O
IEP	NOUN	O	O
quality	NOUN	O	O
for	ADP	O	O
targeted	VERB	O	O
and	CCONJ	O	O
not	ADV	O	O
targeted	VERB	O	O
elements	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
no	DET	O	O
implementation	NOUN	O	O
quality	NOUN	O	O
variables	NOUN	O	O
accounted	VERB	O	O
for	ADP	O	O
variance	NOUN	O	O
in	ADP	O	O
child	NOUN	O	O
outcomes	NOUN	O	O
when	ADP	O	O
analyzed	VERB	O	O
separately	ADV	O	O
.	PUNCT	O	O

When	ADP	O	O
the	DET	O	O
four	ADV	O	O
significant	ADJ	O	O
variables	NOUN	O	O
were	VERB	O	O
compared	VERB	O	O
against	ADP	O	O
each	ADP	O	O
other	PUNCT	O	O
in	ADP	O	O
a	DET	O	O
single	ADJ	O	O
regression	NOUN	O	O
analysis	NOUN	O	O
,	PUNCT	O	O
IEP	NOUN	O	O
quality	NOUN	O	O
accounted	VERB	O	O
for	ADP	O	O
one	NUM	O	O
quarter	NOUN	O	O
of	ADP	O	O
the	DET	O	O
variance	NOUN	O	O
in	ADP	O	O
child	NOUN	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
comparison	NOUN	O	O
of	ADP	O	O
intermittent	ADJ	O	O
vaginal	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	O
with	ADP	O	O
continuous	ADJ	O	O
dinoprostone	NUM	O	O
for	ADP	O	O
cervical	ADJ	O	B-PHYSICAL
ripening	PROPN	O	I-PHYSICAL
and	CCONJ	O	O
labor	NOUN	O	B-PHYSICAL
induction	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
Our	PUNCT	O	O
purpose	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
effect	NOUN	O	O
of	ADP	O	O
vaginal	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	O
(	PUNCT	O	O
Cytotec	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
dinoprostone	NUM	O	O
(	PUNCT	O	O
Cervidil	PUNCT	O	O
)	PUNCT	O	O
on	ADP	O	O
cervical	ADJ	O	B-PHYSICAL
ripening	PROPN	O	I-PHYSICAL
and	CCONJ	O	O
labor	NOUN	O	B-PHYSICAL
induction	NOUN	O	O
.	PUNCT	O	O

STUDY	NOUN	O	O
DESIGN	NOUN	O	O
Two	NUM	O	O
hundred	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
indications	NOUN	O	O
for	ADP	O	O
induction	NOUN	O	O
of	ADP	O	O
labor	NOUN	O	O
and	CCONJ	O	O
unfavorable	ADJ	O	O
cervical	ADJ	O	O
examinations	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	ADV	O	O
vaginally	ADV	O	O
administered	VERB	O	O
misoprostol	NOUN	O	O
(	PUNCT	O	O
prostaglandin	NOUN	O	O
E1	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
the	DET	O	O
dinoprostone	NUM	O	O
(	PUNCT	O	O
prostaglandin	NOUN	O	O
E2	NOUN	O	O
)	PUNCT	O	O
vaginal	ADJ	O	O
insert	PUNCT	O	O
.	PUNCT	O	O

Twenty-five	PUNCT	O	O
microgram	NOUN	O	O
tablets	NOUN	O	O
of	ADP	O	O
misoprostol	NOUN	O	O
were	VERB	O	O
placed	VERB	O	O
in	ADP	O	O
the	DET	O	O
posterior	ADJ	O	O
vaginal	ADJ	O	O
fornix	PUNCT	O	O
every	DET	O	O
4	NUM	O	O
hours	NOUN	O	O
for	ADP	O	O
a	DET	O	O
maximum	NOUN	O	O
of	ADP	O	O
six	NUM	O	O
doses	NOUN	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
misoprostol	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
given	VERB	O	O
after	ADP	O	O
either	CCONJ	O	O
spontaneous	ADJ	O	O
rupture	NOUN	O	O
of	ADP	O	O
membranes	NOUN	O	O
,	PUNCT	O	O
adequate	PUNCT	O	O
cervical	ADJ	O	O
ripening	PROPN	O	O
(	PUNCT	O	O
Bishop	ADJ	O	O
score	NOUN	O	O
of	ADP	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
8	NUM	O	O
or	CCONJ	O	O
cervical	ADJ	O	O
dilatation	NOUN	O	O
of	ADP	O	O
>	PROPN	O	O
or	CCONJ	O	O
=	SYM	O	O
3	NUM	O	O
cm	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
or	CCONJ	O	O
beginning	PUNCT	O	O
of	ADP	O	O
active	ADJ	O	O
labor	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
vaginal	ADJ	O	O
insert	PUNCT	O	O
,	PUNCT	O	O
Cervidil	PUNCT	O	O
,	PUNCT	O	O
containing	VERB	O	O
10	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
dinoprostone	NUM	O	O
in	ADP	O	O
a	DET	O	O
timed-release	NOUN	O	O
preparation	NOUN	O	O
was	VERB	O	O
placed	VERB	O	O
in	ADP	O	O
the	DET	O	O
posterior	ADJ	O	O
vaginal	ADJ	O	O
formix	PUNCT	O	O
for	ADP	O	O
a	DET	O	O
maximum	NOUN	O	O
period	NOUN	O	O
of	ADP	O	O
24	NUM	O	O
hours	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
vaginal	ADJ	O	O
insert	PUNCT	O	O
was	VERB	O	O
removed	VERB	O	O
for	ADP	O	O
spontaneous	ADJ	O	O
rupture	NOUN	O	O
of	ADP	O	O
membranes	NOUN	O	O
,	PUNCT	O	O
entry	NOUN	O	O
into	ADP	O	O
active	ADJ	O	O
labor	NOUN	O	O
,	PUNCT	O	O
adequate	PUNCT	O	O
cervical	ADJ	O	O
ripening	PROPN	O	O
,	PUNCT	O	O
or	CCONJ	O	O
abnormality	NOUN	O	O
of	ADP	O	O
uterine	ADJ	O	O
contractile	ADJ	O	O
pattern	NOUN	O	O
or	CCONJ	O	O
fetal	ADJ	O	O
cardiac	ADJ	O	O
activity	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
the	DET	O	O
200	NUM	O	O
patients	NOUN	O	O
enrolled	VERB	O	O
,	PUNCT	O	O
99	NUM	O	O
were	VERB	O	O
randomized	ADP	O	O
to	ADP	O	O
misoprostol	NOUN	O	O
and	CCONJ	O	O
101	NUM	O	O
to	ADP	O	O
dinoprostone	NUM	O	O
.	PUNCT	O	O

The	DET	O	O
average	ADJ	O	O
interval	NOUN	O	O
from	ADP	O	O
start	NOUN	O	B-PHYSICAL
of	ADP	O	I-PHYSICAL
induction	NOUN	O	O
to	ADP	O	B-PHYSICAL
vaginal	ADJ	O	I-PHYSICAL
delivery	NOUN	O	B-PHYSICAL
was	VERB	O	O
1	NUM	O	O
hour	NOUN	O	O
shorter	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
misoprostol	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
1296.7	NOUN	O	O
+/-	SYM	O	O
722.1	NUM	O	O
minutes	NOUN	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
dinoprostone	NUM	O	O
group	NOUN	O	O
(	PUNCT	O	O
1360.0	NOUN	O	O
+/-	SYM	O	O
792.0	NUM	O	O
minutes	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
this	DET	O	O
difference	NOUN	O	O
was	VERB	O	O
not	ADV	O	O
statistically	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.97	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Oxytocin	NOUN	O	B-OTHER
augmentation	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
labor	NOUN	O	B-OTHER
was	VERB	O	O
used	VERB	O	O
in	ADP	O	O
50	NUM	O	O
(	PUNCT	O	O
50.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
misoprostol-treated	ADP	O	O
patients	NOUN	O	O
and	CCONJ	O	O
43	NUM	O	O
(	PUNCT	O	O
43.5	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
dinoprostone-treated	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
relative	ADJ	O	O
risk	NOUN	O	O
1.14	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
0.86	NUM	O	O
to	ADP	O	O
1.51	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.35	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
between	ADP	O	O
routes	NOUN	O	B-OTHER
of	ADP	O	I-OTHER
delivery	NOUN	O	I-OTHER
with	ADP	O	O
misoprostol	NOUN	O	O
or	CCONJ	O	O
dinoprostone	NUM	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
,	PUNCT	O	O
38	NUM	O	O
patients	NOUN	O	O
(	PUNCT	O	O
19.3	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
had	DET	O	O
cesarean	NOUN	O	O
deliveries	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
prevalence	NOUN	O	O
of	ADP	O	O
tachysystole	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
six	NUM	O	O
or	CCONJ	O	O
more	DET	O	O
uterine	ADJ	O	O
contractions	NOUN	O	O
in	ADP	O	O
a	DET	O	O
10-minute	ADJ	O	O
window	NOUN	O	O
for	ADP	O	O
two	NUM	O	O
consecutive	ADJ	O	O
10-minute	ADJ	O	O
periods	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
misoprostol	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
7.1	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
dinoprostone	NUM	O	O
group	NOUN	O	O
(	PUNCT	O	O
18.4	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
relative	ADJ	O	O
risk	NOUN	O	O
0.52	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
0.31	NUM	O	O
to	ADP	O	O
0.89	NUM	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
frequency	NOUN	O	O
of	ADP	O	O
uterine	ADJ	O	B-PHYSICAL
hyperstimulation	NOUN	O	I-PHYSICAL
or	CCONJ	O	B-PHYSICAL
hypertonus	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Abnormal	ADJ	O	B-PHYSICAL
fetal	ADJ	O	I-PHYSICAL
heart	NOUN	O	I-PHYSICAL
rate	NOUN	O	I-PHYSICAL
tracings	NOUN	O	I-PHYSICAL
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
23	NUM	O	O
(	PUNCT	O	O
23.2	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
misoprostol-treated	VERB	O	O
patients	NOUN	O	O
and	CCONJ	O	O
35	NUM	O	O
(	PUNCT	O	O
35.7	NUM	O	O
%	SYM	O	O
)	PUNCT	O	O
of	ADP	O	O
dinoprostone-treated	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
relative	ADJ	O	O
risk	NOUN	O	O
0.73	NUM	O	O
,	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
0.52	NUM	O	O
to	ADP	O	O
1.01	PUNCT	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.0546	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

No	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
were	VERB	O	O
found	VERB	O	O
in	ADP	O	O
meconium	NOUN	O	B-PHYSICAL
passage	PUNCT	O	I-PHYSICAL
,	PUNCT	O	O
1-	NUM	O	O
or	CCONJ	O	O
5-minute	PUNCT	O	O
Apgar	NOUN	O	B-PHYSICAL
scores	NOUN	O	I-PHYSICAL
<	SYM	O	O
7	NUM	O	O
,	PUNCT	O	O
neonatal	ADJ	O	B-PHYSICAL
resuscitations	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
or	CCONJ	O	O
admissions	NOUN	O	B-OTHER
to	ADP	O	I-OTHER
the	DET	O	I-OTHER
neonatal	ADJ	O	B-OTHER
intensive	PUNCT	O	I-OTHER

Moderate	ADJ	O	O
sodium	NOUN	O	O
restriction	NOUN	O	O
,	PUNCT	O	O
angiotensin	NOUN	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
inhibition	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
thiazide	NOUN	O	O
diuretic	NOUN	O	O
in	ADP	O	O
the	DET	O	O
management	NOUN	O	O
of	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

Dietary	ADJ	O	O
sodium	NOUN	O	O
restriction	NOUN	O	O
alone	ADJ	O	O
is	CCONJ	O	O
effective	ADJ	O	O
in	ADP	O	O
lowering	VERB	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
in	ADP	O	O
some	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
not	ADV	O	O
all	PUNCT	O	O
,	PUNCT	O	O
patients	NOUN	O	O
with	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

Homeostatic	ADJ	O	O
mechanisms	NOUN	O	O
,	PUNCT	O	O
including	VERB	O	O
activation	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renin-aldosterone	ADJ	O	O
system	NOUN	O	O
,	PUNCT	O	O
may	VERB	O	O
counteract	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
sodium	NOUN	O	O
restriction	NOUN	O	O
.	PUNCT	O	O

Angiotensin	NOUN	O	O
converting	VERB	O	O
enzyme	NOUN	O	O
(	PUNCT	O	O
ACE	NOUN	O	O
)	PUNCT	O	O
inhibitors	NOUN	O	O
are	VERB	O	O
also	ADV	O	O
effective	ADJ	O	O
as	ADP	O	O
sole	ADJ	O	O
therapy	NOUN	O	O
in	ADP	O	O
many	DET	O	O
patients	NOUN	O	O
with	ADP	O	O
essential	ADJ	O	O
hypertension	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
may	VERB	O	O
be	VERB	O	O
less	ADV	O	O
effective	ADJ	O	O
in	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
low-renin	NOUN	O	O
hypertension	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
of	ADP	O	O
dietary	ADJ	O	O
sodium	NOUN	O	O
restriction	NOUN	O	O
with	ADP	O	O
blockade	NOUN	O	O
of	ADP	O	O
the	DET	O	O
renin	NOUN	O	O
system	NOUN	O	O
by	ADP	O	O
an	DET	O	O
ACE	NOUN	O	O
inhibitor	NOUN	O	O
is	VERB	O	O
a	DET	O	O
particularly	ADV	O	O
effective	ADJ	O	O
way	NOUN	O	O
to	PROPN	O	O
improve	PUNCT	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
control	NOUN	O	O
.	PUNCT	O	O

Addition	NOUN	O	O
of	ADP	O	O
a	DET	O	O
thiazide	NOUN	O	O
diuretic	NOUN	O	O
will	ADV	O	O
reduce	VERB	O	O
pressure	NOUN	O	O
further	NOUN	O	O
.	PUNCT	O	O

Parents	NOUN	O	O
'	PUNCT	O	O
state	NOUN	O	O
and	CCONJ	O	O
trait	NOUN	O	O
anxiety	NOUN	O	O
:	PUNCT	O	O
relationships	NOUN	O	O
with	ADP	O	O
anxiety	NOUN	O	B-MENTAL
severity	NOUN	O	I-MENTAL
and	CCONJ	O	O
treatment	NOUN	O	O
response	NOUN	O	O
in	ADP	O	O
adolescents	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
spectrum	NOUN	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

Comorbid	ADJ	O	O
anxiety	NOUN	O	O
is	ADJ	O	O
common	ADJ	O	O
among	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
Autism	NOUN	O	O
Spectrum	NOUN	O	O
Disorder	NOUN	O	O
(	PUNCT	O	O
ASD	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
parents	NOUN	O	O
of	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
are	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
have	PUNCT	O	O
anxiety	NOUN	O	O
disorders	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
investigated	VERB	O	O
the	DET	O	O
relationship	NOUN	O	O
between	ADP	O	O
parents	NOUN	O	O
'	PUNCT	O	O
state	NOUN	O	B-MENTAL
and	CCONJ	O	O
trait	NOUN	O	B-MENTAL
anxiety	NOUN	O	I-MENTAL
and	CCONJ	O	O
parent-reported	ADP	O	O
internalizing	VERB	O	O
and	CCONJ	O	O
externalizing	PUNCT	O	O
symptoms	NOUN	O	O
among	ADP	O	O
adolescents	NOUN	O	O
(	PUNCT	O	O
n	NOUN	O	O
=	SYM	O	O
30	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
ASD	NOUN	O	O
,	PUNCT	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
the	DET	O	O
relationship	NOUN	O	O
of	ADP	O	O
parents	NOUN	O	O
'	PUNCT	O	O
anxiety	NOUN	O	O
symptoms	NOUN	O	O
and	CCONJ	O	O
adolescent	NOUN	O	O
treatment	NOUN	O	O
response	NOUN	O	O
in	ADP	O	O
the	DET	O	O
context	NOUN	O	O
of	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

Parental	ADJ	O	O
state	NOUN	O	O
anxiety	NOUN	O	O
correlated	VERB	O	O
with	ADP	O	O
severity	NOUN	O	O
of	ADP	O	O
adolescent	NOUN	O	O
anxiety	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
trait	NOUN	O	O
anxiety	NOUN	O	O
in	ADP	O	O
parents	NOUN	O	O
correlated	VERB	O	O
with	ADP	O	O
parent-reported	VERB	O	O
adolescent	NOUN	O	O
internalizing	SYM	O	O
and	CCONJ	O	O
externalizing	PUNCT	O	O
symptoms	NOUN	O	O
.	PUNCT	O	O

Also	ADV	O	O
,	PUNCT	O	O
parents	NOUN	O	O
of	ADP	O	O
adolescent	NOUN	O	O
treatment	NOUN	O	O
responders	ADP	O	O
experienced	VERB	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
their	PUNCT	O	O
own	ADJ	O	O
trait	NOUN	O	O
anxiety	NOUN	O	O
.	PUNCT	O	O

Findings	NOUN	O	O
highlight	VERB	O	O
the	DET	O	O
importance	NOUN	O	O
of	ADP	O	O
considering	PUNCT	O	O
parental	ADJ	O	O
anxiety	NOUN	O	O
when	ADP	O	O
targeting	VERB	O	O
anxiety	NOUN	O	O
among	ADP	O	O
youth	NOUN	O	O
with	ADP	O	O
ASD	NOUN	O	O
.	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
the	DET	O	O
in	ADP	O	B-OTHER
vitro	ADJ	O	I-OTHER
and	CCONJ	O	I-OTHER
in	ADP	O	I-OTHER
vivo	ADJ	O	I-OTHER
release	NOUN	O	I-OTHER
of	ADP	O	I-OTHER
digoxin	NOUN	O	B-OTHER
from	ADP	O	O
four	NUM	O	O
different	ADJ	O	O
soft	ADJ	O	O
gelatin	NOUN	O	O
capsule	NOUN	O	O
formulations	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
blinded	VERB	O	O
,	PUNCT	O	O
four-treatment	ADJ	O	O
crossover	NOUN	O	O
study	NOUN	O	O
in	ADP	O	O
16	NUM	O	O
normal	ADJ	O	O
adult	NOUN	O	O
male	NOUN	O	O
volunteers	NOUN	O	O
compared	PUNCT	O	O
plasma	NOUN	O	O
concentrations	NOUN	O	O
and	CCONJ	O	O
urinary	ADJ	O	B-OTHER
excretion	NOUN	O	I-OTHER
of	ADP	O	B-OTHER
digoxin	NOUN	O	I-OTHER
,	PUNCT	O	O
measured	VERB	O	O
by	ADP	O	O
radioimmunoassay	NOUN	O	O
,	PUNCT	O	O
after	ADP	O	O
oral	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
soft	ADJ	O	O
gelatin	NOUN	O	O
capsule	NOUN	O	O
formulations	NOUN	O	O
of	ADP	O	O
digoxin	NOUN	O	O
.	PUNCT	O	O

Four	NUM	O	O
0.4-mg	NOUN	O	O
formulations	NOUN	O	O
with	ADP	O	O
different	ADJ	O	O
in	ADP	O	O
vitro	ADJ	O	O
burst	NOUN	O	O
times	NOUN	O	O
and	CCONJ	O	O
dissolution	NOUN	O	O
rates	NOUN	O	O
were	VERB	O	O
administered	VERB	O	O
,	PUNCT	O	O
with	ADP	O	O
2-week	NOUN	O	O
intervals	NOUN	O	O
between	ADP	O	O
treatments	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
two	NUM	O	O
capsules	NOUN	O	O
with	ADP	O	O
lowest	PUNCT	O	O
in	PUNCT	O	O
vitro	ADJ	O	O
burst	NOUN	O	O
times	NOUN	O	O
(	PUNCT	O	O
2.9	NUM	O	O
and	CCONJ	O	O
16	NUM	O	O
min	NOUN	O	O
)	PUNCT	O	O
gave	VERB	O	O
comparable	ADJ	O	O
in	PUNCT	O	O
vivo	ADJ	O	O
results	CCONJ	O	O
.	PUNCT	O	O

The	DET	O	O
other	ADJ	O	O
two	NUM	O	O
capsules	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
in	PUNCT	O	O
vitro	ADJ	O	O
burst	NOUN	O	O
times	NOUN	O	O
of	ADP	O	O
62	NUM	O	O
and	CCONJ	O	O
229	NUM	O	O
min	NOUN	O	O
,	PUNCT	O	O
produced	DET	O	O
significant	ADJ	O	O
delays	NOUN	O	O
in	ADP	O	O
digoxin	NOUN	O	O
absorption	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
vitro-in	ADJ	O	O
vivo	ADP	O	O
correlations	NOUN	O	O
were	VERB	O	O
obtained	VERB	O	O
by	ADP	O	O
comparing	ADP	O	O
the	DET	O	O
logarithm	NOUN	O	O
of	ADP	O	O
the	DET	O	O
in	PUNCT	O	O
vitro	ADJ	O	O
burst	NOUN	O	O
time	NOUN	O	O
with	ADP	O	O
time	NOUN	O	O
to	ADP	O	O
peak	ADJ	O	O
plasma	NOUN	O	B-OTHER
level	NOUN	O	I-OTHER
and	CCONJ	O	O
the	DET	O	O
time	NOUN	O	O
to	ADP	O	O
the	DET	O	O
first	ADJ	O	O
measurable	PUNCT	O	O

[	PUNCT	O	O
Radiotherapy	NOUN	O	O
of	ADP	O	O
malignant	ADJ	O	O
brain	NOUN	O	O
gliomas	NOUN	O	O
using	VERB	O	O
teniposide	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Efficacy	NOUN	O	O
of	ADP	O	O
radiochemotherapy	NOUN	O	O
of	ADP	O	O
malignantly-converted	VERB	O	O
brain	NOUN	O	O
gliomas	NOUN	O	O
using	SYM	O	O
teniposide	NOUN	O	O
was	VERB	O	O
evaluated	VERB	O	O
in	ADP	O	O
a	DET	O	O
randomized	VERB	O	O
prospective	ADJ	O	O
study	NOUN	O	O
.	PUNCT	O	O

Combined	VERB	O	O
use	NOUN	O	O
of	ADP	O	O
cytostatics	NOUN	O	O
and	CCONJ	O	O
irradiation	NOUN	O	O
appeared	VERB	O	O
safe	ADJ	O	O
,	PUNCT	O	O
tolerable	ADJ	O	O
and	CCONJ	O	O
significantly	ADV	O	O
more	ADV	O	O
effective	ADJ	O	O
than	PUNCT	O	O
radiotherapy	NOUN	O	O
alone	ADJ	O	O
as	PUNCT	O	O
assessed	VERB	O	O
by	ADP	O	O
local	VERB	O	B-PHYSICAL
control	NOUN	O	O
of	ADP	O	B-PHYSICAL
tumor	NOUN	O	B-PHYSICAL
and	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
physical	ADJ	O	O
and	CCONJ	O	O
emotional	ADJ	O	O
status	NOUN	O	O
on	ADP	O	O
adherence	NOUN	O	O
to	ADP	O	O
a	DET	O	O
low-fat	NOUN	O	O
dietary	ADJ	O	O
pattern	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Women	NOUN	O	O
's	PUNCT	O	O
Health	NOUN	O	O
Initiative	NOUN	O	O
.	PUNCT	O	O

OBJECTIVE	NOUN	O	O
To	PROPN	O	O
examine	NOUN	O	O
whether	ADP	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
physical	ADJ	O	O
and	CCONJ	O	O
emotional	ADJ	O	O
status	NOUN	O	O
on	ADP	O	O
adherance	NOUN	O	O
to	ADP	O	O
a	DET	O	O
low-fat	NOUN	O	O
(	PUNCT	O	O
20	NUM	O	O
%	ADV	O	O
energy	NOUN	O	O
)	PUNCT	O	O
dietary	ADJ	O	O
pattern	NOUN	O	O
are	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
participation	NOUN	O	O
in	ADP	O	O
an	DET	O	O
intervention	NOUN	O	O
program	NOUN	O	O
(	PUNCT	O	O
attending	ADJ	O	O
sessions	NOUN	O	O
and	CCONJ	O	O
self-monitoring	PUNCT	O	O
)	PUNCT	O	O
.	PUNCT	O	O

DESIGN	NOUN	O	O
The	DET	O	O
Baron	NOUN	O	O
and	CCONJ	O	O
Kenny	NOUN	O	O
mediator	NOUN	O	O
model	NOUN	O	O
,	PUNCT	O	O
a	DET	O	O
series	NOUN	O	O
of	ADP	O	O
4	NUM	O	O
regression	NOUN	O	O
analyses	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
used	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
whether	ADP	O	O
:	PUNCT	O	O
a	PUNCT	O	O
)	PUNCT	O	O
physical	ADJ	O	O
and	CCONJ	O	O
emotional	ADJ	O	O
status	NOUN	O	O
predicted	ADP	O	O
program	NOUN	O	O
participation	NOUN	O	O
,	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
program	NOUN	O	O
participation	NOUN	O	O
predicted	PUNCT	O	O
dietary	ADJ	O	O
adherence	NOUN	O	O
,	PUNCT	O	O
c	NOUN	O	O
)	PUNCT	O	O
physical	ADJ	O	O
and	CCONJ	O	O
emotional	ADJ	O	O
status	NOUN	O	O
factors	NOUN	O	O
predicted	VERB	O	O
dietary	ADJ	O	O
adherence	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
,	PUNCT	O	O
ultimately	ADV	O	O
d	NOUN	O	O
)	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
physical	ADJ	O	O
and	CCONJ	O	O
emotional	ADJ	O	O
status	NOUN	O	O
on	ADP	O	O
dietary	ADJ	O	O
adherence	NOUN	O	O
were	VERB	O	O
mediated	VERB	O	O
by	ADP	O	O
program	NOUN	O	O
participation	NOUN	O	O
.	PUNCT	O	O

SUBJECTS/SETTING	PUNCT	O	O
Data	NOUN	O	O
from	ADP	O	O
13,277	NUM	O	O
postmenopausal	ADJ	O	O
women	NOUN	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
the	DET	O	O
low-fat	NOUN	O	O
intervention	NOUN	O	O
arm	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Women	NOUN	O	O
's	PUNCT	O	O
Health	NOUN	O	O
Initiative	NOUN	O	O
Dietary	ADJ	O	O
Modification	NOUN	O	O
Trial	NOUN	O	O
.	PUNCT	O	O

INTERVENTION	NOUN	O	O
The	DET	O	O
nutrition	NOUN	O	O
goals	NOUN	O	O
for	ADP	O	O
women	NOUN	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	ADP	O	O
the	DET	O	O
low-fat	NOUN	O	O
intervention	NOUN	O	O
were	VERB	O	O
to	PART	O	O
reduce	NOUN	O	O
total	ADJ	O	O
fat	NOUN	O	O
intake	ADJ	O	O
to	ADP	O	O
20	NUM	O	O
%	SYM	O	O
or	CCONJ	O	O
less	DET	O	O
of	ADP	O	O
energy	NOUN	O	O
from	ADP	O	O
fat	NOUN	O	O
and	CCONJ	O	O
to	VERB	O	O
consume	VERB	O	O
5	NUM	O	O
or	CCONJ	O	O
more	DET	O	O
fruit/vegetable	ADJ	O	O
servings	NOUN	O	O
daily	ADJ	O	O
and	CCONJ	O	O
6	NUM	O	O
or	CCONJ	O	O
more	DET	O	O
grain	NOUN	O	O
servings	NOUN	O	O
daily	ADJ	O	O
.	PUNCT	O	O

MAIN	ADJ	O	O
OUTCOME	NOUN	O	O
MEASURES	NOUN	O	O
Year	ADJ	O	O
1	NUM	O	O
program	NOUN	O	O
participation	NOUN	O	O
(	PUNCT	O	O
degree	NOUN	O	O
of	ADP	O	O
attending	PUNCT	O	O
group	NOUN	O	O
sessions	NOUN	O	O
and	CCONJ	O	O
submitting	VERB	O	O
fat	NOUN	O	O
scores	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
adherence	NOUN	O	B-MENTAL
to	ADP	O	I-MENTAL
the	DET	O	I-MENTAL
low-fat	NOUN	O	I-MENTAL
dietary	ADJ	O	I-MENTAL
pattern	NOUN	O	I-MENTAL
(	PUNCT	O	O
percent	NOUN	O	B-MENTAL
energy	NOUN	O	I-MENTAL
from	ADP	O	I-MENTAL
fat	NOUN	O	I-MENTAL
)	PUNCT	O	O
as	PUNCT	O	O
predicted	VERB	O	O
by	ADP	O	O
baseline	NOUN	O	O
physical	ADJ	O	O
and	CCONJ	O	O
emotional	ADJ	O	O
status	NOUN	O	O
(	PUNCT	O	O
eight	NUM	O	O
SF-36	NOUN	O	O
Health	NOUN	O	O
Survey	NOUN	O	O
subscales	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Participating	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
dietary	ADJ	O	O
intervention	NOUN	O	O
program	NOUN	O	O
reduced	VERB	O	O
(	PUNCT	O	O
mediated	ADP	O	O
)	PUNCT	O	O
the	DET	O	O
negative	ADJ	O	O
effect	NOUN	O	O
of	ADP	O	O
poorer	PUNCT	O	B-MENTAL
mental	ADJ	O	I-MENTAL
health	NOUN	O	I-MENTAL
on	ADP	O	O
dietary	ADJ	O	B-MENTAL
adherence	NOUN	O	I-MENTAL
by	ADP	O	O
15	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

Additional	ADJ	O	O
findings	NOUN	O	O
included	VERB	O	O
that	ADP	O	O
a	DET	O	O
10	NUM	O	O
%	SYM	O	O
increase	NOUN	O	O
in	ADP	O	O
physical	ADJ	O	B-PHYSICAL
functioning	PART	O	I-PHYSICAL
increased	VERB	O	O
session	NOUN	O	B-MENTAL
attendance	NOUN	O	I-MENTAL
by	ADP	O	O
0.4	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
10	NUM	O	O
%	SYM	O	O
increase	NOUN	O	O
in	ADP	O	O
mental	ADJ	O	B-MENTAL
health	NOUN	O	I-MENTAL
predicted	VERB	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
percent	NOUN	O	O
energy	NOUN	O	O
from	ADP	O	O
fat	NOUN	O	O
of	ADP	O	O
0.3	NUM	O	O
%	SYM	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Program	NOUN	O	O
participation	NOUN	O	O
had	PUNCT	O	O
a	DET	O	O
marked	VERB	O	O
effect	NOUN	O	O
on	ADP	O	O
dietary	ADJ	O	B-MENTAL
adherence	NOUN	O	I-MENTAL
:	PUNCT	O	O
a	DET	O	O
10	NUM	O	O
%	SYM	O	O
increase	NOUN	O	O
in	ADP	O	O
session	NOUN	O	B-MENTAL
attendance	NOUN	O	I-MENTAL
predicted	VERB	O	O
a	DET	O	O
1.2	NUM	O	O
%	SYM	O	O
decrease	NOUN	O	O
in	ADP	O	O
percent	NOUN	O	O
energy	NOUN	O	O
from	ADP	O	O
fat	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

APPLICATIONS/CONCLUSIONS	ADJ	O	O
Understanding	PROPN	O	O
and	CCONJ	O	O
using	PUNCT	O	O
instruments	NOUN	O	O
to	PART	O	O
assess	NOUN	O	O
the	DET	O	O
physical	ADJ	O	O
and	CCONJ	O	O
emotional	ADJ	O	O
status	NOUN	O	O
of	ADP	O	O
a	DET	O	O
target	NOUN	O	O
population	NOUN	O	O
will	VERB	O	O
help	VERB	O	O
dietetic	ADJ	O	O
professionals	NOUN	O	O
promote	VERB	O	O
healthful	ADJ	O	O
dietary	ADJ	O	O
change	NOUN	O	O
and	CCONJ	O	O
maintenance	NOUN	O	O
.	PUNCT	O	O

Concurrent	ADJ	O	O
alcohol	NOUN	O	O
dependence	NOUN	O	O
among	ADP	O	O
methadone-maintained	ADJ	O	O
cocaine	NOUN	O	O
abusers	NOUN	O	O
is	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
greater	PUNCT	O	O
abstinence	NOUN	O	B-MENTAL
.	PUNCT	O	O

Concurrent	ADJ	O	O
alcohol	NOUN	O	O
dependence	NOUN	O	O
(	PUNCT	O	O
AD	NOUN	O	O
)	PUNCT	O	O
among	ADP	O	O
polysubstance	NOUN	O	O
abusers	NOUN	O	O
has	PUNCT	O	O
been	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
negative	ADJ	O	O
consequences	NOUN	O	O
,	PUNCT	O	O
although	ADP	O	O
it	PRON	O	O
may	ADP	O	O
not	ADV	O	O
necessarily	ADV	O	O
lead	VERB	O	O
to	ADP	O	O
poor	ADJ	O	O
treatment	NOUN	O	O
outcomes	NOUN	O	O
.	PUNCT	O	O

One	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
most	PUNCT	O	O
efficacious	ADJ	O	O
treatments	NOUN	O	O
for	ADP	O	O
cocaine	NOUN	O	O
abuse	NOUN	O	O
is	VERB	O	O
contingency	NOUN	O	O
management	NOUN	O	O
(	PUNCT	O	O
CM	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
but	CCONJ	O	O
little	DET	O	O
research	NOUN	O	O
has	PUNCT	O	O
explored	VERB	O	O
the	DET	O	O
impact	NOUN	O	O
of	ADP	O	O
AD	NOUN	O	O
on	ADP	O	O
abstinence	PUNCT	O	B-MENTAL
outcomes	NOUN	O	I-MENTAL
,	PUNCT	O	O
particularly	ADV	O	O
among	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
methadone	NOUN	O	O
maintenance	NOUN	O	O
.	PUNCT	O	O

Using	VERB	O	O
data	NOUN	O	O
from	ADP	O	O
three	NUM	O	O
trials	NOUN	O	O
of	ADP	O	O
CM	NOUN	O	O
for	ADP	O	O
cocaine	PUNCT	O	O
use	NOUN	O	O
,	PUNCT	O	O
we	NOUN	O	O
compared	VERB	O	O
baseline	NOUN	O	O
characteristics	NOUN	O	O
and	CCONJ	O	O
posttreatment	ADJ	O	O
and	CCONJ	O	O
follow-up	NOUN	O	O
cocaine	NOUN	O	B-PHYSICAL
outcomes	NOUN	O	I-PHYSICAL
between	ADP	O	O
methadone-maintained	PUNCT	O	O
,	PUNCT	O	O
cocaine-dependent	DET	O	O
patients	NOUN	O	O
(	PUNCT	O	O
N	NOUN	O	O
=	SYM	O	O
193	NUM	O	O
)	PUNCT	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
concurrent	ADJ	O	O
AD	NOUN	O	O
,	PUNCT	O	O
randomized	PUNCT	O	O
to	ADP	O	O
standard	ADJ	O	O
care	NOUN	O	O
(	PUNCT	O	O
SC	NOUN	O	O
)	PUNCT	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
CM	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
with	ADP	O	O
and	CCONJ	O	O
without	ADP	O	O
concurrent	ADJ	O	O
AD	NOUN	O	O
had	PUNCT	O	O
similar	ADJ	O	O
baseline	NOUN	O	O
characteristics	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
the	DET	O	O
exception	NOUN	O	O
that	PUNCT	O	O
AD	NOUN	O	O
patients	NOUN	O	O
reported	VERB	O	O
more	DET	O	O
alcohol	NOUN	O	O
use	NOUN	O	O
.	PUNCT	O	O

AD	NOUN	O	O
patients	NOUN	O	O
achieved	VERB	O	O
longer	PUNCT	O	O
durations	NOUN	O	O
of	ADP	O	O
cocaine	NOUN	O	B-MENTAL
abstinence	NOUN	O	I-MENTAL
and	CCONJ	O	O
were	VERB	O	O
more	ADV	O	O
likely	ADJ	O	O
to	PART	O	O
submit	PUNCT	O	O
a	DET	O	O
cocaine-negative	ADJ	O	B-MENTAL
sample	NOUN	O	I-MENTAL
at	ADP	O	O
follow-up	NOUN	O	O
than	PUNCT	O	O
non-AD	NUM	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
randomized	DET	O	O
to	ADP	O	O
CM	NOUN	O	O
achieved	VERB	O	O
better	CCONJ	O	O
outcomes	NOUN	O	O
than	CCONJ	O	O
those	PUNCT	O	O
randomized	VERB	O	O
to	ADP	O	O
SC	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
no	DET	O	O
interaction	NOUN	O	O
between	ADP	O	O
treatment	NOUN	O	O
condition	NOUN	O	O
and	CCONJ	O	O
AD	NOUN	O	O
status	NOUN	O	O
.	PUNCT	O	O

These	DET	O	O
findings	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
cocaine-using	VERB	O	O
methadone	NOUN	O	O
patients	NOUN	O	O
with	ADP	O	O
AD	NOUN	O	O
achieve	VERB	O	O
greater	PUNCT	O	O
cocaine	NOUN	O	B-MENTAL
abstinence	PUNCT	O	I-MENTAL
than	ADP	O	O
their	CCONJ	O	O
non-AD	NUM	O	O
counterparts	NOUN	O	O
and	CCONJ	O	O
should	ADP	O	O
not	ADV	O	O
necessarily	ADV	O	O
be	ADP	O	O
viewed	VERB	O	O
as	PUNCT	O	O
more	VERB	O	O
difficult	ADJ	O	O
to	DET	O	O
treat	CCONJ	O	O
.	PUNCT	O	O

Co-administration	NOUN	O	O
of	ADP	O	O
pethidine	ADJ	O	O
and	CCONJ	O	O
clonidine	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
spinal	ADJ	O	O
anaesthetic	ADJ	O	O
technique	NOUN	O	O
for	ADP	O	O
total	ADJ	O	O
hip	NOUN	O	O
replacement	NOUN	O	O
.	PUNCT	O	O

Co-administration	NOUN	O	O
of	ADP	O	O
pethidine	ADJ	O	O
0.75	NUM	O	O
mg	NOUN	O	O
kg-1	NOUN	O	O
and	CCONJ	O	O
clonidine	NOUN	O	O
75	NUM	O	O
micrograms	NOUN	O	O
intrathecally	ADV	O	O
provided	PUNCT	O	O
good	ADJ	O	O
intraoperative	ADJ	O	O
anaesthesia	NOUN	O	O
for	ADP	O	O
total	ADJ	O	O
hip	NOUN	O	O
replacement	NOUN	O	O
,	PUNCT	O	O
similar	ADJ	O	O
to	ADP	O	O
that	PUNCT	O	O
obtained	VERB	O	O
using	VERB	O	O
0.5	NUM	O	O
%	ADJ	O	O
isobaric	ADJ	O	O
bupivacaine	NOUN	O	O
.	PUNCT	O	O

Sensory	ADJ	O	O
and	CCONJ	O	O
motor	NOUN	O	O
block	NOUN	O	O
were	DET	O	O
of	ADP	O	O
shorter	PUNCT	O	O
duration	NOUN	O	O
than	ADP	O	O
that	PUNCT	O	O
after	ADP	O	O
0.5	NUM	O	O
%	ADJ	O	O
isobaric	ADJ	O	O
bupivacaine	NOUN	O	O
and	CCONJ	O	O
0.5	NUM	O	O
%	ADJ	O	O
isobaric	ADJ	O	O
bupivacaine	NOUN	O	O
with	ADP	O	O
morphine	NOUN	O	O
0.5	NUM	O	O
mg	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
sensory	ADJ	O	O
block	NOUN	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
motor	NOUN	O	O
block	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Postoperative	ADJ	O	B-OTHER
morphine	NOUN	O	I-OTHER
consumption	NOUN	O	I-OTHER
,	PUNCT	O	O
measured	VERB	O	O
using	SYM	O	O
a	DET	O	O
patient-controlled	VERB	O	O
system	NOUN	O	O
,	PUNCT	O	O
was	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
that	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
bupivacaine	NOUN	O	O
only	PUNCT	O	O
group	NOUN	O	O
(	PUNCT	O	O
pethidine-clonidine	NOUN	O	O
:	PUNCT	O	O
median	ADJ	O	O
39	NUM	O	O
mg/24	NOUN	O	O
h	NOUN	O	O
;	PUNCT	O	O
bupivacaine	NOUN	O	O
:	PUNCT	O	O
median	ADJ	O	O
34	NUM	O	O
mg/24	NOUN	O	O
h	NOUN	O	O
)	PUNCT	O	O
but	CCONJ	O	O
greater	PUNCT	O	O
than	VERB	O	O
that	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
bupivacaine-morphine	ADJ	O	O
group	NOUN	O	O
(	PUNCT	O	O
median	ADJ	O	O
8	NUM	O	O
mg/24	NOUN	O	O
h	NOUN	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Visual	ADJ	O	B-PAIN
analogue	NOUN	O	I-PAIN
pain	NOUN	O	I-PAIN
scores	NOUN	O	O
after	ADP	O	O
operation	NOUN	O	O
were	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
those	PUNCT	O	O
with	ADP	O	O
bupivacaine	NOUN	O	O
alone	ADJ	O	O
at	ADP	O	O
all	ADP	O	O
but	CCONJ	O	O
one	NUM	O	O
of	ADP	O	O
the	DET	O	O
recording	VERB	O	O
times	NOUN	O	O
but	CCONJ	O	O
were	VERB	O	O
greater	PUNCT	O	O
than	VERB	O	O
those	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
bupivacaine	NOUN	O	O
and	CCONJ	O	O
morphine	NOUN	O	O
at	ADP	O	O
4	NUM	O	O
,	PUNCT	O	O
6	NUM	O	O
and	CCONJ	O	O
10	NUM	O	O
h	NOUN	O	O
after	ADP	O	O
operation	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.001	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.04	NUM	O	O
,	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.02	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
combination	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
offer	VERB	O	O
any	DET	O	O
major	ADJ	O	O
advantage	NOUN	O	O
over	ADP	O	O
conventional	ADJ	O	O
agents	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Effect	NOUN	O	O
of	ADP	O	O
liu	NOUN	O	O
wei	CCONJ	O	O
di	NOUN	O	O
huang	NOUN	O	O
or	CCONJ	O	O
jin	NOUN	O	O
gui	NOUN	O	O
shen	NOUN	O	O
qi	CCONJ	O	O
decoction	NOUN	O	O
as	PUNCT	O	O
on	ADP	O	O
adjuvant	NOUN	O	O
treatment	NOUN	O	O
in	ADP	O	O
small	ADJ	O	O
cell	NOUN	O	O
lung	NOUN	O	O
cancer	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

Eighty-three	VERB	O	O
patients	NOUN	O	O
with	ADP	O	O
small	ADJ	O	O
cell	NOUN	O	O
lung	NOUN	O	O
cancer	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
with	ADP	O	O
or	CCONJ	O	O
without	ADP	O	O
using	ADP	O	O
a	DET	O	O
traditional	ADJ	O	O
Chinese	NOUN	O	O
Kidney-tonifying	PUNCT	O	O
decoction	NOUN	O	O
(	PUNCT	O	O
Liu	NOUN	O	O
Wei	CCONJ	O	O
Di	ADP	O	O
Huang	PUNCT	O	O
or	CCONJ	O	O
Jin	NOUN	O	O
Gui	NOUN	O	O
Shen	NOUN	O	O
Qi	NOUN	O	O
medicinal	ADJ	O	O
decoction	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
chemotherapy	NOUN	O	O
or	CCONJ	O	O
radiotherapy	NOUN	O	O
courses	ADP	O	O
.	PUNCT	O	O

74	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
availble	ADJ	O	O
to	PART	O	O
be	PUNCT	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
two	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
were	VERB	O	O
well-matched	ADV	O	O
in	ADP	O	O
age	NOUN	O	O
,	PUNCT	O	O
sex	NOUN	O	O
,	PUNCT	O	O
stage	NOUN	O	O
and	CCONJ	O	O
performance	NOUN	O	O
status	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
difference	NOUN	O	O
in	ADP	O	O
response	NOUN	O	O
rate	NOUN	O	B-PHYSICAL
and	CCONJ	O	O
the	DET	O	O
median	ADJ	O	O
survival	NOUN	O	B-MORTALITY
between	ADP	O	O
two	NUM	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
overall	ADJ	O	B-PHYSICAL
response	NOUN	O	O
rate	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
CR+PR	NOUN	O	O
)	PUNCT	O	O
was	VERB	O	O
91.5	NUM	O	O
%	SYM	O	O
for	ADP	O	O
Chinese	NOUN	O	O
herb	PUNCT	O	O
group	NOUN	O	O
and	CCONJ	O	O
46.9	NUM	O	O
%	SYM	O	O
for	ADP	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	ADP	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
median	ADJ	O	O
survival	NOUN	O	B-MORTALITY
was	ADV	O	O
16	NUM	O	O
months	NOUN	O	O
for	ADP	O	O
the	DET	O	O
traditional	ADJ	O	O
Chinese	NOUN	O	O
Kidney-tonifying	PUNCT	O	O
decoction	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
10	NUM	O	O
months	NOUN	O	O
for	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Survival	NOUN	O	B-MORTALITY
curve	NOUN	O	O
(	PUNCT	O	B-MORTALITY
Kaplan-meire	ADV	O	I-MORTALITY
's	PUNCT	O	O
)	PUNCT	O	B-MORTALITY
of	ADP	O	O
the	DET	O	O
Chinese	NOUN	O	O
herb	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
better	PUNCT	O	O
than	PUNCT	O	O
that	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

10	NUM	O	O
patients	NOUN	O	O
of	ADP	O	O
Chinese	NOUN	O	O
herb	ADJ	O	O
group	NOUN	O	O
was	VERB	O	O
alive	ADJ	O	O
beyond	ADP	O	O
more	ADV	O	O
than	ADP	O	O
2	NUM	O	O
years	NOUN	O	O
.	PUNCT	O	O

Until	ADP	O	O
now	ADV	O	O
,	PUNCT	O	O
4	NUM	O	O
patients	NOUN	O	O
in	ADP	O	O
the	DET	O	O
Chinese	NOUN	O	O
herb	ADJ	O	O
group	NOUN	O	O
,	PUNCT	O	O
one	NUM	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
are	VERB	O	O
still	ADV	O	O
enjoying	PUNCT	O	O
their	PUNCT	O	O

Is	PUNCT	O	O
chronic	ADJ	O	O
sildenafil	NOUN	O	O
therapy	NOUN	O	O
safe	ADJ	O	O
and	CCONJ	O	O
clinically	ADV	O	O
beneficial	ADJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
systolic	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
?	PUNCT	O	O

Sildenafil	NOUN	O	O
is	VERB	O	O
a	DET	O	O
selective	ADJ	O	O
phosphodiesterase-5	NOUN	O	O
inhibitor	NOUN	O	O
and	CCONJ	O	O
causes	PUNCT	O	O
vasodilatation	NOUN	O	O
,	PUNCT	O	O
particularly	ADV	O	O
in	ADP	O	O
pulmonary	ADJ	O	O
circulation	NOUN	O	O
.	PUNCT	O	O

Since	ADP	O	O
left	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
may	VERB	O	O
be	VERB	O	O
associated	VERB	O	O
with	ADP	O	O
pulmonary	ADJ	O	O
hypertension	NOUN	O	O
out	PUNCT	O	O
of	ADP	O	O
proportion	NOUN	O	O
to	ADP	O	O
left	PUNCT	O	O
heart	NOUN	O	O
disease	NOUN	O	O
,	PUNCT	O	O
sildenafil	NOUN	O	O
may	PUNCT	O	O
have	PUNCT	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
in	ADP	O	O
such	DET	O	O
patients	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
present	ADJ	O	O
investigation	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
as	ADP	O	O
a	DET	O	O
12-week	NOUN	O	O
,	PUNCT	O	O
single-center	NOUN	O	O
,	PUNCT	O	O
randomized	VERB	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
study	NOUN	O	O
evaluating	PUNCT	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
sildenafil	NOUN	O	O
on	ADP	O	O
mean	NOUN	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
primary	ADJ	O	O
endpoint	NOUN	O	O
)	PUNCT	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
left	ADJ	O	O
systolic	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
.	PUNCT	O	O

Secondary	ADJ	O	O
endpoints	NOUN	O	O
included	DET	O	O
exercise	NOUN	O	B-PHYSICAL
capacity	NOUN	O	I-PHYSICAL
assessed	VERB	O	O
by	ADP	O	O
6-minute	PUNCT	O	B-PHYSICAL
walk	NOUN	O	I-PHYSICAL
test	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

A	DET	O	O
total	NOUN	O	O
of	ADP	O	O
106	NUM	O	O
patients	NOUN	O	O
were	VERB	O	O
randomized	ADJ	O	O
1:1	NUM	O	O
to	ADP	O	O
sildenafil	NOUN	O	O
(	PUNCT	O	O
n=53	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
(	PUNCT	O	O
n=53	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Patients	NOUN	O	O
received	VERB	O	O
sildenafil	NOUN	O	O
25	NUM	O	O
mg	NOUN	O	O
twice	ADV	O	O
a	DET	O	O
day	NOUN	O	O
or	CCONJ	O	O
matching	PUNCT	O	O
placebo	NOUN	O	O
for	ADP	O	O
the	DET	O	O
first	ADJ	O	O
2	NUM	O	O
weeks	NOUN	O	O
and	CCONJ	O	O
50	NUM	O	O
mg	NOUN	O	O
3	NUM	O	O
times	NOUN	O	O
a	DET	O	O
week	NOUN	O	O
for	ADP	O	O
the	DET	O	O
remainder	NOUN	O	O
of	ADP	O	O
the	DET	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
placebo-corrected	VERB	O	O
effect	NOUN	O	O
on	ADP	O	O
mean	NOUN	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
was	VERB	O	O
1.16	NUM	O	O
mm	NOUN	O	O
Hg	NOUN	O	O
(	PUNCT	O	O
95	NUM	O	O
%	SYM	O	O
confidence	NOUN	O	O
interval	NOUN	O	O
,	PUNCT	O	O
-1.6	VERB	O	O
to	ADP	O	O
5.1	PUNCT	O	O
,	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
,	PUNCT	O	O
demonstrating	VERB	O	O
that	ADP	O	O
sildenafil	NOUN	O	O
did	PUNCT	O	O
not	ADV	O	O
decrease	VERB	O	O
mean	NOUN	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
sildenafil	NOUN	O	O
increased	VERB	O	O
the	DET	O	O
6-minute	PUNCT	O	B-PHYSICAL
walk	NOUN	O	I-PHYSICAL
test	NOUN	O	I-PHYSICAL
by	ADP	O	O
a	DET	O	O
nonsignificant	ADJ	O	O
treatment	NOUN	O	O
effect	NOUN	O	O
of	ADP	O	O
14	NUM	O	O
m	NOUN	O	O
(	PUNCT	O	O
P=.67	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Adverse	ADJ	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
occurred	VERB	O	O
in	ADP	O	O
a	DET	O	O
comparable	ADJ	O	O
proportion	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
taking	ADJ	O	O
sildenafil	NOUN	O	O
and	CCONJ	O	O
placebo	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
none	NUM	O	O
of	ADP	O	O
the	DET	O	O
patients	NOUN	O	O
needed	NUM	O	O
to	ADP	O	O
discontinue	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Sildenafil	NOUN	O	O
is	VERB	O	O
well	ADP	O	O
tolerated	ADP	O	B-OTHER
in	ADP	O	O
left	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
patients	NOUN	O	O
and	CCONJ	O	O
does	PUNCT	O	O
not	ADV	O	O
decrease	NUM	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

It	PRON	O	O
can	VERB	O	O
be	VERB	O	O
safely	ADV	O	O
added	ADP	O	O
to	ADP	O	O
standard	ADJ	O	O
heart	NOUN	O	O
failure	NOUN	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
sibutramine	NOUN	O	O
on	ADP	O	O
thermogenesis	NOUN	O	O
in	ADP	O	O
obese	PUNCT	O	O
patients	NOUN	O	O
assessed	VERB	O	O
via	ADP	O	O
immersion	NOUN	O	O
calorimetry	NOUN	O	O
.	PUNCT	O	O

Glucose	NOUN	O	O
utilization	NOUN	O	O
studies	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
sibutramine-induced	VERB	O	O
thermogenesis	NOUN	O	O
is	VERB	O	O
mediated	VERB	O	O
via	ADP	O	O
selective	ADJ	O	O
sympathetic	ADJ	O	O
activation	NOUN	O	O
of	ADP	O	O
brown	ADJ	O	O
adipose	ADJ	O	O
tissue	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
goal	NOUN	O	O
of	ADP	O	O
the	DET	O	O
present	ADJ	O	O
study	NOUN	O	O
was	VERB	O	O
to	ADV	O	O
use	VERB	O	O
a	DET	O	O
new	ADJ	O	O
calorimetry	NOUN	O	O
method	NOUN	O	O
in	ADP	O	O
which	ADP	O	O
resting	PUNCT	O	O
metabolic	ADJ	O	O
rate	NOUN	O	O
is	VERB	O	O
enhanced	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
sibutramine	NOUN	O	O
treatment	NOUN	O	O
on	ADP	O	O
thermogenesis	NOUN	O	O
.	PUNCT	O	O

Sixty	NUM	O	O
obese	PUNCT	O	O
women	NOUN	O	O
were	VERB	O	O
included	VERB	O	O
in	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Subjects	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
into	ADP	O	O
2	NUM	O	O
equal	ADJ	O	O
groups-the	VERB	O	O
placebo	NOUN	O	O
and	CCONJ	O	O
sibutramine	NOUN	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
sibutramine	NOUN	O	O
group	NOUN	O	O
was	VERB	O	O
given	VERB	O	O
sibutramine	NOUN	O	O
10	NUM	O	O
mg	NOUN	O	O
daily	ADJ	O	O
for	ADP	O	O
12	NUM	O	O
wk	NOUN	O	O
.	PUNCT	O	O

At	ADP	O	O
baseline	NOUN	O	O
and	CCONJ	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
the	DET	O	O
12-wk	PUNCT	O	O
treatment	NOUN	O	O
period	NOUN	O	O
,	PUNCT	O	O
thermogenic	ADJ	O	O
measurements	NOUN	O	O
were	VERB	O	O
taken	VERB	O	O
with	ADP	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
water	NOUN	O	B-PHYSICAL
immersion	NOUN	O	I-PHYSICAL
calorimetry	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Subjects	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
at	ADP	O	O
weeks	NOUN	O	O
4	NUM	O	O
,	PUNCT	O	O
8	NUM	O	O
,	PUNCT	O	O
and	CCONJ	O	O
12	NUM	O	O
of	ADP	O	O
treatment	NOUN	O	O
to	PART	O	O
identify	ADJ	O	O
adverse	ADJ	O	O
effects	NOUN	O	O
.	PUNCT	O	O

Body	NOUN	O	O
mass	NOUN	O	O
index	NOUN	O	O
,	PUNCT	O	O
measured	VERB	O	O
at	ADP	O	O
31.5+/-2.05	NUM	O	O
kg/m2	NOUN	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
decreased	PRON	O	O
to	ADP	O	O
30.4+/-2.94	PUNCT	O	O
kg/m	NOUN	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
after	ADP	O	O
12	NUM	O	O
wk	NOUN	O	O
(	PUNCT	O	O
P=.07	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
sibutramine	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
it	PRON	O	O
decreased	VERB	O	O
from	ADP	O	O
33.5+/-4.1	NOUN	O	O
kg/m	NUM	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
to	PUNCT	O	O
30.9+/-4.8	PUNCT	O	O
kg/m	NUM	O	O
(	PUNCT	O	O
2	NUM	O	O
)	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
sibutramine	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
mean	NOUN	O	O
thermogenic	ADJ	O	B-PHYSICAL
response	NOUN	O	I-PHYSICAL
changed	VERB	O	O
from	ADP	O	O
a	DET	O	O
baseline	NOUN	O	O
value	NOUN	O	O
of	ADP	O	O
1.27+/-0.29	NOUN	O	O
kcal/kg/h	NOUN	O	O
to	ADP	O	O
1.44+/-0.13	PUNCT	O	O
kcal/kg/h	NOUN	O	O
after	ADP	O	O
12	NUM	O	O
wk	NOUN	O	O
of	ADP	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
baseline	NOUN	O	O
value	NOUN	O	O
was	VERB	O	O
1.56+/-0.27	PUNCT	O	O
kcal/kg/h	NOUN	O	O
;	PUNCT	O	O
it	PUNCT	O	O
changed	DET	O	O
to	ADP	O	O
1.33+/-0.36	NOUN	O	O
kcal/kg/h	NOUN	O	O
at	ADP	O	O
the	DET	O	O
end	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
wk	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
findings	NOUN	O	O
of	ADP	O	O
this	DET	O	O
study	NOUN	O	O
suggest	VERB	O	O
that	ADP	O	O
sibutramine	NOUN	O	O
treatment	NOUN	O	O
promotes	NOUN	O	O
thermogenesis	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
thus	ADV	O	O
facilitating	VERB	O	O
weight	NOUN	O	O
loss	NOUN	O	B-PHYSICAL
.	PUNCT	O	O

Calorimetry	NOUN	O	O
enhances	ADP	O	O
resting	VERB	O	B-PHYSICAL
metabolism	NOUN	O	I-PHYSICAL
through	ADP	O	O
more	ADV	O	O
efficient	ADJ	O	O
heat	NOUN	O	O
transfer	NOUN	O	O
from	ADP	O	O
the	DET	O	O
body	NOUN	O	O
.	PUNCT	O	O

Transurethral	ADJ	O	O
prostate	NOUN	O	O
resection	NOUN	O	O
and	CCONJ	O	O
bleeding	VERB	O	O
:	PUNCT	O	O
a	DET	O	O
randomized	VERB	O	O
,	PUNCT	O	O
placebo	NOUN	O	O
controlled	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
role	NOUN	O	O
of	ADP	O	O
finasteride	PUNCT	O	O
for	ADP	O	O
decreasing	ADP	O	O
operative	ADJ	O	O
blood	NOUN	O	O
loss	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
Bleeding	PUNCT	O	O
associated	VERB	O	O
with	ADP	O	O
transurethral	ADJ	O	O
prostate	NOUN	O	O
resection	NOUN	O	O
can	ADP	O	O
often	ADV	O	O
be	ADP	O	O
significant	ADJ	O	O
and	CCONJ	O	O
lead	NOUN	O	O
to	ADP	O	O
increased	VERB	O	O
morbidity	NOUN	O	O
and	CCONJ	O	O
occasionally	ADV	O	O
mortality	NOUN	O	O
.	PUNCT	O	O

It	PRON	O	O
has	PUNCT	O	O
been	PUNCT	O	O
shown	VERB	O	O
that	ADP	O	O
finasteride	PUNCT	O	O
decreases	ADP	O	O
bleeding	ADP	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hematuria	NOUN	O	O
of	ADP	O	O
prostatic	ADJ	O	O
origin	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
hypothesized	VERB	O	O
that	ADP	O	O
bleeding	VERB	O	O
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
transurethral	ADJ	O	O
prostate	NOUN	O	O
resection	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
decreased	VERB	O	O
by	ADP	O	O
giving	ADP	O	O
finasteride	ADP	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

MATERIALS	NOUN	O	O
AND	CCONJ	O	O
METHODS	NOUN	O	O
A	PUNCT	O	O
total	VERB	O	O
70	NUM	O	O
patients	NOUN	O	O
scheduled	DET	O	O
to	PART	O	O
undergo	NOUN	O	O
elective	ADJ	O	O
transurethral	ADJ	O	O
prostate	NOUN	O	O
resection	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
5	DET	O	O
mg.	NOUN	O	O
finasteride	PUNCT	O	O
daily	ADJ	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
before	ADP	O	O
surgery	NOUN	O	O
.	PUNCT	O	O

Serum	NOUN	O	B-PHYSICAL
hemoglobin	NOUN	O	I-PHYSICAL
was	VERB	O	O
measured	VERB	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
following	PUNCT	O	O
day	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
volume	NOUN	O	O
of	ADP	O	O
irrigation	NOUN	O	B-OTHER
fluid	NOUN	O	I-OTHER
used	ADP	O	O
and	CCONJ	O	O
its	VERB	O	O
hemoglobin	NOUN	O	O
concentration	NOUN	O	O
as	PUNCT	O	O
well	PUNCT	O	O
as	CCONJ	O	O
resected	PUNCT	O	O
prostate	NOUN	O	O
weight	NOUN	O	O
were	VERB	O	O
recorded	VERB	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
Of	ADP	O	O
the	DET	O	O
68	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
underwent	VERB	O	O
transurethral	ADJ	O	O
prostate	NOUN	O	O
resection	NOUN	O	O
2	NUM	O	O
were	VERB	O	O
withdrawn	ADP	O	O
before	ADP	O	O
surgery	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
so	ADP	O	O
32	NUM	O	O
received	ADP	O	O
finasteride	ADP	O	O
and	CCONJ	O	O
36	NUM	O	O
received	PUNCT	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
significantly	ADV	O	O
less	ADV	O	O
mean	NOUN	O	O
blood	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
in	ADP	O	I-PHYSICAL
irrigation	NOUN	O	I-PHYSICAL
fluid	NOUN	O	I-PHYSICAL
in	ADP	O	O
the	DET	O	O
finasteride	ADP	O	O
group	NOUN	O	O
than	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
43.6	NUM	O	O
versus	CCONJ	O	O
69.3	NUM	O	O
gm	NOUN	O	O
.	PUNCT	O	O

hemoglobin	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
=	SYM	O	O
0.011	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
mean	NOUN	O	O
difference	NOUN	O	O
was	VERB	O	O
more	DET	O	O
significant	ADJ	O	O
when	ADP	O	O
blood	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
per	ADP	O	O
gm	NOUN	O	O
.	PUNCT	O	O

resected	PUNCT	O	O
prostate	NOUN	O	O
was	VERB	O	O
calculated	VERB	O	O
(	PUNCT	O	O
2.65	NUM	O	O
versus	CCONJ	O	O
4.65	NUM	O	O
gm	NOUN	O	O
.	PUNCT	O	O

hemoglobin	NOUN	O	O
per	ADP	O	O
gm	NOUN	O	O
.	PUNCT	O	O

prostate	NOUN	O	O
,	PUNCT	O	O
p	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
shows	NOUN	O	O
that	ADP	O	O
finasteride	PUNCT	O	O
given	VERB	O	O
for	ADP	O	O
2	NUM	O	O
weeks	NOUN	O	O
preoperatively	ADP	O	O
decreases	VERB	O	O
bleeding	ADP	O	B-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
undergoing	VERB	O	O
transurethral	ADJ	O	O
prostate	NOUN	O	O
resection	NOUN	O	O
.	PUNCT	O	O

Further	DET	O	O
study	NOUN	O	O
is	VERB	O	O
required	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
the	DET	O	O
optimal	ADJ	O	O
timing	VERB	O	O
and	CCONJ	O	O
dose	NOUN	O	O
duration	NOUN	O	O
to	PART	O	O
minimize	NOUN	O	O
blood	NOUN	O	B-PHYSICAL
loss	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
identify	ADJ	O	O
how	ADP	O	O
relevant	ADJ	O	O
such	PUNCT	O	O
a	ADP	O	O
decrease	NOUN	O	O
in	ADP	O	O
bleeding	PUNCT	O	O
is	VERB	O	O
in	ADP	O	O
clinical	ADJ	O	O
practice	NOUN	O	O
.	PUNCT	O	O

Treatment	NOUN	O	O
of	ADP	O	O
stable	ADJ	O	O
angina	NOUN	O	O
of	ADP	O	O
effort	NOUN	O	O
with	ADP	O	O
verapamil	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	DET	O	O
randomized	VERB	O	O
crossover	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
verapamil	NOUN	O	O
were	VERB	O	O
assessed	VERB	O	O
in	ADP	O	O
26	NUM	O	O
patients	NOUN	O	O
with	ADP	O	O
stable	ADJ	O	O
exertional	ADJ	O	O
angina	NOUN	O	O
pectoris	NOUN	O	O
in	ADP	O	O
a	DET	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
,	PUNCT	O	O
randomized	VERB	O	O
crossover	NOUN	O	O
protocol	NOUN	O	O
using	VERB	O	O
serial	ADJ	O	O
treadmill	NOUN	O	O
tests	NOUN	O	O
.	PUNCT	O	O

Verapamil	NOUN	O	O
,	PUNCT	O	O
480	NUM	O	O
mg/day	NOUN	O	O
,	PUNCT	O	O
reduced	ADV	O	O
anginal	ADJ	O	B-PHYSICAL
frequency	NOUN	O	I-PHYSICAL
from	ADP	O	O
5.6	NUM	O	O
+/-	SYM	O	O
7.3	NUM	O	O
to	ADP	O	O
2.2	NUM	O	O
+/-	SYM	O	O
3.9	NUM	O	O
attacks	NOUN	O	O
per	ADP	O	O
week	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.001	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
nitroglycerin	NOUN	O	B-OTHER
consumption	NOUN	O	I-OTHER
from	ADP	O	O
3.4	ADP	O	O
+/-	SYM	O	O
4.9	NUM	O	O
to	ADP	O	O
1.2	NUM	O	O
+/-	SYM	O	O
2.5	NUM	O	O
tablets	ADV	O	O
per	ADP	O	O
week	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
compared	VERB	O	O
with	ADP	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Treadmill	ADP	O	B-PHYSICAL
time	NOUN	O	I-PHYSICAL
increased	VERB	O	O
from	ADP	O	O
6.4	NUM	O	O
+/-	SYM	O	O
2.1	NUM	O	O
minutes	NOUN	O	O
during	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
phase	NOUN	O	O
to	ADP	O	O
7.5	PUNCT	O	O
+/-	SYM	O	O
1.8	NUM	O	O
minutes	NOUN	O	O
during	ADP	O	O
the	DET	O	O
verapamil	NOUN	O	O
phase	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Verapamil	NOUN	O	O
's	PUNCT	O	O
beneficial	ADJ	O	O
effect	NOUN	O	O
appeared	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
related	VERB	O	O
,	PUNCT	O	O
in	ADP	O	O
part	NOUN	O	O
,	PUNCT	O	O
to	ADP	O	O
a	DET	O	O
10	NUM	O	O
%	SYM	O	O
reduction	NOUN	O	O
of	ADP	O	O
the	DET	O	O
rate-pressure	NOUN	O	B-PHYSICAL
product	NOUN	O	I-PHYSICAL
at	ADP	O	O
rest	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
12	NUM	O	O
%	SYM	O	O
reduction	NOUN	O	O
during	ADP	O	O
submaximal	ADJ	O	O
exercise	NOUN	O	O
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.001	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Verapamil	NOUN	O	O
also	ADV	O	O
caused	ADJ	O	O
less	DET	O	O
marked	VERB	O	O
ST-segment	ADJ	O	B-PHYSICAL
depressions	NOUN	O	I-PHYSICAL
at	ADP	O	I-PHYSICAL
peak	ADJ	O	O
exercise	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
p	NOUN	O	O
less	ADV	O	O
than	PUNCT	O	O
0.05	NUM	O	O
)	PUNCT	O	O
at	ADP	O	O
a	DET	O	O
similar	ADJ	O	O
rate-pressure	NOUN	O	O
product	NOUN	O	O
,	PUNCT	O	O
suggesting	VERB	O	O
a	DET	O	O
favorable	ADJ	O	O
redistribution	NOUN	O	O
of	ADP	O	O
coronary	ADJ	O	B-PHYSICAL
blood	NOUN	O	B-PHYSICAL
flow	NOUN	O	B-PHYSICAL
to	ADP	O	O
the	DET	O	O
ischemic	ADJ	O	O
zone	NOUN	O	O
.	PUNCT	O	O

Side	NOUN	O	O
effects	NOUN	O	O
from	ADP	O	O
verapamil	NOUN	O	O
were	VERB	O	O
minimal	ADJ	O	O
,	PUNCT	O	O
consisting	PUNCT	O	O
mainly	DET	O	O
of	PUNCT	O	O

Comparison	NOUN	O	O
of	ADP	O	O
rectal	ADJ	O	O
midazolam	NOUN	O	O
and	CCONJ	O	O
diazepam	NOUN	O	O
for	ADP	O	O
premedication	NOUN	O	O
in	ADP	O	O
pediatric	ADJ	O	O
dental	ADJ	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Rectally	ADV	O	O
administered	ADP	O	O
midazolam	NOUN	O	O
(	PUNCT	O	O
0.35	NUM	O	O
mg/kg	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
diazepam	NOUN	O	O
(	PUNCT	O	O
0.70	NUM	O	O
mg/kg	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
each	DET	O	O
other	ADJ	O	O
and	CCONJ	O	O
with	ADP	O	O
placebo	NOUN	O	O
for	ADP	O	O
preanesthetic	ADJ	O	O
medication	NOUN	O	O
in	ADP	O	O
children	NOUN	O	O
undergoing	SYM	O	O
dental	ADJ	O	O
extractions	NOUN	O	O
.	PUNCT	O	O

All	DET	O	O
rectal	ADJ	O	O
medications	NOUN	O	O
were	VERB	O	O
very	VERB	O	O
well	VERB	O	O
accepted	ADP	O	O
,	PUNCT	O	O
but	CCONJ	O	O
mask	NOUN	O	B-MENTAL
acceptance	NOUN	O	I-MENTAL
,	PUNCT	O	O
improvement	NOUN	O	O
in	ADP	O	O
anxiety	NOUN	O	B-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
sedation	NOUN	O	B-MENTAL
were	VERB	O	O
best	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
midazolam	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

Improvement	NOUN	O	O
in	ADP	O	O
anxiety	NOUN	O	B-MENTAL
and	CCONJ	O	O
sedation	NOUN	O	B-MENTAL
were	VERB	O	O
significantly	ADV	O	O
better	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
two	NUM	O	O
drug	NOUN	O	O
groups	NOUN	O	O
than	CCONJ	O	O
in	ADP	O	O
those	PUNCT	O	O
patients	NOUN	O	O
who	PROPN	O	O
had	PUNCT	O	O
received	PUNCT	O	O
placebo	NOUN	O	O
.	PUNCT	O	O

Thirty	NUM	O	O
minutes	NOUN	O	O
after	ADP	O	O
rectal	ADJ	O	O
administration	NOUN	O	O
of	ADP	O	O
midazolam	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
decrease	NOUN	O	O
in	ADP	O	O
both	CCONJ	O	O
systolic	ADJ	O	B-PHYSICAL
and	CCONJ	O	I-PHYSICAL
diastolic	ADJ	O	I-PHYSICAL
blood	NOUN	O	I-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
and	CCONJ	O	O
heart	NOUN	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

Although	ADP	O	O
these	DET	O	O
decreases	NOUN	O	O
differed	VERB	O	O
significantly	ADV	O	O
from	ADP	O	O
the	DET	O	O
premedication	NOUN	O	O
values	NOUN	O	O
,	PUNCT	O	O
they	PUNCT	O	O
were	VERB	O	O
probably	DET	O	O
of	ADP	O	O
little	DET	O	O
clinical	ADJ	O	O
importance	NOUN	O	O
.	PUNCT	O	O

Only	ADV	O	O
minor	ADJ	O	B-ADVERSE-EFFECTS
adverse	ADJ	O	I-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
were	VERB	O	O
observed	VERB	O	O
in	ADP	O	O
this	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Overall	ADJ	O	O
rectally	ADV	O	O
administered	ADP	O	O
midazolam	NOUN	O	O
appeared	VERB	O	O
to	PART	O	O
be	PUNCT	O	O
somewhat	ADV	O	O
more	ADV	O	O
efficacious	ADJ	O	O
than	ADP	O	O
diazepam	NOUN	O	O
.	PUNCT	O	O

[	PUNCT	O	O
Dose-reduced	PROPN	O	O
antihypertensive	ADJ	O	O
agents	NOUN	O	O
--	PUNCT	O	O
use	CCONJ	O	O
in	ADP	O	O
complex	PUNCT	O	O
nonmedicamentous	ADJ	O	O
therapy	NOUN	O	O
of	ADP	O	O
hypertension	NOUN	O	O
]	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
order	NOUN	O	O
to	PART	O	O
estimate	NOUN	O	O
the	DET	O	O
influence	NOUN	O	O
of	ADP	O	O
a	DET	O	O
non-medicamentous	ADP	O	O
therapy	NOUN	O	O
(	PUNCT	O	O
CNT	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
the	DET	O	O
consumption	NOUN	O	O
of	ADP	O	O
medicaments	NOUN	O	O
and	CCONJ	O	O
coronary	ADJ	O	O
risk	NOUN	O	O
in	ADP	O	O
high	ADJ	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
73	VERB	O	O
hypertensives	NOUN	O	O
of	ADP	O	O
a	DET	O	O
medicamentously	ADV	O	O
stabilized	VERB	O	O
CNT-group	NOUN	O	O
were	VERB	O	O
examined	VERB	O	O
in	ADP	O	O
comparison	NOUN	O	O
to	ADP	O	O
a	DET	O	O
group	NOUN	O	O
of	ADP	O	O
the	DET	O	O
same	ADJ	O	O
size	NOUN	O	O
of	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
hypertension	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
managed	PROPN	O	O
exclusively	ADV	O	O
medicamentously	ADV	O	O
for	ADP	O	O
behaviour	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	O
pressure	NOUN	O	O
,	PUNCT	O	O
need	VERB	O	O
of	ADP	O	O
antihypertensive	ADJ	O	O
drugs	NOUN	O	O
and	CCONJ	O	O
changes	NOUN	O	O
of	ADP	O	O
hypertension-associated	VERB	O	O
risk	NOUN	O	O
factors	NOUN	O	O
.	PUNCT	O	O

After	ADP	O	O
an	DET	O	O
exactly	ADV	O	O
controlled	VERB	O	O
6-month	NOUN	O	O
treatment	NOUN	O	O
hypertensives	DET	O	O
with	ADP	O	O
additionally	ADJ	O	O
recommended	DET	O	O
far-reaching	ADP	O	O
CNT	NOUN	O	O
showed	VERB	O	O
an	DET	O	O
economization	NOUN	O	O
of	ADP	O	O
medicaments	NOUN	O	O
by	ADP	O	O
scarcely	PUNCT	O	O
the	DET	O	O
half	NOUN	O	O
in	ADP	O	O
comparison	NOUN	O	O
to	ADP	O	O
the	DET	O	O
reference	NOUN	O	O
group	NOUN	O	O
.	PUNCT	O	O

By	ADP	O	O
means	NOUN	O	O
of	ADP	O	O
suitable	ADJ	O	O
control	NOUN	O	O
methods	CCONJ	O	O
a	DET	O	O
causal	ADJ	O	O
non-medicamentously	NOUN	O	O
conditioned	VERB	O	O
decrease	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	B-PHYSICAL
pressure	NOUN	O	I-PHYSICAL
could	VERB	O	O
be	VERB	O	O
excluded	VERB	O	O
.	PUNCT	O	O

A	DET	O	O
different	ADJ	O	O
need	NOUN	O	O
of	ADP	O	O
antihypertensive	ADJ	O	O
drugs	NOUN	O	O
was	VERB	O	O
simulated	VERB	O	O
by	ADP	O	O
the	DET	O	O
exacter	ADJ	O	O
intake	NOUN	O	O
of	ADP	O	O
medicaments	NOUN	O	O
in	ADP	O	O
the	DET	O	O
index-patients	NOUN	O	O
.	PUNCT	O	O

Notwithstanding	PUNCT	O	O
the	DET	O	O
metabolic	ADJ	O	O
effects	NOUN	O	O
of	ADP	O	O
the	DET	O	O
additional	ADJ	O	O
therapy	NOUN	O	O
have	PUNCT	O	O
induced	VERB	O	O
a	DET	O	O
positive	ADJ	O	O
change	NOUN	O	O
of	ADP	O	O
atherogenic	ADJ	O	B-PHYSICAL
lipids	NOUN	O	I-PHYSICAL
.	PUNCT	O	O

The	DET	O	O
examinations	NOUN	O	O
indicate	VERB	O	O
in	ADP	O	O
general	NOUN	O	O
the	DET	O	O
difficulty	NOUN	O	O
of	ADP	O	O
the	DET	O	O
judgement	NOUN	O	O
of	ADP	O	O
efficacy	NOUN	O	O
of	ADP	O	O
non-medicamentous	ADJ	O	O
therapeutic	ADJ	O	O
measures	NOUN	O	O
in	ADP	O	O
connection	NOUN	O	O
with	ADP	O	O
a	DET	O	O
rational	ADJ	O	O
dose-reduced	VERB	O	O
long-term	NOUN	O	O
therapy	NOUN	O	O
with	ADP	O	O
antihypertensive	ADJ	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Pegfilgrastim	NOUN	O	O
for	ADP	O	O
peripheral	ADJ	O	O
CD34+	NOUN	O	O
mobilization	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
solid	ADJ	O	O
tumours	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
efficacy	NOUN	O	O
of	ADP	O	O
pegfilgrastim+/-chemotherapy	NOUN	O	O
for	ADP	O	O
mobilizing	PUNCT	O	O
stem	NOUN	O	O
cells	NOUN	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
solid	ADJ	O	O
tumours	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
.	PUNCT	O	O

In	ADP	O	O
cycle	NOUN	O	O
0	NUM	O	O
,	PUNCT	O	O
a	DET	O	O
14-day	NOUN	O	O
prechemotherapy	NOUN	O	O
cycle	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
(	PUNCT	O	O
N=61	NOUN	O	O
)	PUNCT	O	O
were	VERB	O	O
randomized	VERB	O	O
open-label	NOUN	O	O
to	VERB	O	O
single	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
pegfilgrastim	NOUN	O	O
(	PUNCT	O	O
6	NUM	O	O
,	PUNCT	O	O
12	NUM	O	O
or	CCONJ	O	O
18	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
or	CCONJ	O	O
daily	ADJ	O	O
filgrastim	NOUN	O	O
(	PUNCT	O	O
10	NUM	O	O
microg/kg	NOUN	O	O
)	PUNCT	O	O
for	ADP	O	O
<	SYM	O	O
or	CCONJ	O	O
=7	ADP	O	O
days	NOUN	O	O
.	PUNCT	O	O

Mean	ADJ	O	O
peak	ADJ	O	O
peripheral	ADJ	O	B-PHYSICAL
CD34+	NOUN	O	I-PHYSICAL
cell	NOUN	O	I-PHYSICAL
counts	NOUN	O	I-PHYSICAL
increased	VERB	O	O
with	ADP	O	O
pegfilgrastim	ADJ	O	O
dose	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
were	VERB	O	O
significantly	ADV	O	O
higher	PUNCT	O	O
than	PUNCT	O	O
filgrastim	NOUN	O	O
only	ADV	O	O
at	ADP	O	O
the	DET	O	O
18	NUM	O	O
mg	NOUN	O	O
dose	NOUN	O	O
(	PUNCT	O	O
10.17	ADJ	O	O
vs	CCONJ	O	O
4.96	NUM	O	O
x	ADJ	O	O
10	NUM	O	O
(	PUNCT	O	O
4	NUM	O	O
)	PUNCT	O	O
/ml	ADV	O	O
;	PUNCT	O	O
P=0.014	ADV	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
the	DET	O	O
clinically	ADV	O	O
relevant	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
days	NOUN	O	O
3-7	NUM	O	O
,	PUNCT	O	O
both	PUNCT	O	O
12	NUM	O	O
and	CCONJ	O	O
18	NUM	O	O
mg	NOUN	O	O
pegfilgrastim	NOUN	O	O
doses	NOUN	O	O
produced	VERB	O	O
significantly	ADV	O	B-PHYSICAL
higher	PUNCT	O	O
peak	ADJ	O	O
CD34+	NOUN	O	B-PHYSICAL
counts	NOUN	O	I-PHYSICAL
(	PUNCT	O	O
8.18	ADP	O	O
and	CCONJ	O	O
9.96	NUM	O	O
vs	CCONJ	O	O
4.51	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
4	NUM	O	O
)	PUNCT	O	O
/ml	NOUN	O	O
for	ADP	O	O
filgrastim	NOUN	O	O
;	PUNCT	O	O
P=0.034	ADP	O	O
and	CCONJ	O	O
0.006	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
cycle	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
patients	NOUN	O	O
received	VERB	O	O
carboplatin/paclitaxel	NOUN	O	O
on	ADP	O	O
day	NOUN	O	O
1	NUM	O	O
,	PUNCT	O	O
followed	VERB	O	O
from	ADP	O	O
day	NOUN	O	O
2	NUM	O	O
by	ADP	O	O
pegfilgrastim	NOUN	O	O
6-18	NUM	O	O
mg	NOUN	O	O
or	CCONJ	O	O
daily	ADJ	O	O
filgrastim	NOUN	O	O
(	PUNCT	O	O
5	NUM	O	O
microg/kg/day	NOUN	O	O
for	ADP	O	O
<	SYM	O	O
or	CCONJ	O	O
=14	ADP	O	O
days	NOUN	O	O
)	PUNCT	O	O
as	PUNCT	O	O
per	ADP	O	O
randomization	NOUN	O	O
in	ADP	O	O
cycle	NOUN	O	O
0	NUM	O	O
.	PUNCT	O	O

There	PUNCT	O	O
were	VERB	O	O
no	DET	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
mean	NOUN	O	O
peak	ADJ	O	O
CD34+	NOUN	O	B-PHYSICAL
count	NOUN	O	I-PHYSICAL
between	ADP	O	O
pegfilgrastim	NOUN	O	O
and	CCONJ	O	O
filgrastim	NOUN	O	O
,	PUNCT	O	O
but	CCONJ	O	O
there	PUNCT	O	O
was	VERB	O	O
an	DET	O	O
advantage	NOUN	O	O
for	ADP	O	O
pegfilgrastim	NOUN	O	O
18	NUM	O	O
mg	NOUN	O	O
in	ADP	O	O
the	DET	O	O
relevant	ADJ	O	O
period	NOUN	O	O
of	ADP	O	O
days	NOUN	O	O
7-12	NUM	O	O
(	PUNCT	O	O
3.14	NUM	O	O
vs	CCONJ	O	O
1.19	NUM	O	O
x	SYM	O	O
10	NUM	O	O
(	PUNCT	O	O
4	NUM	O	O
)	PUNCT	O	O
/ml	ADV	O	O
;	PUNCT	O	O
P=0.043	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

A	DET	O	O
single	ADJ	O	O
pegfilgrastim	ADJ	O	O
dose	NOUN	O	O
(	PUNCT	O	O
>	ADJ	O	O
or	CCONJ	O	O
=6	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
could	VERB	O	O
be	VERB	O	O
substituted	VERB	O	O
for	ADP	O	O
daily	ADJ	O	O
filgrastim	NOUN	O	O
in	PUNCT	O	O

Genotyping	SYM	O	O
of	ADP	O	O
CYP21	NOUN	O	O
,	PUNCT	O	O
linked	VERB	O	O
chromosome	NOUN	O	O
6p	PUNCT	O	O
markers	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
sex-specific	ADJ	O	O
gene	NOUN	O	O
in	ADP	O	O
neonatal	ADJ	O	O
screening	VERB	O	O
for	ADP	O	O
congenital	ADJ	O	O
adrenal	ADJ	O	O
hyperplasia	NOUN	O	O
.	PUNCT	O	O

We	PRON	O	O
investigated	VERB	O	O
the	DET	O	O
feasibility	NOUN	O	B-OTHER
and	CCONJ	O	I-OTHER
diagnostic	ADJ	O	I-OTHER
utility	NOUN	O	I-OTHER
of	ADP	O	O
genotyping	VERB	O	O
9	NUM	O	O
CYP21	NOUN	O	O
mutations	NOUN	O	O
,	PUNCT	O	O
linked	VERB	O	O
chromosome	NOUN	O	O
6p	PUNCT	O	O
markers	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
a	DET	O	O
dimorphic	ADJ	O	O
X-Y	NOUN	O	O
marker	NOUN	O	O
from	ADP	O	O
neonatal	ADJ	O	O
screening	VERB	O	O
samples	NOUN	O	O
.	PUNCT	O	O

Blood-impregnated	VERB	O	O
filter	PUNCT	O	O
papers	NOUN	O	O
(	PUNCT	O	O
Guthrie	NOUN	O	O
cards	ADJ	O	O
)	PUNCT	O	O
from	ADP	O	O
603	NUM	O	O
randomly	ADV	O	O
chosen	PUNCT	O	O
New	ADJ	O	O
Zealand	NOUN	O	O
neonates	NOUN	O	O
were	ADV	O	O
genotyped	VERB	O	O
blind	ADJ	O	O
to	ADP	O	O
17-hydroxyprogesterone	NOUN	O	O
(	PUNCT	O	O
17-OHP	ADV	O	O
)	PUNCT	O	O
levels	NOUN	O	O
.	PUNCT	O	O

Another	DET	O	O
50	NUM	O	O
samples	NOUN	O	O
from	ADP	O	O
Swiss	NOUN	O	O
and	CCONJ	O	O
North	NOUN	O	O
American	ADJ	O	O
infants	NOUN	O	O
with	ADP	O	O
correlative	ADJ	O	O
hormonal	ADJ	O	O
data	NOUN	O	O
were	VERB	O	O
also	ADV	O	O
genotyped	VERB	O	O
.	PUNCT	O	O

DNA	NOUN	O	O
was	VERB	O	O
extracted	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
gene-specific	ADJ	O	O
PCR	NOUN	O	O
was	VERB	O	O
performed	VERB	O	O
.	PUNCT	O	O

CYP21	NOUN	O	O
PCR	NOUN	O	O
products	NOUN	O	O
were	VERB	O	O
subjected	VERB	O	O
to	ADP	O	O
ligase	NOUN	O	O
detection	NOUN	O	O
reaction	NOUN	O	O
,	PUNCT	O	O
simultaneously	ADP	O	O
analyzing	PROPN	O	O
9	NUM	O	O
CYP21	NOUN	O	O
mutations	NOUN	O	O
;	PUNCT	O	O
PCR	NOUN	O	O
products	NOUN	O	O
of	ADP	O	O
other	ADJ	O	O
genes	NOUN	O	O
were	VERB	O	O
subjected	VERB	O	O
to	ADP	O	O
direct	ADJ	O	O
gel	NOUN	O	O
analysis	NOUN	O	O
.	PUNCT	O	O

CYP21	NOUN	O	O
genotyping	VERB	O	O
indicated	VERB	O	O
a	DET	O	O
heterozygote	ADJ	O	B-PHYSICAL
rate	NOUN	O	I-PHYSICAL
of	ADP	O	O
2.8	NUM	O	O
%	SYM	O	O
for	ADP	O	O
classic	ADJ	O	O
mutations	NOUN	O	O
(	PUNCT	O	O
excluding	ADJ	O	O
CYP21	NOUN	O	O
deletions	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
and	CCONJ	O	O
2.0	NUM	O	O
%	SYM	O	O
for	ADP	O	O
nonclassic	ADJ	O	O
mutations	NOUN	O	O
in	ADP	O	O
New	ADJ	O	O
Zealanders	NOUN	O	O
.	PUNCT	O	O

Ten	NUM	O	O
full-term	NOUN	O	O
affected	VERB	O	O
neonates	NOUN	O	O
showed	VERB	O	O
a	DET	O	O
wide	ADJ	O	B-PHYSICAL
range	NOUN	O	O
of	ADP	O	B-PHYSICAL
17-OHP	ADJ	O	I-PHYSICAL
levels	NOUN	O	B-PHYSICAL
(	PUNCT	O	O
15-1400	NUM	O	O
nmol/L	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Sick	NOUN	O	O
or	CCONJ	O	O
preterm	NOUN	O	O
infants	NOUN	O	O
or	CCONJ	O	O
infants	NOUN	O	O
screened	VERB	O	O
on	ADP	O	O
the	DET	O	O
first	ADJ	O	O
day	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
with	ADP	O	O
high	ADJ	O	O
17-OHP	ADV	O	B-PHYSICAL
proved	PUNCT	O	O
genetically	ADV	O	O
unaffected	VERB	O	O
.	PUNCT	O	O

Genetic	ADJ	O	B-PHYSICAL
linkage	NOUN	O	O
disequilibrium	NOUN	O	B-PHYSICAL
was	VERB	O	O
found	VERB	O	O
between	ADP	O	O
two	NUM	O	O
CYP21	NOUN	O	O
mutations	NOUN	O	O
and	CCONJ	O	O
chromosome	NOUN	O	O
6p	PUNCT	O	O
markers	NOUN	O	O
.	PUNCT	O	O

Guthrie	NOUN	O	O
cards	NOUN	O	O
can	VERB	O	O
be	VERB	O	O
used	VERB	O	O
to	PUNCT	O	O
accurately	ADJ	O	O
genotype	NOUN	O	O
CYP21	NOUN	O	B-PHYSICAL
and	CCONJ	O	B-PHYSICAL
other	ADJ	O	I-PHYSICAL
relevant	ADJ	O	I-PHYSICAL
markers	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
potentially	ADV	O	O
enhancing	ADP	O	O
the	DET	O	O
specificity	NOUN	O	O
and	PUNCT	O	O

Randomized	VERB	O	O
trial	NOUN	O	O
of	ADP	O	O
tailored	VERB	O	O
skin	NOUN	O	O
cancer	NOUN	O	O
prevention	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
:	PUNCT	O	O
the	DET	O	O
Project	NOUN	O	O
SCAPE	NOUN	O	O
family	NOUN	O	O
study	NOUN	O	O
.	PUNCT	O	O

This	DET	O	O
study	NOUN	O	O
evaluated	VERB	O	O
a	DET	O	O
tailored	VERB	O	O
intervention	NOUN	O	O
to	ADJ	O	O
promote	PUNCT	O	O
sun	PUNCT	O	O
protection	NOUN	O	O
in	ADP	O	O
parents	NOUN	O	O
and	CCONJ	O	O
their	PROPN	O	O
children	NOUN	O	O
,	PUNCT	O	O
hypothesizing	PUNCT	O	O
that	ADP	O	O
the	DET	O	O
tailored	VERB	O	O
intervention	NOUN	O	O
would	VERB	O	O
lead	VERB	O	O
to	ADP	O	O
improved	NOUN	O	O
skin	NOUN	O	B-MENTAL
cancer	NOUN	O	I-MENTAL
prevention	NOUN	O	I-MENTAL
behaviors	NOUN	O	I-MENTAL
compared	VERB	O	O
to	ADP	O	O
generic	ADJ	O	O
materials	NOUN	O	O
.	PUNCT	O	O

Families	NOUN	O	O
were	VERB	O	O
recruited	VERB	O	O
through	ADP	O	O
schools	NOUN	O	O
and	CCONJ	O	O
community	NOUN	O	O
centers	NOUN	O	O
and	CCONJ	O	O
were	VERB	O	O
included	VERB	O	O
if	PUNCT	O	O
there	PUNCT	O	O
was	VERB	O	O
1	NUM	O	O
child	NOUN	O	O
in	ADP	O	O
Grades	PROPN	O	O
1-3	NUM	O	O
at	ADP	O	O
moderate	ADJ	O	O
to	ADP	O	O
high	ADJ	O	O
risk	NOUN	O	O
for	ADP	O	O
skin	NOUN	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Participants	NOUN	O	O
were	VERB	O	O
randomized	VERB	O	O
into	ADP	O	O
one	NUM	O	O
of	ADP	O	O
two	NUM	O	O
intervention	NOUN	O	O
groups	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
tailored	VERB	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
in	ADP	O	O
which	ADP	O	O
they	PRON	O	O
received	VERB	O	O
personalized	VERB	O	O
skin	NOUN	O	O
cancer	NOUN	O	O
education	NOUN	O	O
through	ADP	O	O
the	DET	O	O
mail	NOUN	O	O
;	PUNCT	O	O
or	CCONJ	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
who	ADP	O	O
received	VERB	O	O
generic	ADP	O	O
skin	NOUN	O	O
cancer	NOUN	O	O
information	NOUN	O	O
materials	NOUN	O	O
.	PUNCT	O	O

Before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
parents	NOUN	O	O
completed	VERB	O	O
questionnaires	NOUN	O	O
about	ADP	O	O
their	VERB	O	O
and	CCONJ	O	O
their	ADP	O	O
children	NOUN	O	O
's	PUNCT	O	O
skin	NOUN	O	O
cancer	NOUN	O	O
risk	NOUN	O	O
and	CCONJ	O	O
prevention	NOUN	O	O
knowledge	NOUN	O	O
and	CCONJ	O	O
behaviors	NOUN	O	O
.	PUNCT	O	O

Parents	NOUN	O	O
also	ADV	O	O
completed	ADP	O	O
4-day	NOUN	O	O
sun	PUNCT	O	O
exposure	NOUN	O	O
and	CCONJ	O	O
protection	NOUN	O	O
diaries	NOUN	O	O
for	ADP	O	O
their	PUNCT	O	O
child	NOUN	O	O
and	CCONJ	O	O
themselves	PUNCT	O	O
.	PUNCT	O	O

Tailored	VERB	O	O
group	NOUN	O	O
participants	NOUN	O	O
demonstrated	VERB	O	O
significantly	ADP	O	B-MENTAL
greater	PUNCT	O	O
positive	ADJ	O	O
changes	NOUN	O	B-MENTAL
in	ADP	O	I-MENTAL
prevention	NOUN	O	B-MENTAL
behavior	NOUN	O	I-MENTAL
after	ADP	O	O
the	DET	O	O
intervention	NOUN	O	O
,	PUNCT	O	O
including	PUNCT	O	O

Effects	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
oral	ADJ	O	O
analgesics	NOUN	O	O
on	ADP	O	O
postoperative	ADJ	O	O
pain	NOUN	O	O
following	VERB	O	O
root	NOUN	O	O
canal	NOUN	O	O
preparation	NOUN	O	O
:	PUNCT	O	O
a	DET	O	O
controlled	VERB	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
.	PUNCT	O	O

AIM	NOUN	O	O
To	ADV	O	O
compare	NOUN	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
single	ADJ	O	O
doses	NOUN	O	O
of	ADP	O	O
three	NUM	O	O
oral	ADJ	O	O
medications	NOUN	O	O
on	ADP	O	O
postoperative	ADJ	O	O
pain	NOUN	O	B-PAIN
following	VERB	O	O
instrumentation	NOUN	O	O
of	ADP	O	O
root	NOUN	O	O
canals	ADJ	O	O
in	ADP	O	O
teeth	NOUN	O	O
with	ADP	O	O
irreversible	ADJ	O	O
pulpitis	NOUN	O	O
.	PUNCT	O	O

METHODOLOGY	NOUN	O	O
In	ADP	O	O
this	DET	O	O
double-blind	ADJ	O	O
clinical	ADJ	O	O
trial	NOUN	O	O
,	PUNCT	O	O
100	NUM	O	O
patients	NOUN	O	O
who	ADP	O	O
had	VERB	O	O
anterior	ADJ	O	O
or	CCONJ	O	O
premolar	ADJ	O	O
teeth	NOUN	O	O
with	ADP	O	O
irreversible	ADJ	O	O
pulpitis	NOUN	O	O
without	ADP	O	O
any	DET	O	O
signs	NOUN	O	O
and	CCONJ	O	O
symptoms	NOUN	O	O
of	ADP	O	O
acute	ADJ	O	O
or	CCONJ	O	O
chronic	ADJ	O	O
apical	ADJ	O	O
periodontitis	NOUN	O	O
and	CCONJ	O	O
moderate	ADJ	O	O
to	ADP	O	O
severe	ADJ	O	O
pain	NOUN	O	O
were	VERB	O	O
divided	VERB	O	O
by	ADP	O	O
balanced	PUNCT	O	O
block	ADP	O	O
random	ADJ	O	O
allocation	NOUN	O	O
into	ADP	O	O
four	NUM	O	O
groups	NOUN	O	O
of	ADP	O	O
25	NUM	O	O
each	PUNCT	O	O
,	PUNCT	O	O
a	DET	O	O
control	NOUN	O	O
group	NOUN	O	O
receiving	VERB	O	O
a	DET	O	O
placebo	NOUN	O	O
medication	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
three	NUM	O	O
experimental	ADJ	O	O
groups	NOUN	O	O
receiving	VERB	O	O
a	DET	O	O
single	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
either	PUNCT	O	O
Tramadol	NOUN	O	O
(	PUNCT	O	O
100	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
,	PUNCT	O	O
Novafen	NOUN	O	O
(	PUNCT	O	O
325	NUM	O	O
mg	NOUN	O	O
of	ADP	O	O
paracetamol	NOUN	O	O
,	PUNCT	O	O
200	NUM	O	O
mg	NOUN	O	O
ibuprofen	NOUN	O	O
and	CCONJ	O	O
40	NUM	O	O
mg	NOUN	O	O
caffeine	NOUN	O	O
anhydrous	ADJ	O	O
)	PUNCT	O	O
or	CCONJ	O	O
Naproxen	NOUN	O	O
(	PUNCT	O	O
500	NUM	O	O
mg	NOUN	O	O
)	PUNCT	O	O
immediately	ADV	O	O
after	ADP	O	O
the	DET	O	O
first	ADJ	O	O
appointment	NOUN	O	O
where	ADP	O	O
the	DET	O	O
pulp	NOUN	O	O
was	VERB	O	O
removed	VERB	O	O
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
canals	NUM	O	O
were	VERB	O	O
fully	ADV	O	O
prepared	VERB	O	O
.	PUNCT	O	O

The	DET	O	O
intensity	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	B-PAIN
was	VERB	O	O
scored	VERB	O	O
based	VERB	O	O
on	ADP	O	O
10-point	NOUN	O	O
VAS	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
for	ADP	O	O
up	PUNCT	O	O
to	ADP	O	O
24	NUM	O	O
h	NOUN	O	O
postoperatively	NOUN	O	O
.	PUNCT	O	O

Data	NOUN	O	O
were	VERB	O	O
submitted	VERB	O	O
to	ADP	O	O
repeated	VERB	O	O
analysis	NOUN	O	O
of	ADP	O	O
variance	NOUN	O	O
.	PUNCT	O	O

RESULTS	NOUN	O	O
At	ADP	O	O
the	DET	O	O
6	NUM	O	O
,	PUNCT	O	O
12	NUM	O	O
and	CCONJ	O	O
24	NUM	O	O
h	NOUN	O	O
postoperative	ADJ	O	O
intervals	NOUN	O	O
after	ADP	O	O
drug	NOUN	O	O
administration	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
intensity	NOUN	O	O
of	ADP	O	O
pain	NOUN	O	B-PAIN
was	VERB	O	O
significantly	ADV	O	O
lower	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
experimental	ADJ	O	O
groups	NOUN	O	O
than	CCONJ	O	O
in	ADP	O	O
the	DET	O	O
placebo	NOUN	O	O
group	NOUN	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.01	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Tramadol	ADV	O	O
was	ADV	O	O
significantly	ADV	O	O
less	ADV	O	O
effective	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
than	PUNCT	O	O
Naproxen	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
Novafen	NOUN	O	O
that	PUNCT	O	O
were	VERB	O	O
similar	ADJ	O	O
to	ADP	O	O
each	DET	O	O
other	PUNCT	O	O
(	PUNCT	O	O
P	NOUN	O	O
>	SYM	O	O
0.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

CONCLUSION	NOUN	O	O
A	PUNCT	O	O
single	ADJ	O	O
oral	ADJ	O	O
dose	NOUN	O	O
of	ADP	O	O
Naproxen	NOUN	O	O
,	PUNCT	O	O
Novafen	NOUN	O	O
and	CCONJ	O	O
Tramadol	PUNCT	O	O
taken	VERB	O	O
immediately	CCONJ	O	O
after	ADP	O	O
treatment	NOUN	O	O
reduced	VERB	O	O
postoperative	ADJ	O	O
pain	NOUN	O	O
following	VERB	O	O
pulpectomy	NOUN	O	O
and	CCONJ	O	O
root	NOUN	O	O
canal	NOUN	O	O
preparation	NOUN	O	O
of	ADP	O	O
teeth	NOUN	O	O
with	ADP	O	O
irreversible	ADJ	O	O
pulpitis	NOUN	O	O
.	PUNCT	O	O

Recombinant	ADJ	O	O
human	NOUN	O	O
erythropoietin	NOUN	O	O
therapy	NOUN	O	O
for	ADP	O	O
anemic	ADJ	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
on	ADP	O	O
combination	NOUN	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

BACKGROUND	NOUN	O	O
Patients	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
cancer	NOUN	O	O
frequently	ADV	O	O
experience	ADP	O	O
clinically	ADV	O	O
significant	ADJ	O	O
anemia	NOUN	O	B-PHYSICAL
,	PUNCT	O	O
which	ADP	O	O
is	VERB	O	O
often	ADV	O	O
exacerbated	VERB	O	O
by	ADP	O	O
myelosuppressive	ADJ	O	O
chemotherapy	NOUN	O	O
.	PUNCT	O	O

Consistent	ADJ	O	O
with	ADP	O	O
the	DET	O	O
anemia	NOUN	O	O
of	ADP	O	O
chronic	ADJ	O	O
disease	NOUN	O	O
,	PUNCT	O	O
studies	NOUN	O	O
have	PUNCT	O	O
documented	ADP	O	O
serum	NOUN	O	O
erythropoietin	NOUN	O	O
levels	NOUN	O	O
that	ADP	O	O
are	VERB	O	O
inappropriately	ADV	O	O
low	ADJ	O	O
for	ADP	O	O
the	DET	O	O
degree	NOUN	O	O
of	ADP	O	O
anemia	NOUN	O	O
in	ADP	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
.	PUNCT	O	O

Myelosuppressive	ADJ	O	O
chemotherapy	NOUN	O	O
impairs	ADV	O	O
erythropoiesis	NOUN	O	O
,	PUNCT	O	O
which	ADP	O	O
may	VERB	O	O
not	ADV	O	O
fully	ADV	O	O
recover	PART	O	O
between	ADP	O	O
treatment	NOUN	O	O
cycles	NOUN	O	O
.	PUNCT	O	O

Recombinant	ADJ	O	O
human	NOUN	O	O
erythropoietin	NOUN	O	O
(	PUNCT	O	O
rHuEPO	ADV	O	O
)	PUNCT	O	O
has	PUNCT	O	O
been	PUNCT	O	O
used	VERB	O	O
safely	ADV	O	O
and	CCONJ	O	O
effectively	ADV	O	O
to	PART	O	O
treat	CCONJ	O	O
anemia	PUNCT	O	O
in	ADP	O	O
AIDS	NOUN	O	O
patients	NOUN	O	O
receiving	ADP	O	O
zidovudine	NOUN	O	O
(	PUNCT	O	O
AZT	NOUN	O	O
)	PUNCT	O	O
and	CCONJ	O	O
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
chronic	ADJ	O	O
renal	ADJ	O	O
failure	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
This	DET	O	O
study	NOUN	O	O
was	VERB	O	O
designed	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
the	DET	O	O
clinical	ADJ	O	O
role	NOUN	O	O
of	ADP	O	O
rHuEPO	ADV	O	O
in	ADP	O	O
reducing	VERB	O	O
symptomatic	ADJ	O	B-PHYSICAL
anemia	NOUN	O	I-PHYSICAL
in	ADP	O	O
patients	NOUN	O	O
with	ADP	O	O
advanced	VERB	O	O
cancer	NOUN	O	O
who	ADP	O	O
were	VERB	O	O
receiving	ADP	O	O
myelosuppressive	ADJ	O	O
chemotherapy	NOUN	O	O
(	PUNCT	O	O
excluding	ADP	O	O
cisplatin	NOUN	O	O
)	PUNCT	O	O
.	PUNCT	O	O

METHODS	NOUN	O	O
We	PRON	O	O
studied	VERB	O	O
153	NUM	O	O
anemic	ADJ	O	O
cancer	NOUN	O	O
patients	NOUN	O	O
receiving	VERB	O	O
cyclic	ADJ	O	O
combination	NOUN	O	O
chemotherapy	NOUN	O	O
in	ADP	O	O
a	DET	O	O
prospective	ADJ	O	O
multicenter	NOUN	O	O
,	PUNCT	O	O
double-blind	ADJ	O	O
,	PUNCT	O	O
placebo-controlled	VERB	O	O
trial	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
patients	NOUN	O	O
were	VERB	O	O
randomly	ADV	O	O
assigned	VERB	O	O
to	PART	O	O
receive	NOUN	O	O
either	PUNCT	O	O
rHuEPO	ADV	O	O
(	PUNCT	O	O
150	NUM	O	O
U/kg	NOUN	O	O
)	PUNCT	O	O
or	CCONJ	O	O
placebo	NOUN	O	O
subcutaneously	ADV	O	O
three	NUM	O	O
times	NOUN	O	O
a	DET	O	O
week	NOUN	O	O
for	ADP	O	O
a	DET	O	O
maximum	NOUN	O	O
of	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
or	CCONJ	O	O
until	ADP	O	O
the	DET	O	O
hematocrit	NOUN	O	B-PHYSICAL
level	NOUN	O	I-PHYSICAL
increased	VERB	O	O
to	ADP	O	O
38	NUM	O	O
%	SYM	O	O
-40	NUM	O	O
%	SYM	O	O
.	PUNCT	O	O

If	PUNCT	O	O
the	DET	O	O
hematocrit	NOUN	O	B-PHYSICAL
reached	ADP	O	O
this	DET	O	O
target	NOUN	O	O
level	NOUN	O	O
before	ADP	O	O
12	NUM	O	O
weeks	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
rHuEPO	PUNCT	O	O
dose	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
reduced	VERB	O	O
to	PART	O	O
maintain	ADV	O	O
the	DET	O	O
hematocrit	NOUN	O	O
at	ADP	O	O
that	PUNCT	O	O
level	NOUN	O	O
for	ADP	O	O
the	DET	O	O
duration	NOUN	O	O
of	ADP	O	O
the	DET	O	O
study	NOUN	O	O
.	PUNCT	O	O

Response	NOUN	O	O
to	ADP	O	O
rHuEPO	ADV	O	O
therapy	NOUN	O	O
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
measuring	VERB	O	O
changes	NOUN	O	O
in	ADP	O	O
hematocrit	NOUN	O	B-PHYSICAL
level	NOUN	O	I-PHYSICAL
,	PUNCT	O	O
transfusion	NOUN	O	B-OTHER
requirements	NOUN	O	I-OTHER
,	PUNCT	O	O
and	CCONJ	O	O
quality	NOUN	O	O
of	ADP	O	O
life	NOUN	O	O
.	PUNCT	O	O

Quality-of-life	NOUN	O	B-OTHER
assessment	NOUN	O	O
was	VERB	O	O
based	VERB	O	O
on	ADP	O	O
patients	NOUN	O	O
'	PUNCT	O	O
responses	CCONJ	O	O
to	ADP	O	O
questionnaires	NOUN	O	O
before	ADP	O	O
and	CCONJ	O	O
after	ADP	O	O
the	DET	O	O
courses	NOUN	O	O
of	ADP	O	O
therapy	NOUN	O	O
.	PUNCT	O	O

RESULTS	PUNCT	O	O
The	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
hematocrit	NOUN	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
rHuEPO-treated	VERB	O	O
group	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
hematocrit	NOUN	O	B-PHYSICAL
in	ADP	O	O
the	DET	O	O
placebo-treated	DET	O	O
group	NOUN	O	O
was	VERB	O	O
statistically	ADV	O	O
significant	ADJ	O	O
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.0001	NUM	O	O
)	PUNCT	O	O
as	VERB	O	O
measured	VERB	O	O
by	ADP	O	O
percentage	NOUN	O	O
point	NOUN	O	O
of	ADP	O	O
change	NOUN	O	O
from	ADP	O	O
baseline	NOUN	O	O
to	ADP	O	O
final	ADJ	O	O
evaluation	NOUN	O	O
,	PUNCT	O	O
by	ADP	O	O
an	DET	O	O
increase	NOUN	O	O
in	ADP	O	O
hematocrit	NOUN	O	B-PHYSICAL
level	NOUN	O	O
of	ADP	O	O
six	NUM	O	O
percentage	NOUN	O	O
points	DET	O	O
or	CCONJ	O	O
more	DET	O	O
unrelated	VERB	O	O
to	ADP	O	O
transfusion	NOUN	O	O
,	PUNCT	O	O
and	CCONJ	O	O
by	ADP	O	O
a	DET	O	O
rise	NOUN	O	O
in	ADP	O	O
hematocrit	NOUN	O	B-PHYSICAL
level	NOUN	O	I-PHYSICAL
to	ADP	O	O
38	NUM	O	O
%	SYM	O	O
or	CCONJ	O	O
more	DET	O	O
unrelated	VERB	O	O
to	ADP	O	O
transfusion	NOUN	O	O
.	PUNCT	O	O

There	PUNCT	O	O
was	VERB	O	O
a	DET	O	O
trend	NOUN	O	O
toward	ADP	O	O
the	DET	O	O
reduction	NOUN	O	O
in	ADP	O	O
mean	NOUN	O	O
units	NOUN	O	O
of	ADP	O	O
blood	NOUN	O	B-OTHER
transfused	PUNCT	O	I-OTHER
per	ADP	O	I-OTHER
patient	NOUN	O	I-OTHER
during	ADP	O	O
months	NOUN	O	O
2	NUM	O	O
and	CCONJ	O	O
3	NUM	O	O
of	ADP	O	O
therapy	NOUN	O	O
combined	VERB	O	O
in	ADP	O	O
rHuEPO-treated	VERB	O	O
patients	NOUN	O	O
compared	VERB	O	O
with	ADP	O	O
placebo-treated	VERB	O	O
patients	NOUN	O	O
(	PUNCT	O	O
0.91	NUM	O	O
U	NOUN	O	O
versus	CCONJ	O	O
1.65	NUM	O	O
U	NOUN	O	O
;	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.056	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

In	ADP	O	O
addition	NOUN	O	O
,	PUNCT	O	O
rHuEPO-treated	PUNCT	O	O
patients	NOUN	O	O
experienced	VERB	O	O
a	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
improvement	NOUN	O	O
in	ADP	O	O
energy	NOUN	O	B-OTHER
level	NOUN	O	I-OTHER
and	CCONJ	O	O
ability	NOUN	O	B-OTHER
to	PART	O	I-OTHER
perform	NOUN	O	I-OTHER
daily	DET	O	I-OTHER
activities	NOUN	O	I-OTHER
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
or	CCONJ	O	O
=	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
.	PUNCT	O	O

The	DET	O	O
two	NUM	O	O
treatment	NOUN	O	O
groups	NOUN	O	O
showed	VERB	O	O
no	DET	O	O
statistically	ADV	O	O
significant	ADJ	O	O
differences	NOUN	O	O
in	ADP	O	O
toxic	ADJ	O	B-ADVERSE-EFFECTS
effects	NOUN	O	I-ADVERSE-EFFECTS
except	PUNCT	O	O
for	ADP	O	O
increased	CCONJ	O	O
incidence	NOUN	O	O
of	ADP	O	O
diaphoresis	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
P	NOUN	O	O
<	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
and	CCONJ	O	O
diarrhea	NOUN	O	B-ADVERSE-EFFECTS
(	PUNCT	O	O
P	NOUN	O	O
=	SYM	O	O
.05	NUM	O	O
)	PUNCT	O	O
in	ADP	O	O
the	DET	O	O
rHuEPO-treated	VERB	O	O
group	NOUN	O	O
.	PUNCT	O	O

CONCLUSIONS	NOUN	O	O
We	PRON	O	O
conclude	VERB	O	O
that	ADP	O	O
rHuEPO	ADV	O	O
is	ADJ	O	O
safe	ADJ	O	O
and	CCONJ	O	O
effective	ADJ	O	O
for	ADP	O	O
reversing	VERB	O	O
anemia	NOUN	O	B-PHYSICAL
related	VERB	O	O
to	ADP	O	O
advanced	VERB	O	O
cancer	NOUN	O	O
or	CCONJ	O	O
to	ADP	O	O
chemotherapy	NOUN	O	O
for	ADP	O	O
cancer	NOUN	O	O
.	PUNCT	O	O

Enhanced	DET	O	O
small	ADJ	O	O
group	NOUN	O	O
instruction	NOUN	O	O
using	PUNCT	O	O
choral	PUNCT	O	O
responding	PUNCT	O	O
and	CCONJ	O	O
student	ADJ	O	O
interaction	NOUN	O	O
for	ADP	O	O
children	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
and	CCONJ	O	O
developmental	ADJ	O	O
disabilities	NOUN	O	O
.	PUNCT	O	O

The	DET	O	O
use	NOUN	O	O
of	ADP	O	O
effective	ADJ	O	O
instructional	ADJ	O	O
strategies	NOUN	O	O
in	ADP	O	O
small	ADJ	O	O
groups	NOUN	O	O
was	VERB	O	O
investigated	VERB	O	O
to	PART	O	O
determine	NOUN	O	O
learning	ADP	O	O
effects	NOUN	O	O
for	ADP	O	O
24	NUM	O	O
elementary	ADP	O	O
age	NOUN	O	O
students	NOUN	O	O
with	ADP	O	O
autism	NOUN	O	O
and	CCONJ	O	O
developmental	ADJ	O	O
disabilities	NOUN	O	O
.	PUNCT	O	O

Effective	ADJ	O	O
strategies	NOUN	O	O
included	VERB	O	O
(	PUNCT	O	O
a	NOUN	O	O
)	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
choral	ADJ	O	O
responding	PUNCT	O	O
;	PUNCT	O	O
(	PUNCT	O	O
b	NOUN	O	O
)	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
student-to-student	ADJ	O	O
responding	ADV	O	O
;	PUNCT	O	O
(	PUNCT	O	O
c	NOUN	O	O
)	PUNCT	O	O
the	DET	O	O
rotation	NOUN	O	O
of	ADP	O	O
materials	NOUN	O	O
every	DET	O	O
5	NUM	O	O
minutes	NOUN	O	O
during	ADP	O	O
the	DET	O	O
30-minute	NOUN	O	O
group	NOUN	O	O
while	ADP	O	O
teaching	ADP	O	O
2	NUM	O	O
to	ADP	O	O
3	NUM	O	O
concepts	NOUN	O	O
;	PUNCT	O	O
and	CCONJ	O	O
(	PUNCT	O	O
d	NOUN	O	O
)	PUNCT	O	O
the	DET	O	O
use	NOUN	O	O
of	ADP	O	O
random	ADJ	O	O
,	PUNCT	O	O
unpredictable	ADP	O	O
trials	NOUN	O	O
for	ADP	O	O
student	NOUN	O	O
responding	PUNCT	O	O
.	PUNCT	O	O

Thirty-minute	PUNCT	O	O
language	NOUN	O	O
groups	NOUN	O	O
were	VERB	O	O
targeted	VERB	O	O
to	VERB	O	O
teach	ADP	O	O
receptive	ADJ	O	O
and	CCONJ	O	O
expressive	ADJ	O	O
skills	NOUN	O	O
using	VERB	O	O
pictures	VERB	O	O
and	CCONJ	O	O
common	ADJ	O	O
objects	ADV	O	O
across	ADP	O	O
five	NUM	O	O
categories	NOUN	O	O
(	PUNCT	O	O
e.g.	ADP	O	O
,	PUNCT	O	O
household	NOUN	O	O
items	ADJ	O	O
,	PUNCT	O	O
foods	ADJ	O	O
)	PUNCT	O	O
.	PUNCT	O	O

Results	NOUN	O	O
showed	VERB	O	O
increased	VERB	O	O
opportunities	NOUN	O	B-MENTAL
to	PART	O	I-MENTAL
respond	ADP	O	I-MENTAL
,	PUNCT	O	O
increased	VERB	O	O
levels	NOUN	O	B-MENTAL
of	ADP	O	I-MENTAL
responding	PUNCT	O	I-MENTAL
and	CCONJ	O	I-MENTAL
academic	ADJ	O	I-MENTAL
engagement	NOUN	O	I-MENTAL
,	PUNCT	O	O
higher	PUNCT	O	B-PHYSICAL
gains	NOUN	O	I-PHYSICAL
on	ADP	O	O
weekly	ADV	O	B-MENTAL
criterion-referenced	VERB	O	I-MENTAL
pre-	ADJ	O	I-MENTAL
and	CCONJ	O	I-MENTAL
posttests	ADP	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
decreased	ADV	O	O
passive	ADJ	O	B-MENTAL
and	CCONJ	O	I-MENTAL
inappropriate	PUNCT	O	I-MENTAL
student	ADJ	O	I-MENTAL
behavior	NOUN	O	I-MENTAL
during	ADP	O	O
interventions	NOUN	O	O
.	PUNCT	O	O

Double-blind	ADJ	O	O
comparison	NOUN	O	O
of	ADP	O	O
doxepin	NOUN	O	O
versus	CCONJ	O	O
bupropion	NOUN	O	O
in	ADP	O	O
outpatients	ADJ	O	O
with	ADP	O	O
a	DET	O	O
major	ADJ	O	O
depressive	ADJ	O	O
disorder	NOUN	O	O
.	PUNCT	O	O

A	DET	O	O
double-blind	ADJ	O	O
controlled	VERB	O	O
study	NOUN	O	O
comparing	VERB	O	O
the	DET	O	O
effects	NOUN	O	O
of	ADP	O	O
bupropion	NOUN	O	O
to	ADP	O	O
doxepin	NOUN	O	O
in	ADP	O	O
outpatients	ADJ	O	O
with	ADP	O	O
primary	ADJ	O	O
depression	NOUN	O	O
was	VERB	O	O
conducted	VERB	O	O
to	PART	O	O
evaluate	NOUN	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	B-OTHER
differences	NOUN	O	O
between	ADP	O	O
the	DET	O	O
two	NUM	O	O
drugs	NOUN	O	O
.	PUNCT	O	O

Following	VERB	O	O
a	DET	O	O
7-day	NOUN	O	O
placebo	NOUN	O	O
washout	PUNCT	O	O
period	NOUN	O	O
,	PUNCT	O	O
patients	NOUN	O	O
could	VERB	O	O
be	VERB	O	O
treated	VERB	O	O
for	ADP	O	O
up	PUNCT	O	O
to	PUNCT	O	O
13	NUM	O	O
weeks	NOUN	O	O
on	ADP	O	O
either	CCONJ	O	O
treatment	NOUN	O	O
.	PUNCT	O	O

Antidepressant	NOUN	O	B-MENTAL
response	NOUN	O	I-MENTAL
was	VERB	O	O
assessed	VERB	O	O
by	ADP	O	O
the	DET	O	O
Hamilton	PUNCT	O	B-MENTAL
Depression	NOUN	O	I-MENTAL
and	CCONJ	O	I-MENTAL
Anxiety	NOUN	O	I-MENTAL
Scales	PUNCT	O	O
,	PUNCT	O	O
Clinical	ADJ	O	B-MENTAL
Global	ADJ	O	I-MENTAL
Severity	NOUN	O	I-MENTAL
and	CCONJ	O	O
Improvement	NOUN	O	B-MENTAL
Ratings	PROPN	O	I-MENTAL
,	PUNCT	O	O
and	CCONJ	O	O
the	DET	O	O
Zung	PUNCT	O	B-MENTAL
Self-Rating	PUNCT	O	I-MENTAL
Depression	NOUN	O	I-MENTAL
Scale	NOUN	O	O
.	PUNCT	O	O

Comparable	ADJ	O	O
efficacy	NOUN	O	O
between	ADP	O	O
the	DET	O	O
compounds	NOUN	O	O
was	VERB	O	O
found	VERB	O	O
across	ADP	O	O
the	DET	O	O
13-week	PUNCT	O	O
study	NOUN	O	O
.	PUNCT	O	O

Doxepin	NOUN	O	O
differed	VERB	O	O
from	ADP	O	O
bupropion	NOUN	O	O
mainly	ADV	O	O
on	ADP	O	O
the	DET	O	O
sleep	ADV	O	B-MENTAL
factor	NOUN	O	O
of	ADP	O	B-MENTAL
the	DET	O	I-MENTAL
Hamilton	PUNCT	O	I-MENTAL
Depression	NOUN	O	B-MENTAL
Scale	NOUN	O	O
,	PUNCT	O	O
with	ADP	O	O
doxepin	NOUN	O	O
improving	PUNCT	O	O
sleep	ADP	O	O
to	ADP	O	O
a	DET	O	O
greater	PUNCT	O	O
extent	NOUN	O	O
than	PUNCT	O	O
bupropion	NOUN	O	O
.	PUNCT	O	O

Doxepin	NOUN	O	O
produced	VERB	O	O
a	DET	O	O
greater	PUNCT	O	O
incidence	NOUN	O	O
of	ADP	O	O
anticholinergic	ADJ	O	B-ADVERSE-EFFECTS
side	NOUN	O	I-ADVERSE-EFFECTS
effects	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
including	CCONJ	O	O
dry	ADJ	O	B-ADVERSE-EFFECTS
mouth	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
constipation	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
sleepiness	NOUN	O	B-ADVERSE-EFFECTS
,	PUNCT	O	O
and	PUNCT	O	O

Effectiveness	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
the	DET	O	O
Levitan	NOUN	O	O
FPS	NOUN	O	O
Scope?	NOUN	O	O
for	ADP	O	O
tracheal	ADJ	O	O
intubation	NOUN	O	O
under	ADP	O	O
general	ADJ	O	O
anesthesia	NOUN	O	O
with	ADP	O	O
a	DET	O	O
simulated	VERB	O	O
difficult	ADJ	O	O
airway	NOUN	O	O
.	PUNCT	O	O

PURPOSE	NOUN	O	O
Studies	NOUN	O	O
show	VERB	O	O
that	ADP	O	O
the	DET	O	O
Levitan	NOUN	O	O
FPS	NOUN	O	O
(	PUNCT	O	O
first	PUNCT	O	O
pass	PUNCT	O	O
success	NOUN	O	O
)	PUNCT	O	O
Scope?	NOUN	O	O
(	PUNCT	O	O
LFS	NOUN	O	O
)	PUNCT	O	O
is	VERB	O	O
analogous	ADJ	O	O
to	ADP	O	O
a	DET	O	O
bougie	ADJ	O	O
in	ADP	O	O
simulated	DET	O	O
difficult	ADJ	O	O
airways	NOUN	O	O
with	ADP	O	O
comparable	ADJ	O	O
tracheal	ADJ	O	O
intubation	NOUN	O	O
success	NOUN	O	O
rates	NOUN	O	O
.	PUNCT	O	O

In	ADP	O	O
this	DET	O	O
study	NOUN	O	O
,	PUNCT	O	O
the	DET	O	O
efficacy	NOUN	O	O
and	CCONJ	O	O
safety	NOUN	O	O
of	ADP	O	O
tracheal	ADJ	O	O
intubation	NOUN	O	O
with	ADP	O	O
the	DET	O	O
LFS	NOUN	O	O
was	VERB	O	O
compared	VERB	O	O
with	ADP	O	O
that	PUNCT	O	O
of	ADP	O	O
the	DET	O	O
Macintosh	NOUN	O	O
laryngoscope	NOUN	O	O
utilizing	ADP	O	O
manual	ADJ	O	O
in-line	NOUN	O	O
stabilization	NOUN	O	O
(	PUNCT	O	O
MILS	NOUN	O	O
)	PUNCT	O	O
to	PUNCT	O	O
simulate	ADJ	O	O
difficult	ADJ	O	O
airways	NOUN	O	O
.	PUNCT	O	O

